<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Combined corticosteroid and long‐acting beta2‐agonist in one inhaler versus inhaled corticosteroids alone for chronic obstructive pulmonary disease - Nannini, LJ - 2013 | Cochrane Library</title> <meta content="Combined corticosteroid and long‐acting beta2‐agonist in one inhaler versus inhaled corticosteroids alone for chronic obstructive pulmonary disease - Nannini, LJ - 2013 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD006826.pub2/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Combined corticosteroid and long‐acting beta2‐agonist in one inhaler versus inhaled corticosteroids alone for chronic obstructive pulmonary disease - Nannini, LJ - 2013 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD006826.pub2/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD006826.pub2" name="dc.identifier" scheme="DOI"/> <meta content="Combined corticosteroid and long‐acting beta&lt;sub&gt;2&lt;/sub&gt;‐agonist in one inhaler versus inhaled corticosteroids alone for chronic obstructive pulmonary disease" name="citation_title"/> <meta content="Luis Javier Nannini" name="citation_author"/> <meta content="Hospital E Peron" name="citation_author_institution"/> <meta content="nanninilj@circulomedicorosario.org" name="citation_author_email"/> <meta content="Phillippa Poole" name="citation_author"/> <meta content="University of Auckland" name="citation_author_institution"/> <meta content="Stephen J Milan" name="citation_author"/> <meta content="St George's, University of London" name="citation_author_institution"/> <meta content="Annabel Kesterton" name="citation_author"/> <meta content="St George's University of London" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="8" name="citation_issue"/> <meta content="10.1002/14651858.CD006826.pub2" name="citation_doi"/> <meta content="2013" name="citation_date"/> <meta content="2013/08/30" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD006826.pub2/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD006826.pub2/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD006826.pub2/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Adrenal Cortex Hormones [*administration &amp; dosage, adverse effects]; Adrenergic beta‐2 Receptor Agonists [*administration &amp; dosage, adverse effects]; Albuterol [administration &amp; dosage, adverse effects, analogs &amp; derivatives]; Androstadienes [administration &amp; dosage, adverse effects]; Bronchodilator Agents [administration &amp; dosage, adverse effects]; Budesonide [administration &amp; dosage, adverse effects]; Drug Combinations; Drug Therapy, Combination [adverse effects, methods]; Ethanolamines [administration &amp; dosage, adverse effects]; Fluticasone‐Salmeterol Drug Combination; Formoterol Fumarate; Nebulizers and Vaporizers; Pneumonia [chemically induced]; Pulmonary Disease, Chronic Obstructive [*drug therapy, mortality]; Randomized Controlled Trials as Topic; Steroids [*administration &amp; dosage, adverse effects]" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006826.pub2&amp;doi=10.1002/14651858.CD006826.pub2&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006826.pub2&amp;doi=10.1002/14651858.CD006826.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006826.pub2&amp;doi=10.1002/14651858.CD006826.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006826.pub2&amp;doi=10.1002/14651858.CD006826.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006826.pub2&amp;doi=10.1002/14651858.CD006826.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006826.pub2&amp;doi=10.1002/14651858.CD006826.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006826.pub2&amp;doi=10.1002/14651858.CD006826.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006826.pub2&amp;doi=10.1002/14651858.CD006826.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006826.pub2&amp;doi=10.1002/14651858.CD006826.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006826.pub2&amp;doi=10.1002/14651858.CD006826.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006826.pub2&amp;doi=10.1002/14651858.CD006826.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006826.pub2&amp;doi=10.1002/14651858.CD006826.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006826.pub2&amp;doi=10.1002/14651858.CD006826.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006826.pub2&amp;doi=10.1002/14651858.CD006826.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006826.pub2&amp;doi=10.1002/14651858.CD006826.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006826.pub2&amp;doi=10.1002/14651858.CD006826.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006826.pub2&amp;doi=10.1002/14651858.CD006826.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006826.pub2&amp;doi=10.1002/14651858.CD006826.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006826.pub2&amp;doi=10.1002/14651858.CD006826.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006826.pub2&amp;doi=10.1002/14651858.CD006826.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006826.pub2&amp;doi=10.1002/14651858.CD006826.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006826.pub2&amp;doi=10.1002/14651858.CD006826.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006826.pub2&amp;doi=10.1002/14651858.CD006826.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772874000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772901000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000"}};Liferay.authToken="Xx9QLps0";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD006826\x2epub2\x26doi\x3d10\x2e1002\x2f14651858\x2eCD006826\x2epub2\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD006826\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD006826\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513679709000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","fr","fa"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD006826.pub2",title:"Combined corticosteroid and long\\u2010acting beta\u003csub\u003e2\u003c/sub\u003e\\u2010agonist in one inhaler versus inhaled corticosteroids alone for chronic obstructive pulmonary disease",firstPublishedDate:"Aug 30, 2013 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Airways Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734064000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=Xx9QLps0&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD006826.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD006826.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD006826.pub2/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD006826.pub2/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD006826.pub2%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD006826.pub2/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD006826.pub2/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD006826.pub2/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD006826.pub2/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD006826.PUB2" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD006826.pub2/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD006826.PUB2" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD006826.pub2/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD006826.pub2/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>1973 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD006826.pub2" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006826.pub2/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006826.pub2/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006826.pub2/full#CD006826-abs-0003"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006826.pub2/full#CD006826-sec-0124"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006826.pub2/full#CD006826-sec-0022"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006826.pub2/full#CD006826-sec-0023"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006826.pub2/full#CD006826-sec-0028"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006826.pub2/full#CD006826-sec-0029"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006826.pub2/full#CD006826-sec-0052"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006826.pub2/full#CD006826-sec-0118"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD006826.pub2/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006826.pub2/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006826.pub2/appendices#CD006826-sec-0129"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006826.pub2/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006826.pub2/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD006826.pub2/media/CDSR/CD006826/table_n/CD006826StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD006826.pub2/media/CDSR/CD006826/table_n/CD006826StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006826.pub2/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006826.pub2/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006826.pub2/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD006826.pub2/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD006826.pub2/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD006826.pub2/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2014 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD006826.pub2/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Combined corticosteroid and long‐acting beta<sub>2</sub>‐agonist in one inhaler versus inhaled corticosteroids alone for chronic obstructive pulmonary disease </h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD006826.pub2/information#CD006826-cr-0002"><i class="icon corresponding-author fa fa-envelope"></i>Luis Javier Nannini</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD006826.pub2/information#CD006826-cr-0003">Phillippa Poole</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD006826.pub2/information#CD006826-cr-0004">Stephen J Milan</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD006826.pub2/information#CD006826-cr-0005">Annabel Kesterton</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD006826.pub2/information/en#CD006826-sec-0139">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 30 August 2013 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD006826.pub2/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD006826.pub2">https://doi.org/10.1002/14651858.CD006826.pub2</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD006826-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD006826-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD006826-abs-0005">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD006826-abs-0007">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD006826-abs-0002">Français</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD006826-abs-0001" lang="en"> <section id="CD006826-sec-0001"> <h3 class="title" id="CD006826-sec-0001">Background</h3> <p>Both long‐acting beta<sub>2</sub>‐agonists and inhaled corticosteroids have been recommended in guidelines for the treatment of chronic obstructive pulmonary disease (COPD). Their co‐administration in a combined inhaler is intended to facilitate adherence to medication regimens and to improve efficacy. Three preparations are currently available: fluticasone propionate/salmeterol (FPS). budesonide/formoterol (BDF) and mometasone furoate/formoterol (MF/F). </p> </section> <section id="CD006826-sec-0002"> <h3 class="title" id="CD006826-sec-0002">Objectives</h3> <p>To assess the efficacy and safety of combined long‐acting beta<sub>2</sub>‐agonist and inhaled corticosteroid (LABA/ICS) preparations, as measured by clinical endpoints and pulmonary function testing, compared with inhaled corticosteroids (ICS) alone, in the treatment of adults with chronic obstructive pulmonary disease (COPD). </p> </section> <section id="CD006826-sec-0003"> <h3 class="title" id="CD006826-sec-0003">Search methods</h3> <p>We searched the Cochrane Airways Group Specialised Register of trials, which is compiled from systematic searches of multiple literature databases. The search was conducted in June 2013. In addition, we checked the reference lists of included studies and contacted the relevant manufacturers. </p> </section> <section id="CD006826-sec-0004"> <h3 class="title" id="CD006826-sec-0004">Selection criteria</h3> <p>Studies were included if they were randomised and double‐blind. Compared studies combined LABA/ICS with the ICS component. </p> </section> <section id="CD006826-sec-0005"> <h3 class="title" id="CD006826-sec-0005">Data collection and analysis</h3> <p>Two review authors independently assessed trial quality and extracted data. The primary outcomes were exacerbations, mortality and pneumonia. Health‐related quality of life (as measured by validated scales), lung function and side effects were secondary outcomes. Dichotomous data were analysed as fixed‐effect odds ratios with 95% confidence intervals (CIs), and continuous data as mean differences or rate ratios and 95% CIs. </p> </section> <section id="CD006826-sec-0006"> <h3 class="title" id="CD006826-sec-0006">Main results</h3> <p>A total of 15 studies of good methodological quality met the inclusion criteria by randomly assigning 7814 participants with predominantly poorly reversible, severe COPD. Data were most plentiful for the FPS combination. Exacerbation rates were significantly reduced with combination therapies (rate ratio 0.87, 95% CI 0.80 to 0.94, 6 studies, N = 5601) compared with ICS alone. The mean exacerbation rate in the control (ICS) arms of the six included studies was 1.21 exacerbations per participant per year (range 0.88 to 1.60), and we would expect this to be reduced to a rate of 1.05 (95% CI 0.97 to 1.14) among those given combination therapy. Mortality was also lower with the combination (odds ratio (OR) 0.78, 95% CI 0.64 to 0.94, 12 studies, N = 7518) than with ICS alone, but this was heavily weighted by a three‐year study of FPS. When this study was removed, no significant mortality difference was noted. The reduction in exacerbations did not translate into significantly reduced rates of hospitalisation due to COPD exacerbation (OR 0.93, 95% CI 0.80 to 1.07, 10 studies, N = 7060). Lung function data favoured combination treatment in the FPS, BDF and MF/F trials, but the improvement was small. Small improvements in health‐related quality of life were measured on the St George's Respiratory Questionnaire (SGRQ) with FPS or BDF compared with ICS, but this was well below the minimum clinically important difference. Adverse event profiles were similar between the two treatments arms, and rates of pneumonia when it was diagnosed by chest x‐ray (CXR) were lower than those reported in earlier trials. </p> </section> <section id="CD006826-sec-0007"> <h3 class="title" id="CD006826-sec-0007">Authors' conclusions</h3> <p>Combination ICS and LABA offer some clinical benefits in COPD compared with ICS alone, especially for reduction in exacerbations. This review does not support the use of ICS alone when LABAs are available. Adverse events were not significantly different between treatments. Further long‐term assessments using practical outcomes of current and new 24‐hour LABAs will help determine their efficacy and safety. For robust comparisons as to their relative effects, long‐term head‐to‐head comparisons are needed. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD006826-abs-0003" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD006826-abs-0003">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD006826-abs-0006">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD006826-abs-0008">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD006826-abs-0004">Français</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD006826-abs-0003" lang="en"> <h3>Combination therapy of inhaled steroids and long‐acting beta2‐agonists compared to inhaled steroids alone for people with COPD </h3> <p>Combinations of two classes of medication (long‐acting beta<sub>2</sub>‐agonists (LABAs) and inhaled corticosteroids (ICS)) in one inhaler have been developed to treat people with COPD, as this may make it easier to take the medication. Three brands of combined inhaler are currently available: budesonide/formoterol (BDF－'Symbicort'), fluticasone propionate/salmeterol (FPS－'Advair' or 'Seretide') and mometasone furoate/formoterol (MF/F－'Dulera'). Both the ICS part and the LABA component of each inhaler are aimed at reducing flare‐ups of COPD, which can be debilitating and costly. In addition, the LABA component may improve day‐to‐day symptoms such as breathlessness and exercise tolerance. </p> <p>Our review found 15 studies that compared a combination of ICS/LABA with ICS alone. We found that on the whole, combination inhalers reduced the frequency of flare‐ups (not including hospitalisations) compared with ICS alone. The studies showed that on average, the number of exacerbations per participant was reduced, as was the probability of death, during treatment. Quality of life and lung function showed improvement with combination treatment compared with ICS, but no difference between them was noted in terms of adverse effects, or the likelihood of having no flare‐ups at all. Future research should assess the efficacy of BDF and MF/F because most evidence gathered to date, including for mortality, has been drawn from FPS studies. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD006826-sec-0124" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD006826-sec-0124"></div> <h3 class="title" id="CD006826-sec-0125">Implications for practice</h3> <section id="CD006826-sec-0125"> <p>In participants with moderate and severe COPD, clinical benefit is evident when LABA and ICS are co‐administered rather than ICS alone. Even though patients do not all perceive a better quality of life, they may live longer and have fewer exacerbations with combination therapy versus ICS alone. However, the evidence does not support the likelihood of being exacerbation‐free or having fewer hospitalisations during the treatment period. The reduction in exacerbations varies, depending on the frequency of these events in individual patients. The mortality benefit will take at least two years to be evident and has been shown only for the FPS combination. Available evidence is most plentiful for the FPS combination and is heavily weighted by the three‐year TORCH trial. </p> <p>What is unclear is whether combination LABA/ICS therapy is better than LABA or ICS administered separately, or 4 times daily use of short‐acting beta<sub>2</sub>‐agonists with ICS. All of the combination inhalers in this review were given twice a day. In addition to potential adherence benefits associated with the combination inhaler, its use guarantees that a patient receives both medicines simultaneously, which may not be the case if they are administered via separate inhalers. Further, evidence that LABAs and ICS have complementary and synergistic effects when delivered as combination therapy from a single inhaler is increasing (<a href="./references#CD006826-bbs2-0072" title="HananiaNA . The impact of inhaled corticosteroid and long‐acting beta‐agonist combination therapy on outcomes in COPD. Pulmonary Pharmacology and Therapeutics2008;21(3):540‐50. ">Hanania 2008</a>). Although we conclude that unopposed ICS with no LABA co‐administration is an inferior strategy in COPD, the minimum effective dose of inhaled steroids remains unclear. The three combination inhalers showed similar effects on review outcomes, including adverse effects, but should ideally be subjected to simple head‐to‐head comparisons over long periods of time. We have not been able to identify differences between the combination inhalers on the basis of currently available evidence. </p> </section> <h3 class="title" id="CD006826-sec-0126">Implications for research</h3> <section id="CD006826-sec-0126"> <p>The findings of the TORCH study need to be confirmed, as it is the only trial to show a decrease in mortality over the study period. We suggest that the circumstances surrounding any death should be fully documented and categorised as to likely clinical mechanism, and that all patients should have their vital status ascertained (whether they complete the study or drop out). If confirmed, a multipartite programme of clinical and basic science research should be enlisted to elucidate the mechanism of reduction in mortality, given that this is the only pharmaceutical yet shown to reduce mortality in COPD. </p> <p>Future studies might address the impact of any reduction in exacerbations on health care utilisation (e.g. bed days, unscheduled general practitioner or emergency room visits). This could help inform a cost‐benefit analysis. </p> <p>Which combination and which dose and duration of ICS should be selected in COPD have not yet been explored adequately. We also do not know whether use of a combination is superior to separate administration of the two inhalers. Obviously the best way to test these relative benefits and adverse effects for each of the combinations is to perform a simple and direct long‐term comparison among, for example, FPS, BDF and MF/F treatments. This might best be done in well‐categorised, stable COPD patients receiving primary care. </p> <p>New combinations of ICS with 24‐hour LABAs such as indacaterol, vilanterol or olodaterol are emerging. Are these just "me too" medicines, or do they offer an advantage? Updating this review within a short space of time will be imperative. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD006826-sec-0022" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD006826-sec-0022"></div> <div class="table" id="CD006826-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">All combined inhalers－participants with one or more exacerbations</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Combined steroid/LABA inhalers versus LABA alone for people with COPD</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> patients with COPD<br/> <b>Settings:</b> community<br/> <b>Intervention:</b> All combined inhalers－primary outcomes </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No. of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Control</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> All combined inhalers－primary outcomes</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Exacerbation rates per participant per year</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>1.21<sup>1</sup> </b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>1.05</b> </p> <p>(0.97 to 1.14)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Rate ratio 0.87</b> (0.80 to 0.94) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5601<br/> (6 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊝<br/> <b>moderate<sup>2</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Mortality</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>71 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>56 per 1000</b> <br/> (47 to 67) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>OR 0.78</b> <br/> (0.64 to 0.94) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7518<br/> (12 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊕<br/> <b>high<sup>3</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Pneumonia</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>85 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>91 per 1000</b> <br/> (78 to 107) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>OR 1.08</b> <br/> (0.91 to 1.28) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7320<br/> (12 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊝⊝<br/> <b>low<sup>2,4</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Hospitalisations due to COPD exacerbations</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>127 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>119 per 1000</b> <br/> (104 to 134) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 0.93</b> <br/> (0.8 to 1.07) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7060<br/> (10 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low<sup>2,4</sup> </b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Adverse events</b> －<b>serious</b> </p> <p>Fluticasone/salmeterol (FPS) versus fluticasone (FP)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>54 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>57 per 1000</b> <br/> (45 to 71) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>OR 1.05</b> <br/> (0.82 to 1.34) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5055<br/> (7 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊝⊝<br/> <b>low<sup>2,4</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Adverse events</b> －<b>serious events</b> Budesonide/formoterol (BDF) versus budesonide (BD) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>207 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>195 per 1000</b> <br/> (158 to 240) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>OR 0.93</b> <br/> (0.72 to 1.21) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1469<br/> (3 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊝⊝⊝<br/> <b>very low<sup>2,4,5</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Adverse events</b> －<b>serious</b> Mometasone/formoterol (MF/F) versus Mometasone (MF) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>78 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>80 per 1000</b> <br/> (50 to 123) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>OR 1.03</b> <br/> (0.63 to 1.67) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>905<br/> (2 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊝⊝<br/> <b>low<sup>2,4</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>OR:</b> Odds ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence:<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Mean exacerbation rate in the ICS arms of the included studies (range 0.88 to 1.60 per participant per year). </p> <p><sup>2</sup>(‐1 limitations) due to high risk of attrition bias. </p> <p><sup>3</sup>We did not deduct a point for attrition bias because most of the data on mortality were derived from TORCH. </p> <p><sup>4</sup>(‐1 imprecision) confidence interval cannot rule out differences in either direction. </p> <p><sup>5</sup>A point is deducted to reflect the considerable heterogeneity in this analysis (I<sup>2</sup> = 66%). </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD006826-sec-0023" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD006826-sec-0023"></div> <section id="CD006826-sec-0024"> <h3 class="title" id="CD006826-sec-0024">Description of the condition</h3> <p>Chronic obstructive pulmonary disease (COPD) is currently the fourth leading cause of death in most industrialised countries but is projected to be the third leading cause of death worldwide by 2020 (<a href="./references#CD006826-bbs2-0071" title="Global Strategy forDiagnosis , Management , Prevention ofCOPD . Global Initiative for Chronic Obstructive Lung Disease (GOLD), 2011. http://www.goldcopd.org. ">GOLD 2011</a>). An estimated three million people are affected by COPD in the UK alone (<a href="./references#CD006826-bbs2-0077" title="London: National Clinical Guideline Centre. Management of chronic obstructive pulmonary disease in adults in primary and secondary care, 2010. http://guidance.nice.org.uk/CG101/Guidance/pdf/English. ">NCGC 2010</a>). In the most recent global guidelines, COPD is defined as "a common preventable and treatable disease, characterised by persistent airflow limitation that is usually progressive and associated with an enhanced chronic inflammatory response in the airways and the lung to noxious particles or gases. Exacerbations and co‐morbidities contribute to the overall severity in individual patients" (<a href="./references#CD006826-bbs2-0071" title="Global Strategy forDiagnosis , Management , Prevention ofCOPD . Global Initiative for Chronic Obstructive Lung Disease (GOLD), 2011. http://www.goldcopd.org. ">GOLD 2011</a>). </p> <p>The disease is caused predominantly by smoking. Smoke and other irritants trigger airway inflammation (i.e. bronchial infiltration of neutrophils, macrophages, lymphocytes and mast cells and increasing evidence of autoimmunity) (<a href="./references#CD006826-bbs2-0067" title="CosioMG , SaettaM , AgustiA . Immunologic aspects of chronic obstructive pulmonary disease. New England Journal of Medicine2009;360:2445‐54. ">Cosio 2009</a>). As a result, patients generally show progressive loss of lung function, accompanied by worsening respiratory symptoms, more frequent exacerbations and deterioration in health status (<a href="./references#CD006826-bbs2-0071" title="Global Strategy forDiagnosis , Management , Prevention ofCOPD . Global Initiative for Chronic Obstructive Lung Disease (GOLD), 2011. http://www.goldcopd.org. ">GOLD 2011</a>]. In addition to these effects on patients, exacerbations are costly to the healthcare system. </p> <p>All cases of COPD are characterised by airway obstruction, which is defined as a reduced post‐bronchodilator lung function ratio (forced expiratory volume in 1 second (FEV<sub>1</sub>)/forced vital capacity (FVC) &lt; 0.7), but in reality, COPD is a heterogeneous syndrome (<a href="./references#CD006826-bbs2-0071" title="Global Strategy forDiagnosis , Management , Prevention ofCOPD . Global Initiative for Chronic Obstructive Lung Disease (GOLD), 2011. http://www.goldcopd.org. ">GOLD 2011</a>). It has been suggested that some phenotypes of COPD involved more chronic systemic inflammation, which has an impact on co‐morbidities, such as cardiovascular disease (<a href="./references#CD006826-bbs2-0070" title="Garcia‐AymerichJ , GómezFP , BenetM , FarreroE , BasagañaX , GayeteÀ , et al. Identification and prospective validation of clinically relevant chronic obstructive pulmonary disease (COPD) subtypes. Thorax [published online first] 21 December 2010;66(5):430‐7. ">Garcia‐Aymerich 2011</a>). Some patients deteriorate more quickly than others, and variability in the degree of airways reversibility exhibited to bronchodilators has been noted. Previously, COPD severity was defined solely by FEV<sub>1</sub> % predicted compared with normal. The most recent definition grades severity of COPD using a combination of symptoms, lung function and number of exacerbations per year (<a href="./references#CD006826-bbs2-0071" title="Global Strategy forDiagnosis , Management , Prevention ofCOPD . Global Initiative for Chronic Obstructive Lung Disease (GOLD), 2011. http://www.goldcopd.org. ">GOLD 2011</a>). </p> <p>All patients with COPD should be considered for smoking cessation interventions, pulmonary rehabilitation, annual influenza vaccination and five‐yearly pneumococcal vaccination (<a href="./references#CD006826-bbs2-0071" title="Global Strategy forDiagnosis , Management , Prevention ofCOPD . Global Initiative for Chronic Obstructive Lung Disease (GOLD), 2011. http://www.goldcopd.org. ">GOLD 2011</a>). Smoking cessation is the only intervention that slows the decline in lung function (<a href="./references#CD006826-bbs2-0076" title="KohansalR , Martinez‐CamblorP , AgustiA , BuistAS , ManninoDM , SorianoJB . The natural history of chronic airflow obstruction revisited: an analysis of the Framingham offspring cohort. American Journal of Respiratory and Critical Care Medicine2009;180(1):3‐10. ">Kohansal 2009</a>). In the absence of a significant disease‐modifying effect, use of medication in COPD is largely guided by patient symptoms and exacerbation frequency. An increasing array of medicines are used in COPD, both alone and in combination. Some of these medicines are relatively expensive, so it is important to assess their relative benefits, so as to guide rational usage. It should be noted that in the decades to come, a disproportionate burden of the costs of COPD will be borne by developing countries, where smoking rates, and thus COPD prevalence, remain high. </p> <p>Inhaled corticosteroids (ICS), long‐acting beta<sub>2</sub>‐agonists (LABAs) and long‐acting anti‐muscarinic agents (LAMAs) have been shown to be effective for some clinical outcomes in COPD, such as symptoms, exercise tolerance, quality of life and exacerbations. </p> <p>Use of ICS may be associated with short‐term increases in FEV<sub>1</sub> and significant reduction in exacerbations (<a href="./references#CD006826-bbs2-0082" title="YangIA , ClarkeMS , SimEHA , FongKM . Inhaled corticosteroids for stable chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews2012, Issue 7. [DOI: 10.1002/14651858.CD002991.pub3] ">Yang 2012</a>). On the other hand, use of ICS has been associated with an increase in the number of cases of pneumonia (<a href="./references#CD006826-bbs2-0013" title="BriggsAH , GlickHA , Lozano‐OrtegaG , SpencerM , CalverleyPM , JonesPW , et al. Is treatment with ICS and LABA cost‐effective for COPD? Multinational economic analysis of the TORCH study. European Respiratory Journal2010; Vol. 35, issue 3:532‐9. CalverleyPM , AndersonJA , CelliB , FergusonGT , JenkinsC , JonesPW , et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease.[see comment]. New England Journal of Medicine2007; Vol. 356, issue 8:775‐89. CalverleyPMA , AndersonJA , CelliB , FergusonGT , JenkinsC , JonesPW , et al. Cardiovascular events in patients with chronic obstructive pulmonary disease: TORCH study results. Thorax2010;65:719‐25. CalverleyPMA , AndersonJA , CelliB , FergusonGT , JenkinsC , JonesPW , et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. New England Journal of Medicine2007;356(8):775‐89. CalverleyPMA , CelliB , FergusonG , JenkinsC , JonesPW , PrideNB , et al. Baseline characteristics of the first 5,000 COPD patients enrolled in the TORCH survival study. European Respiratory Journal2003;22 Suppl 45:578s. CelliB , CalverleyPMA , AndersonJA , FergusonGT , JenkinsC , JonesPW , et al. The TORCH (TOwards a Revolution in COPD Health) study: salmeterol/fluticasone propionate (SFC) improves health status, reduces exacerbations and improves lung function over three years. European Respiratory Journal2006;28 Suppl 50:34s. CelliB , VestboJ , JenkinsCR , JonesPW , FergusonGT , CalverleyPM , et al. Sex differences in mortality and clinical expressions of patients with chronic obstructive pulmonary disease: the TORCH experience. American Journal of Respiratory and Critical Care Medicine2011;183(3):317‐22. CelliBR , ThomasNE , AndersonJA , FergusonGT , JenkinsCR , JonesPW , et al. Effect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease: results from the TORCH study. American Journal of Respiratory and Critical Care Medicine2008;174(4):332‐8. CrimC , CalverleyPM , AndersonJA , CelliB , FergusonGT , JenkinsC , et al. Pneumonia risk in COPD patients receiving inhaled corticosteroids alone or in combination: TORCH study results. European Respiratory Journal2009;34(3):641‐7. FergusonGT , CalverleyPM , AndersonJA , JenkinsCR , JonesPW , WillitsLR , et al. Prevalence and progression of osteoporosis in patients with COPD: results from the TOwards a Revolution in COPD Health study. Chest2009; Vol. 136, issue 0012‐3692:1456‐65. FergusonGT , CalverleyPMA , AndersonJA , et al. The TORCH (TOwards a Revolution in COPD Health) study: salmeterol/fluticasone propionate (SFC) improves survival in COPD over three years. European Respiratory Journal2006;28 Suppl 50:34s. GlaxoSmithKlineSCO30003 . A multicentre, randomised, double‐blind, parallel group, placebo‐controlled study to investigate the long‐term effects of salmeterol/fluticasone propionate (SERETIDE/VIANI/ADVAIR) 50/500mcg bd, salmeterol 50mcg bd and fluticasone propionate 500mcg bd, all delivered via the DISKUS/ACCUHALER inhaler, on the survival of subjects with chronic obstructive pulmonary disease (COPD) over 3 years of treatment. GlaxoSmithKline Clinical Trial Register2006. HoughtonCM , LawsonN , BorrillZL , WixonCL , YoxallS , LangleySJ , et al. Comparison of the effects of salmeterol/fluticasone propionate with fluticasone propionate on airway physiology in adults with mild persistent asthma. Respiratory Research2007;8:52. JenkinsCR , CalverleyPMA , CelliB , FergusonG , JonesPW , PrideN , et al. Seasonal patterns of exacerbation rates in the TORCH survival study, 2007. http://www.abstracts2view.comA839. JenkinsCR , CelliB , AndersonJA , FergusonGT , JonesPW , VestboJ , et al. Seasonality and determinants of moderate and severe COPD exacerbations in the TORCH study. European Respiratory Journal2012;39(1):38‐45. JenkinsCR , JonesPW , CalverleyPM , CelliB , AndersonJA , FergusonGT , et al. Efficacy of salmeterol/fluticasone propionate by GOLD stage of chronic obstructive pulmonary disease: analysis from the randomised, placebo‐controlled TORCH study. Respiratory Research2009;10:59. JohnsonM , AgustiAG , BarnesNC . Reflections on TORCH: potential mechanisms for the survival benefit of salmeterol/fluticasone propionate in COPD patients. COPD2008;5(6):369‐75. JonesPW , AndersonJA , CalverleyPM , CelliBR , FergusonGT , JenkinsC , et al. TORCH Investigators. Health status in the TORCH study of COPD: treatment efficacy and other determinants of change. Respiratory Research2011;12:71. JonesPW , CalverleyP , CelliB , FergusonG , JenkinsC , PrideN . Trans‐regional validity of the SGRQ in the TORCH survival study, 2007. http://www.abstracts2view.comA122. McGarveyLP , JohnM , AndersonJA , ZvarichMT , WiseRA . Ascertainment of cause‐specific mortality in COPD: operations of the TORCH Clinical Endpoint Committee. Thorax2007;62:411‐5. NCT00268216 . See detailed description, 2000. http://clinicaltrials.gov/show/NCT00268216. [] SCO30003 . A multicentre, randomised, double‐blind, parallel group, placebo‐controlled study to investigate the long‐term effects of salmeterol/fluticasone propionate (SERETIDE®/VIANI®/ADVAIR®) 50/500mcg bd, salmeterol 50mcg bd and fluticasone propionate 500mcg bd, all delivered via the DISKUS®/ACCUHALER® inhaler, on the survival of subjects with chronic obstructive pulmonary disease (COPD) over 3 years of treatment, 2006. www.ctr.gsk.co.uk. VestboJ , AndersonJA , CalverleyPM , CelliB , FergusonGT , JenkinsC , et al. Adherence to inhaled therapy, mortality and hospital admission in COPD. Thorax2009;64(11):939‐43. VestboJ , CalverleyP , CelliB , FergusonG , JenkinsC , JonesP , et al. The TORCH (TOwards a Revolution in COPD Health) survival study protocol. European Respiratory Journal2004;24(2):206‐10. WiseRA , McGarveyLP , JohnM , AndersonJA , ZvarichMT . Reliability of cause‐specific mortality adjudication in a COPD clinical trial, 2007. http://www.abstracts2view.comA120. ">TORCH</a>; <a href="./references#CD006826-bbs2-0071" title="Global Strategy forDiagnosis , Management , Prevention ofCOPD . Global Initiative for Chronic Obstructive Lung Disease (GOLD), 2011. http://www.goldcopd.org. ">GOLD 2011</a>) and of other adverse outcomes such as hoarseness and oral candidiasis. <a href="./references#CD006826-bbs2-0071" title="Global Strategy forDiagnosis , Management , Prevention ofCOPD . Global Initiative for Chronic Obstructive Lung Disease (GOLD), 2011. http://www.goldcopd.org. ">GOLD 2011</a> recommended that ICS should be used in patients with an FEV<sub>1</sub> &lt; 50% predicted (GOLD stages 3 and 4 or quadrant C and D) and a history of ≥ 2 exacerbations (<a href="./references#CD006826-bbs2-0071" title="Global Strategy forDiagnosis , Management , Prevention ofCOPD . Global Initiative for Chronic Obstructive Lung Disease (GOLD), 2011. http://www.goldcopd.org. ">GOLD 2011</a>). National Institute for Health and Clinical Excellence (NICE) guidelines have recommended adding a LABA (or LAMA) to an ICS in a combination inhaler, if FEV<sub>1</sub> is &lt; 50% predicted. NICE has also recommended use of a combined LABA/ICS inhaler in people with stable COPD with an FEV<sub>1</sub> ≥ 50% who remain breathless or have exacerbations despite maintenance therapy with a LABA (<a href="./references#CD006826-bbs2-0078" title="CG101 Chronic obstructive pulmonary disease (update): NICE guideline, 2010. http://guidance.nice.org.uk/CG101/NICEGuidance/pdf/English. ">NICE 2010</a>; <a href="./references#CD006826-bbs2-0071" title="Global Strategy forDiagnosis , Management , Prevention ofCOPD . Global Initiative for Chronic Obstructive Lung Disease (GOLD), 2011. http://www.goldcopd.org. ">GOLD 2011</a>). </p> </section> <section id="CD006826-sec-0025"> <h3 class="title" id="CD006826-sec-0025">Description of the intervention</h3> <p>The two medicines of interest in this review are LABAs and ICS, with a particular focus on the comparison between use of a combination inhaler of LABA and ICS versus ICS alone. These medicines are taken by inhaler twice a day. </p> </section> <section id="CD006826-sec-0026"> <h3 class="title" id="CD006826-sec-0026">How the intervention might work</h3> <p>Both ICS and LABA components have been shown to prevent some COPD exacerbations and to improve health‐related quality of life. LABAs also improve symptoms and exercise tolerance (<a href="./references#CD006826-bbs2-0064" title="AppletonS , PooleP , SmithB , VealeA , LassersonTJ , ChanMM , et al. Long‐acting beta2‐agonists for poorly reversible chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews2006, Issue 3. [DOI: 10.1002/14651858.CD001104.pub2] ">Appleton 2006</a>). Inhaled corticosteroids reduce the frequency and severity of exacerbations (<a href="./references#CD006826-bbs2-0082" title="YangIA , ClarkeMS , SimEHA , FongKM . Inhaled corticosteroids for stable chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews2012, Issue 7. [DOI: 10.1002/14651858.CD002991.pub3] ">Yang 2012</a>) but have not yet been shown to slow disease progression or improve mortality rates (<a href="./references#CD006826-bbs2-0013" title="BriggsAH , GlickHA , Lozano‐OrtegaG , SpencerM , CalverleyPM , JonesPW , et al. Is treatment with ICS and LABA cost‐effective for COPD? Multinational economic analysis of the TORCH study. European Respiratory Journal2010; Vol. 35, issue 3:532‐9. CalverleyPM , AndersonJA , CelliB , FergusonGT , JenkinsC , JonesPW , et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease.[see comment]. New England Journal of Medicine2007; Vol. 356, issue 8:775‐89. CalverleyPMA , AndersonJA , CelliB , FergusonGT , JenkinsC , JonesPW , et al. Cardiovascular events in patients with chronic obstructive pulmonary disease: TORCH study results. Thorax2010;65:719‐25. CalverleyPMA , AndersonJA , CelliB , FergusonGT , JenkinsC , JonesPW , et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. New England Journal of Medicine2007;356(8):775‐89. CalverleyPMA , CelliB , FergusonG , JenkinsC , JonesPW , PrideNB , et al. Baseline characteristics of the first 5,000 COPD patients enrolled in the TORCH survival study. European Respiratory Journal2003;22 Suppl 45:578s. CelliB , CalverleyPMA , AndersonJA , FergusonGT , JenkinsC , JonesPW , et al. The TORCH (TOwards a Revolution in COPD Health) study: salmeterol/fluticasone propionate (SFC) improves health status, reduces exacerbations and improves lung function over three years. European Respiratory Journal2006;28 Suppl 50:34s. CelliB , VestboJ , JenkinsCR , JonesPW , FergusonGT , CalverleyPM , et al. Sex differences in mortality and clinical expressions of patients with chronic obstructive pulmonary disease: the TORCH experience. American Journal of Respiratory and Critical Care Medicine2011;183(3):317‐22. CelliBR , ThomasNE , AndersonJA , FergusonGT , JenkinsCR , JonesPW , et al. Effect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease: results from the TORCH study. American Journal of Respiratory and Critical Care Medicine2008;174(4):332‐8. CrimC , CalverleyPM , AndersonJA , CelliB , FergusonGT , JenkinsC , et al. Pneumonia risk in COPD patients receiving inhaled corticosteroids alone or in combination: TORCH study results. European Respiratory Journal2009;34(3):641‐7. FergusonGT , CalverleyPM , AndersonJA , JenkinsCR , JonesPW , WillitsLR , et al. Prevalence and progression of osteoporosis in patients with COPD: results from the TOwards a Revolution in COPD Health study. Chest2009; Vol. 136, issue 0012‐3692:1456‐65. FergusonGT , CalverleyPMA , AndersonJA , et al. The TORCH (TOwards a Revolution in COPD Health) study: salmeterol/fluticasone propionate (SFC) improves survival in COPD over three years. European Respiratory Journal2006;28 Suppl 50:34s. GlaxoSmithKlineSCO30003 . A multicentre, randomised, double‐blind, parallel group, placebo‐controlled study to investigate the long‐term effects of salmeterol/fluticasone propionate (SERETIDE/VIANI/ADVAIR) 50/500mcg bd, salmeterol 50mcg bd and fluticasone propionate 500mcg bd, all delivered via the DISKUS/ACCUHALER inhaler, on the survival of subjects with chronic obstructive pulmonary disease (COPD) over 3 years of treatment. GlaxoSmithKline Clinical Trial Register2006. HoughtonCM , LawsonN , BorrillZL , WixonCL , YoxallS , LangleySJ , et al. Comparison of the effects of salmeterol/fluticasone propionate with fluticasone propionate on airway physiology in adults with mild persistent asthma. Respiratory Research2007;8:52. JenkinsCR , CalverleyPMA , CelliB , FergusonG , JonesPW , PrideN , et al. Seasonal patterns of exacerbation rates in the TORCH survival study, 2007. http://www.abstracts2view.comA839. JenkinsCR , CelliB , AndersonJA , FergusonGT , JonesPW , VestboJ , et al. Seasonality and determinants of moderate and severe COPD exacerbations in the TORCH study. European Respiratory Journal2012;39(1):38‐45. JenkinsCR , JonesPW , CalverleyPM , CelliB , AndersonJA , FergusonGT , et al. Efficacy of salmeterol/fluticasone propionate by GOLD stage of chronic obstructive pulmonary disease: analysis from the randomised, placebo‐controlled TORCH study. Respiratory Research2009;10:59. JohnsonM , AgustiAG , BarnesNC . Reflections on TORCH: potential mechanisms for the survival benefit of salmeterol/fluticasone propionate in COPD patients. COPD2008;5(6):369‐75. JonesPW , AndersonJA , CalverleyPM , CelliBR , FergusonGT , JenkinsC , et al. TORCH Investigators. Health status in the TORCH study of COPD: treatment efficacy and other determinants of change. Respiratory Research2011;12:71. JonesPW , CalverleyP , CelliB , FergusonG , JenkinsC , PrideN . Trans‐regional validity of the SGRQ in the TORCH survival study, 2007. http://www.abstracts2view.comA122. McGarveyLP , JohnM , AndersonJA , ZvarichMT , WiseRA . Ascertainment of cause‐specific mortality in COPD: operations of the TORCH Clinical Endpoint Committee. Thorax2007;62:411‐5. NCT00268216 . See detailed description, 2000. http://clinicaltrials.gov/show/NCT00268216. [] SCO30003 . A multicentre, randomised, double‐blind, parallel group, placebo‐controlled study to investigate the long‐term effects of salmeterol/fluticasone propionate (SERETIDE®/VIANI®/ADVAIR®) 50/500mcg bd, salmeterol 50mcg bd and fluticasone propionate 500mcg bd, all delivered via the DISKUS®/ACCUHALER® inhaler, on the survival of subjects with chronic obstructive pulmonary disease (COPD) over 3 years of treatment, 2006. www.ctr.gsk.co.uk. VestboJ , AndersonJA , CalverleyPM , CelliB , FergusonGT , JenkinsC , et al. Adherence to inhaled therapy, mortality and hospital admission in COPD. Thorax2009;64(11):939‐43. VestboJ , CalverleyP , CelliB , FergusonG , JenkinsC , JonesP , et al. The TORCH (TOwards a Revolution in COPD Health) survival study protocol. European Respiratory Journal2004;24(2):206‐10. WiseRA , McGarveyLP , JohnM , AndersonJA , ZvarichMT . Reliability of cause‐specific mortality adjudication in a COPD clinical trial, 2007. http://www.abstracts2view.comA120. ">TORCH</a>). It is postulated that ICS work by reducing airways inflammation, but the dose response is not the same as that seen in asthma (<a href="./references#CD006826-bbs2-0071" title="Global Strategy forDiagnosis , Management , Prevention ofCOPD . Global Initiative for Chronic Obstructive Lung Disease (GOLD), 2011. http://www.goldcopd.org. ">GOLD 2011</a>). Other possibilities include the effects on chronic systemic inflammation and on autoimmunity. Finally, some evidence of a synergistic action has been reported when ICS and LABAs are jointly administered. LABAs and ICS may interact in a beneficial way, with corticosteroids preventing loss of function of beta<sub>2</sub>‐agonists with long‐term use, whereas beta<sub>2</sub>‐agonists may potentiate the local anti‐inflammatory actions of corticosteroids (<a href="./references#CD006826-bbs2-0065" title="BarnesPJ . Scientific rationale for inhaled combination therapy with long‐acting b2‐agonists and corticosteroids. European Respiratory Journal2002;19:182‐91. ">Barnes 2002</a>). </p> </section> <section id="CD006826-sec-0027"> <h3 class="title" id="CD006826-sec-0027">Why it is important to do this review</h3> <p>The aim of this series of reviews is to document available evidence for the relative effectiveness of two commonly used treatments in COPD (ICS and LABAs) when given in combination. The convenience and complementary effects of anti‐inflammatory and bronchodilator when combined in a single inhaler is appealing but needs to be borne out in trials. The possibility of harmful effects needs to be explored, especially in the light of concerns over pneumonia associated with ICS. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD006826-sec-0028" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD006826-sec-0028"></div> <p>To assess the efficacy and safety of combined long‐acting beta<sub>2</sub>‐agonist and inhaled corticosteroid (LABA/ICS) preparations, as measured by clinical endpoints and pulmonary function testing, compared with inhaled corticosteroids (ICS) alone, in the treatment of adults with chronic obstructive pulmonary disease (COPD). </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD006826-sec-0029" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD006826-sec-0029"></div> <section id="CD006826-sec-0030"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD006826-sec-0031"> <h4 class="title">Types of studies</h4> <p>Randomised, double‐blind, parallel‐group clinical trials of at least four weeks' duration comparing combination ICS and LABA with its component ICS alone. </p> </section> <section id="CD006826-sec-0032"> <h4 class="title">Types of participants</h4> <p>Adult patients (age &gt; 40 years) with known, stable COPD fulfilling American Thoracic Society (ATS), European Respiratory Society (ERS) and Global Initiative for Chronic Obstructive Lung Disease (GOLD) diagnostic criteria. Patients were to be clinically stable and without evidence of an exacerbation for one month before study entry. Patients with significant diseases other than COPD－a diagnosis of asthma, cystic fibrosis, bronchiectasis or other lung diseases－were excluded; however, patients with partial reversibility on pulmonary function testing were included. </p> </section> <section id="CD006826-sec-0033"> <h4 class="title">Types of interventions</h4> <p> <ul id="CD006826-list-0001"> <li> <p>Fluticasone propionate/salmeterol (FPS) versus fluticasone propionate (FP)</p> </li> <li> <p>Budesonide/formoterol (BDF) versus budesonide (BD)</p> </li> <li> <p>Mometasone furoate/formoterol (MF/F) versus mometasone furoate (MF)</p> </li> </ul> </p> <p>Study duration was a minimum of four weeks. Concomitant therapy was permitted; however, trials in which participants were randomly assigned to tiotropium+combined ICS/LABA therapy versus tiotropium+ICS were excluded from the review, as this comparison is already considered in <a href="./references#CD006826-bbs2-0075" title="KarnerC , CatesCJ . Combination inhaled steroid and long‐acting beta2‐agonist in addition to tiotropium versus tiotropium or combination alone for chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews2011, Issue 3. [DOI: 10.1002/14651858.CD008532.pub2] ">Karner 2011</a>. </p> <p>Studies in which the ICS dose in the ICS/LABA arm  was less than 80% of the ICS dose in the ICS‐only arm were excluded. </p> </section> <section id="CD006826-sec-0034"> <h4 class="title">Types of outcome measures</h4> <section id="CD006826-sec-0035"> <h5 class="title">Primary outcomes</h5> <p> <ul id="CD006826-list-0002"> <li> <p>All exacerbations</p> </li> <li> <p>Hospitalisations due to COPD exacerbation</p> </li> <li> <p>Mortality</p> </li> <li> <p>Pneumonia</p> </li> </ul> </p> </section> <section id="CD006826-sec-0036"> <h5 class="title">Secondary outcomes</h5> <p> <ul id="CD006826-list-0003"> <li> <p>Change in FEV<sub>1</sub> and change in FVC: trough, peak and average; and other measures of pulmonary function </p> </li> <li> <p>Exercise performance－six‐minute walk and other measures</p> </li> <li> <p>Quality of life (as measured on a validated scale, e.g. St George's Respiratory Questionnaire (SGRQ), Chronic Respiratory Disease Questionnaire (CRDQ)) </p> </li> <li> <p>Self‐rated symptom score/symptoms of breathlessness</p> </li> <li> <p>Inhaled rescue medication used during the treatment period and concomitant medication usage, including antibiotics and steroids </p> </li> <li> <p>Number of days (or nights) participant experienced symptoms</p> </li> <li> <p>Area under the curve as the beta<sub>2</sub>‐agonist response after the first and last morning doses of LABA/ICS </p> </li> <li> <p>Per cent response to salbutamol from baseline FEV<sub>1</sub>, with tachyphylaxis noted </p> </li> <li> <p>Pharmacoeconomic advantages</p> </li> <li> <p>Adverse events－palpitations, tremor, hoarseness/dysphonia, oral candidiasis, cataracts, skin bruising, bone fracture, bone density, plasma cortisol level </p> </li> <li> <p>Rate of withdrawal due to lack of efficacy or COPD deterioration .</p> </li> <li> <p>Rate of withdrawal due to adverse events</p> </li> </ul> </p> </section> </section> </section> <section id="CD006826-sec-0037"> <h3 class="title">Search methods for identification of studies</h3> <section id="CD006826-sec-0038"> <h4 class="title">Electronic searches</h4> <p>We searched the Cochrane Airways Group Specialised Register of trials, which is maintained by the Trials Search Co‐ordinator for the Group. The Register contains trial reports identified through systematic searches of bibliographic databases, including the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, EMBASE, CINAHL, AMED, and PsycINFO, and by handsearching of respiratory journals and meeting abstracts (please see <a href="./appendices#CD006826-sec-0130">Appendix 1</a> for further details). All records in the Specialised Register coded as 'COPD' were searched using the following terms:<br/> <br/> (((beta* and agonist*) and long*) or ((beta* and adrenergic*) and long*) and (*steroid or steroid* OR corticosteroid*)) or (fluticasone and salmeterol) or Seretide or Advair or (formoterol and budesonide) or Symbicort </p> <p>The search was conducted in June 2013, and no restriction on the language of the publication was applied. </p> </section> <section id="CD006826-sec-0039"> <h4 class="title">Searching other resources</h4> <p>We reviewed reference lists of all primary studies and review articles for additional references. We contacted authors of identified randomised trials about other published and unpublished studies. In addition, we contacted Allen &amp; Hanburys Ltd, for GlaxoSmithKline (GSK), the manufacturer of fluticasone/salmeterol (Advair/Seretide/Viani), and AstraZeneca, which manufactures budesonide/formoterol (Symbicort), and consulted their online registers of trials. </p> </section> </section> <section id="CD006826-sec-0040"> <h3 class="title" id="CD006826-sec-0040">Data collection and analysis</h3> <section id="CD006826-sec-0041"> <h4 class="title">Selection of studies</h4> <p>Step I. Two review authors independently identified abstracts of trials that appeared potentially relevant.<br/> <br/> Step II. Using the full text of each study, two review authors independently selected trials for inclusion in the review. Simple agreement was required, and third party adjudication was used to resolve differences.<br/> <br/> Step III. After a preliminary review of all studies to confirm the basic requirements, two review authors assessed the methodological quality of included trials with particular emphasis on concealment of allocation, which was ranked using the Cochrane risk of bias tool (<a href="./references#CD006826-bbs2-0073" title="HigginsJPT , GreenS , editors. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. www.cochrane‐handbook.org. ">Higgins 2011</a>). </p> </section> <section id="CD006826-sec-0042"> <h4 class="title">Data extraction and management</h4> <p>Two review authors independently extracted data from included trials and entered results into the Cochrane Collaboration software program (<a href="./references#CD006826-bbs2-0079" title="The Cochrane Collaboration. Copenhagen: The Nordic Cochrane Centre. Review Manager (RevMan). Version 5.2. The Cochrane Collaboration. Copenhagen: The Nordic Cochrane Centre, 2012. ">RevMan 5.2</a>). In some cases, we estimated information regarding outcomes from graphs. Data extraction included the following items. </p> <p> <ul id="CD006826-list-0004"> <li> <p><b>Population</b>: age, gender, smoking status, study setting (country, practice setting), inclusion and exclusion criteria. </p> </li> <li> <p><b>Intervention</b>: dose, delivery device, duration. </p> </li> <li> <p><b>Control</b>: concurrent treatments (ipratropium, beta<sub>2</sub>‐agonist, inhaled and systemic corticosteroids). </p> </li> <li> <p><b>Outcomes</b>: Pulmonary function measures (baseline and follow‐up FEV<sub>1</sub> and FVC), timing of pulmonary function measures, 6‐minute walk, urgent visits, admissions, self‐rated symptom score/symptoms, quality‐of‐life instruments, adverse events (palpitations, dry mouth, blurred vision, urinary obstruction and constipation), assessors, adjudicator of clinical endpoints. Mortality outcome data were collected from studies of longer than one year's duration, when they were available. </p> </li> <li> <p><b>Design</b>: method of randomisation, presence and type of run‐in period, study design (parallel, cross‐over). </p> </li> </ul> </p> </section> <section id="CD006826-sec-0043"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>The risk of bias in included studies was assessed using the Cochrane Collaboration's risk of bias tool (<a href="./references#CD006826-bbs2-0073" title="HigginsJPT , GreenS , editors. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. www.cochrane‐handbook.org. ">Higgins 2011</a>). Two review authors (SJM, AK) assessed the risk of bias for all included studies with regard to random sequence generation, allocation concealment, blinding, incomplete outcome data and selective outcome reporting. Each item was assessed as high, low or unclear risk of bias when relevant information was reported in the randomised controlled trial. </p> </section> <section id="CD006826-sec-0044"> <h4 class="title">Measures of treatment effect</h4> <p>For continuous variables, a fixed‐effect mean difference (MD) was used for outcomes measured on the same metric. Standardised mean difference (SMD) and 95% confidence interval (CI) were calculated for outcomes for which data were combined from studies using different metrics. All similar studies were to be pooled using fixed‐effect MD/SMD and 95% CIs. When mean treatment differences were reported, data were entered as generic inverse variance (GIV), provided a standard error for the difference could be extracted or imputed. When this method was used, the effect size was reported from the original papers, for example, as rate ratio. This method (GIV) was not available when the protocol was written for the review, so it was not prespecified. </p> <p>For dichotomous variables, a fixed‐effect odds ratio (OR) with 95% CI was calculated for individual studies. All similar studies were pooled using fixed‐effect OR and 95% CIs. </p> <p>The reported confidence interval or P value was used to calculate standard deviations, or standard errors, for results when these were not reported and could not be obtained from the authors of the papers. </p> </section> <section id="CD006826-sec-0045"> <h4 class="title">Unit of analysis issues</h4> <p>The unit of analysis was the participant, so dichotomous outcomes were analysed for participants who suffered one or more events (such as admission to hospital). </p> </section> <section id="CD006826-sec-0046"> <h4 class="title">Dealing with missing data</h4> <p>If outcome data or information on trial design was missing, we attempted to contact authors for clarification. </p> </section> <section id="CD006826-sec-0047"> <h4 class="title">Assessment of heterogeneity</h4> <p>For pooled effects, heterogeneity was tested using the I<sup>2</sup> measurement of the degree of variation between studies, not attributable by the play of chance. If heterogeneity was found (I<sup>2</sup> statistic &gt; 20%), a random‐effects model was used to determine the impact of heterogeneity on the overall pooled effect. In addition, the robustness of the results was tested when possible, using a sensitivity analysis based on the quality of the trials. </p> <p>I<sup>2</sup> (<a href="./references#CD006826-bbs2-0073" title="HigginsJPT , GreenS , editors. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. www.cochrane‐handbook.org. ">Higgins 2011</a>) was also considered and interpreted in relation to the following guidance. </p> <p> <ul id="CD006826-list-0005"> <li> <p>0% to 40%: might not be important.</p> </li> <li> <p>30% to 60%: may represent moderate heterogeneity.</p> </li> <li> <p>50% to 90%: may represent substantial heterogeneity.</p> </li> <li> <p>75% to 100%: may represent considerable heterogeneity.</p> </li> </ul> </p> <p>The Chi<sup>2</sup> test was similarly considered (P value &lt; 0.10), but we regarded I<sup>2</sup> as our primary measure of heterogeneity. </p> </section> <section id="CD006826-sec-0048"> <h4 class="title">Assessment of reporting biases</h4> <p>We planned to evaluate publication bias using visual inspection of funnel plots if the number of trials aggregated in the analyses was adequate (&gt; 10). However, we recognised that an asymmetrical funnel plot can reflect heterogeneity, outcome reporting bias and small study effects and therefore is not necessarily a reflection of publication bias. </p> </section> <section id="CD006826-sec-0049"> <h4 class="title">Data synthesis</h4> <p>We combined trials using <a href="./references#CD006826-bbs2-0079" title="The Cochrane Collaboration. Copenhagen: The Nordic Cochrane Centre. Review Manager (RevMan). Version 5.2. The Cochrane Collaboration. Copenhagen: The Nordic Cochrane Centre, 2012. ">RevMan 5.2</a>. Continuous variables were combined using an MD or an SMD and were reported together with a 95% CI. We combined dichotomous variables using an OR with 95% CI. The pooled OR and its 95% CI were used to calculate numbers needed to treat for an additional harmful/beneficial outcome (NNTH/NNTB) using <a href="./references#CD006826-bbs2-0081" title="CatesCJ . Visual Rx. Version 3.0, 2008, www.nntonline.net. ">Visual Rx</a>. The control event rates used to calculate illustrative NNTHs and NNTBs were taken from the event rates in the individual trials and have been reported along with the corresponding duration of the trial (because NNTH and NNTB are time dependent; <a href="./references#CD006826-bbs2-0066" title="CatesC J . Inhaled corticosteroids in COPD: quantifying risks and benefits. Thorax [published online first] 14 December 2012. [DOI: 10.1136/thoraxjnl‐2012‐202959] ">Cates 2012</a>). </p> </section> <section id="CD006826-sec-0050"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>Although we separated steroids and long‐acting beta<sub>2</sub>‐agonists by type, we pooled studies with differing dosages of the same drug. We planned <i>a priori</i> subgroups as follows. </p> <p> <ul id="CD006826-list-0006"> <li> <p>Disease severity (related to baseline FEV<sub>1</sub> and placebo group exacerbation rate) according to GOLD staging = 2A, 2B (moderate COPD, characterised by deteriorating lung function (A = FEV<sub>1</sub> &lt; 80% predicted; B = FEV<sub>1</sub> &lt; 50% predicted) and progression of symptoms) and 3 (severe COPD, characterised by severe airflow limitation (FEV<sub>1</sub> &lt; 30% predicted) and the presence of respiratory failure or clinical signs of right heart failure (<a href="./references#CD006826-bbs2-0071" title="Global Strategy forDiagnosis , Management , Prevention ofCOPD . Global Initiative for Chronic Obstructive Lung Disease (GOLD), 2011. http://www.goldcopd.org. ">GOLD 2011</a>)). </p> </li> <li> <p>Prior inhaled corticosteroid plus long‐acting beta<sub>2</sub>‐agonist use (dichotomised as yes/no). </p> </li> <li> <p>Concurrent therapy with routine beta<sub>2</sub>‐agonist use (short‐ or long‐acting) and corticosteroid (systemic or inhaled) or theophylline use (dichotomised as yes/no). </p> </li> <li> <p>Reversibility of airflow obstruction with beta<sub>2</sub>‐agonist therapy (dichotomised as partial/none). Definition: &gt; 12% and &gt; 200 mL from baseline FEV<sub>1</sub> or &gt; 12% as a per cent of the predicted normal value following metered‐dose inhaler (MDI) salbutamol 200 to 400. </p> </li> <li> <p>Dose, duration and delivery method of therapy.</p> </li> </ul> </p> </section> <section id="CD006826-sec-0051"> <h4 class="title">Sensitivity analysis</h4> <p>In addition, sensitivity analyses were performed using the following domains.</p> <p> <ul id="CD006826-list-0007"> <li> <p>Methodological quality: using a quality‐weighted analysis to allow for the use of all trials. </p> </li> <li> <p>Random‐effects versus fixed‐effect modelling.</p> </li> </ul> </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD006826-sec-0052" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD006826-sec-0052"></div> <section id="CD006826-sec-0053"> <h3 class="title">Description of studies</h3> <section id="CD006826-sec-0054"> <h4 class="title">Results of the search</h4> <p>For details of the search history, see <a href="#CD006826-tbl-0002">Table 1</a>. For the study flow diagram, see <a href="#CD006826-fig-0001">Figure 1</a>. </p> <div class="figure" id="CD006826-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Study flow diagram." data-id="CD006826-fig-0001" src="/cdsr/doi/10.1002/14651858.CD006826.pub2/media/CDSR/CD006826/image_n/nCD006826-AFig-FIG01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> </div> <div class="table" id="CD006826-tbl-0002"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Search history</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Version</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Detail</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1st published version－Issue 4, 2003 (all years to April 2002)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>References identified: 34<br/> References retrieved: 7<br/> Studies excluded: 3 (Cazzola 2000; Chapman 2002; Soriano 2002)<br/> Studies identified from supplementary searching: 4 (Dal Negro 2003; <a href="./references#CD006826-bbs2-0004" title="HananiaNA , DarkenP , HorstmanD , ReisnerC , LeeB , DavisS , et al. The efficacy and safety of fluticasone propionate (250 micro g)/salmeterol (50 micro g) combined in the diskus inhaler for the treatment of COPD. Chest2003;124(3):834‐43. HananiaNA , RamsdellJ , PayneK , DavisS , HorstmanD , LeeB , et al. Improvements in airflow and dyspnea in COPD patients following 24 weeks treatment with salmeterol 50mcg and fluticasone propionate 250mcg alone or in combination via the diskus. American Journal of Respiratory &amp; Critical Care Medicine2001;163(5 Suppl):A279. HorstmanD , DarkenP , DavisS , LeeB . Improvements in FEV1 and symptoms in poorly reversible COPD patients following treatment with salmeterol 50mcg/fluticasone propionate 250mcg combination [Abstract]. European Respiratory Journal2003;22 Suppl 45:P434. MahlerDA , DarkenP , BrownCP , KnobilK . Predicting lung function responses to combination therapy in chronic obstructive pulmonary disease (COPD) [Abstract]. National COPD Conference; November 14‐15, 2003; Arlington, Virginia. Abstract 1081. MahlerDA , DarkenP , BrownCP , KnobilK . Predicting lung function responses to salmeterol/fluticasone propionate combination therapy in COPD [Abstract]. European Respiratory Journal2003;22 Suppl 45:P429. SFCA3007 . A randomized, double‐blind, placebo‐controlled, parallel‐group trial evaluating the safety and efficacy of the DISKUS formulations of salmeterol (SAL) 50mcg BID and fluticasone propionate (FP) 250mcg BID individually and in combination as salmeterol 50mcg/fluticasone propionate 250mcg BID (SFC 50/250) compared to placebo in COPD subjects. GlaxoSmithKline Clinical Trials Register (http:ctr.gsk.co.uk)2005. SpencerM , WireP , LeeB , ChangCN , DarkenP , HorstmanD . Patients with COPD using salmeterol/fluticasone propionate combination therapy experience improved quality of life. European Respiratory Journal2003;22 Suppl 45:51s. SpencerMD , KariaN , AndersonJ . The clinical significance of treatment benefits with the salmeterol/fluticasone propionate 50/500mcg combination in COPD. European Respiratory Journal2004;24 Suppl 48:290s. ">Hanania 2003</a>－both included; Cazzola 2002a; Cazzola 2004－both excluded)<br/> Studies included: 4 </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2nd published version－Issue 3, 2004 (April 2003 to April 2004)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>References identified: 12<br/> References retrieved: 3 (2 papers full publication of a previously included or cited studies study (Dal Negro 2003; <a href="./references#CD006826-bbs2-0004" title="HananiaNA , DarkenP , HorstmanD , ReisnerC , LeeB , DavisS , et al. The efficacy and safety of fluticasone propionate (250 micro g)/salmeterol (50 micro g) combined in the diskus inhaler for the treatment of COPD. Chest2003;124(3):834‐43. HananiaNA , RamsdellJ , PayneK , DavisS , HorstmanD , LeeB , et al. Improvements in airflow and dyspnea in COPD patients following 24 weeks treatment with salmeterol 50mcg and fluticasone propionate 250mcg alone or in combination via the diskus. American Journal of Respiratory &amp; Critical Care Medicine2001;163(5 Suppl):A279. HorstmanD , DarkenP , DavisS , LeeB . Improvements in FEV1 and symptoms in poorly reversible COPD patients following treatment with salmeterol 50mcg/fluticasone propionate 250mcg combination [Abstract]. European Respiratory Journal2003;22 Suppl 45:P434. MahlerDA , DarkenP , BrownCP , KnobilK . Predicting lung function responses to combination therapy in chronic obstructive pulmonary disease (COPD) [Abstract]. National COPD Conference; November 14‐15, 2003; Arlington, Virginia. Abstract 1081. MahlerDA , DarkenP , BrownCP , KnobilK . Predicting lung function responses to salmeterol/fluticasone propionate combination therapy in COPD [Abstract]. European Respiratory Journal2003;22 Suppl 45:P429. SFCA3007 . A randomized, double‐blind, placebo‐controlled, parallel‐group trial evaluating the safety and efficacy of the DISKUS formulations of salmeterol (SAL) 50mcg BID and fluticasone propionate (FP) 250mcg BID individually and in combination as salmeterol 50mcg/fluticasone propionate 250mcg BID (SFC 50/250) compared to placebo in COPD subjects. GlaxoSmithKline Clinical Trials Register (http:ctr.gsk.co.uk)2005. SpencerM , WireP , LeeB , ChangCN , DarkenP , HorstmanD . Patients with COPD using salmeterol/fluticasone propionate combination therapy experience improved quality of life. European Respiratory Journal2003;22 Suppl 45:51s. SpencerMD , KariaN , AndersonJ . The clinical significance of treatment benefits with the salmeterol/fluticasone propionate 50/500mcg combination in COPD. European Respiratory Journal2004;24 Suppl 48:290s. ">Hanania 2003</a>)). Handsearching identified two further references to the COSMIC 2003 study<br/> Studies identified from supplementary searching: 1 (<a href="./references#CD006826-bbs2-0014" title="CalverleyP , PauwelsR , VestboJ , JonesP , PrideN , GulsvikA , et al. Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial. Lancet2003;361(9356):449‐56. CalverleyPMA , PauwelsRA , VestboJ , JonesPW , PrideNB , GulsvikA , et al. Clinical improvements with salmeterol / fluticasone propionate combination in differing severities of COPD, 2003. http://www.abstracts2view.comA035 [Poster D50]. CalverleyPMA , PauwelsRA , VestboJ , JonesPW , PrideNB , GulsvikA , et al. Salmeterol/Fluticasone propionate combination for one year provides greater clinical benefit than its individual components. Proceedings of the 98th International American Thoracic Society Conference http://www.abstracts‐on‐line.com/abstracts/ATS; May 17‐22, 2002; Atlanta, Georgia. A98 [Poster 306]. CalverlyPMA , PauwelsR , VestboJ , JonesP , PrideN , GulsvikA , et al. Safety of salmeterol/fluticasone propionate combination in the treatment of chronic obstructive pulmonary disease. European Respiratory Journal2002;20 Suppl 38:242 [P1572]. HunjanMK , ChandlerF . Numbers needed to treat (NNT) to avoid an exacerbation in patients with chronic obstructive pulmonary disease (COPD) using salmeterol/fluticasone propionate combination (SFC) and associated costs [Abstract]. American Thoracic Society 100th International Conference; May 21‐26, 2004; Orlando, Florida. D22 [Poster 503]. HunjanMK , WilliamsDT . Costs of avoiding exacerbations in patients with chronic obstructive pulmonary disease (COPD) treated with salmeterol/ fluticasone propionate combination (seretide) and salmeterol. European Respiratory Journal2004;24 Suppl 48:291s. HunjanMK , WilliamsDT . Salmeterol/ fluticasone propionate combination is clinically effective in avoiding exacerbations in patients with moderate/severe COPD. European Respiratory Journal2004;24 Suppl 48:513s. JonesPW , EdinHM , AndersonJ . Salmeterol/fluticasone propionate combination improves health status in COPD patients. Proceedings of the 98th International American Thoracic Society Conference http://www.abstracts‐on‐line.com/abstracts/ATS; May 17‐22, 2002; Atlanta, Georgia. A39 [Poster K39]. JonesPW , StåhlE . Budesonide /formoterol sustains clinically relevant improvements in health status in COPD [Abstract]. European Respiratory Journal2005;26 Suppl 49:Abstract 1352. JonesPW , VestboJ , PauwelsRA , CalverleyPMA , AndersonJA , SpencerMD . Informative drop out in COPD studies: investigation of health status of withdrawals in the TRISTAN study. Proceedings of the 13th ERS Annual Congress; September 27, 2003; Vienna, Austria. P1593. NitschmannS . Inhalational combination therapy in chronic obstructive lung disease. Tristan study. German Internist2004;45(6):727‐8. PauwelsR , VestboJ , CalverleyPMA , JonesPW , PrideNB , GulsvikA . Characterization of exacerbations in the TRISTAN study of salmeterol / fluticasone propionate (SFC) combination in moderate to severe COPD, 2006. http://www.abstracts2view.com. PauwelsRA , CalverlyPMA , VestboJ , JonesPW , PrideN , GulsvikA , et al. Reduction of exacerbations with salmeterol/fluticasone combination 50/500 mcg bd in the treatment of chronic obstructive pulmonary disease. European Respiratory Journal2002;20 Suppl 38:240 [P1569]. SFCB3024 . A multicentre, randomised, double‐blind, parallel group, placebo‐controlled study to compare the efficacy and safety of the salmeterol/FP combination product at a strength of 50/500mcg bd with salmeterol 50mcg bd alone and FP 500mcg bd alone, delivered via the DISKUS™/ACCUHALER™, in the treatment of subjects with chronic obstructive pulmonary disease (COPD) for 12 months. GlaxoSmithKline Clinical Trials Register (http:ctr.gsk.co.uk)2005. SpencerM , BriggsAH , GrossmanRF , RanceL . Development of an economic model to assess the cost effectiveness of treatment interventions for chronic obstructive pulmonary disease. Pharmacoeconomics2005;23(6):619‐37. SpencerMD , KariaN , AndersonJ . The clinical significance of treatment benefits with the salmeterol/fluticasone propionate 50/500mcg combination in COPD. European Respiratory Journal2004;24 Suppl 48:290s. VestboJ , CalverleyPMA , PauwelsR , JonesP , PrideN , GulsvikA , et al. Absence of gender susceptibility to the combination of salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease. European Respiratory Journal2002;20 Suppl 38:240 [P1570]. VestboJ , PauwelsR , AndersonJA , JonesP , CalverleyP . Early onset of effect of salmeterol and fluticasone propionate in chronic obstructive pulmonary disease. Thorax2005;60(4):301‐4. VestboJ , PauwelsRS , CalverleyPMA , JonesPW , PrideNB , GulsvikA . Salmeterol / fluticasone propionate combination produces improvement in lung function detectable within 24 hours in moderate to severe COPD, 2003. http://www.abstracts2view.com. VestboJ , SorianoJB , AndersonJA , CalverleyP , PauwelsR , JonesP . Gender does not influence the response to the combination of salmeterol and fluticasone propionate in COPD. Respiratory Medicine2004;98(11):1045‐50. ">TRISTAN</a>)<br/> New studies included: 2<br/> Total studies included: 6 </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3rd published version－Issue 3, 2005 (April 2004 to April 2005)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>References identified: 52<br/> References retrieved: 46 (references to studies already included/excluded/ongoing: 24)<br/> New unique studies identified: 10 (ongoing studies: 2)<br/> New studies included: 0<br/> Total studies included: 6 </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4th published version－April 2005 to April 2007</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>References identified: 66<br/> References retrieved: 27 (references to studies already included/excluded/ongoing)<br/> New unique studies identified: 8 (ongoing studies: 0)<br/> New studies included: 1<br/> Total studies included: 7 </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Present version－April 2007 to June 2013</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>References identified: 209<br/> References retrieved: 63 (references to studies already included/excluded/ongoing: 6)<br/> New unique studies identified: 57 (ongoing studies: 0)<br/> New studies included: 8<br/> Total studies included: 15 </p> </td> </tr> </tbody> </table> </div> </section> <section id="CD006826-sec-0055"> <h4 class="title">Included studies</h4> <p>Fifteen studies, with a total of 7814 participants, met the review entry criteria. For a full description of baseline characteristics, methods used and inclusion and exclusion entry criteria of individual studies, see <a href="./references#CD006826-sec-0145" title="">Characteristics of included studies</a>. </p> <section id="CD006826-sec-0056"> <h5 class="title">Design</h5> <p>All trials had a randomised, double‐blind, parallel‐group design. Details of randomisation and blinding are included in <a href="./references#CD006826-sec-0145" title="">Characteristics of included studies</a>. </p> </section> <section id="CD006826-sec-0057"> <h5 class="title">Participants</h5> <p>Participants suffered from COPD, with variable definitions of COPD and reversibility. COPD was defined by national or international criteria, including ATS (<a href="./references#CD006826-bbs2-0004" title="HananiaNA , DarkenP , HorstmanD , ReisnerC , LeeB , DavisS , et al. The efficacy and safety of fluticasone propionate (250 micro g)/salmeterol (50 micro g) combined in the diskus inhaler for the treatment of COPD. Chest2003;124(3):834‐43. HananiaNA , RamsdellJ , PayneK , DavisS , HorstmanD , LeeB , et al. Improvements in airflow and dyspnea in COPD patients following 24 weeks treatment with salmeterol 50mcg and fluticasone propionate 250mcg alone or in combination via the diskus. American Journal of Respiratory &amp; Critical Care Medicine2001;163(5 Suppl):A279. HorstmanD , DarkenP , DavisS , LeeB . Improvements in FEV1 and symptoms in poorly reversible COPD patients following treatment with salmeterol 50mcg/fluticasone propionate 250mcg combination [Abstract]. European Respiratory Journal2003;22 Suppl 45:P434. MahlerDA , DarkenP , BrownCP , KnobilK . Predicting lung function responses to combination therapy in chronic obstructive pulmonary disease (COPD) [Abstract]. National COPD Conference; November 14‐15, 2003; Arlington, Virginia. Abstract 1081. MahlerDA , DarkenP , BrownCP , KnobilK . Predicting lung function responses to salmeterol/fluticasone propionate combination therapy in COPD [Abstract]. European Respiratory Journal2003;22 Suppl 45:P429. SFCA3007 . A randomized, double‐blind, placebo‐controlled, parallel‐group trial evaluating the safety and efficacy of the DISKUS formulations of salmeterol (SAL) 50mcg BID and fluticasone propionate (FP) 250mcg BID individually and in combination as salmeterol 50mcg/fluticasone propionate 250mcg BID (SFC 50/250) compared to placebo in COPD subjects. GlaxoSmithKline Clinical Trials Register (http:ctr.gsk.co.uk)2005. SpencerM , WireP , LeeB , ChangCN , DarkenP , HorstmanD . Patients with COPD using salmeterol/fluticasone propionate combination therapy experience improved quality of life. European Respiratory Journal2003;22 Suppl 45:51s. SpencerMD , KariaN , AndersonJ . The clinical significance of treatment benefits with the salmeterol/fluticasone propionate 50/500mcg combination in COPD. European Respiratory Journal2004;24 Suppl 48:290s. ">Hanania 2003</a>; <a href="./references#CD006826-bbs2-0006" title="MahlerDA , DarkenP , BrownCP , KnobilK . Predicting lung function responses to combination therapy in chronic obstructive pulmonary disease (COPD), 2003. http://www.abstracts2view.com. MahlerDA , WireP , HorstmanD , ChangCN , YatesJ , FischerT , et al. Effectiveness of fluticasone propionate and salmeterol combination delivered via the diskus device in the treatment of chronic obstructive pulmonary disease. American Journal of Respiratory Critical Care Medicine2002;166(8):1084‐91. SFCA3006 . A randomized, double‐blind, placebo‐controlled, parallel‐group trial evaluating the safety and efficacy of the DISKUS formulations of salmeterol (SAL) 50mcg BID and fluticasone propionate (FP) 500mcg BID individually and in combination as salmeterol 50mcg/fluticasone propionate 500mcg BID (SFC 50/500) compared to placebo in COPD subjects. GlaxoSmithKline Clinical Trials Register (http:ctr.gsk.co.uk)2005. SpencerM , WireP , LeeB , ChangCN , DarkenP , HorstmanD . Patients with COPD using salmeterol/fluticasone propionate combination therapy experience improved quality of life. European Respiratory Journal2003;22 Suppl 45:51s. SpencerMD , AndersonJA . Salmeterol/fluticasone combination produces clinically important benefits in dyspnea and fatigue [Abstract]. American Thoracic Society 2005 International Conference; May 20‐25, 2005; San Diego, California. B93 [Poster 308]. SpencerMD , KariaN , AndersonJ . The clinical significance of treatment benefits with the salmeterol/fluticasone propionate 50/500mcg combination in COPD. European Respiratory Journal2004;24 Suppl 48:290s. ">Mahler 2002</a>), ERS (<a href="./references#CD006826-bbs2-0013" title="BriggsAH , GlickHA , Lozano‐OrtegaG , SpencerM , CalverleyPM , JonesPW , et al. Is treatment with ICS and LABA cost‐effective for COPD? Multinational economic analysis of the TORCH study. European Respiratory Journal2010; Vol. 35, issue 3:532‐9. CalverleyPM , AndersonJA , CelliB , FergusonGT , JenkinsC , JonesPW , et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease.[see comment]. New England Journal of Medicine2007; Vol. 356, issue 8:775‐89. CalverleyPMA , AndersonJA , CelliB , FergusonGT , JenkinsC , JonesPW , et al. Cardiovascular events in patients with chronic obstructive pulmonary disease: TORCH study results. Thorax2010;65:719‐25. CalverleyPMA , AndersonJA , CelliB , FergusonGT , JenkinsC , JonesPW , et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. New England Journal of Medicine2007;356(8):775‐89. CalverleyPMA , CelliB , FergusonG , JenkinsC , JonesPW , PrideNB , et al. Baseline characteristics of the first 5,000 COPD patients enrolled in the TORCH survival study. European Respiratory Journal2003;22 Suppl 45:578s. CelliB , CalverleyPMA , AndersonJA , FergusonGT , JenkinsC , JonesPW , et al. The TORCH (TOwards a Revolution in COPD Health) study: salmeterol/fluticasone propionate (SFC) improves health status, reduces exacerbations and improves lung function over three years. European Respiratory Journal2006;28 Suppl 50:34s. CelliB , VestboJ , JenkinsCR , JonesPW , FergusonGT , CalverleyPM , et al. Sex differences in mortality and clinical expressions of patients with chronic obstructive pulmonary disease: the TORCH experience. American Journal of Respiratory and Critical Care Medicine2011;183(3):317‐22. CelliBR , ThomasNE , AndersonJA , FergusonGT , JenkinsCR , JonesPW , et al. Effect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease: results from the TORCH study. American Journal of Respiratory and Critical Care Medicine2008;174(4):332‐8. CrimC , CalverleyPM , AndersonJA , CelliB , FergusonGT , JenkinsC , et al. Pneumonia risk in COPD patients receiving inhaled corticosteroids alone or in combination: TORCH study results. European Respiratory Journal2009;34(3):641‐7. FergusonGT , CalverleyPM , AndersonJA , JenkinsCR , JonesPW , WillitsLR , et al. Prevalence and progression of osteoporosis in patients with COPD: results from the TOwards a Revolution in COPD Health study. Chest2009; Vol. 136, issue 0012‐3692:1456‐65. FergusonGT , CalverleyPMA , AndersonJA , et al. The TORCH (TOwards a Revolution in COPD Health) study: salmeterol/fluticasone propionate (SFC) improves survival in COPD over three years. European Respiratory Journal2006;28 Suppl 50:34s. GlaxoSmithKlineSCO30003 . A multicentre, randomised, double‐blind, parallel group, placebo‐controlled study to investigate the long‐term effects of salmeterol/fluticasone propionate (SERETIDE/VIANI/ADVAIR) 50/500mcg bd, salmeterol 50mcg bd and fluticasone propionate 500mcg bd, all delivered via the DISKUS/ACCUHALER inhaler, on the survival of subjects with chronic obstructive pulmonary disease (COPD) over 3 years of treatment. GlaxoSmithKline Clinical Trial Register2006. HoughtonCM , LawsonN , BorrillZL , WixonCL , YoxallS , LangleySJ , et al. Comparison of the effects of salmeterol/fluticasone propionate with fluticasone propionate on airway physiology in adults with mild persistent asthma. Respiratory Research2007;8:52. JenkinsCR , CalverleyPMA , CelliB , FergusonG , JonesPW , PrideN , et al. Seasonal patterns of exacerbation rates in the TORCH survival study, 2007. http://www.abstracts2view.comA839. JenkinsCR , CelliB , AndersonJA , FergusonGT , JonesPW , VestboJ , et al. Seasonality and determinants of moderate and severe COPD exacerbations in the TORCH study. European Respiratory Journal2012;39(1):38‐45. JenkinsCR , JonesPW , CalverleyPM , CelliB , AndersonJA , FergusonGT , et al. Efficacy of salmeterol/fluticasone propionate by GOLD stage of chronic obstructive pulmonary disease: analysis from the randomised, placebo‐controlled TORCH study. Respiratory Research2009;10:59. JohnsonM , AgustiAG , BarnesNC . Reflections on TORCH: potential mechanisms for the survival benefit of salmeterol/fluticasone propionate in COPD patients. COPD2008;5(6):369‐75. JonesPW , AndersonJA , CalverleyPM , CelliBR , FergusonGT , JenkinsC , et al. TORCH Investigators. Health status in the TORCH study of COPD: treatment efficacy and other determinants of change. Respiratory Research2011;12:71. JonesPW , CalverleyP , CelliB , FergusonG , JenkinsC , PrideN . Trans‐regional validity of the SGRQ in the TORCH survival study, 2007. http://www.abstracts2view.comA122. McGarveyLP , JohnM , AndersonJA , ZvarichMT , WiseRA . Ascertainment of cause‐specific mortality in COPD: operations of the TORCH Clinical Endpoint Committee. Thorax2007;62:411‐5. NCT00268216 . See detailed description, 2000. http://clinicaltrials.gov/show/NCT00268216. [] SCO30003 . A multicentre, randomised, double‐blind, parallel group, placebo‐controlled study to investigate the long‐term effects of salmeterol/fluticasone propionate (SERETIDE®/VIANI®/ADVAIR®) 50/500mcg bd, salmeterol 50mcg bd and fluticasone propionate 500mcg bd, all delivered via the DISKUS®/ACCUHALER® inhaler, on the survival of subjects with chronic obstructive pulmonary disease (COPD) over 3 years of treatment, 2006. www.ctr.gsk.co.uk. VestboJ , AndersonJA , CalverleyPM , CelliB , FergusonGT , JenkinsC , et al. Adherence to inhaled therapy, mortality and hospital admission in COPD. Thorax2009;64(11):939‐43. VestboJ , CalverleyP , CelliB , FergusonG , JenkinsC , JonesP , et al. The TORCH (TOwards a Revolution in COPD Health) survival study protocol. European Respiratory Journal2004;24(2):206‐10. WiseRA , McGarveyLP , JohnM , AndersonJA , ZvarichMT . Reliability of cause‐specific mortality adjudication in a COPD clinical trial, 2007. http://www.abstracts2view.comA120. ">TORCH</a>; <a href="./references#CD006826-bbs2-0014" title="CalverleyP , PauwelsR , VestboJ , JonesP , PrideN , GulsvikA , et al. Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial. Lancet2003;361(9356):449‐56. CalverleyPMA , PauwelsRA , VestboJ , JonesPW , PrideNB , GulsvikA , et al. Clinical improvements with salmeterol / fluticasone propionate combination in differing severities of COPD, 2003. http://www.abstracts2view.comA035 [Poster D50]. CalverleyPMA , PauwelsRA , VestboJ , JonesPW , PrideNB , GulsvikA , et al. Salmeterol/Fluticasone propionate combination for one year provides greater clinical benefit than its individual components. Proceedings of the 98th International American Thoracic Society Conference http://www.abstracts‐on‐line.com/abstracts/ATS; May 17‐22, 2002; Atlanta, Georgia. A98 [Poster 306]. CalverlyPMA , PauwelsR , VestboJ , JonesP , PrideN , GulsvikA , et al. Safety of salmeterol/fluticasone propionate combination in the treatment of chronic obstructive pulmonary disease. European Respiratory Journal2002;20 Suppl 38:242 [P1572]. HunjanMK , ChandlerF . Numbers needed to treat (NNT) to avoid an exacerbation in patients with chronic obstructive pulmonary disease (COPD) using salmeterol/fluticasone propionate combination (SFC) and associated costs [Abstract]. American Thoracic Society 100th International Conference; May 21‐26, 2004; Orlando, Florida. D22 [Poster 503]. HunjanMK , WilliamsDT . Costs of avoiding exacerbations in patients with chronic obstructive pulmonary disease (COPD) treated with salmeterol/ fluticasone propionate combination (seretide) and salmeterol. European Respiratory Journal2004;24 Suppl 48:291s. HunjanMK , WilliamsDT . Salmeterol/ fluticasone propionate combination is clinically effective in avoiding exacerbations in patients with moderate/severe COPD. European Respiratory Journal2004;24 Suppl 48:513s. JonesPW , EdinHM , AndersonJ . Salmeterol/fluticasone propionate combination improves health status in COPD patients. Proceedings of the 98th International American Thoracic Society Conference http://www.abstracts‐on‐line.com/abstracts/ATS; May 17‐22, 2002; Atlanta, Georgia. A39 [Poster K39]. JonesPW , StåhlE . Budesonide /formoterol sustains clinically relevant improvements in health status in COPD [Abstract]. European Respiratory Journal2005;26 Suppl 49:Abstract 1352. JonesPW , VestboJ , PauwelsRA , CalverleyPMA , AndersonJA , SpencerMD . Informative drop out in COPD studies: investigation of health status of withdrawals in the TRISTAN study. Proceedings of the 13th ERS Annual Congress; September 27, 2003; Vienna, Austria. P1593. NitschmannS . Inhalational combination therapy in chronic obstructive lung disease. Tristan study. German Internist2004;45(6):727‐8. PauwelsR , VestboJ , CalverleyPMA , JonesPW , PrideNB , GulsvikA . Characterization of exacerbations in the TRISTAN study of salmeterol / fluticasone propionate (SFC) combination in moderate to severe COPD, 2006. http://www.abstracts2view.com. PauwelsRA , CalverlyPMA , VestboJ , JonesPW , PrideN , GulsvikA , et al. Reduction of exacerbations with salmeterol/fluticasone combination 50/500 mcg bd in the treatment of chronic obstructive pulmonary disease. European Respiratory Journal2002;20 Suppl 38:240 [P1569]. SFCB3024 . A multicentre, randomised, double‐blind, parallel group, placebo‐controlled study to compare the efficacy and safety of the salmeterol/FP combination product at a strength of 50/500mcg bd with salmeterol 50mcg bd alone and FP 500mcg bd alone, delivered via the DISKUS™/ACCUHALER™, in the treatment of subjects with chronic obstructive pulmonary disease (COPD) for 12 months. GlaxoSmithKline Clinical Trials Register (http:ctr.gsk.co.uk)2005. SpencerM , BriggsAH , GrossmanRF , RanceL . Development of an economic model to assess the cost effectiveness of treatment interventions for chronic obstructive pulmonary disease. Pharmacoeconomics2005;23(6):619‐37. SpencerMD , KariaN , AndersonJ . The clinical significance of treatment benefits with the salmeterol/fluticasone propionate 50/500mcg combination in COPD. European Respiratory Journal2004;24 Suppl 48:290s. VestboJ , CalverleyPMA , PauwelsR , JonesP , PrideN , GulsvikA , et al. Absence of gender susceptibility to the combination of salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease. European Respiratory Journal2002;20 Suppl 38:240 [P1570]. VestboJ , PauwelsR , AndersonJA , JonesP , CalverleyP . Early onset of effect of salmeterol and fluticasone propionate in chronic obstructive pulmonary disease. Thorax2005;60(4):301‐4. VestboJ , PauwelsRS , CalverleyPMA , JonesPW , PrideNB , GulsvikA . Salmeterol / fluticasone propionate combination produces improvement in lung function detectable within 24 hours in moderate to severe COPD, 2003. http://www.abstracts2view.com. VestboJ , SorianoJB , AndersonJA , CalverleyP , PauwelsR , JonesP . Gender does not influence the response to the combination of salmeterol and fluticasone propionate in COPD. Respiratory Medicine2004;98(11):1045‐50. ">TRISTAN</a>) and GOLD (<a href="./references#CD006826-bbs2-0002" title="AstraZenecaSD . A placebo‐controlled 12‐month efficacy study of the fixed combination budesonide/formoterol compared to budesonide and formoterol as monotherapies in patients with chronic obstructive pulmonary disease (COPD). AstraZeneca Clinical Trials2002. BorgstromL , AskingL , OlssonH , PetersonS . Lack of interaction between disease severity and therapeutic response with budesonide/formoterol in a single inhaler [Abstract]. American Thoracic Society 100th International Conference; May 21‐26; 2004, Orlando, Florida. C22 [Poster 505]. CalverleyPM , BonsawatW , CsekeZ , ZhongN , PetersonS , OlssonH . Maintenance therapy with budesonide and formoterol in chronic obstructive pulmonary disease. European Respiratory Journal2003;22(6):912‐9. CalverleyPMA , CsekeZ , PetersonS . Budesonide/formoterol reduces the use of oral corticosteroids in the treatment of COPD [Abstract]. European Respiratory Journal2003;22 Suppl 45:P436. CalverleyPMA , KunaP , OlssonH . COPD exacerbations are reduced by budesonide/formoterol in a single inhaler [Abstract]. European Respiratory Journal2003;22 Suppl 45:P1587. CalverleyPMA , OlssonH , Symbicort International COPD Study Group. Budesonide/formoterol ina single inhaler sustains improvements in lung function over 12 months compared with monocomponents and placebo in patients with COPD [abstract]. American Thoracic Society 99th International Conference; May 16‐21, 2003; Seattle, Washington. B024 [Poster 418]. CalverleyPMA , PetersonS . Combining budesonide/formoterol in a single inhale reduces exacerbation frequency in COPD [abstract]. American Thoracic Society 99th International Conference; May 16‐21, 2003; Seattle, Washington. D092 [Poster 211]. CalverleyPMA , StåhlE , JonesPW . Budesonide/formoterol improves the general health status of patients with COPD [Abstract]. American Thoracic Society 2005 International Conference; May 20‐25, 2005; San Diego, California. B93 [Poster 303]. CalverleyPMA , SzafranskiW , AnderssonA . Budesonide/formoterol is a well‐tolerated long term maintenance therapy for COPD. European Respiratory Journal2005;26 Suppl 49:Poster 1917. CalverleyPMA , ThompsonNC , OlssonH . Budesonide/formoterol in a single inhaler sustains lung function improvements in COPD [Abstract]. European Respiratory Journal2003;22 Suppl 45:P435. HalpinD , StåhlE , LundbackB , AndersonF , PetersonS . Treatment costs and number needed to treat (NNT) with budesonide/formoterol to avoid one exacerbation of COPD [Abstract]. American Thoracic Society 100th International Conference; May 21‐26, 2004; Orlando, Florida. D22 [Poster 525]. HalpinDMG , LarssonT , CalverleyPMA . How many patients with COPD must be treated with budesonide/formoterol compared with formoterol alone to avoid 1 day of oral steroid use? [Abstract]. American Thoracic Society 2005 International Conference; May 20‐25, 2005; San Diego, California. B93 [Poster 314]. JonesPW , StahlE . Budesonide/formoterol in a single inhaler improves health status in patients with COPD [abstract]. American Thoracic Society 99th International Conference; May 16‐21, 2003; Orlando, Florida. B024 [Poster 419]. JonesPW , StåhlE . Budesonide /formoterol sustains clinically relevant improvements in health status in COPD [Abstract]. European Respiratory Journal2005;26 Suppl 49:Abstract 1352. JonesPW , StåhlE . Reducing exacerbations leads to a better health‐related quality of life in patients with COPD. 13th ERS Annual Congress; September 27, 2003; Vienna, Austria. P1586. LofdahlCG . Reducing the impact of COPD exacerbations: Clinical efficacy of budesonide/formoterol. European Respiratory Review2004;13(88):14‐21. LofdahlCG , AndreassonE , SvenssonK , EricssonA . Budesonide/formoterol in a single inhaler improves health status in patients with COPD without increasing healthcare costs [Abstract]. European Respiratory Journal2003;22 Suppl 45:P433. LofdahlCG , EricssonA , SvenssonK , AndreassonE . Cost effectiveness of budesonide/formoterol in a single inhaler for COPD compared with each monocomponent used alone. Pharmacoeconomics2005;23(4):365‐75. ">Calverley 2003</a>; <a href="./references#CD006826-bbs2-0005" title="LapperreTS , Snoeck‐StrobandJB , GosmanMM , JansenDF , vanSchadewijkA , ThiadensHA , et al. Effect of fluticasone with and without salmeterol on pulmonary outcomes in chronic obstructive pulmonary disease: a randomized trial. Annals of Internal Medicine2009; Vol. 151, issue 8:517‐27. ">Lapperre 2009</a>; <a href="./references#CD006826-bbs2-0009" title="NCT00120978 . Advair－CRP Study. http://clinicaltrials.gov/show/NCT001209782004. [] SinDD , ManSF , MarciniukDD , FordG , FitzGeraldM , WongE , et al. Can inhaled fluticasone alone or in combination with salmeterol reduce systemic inflammation in chronic obstructive pulmonary disease? Study protocol for a randomized controlled trial [NCT00120978]. BMC Pulmonary Medicine2006;6(6):3. SinDD , ManSF , MarciniukDD , FordG , FitzGeraldM , WongE , et al. The effects of fluticasone with or without salmeterol on systemic biomarkers of inflammation in chronic obstructive pulmonary disease. American Journal of Respiratory and Critical Care Medicine2008; Vol. 177, issue 11:1207‐14. ">Sin 2008</a>; <a href="./references#CD006826-bbs2-0010" title="AndersonP . Budesonide/formoterol in a single inhaler (Symbicort) provides early and sustained improvement in lung function in moderate to severe COPD [Abstract]. Thorax2002;57(Suppl III):iii43. AstraZenecaSD . A placebo‐controlled 12 month efficacy study of the fixed combination budesonide/formoterol compared with budesonide and formoterol as monotherapies in patients with chronic obstructive pulmonary disease (COPD). AstraZeneca Clinical Trials2001. BorgstromL , AskingL , OlssonH , PetersonS . Lack of interaction between disease severity and therapeutic response with budesonide/formoterol in a single inhaler [Abstract]. American Thoracic Society 100th International Conference; May 21‐26, 2004; Orlando, Florida. C22 [Poster 505]. CalverleyP , PauwelsR , LofdahlCG , SvenssonK , HigenbottamT , et al. Relationship between respiratory symptoms and medical treatment in exacerbations of COPD. European Respiratory Journal2005;26(3):406‐13. CalverleyPMA . Effect of budesonide/formoterol on severe exacerbations and lung function in moderate to severe COPD. Thorax. BTS Winter Meeting 2002:S145. CalverleyPMA , SzafranskiW , AnderssonA . Budesonide/formoterol is a well‐tolerated long term maintenance therapy for COPD. European Respiratory Journal2005;26 Suppl 49:Poster 1917. CalverleyPMA , ThompsonNC , OlssonH . Budesonide/formoterol in a single inhaler sustains lung function improvements in COPD [Abstract]. European Respiratory Journal2003;22 Suppl 45:P435. CampbellLM , SzafranskiW . Budesonide/formoterol in a single inhaler (Symbicort) provides sustained relief from symptoms in moderate to severe COPD. Thorax. BTS Winter Meeting 2002:S143. CampellLW , SzafranskiW . Budesonide/Formoterol in a single inhaler (Symbicort) reduces severe exacerbations in patients with moderate‐severe COPD. Thorax. BTS Winter Meeting 2002:S141. DahlR , CukierA , OlssonH . Budesonide/formoterol in a single inhaler reduces severe and mild exacerbations in patients with moderate to severe COPD. European Respiratory Journal2002;20 Suppl 38:242 [P1575]. EgedeF , MengaG . Budesonide/formoterol in a single inhaler provides sustained relief from symptoms and night‐time awakenings in moderate‐severe COPD: results from symptoms and night‐time awakenings in moderate to severe COPD: results from a 1‐year study. European Respiratory Journal2002;20 Suppl 38:242 [P1574]. HalpinD , StahlE , LundbackB , AndersonF , PetersonS . Treatment costs and number needed to treat (NNT) with budesonide/formoterol to avoid one exacerbation of COPD [Abstract]. American Thoracic Society 100th International Conference; May 21‐26, 2004; Orlando, Florida. D22 [Poster 525]. JonesPW , StahlE , SvenssonK . Improvement in health status in patients with moderate to severe COPD after treatment with budesonide/formoterol in a single inhaler. European Respiratory Journal2002;20 Suppl 38:250 [P1613]. KorsgaardJ , SansoresR . Budesonide/formoterol (single inhaler) provides sustained relief from shortness of breath and chest tightness in a 1‐year study of patients with moderate to severe COPD. European Respiratory Journal2002;20 Suppl 38:242 [P1577]. LangeP , SaenzC . Budesonide/formoterol in a single inhaler is well tolerated in patients with moderate to severe COPD: results of a 1 year study. European Respiratory Journal2002;20 Suppl 38:242 [P1573]. LofdahlCG . Reducing the impact of COPD exacerbations: clinical efficacy of budesonide/formoterol. European Respiratory Review2004;13(88):14‐21. MilanowskiJ , NahabedianS . Budesonide/formoterol in a single inhaler acts rapidly to improve lung function and relieve symptoms in patients with moderate to severe COPD. European Respiratory Journal2002;20 Suppl 38:242 [P1576]. SzafranskiW , CukierA , RamirezA , MengaG , SansoresR , NahabedianS , et al. Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease. European Respiratory Journal2003;21(1):74‐81. ">Szafranski 2003</a>). In seven studies, the definition was based on lung function tests (<a href="./references#CD006826-bbs2-0001" title="BourbeauJ , ChristodoulopoulosP , MaltaisF , YamauchiY , OlivensteinR , HamidQ . Effect of salmeterol/fluticasone propionate on airway inflammation in COPD: a randomised controlled trial. Thorax2007; Vol. 62, issue 11:938‐43. ">Bourbeau 2007</a>; <a href="./references#CD006826-bbs2-0003" title="DohertyDE , KerwinE , TashkinDP , Matiz‐BuenoCE , ShekarT , BanerjeeS , et al. Combined mometasone furoate and formoterol in patients with moderate to very severe chronic obstructive pulmonary disease (COPD): phase 3 efficacy and safety study [Abstract]. Journal of Allergy and Clinical Immunology2012; Vol. 129, issue 2 Suppl:AB75 [283]. DohertyDE , TashkinDP , KerwinE , KnorrBA , ShekarT , BanerjeeS , et al. Effects of mometasone furoate/formoterol fumarate fixed‐dose combination formulation on chronic obstructive pulmonary disease (COPD): results from a 52‐week Phase III trial in subjects with moderate‐to‐very severe COPD. International Journal of Chronic Obstructive Pulmonary Disease2012; Vol. 7, issue 1178‐2005 (Electronic). 1176‐9106 (Linking):57‐71. NCT00383721 . A Randomized, 26‐Week, Placebo‐Controlled Efficacy and Safety Study With a 26‐Week Long‐Term Safety Extension, of High‐ and Medium‐Dose Inhaled Mometasone Furoate/Formoterol Fixed‐Dose Combination Formulation Compared With Formoterol and High‐Dose Inhaled Mometasone Furoate Monotherapy in Subjects With Moderate to Severe COPD, 2006. http://clinicaltrials.gov/show/NCT00383721. [] ">Doherty 2012</a>; <a href="./references#CD006826-bbs2-0007" title="NCT00358358 . Trial SCO104925. See detailed description, 2006. http://clinicaltrials.gov/show/NCT00358358. [] ">NCT00358358</a>; <a href="./references#CD006826-bbs2-0008" title="SFCT01 . A Multicentre, Randomised, Double‐Blind, Parallel Group, Placebo‐Controlled Study to Compare the Efficacy and Safety of Inhaled Salmeterol/Fluticasone Propionate Combination Product 25/250 µg Two Puffs Bd and Fluticasone Propionate 250µg Two Puffs Bd Alone, All Administered Via Metered Dose Inhalers (MDI), in the Treatment of Subjects with Chronic Obstructive Pulmonary Disease (COPD) for 52 Weeks. GlaxoSmithKline Clinical Trials Register (http:ctr.gsk.co.uk)2005. ">SFCT01</a>, <a href="./references#CD006826-bbs2-0011" title="Astrazeneca(D5899C00002) . A 6‐month double‐blind, double‐dummy, randomized, parallel group, multicenter efficacy &amp; safety study of Symbicort® pMDI 2 × 160/4.5mg &amp; 80/4.5mg bid compared to Formoterol TBH, Budesonide pMDI (&amp; the combination) &amp; placebo in COPD patients. www.astrazenecaclinicaltrials.com (accessed 8 April 2008). BleeckerER , MeyersDA , BaileyWC , SimsA‐M , BujacSR , GoldmanM , et al. ADRB2 polymorphisms and budesonide/formoterol responses in COPDADRB2 polymorphisms and treatment response in COPD. Chest2012;142(2):320‐8. TashkinDP , RennardSI , MartinP , GoldmanM , SilkoffPE . Efficacy of budesonide/formoterol administered via one pressurized metered‐dose inhaler over 6 months in patients with chronic obstructive pulmonary disease [Abstract]. Chest2008; Vol. 134, issue 4:105001s. TashkinDP , RennardSI , MartinP , RamachandranS , MartinUJ , SilkoffPE , et al. Efficacy and safety of budesonide and formoterol in one pressurized metered‐dose inhaler in patients with moderate to very severe chronic obstructive pulmonary disease : results of a 6‐month randomized clinical trial. Drugs2008; Vol. 68, issue 0012‐6667 (Print):1975‐2000. ">Tashkin 2008</a>; <a href="./references#CD006826-bbs2-0012" title="KerwinE , TashkinDP , Matiz‐BuenoCE , DohertyDE , ShekarT , BanerjeeS , et al. Clinical efficacy and safety of combined mometasone furoate and formoterol in patients with moderate to very severe chronic obstructive pulmonary disease (COPD) [Abstract]. Journal of Allergy and Clinical Immunology2012; Vol. 129, issue 2 Suppl:AB201 [759]. NCT00383435 . A Randomized, 26‐Week, Placebo‐Controlled Efficacy and Safety Study With a 26‐Week Long‐Term Safety Extension, of High‐ and Medium‐Dose Inhaled Mometasone Furoate/Formoterol Fixed‐Dose Combination Formulation Compared With Formoterol and High‐Dose Inhaled Mometasone Furoate Monotherapy in Subjects With Moderate to Severe COPD, 2006. http://clinicaltrials.gov/show/NCT00383435. [] TashkinDP , DohertyDE , KerwinE , Matiz‐BuenoCE , KnorrB , ShekarT , et al. Efficacy and safety of a fixed‐dose combination of mometasone furoate and formoterol fumarate in subjects with moderate to very severe COPD: results from a 52‐week Phase III trial. International Journal of Chronic Obstructive Pulmonary Disease2012; Vol. 7, issue 1178‐2005 (Electronic). 1176‐9106 (Linking):43‐55. ">Tashkin 2012</a>; <a href="./references#CD006826-bbs2-0015" title="ZhongN , ZhengJ , WenF , YangL , ChenP , XiuQ , et al. Efficacy and safety of budesonide/formoterol via a dry powder inhaler in Chinese patients with chronic obstructive pulmonary disease. Current Medical Research and Opinion2012; Vol. 28, issue 2:257‐65. ZhongN , ZhengJ , WenF , YangL , ChenP , XiuQ , et al. Efficacy and safety of inhalation of budesonide/formoterol via turbuhaler in Chinese patients with chronic obstructive pulmonary disease [Abstract]. Chest2011; Vol. 140, issue 4:5225A. ">Zhong 2012</a>). Participant populations in the studies suffered from moderate and severe COPD. <a href="./references#CD006826-bbs2-0004" title="HananiaNA , DarkenP , HorstmanD , ReisnerC , LeeB , DavisS , et al. The efficacy and safety of fluticasone propionate (250 micro g)/salmeterol (50 micro g) combined in the diskus inhaler for the treatment of COPD. Chest2003;124(3):834‐43. HananiaNA , RamsdellJ , PayneK , DavisS , HorstmanD , LeeB , et al. Improvements in airflow and dyspnea in COPD patients following 24 weeks treatment with salmeterol 50mcg and fluticasone propionate 250mcg alone or in combination via the diskus. American Journal of Respiratory &amp; Critical Care Medicine2001;163(5 Suppl):A279. HorstmanD , DarkenP , DavisS , LeeB . Improvements in FEV1 and symptoms in poorly reversible COPD patients following treatment with salmeterol 50mcg/fluticasone propionate 250mcg combination [Abstract]. European Respiratory Journal2003;22 Suppl 45:P434. MahlerDA , DarkenP , BrownCP , KnobilK . Predicting lung function responses to combination therapy in chronic obstructive pulmonary disease (COPD) [Abstract]. National COPD Conference; November 14‐15, 2003; Arlington, Virginia. Abstract 1081. MahlerDA , DarkenP , BrownCP , KnobilK . Predicting lung function responses to salmeterol/fluticasone propionate combination therapy in COPD [Abstract]. European Respiratory Journal2003;22 Suppl 45:P429. SFCA3007 . A randomized, double‐blind, placebo‐controlled, parallel‐group trial evaluating the safety and efficacy of the DISKUS formulations of salmeterol (SAL) 50mcg BID and fluticasone propionate (FP) 250mcg BID individually and in combination as salmeterol 50mcg/fluticasone propionate 250mcg BID (SFC 50/250) compared to placebo in COPD subjects. GlaxoSmithKline Clinical Trials Register (http:ctr.gsk.co.uk)2005. SpencerM , WireP , LeeB , ChangCN , DarkenP , HorstmanD . Patients with COPD using salmeterol/fluticasone propionate combination therapy experience improved quality of life. European Respiratory Journal2003;22 Suppl 45:51s. SpencerMD , KariaN , AndersonJ . The clinical significance of treatment benefits with the salmeterol/fluticasone propionate 50/500mcg combination in COPD. European Respiratory Journal2004;24 Suppl 48:290s. ">Hanania 2003</a> and <a href="./references#CD006826-bbs2-0006" title="MahlerDA , DarkenP , BrownCP , KnobilK . Predicting lung function responses to combination therapy in chronic obstructive pulmonary disease (COPD), 2003. http://www.abstracts2view.com. MahlerDA , WireP , HorstmanD , ChangCN , YatesJ , FischerT , et al. Effectiveness of fluticasone propionate and salmeterol combination delivered via the diskus device in the treatment of chronic obstructive pulmonary disease. American Journal of Respiratory Critical Care Medicine2002;166(8):1084‐91. SFCA3006 . A randomized, double‐blind, placebo‐controlled, parallel‐group trial evaluating the safety and efficacy of the DISKUS formulations of salmeterol (SAL) 50mcg BID and fluticasone propionate (FP) 500mcg BID individually and in combination as salmeterol 50mcg/fluticasone propionate 500mcg BID (SFC 50/500) compared to placebo in COPD subjects. GlaxoSmithKline Clinical Trials Register (http:ctr.gsk.co.uk)2005. SpencerM , WireP , LeeB , ChangCN , DarkenP , HorstmanD . Patients with COPD using salmeterol/fluticasone propionate combination therapy experience improved quality of life. European Respiratory Journal2003;22 Suppl 45:51s. SpencerMD , AndersonJA . Salmeterol/fluticasone combination produces clinically important benefits in dyspnea and fatigue [Abstract]. American Thoracic Society 2005 International Conference; May 20‐25, 2005; San Diego, California. B93 [Poster 308]. SpencerMD , KariaN , AndersonJ . The clinical significance of treatment benefits with the salmeterol/fluticasone propionate 50/500mcg combination in COPD. European Respiratory Journal2004;24 Suppl 48:290s. ">Mahler 2002</a> enrolled participants with both reversible and non‐reversible COPD. </p> </section> <section id="CD006826-sec-0058"> <h5 class="title">Interventions</h5> <p>Three comparisons were made. The first was fluticasone propionate/salmeterol (FPS) versus fluticasone (9 studies, 5132 participants: <a href="./references#CD006826-bbs2-0001" title="BourbeauJ , ChristodoulopoulosP , MaltaisF , YamauchiY , OlivensteinR , HamidQ . Effect of salmeterol/fluticasone propionate on airway inflammation in COPD: a randomised controlled trial. Thorax2007; Vol. 62, issue 11:938‐43. ">Bourbeau 2007</a>; <a href="./references#CD006826-bbs2-0004" title="HananiaNA , DarkenP , HorstmanD , ReisnerC , LeeB , DavisS , et al. The efficacy and safety of fluticasone propionate (250 micro g)/salmeterol (50 micro g) combined in the diskus inhaler for the treatment of COPD. Chest2003;124(3):834‐43. HananiaNA , RamsdellJ , PayneK , DavisS , HorstmanD , LeeB , et al. Improvements in airflow and dyspnea in COPD patients following 24 weeks treatment with salmeterol 50mcg and fluticasone propionate 250mcg alone or in combination via the diskus. American Journal of Respiratory &amp; Critical Care Medicine2001;163(5 Suppl):A279. HorstmanD , DarkenP , DavisS , LeeB . Improvements in FEV1 and symptoms in poorly reversible COPD patients following treatment with salmeterol 50mcg/fluticasone propionate 250mcg combination [Abstract]. European Respiratory Journal2003;22 Suppl 45:P434. MahlerDA , DarkenP , BrownCP , KnobilK . Predicting lung function responses to combination therapy in chronic obstructive pulmonary disease (COPD) [Abstract]. National COPD Conference; November 14‐15, 2003; Arlington, Virginia. Abstract 1081. MahlerDA , DarkenP , BrownCP , KnobilK . Predicting lung function responses to salmeterol/fluticasone propionate combination therapy in COPD [Abstract]. European Respiratory Journal2003;22 Suppl 45:P429. SFCA3007 . A randomized, double‐blind, placebo‐controlled, parallel‐group trial evaluating the safety and efficacy of the DISKUS formulations of salmeterol (SAL) 50mcg BID and fluticasone propionate (FP) 250mcg BID individually and in combination as salmeterol 50mcg/fluticasone propionate 250mcg BID (SFC 50/250) compared to placebo in COPD subjects. GlaxoSmithKline Clinical Trials Register (http:ctr.gsk.co.uk)2005. SpencerM , WireP , LeeB , ChangCN , DarkenP , HorstmanD . Patients with COPD using salmeterol/fluticasone propionate combination therapy experience improved quality of life. European Respiratory Journal2003;22 Suppl 45:51s. SpencerMD , KariaN , AndersonJ . The clinical significance of treatment benefits with the salmeterol/fluticasone propionate 50/500mcg combination in COPD. European Respiratory Journal2004;24 Suppl 48:290s. ">Hanania 2003</a>; <a href="./references#CD006826-bbs2-0005" title="LapperreTS , Snoeck‐StrobandJB , GosmanMM , JansenDF , vanSchadewijkA , ThiadensHA , et al. Effect of fluticasone with and without salmeterol on pulmonary outcomes in chronic obstructive pulmonary disease: a randomized trial. Annals of Internal Medicine2009; Vol. 151, issue 8:517‐27. ">Lapperre 2009</a>; <a href="./references#CD006826-bbs2-0006" title="MahlerDA , DarkenP , BrownCP , KnobilK . Predicting lung function responses to combination therapy in chronic obstructive pulmonary disease (COPD), 2003. http://www.abstracts2view.com. MahlerDA , WireP , HorstmanD , ChangCN , YatesJ , FischerT , et al. Effectiveness of fluticasone propionate and salmeterol combination delivered via the diskus device in the treatment of chronic obstructive pulmonary disease. American Journal of Respiratory Critical Care Medicine2002;166(8):1084‐91. SFCA3006 . A randomized, double‐blind, placebo‐controlled, parallel‐group trial evaluating the safety and efficacy of the DISKUS formulations of salmeterol (SAL) 50mcg BID and fluticasone propionate (FP) 500mcg BID individually and in combination as salmeterol 50mcg/fluticasone propionate 500mcg BID (SFC 50/500) compared to placebo in COPD subjects. GlaxoSmithKline Clinical Trials Register (http:ctr.gsk.co.uk)2005. SpencerM , WireP , LeeB , ChangCN , DarkenP , HorstmanD . Patients with COPD using salmeterol/fluticasone propionate combination therapy experience improved quality of life. European Respiratory Journal2003;22 Suppl 45:51s. SpencerMD , AndersonJA . Salmeterol/fluticasone combination produces clinically important benefits in dyspnea and fatigue [Abstract]. American Thoracic Society 2005 International Conference; May 20‐25, 2005; San Diego, California. B93 [Poster 308]. SpencerMD , KariaN , AndersonJ . The clinical significance of treatment benefits with the salmeterol/fluticasone propionate 50/500mcg combination in COPD. European Respiratory Journal2004;24 Suppl 48:290s. ">Mahler 2002</a>; <a href="./references#CD006826-bbs2-0007" title="NCT00358358 . Trial SCO104925. See detailed description, 2006. http://clinicaltrials.gov/show/NCT00358358. [] ">NCT00358358</a>; <a href="./references#CD006826-bbs2-0008" title="SFCT01 . A Multicentre, Randomised, Double‐Blind, Parallel Group, Placebo‐Controlled Study to Compare the Efficacy and Safety of Inhaled Salmeterol/Fluticasone Propionate Combination Product 25/250 µg Two Puffs Bd and Fluticasone Propionate 250µg Two Puffs Bd Alone, All Administered Via Metered Dose Inhalers (MDI), in the Treatment of Subjects with Chronic Obstructive Pulmonary Disease (COPD) for 52 Weeks. GlaxoSmithKline Clinical Trials Register (http:ctr.gsk.co.uk)2005. ">SFCT01</a>; <a href="./references#CD006826-bbs2-0009" title="NCT00120978 . Advair－CRP Study. http://clinicaltrials.gov/show/NCT001209782004. [] SinDD , ManSF , MarciniukDD , FordG , FitzGeraldM , WongE , et al. Can inhaled fluticasone alone or in combination with salmeterol reduce systemic inflammation in chronic obstructive pulmonary disease? Study protocol for a randomized controlled trial [NCT00120978]. BMC Pulmonary Medicine2006;6(6):3. SinDD , ManSF , MarciniukDD , FordG , FitzGeraldM , WongE , et al. The effects of fluticasone with or without salmeterol on systemic biomarkers of inflammation in chronic obstructive pulmonary disease. American Journal of Respiratory and Critical Care Medicine2008; Vol. 177, issue 11:1207‐14. ">Sin 2008</a>; <a href="./references#CD006826-bbs2-0013" title="BriggsAH , GlickHA , Lozano‐OrtegaG , SpencerM , CalverleyPM , JonesPW , et al. Is treatment with ICS and LABA cost‐effective for COPD? Multinational economic analysis of the TORCH study. European Respiratory Journal2010; Vol. 35, issue 3:532‐9. CalverleyPM , AndersonJA , CelliB , FergusonGT , JenkinsC , JonesPW , et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease.[see comment]. New England Journal of Medicine2007; Vol. 356, issue 8:775‐89. CalverleyPMA , AndersonJA , CelliB , FergusonGT , JenkinsC , JonesPW , et al. Cardiovascular events in patients with chronic obstructive pulmonary disease: TORCH study results. Thorax2010;65:719‐25. CalverleyPMA , AndersonJA , CelliB , FergusonGT , JenkinsC , JonesPW , et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. New England Journal of Medicine2007;356(8):775‐89. CalverleyPMA , CelliB , FergusonG , JenkinsC , JonesPW , PrideNB , et al. Baseline characteristics of the first 5,000 COPD patients enrolled in the TORCH survival study. European Respiratory Journal2003;22 Suppl 45:578s. CelliB , CalverleyPMA , AndersonJA , FergusonGT , JenkinsC , JonesPW , et al. The TORCH (TOwards a Revolution in COPD Health) study: salmeterol/fluticasone propionate (SFC) improves health status, reduces exacerbations and improves lung function over three years. European Respiratory Journal2006;28 Suppl 50:34s. CelliB , VestboJ , JenkinsCR , JonesPW , FergusonGT , CalverleyPM , et al. Sex differences in mortality and clinical expressions of patients with chronic obstructive pulmonary disease: the TORCH experience. American Journal of Respiratory and Critical Care Medicine2011;183(3):317‐22. CelliBR , ThomasNE , AndersonJA , FergusonGT , JenkinsCR , JonesPW , et al. Effect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease: results from the TORCH study. American Journal of Respiratory and Critical Care Medicine2008;174(4):332‐8. CrimC , CalverleyPM , AndersonJA , CelliB , FergusonGT , JenkinsC , et al. Pneumonia risk in COPD patients receiving inhaled corticosteroids alone or in combination: TORCH study results. European Respiratory Journal2009;34(3):641‐7. FergusonGT , CalverleyPM , AndersonJA , JenkinsCR , JonesPW , WillitsLR , et al. Prevalence and progression of osteoporosis in patients with COPD: results from the TOwards a Revolution in COPD Health study. Chest2009; Vol. 136, issue 0012‐3692:1456‐65. FergusonGT , CalverleyPMA , AndersonJA , et al. The TORCH (TOwards a Revolution in COPD Health) study: salmeterol/fluticasone propionate (SFC) improves survival in COPD over three years. European Respiratory Journal2006;28 Suppl 50:34s. GlaxoSmithKlineSCO30003 . A multicentre, randomised, double‐blind, parallel group, placebo‐controlled study to investigate the long‐term effects of salmeterol/fluticasone propionate (SERETIDE/VIANI/ADVAIR) 50/500mcg bd, salmeterol 50mcg bd and fluticasone propionate 500mcg bd, all delivered via the DISKUS/ACCUHALER inhaler, on the survival of subjects with chronic obstructive pulmonary disease (COPD) over 3 years of treatment. GlaxoSmithKline Clinical Trial Register2006. HoughtonCM , LawsonN , BorrillZL , WixonCL , YoxallS , LangleySJ , et al. Comparison of the effects of salmeterol/fluticasone propionate with fluticasone propionate on airway physiology in adults with mild persistent asthma. Respiratory Research2007;8:52. JenkinsCR , CalverleyPMA , CelliB , FergusonG , JonesPW , PrideN , et al. Seasonal patterns of exacerbation rates in the TORCH survival study, 2007. http://www.abstracts2view.comA839. JenkinsCR , CelliB , AndersonJA , FergusonGT , JonesPW , VestboJ , et al. Seasonality and determinants of moderate and severe COPD exacerbations in the TORCH study. European Respiratory Journal2012;39(1):38‐45. JenkinsCR , JonesPW , CalverleyPM , CelliB , AndersonJA , FergusonGT , et al. Efficacy of salmeterol/fluticasone propionate by GOLD stage of chronic obstructive pulmonary disease: analysis from the randomised, placebo‐controlled TORCH study. Respiratory Research2009;10:59. JohnsonM , AgustiAG , BarnesNC . Reflections on TORCH: potential mechanisms for the survival benefit of salmeterol/fluticasone propionate in COPD patients. COPD2008;5(6):369‐75. JonesPW , AndersonJA , CalverleyPM , CelliBR , FergusonGT , JenkinsC , et al. TORCH Investigators. Health status in the TORCH study of COPD: treatment efficacy and other determinants of change. Respiratory Research2011;12:71. JonesPW , CalverleyP , CelliB , FergusonG , JenkinsC , PrideN . Trans‐regional validity of the SGRQ in the TORCH survival study, 2007. http://www.abstracts2view.comA122. McGarveyLP , JohnM , AndersonJA , ZvarichMT , WiseRA . Ascertainment of cause‐specific mortality in COPD: operations of the TORCH Clinical Endpoint Committee. Thorax2007;62:411‐5. NCT00268216 . See detailed description, 2000. http://clinicaltrials.gov/show/NCT00268216. [] SCO30003 . A multicentre, randomised, double‐blind, parallel group, placebo‐controlled study to investigate the long‐term effects of salmeterol/fluticasone propionate (SERETIDE®/VIANI®/ADVAIR®) 50/500mcg bd, salmeterol 50mcg bd and fluticasone propionate 500mcg bd, all delivered via the DISKUS®/ACCUHALER® inhaler, on the survival of subjects with chronic obstructive pulmonary disease (COPD) over 3 years of treatment, 2006. www.ctr.gsk.co.uk. VestboJ , AndersonJA , CalverleyPM , CelliB , FergusonGT , JenkinsC , et al. Adherence to inhaled therapy, mortality and hospital admission in COPD. Thorax2009;64(11):939‐43. VestboJ , CalverleyP , CelliB , FergusonG , JenkinsC , JonesP , et al. The TORCH (TOwards a Revolution in COPD Health) survival study protocol. European Respiratory Journal2004;24(2):206‐10. WiseRA , McGarveyLP , JohnM , AndersonJA , ZvarichMT . Reliability of cause‐specific mortality adjudication in a COPD clinical trial, 2007. http://www.abstracts2view.comA120. ">TORCH</a>; <a href="./references#CD006826-bbs2-0014" title="CalverleyP , PauwelsR , VestboJ , JonesP , PrideN , GulsvikA , et al. Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial. Lancet2003;361(9356):449‐56. CalverleyPMA , PauwelsRA , VestboJ , JonesPW , PrideNB , GulsvikA , et al. Clinical improvements with salmeterol / fluticasone propionate combination in differing severities of COPD, 2003. http://www.abstracts2view.comA035 [Poster D50]. CalverleyPMA , PauwelsRA , VestboJ , JonesPW , PrideNB , GulsvikA , et al. Salmeterol/Fluticasone propionate combination for one year provides greater clinical benefit than its individual components. Proceedings of the 98th International American Thoracic Society Conference http://www.abstracts‐on‐line.com/abstracts/ATS; May 17‐22, 2002; Atlanta, Georgia. A98 [Poster 306]. CalverlyPMA , PauwelsR , VestboJ , JonesP , PrideN , GulsvikA , et al. Safety of salmeterol/fluticasone propionate combination in the treatment of chronic obstructive pulmonary disease. European Respiratory Journal2002;20 Suppl 38:242 [P1572]. HunjanMK , ChandlerF . Numbers needed to treat (NNT) to avoid an exacerbation in patients with chronic obstructive pulmonary disease (COPD) using salmeterol/fluticasone propionate combination (SFC) and associated costs [Abstract]. American Thoracic Society 100th International Conference; May 21‐26, 2004; Orlando, Florida. D22 [Poster 503]. HunjanMK , WilliamsDT . Costs of avoiding exacerbations in patients with chronic obstructive pulmonary disease (COPD) treated with salmeterol/ fluticasone propionate combination (seretide) and salmeterol. European Respiratory Journal2004;24 Suppl 48:291s. HunjanMK , WilliamsDT . Salmeterol/ fluticasone propionate combination is clinically effective in avoiding exacerbations in patients with moderate/severe COPD. European Respiratory Journal2004;24 Suppl 48:513s. JonesPW , EdinHM , AndersonJ . Salmeterol/fluticasone propionate combination improves health status in COPD patients. Proceedings of the 98th International American Thoracic Society Conference http://www.abstracts‐on‐line.com/abstracts/ATS; May 17‐22, 2002; Atlanta, Georgia. A39 [Poster K39]. JonesPW , StåhlE . Budesonide /formoterol sustains clinically relevant improvements in health status in COPD [Abstract]. European Respiratory Journal2005;26 Suppl 49:Abstract 1352. JonesPW , VestboJ , PauwelsRA , CalverleyPMA , AndersonJA , SpencerMD . Informative drop out in COPD studies: investigation of health status of withdrawals in the TRISTAN study. Proceedings of the 13th ERS Annual Congress; September 27, 2003; Vienna, Austria. P1593. NitschmannS . Inhalational combination therapy in chronic obstructive lung disease. Tristan study. German Internist2004;45(6):727‐8. PauwelsR , VestboJ , CalverleyPMA , JonesPW , PrideNB , GulsvikA . Characterization of exacerbations in the TRISTAN study of salmeterol / fluticasone propionate (SFC) combination in moderate to severe COPD, 2006. http://www.abstracts2view.com. PauwelsRA , CalverlyPMA , VestboJ , JonesPW , PrideN , GulsvikA , et al. Reduction of exacerbations with salmeterol/fluticasone combination 50/500 mcg bd in the treatment of chronic obstructive pulmonary disease. European Respiratory Journal2002;20 Suppl 38:240 [P1569]. SFCB3024 . A multicentre, randomised, double‐blind, parallel group, placebo‐controlled study to compare the efficacy and safety of the salmeterol/FP combination product at a strength of 50/500mcg bd with salmeterol 50mcg bd alone and FP 500mcg bd alone, delivered via the DISKUS™/ACCUHALER™, in the treatment of subjects with chronic obstructive pulmonary disease (COPD) for 12 months. GlaxoSmithKline Clinical Trials Register (http:ctr.gsk.co.uk)2005. SpencerM , BriggsAH , GrossmanRF , RanceL . Development of an economic model to assess the cost effectiveness of treatment interventions for chronic obstructive pulmonary disease. Pharmacoeconomics2005;23(6):619‐37. SpencerMD , KariaN , AndersonJ . The clinical significance of treatment benefits with the salmeterol/fluticasone propionate 50/500mcg combination in COPD. European Respiratory Journal2004;24 Suppl 48:290s. VestboJ , CalverleyPMA , PauwelsR , JonesP , PrideN , GulsvikA , et al. Absence of gender susceptibility to the combination of salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease. European Respiratory Journal2002;20 Suppl 38:240 [P1570]. VestboJ , PauwelsR , AndersonJA , JonesP , CalverleyP . Early onset of effect of salmeterol and fluticasone propionate in chronic obstructive pulmonary disease. Thorax2005;60(4):301‐4. VestboJ , PauwelsRS , CalverleyPMA , JonesPW , PrideNB , GulsvikA . Salmeterol / fluticasone propionate combination produces improvement in lung function detectable within 24 hours in moderate to severe COPD, 2003. http://www.abstracts2view.com. VestboJ , SorianoJB , AndersonJA , CalverleyP , PauwelsR , JonesP . Gender does not influence the response to the combination of salmeterol and fluticasone propionate in COPD. Respiratory Medicine2004;98(11):1045‐50. ">TRISTAN</a>), the second budesonide/formoterol versus budesonide (4 studies, 1777 participants: <a href="./references#CD006826-bbs2-0002" title="AstraZenecaSD . A placebo‐controlled 12‐month efficacy study of the fixed combination budesonide/formoterol compared to budesonide and formoterol as monotherapies in patients with chronic obstructive pulmonary disease (COPD). AstraZeneca Clinical Trials2002. BorgstromL , AskingL , OlssonH , PetersonS . Lack of interaction between disease severity and therapeutic response with budesonide/formoterol in a single inhaler [Abstract]. American Thoracic Society 100th International Conference; May 21‐26; 2004, Orlando, Florida. C22 [Poster 505]. CalverleyPM , BonsawatW , CsekeZ , ZhongN , PetersonS , OlssonH . Maintenance therapy with budesonide and formoterol in chronic obstructive pulmonary disease. European Respiratory Journal2003;22(6):912‐9. CalverleyPMA , CsekeZ , PetersonS . Budesonide/formoterol reduces the use of oral corticosteroids in the treatment of COPD [Abstract]. European Respiratory Journal2003;22 Suppl 45:P436. CalverleyPMA , KunaP , OlssonH . COPD exacerbations are reduced by budesonide/formoterol in a single inhaler [Abstract]. European Respiratory Journal2003;22 Suppl 45:P1587. CalverleyPMA , OlssonH , Symbicort International COPD Study Group. Budesonide/formoterol ina single inhaler sustains improvements in lung function over 12 months compared with monocomponents and placebo in patients with COPD [abstract]. American Thoracic Society 99th International Conference; May 16‐21, 2003; Seattle, Washington. B024 [Poster 418]. CalverleyPMA , PetersonS . Combining budesonide/formoterol in a single inhale reduces exacerbation frequency in COPD [abstract]. American Thoracic Society 99th International Conference; May 16‐21, 2003; Seattle, Washington. D092 [Poster 211]. CalverleyPMA , StåhlE , JonesPW . Budesonide/formoterol improves the general health status of patients with COPD [Abstract]. American Thoracic Society 2005 International Conference; May 20‐25, 2005; San Diego, California. B93 [Poster 303]. CalverleyPMA , SzafranskiW , AnderssonA . Budesonide/formoterol is a well‐tolerated long term maintenance therapy for COPD. European Respiratory Journal2005;26 Suppl 49:Poster 1917. CalverleyPMA , ThompsonNC , OlssonH . Budesonide/formoterol in a single inhaler sustains lung function improvements in COPD [Abstract]. European Respiratory Journal2003;22 Suppl 45:P435. HalpinD , StåhlE , LundbackB , AndersonF , PetersonS . Treatment costs and number needed to treat (NNT) with budesonide/formoterol to avoid one exacerbation of COPD [Abstract]. American Thoracic Society 100th International Conference; May 21‐26, 2004; Orlando, Florida. D22 [Poster 525]. HalpinDMG , LarssonT , CalverleyPMA . How many patients with COPD must be treated with budesonide/formoterol compared with formoterol alone to avoid 1 day of oral steroid use? [Abstract]. American Thoracic Society 2005 International Conference; May 20‐25, 2005; San Diego, California. B93 [Poster 314]. JonesPW , StahlE . Budesonide/formoterol in a single inhaler improves health status in patients with COPD [abstract]. American Thoracic Society 99th International Conference; May 16‐21, 2003; Orlando, Florida. B024 [Poster 419]. JonesPW , StåhlE . Budesonide /formoterol sustains clinically relevant improvements in health status in COPD [Abstract]. European Respiratory Journal2005;26 Suppl 49:Abstract 1352. JonesPW , StåhlE . Reducing exacerbations leads to a better health‐related quality of life in patients with COPD. 13th ERS Annual Congress; September 27, 2003; Vienna, Austria. P1586. LofdahlCG . Reducing the impact of COPD exacerbations: Clinical efficacy of budesonide/formoterol. European Respiratory Review2004;13(88):14‐21. LofdahlCG , AndreassonE , SvenssonK , EricssonA . Budesonide/formoterol in a single inhaler improves health status in patients with COPD without increasing healthcare costs [Abstract]. European Respiratory Journal2003;22 Suppl 45:P433. LofdahlCG , EricssonA , SvenssonK , AndreassonE . Cost effectiveness of budesonide/formoterol in a single inhaler for COPD compared with each monocomponent used alone. Pharmacoeconomics2005;23(4):365‐75. ">Calverley 2003</a>; <a href="./references#CD006826-bbs2-0010" title="AndersonP . Budesonide/formoterol in a single inhaler (Symbicort) provides early and sustained improvement in lung function in moderate to severe COPD [Abstract]. Thorax2002;57(Suppl III):iii43. AstraZenecaSD . A placebo‐controlled 12 month efficacy study of the fixed combination budesonide/formoterol compared with budesonide and formoterol as monotherapies in patients with chronic obstructive pulmonary disease (COPD). AstraZeneca Clinical Trials2001. BorgstromL , AskingL , OlssonH , PetersonS . Lack of interaction between disease severity and therapeutic response with budesonide/formoterol in a single inhaler [Abstract]. American Thoracic Society 100th International Conference; May 21‐26, 2004; Orlando, Florida. C22 [Poster 505]. CalverleyP , PauwelsR , LofdahlCG , SvenssonK , HigenbottamT , et al. Relationship between respiratory symptoms and medical treatment in exacerbations of COPD. European Respiratory Journal2005;26(3):406‐13. CalverleyPMA . Effect of budesonide/formoterol on severe exacerbations and lung function in moderate to severe COPD. Thorax. BTS Winter Meeting 2002:S145. CalverleyPMA , SzafranskiW , AnderssonA . Budesonide/formoterol is a well‐tolerated long term maintenance therapy for COPD. European Respiratory Journal2005;26 Suppl 49:Poster 1917. CalverleyPMA , ThompsonNC , OlssonH . Budesonide/formoterol in a single inhaler sustains lung function improvements in COPD [Abstract]. European Respiratory Journal2003;22 Suppl 45:P435. CampbellLM , SzafranskiW . Budesonide/formoterol in a single inhaler (Symbicort) provides sustained relief from symptoms in moderate to severe COPD. Thorax. BTS Winter Meeting 2002:S143. CampellLW , SzafranskiW . Budesonide/Formoterol in a single inhaler (Symbicort) reduces severe exacerbations in patients with moderate‐severe COPD. Thorax. BTS Winter Meeting 2002:S141. DahlR , CukierA , OlssonH . Budesonide/formoterol in a single inhaler reduces severe and mild exacerbations in patients with moderate to severe COPD. European Respiratory Journal2002;20 Suppl 38:242 [P1575]. EgedeF , MengaG . Budesonide/formoterol in a single inhaler provides sustained relief from symptoms and night‐time awakenings in moderate‐severe COPD: results from symptoms and night‐time awakenings in moderate to severe COPD: results from a 1‐year study. European Respiratory Journal2002;20 Suppl 38:242 [P1574]. HalpinD , StahlE , LundbackB , AndersonF , PetersonS . Treatment costs and number needed to treat (NNT) with budesonide/formoterol to avoid one exacerbation of COPD [Abstract]. American Thoracic Society 100th International Conference; May 21‐26, 2004; Orlando, Florida. D22 [Poster 525]. JonesPW , StahlE , SvenssonK . Improvement in health status in patients with moderate to severe COPD after treatment with budesonide/formoterol in a single inhaler. European Respiratory Journal2002;20 Suppl 38:250 [P1613]. KorsgaardJ , SansoresR . Budesonide/formoterol (single inhaler) provides sustained relief from shortness of breath and chest tightness in a 1‐year study of patients with moderate to severe COPD. European Respiratory Journal2002;20 Suppl 38:242 [P1577]. LangeP , SaenzC . Budesonide/formoterol in a single inhaler is well tolerated in patients with moderate to severe COPD: results of a 1 year study. European Respiratory Journal2002;20 Suppl 38:242 [P1573]. LofdahlCG . Reducing the impact of COPD exacerbations: clinical efficacy of budesonide/formoterol. European Respiratory Review2004;13(88):14‐21. MilanowskiJ , NahabedianS . Budesonide/formoterol in a single inhaler acts rapidly to improve lung function and relieve symptoms in patients with moderate to severe COPD. European Respiratory Journal2002;20 Suppl 38:242 [P1576]. SzafranskiW , CukierA , RamirezA , MengaG , SansoresR , NahabedianS , et al. Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease. European Respiratory Journal2003;21(1):74‐81. ">Szafranski 2003</a>; <a href="./references#CD006826-bbs2-0011" title="Astrazeneca(D5899C00002) . A 6‐month double‐blind, double‐dummy, randomized, parallel group, multicenter efficacy &amp; safety study of Symbicort® pMDI 2 × 160/4.5mg &amp; 80/4.5mg bid compared to Formoterol TBH, Budesonide pMDI (&amp; the combination) &amp; placebo in COPD patients. www.astrazenecaclinicaltrials.com (accessed 8 April 2008). BleeckerER , MeyersDA , BaileyWC , SimsA‐M , BujacSR , GoldmanM , et al. ADRB2 polymorphisms and budesonide/formoterol responses in COPDADRB2 polymorphisms and treatment response in COPD. Chest2012;142(2):320‐8. TashkinDP , RennardSI , MartinP , GoldmanM , SilkoffPE . Efficacy of budesonide/formoterol administered via one pressurized metered‐dose inhaler over 6 months in patients with chronic obstructive pulmonary disease [Abstract]. Chest2008; Vol. 134, issue 4:105001s. TashkinDP , RennardSI , MartinP , RamachandranS , MartinUJ , SilkoffPE , et al. Efficacy and safety of budesonide and formoterol in one pressurized metered‐dose inhaler in patients with moderate to very severe chronic obstructive pulmonary disease : results of a 6‐month randomized clinical trial. Drugs2008; Vol. 68, issue 0012‐6667 (Print):1975‐2000. ">Tashkin 2008</a>; <a href="./references#CD006826-bbs2-0015" title="ZhongN , ZhengJ , WenF , YangL , ChenP , XiuQ , et al. Efficacy and safety of budesonide/formoterol via a dry powder inhaler in Chinese patients with chronic obstructive pulmonary disease. Current Medical Research and Opinion2012; Vol. 28, issue 2:257‐65. ZhongN , ZhengJ , WenF , YangL , ChenP , XiuQ , et al. Efficacy and safety of inhalation of budesonide/formoterol via turbuhaler in Chinese patients with chronic obstructive pulmonary disease [Abstract]. Chest2011; Vol. 140, issue 4:5225A. ">Zhong 2012</a>) and the third mometasone furoate and formoterol combined (MF/F) versus mometasone furoate (MF). Only two studies were identified, with a total of 905 participants (<a href="./references#CD006826-bbs2-0003" title="DohertyDE , KerwinE , TashkinDP , Matiz‐BuenoCE , ShekarT , BanerjeeS , et al. Combined mometasone furoate and formoterol in patients with moderate to very severe chronic obstructive pulmonary disease (COPD): phase 3 efficacy and safety study [Abstract]. Journal of Allergy and Clinical Immunology2012; Vol. 129, issue 2 Suppl:AB75 [283]. DohertyDE , TashkinDP , KerwinE , KnorrBA , ShekarT , BanerjeeS , et al. Effects of mometasone furoate/formoterol fumarate fixed‐dose combination formulation on chronic obstructive pulmonary disease (COPD): results from a 52‐week Phase III trial in subjects with moderate‐to‐very severe COPD. International Journal of Chronic Obstructive Pulmonary Disease2012; Vol. 7, issue 1178‐2005 (Electronic). 1176‐9106 (Linking):57‐71. NCT00383721 . A Randomized, 26‐Week, Placebo‐Controlled Efficacy and Safety Study With a 26‐Week Long‐Term Safety Extension, of High‐ and Medium‐Dose Inhaled Mometasone Furoate/Formoterol Fixed‐Dose Combination Formulation Compared With Formoterol and High‐Dose Inhaled Mometasone Furoate Monotherapy in Subjects With Moderate to Severe COPD, 2006. http://clinicaltrials.gov/show/NCT00383721. [] ">Doherty 2012</a>; <a href="./references#CD006826-bbs2-0012" title="KerwinE , TashkinDP , Matiz‐BuenoCE , DohertyDE , ShekarT , BanerjeeS , et al. Clinical efficacy and safety of combined mometasone furoate and formoterol in patients with moderate to very severe chronic obstructive pulmonary disease (COPD) [Abstract]. Journal of Allergy and Clinical Immunology2012; Vol. 129, issue 2 Suppl:AB201 [759]. NCT00383435 . A Randomized, 26‐Week, Placebo‐Controlled Efficacy and Safety Study With a 26‐Week Long‐Term Safety Extension, of High‐ and Medium‐Dose Inhaled Mometasone Furoate/Formoterol Fixed‐Dose Combination Formulation Compared With Formoterol and High‐Dose Inhaled Mometasone Furoate Monotherapy in Subjects With Moderate to Severe COPD, 2006. http://clinicaltrials.gov/show/NCT00383435. [] TashkinDP , DohertyDE , KerwinE , Matiz‐BuenoCE , KnorrB , ShekarT , et al. Efficacy and safety of a fixed‐dose combination of mometasone furoate and formoterol fumarate in subjects with moderate to very severe COPD: results from a 52‐week Phase III trial. International Journal of Chronic Obstructive Pulmonary Disease2012; Vol. 7, issue 1178‐2005 (Electronic). 1176‐9106 (Linking):43‐55. ">Tashkin 2012</a>). </p> <p>In one of the fluticasone propionate/salmeterol studies, the combination of ICS/LABA was FPS at a dose of 250 mcg/50 mcg twice daily versus fluticasone propionate (FP) 250 mcg twice daily (<a href="./references#CD006826-bbs2-0004" title="HananiaNA , DarkenP , HorstmanD , ReisnerC , LeeB , DavisS , et al. The efficacy and safety of fluticasone propionate (250 micro g)/salmeterol (50 micro g) combined in the diskus inhaler for the treatment of COPD. Chest2003;124(3):834‐43. HananiaNA , RamsdellJ , PayneK , DavisS , HorstmanD , LeeB , et al. Improvements in airflow and dyspnea in COPD patients following 24 weeks treatment with salmeterol 50mcg and fluticasone propionate 250mcg alone or in combination via the diskus. American Journal of Respiratory &amp; Critical Care Medicine2001;163(5 Suppl):A279. HorstmanD , DarkenP , DavisS , LeeB . Improvements in FEV1 and symptoms in poorly reversible COPD patients following treatment with salmeterol 50mcg/fluticasone propionate 250mcg combination [Abstract]. European Respiratory Journal2003;22 Suppl 45:P434. MahlerDA , DarkenP , BrownCP , KnobilK . Predicting lung function responses to combination therapy in chronic obstructive pulmonary disease (COPD) [Abstract]. National COPD Conference; November 14‐15, 2003; Arlington, Virginia. Abstract 1081. MahlerDA , DarkenP , BrownCP , KnobilK . Predicting lung function responses to salmeterol/fluticasone propionate combination therapy in COPD [Abstract]. European Respiratory Journal2003;22 Suppl 45:P429. SFCA3007 . A randomized, double‐blind, placebo‐controlled, parallel‐group trial evaluating the safety and efficacy of the DISKUS formulations of salmeterol (SAL) 50mcg BID and fluticasone propionate (FP) 250mcg BID individually and in combination as salmeterol 50mcg/fluticasone propionate 250mcg BID (SFC 50/250) compared to placebo in COPD subjects. GlaxoSmithKline Clinical Trials Register (http:ctr.gsk.co.uk)2005. SpencerM , WireP , LeeB , ChangCN , DarkenP , HorstmanD . Patients with COPD using salmeterol/fluticasone propionate combination therapy experience improved quality of life. European Respiratory Journal2003;22 Suppl 45:51s. SpencerMD , KariaN , AndersonJ . The clinical significance of treatment benefits with the salmeterol/fluticasone propionate 50/500mcg combination in COPD. European Respiratory Journal2004;24 Suppl 48:290s. ">Hanania 2003</a>). In the remainder of the FPS studies (<a href="./references#CD006826-bbs2-0001" title="BourbeauJ , ChristodoulopoulosP , MaltaisF , YamauchiY , OlivensteinR , HamidQ . Effect of salmeterol/fluticasone propionate on airway inflammation in COPD: a randomised controlled trial. Thorax2007; Vol. 62, issue 11:938‐43. ">Bourbeau 2007</a>; <a href="./references#CD006826-bbs2-0005" title="LapperreTS , Snoeck‐StrobandJB , GosmanMM , JansenDF , vanSchadewijkA , ThiadensHA , et al. Effect of fluticasone with and without salmeterol on pulmonary outcomes in chronic obstructive pulmonary disease: a randomized trial. Annals of Internal Medicine2009; Vol. 151, issue 8:517‐27. ">Lapperre 2009</a>; <a href="./references#CD006826-bbs2-0006" title="MahlerDA , DarkenP , BrownCP , KnobilK . Predicting lung function responses to combination therapy in chronic obstructive pulmonary disease (COPD), 2003. http://www.abstracts2view.com. MahlerDA , WireP , HorstmanD , ChangCN , YatesJ , FischerT , et al. Effectiveness of fluticasone propionate and salmeterol combination delivered via the diskus device in the treatment of chronic obstructive pulmonary disease. American Journal of Respiratory Critical Care Medicine2002;166(8):1084‐91. SFCA3006 . A randomized, double‐blind, placebo‐controlled, parallel‐group trial evaluating the safety and efficacy of the DISKUS formulations of salmeterol (SAL) 50mcg BID and fluticasone propionate (FP) 500mcg BID individually and in combination as salmeterol 50mcg/fluticasone propionate 500mcg BID (SFC 50/500) compared to placebo in COPD subjects. GlaxoSmithKline Clinical Trials Register (http:ctr.gsk.co.uk)2005. SpencerM , WireP , LeeB , ChangCN , DarkenP , HorstmanD . Patients with COPD using salmeterol/fluticasone propionate combination therapy experience improved quality of life. European Respiratory Journal2003;22 Suppl 45:51s. SpencerMD , AndersonJA . Salmeterol/fluticasone combination produces clinically important benefits in dyspnea and fatigue [Abstract]. American Thoracic Society 2005 International Conference; May 20‐25, 2005; San Diego, California. B93 [Poster 308]. SpencerMD , KariaN , AndersonJ . The clinical significance of treatment benefits with the salmeterol/fluticasone propionate 50/500mcg combination in COPD. European Respiratory Journal2004;24 Suppl 48:290s. ">Mahler 2002</a>; <a href="./references#CD006826-bbs2-0007" title="NCT00358358 . Trial SCO104925. See detailed description, 2006. http://clinicaltrials.gov/show/NCT00358358. [] ">NCT00358358</a>; <a href="./references#CD006826-bbs2-0008" title="SFCT01 . A Multicentre, Randomised, Double‐Blind, Parallel Group, Placebo‐Controlled Study to Compare the Efficacy and Safety of Inhaled Salmeterol/Fluticasone Propionate Combination Product 25/250 µg Two Puffs Bd and Fluticasone Propionate 250µg Two Puffs Bd Alone, All Administered Via Metered Dose Inhalers (MDI), in the Treatment of Subjects with Chronic Obstructive Pulmonary Disease (COPD) for 52 Weeks. GlaxoSmithKline Clinical Trials Register (http:ctr.gsk.co.uk)2005. ">SFCT01</a>; <a href="./references#CD006826-bbs2-0009" title="NCT00120978 . Advair－CRP Study. http://clinicaltrials.gov/show/NCT001209782004. [] SinDD , ManSF , MarciniukDD , FordG , FitzGeraldM , WongE , et al. Can inhaled fluticasone alone or in combination with salmeterol reduce systemic inflammation in chronic obstructive pulmonary disease? Study protocol for a randomized controlled trial [NCT00120978]. BMC Pulmonary Medicine2006;6(6):3. SinDD , ManSF , MarciniukDD , FordG , FitzGeraldM , WongE , et al. The effects of fluticasone with or without salmeterol on systemic biomarkers of inflammation in chronic obstructive pulmonary disease. American Journal of Respiratory and Critical Care Medicine2008; Vol. 177, issue 11:1207‐14. ">Sin 2008</a>; <a href="./references#CD006826-bbs2-0013" title="BriggsAH , GlickHA , Lozano‐OrtegaG , SpencerM , CalverleyPM , JonesPW , et al. Is treatment with ICS and LABA cost‐effective for COPD? Multinational economic analysis of the TORCH study. European Respiratory Journal2010; Vol. 35, issue 3:532‐9. CalverleyPM , AndersonJA , CelliB , FergusonGT , JenkinsC , JonesPW , et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease.[see comment]. New England Journal of Medicine2007; Vol. 356, issue 8:775‐89. CalverleyPMA , AndersonJA , CelliB , FergusonGT , JenkinsC , JonesPW , et al. Cardiovascular events in patients with chronic obstructive pulmonary disease: TORCH study results. Thorax2010;65:719‐25. CalverleyPMA , AndersonJA , CelliB , FergusonGT , JenkinsC , JonesPW , et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. New England Journal of Medicine2007;356(8):775‐89. CalverleyPMA , CelliB , FergusonG , JenkinsC , JonesPW , PrideNB , et al. Baseline characteristics of the first 5,000 COPD patients enrolled in the TORCH survival study. European Respiratory Journal2003;22 Suppl 45:578s. CelliB , CalverleyPMA , AndersonJA , FergusonGT , JenkinsC , JonesPW , et al. The TORCH (TOwards a Revolution in COPD Health) study: salmeterol/fluticasone propionate (SFC) improves health status, reduces exacerbations and improves lung function over three years. European Respiratory Journal2006;28 Suppl 50:34s. CelliB , VestboJ , JenkinsCR , JonesPW , FergusonGT , CalverleyPM , et al. Sex differences in mortality and clinical expressions of patients with chronic obstructive pulmonary disease: the TORCH experience. American Journal of Respiratory and Critical Care Medicine2011;183(3):317‐22. CelliBR , ThomasNE , AndersonJA , FergusonGT , JenkinsCR , JonesPW , et al. Effect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease: results from the TORCH study. American Journal of Respiratory and Critical Care Medicine2008;174(4):332‐8. CrimC , CalverleyPM , AndersonJA , CelliB , FergusonGT , JenkinsC , et al. Pneumonia risk in COPD patients receiving inhaled corticosteroids alone or in combination: TORCH study results. European Respiratory Journal2009;34(3):641‐7. FergusonGT , CalverleyPM , AndersonJA , JenkinsCR , JonesPW , WillitsLR , et al. Prevalence and progression of osteoporosis in patients with COPD: results from the TOwards a Revolution in COPD Health study. Chest2009; Vol. 136, issue 0012‐3692:1456‐65. FergusonGT , CalverleyPMA , AndersonJA , et al. The TORCH (TOwards a Revolution in COPD Health) study: salmeterol/fluticasone propionate (SFC) improves survival in COPD over three years. European Respiratory Journal2006;28 Suppl 50:34s. GlaxoSmithKlineSCO30003 . A multicentre, randomised, double‐blind, parallel group, placebo‐controlled study to investigate the long‐term effects of salmeterol/fluticasone propionate (SERETIDE/VIANI/ADVAIR) 50/500mcg bd, salmeterol 50mcg bd and fluticasone propionate 500mcg bd, all delivered via the DISKUS/ACCUHALER inhaler, on the survival of subjects with chronic obstructive pulmonary disease (COPD) over 3 years of treatment. GlaxoSmithKline Clinical Trial Register2006. HoughtonCM , LawsonN , BorrillZL , WixonCL , YoxallS , LangleySJ , et al. Comparison of the effects of salmeterol/fluticasone propionate with fluticasone propionate on airway physiology in adults with mild persistent asthma. Respiratory Research2007;8:52. JenkinsCR , CalverleyPMA , CelliB , FergusonG , JonesPW , PrideN , et al. Seasonal patterns of exacerbation rates in the TORCH survival study, 2007. http://www.abstracts2view.comA839. JenkinsCR , CelliB , AndersonJA , FergusonGT , JonesPW , VestboJ , et al. Seasonality and determinants of moderate and severe COPD exacerbations in the TORCH study. European Respiratory Journal2012;39(1):38‐45. JenkinsCR , JonesPW , CalverleyPM , CelliB , AndersonJA , FergusonGT , et al. Efficacy of salmeterol/fluticasone propionate by GOLD stage of chronic obstructive pulmonary disease: analysis from the randomised, placebo‐controlled TORCH study. Respiratory Research2009;10:59. JohnsonM , AgustiAG , BarnesNC . Reflections on TORCH: potential mechanisms for the survival benefit of salmeterol/fluticasone propionate in COPD patients. COPD2008;5(6):369‐75. JonesPW , AndersonJA , CalverleyPM , CelliBR , FergusonGT , JenkinsC , et al. TORCH Investigators. Health status in the TORCH study of COPD: treatment efficacy and other determinants of change. Respiratory Research2011;12:71. JonesPW , CalverleyP , CelliB , FergusonG , JenkinsC , PrideN . Trans‐regional validity of the SGRQ in the TORCH survival study, 2007. http://www.abstracts2view.comA122. McGarveyLP , JohnM , AndersonJA , ZvarichMT , WiseRA . Ascertainment of cause‐specific mortality in COPD: operations of the TORCH Clinical Endpoint Committee. Thorax2007;62:411‐5. NCT00268216 . See detailed description, 2000. http://clinicaltrials.gov/show/NCT00268216. [] SCO30003 . A multicentre, randomised, double‐blind, parallel group, placebo‐controlled study to investigate the long‐term effects of salmeterol/fluticasone propionate (SERETIDE®/VIANI®/ADVAIR®) 50/500mcg bd, salmeterol 50mcg bd and fluticasone propionate 500mcg bd, all delivered via the DISKUS®/ACCUHALER® inhaler, on the survival of subjects with chronic obstructive pulmonary disease (COPD) over 3 years of treatment, 2006. www.ctr.gsk.co.uk. VestboJ , AndersonJA , CalverleyPM , CelliB , FergusonGT , JenkinsC , et al. Adherence to inhaled therapy, mortality and hospital admission in COPD. Thorax2009;64(11):939‐43. VestboJ , CalverleyP , CelliB , FergusonG , JenkinsC , JonesP , et al. The TORCH (TOwards a Revolution in COPD Health) survival study protocol. European Respiratory Journal2004;24(2):206‐10. WiseRA , McGarveyLP , JohnM , AndersonJA , ZvarichMT . Reliability of cause‐specific mortality adjudication in a COPD clinical trial, 2007. http://www.abstracts2view.comA120. ">TORCH</a>; <a href="./references#CD006826-bbs2-0014" title="CalverleyP , PauwelsR , VestboJ , JonesP , PrideN , GulsvikA , et al. Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial. Lancet2003;361(9356):449‐56. CalverleyPMA , PauwelsRA , VestboJ , JonesPW , PrideNB , GulsvikA , et al. Clinical improvements with salmeterol / fluticasone propionate combination in differing severities of COPD, 2003. http://www.abstracts2view.comA035 [Poster D50]. CalverleyPMA , PauwelsRA , VestboJ , JonesPW , PrideNB , GulsvikA , et al. Salmeterol/Fluticasone propionate combination for one year provides greater clinical benefit than its individual components. Proceedings of the 98th International American Thoracic Society Conference http://www.abstracts‐on‐line.com/abstracts/ATS; May 17‐22, 2002; Atlanta, Georgia. A98 [Poster 306]. CalverlyPMA , PauwelsR , VestboJ , JonesP , PrideN , GulsvikA , et al. Safety of salmeterol/fluticasone propionate combination in the treatment of chronic obstructive pulmonary disease. European Respiratory Journal2002;20 Suppl 38:242 [P1572]. HunjanMK , ChandlerF . Numbers needed to treat (NNT) to avoid an exacerbation in patients with chronic obstructive pulmonary disease (COPD) using salmeterol/fluticasone propionate combination (SFC) and associated costs [Abstract]. American Thoracic Society 100th International Conference; May 21‐26, 2004; Orlando, Florida. D22 [Poster 503]. HunjanMK , WilliamsDT . Costs of avoiding exacerbations in patients with chronic obstructive pulmonary disease (COPD) treated with salmeterol/ fluticasone propionate combination (seretide) and salmeterol. European Respiratory Journal2004;24 Suppl 48:291s. HunjanMK , WilliamsDT . Salmeterol/ fluticasone propionate combination is clinically effective in avoiding exacerbations in patients with moderate/severe COPD. European Respiratory Journal2004;24 Suppl 48:513s. JonesPW , EdinHM , AndersonJ . Salmeterol/fluticasone propionate combination improves health status in COPD patients. Proceedings of the 98th International American Thoracic Society Conference http://www.abstracts‐on‐line.com/abstracts/ATS; May 17‐22, 2002; Atlanta, Georgia. A39 [Poster K39]. JonesPW , StåhlE . Budesonide /formoterol sustains clinically relevant improvements in health status in COPD [Abstract]. European Respiratory Journal2005;26 Suppl 49:Abstract 1352. JonesPW , VestboJ , PauwelsRA , CalverleyPMA , AndersonJA , SpencerMD . Informative drop out in COPD studies: investigation of health status of withdrawals in the TRISTAN study. Proceedings of the 13th ERS Annual Congress; September 27, 2003; Vienna, Austria. P1593. NitschmannS . Inhalational combination therapy in chronic obstructive lung disease. Tristan study. German Internist2004;45(6):727‐8. PauwelsR , VestboJ , CalverleyPMA , JonesPW , PrideNB , GulsvikA . Characterization of exacerbations in the TRISTAN study of salmeterol / fluticasone propionate (SFC) combination in moderate to severe COPD, 2006. http://www.abstracts2view.com. PauwelsRA , CalverlyPMA , VestboJ , JonesPW , PrideN , GulsvikA , et al. Reduction of exacerbations with salmeterol/fluticasone combination 50/500 mcg bd in the treatment of chronic obstructive pulmonary disease. European Respiratory Journal2002;20 Suppl 38:240 [P1569]. SFCB3024 . A multicentre, randomised, double‐blind, parallel group, placebo‐controlled study to compare the efficacy and safety of the salmeterol/FP combination product at a strength of 50/500mcg bd with salmeterol 50mcg bd alone and FP 500mcg bd alone, delivered via the DISKUS™/ACCUHALER™, in the treatment of subjects with chronic obstructive pulmonary disease (COPD) for 12 months. GlaxoSmithKline Clinical Trials Register (http:ctr.gsk.co.uk)2005. SpencerM , BriggsAH , GrossmanRF , RanceL . Development of an economic model to assess the cost effectiveness of treatment interventions for chronic obstructive pulmonary disease. Pharmacoeconomics2005;23(6):619‐37. SpencerMD , KariaN , AndersonJ . The clinical significance of treatment benefits with the salmeterol/fluticasone propionate 50/500mcg combination in COPD. European Respiratory Journal2004;24 Suppl 48:290s. VestboJ , CalverleyPMA , PauwelsR , JonesP , PrideN , GulsvikA , et al. Absence of gender susceptibility to the combination of salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease. European Respiratory Journal2002;20 Suppl 38:240 [P1570]. VestboJ , PauwelsR , AndersonJA , JonesP , CalverleyP . Early onset of effect of salmeterol and fluticasone propionate in chronic obstructive pulmonary disease. Thorax2005;60(4):301‐4. VestboJ , PauwelsRS , CalverleyPMA , JonesPW , PrideNB , GulsvikA . Salmeterol / fluticasone propionate combination produces improvement in lung function detectable within 24 hours in moderate to severe COPD, 2003. http://www.abstracts2view.com. VestboJ , SorianoJB , AndersonJA , CalverleyP , PauwelsR , JonesP . Gender does not influence the response to the combination of salmeterol and fluticasone propionate in COPD. Respiratory Medicine2004;98(11):1045‐50. ">TRISTAN</a>), the dose was 500 mcg/50 mcg twice daily versus FP 500 mcg twice daily. </p> <p>In two of the budesonide/formoterol studies (<a href="./references#CD006826-bbs2-0002" title="AstraZenecaSD . A placebo‐controlled 12‐month efficacy study of the fixed combination budesonide/formoterol compared to budesonide and formoterol as monotherapies in patients with chronic obstructive pulmonary disease (COPD). AstraZeneca Clinical Trials2002. BorgstromL , AskingL , OlssonH , PetersonS . Lack of interaction between disease severity and therapeutic response with budesonide/formoterol in a single inhaler [Abstract]. American Thoracic Society 100th International Conference; May 21‐26; 2004, Orlando, Florida. C22 [Poster 505]. CalverleyPM , BonsawatW , CsekeZ , ZhongN , PetersonS , OlssonH . Maintenance therapy with budesonide and formoterol in chronic obstructive pulmonary disease. European Respiratory Journal2003;22(6):912‐9. CalverleyPMA , CsekeZ , PetersonS . Budesonide/formoterol reduces the use of oral corticosteroids in the treatment of COPD [Abstract]. European Respiratory Journal2003;22 Suppl 45:P436. CalverleyPMA , KunaP , OlssonH . COPD exacerbations are reduced by budesonide/formoterol in a single inhaler [Abstract]. European Respiratory Journal2003;22 Suppl 45:P1587. CalverleyPMA , OlssonH , Symbicort International COPD Study Group. Budesonide/formoterol ina single inhaler sustains improvements in lung function over 12 months compared with monocomponents and placebo in patients with COPD [abstract]. American Thoracic Society 99th International Conference; May 16‐21, 2003; Seattle, Washington. B024 [Poster 418]. CalverleyPMA , PetersonS . Combining budesonide/formoterol in a single inhale reduces exacerbation frequency in COPD [abstract]. American Thoracic Society 99th International Conference; May 16‐21, 2003; Seattle, Washington. D092 [Poster 211]. CalverleyPMA , StåhlE , JonesPW . Budesonide/formoterol improves the general health status of patients with COPD [Abstract]. American Thoracic Society 2005 International Conference; May 20‐25, 2005; San Diego, California. B93 [Poster 303]. CalverleyPMA , SzafranskiW , AnderssonA . Budesonide/formoterol is a well‐tolerated long term maintenance therapy for COPD. European Respiratory Journal2005;26 Suppl 49:Poster 1917. CalverleyPMA , ThompsonNC , OlssonH . Budesonide/formoterol in a single inhaler sustains lung function improvements in COPD [Abstract]. European Respiratory Journal2003;22 Suppl 45:P435. HalpinD , StåhlE , LundbackB , AndersonF , PetersonS . Treatment costs and number needed to treat (NNT) with budesonide/formoterol to avoid one exacerbation of COPD [Abstract]. American Thoracic Society 100th International Conference; May 21‐26, 2004; Orlando, Florida. D22 [Poster 525]. HalpinDMG , LarssonT , CalverleyPMA . How many patients with COPD must be treated with budesonide/formoterol compared with formoterol alone to avoid 1 day of oral steroid use? [Abstract]. American Thoracic Society 2005 International Conference; May 20‐25, 2005; San Diego, California. B93 [Poster 314]. JonesPW , StahlE . Budesonide/formoterol in a single inhaler improves health status in patients with COPD [abstract]. American Thoracic Society 99th International Conference; May 16‐21, 2003; Orlando, Florida. B024 [Poster 419]. JonesPW , StåhlE . Budesonide /formoterol sustains clinically relevant improvements in health status in COPD [Abstract]. European Respiratory Journal2005;26 Suppl 49:Abstract 1352. JonesPW , StåhlE . Reducing exacerbations leads to a better health‐related quality of life in patients with COPD. 13th ERS Annual Congress; September 27, 2003; Vienna, Austria. P1586. LofdahlCG . Reducing the impact of COPD exacerbations: Clinical efficacy of budesonide/formoterol. European Respiratory Review2004;13(88):14‐21. LofdahlCG , AndreassonE , SvenssonK , EricssonA . Budesonide/formoterol in a single inhaler improves health status in patients with COPD without increasing healthcare costs [Abstract]. European Respiratory Journal2003;22 Suppl 45:P433. LofdahlCG , EricssonA , SvenssonK , AndreassonE . Cost effectiveness of budesonide/formoterol in a single inhaler for COPD compared with each monocomponent used alone. Pharmacoeconomics2005;23(4):365‐75. ">Calverley 2003</a> and <a href="./references#CD006826-bbs2-0010" title="AndersonP . Budesonide/formoterol in a single inhaler (Symbicort) provides early and sustained improvement in lung function in moderate to severe COPD [Abstract]. Thorax2002;57(Suppl III):iii43. AstraZenecaSD . A placebo‐controlled 12 month efficacy study of the fixed combination budesonide/formoterol compared with budesonide and formoterol as monotherapies in patients with chronic obstructive pulmonary disease (COPD). AstraZeneca Clinical Trials2001. BorgstromL , AskingL , OlssonH , PetersonS . Lack of interaction between disease severity and therapeutic response with budesonide/formoterol in a single inhaler [Abstract]. American Thoracic Society 100th International Conference; May 21‐26, 2004; Orlando, Florida. C22 [Poster 505]. CalverleyP , PauwelsR , LofdahlCG , SvenssonK , HigenbottamT , et al. Relationship between respiratory symptoms and medical treatment in exacerbations of COPD. European Respiratory Journal2005;26(3):406‐13. CalverleyPMA . Effect of budesonide/formoterol on severe exacerbations and lung function in moderate to severe COPD. Thorax. BTS Winter Meeting 2002:S145. CalverleyPMA , SzafranskiW , AnderssonA . Budesonide/formoterol is a well‐tolerated long term maintenance therapy for COPD. European Respiratory Journal2005;26 Suppl 49:Poster 1917. CalverleyPMA , ThompsonNC , OlssonH . Budesonide/formoterol in a single inhaler sustains lung function improvements in COPD [Abstract]. European Respiratory Journal2003;22 Suppl 45:P435. CampbellLM , SzafranskiW . Budesonide/formoterol in a single inhaler (Symbicort) provides sustained relief from symptoms in moderate to severe COPD. Thorax. BTS Winter Meeting 2002:S143. CampellLW , SzafranskiW . Budesonide/Formoterol in a single inhaler (Symbicort) reduces severe exacerbations in patients with moderate‐severe COPD. Thorax. BTS Winter Meeting 2002:S141. DahlR , CukierA , OlssonH . Budesonide/formoterol in a single inhaler reduces severe and mild exacerbations in patients with moderate to severe COPD. European Respiratory Journal2002;20 Suppl 38:242 [P1575]. EgedeF , MengaG . Budesonide/formoterol in a single inhaler provides sustained relief from symptoms and night‐time awakenings in moderate‐severe COPD: results from symptoms and night‐time awakenings in moderate to severe COPD: results from a 1‐year study. European Respiratory Journal2002;20 Suppl 38:242 [P1574]. HalpinD , StahlE , LundbackB , AndersonF , PetersonS . Treatment costs and number needed to treat (NNT) with budesonide/formoterol to avoid one exacerbation of COPD [Abstract]. American Thoracic Society 100th International Conference; May 21‐26, 2004; Orlando, Florida. D22 [Poster 525]. JonesPW , StahlE , SvenssonK . Improvement in health status in patients with moderate to severe COPD after treatment with budesonide/formoterol in a single inhaler. European Respiratory Journal2002;20 Suppl 38:250 [P1613]. KorsgaardJ , SansoresR . Budesonide/formoterol (single inhaler) provides sustained relief from shortness of breath and chest tightness in a 1‐year study of patients with moderate to severe COPD. European Respiratory Journal2002;20 Suppl 38:242 [P1577]. LangeP , SaenzC . Budesonide/formoterol in a single inhaler is well tolerated in patients with moderate to severe COPD: results of a 1 year study. European Respiratory Journal2002;20 Suppl 38:242 [P1573]. LofdahlCG . Reducing the impact of COPD exacerbations: clinical efficacy of budesonide/formoterol. European Respiratory Review2004;13(88):14‐21. MilanowskiJ , NahabedianS . Budesonide/formoterol in a single inhaler acts rapidly to improve lung function and relieve symptoms in patients with moderate to severe COPD. European Respiratory Journal2002;20 Suppl 38:242 [P1576]. SzafranskiW , CukierA , RamirezA , MengaG , SansoresR , NahabedianS , et al. Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease. European Respiratory Journal2003;21(1):74‐81. ">Szafranski 2003</a>), the combination ICS/LABA was budesonide/formoterol (BDF) (320 mcg/9 mcg twice daily). This was compared with budesonide (BD; 400 mcg twice daily). The dosage of the combined preparation and of the separate medications remained stable throughout the studies. In <a href="./references#CD006826-bbs2-0002" title="AstraZenecaSD . A placebo‐controlled 12‐month efficacy study of the fixed combination budesonide/formoterol compared to budesonide and formoterol as monotherapies in patients with chronic obstructive pulmonary disease (COPD). AstraZeneca Clinical Trials2002. BorgstromL , AskingL , OlssonH , PetersonS . Lack of interaction between disease severity and therapeutic response with budesonide/formoterol in a single inhaler [Abstract]. American Thoracic Society 100th International Conference; May 21‐26; 2004, Orlando, Florida. C22 [Poster 505]. CalverleyPM , BonsawatW , CsekeZ , ZhongN , PetersonS , OlssonH . Maintenance therapy with budesonide and formoterol in chronic obstructive pulmonary disease. European Respiratory Journal2003;22(6):912‐9. CalverleyPMA , CsekeZ , PetersonS . Budesonide/formoterol reduces the use of oral corticosteroids in the treatment of COPD [Abstract]. European Respiratory Journal2003;22 Suppl 45:P436. CalverleyPMA , KunaP , OlssonH . COPD exacerbations are reduced by budesonide/formoterol in a single inhaler [Abstract]. European Respiratory Journal2003;22 Suppl 45:P1587. CalverleyPMA , OlssonH , Symbicort International COPD Study Group. Budesonide/formoterol ina single inhaler sustains improvements in lung function over 12 months compared with monocomponents and placebo in patients with COPD [abstract]. American Thoracic Society 99th International Conference; May 16‐21, 2003; Seattle, Washington. B024 [Poster 418]. CalverleyPMA , PetersonS . Combining budesonide/formoterol in a single inhale reduces exacerbation frequency in COPD [abstract]. American Thoracic Society 99th International Conference; May 16‐21, 2003; Seattle, Washington. D092 [Poster 211]. CalverleyPMA , StåhlE , JonesPW . Budesonide/formoterol improves the general health status of patients with COPD [Abstract]. American Thoracic Society 2005 International Conference; May 20‐25, 2005; San Diego, California. B93 [Poster 303]. CalverleyPMA , SzafranskiW , AnderssonA . Budesonide/formoterol is a well‐tolerated long term maintenance therapy for COPD. European Respiratory Journal2005;26 Suppl 49:Poster 1917. CalverleyPMA , ThompsonNC , OlssonH . Budesonide/formoterol in a single inhaler sustains lung function improvements in COPD [Abstract]. European Respiratory Journal2003;22 Suppl 45:P435. HalpinD , StåhlE , LundbackB , AndersonF , PetersonS . Treatment costs and number needed to treat (NNT) with budesonide/formoterol to avoid one exacerbation of COPD [Abstract]. American Thoracic Society 100th International Conference; May 21‐26, 2004; Orlando, Florida. D22 [Poster 525]. HalpinDMG , LarssonT , CalverleyPMA . How many patients with COPD must be treated with budesonide/formoterol compared with formoterol alone to avoid 1 day of oral steroid use? [Abstract]. American Thoracic Society 2005 International Conference; May 20‐25, 2005; San Diego, California. B93 [Poster 314]. JonesPW , StahlE . Budesonide/formoterol in a single inhaler improves health status in patients with COPD [abstract]. American Thoracic Society 99th International Conference; May 16‐21, 2003; Orlando, Florida. B024 [Poster 419]. JonesPW , StåhlE . Budesonide /formoterol sustains clinically relevant improvements in health status in COPD [Abstract]. European Respiratory Journal2005;26 Suppl 49:Abstract 1352. JonesPW , StåhlE . Reducing exacerbations leads to a better health‐related quality of life in patients with COPD. 13th ERS Annual Congress; September 27, 2003; Vienna, Austria. P1586. LofdahlCG . Reducing the impact of COPD exacerbations: Clinical efficacy of budesonide/formoterol. European Respiratory Review2004;13(88):14‐21. LofdahlCG , AndreassonE , SvenssonK , EricssonA . Budesonide/formoterol in a single inhaler improves health status in patients with COPD without increasing healthcare costs [Abstract]. European Respiratory Journal2003;22 Suppl 45:P433. LofdahlCG , EricssonA , SvenssonK , AndreassonE . Cost effectiveness of budesonide/formoterol in a single inhaler for COPD compared with each monocomponent used alone. Pharmacoeconomics2005;23(4):365‐75. ">Calverley 2003</a>, all participants had a two‐week run‐in treatment with oral corticosteroids, inhaled formoterol and prn short‐acting beta<sub>2</sub>‐agonists. In <a href="./references#CD006826-bbs2-0011" title="Astrazeneca(D5899C00002) . A 6‐month double‐blind, double‐dummy, randomized, parallel group, multicenter efficacy &amp; safety study of Symbicort® pMDI 2 × 160/4.5mg &amp; 80/4.5mg bid compared to Formoterol TBH, Budesonide pMDI (&amp; the combination) &amp; placebo in COPD patients. www.astrazenecaclinicaltrials.com (accessed 8 April 2008). BleeckerER , MeyersDA , BaileyWC , SimsA‐M , BujacSR , GoldmanM , et al. ADRB2 polymorphisms and budesonide/formoterol responses in COPDADRB2 polymorphisms and treatment response in COPD. Chest2012;142(2):320‐8. TashkinDP , RennardSI , MartinP , GoldmanM , SilkoffPE . Efficacy of budesonide/formoterol administered via one pressurized metered‐dose inhaler over 6 months in patients with chronic obstructive pulmonary disease [Abstract]. Chest2008; Vol. 134, issue 4:105001s. TashkinDP , RennardSI , MartinP , RamachandranS , MartinUJ , SilkoffPE , et al. Efficacy and safety of budesonide and formoterol in one pressurized metered‐dose inhaler in patients with moderate to very severe chronic obstructive pulmonary disease : results of a 6‐month randomized clinical trial. Drugs2008; Vol. 68, issue 0012‐6667 (Print):1975‐2000. ">Tashkin 2008</a>, the comparison was made between BDF (160/4.5 mcg/dose) 2 inhalations twice daily versus BD (160 mcg/dose) 2 inhalations twice daily, and in <a href="./references#CD006826-bbs2-0015" title="ZhongN , ZhengJ , WenF , YangL , ChenP , XiuQ , et al. Efficacy and safety of budesonide/formoterol via a dry powder inhaler in Chinese patients with chronic obstructive pulmonary disease. Current Medical Research and Opinion2012; Vol. 28, issue 2:257‐65. ZhongN , ZhengJ , WenF , YangL , ChenP , XiuQ , et al. Efficacy and safety of inhalation of budesonide/formoterol via turbuhaler in Chinese patients with chronic obstructive pulmonary disease [Abstract]. Chest2011; Vol. 140, issue 4:5225A. ">Zhong 2012</a>, the comparison was between BDF (160/4.5 mcg/dose) 2 inhalations twice daily versus BD (200 mcg/dose) 2 inhalations twice daily. </p> <p>In the two mometasone furoate and formoterol combined (MF/F) versus mometasone furoate (MF) studies (<a href="./references#CD006826-bbs2-0003" title="DohertyDE , KerwinE , TashkinDP , Matiz‐BuenoCE , ShekarT , BanerjeeS , et al. Combined mometasone furoate and formoterol in patients with moderate to very severe chronic obstructive pulmonary disease (COPD): phase 3 efficacy and safety study [Abstract]. Journal of Allergy and Clinical Immunology2012; Vol. 129, issue 2 Suppl:AB75 [283]. DohertyDE , TashkinDP , KerwinE , KnorrBA , ShekarT , BanerjeeS , et al. Effects of mometasone furoate/formoterol fumarate fixed‐dose combination formulation on chronic obstructive pulmonary disease (COPD): results from a 52‐week Phase III trial in subjects with moderate‐to‐very severe COPD. International Journal of Chronic Obstructive Pulmonary Disease2012; Vol. 7, issue 1178‐2005 (Electronic). 1176‐9106 (Linking):57‐71. NCT00383721 . A Randomized, 26‐Week, Placebo‐Controlled Efficacy and Safety Study With a 26‐Week Long‐Term Safety Extension, of High‐ and Medium‐Dose Inhaled Mometasone Furoate/Formoterol Fixed‐Dose Combination Formulation Compared With Formoterol and High‐Dose Inhaled Mometasone Furoate Monotherapy in Subjects With Moderate to Severe COPD, 2006. http://clinicaltrials.gov/show/NCT00383721. [] ">Doherty 2012</a>; <a href="./references#CD006826-bbs2-0012" title="KerwinE , TashkinDP , Matiz‐BuenoCE , DohertyDE , ShekarT , BanerjeeS , et al. Clinical efficacy and safety of combined mometasone furoate and formoterol in patients with moderate to very severe chronic obstructive pulmonary disease (COPD) [Abstract]. Journal of Allergy and Clinical Immunology2012; Vol. 129, issue 2 Suppl:AB201 [759]. NCT00383435 . A Randomized, 26‐Week, Placebo‐Controlled Efficacy and Safety Study With a 26‐Week Long‐Term Safety Extension, of High‐ and Medium‐Dose Inhaled Mometasone Furoate/Formoterol Fixed‐Dose Combination Formulation Compared With Formoterol and High‐Dose Inhaled Mometasone Furoate Monotherapy in Subjects With Moderate to Severe COPD, 2006. http://clinicaltrials.gov/show/NCT00383435. [] TashkinDP , DohertyDE , KerwinE , Matiz‐BuenoCE , KnorrB , ShekarT , et al. Efficacy and safety of a fixed‐dose combination of mometasone furoate and formoterol fumarate in subjects with moderate to very severe COPD: results from a 52‐week Phase III trial. International Journal of Chronic Obstructive Pulmonary Disease2012; Vol. 7, issue 1178‐2005 (Electronic). 1176‐9106 (Linking):43‐55. ">Tashkin 2012</a>), the comparison was between MF/F 400/10 mcg twice daily versus MF 400 mcg twice daily. For details of co‐medication and run‐in periods on all 15 studies, please see <a href="./references#CD006826-sec-0145" title="">Characteristics of included studies</a>. </p> </section> <section id="CD006826-sec-0059"> <h5 class="title">Duration</h5> <p> <ul id="CD006826-list-0008"> <li> <p>156 weeks: <a href="./references#CD006826-bbs2-0013" title="BriggsAH , GlickHA , Lozano‐OrtegaG , SpencerM , CalverleyPM , JonesPW , et al. Is treatment with ICS and LABA cost‐effective for COPD? Multinational economic analysis of the TORCH study. European Respiratory Journal2010; Vol. 35, issue 3:532‐9. CalverleyPM , AndersonJA , CelliB , FergusonGT , JenkinsC , JonesPW , et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease.[see comment]. New England Journal of Medicine2007; Vol. 356, issue 8:775‐89. CalverleyPMA , AndersonJA , CelliB , FergusonGT , JenkinsC , JonesPW , et al. Cardiovascular events in patients with chronic obstructive pulmonary disease: TORCH study results. Thorax2010;65:719‐25. CalverleyPMA , AndersonJA , CelliB , FergusonGT , JenkinsC , JonesPW , et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. New England Journal of Medicine2007;356(8):775‐89. CalverleyPMA , CelliB , FergusonG , JenkinsC , JonesPW , PrideNB , et al. Baseline characteristics of the first 5,000 COPD patients enrolled in the TORCH survival study. European Respiratory Journal2003;22 Suppl 45:578s. CelliB , CalverleyPMA , AndersonJA , FergusonGT , JenkinsC , JonesPW , et al. The TORCH (TOwards a Revolution in COPD Health) study: salmeterol/fluticasone propionate (SFC) improves health status, reduces exacerbations and improves lung function over three years. European Respiratory Journal2006;28 Suppl 50:34s. CelliB , VestboJ , JenkinsCR , JonesPW , FergusonGT , CalverleyPM , et al. Sex differences in mortality and clinical expressions of patients with chronic obstructive pulmonary disease: the TORCH experience. American Journal of Respiratory and Critical Care Medicine2011;183(3):317‐22. CelliBR , ThomasNE , AndersonJA , FergusonGT , JenkinsCR , JonesPW , et al. Effect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease: results from the TORCH study. American Journal of Respiratory and Critical Care Medicine2008;174(4):332‐8. CrimC , CalverleyPM , AndersonJA , CelliB , FergusonGT , JenkinsC , et al. Pneumonia risk in COPD patients receiving inhaled corticosteroids alone or in combination: TORCH study results. European Respiratory Journal2009;34(3):641‐7. FergusonGT , CalverleyPM , AndersonJA , JenkinsCR , JonesPW , WillitsLR , et al. Prevalence and progression of osteoporosis in patients with COPD: results from the TOwards a Revolution in COPD Health study. Chest2009; Vol. 136, issue 0012‐3692:1456‐65. FergusonGT , CalverleyPMA , AndersonJA , et al. The TORCH (TOwards a Revolution in COPD Health) study: salmeterol/fluticasone propionate (SFC) improves survival in COPD over three years. European Respiratory Journal2006;28 Suppl 50:34s. GlaxoSmithKlineSCO30003 . A multicentre, randomised, double‐blind, parallel group, placebo‐controlled study to investigate the long‐term effects of salmeterol/fluticasone propionate (SERETIDE/VIANI/ADVAIR) 50/500mcg bd, salmeterol 50mcg bd and fluticasone propionate 500mcg bd, all delivered via the DISKUS/ACCUHALER inhaler, on the survival of subjects with chronic obstructive pulmonary disease (COPD) over 3 years of treatment. GlaxoSmithKline Clinical Trial Register2006. HoughtonCM , LawsonN , BorrillZL , WixonCL , YoxallS , LangleySJ , et al. Comparison of the effects of salmeterol/fluticasone propionate with fluticasone propionate on airway physiology in adults with mild persistent asthma. Respiratory Research2007;8:52. JenkinsCR , CalverleyPMA , CelliB , FergusonG , JonesPW , PrideN , et al. Seasonal patterns of exacerbation rates in the TORCH survival study, 2007. http://www.abstracts2view.comA839. JenkinsCR , CelliB , AndersonJA , FergusonGT , JonesPW , VestboJ , et al. Seasonality and determinants of moderate and severe COPD exacerbations in the TORCH study. European Respiratory Journal2012;39(1):38‐45. JenkinsCR , JonesPW , CalverleyPM , CelliB , AndersonJA , FergusonGT , et al. Efficacy of salmeterol/fluticasone propionate by GOLD stage of chronic obstructive pulmonary disease: analysis from the randomised, placebo‐controlled TORCH study. Respiratory Research2009;10:59. JohnsonM , AgustiAG , BarnesNC . Reflections on TORCH: potential mechanisms for the survival benefit of salmeterol/fluticasone propionate in COPD patients. COPD2008;5(6):369‐75. JonesPW , AndersonJA , CalverleyPM , CelliBR , FergusonGT , JenkinsC , et al. TORCH Investigators. Health status in the TORCH study of COPD: treatment efficacy and other determinants of change. Respiratory Research2011;12:71. JonesPW , CalverleyP , CelliB , FergusonG , JenkinsC , PrideN . Trans‐regional validity of the SGRQ in the TORCH survival study, 2007. http://www.abstracts2view.comA122. McGarveyLP , JohnM , AndersonJA , ZvarichMT , WiseRA . Ascertainment of cause‐specific mortality in COPD: operations of the TORCH Clinical Endpoint Committee. Thorax2007;62:411‐5. NCT00268216 . See detailed description, 2000. http://clinicaltrials.gov/show/NCT00268216. [] SCO30003 . A multicentre, randomised, double‐blind, parallel group, placebo‐controlled study to investigate the long‐term effects of salmeterol/fluticasone propionate (SERETIDE®/VIANI®/ADVAIR®) 50/500mcg bd, salmeterol 50mcg bd and fluticasone propionate 500mcg bd, all delivered via the DISKUS®/ACCUHALER® inhaler, on the survival of subjects with chronic obstructive pulmonary disease (COPD) over 3 years of treatment, 2006. www.ctr.gsk.co.uk. VestboJ , AndersonJA , CalverleyPM , CelliB , FergusonGT , JenkinsC , et al. Adherence to inhaled therapy, mortality and hospital admission in COPD. Thorax2009;64(11):939‐43. VestboJ , CalverleyP , CelliB , FergusonG , JenkinsC , JonesP , et al. The TORCH (TOwards a Revolution in COPD Health) survival study protocol. European Respiratory Journal2004;24(2):206‐10. WiseRA , McGarveyLP , JohnM , AndersonJA , ZvarichMT . Reliability of cause‐specific mortality adjudication in a COPD clinical trial, 2007. http://www.abstracts2view.comA120. ">TORCH</a>. </p> </li> <li> <p>128 weeks: <a href="./references#CD006826-bbs2-0005" title="LapperreTS , Snoeck‐StrobandJB , GosmanMM , JansenDF , vanSchadewijkA , ThiadensHA , et al. Effect of fluticasone with and without salmeterol on pulmonary outcomes in chronic obstructive pulmonary disease: a randomized trial. Annals of Internal Medicine2009; Vol. 151, issue 8:517‐27. ">Lapperre 2009</a> </p> </li> <li> <p>52 weeks: <a href="./references#CD006826-bbs2-0002" title="AstraZenecaSD . A placebo‐controlled 12‐month efficacy study of the fixed combination budesonide/formoterol compared to budesonide and formoterol as monotherapies in patients with chronic obstructive pulmonary disease (COPD). AstraZeneca Clinical Trials2002. BorgstromL , AskingL , OlssonH , PetersonS . Lack of interaction between disease severity and therapeutic response with budesonide/formoterol in a single inhaler [Abstract]. American Thoracic Society 100th International Conference; May 21‐26; 2004, Orlando, Florida. C22 [Poster 505]. CalverleyPM , BonsawatW , CsekeZ , ZhongN , PetersonS , OlssonH . Maintenance therapy with budesonide and formoterol in chronic obstructive pulmonary disease. European Respiratory Journal2003;22(6):912‐9. CalverleyPMA , CsekeZ , PetersonS . Budesonide/formoterol reduces the use of oral corticosteroids in the treatment of COPD [Abstract]. European Respiratory Journal2003;22 Suppl 45:P436. CalverleyPMA , KunaP , OlssonH . COPD exacerbations are reduced by budesonide/formoterol in a single inhaler [Abstract]. European Respiratory Journal2003;22 Suppl 45:P1587. CalverleyPMA , OlssonH , Symbicort International COPD Study Group. Budesonide/formoterol ina single inhaler sustains improvements in lung function over 12 months compared with monocomponents and placebo in patients with COPD [abstract]. American Thoracic Society 99th International Conference; May 16‐21, 2003; Seattle, Washington. B024 [Poster 418]. CalverleyPMA , PetersonS . Combining budesonide/formoterol in a single inhale reduces exacerbation frequency in COPD [abstract]. American Thoracic Society 99th International Conference; May 16‐21, 2003; Seattle, Washington. D092 [Poster 211]. CalverleyPMA , StåhlE , JonesPW . Budesonide/formoterol improves the general health status of patients with COPD [Abstract]. American Thoracic Society 2005 International Conference; May 20‐25, 2005; San Diego, California. B93 [Poster 303]. CalverleyPMA , SzafranskiW , AnderssonA . Budesonide/formoterol is a well‐tolerated long term maintenance therapy for COPD. European Respiratory Journal2005;26 Suppl 49:Poster 1917. CalverleyPMA , ThompsonNC , OlssonH . Budesonide/formoterol in a single inhaler sustains lung function improvements in COPD [Abstract]. European Respiratory Journal2003;22 Suppl 45:P435. HalpinD , StåhlE , LundbackB , AndersonF , PetersonS . Treatment costs and number needed to treat (NNT) with budesonide/formoterol to avoid one exacerbation of COPD [Abstract]. American Thoracic Society 100th International Conference; May 21‐26, 2004; Orlando, Florida. D22 [Poster 525]. HalpinDMG , LarssonT , CalverleyPMA . How many patients with COPD must be treated with budesonide/formoterol compared with formoterol alone to avoid 1 day of oral steroid use? [Abstract]. American Thoracic Society 2005 International Conference; May 20‐25, 2005; San Diego, California. B93 [Poster 314]. JonesPW , StahlE . Budesonide/formoterol in a single inhaler improves health status in patients with COPD [abstract]. American Thoracic Society 99th International Conference; May 16‐21, 2003; Orlando, Florida. B024 [Poster 419]. JonesPW , StåhlE . Budesonide /formoterol sustains clinically relevant improvements in health status in COPD [Abstract]. European Respiratory Journal2005;26 Suppl 49:Abstract 1352. JonesPW , StåhlE . Reducing exacerbations leads to a better health‐related quality of life in patients with COPD. 13th ERS Annual Congress; September 27, 2003; Vienna, Austria. P1586. LofdahlCG . Reducing the impact of COPD exacerbations: Clinical efficacy of budesonide/formoterol. European Respiratory Review2004;13(88):14‐21. LofdahlCG , AndreassonE , SvenssonK , EricssonA . Budesonide/formoterol in a single inhaler improves health status in patients with COPD without increasing healthcare costs [Abstract]. European Respiratory Journal2003;22 Suppl 45:P433. LofdahlCG , EricssonA , SvenssonK , AndreassonE . Cost effectiveness of budesonide/formoterol in a single inhaler for COPD compared with each monocomponent used alone. Pharmacoeconomics2005;23(4):365‐75. ">Calverley 2003</a>; <a href="./references#CD006826-bbs2-0008" title="SFCT01 . A Multicentre, Randomised, Double‐Blind, Parallel Group, Placebo‐Controlled Study to Compare the Efficacy and Safety of Inhaled Salmeterol/Fluticasone Propionate Combination Product 25/250 µg Two Puffs Bd and Fluticasone Propionate 250µg Two Puffs Bd Alone, All Administered Via Metered Dose Inhalers (MDI), in the Treatment of Subjects with Chronic Obstructive Pulmonary Disease (COPD) for 52 Weeks. GlaxoSmithKline Clinical Trials Register (http:ctr.gsk.co.uk)2005. ">SFCT01</a>; <a href="./references#CD006826-bbs2-0010" title="AndersonP . Budesonide/formoterol in a single inhaler (Symbicort) provides early and sustained improvement in lung function in moderate to severe COPD [Abstract]. Thorax2002;57(Suppl III):iii43. AstraZenecaSD . A placebo‐controlled 12 month efficacy study of the fixed combination budesonide/formoterol compared with budesonide and formoterol as monotherapies in patients with chronic obstructive pulmonary disease (COPD). AstraZeneca Clinical Trials2001. BorgstromL , AskingL , OlssonH , PetersonS . Lack of interaction between disease severity and therapeutic response with budesonide/formoterol in a single inhaler [Abstract]. American Thoracic Society 100th International Conference; May 21‐26, 2004; Orlando, Florida. C22 [Poster 505]. CalverleyP , PauwelsR , LofdahlCG , SvenssonK , HigenbottamT , et al. Relationship between respiratory symptoms and medical treatment in exacerbations of COPD. European Respiratory Journal2005;26(3):406‐13. CalverleyPMA . Effect of budesonide/formoterol on severe exacerbations and lung function in moderate to severe COPD. Thorax. BTS Winter Meeting 2002:S145. CalverleyPMA , SzafranskiW , AnderssonA . Budesonide/formoterol is a well‐tolerated long term maintenance therapy for COPD. European Respiratory Journal2005;26 Suppl 49:Poster 1917. CalverleyPMA , ThompsonNC , OlssonH . Budesonide/formoterol in a single inhaler sustains lung function improvements in COPD [Abstract]. European Respiratory Journal2003;22 Suppl 45:P435. CampbellLM , SzafranskiW . Budesonide/formoterol in a single inhaler (Symbicort) provides sustained relief from symptoms in moderate to severe COPD. Thorax. BTS Winter Meeting 2002:S143. CampellLW , SzafranskiW . Budesonide/Formoterol in a single inhaler (Symbicort) reduces severe exacerbations in patients with moderate‐severe COPD. Thorax. BTS Winter Meeting 2002:S141. DahlR , CukierA , OlssonH . Budesonide/formoterol in a single inhaler reduces severe and mild exacerbations in patients with moderate to severe COPD. European Respiratory Journal2002;20 Suppl 38:242 [P1575]. EgedeF , MengaG . Budesonide/formoterol in a single inhaler provides sustained relief from symptoms and night‐time awakenings in moderate‐severe COPD: results from symptoms and night‐time awakenings in moderate to severe COPD: results from a 1‐year study. European Respiratory Journal2002;20 Suppl 38:242 [P1574]. HalpinD , StahlE , LundbackB , AndersonF , PetersonS . Treatment costs and number needed to treat (NNT) with budesonide/formoterol to avoid one exacerbation of COPD [Abstract]. American Thoracic Society 100th International Conference; May 21‐26, 2004; Orlando, Florida. D22 [Poster 525]. JonesPW , StahlE , SvenssonK . Improvement in health status in patients with moderate to severe COPD after treatment with budesonide/formoterol in a single inhaler. European Respiratory Journal2002;20 Suppl 38:250 [P1613]. KorsgaardJ , SansoresR . Budesonide/formoterol (single inhaler) provides sustained relief from shortness of breath and chest tightness in a 1‐year study of patients with moderate to severe COPD. European Respiratory Journal2002;20 Suppl 38:242 [P1577]. LangeP , SaenzC . Budesonide/formoterol in a single inhaler is well tolerated in patients with moderate to severe COPD: results of a 1 year study. European Respiratory Journal2002;20 Suppl 38:242 [P1573]. LofdahlCG . Reducing the impact of COPD exacerbations: clinical efficacy of budesonide/formoterol. European Respiratory Review2004;13(88):14‐21. MilanowskiJ , NahabedianS . Budesonide/formoterol in a single inhaler acts rapidly to improve lung function and relieve symptoms in patients with moderate to severe COPD. European Respiratory Journal2002;20 Suppl 38:242 [P1576]. SzafranskiW , CukierA , RamirezA , MengaG , SansoresR , NahabedianS , et al. Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease. European Respiratory Journal2003;21(1):74‐81. ">Szafranski 2003</a>; <a href="./references#CD006826-bbs2-0014" title="CalverleyP , PauwelsR , VestboJ , JonesP , PrideN , GulsvikA , et al. Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial. Lancet2003;361(9356):449‐56. CalverleyPMA , PauwelsRA , VestboJ , JonesPW , PrideNB , GulsvikA , et al. Clinical improvements with salmeterol / fluticasone propionate combination in differing severities of COPD, 2003. http://www.abstracts2view.comA035 [Poster D50]. CalverleyPMA , PauwelsRA , VestboJ , JonesPW , PrideNB , GulsvikA , et al. Salmeterol/Fluticasone propionate combination for one year provides greater clinical benefit than its individual components. Proceedings of the 98th International American Thoracic Society Conference http://www.abstracts‐on‐line.com/abstracts/ATS; May 17‐22, 2002; Atlanta, Georgia. A98 [Poster 306]. CalverlyPMA , PauwelsR , VestboJ , JonesP , PrideN , GulsvikA , et al. Safety of salmeterol/fluticasone propionate combination in the treatment of chronic obstructive pulmonary disease. European Respiratory Journal2002;20 Suppl 38:242 [P1572]. HunjanMK , ChandlerF . Numbers needed to treat (NNT) to avoid an exacerbation in patients with chronic obstructive pulmonary disease (COPD) using salmeterol/fluticasone propionate combination (SFC) and associated costs [Abstract]. American Thoracic Society 100th International Conference; May 21‐26, 2004; Orlando, Florida. D22 [Poster 503]. HunjanMK , WilliamsDT . Costs of avoiding exacerbations in patients with chronic obstructive pulmonary disease (COPD) treated with salmeterol/ fluticasone propionate combination (seretide) and salmeterol. European Respiratory Journal2004;24 Suppl 48:291s. HunjanMK , WilliamsDT . Salmeterol/ fluticasone propionate combination is clinically effective in avoiding exacerbations in patients with moderate/severe COPD. European Respiratory Journal2004;24 Suppl 48:513s. JonesPW , EdinHM , AndersonJ . Salmeterol/fluticasone propionate combination improves health status in COPD patients. Proceedings of the 98th International American Thoracic Society Conference http://www.abstracts‐on‐line.com/abstracts/ATS; May 17‐22, 2002; Atlanta, Georgia. A39 [Poster K39]. JonesPW , StåhlE . Budesonide /formoterol sustains clinically relevant improvements in health status in COPD [Abstract]. European Respiratory Journal2005;26 Suppl 49:Abstract 1352. JonesPW , VestboJ , PauwelsRA , CalverleyPMA , AndersonJA , SpencerMD . Informative drop out in COPD studies: investigation of health status of withdrawals in the TRISTAN study. Proceedings of the 13th ERS Annual Congress; September 27, 2003; Vienna, Austria. P1593. NitschmannS . Inhalational combination therapy in chronic obstructive lung disease. Tristan study. German Internist2004;45(6):727‐8. PauwelsR , VestboJ , CalverleyPMA , JonesPW , PrideNB , GulsvikA . Characterization of exacerbations in the TRISTAN study of salmeterol / fluticasone propionate (SFC) combination in moderate to severe COPD, 2006. http://www.abstracts2view.com. PauwelsRA , CalverlyPMA , VestboJ , JonesPW , PrideN , GulsvikA , et al. Reduction of exacerbations with salmeterol/fluticasone combination 50/500 mcg bd in the treatment of chronic obstructive pulmonary disease. European Respiratory Journal2002;20 Suppl 38:240 [P1569]. SFCB3024 . A multicentre, randomised, double‐blind, parallel group, placebo‐controlled study to compare the efficacy and safety of the salmeterol/FP combination product at a strength of 50/500mcg bd with salmeterol 50mcg bd alone and FP 500mcg bd alone, delivered via the DISKUS™/ACCUHALER™, in the treatment of subjects with chronic obstructive pulmonary disease (COPD) for 12 months. GlaxoSmithKline Clinical Trials Register (http:ctr.gsk.co.uk)2005. SpencerM , BriggsAH , GrossmanRF , RanceL . Development of an economic model to assess the cost effectiveness of treatment interventions for chronic obstructive pulmonary disease. Pharmacoeconomics2005;23(6):619‐37. SpencerMD , KariaN , AndersonJ . The clinical significance of treatment benefits with the salmeterol/fluticasone propionate 50/500mcg combination in COPD. European Respiratory Journal2004;24 Suppl 48:290s. VestboJ , CalverleyPMA , PauwelsR , JonesP , PrideN , GulsvikA , et al. Absence of gender susceptibility to the combination of salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease. European Respiratory Journal2002;20 Suppl 38:240 [P1570]. VestboJ , PauwelsR , AndersonJA , JonesP , CalverleyP . Early onset of effect of salmeterol and fluticasone propionate in chronic obstructive pulmonary disease. Thorax2005;60(4):301‐4. VestboJ , PauwelsRS , CalverleyPMA , JonesPW , PrideNB , GulsvikA . Salmeterol / fluticasone propionate combination produces improvement in lung function detectable within 24 hours in moderate to severe COPD, 2003. http://www.abstracts2view.com. VestboJ , SorianoJB , AndersonJA , CalverleyP , PauwelsR , JonesP . Gender does not influence the response to the combination of salmeterol and fluticasone propionate in COPD. Respiratory Medicine2004;98(11):1045‐50. ">TRISTAN</a>. </p> </li> <li> <p>26 weeks: <a href="./references#CD006826-bbs2-0003" title="DohertyDE , KerwinE , TashkinDP , Matiz‐BuenoCE , ShekarT , BanerjeeS , et al. Combined mometasone furoate and formoterol in patients with moderate to very severe chronic obstructive pulmonary disease (COPD): phase 3 efficacy and safety study [Abstract]. Journal of Allergy and Clinical Immunology2012; Vol. 129, issue 2 Suppl:AB75 [283]. DohertyDE , TashkinDP , KerwinE , KnorrBA , ShekarT , BanerjeeS , et al. Effects of mometasone furoate/formoterol fumarate fixed‐dose combination formulation on chronic obstructive pulmonary disease (COPD): results from a 52‐week Phase III trial in subjects with moderate‐to‐very severe COPD. International Journal of Chronic Obstructive Pulmonary Disease2012; Vol. 7, issue 1178‐2005 (Electronic). 1176‐9106 (Linking):57‐71. NCT00383721 . A Randomized, 26‐Week, Placebo‐Controlled Efficacy and Safety Study With a 26‐Week Long‐Term Safety Extension, of High‐ and Medium‐Dose Inhaled Mometasone Furoate/Formoterol Fixed‐Dose Combination Formulation Compared With Formoterol and High‐Dose Inhaled Mometasone Furoate Monotherapy in Subjects With Moderate to Severe COPD, 2006. http://clinicaltrials.gov/show/NCT00383721. [] ">Doherty 2012</a>; <a href="./references#CD006826-bbs2-0011" title="Astrazeneca(D5899C00002) . A 6‐month double‐blind, double‐dummy, randomized, parallel group, multicenter efficacy &amp; safety study of Symbicort® pMDI 2 × 160/4.5mg &amp; 80/4.5mg bid compared to Formoterol TBH, Budesonide pMDI (&amp; the combination) &amp; placebo in COPD patients. www.astrazenecaclinicaltrials.com (accessed 8 April 2008). BleeckerER , MeyersDA , BaileyWC , SimsA‐M , BujacSR , GoldmanM , et al. ADRB2 polymorphisms and budesonide/formoterol responses in COPDADRB2 polymorphisms and treatment response in COPD. Chest2012;142(2):320‐8. TashkinDP , RennardSI , MartinP , GoldmanM , SilkoffPE . Efficacy of budesonide/formoterol administered via one pressurized metered‐dose inhaler over 6 months in patients with chronic obstructive pulmonary disease [Abstract]. Chest2008; Vol. 134, issue 4:105001s. TashkinDP , RennardSI , MartinP , RamachandranS , MartinUJ , SilkoffPE , et al. Efficacy and safety of budesonide and formoterol in one pressurized metered‐dose inhaler in patients with moderate to very severe chronic obstructive pulmonary disease : results of a 6‐month randomized clinical trial. Drugs2008; Vol. 68, issue 0012‐6667 (Print):1975‐2000. ">Tashkin 2008</a>; <a href="./references#CD006826-bbs2-0012" title="KerwinE , TashkinDP , Matiz‐BuenoCE , DohertyDE , ShekarT , BanerjeeS , et al. Clinical efficacy and safety of combined mometasone furoate and formoterol in patients with moderate to very severe chronic obstructive pulmonary disease (COPD) [Abstract]. Journal of Allergy and Clinical Immunology2012; Vol. 129, issue 2 Suppl:AB201 [759]. NCT00383435 . A Randomized, 26‐Week, Placebo‐Controlled Efficacy and Safety Study With a 26‐Week Long‐Term Safety Extension, of High‐ and Medium‐Dose Inhaled Mometasone Furoate/Formoterol Fixed‐Dose Combination Formulation Compared With Formoterol and High‐Dose Inhaled Mometasone Furoate Monotherapy in Subjects With Moderate to Severe COPD, 2006. http://clinicaltrials.gov/show/NCT00383435. [] TashkinDP , DohertyDE , KerwinE , Matiz‐BuenoCE , KnorrB , ShekarT , et al. Efficacy and safety of a fixed‐dose combination of mometasone furoate and formoterol fumarate in subjects with moderate to very severe COPD: results from a 52‐week Phase III trial. International Journal of Chronic Obstructive Pulmonary Disease2012; Vol. 7, issue 1178‐2005 (Electronic). 1176‐9106 (Linking):43‐55. ">Tashkin 2012</a>. </p> </li> <li> <p>24 weeks: <a href="./references#CD006826-bbs2-0004" title="HananiaNA , DarkenP , HorstmanD , ReisnerC , LeeB , DavisS , et al. The efficacy and safety of fluticasone propionate (250 micro g)/salmeterol (50 micro g) combined in the diskus inhaler for the treatment of COPD. Chest2003;124(3):834‐43. HananiaNA , RamsdellJ , PayneK , DavisS , HorstmanD , LeeB , et al. Improvements in airflow and dyspnea in COPD patients following 24 weeks treatment with salmeterol 50mcg and fluticasone propionate 250mcg alone or in combination via the diskus. American Journal of Respiratory &amp; Critical Care Medicine2001;163(5 Suppl):A279. HorstmanD , DarkenP , DavisS , LeeB . Improvements in FEV1 and symptoms in poorly reversible COPD patients following treatment with salmeterol 50mcg/fluticasone propionate 250mcg combination [Abstract]. European Respiratory Journal2003;22 Suppl 45:P434. MahlerDA , DarkenP , BrownCP , KnobilK . Predicting lung function responses to combination therapy in chronic obstructive pulmonary disease (COPD) [Abstract]. National COPD Conference; November 14‐15, 2003; Arlington, Virginia. Abstract 1081. MahlerDA , DarkenP , BrownCP , KnobilK . Predicting lung function responses to salmeterol/fluticasone propionate combination therapy in COPD [Abstract]. European Respiratory Journal2003;22 Suppl 45:P429. SFCA3007 . A randomized, double‐blind, placebo‐controlled, parallel‐group trial evaluating the safety and efficacy of the DISKUS formulations of salmeterol (SAL) 50mcg BID and fluticasone propionate (FP) 250mcg BID individually and in combination as salmeterol 50mcg/fluticasone propionate 250mcg BID (SFC 50/250) compared to placebo in COPD subjects. GlaxoSmithKline Clinical Trials Register (http:ctr.gsk.co.uk)2005. SpencerM , WireP , LeeB , ChangCN , DarkenP , HorstmanD . Patients with COPD using salmeterol/fluticasone propionate combination therapy experience improved quality of life. European Respiratory Journal2003;22 Suppl 45:51s. SpencerMD , KariaN , AndersonJ . The clinical significance of treatment benefits with the salmeterol/fluticasone propionate 50/500mcg combination in COPD. European Respiratory Journal2004;24 Suppl 48:290s. ">Hanania 2003</a>; <a href="./references#CD006826-bbs2-0006" title="MahlerDA , DarkenP , BrownCP , KnobilK . Predicting lung function responses to combination therapy in chronic obstructive pulmonary disease (COPD), 2003. http://www.abstracts2view.com. MahlerDA , WireP , HorstmanD , ChangCN , YatesJ , FischerT , et al. Effectiveness of fluticasone propionate and salmeterol combination delivered via the diskus device in the treatment of chronic obstructive pulmonary disease. American Journal of Respiratory Critical Care Medicine2002;166(8):1084‐91. SFCA3006 . A randomized, double‐blind, placebo‐controlled, parallel‐group trial evaluating the safety and efficacy of the DISKUS formulations of salmeterol (SAL) 50mcg BID and fluticasone propionate (FP) 500mcg BID individually and in combination as salmeterol 50mcg/fluticasone propionate 500mcg BID (SFC 50/500) compared to placebo in COPD subjects. GlaxoSmithKline Clinical Trials Register (http:ctr.gsk.co.uk)2005. SpencerM , WireP , LeeB , ChangCN , DarkenP , HorstmanD . Patients with COPD using salmeterol/fluticasone propionate combination therapy experience improved quality of life. European Respiratory Journal2003;22 Suppl 45:51s. SpencerMD , AndersonJA . Salmeterol/fluticasone combination produces clinically important benefits in dyspnea and fatigue [Abstract]. American Thoracic Society 2005 International Conference; May 20‐25, 2005; San Diego, California. B93 [Poster 308]. SpencerMD , KariaN , AndersonJ . The clinical significance of treatment benefits with the salmeterol/fluticasone propionate 50/500mcg combination in COPD. European Respiratory Journal2004;24 Suppl 48:290s. ">Mahler 2002</a>; <a href="./references#CD006826-bbs2-0015" title="ZhongN , ZhengJ , WenF , YangL , ChenP , XiuQ , et al. Efficacy and safety of budesonide/formoterol via a dry powder inhaler in Chinese patients with chronic obstructive pulmonary disease. Current Medical Research and Opinion2012; Vol. 28, issue 2:257‐65. ZhongN , ZhengJ , WenF , YangL , ChenP , XiuQ , et al. Efficacy and safety of inhalation of budesonide/formoterol via turbuhaler in Chinese patients with chronic obstructive pulmonary disease [Abstract]. Chest2011; Vol. 140, issue 4:5225A. ">Zhong 2012</a>. </p> </li> <li> <p>16 weeks: <a href="./references#CD006826-bbs2-0001" title="BourbeauJ , ChristodoulopoulosP , MaltaisF , YamauchiY , OlivensteinR , HamidQ . Effect of salmeterol/fluticasone propionate on airway inflammation in COPD: a randomised controlled trial. Thorax2007; Vol. 62, issue 11:938‐43. ">Bourbeau 2007</a>. </p> </li> <li> <p>12 weeks: <a href="./references#CD006826-bbs2-0007" title="NCT00358358 . Trial SCO104925. See detailed description, 2006. http://clinicaltrials.gov/show/NCT00358358. [] ">NCT00358358</a>. </p> </li> <li> <p>4 weeks: <a href="./references#CD006826-bbs2-0009" title="NCT00120978 . Advair－CRP Study. http://clinicaltrials.gov/show/NCT001209782004. [] SinDD , ManSF , MarciniukDD , FordG , FitzGeraldM , WongE , et al. Can inhaled fluticasone alone or in combination with salmeterol reduce systemic inflammation in chronic obstructive pulmonary disease? Study protocol for a randomized controlled trial [NCT00120978]. BMC Pulmonary Medicine2006;6(6):3. SinDD , ManSF , MarciniukDD , FordG , FitzGeraldM , WongE , et al. The effects of fluticasone with or without salmeterol on systemic biomarkers of inflammation in chronic obstructive pulmonary disease. American Journal of Respiratory and Critical Care Medicine2008; Vol. 177, issue 11:1207‐14. ">Sin 2008</a>. </p> </li> </ul> </p> </section> <section id="CD006826-sec-0060"> <h5 class="title">Outcomes</h5> <p>Exacerbations were stratified by medication given (oral steroid and/or antibiotic treatment in <a href="./references#CD006826-bbs2-0002" title="AstraZenecaSD . A placebo‐controlled 12‐month efficacy study of the fixed combination budesonide/formoterol compared to budesonide and formoterol as monotherapies in patients with chronic obstructive pulmonary disease (COPD). AstraZeneca Clinical Trials2002. BorgstromL , AskingL , OlssonH , PetersonS . Lack of interaction between disease severity and therapeutic response with budesonide/formoterol in a single inhaler [Abstract]. American Thoracic Society 100th International Conference; May 21‐26; 2004, Orlando, Florida. C22 [Poster 505]. CalverleyPM , BonsawatW , CsekeZ , ZhongN , PetersonS , OlssonH . Maintenance therapy with budesonide and formoterol in chronic obstructive pulmonary disease. European Respiratory Journal2003;22(6):912‐9. CalverleyPMA , CsekeZ , PetersonS . Budesonide/formoterol reduces the use of oral corticosteroids in the treatment of COPD [Abstract]. European Respiratory Journal2003;22 Suppl 45:P436. CalverleyPMA , KunaP , OlssonH . COPD exacerbations are reduced by budesonide/formoterol in a single inhaler [Abstract]. European Respiratory Journal2003;22 Suppl 45:P1587. CalverleyPMA , OlssonH , Symbicort International COPD Study Group. Budesonide/formoterol ina single inhaler sustains improvements in lung function over 12 months compared with monocomponents and placebo in patients with COPD [abstract]. American Thoracic Society 99th International Conference; May 16‐21, 2003; Seattle, Washington. B024 [Poster 418]. CalverleyPMA , PetersonS . Combining budesonide/formoterol in a single inhale reduces exacerbation frequency in COPD [abstract]. American Thoracic Society 99th International Conference; May 16‐21, 2003; Seattle, Washington. D092 [Poster 211]. CalverleyPMA , StåhlE , JonesPW . Budesonide/formoterol improves the general health status of patients with COPD [Abstract]. American Thoracic Society 2005 International Conference; May 20‐25, 2005; San Diego, California. B93 [Poster 303]. CalverleyPMA , SzafranskiW , AnderssonA . Budesonide/formoterol is a well‐tolerated long term maintenance therapy for COPD. European Respiratory Journal2005;26 Suppl 49:Poster 1917. CalverleyPMA , ThompsonNC , OlssonH . Budesonide/formoterol in a single inhaler sustains lung function improvements in COPD [Abstract]. European Respiratory Journal2003;22 Suppl 45:P435. HalpinD , StåhlE , LundbackB , AndersonF , PetersonS . Treatment costs and number needed to treat (NNT) with budesonide/formoterol to avoid one exacerbation of COPD [Abstract]. American Thoracic Society 100th International Conference; May 21‐26, 2004; Orlando, Florida. D22 [Poster 525]. HalpinDMG , LarssonT , CalverleyPMA . How many patients with COPD must be treated with budesonide/formoterol compared with formoterol alone to avoid 1 day of oral steroid use? [Abstract]. American Thoracic Society 2005 International Conference; May 20‐25, 2005; San Diego, California. B93 [Poster 314]. JonesPW , StahlE . Budesonide/formoterol in a single inhaler improves health status in patients with COPD [abstract]. American Thoracic Society 99th International Conference; May 16‐21, 2003; Orlando, Florida. B024 [Poster 419]. JonesPW , StåhlE . Budesonide /formoterol sustains clinically relevant improvements in health status in COPD [Abstract]. European Respiratory Journal2005;26 Suppl 49:Abstract 1352. JonesPW , StåhlE . Reducing exacerbations leads to a better health‐related quality of life in patients with COPD. 13th ERS Annual Congress; September 27, 2003; Vienna, Austria. P1586. LofdahlCG . Reducing the impact of COPD exacerbations: Clinical efficacy of budesonide/formoterol. European Respiratory Review2004;13(88):14‐21. LofdahlCG , AndreassonE , SvenssonK , EricssonA . Budesonide/formoterol in a single inhaler improves health status in patients with COPD without increasing healthcare costs [Abstract]. European Respiratory Journal2003;22 Suppl 45:P433. LofdahlCG , EricssonA , SvenssonK , AndreassonE . Cost effectiveness of budesonide/formoterol in a single inhaler for COPD compared with each monocomponent used alone. Pharmacoeconomics2005;23(4):365‐75. ">Calverley 2003</a>; <a href="./references#CD006826-bbs2-0008" title="SFCT01 . A Multicentre, Randomised, Double‐Blind, Parallel Group, Placebo‐Controlled Study to Compare the Efficacy and Safety of Inhaled Salmeterol/Fluticasone Propionate Combination Product 25/250 µg Two Puffs Bd and Fluticasone Propionate 250µg Two Puffs Bd Alone, All Administered Via Metered Dose Inhalers (MDI), in the Treatment of Subjects with Chronic Obstructive Pulmonary Disease (COPD) for 52 Weeks. GlaxoSmithKline Clinical Trials Register (http:ctr.gsk.co.uk)2005. ">SFCT01</a>; <a href="./references#CD006826-bbs2-0010" title="AndersonP . Budesonide/formoterol in a single inhaler (Symbicort) provides early and sustained improvement in lung function in moderate to severe COPD [Abstract]. Thorax2002;57(Suppl III):iii43. AstraZenecaSD . A placebo‐controlled 12 month efficacy study of the fixed combination budesonide/formoterol compared with budesonide and formoterol as monotherapies in patients with chronic obstructive pulmonary disease (COPD). AstraZeneca Clinical Trials2001. BorgstromL , AskingL , OlssonH , PetersonS . Lack of interaction between disease severity and therapeutic response with budesonide/formoterol in a single inhaler [Abstract]. American Thoracic Society 100th International Conference; May 21‐26, 2004; Orlando, Florida. C22 [Poster 505]. CalverleyP , PauwelsR , LofdahlCG , SvenssonK , HigenbottamT , et al. Relationship between respiratory symptoms and medical treatment in exacerbations of COPD. European Respiratory Journal2005;26(3):406‐13. CalverleyPMA . Effect of budesonide/formoterol on severe exacerbations and lung function in moderate to severe COPD. Thorax. BTS Winter Meeting 2002:S145. CalverleyPMA , SzafranskiW , AnderssonA . Budesonide/formoterol is a well‐tolerated long term maintenance therapy for COPD. European Respiratory Journal2005;26 Suppl 49:Poster 1917. CalverleyPMA , ThompsonNC , OlssonH . Budesonide/formoterol in a single inhaler sustains lung function improvements in COPD [Abstract]. European Respiratory Journal2003;22 Suppl 45:P435. CampbellLM , SzafranskiW . Budesonide/formoterol in a single inhaler (Symbicort) provides sustained relief from symptoms in moderate to severe COPD. Thorax. BTS Winter Meeting 2002:S143. CampellLW , SzafranskiW . Budesonide/Formoterol in a single inhaler (Symbicort) reduces severe exacerbations in patients with moderate‐severe COPD. Thorax. BTS Winter Meeting 2002:S141. DahlR , CukierA , OlssonH . Budesonide/formoterol in a single inhaler reduces severe and mild exacerbations in patients with moderate to severe COPD. European Respiratory Journal2002;20 Suppl 38:242 [P1575]. EgedeF , MengaG . Budesonide/formoterol in a single inhaler provides sustained relief from symptoms and night‐time awakenings in moderate‐severe COPD: results from symptoms and night‐time awakenings in moderate to severe COPD: results from a 1‐year study. European Respiratory Journal2002;20 Suppl 38:242 [P1574]. HalpinD , StahlE , LundbackB , AndersonF , PetersonS . Treatment costs and number needed to treat (NNT) with budesonide/formoterol to avoid one exacerbation of COPD [Abstract]. American Thoracic Society 100th International Conference; May 21‐26, 2004; Orlando, Florida. D22 [Poster 525]. JonesPW , StahlE , SvenssonK . Improvement in health status in patients with moderate to severe COPD after treatment with budesonide/formoterol in a single inhaler. European Respiratory Journal2002;20 Suppl 38:250 [P1613]. KorsgaardJ , SansoresR . Budesonide/formoterol (single inhaler) provides sustained relief from shortness of breath and chest tightness in a 1‐year study of patients with moderate to severe COPD. European Respiratory Journal2002;20 Suppl 38:242 [P1577]. LangeP , SaenzC . Budesonide/formoterol in a single inhaler is well tolerated in patients with moderate to severe COPD: results of a 1 year study. European Respiratory Journal2002;20 Suppl 38:242 [P1573]. LofdahlCG . Reducing the impact of COPD exacerbations: clinical efficacy of budesonide/formoterol. European Respiratory Review2004;13(88):14‐21. MilanowskiJ , NahabedianS . Budesonide/formoterol in a single inhaler acts rapidly to improve lung function and relieve symptoms in patients with moderate to severe COPD. European Respiratory Journal2002;20 Suppl 38:242 [P1576]. SzafranskiW , CukierA , RamirezA , MengaG , SansoresR , NahabedianS , et al. Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease. European Respiratory Journal2003;21(1):74‐81. ">Szafranski 2003</a>; <a href="./references#CD006826-bbs2-0013" title="BriggsAH , GlickHA , Lozano‐OrtegaG , SpencerM , CalverleyPM , JonesPW , et al. Is treatment with ICS and LABA cost‐effective for COPD? Multinational economic analysis of the TORCH study. European Respiratory Journal2010; Vol. 35, issue 3:532‐9. CalverleyPM , AndersonJA , CelliB , FergusonGT , JenkinsC , JonesPW , et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease.[see comment]. New England Journal of Medicine2007; Vol. 356, issue 8:775‐89. CalverleyPMA , AndersonJA , CelliB , FergusonGT , JenkinsC , JonesPW , et al. Cardiovascular events in patients with chronic obstructive pulmonary disease: TORCH study results. Thorax2010;65:719‐25. CalverleyPMA , AndersonJA , CelliB , FergusonGT , JenkinsC , JonesPW , et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. New England Journal of Medicine2007;356(8):775‐89. CalverleyPMA , CelliB , FergusonG , JenkinsC , JonesPW , PrideNB , et al. Baseline characteristics of the first 5,000 COPD patients enrolled in the TORCH survival study. European Respiratory Journal2003;22 Suppl 45:578s. CelliB , CalverleyPMA , AndersonJA , FergusonGT , JenkinsC , JonesPW , et al. The TORCH (TOwards a Revolution in COPD Health) study: salmeterol/fluticasone propionate (SFC) improves health status, reduces exacerbations and improves lung function over three years. European Respiratory Journal2006;28 Suppl 50:34s. CelliB , VestboJ , JenkinsCR , JonesPW , FergusonGT , CalverleyPM , et al. Sex differences in mortality and clinical expressions of patients with chronic obstructive pulmonary disease: the TORCH experience. American Journal of Respiratory and Critical Care Medicine2011;183(3):317‐22. CelliBR , ThomasNE , AndersonJA , FergusonGT , JenkinsCR , JonesPW , et al. Effect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease: results from the TORCH study. American Journal of Respiratory and Critical Care Medicine2008;174(4):332‐8. CrimC , CalverleyPM , AndersonJA , CelliB , FergusonGT , JenkinsC , et al. Pneumonia risk in COPD patients receiving inhaled corticosteroids alone or in combination: TORCH study results. European Respiratory Journal2009;34(3):641‐7. FergusonGT , CalverleyPM , AndersonJA , JenkinsCR , JonesPW , WillitsLR , et al. Prevalence and progression of osteoporosis in patients with COPD: results from the TOwards a Revolution in COPD Health study. Chest2009; Vol. 136, issue 0012‐3692:1456‐65. FergusonGT , CalverleyPMA , AndersonJA , et al. The TORCH (TOwards a Revolution in COPD Health) study: salmeterol/fluticasone propionate (SFC) improves survival in COPD over three years. European Respiratory Journal2006;28 Suppl 50:34s. GlaxoSmithKlineSCO30003 . A multicentre, randomised, double‐blind, parallel group, placebo‐controlled study to investigate the long‐term effects of salmeterol/fluticasone propionate (SERETIDE/VIANI/ADVAIR) 50/500mcg bd, salmeterol 50mcg bd and fluticasone propionate 500mcg bd, all delivered via the DISKUS/ACCUHALER inhaler, on the survival of subjects with chronic obstructive pulmonary disease (COPD) over 3 years of treatment. GlaxoSmithKline Clinical Trial Register2006. HoughtonCM , LawsonN , BorrillZL , WixonCL , YoxallS , LangleySJ , et al. Comparison of the effects of salmeterol/fluticasone propionate with fluticasone propionate on airway physiology in adults with mild persistent asthma. Respiratory Research2007;8:52. JenkinsCR , CalverleyPMA , CelliB , FergusonG , JonesPW , PrideN , et al. Seasonal patterns of exacerbation rates in the TORCH survival study, 2007. http://www.abstracts2view.comA839. JenkinsCR , CelliB , AndersonJA , FergusonGT , JonesPW , VestboJ , et al. Seasonality and determinants of moderate and severe COPD exacerbations in the TORCH study. European Respiratory Journal2012;39(1):38‐45. JenkinsCR , JonesPW , CalverleyPM , CelliB , AndersonJA , FergusonGT , et al. Efficacy of salmeterol/fluticasone propionate by GOLD stage of chronic obstructive pulmonary disease: analysis from the randomised, placebo‐controlled TORCH study. Respiratory Research2009;10:59. JohnsonM , AgustiAG , BarnesNC . Reflections on TORCH: potential mechanisms for the survival benefit of salmeterol/fluticasone propionate in COPD patients. COPD2008;5(6):369‐75. JonesPW , AndersonJA , CalverleyPM , CelliBR , FergusonGT , JenkinsC , et al. TORCH Investigators. Health status in the TORCH study of COPD: treatment efficacy and other determinants of change. Respiratory Research2011;12:71. JonesPW , CalverleyP , CelliB , FergusonG , JenkinsC , PrideN . Trans‐regional validity of the SGRQ in the TORCH survival study, 2007. http://www.abstracts2view.comA122. McGarveyLP , JohnM , AndersonJA , ZvarichMT , WiseRA . Ascertainment of cause‐specific mortality in COPD: operations of the TORCH Clinical Endpoint Committee. Thorax2007;62:411‐5. NCT00268216 . See detailed description, 2000. http://clinicaltrials.gov/show/NCT00268216. [] SCO30003 . A multicentre, randomised, double‐blind, parallel group, placebo‐controlled study to investigate the long‐term effects of salmeterol/fluticasone propionate (SERETIDE®/VIANI®/ADVAIR®) 50/500mcg bd, salmeterol 50mcg bd and fluticasone propionate 500mcg bd, all delivered via the DISKUS®/ACCUHALER® inhaler, on the survival of subjects with chronic obstructive pulmonary disease (COPD) over 3 years of treatment, 2006. www.ctr.gsk.co.uk. VestboJ , AndersonJA , CalverleyPM , CelliB , FergusonGT , JenkinsC , et al. Adherence to inhaled therapy, mortality and hospital admission in COPD. Thorax2009;64(11):939‐43. VestboJ , CalverleyP , CelliB , FergusonG , JenkinsC , JonesP , et al. The TORCH (TOwards a Revolution in COPD Health) survival study protocol. European Respiratory Journal2004;24(2):206‐10. WiseRA , McGarveyLP , JohnM , AndersonJA , ZvarichMT . Reliability of cause‐specific mortality adjudication in a COPD clinical trial, 2007. http://www.abstracts2view.comA120. ">TORCH</a>; <a href="./references#CD006826-bbs2-0014" title="CalverleyP , PauwelsR , VestboJ , JonesP , PrideN , GulsvikA , et al. Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial. Lancet2003;361(9356):449‐56. CalverleyPMA , PauwelsRA , VestboJ , JonesPW , PrideNB , GulsvikA , et al. Clinical improvements with salmeterol / fluticasone propionate combination in differing severities of COPD, 2003. http://www.abstracts2view.comA035 [Poster D50]. CalverleyPMA , PauwelsRA , VestboJ , JonesPW , PrideNB , GulsvikA , et al. Salmeterol/Fluticasone propionate combination for one year provides greater clinical benefit than its individual components. Proceedings of the 98th International American Thoracic Society Conference http://www.abstracts‐on‐line.com/abstracts/ATS; May 17‐22, 2002; Atlanta, Georgia. A98 [Poster 306]. CalverlyPMA , PauwelsR , VestboJ , JonesP , PrideN , GulsvikA , et al. Safety of salmeterol/fluticasone propionate combination in the treatment of chronic obstructive pulmonary disease. European Respiratory Journal2002;20 Suppl 38:242 [P1572]. HunjanMK , ChandlerF . Numbers needed to treat (NNT) to avoid an exacerbation in patients with chronic obstructive pulmonary disease (COPD) using salmeterol/fluticasone propionate combination (SFC) and associated costs [Abstract]. American Thoracic Society 100th International Conference; May 21‐26, 2004; Orlando, Florida. D22 [Poster 503]. HunjanMK , WilliamsDT . Costs of avoiding exacerbations in patients with chronic obstructive pulmonary disease (COPD) treated with salmeterol/ fluticasone propionate combination (seretide) and salmeterol. European Respiratory Journal2004;24 Suppl 48:291s. HunjanMK , WilliamsDT . Salmeterol/ fluticasone propionate combination is clinically effective in avoiding exacerbations in patients with moderate/severe COPD. European Respiratory Journal2004;24 Suppl 48:513s. JonesPW , EdinHM , AndersonJ . Salmeterol/fluticasone propionate combination improves health status in COPD patients. Proceedings of the 98th International American Thoracic Society Conference http://www.abstracts‐on‐line.com/abstracts/ATS; May 17‐22, 2002; Atlanta, Georgia. A39 [Poster K39]. JonesPW , StåhlE . Budesonide /formoterol sustains clinically relevant improvements in health status in COPD [Abstract]. European Respiratory Journal2005;26 Suppl 49:Abstract 1352. JonesPW , VestboJ , PauwelsRA , CalverleyPMA , AndersonJA , SpencerMD . Informative drop out in COPD studies: investigation of health status of withdrawals in the TRISTAN study. Proceedings of the 13th ERS Annual Congress; September 27, 2003; Vienna, Austria. P1593. NitschmannS . Inhalational combination therapy in chronic obstructive lung disease. Tristan study. German Internist2004;45(6):727‐8. PauwelsR , VestboJ , CalverleyPMA , JonesPW , PrideNB , GulsvikA . Characterization of exacerbations in the TRISTAN study of salmeterol / fluticasone propionate (SFC) combination in moderate to severe COPD, 2006. http://www.abstracts2view.com. PauwelsRA , CalverlyPMA , VestboJ , JonesPW , PrideN , GulsvikA , et al. Reduction of exacerbations with salmeterol/fluticasone combination 50/500 mcg bd in the treatment of chronic obstructive pulmonary disease. European Respiratory Journal2002;20 Suppl 38:240 [P1569]. SFCB3024 . A multicentre, randomised, double‐blind, parallel group, placebo‐controlled study to compare the efficacy and safety of the salmeterol/FP combination product at a strength of 50/500mcg bd with salmeterol 50mcg bd alone and FP 500mcg bd alone, delivered via the DISKUS™/ACCUHALER™, in the treatment of subjects with chronic obstructive pulmonary disease (COPD) for 12 months. GlaxoSmithKline Clinical Trials Register (http:ctr.gsk.co.uk)2005. SpencerM , BriggsAH , GrossmanRF , RanceL . Development of an economic model to assess the cost effectiveness of treatment interventions for chronic obstructive pulmonary disease. Pharmacoeconomics2005;23(6):619‐37. SpencerMD , KariaN , AndersonJ . The clinical significance of treatment benefits with the salmeterol/fluticasone propionate 50/500mcg combination in COPD. European Respiratory Journal2004;24 Suppl 48:290s. VestboJ , CalverleyPMA , PauwelsR , JonesP , PrideN , GulsvikA , et al. Absence of gender susceptibility to the combination of salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease. European Respiratory Journal2002;20 Suppl 38:240 [P1570]. VestboJ , PauwelsR , AndersonJA , JonesP , CalverleyP . Early onset of effect of salmeterol and fluticasone propionate in chronic obstructive pulmonary disease. Thorax2005;60(4):301‐4. VestboJ , PauwelsRS , CalverleyPMA , JonesPW , PrideNB , GulsvikA . Salmeterol / fluticasone propionate combination produces improvement in lung function detectable within 24 hours in moderate to severe COPD, 2003. http://www.abstracts2view.com. VestboJ , SorianoJB , AndersonJA , CalverleyP , PauwelsR , JonesP . Gender does not influence the response to the combination of salmeterol and fluticasone propionate in COPD. Respiratory Medicine2004;98(11):1045‐50. ">TRISTAN</a>) or hospitalisation (<a href="./references#CD006826-bbs2-0013" title="BriggsAH , GlickHA , Lozano‐OrtegaG , SpencerM , CalverleyPM , JonesPW , et al. Is treatment with ICS and LABA cost‐effective for COPD? Multinational economic analysis of the TORCH study. European Respiratory Journal2010; Vol. 35, issue 3:532‐9. CalverleyPM , AndersonJA , CelliB , FergusonGT , JenkinsC , JonesPW , et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease.[see comment]. New England Journal of Medicine2007; Vol. 356, issue 8:775‐89. CalverleyPMA , AndersonJA , CelliB , FergusonGT , JenkinsC , JonesPW , et al. Cardiovascular events in patients with chronic obstructive pulmonary disease: TORCH study results. Thorax2010;65:719‐25. CalverleyPMA , AndersonJA , CelliB , FergusonGT , JenkinsC , JonesPW , et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. New England Journal of Medicine2007;356(8):775‐89. CalverleyPMA , CelliB , FergusonG , JenkinsC , JonesPW , PrideNB , et al. Baseline characteristics of the first 5,000 COPD patients enrolled in the TORCH survival study. European Respiratory Journal2003;22 Suppl 45:578s. CelliB , CalverleyPMA , AndersonJA , FergusonGT , JenkinsC , JonesPW , et al. The TORCH (TOwards a Revolution in COPD Health) study: salmeterol/fluticasone propionate (SFC) improves health status, reduces exacerbations and improves lung function over three years. European Respiratory Journal2006;28 Suppl 50:34s. CelliB , VestboJ , JenkinsCR , JonesPW , FergusonGT , CalverleyPM , et al. Sex differences in mortality and clinical expressions of patients with chronic obstructive pulmonary disease: the TORCH experience. American Journal of Respiratory and Critical Care Medicine2011;183(3):317‐22. CelliBR , ThomasNE , AndersonJA , FergusonGT , JenkinsCR , JonesPW , et al. Effect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease: results from the TORCH study. American Journal of Respiratory and Critical Care Medicine2008;174(4):332‐8. CrimC , CalverleyPM , AndersonJA , CelliB , FergusonGT , JenkinsC , et al. Pneumonia risk in COPD patients receiving inhaled corticosteroids alone or in combination: TORCH study results. European Respiratory Journal2009;34(3):641‐7. FergusonGT , CalverleyPM , AndersonJA , JenkinsCR , JonesPW , WillitsLR , et al. Prevalence and progression of osteoporosis in patients with COPD: results from the TOwards a Revolution in COPD Health study. Chest2009; Vol. 136, issue 0012‐3692:1456‐65. FergusonGT , CalverleyPMA , AndersonJA , et al. The TORCH (TOwards a Revolution in COPD Health) study: salmeterol/fluticasone propionate (SFC) improves survival in COPD over three years. European Respiratory Journal2006;28 Suppl 50:34s. GlaxoSmithKlineSCO30003 . A multicentre, randomised, double‐blind, parallel group, placebo‐controlled study to investigate the long‐term effects of salmeterol/fluticasone propionate (SERETIDE/VIANI/ADVAIR) 50/500mcg bd, salmeterol 50mcg bd and fluticasone propionate 500mcg bd, all delivered via the DISKUS/ACCUHALER inhaler, on the survival of subjects with chronic obstructive pulmonary disease (COPD) over 3 years of treatment. GlaxoSmithKline Clinical Trial Register2006. HoughtonCM , LawsonN , BorrillZL , WixonCL , YoxallS , LangleySJ , et al. Comparison of the effects of salmeterol/fluticasone propionate with fluticasone propionate on airway physiology in adults with mild persistent asthma. Respiratory Research2007;8:52. JenkinsCR , CalverleyPMA , CelliB , FergusonG , JonesPW , PrideN , et al. Seasonal patterns of exacerbation rates in the TORCH survival study, 2007. http://www.abstracts2view.comA839. JenkinsCR , CelliB , AndersonJA , FergusonGT , JonesPW , VestboJ , et al. Seasonality and determinants of moderate and severe COPD exacerbations in the TORCH study. European Respiratory Journal2012;39(1):38‐45. JenkinsCR , JonesPW , CalverleyPM , CelliB , AndersonJA , FergusonGT , et al. Efficacy of salmeterol/fluticasone propionate by GOLD stage of chronic obstructive pulmonary disease: analysis from the randomised, placebo‐controlled TORCH study. Respiratory Research2009;10:59. JohnsonM , AgustiAG , BarnesNC . Reflections on TORCH: potential mechanisms for the survival benefit of salmeterol/fluticasone propionate in COPD patients. COPD2008;5(6):369‐75. JonesPW , AndersonJA , CalverleyPM , CelliBR , FergusonGT , JenkinsC , et al. TORCH Investigators. Health status in the TORCH study of COPD: treatment efficacy and other determinants of change. Respiratory Research2011;12:71. JonesPW , CalverleyP , CelliB , FergusonG , JenkinsC , PrideN . Trans‐regional validity of the SGRQ in the TORCH survival study, 2007. http://www.abstracts2view.comA122. McGarveyLP , JohnM , AndersonJA , ZvarichMT , WiseRA . Ascertainment of cause‐specific mortality in COPD: operations of the TORCH Clinical Endpoint Committee. Thorax2007;62:411‐5. NCT00268216 . See detailed description, 2000. http://clinicaltrials.gov/show/NCT00268216. [] SCO30003 . A multicentre, randomised, double‐blind, parallel group, placebo‐controlled study to investigate the long‐term effects of salmeterol/fluticasone propionate (SERETIDE®/VIANI®/ADVAIR®) 50/500mcg bd, salmeterol 50mcg bd and fluticasone propionate 500mcg bd, all delivered via the DISKUS®/ACCUHALER® inhaler, on the survival of subjects with chronic obstructive pulmonary disease (COPD) over 3 years of treatment, 2006. www.ctr.gsk.co.uk. VestboJ , AndersonJA , CalverleyPM , CelliB , FergusonGT , JenkinsC , et al. Adherence to inhaled therapy, mortality and hospital admission in COPD. Thorax2009;64(11):939‐43. VestboJ , CalverleyP , CelliB , FergusonG , JenkinsC , JonesP , et al. The TORCH (TOwards a Revolution in COPD Health) survival study protocol. European Respiratory Journal2004;24(2):206‐10. WiseRA , McGarveyLP , JohnM , AndersonJA , ZvarichMT . Reliability of cause‐specific mortality adjudication in a COPD clinical trial, 2007. http://www.abstracts2view.comA120. ">TORCH</a>; <a href="./references#CD006826-bbs2-0014" title="CalverleyP , PauwelsR , VestboJ , JonesP , PrideN , GulsvikA , et al. Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial. Lancet2003;361(9356):449‐56. CalverleyPMA , PauwelsRA , VestboJ , JonesPW , PrideNB , GulsvikA , et al. Clinical improvements with salmeterol / fluticasone propionate combination in differing severities of COPD, 2003. http://www.abstracts2view.comA035 [Poster D50]. CalverleyPMA , PauwelsRA , VestboJ , JonesPW , PrideNB , GulsvikA , et al. Salmeterol/Fluticasone propionate combination for one year provides greater clinical benefit than its individual components. Proceedings of the 98th International American Thoracic Society Conference http://www.abstracts‐on‐line.com/abstracts/ATS; May 17‐22, 2002; Atlanta, Georgia. A98 [Poster 306]. CalverlyPMA , PauwelsR , VestboJ , JonesP , PrideN , GulsvikA , et al. Safety of salmeterol/fluticasone propionate combination in the treatment of chronic obstructive pulmonary disease. European Respiratory Journal2002;20 Suppl 38:242 [P1572]. HunjanMK , ChandlerF . Numbers needed to treat (NNT) to avoid an exacerbation in patients with chronic obstructive pulmonary disease (COPD) using salmeterol/fluticasone propionate combination (SFC) and associated costs [Abstract]. American Thoracic Society 100th International Conference; May 21‐26, 2004; Orlando, Florida. D22 [Poster 503]. HunjanMK , WilliamsDT . Costs of avoiding exacerbations in patients with chronic obstructive pulmonary disease (COPD) treated with salmeterol/ fluticasone propionate combination (seretide) and salmeterol. European Respiratory Journal2004;24 Suppl 48:291s. HunjanMK , WilliamsDT . Salmeterol/ fluticasone propionate combination is clinically effective in avoiding exacerbations in patients with moderate/severe COPD. European Respiratory Journal2004;24 Suppl 48:513s. JonesPW , EdinHM , AndersonJ . Salmeterol/fluticasone propionate combination improves health status in COPD patients. Proceedings of the 98th International American Thoracic Society Conference http://www.abstracts‐on‐line.com/abstracts/ATS; May 17‐22, 2002; Atlanta, Georgia. A39 [Poster K39]. JonesPW , StåhlE . Budesonide /formoterol sustains clinically relevant improvements in health status in COPD [Abstract]. European Respiratory Journal2005;26 Suppl 49:Abstract 1352. JonesPW , VestboJ , PauwelsRA , CalverleyPMA , AndersonJA , SpencerMD . Informative drop out in COPD studies: investigation of health status of withdrawals in the TRISTAN study. Proceedings of the 13th ERS Annual Congress; September 27, 2003; Vienna, Austria. P1593. NitschmannS . Inhalational combination therapy in chronic obstructive lung disease. Tristan study. German Internist2004;45(6):727‐8. PauwelsR , VestboJ , CalverleyPMA , JonesPW , PrideNB , GulsvikA . Characterization of exacerbations in the TRISTAN study of salmeterol / fluticasone propionate (SFC) combination in moderate to severe COPD, 2006. http://www.abstracts2view.com. PauwelsRA , CalverlyPMA , VestboJ , JonesPW , PrideN , GulsvikA , et al. Reduction of exacerbations with salmeterol/fluticasone combination 50/500 mcg bd in the treatment of chronic obstructive pulmonary disease. European Respiratory Journal2002;20 Suppl 38:240 [P1569]. SFCB3024 . A multicentre, randomised, double‐blind, parallel group, placebo‐controlled study to compare the efficacy and safety of the salmeterol/FP combination product at a strength of 50/500mcg bd with salmeterol 50mcg bd alone and FP 500mcg bd alone, delivered via the DISKUS™/ACCUHALER™, in the treatment of subjects with chronic obstructive pulmonary disease (COPD) for 12 months. GlaxoSmithKline Clinical Trials Register (http:ctr.gsk.co.uk)2005. SpencerM , BriggsAH , GrossmanRF , RanceL . Development of an economic model to assess the cost effectiveness of treatment interventions for chronic obstructive pulmonary disease. Pharmacoeconomics2005;23(6):619‐37. SpencerMD , KariaN , AndersonJ . The clinical significance of treatment benefits with the salmeterol/fluticasone propionate 50/500mcg combination in COPD. European Respiratory Journal2004;24 Suppl 48:290s. VestboJ , CalverleyPMA , PauwelsR , JonesP , PrideN , GulsvikA , et al. Absence of gender susceptibility to the combination of salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease. European Respiratory Journal2002;20 Suppl 38:240 [P1570]. VestboJ , PauwelsR , AndersonJA , JonesP , CalverleyP . Early onset of effect of salmeterol and fluticasone propionate in chronic obstructive pulmonary disease. Thorax2005;60(4):301‐4. VestboJ , PauwelsRS , CalverleyPMA , JonesPW , PrideNB , GulsvikA . Salmeterol / fluticasone propionate combination produces improvement in lung function detectable within 24 hours in moderate to severe COPD, 2003. http://www.abstracts2view.com. VestboJ , SorianoJB , AndersonJA , CalverleyP , PauwelsR , JonesP . Gender does not influence the response to the combination of salmeterol and fluticasone propionate in COPD. Respiratory Medicine2004;98(11):1045‐50. ">TRISTAN</a>). In <a href="./references#CD006826-bbs2-0011" title="Astrazeneca(D5899C00002) . A 6‐month double‐blind, double‐dummy, randomized, parallel group, multicenter efficacy &amp; safety study of Symbicort® pMDI 2 × 160/4.5mg &amp; 80/4.5mg bid compared to Formoterol TBH, Budesonide pMDI (&amp; the combination) &amp; placebo in COPD patients. www.astrazenecaclinicaltrials.com (accessed 8 April 2008). BleeckerER , MeyersDA , BaileyWC , SimsA‐M , BujacSR , GoldmanM , et al. ADRB2 polymorphisms and budesonide/formoterol responses in COPDADRB2 polymorphisms and treatment response in COPD. Chest2012;142(2):320‐8. TashkinDP , RennardSI , MartinP , GoldmanM , SilkoffPE . Efficacy of budesonide/formoterol administered via one pressurized metered‐dose inhaler over 6 months in patients with chronic obstructive pulmonary disease [Abstract]. Chest2008; Vol. 134, issue 4:105001s. TashkinDP , RennardSI , MartinP , RamachandranS , MartinUJ , SilkoffPE , et al. Efficacy and safety of budesonide and formoterol in one pressurized metered‐dose inhaler in patients with moderate to very severe chronic obstructive pulmonary disease : results of a 6‐month randomized clinical trial. Drugs2008; Vol. 68, issue 0012‐6667 (Print):1975‐2000. ">Tashkin 2008</a>, exacerbations were defined as worsening of COPD symptoms that required treatment with oral corticosteroids and/or hospitalisation. <a href="./references#CD006826-bbs2-0009" title="NCT00120978 . Advair－CRP Study. http://clinicaltrials.gov/show/NCT001209782004. [] SinDD , ManSF , MarciniukDD , FordG , FitzGeraldM , WongE , et al. Can inhaled fluticasone alone or in combination with salmeterol reduce systemic inflammation in chronic obstructive pulmonary disease? Study protocol for a randomized controlled trial [NCT00120978]. BMC Pulmonary Medicine2006;6(6):3. SinDD , ManSF , MarciniukDD , FordG , FitzGeraldM , WongE , et al. The effects of fluticasone with or without salmeterol on systemic biomarkers of inflammation in chronic obstructive pulmonary disease. American Journal of Respiratory and Critical Care Medicine2008; Vol. 177, issue 11:1207‐14. ">Sin 2008</a> and <a href="./references#CD006826-bbs2-0015" title="ZhongN , ZhengJ , WenF , YangL , ChenP , XiuQ , et al. Efficacy and safety of budesonide/formoterol via a dry powder inhaler in Chinese patients with chronic obstructive pulmonary disease. Current Medical Research and Opinion2012; Vol. 28, issue 2:257‐65. ZhongN , ZhengJ , WenF , YangL , ChenP , XiuQ , et al. Efficacy and safety of inhalation of budesonide/formoterol via turbuhaler in Chinese patients with chronic obstructive pulmonary disease [Abstract]. Chest2011; Vol. 140, issue 4:5225A. ">Zhong 2012</a> also included the use of antibiotics, an emergency room visit or both in their definition. <a href="./references#CD006826-bbs2-0003" title="DohertyDE , KerwinE , TashkinDP , Matiz‐BuenoCE , ShekarT , BanerjeeS , et al. Combined mometasone furoate and formoterol in patients with moderate to very severe chronic obstructive pulmonary disease (COPD): phase 3 efficacy and safety study [Abstract]. Journal of Allergy and Clinical Immunology2012; Vol. 129, issue 2 Suppl:AB75 [283]. DohertyDE , TashkinDP , KerwinE , KnorrBA , ShekarT , BanerjeeS , et al. Effects of mometasone furoate/formoterol fumarate fixed‐dose combination formulation on chronic obstructive pulmonary disease (COPD): results from a 52‐week Phase III trial in subjects with moderate‐to‐very severe COPD. International Journal of Chronic Obstructive Pulmonary Disease2012; Vol. 7, issue 1178‐2005 (Electronic). 1176‐9106 (Linking):57‐71. NCT00383721 . A Randomized, 26‐Week, Placebo‐Controlled Efficacy and Safety Study With a 26‐Week Long‐Term Safety Extension, of High‐ and Medium‐Dose Inhaled Mometasone Furoate/Formoterol Fixed‐Dose Combination Formulation Compared With Formoterol and High‐Dose Inhaled Mometasone Furoate Monotherapy in Subjects With Moderate to Severe COPD, 2006. http://clinicaltrials.gov/show/NCT00383721. [] ">Doherty 2012</a> and <a href="./references#CD006826-bbs2-0012" title="KerwinE , TashkinDP , Matiz‐BuenoCE , DohertyDE , ShekarT , BanerjeeS , et al. Clinical efficacy and safety of combined mometasone furoate and formoterol in patients with moderate to very severe chronic obstructive pulmonary disease (COPD) [Abstract]. Journal of Allergy and Clinical Immunology2012; Vol. 129, issue 2 Suppl:AB201 [759]. NCT00383435 . A Randomized, 26‐Week, Placebo‐Controlled Efficacy and Safety Study With a 26‐Week Long‐Term Safety Extension, of High‐ and Medium‐Dose Inhaled Mometasone Furoate/Formoterol Fixed‐Dose Combination Formulation Compared With Formoterol and High‐Dose Inhaled Mometasone Furoate Monotherapy in Subjects With Moderate to Severe COPD, 2006. http://clinicaltrials.gov/show/NCT00383435. [] TashkinDP , DohertyDE , KerwinE , Matiz‐BuenoCE , KnorrB , ShekarT , et al. Efficacy and safety of a fixed‐dose combination of mometasone furoate and formoterol fumarate in subjects with moderate to very severe COPD: results from a 52‐week Phase III trial. International Journal of Chronic Obstructive Pulmonary Disease2012; Vol. 7, issue 1178‐2005 (Electronic). 1176‐9106 (Linking):43‐55. ">Tashkin 2012</a> stratify exacerbations into mild, moderate or severe. Exacerbation data were not reported in <a href="./references#CD006826-bbs2-0005" title="LapperreTS , Snoeck‐StrobandJB , GosmanMM , JansenDF , vanSchadewijkA , ThiadensHA , et al. Effect of fluticasone with and without salmeterol on pulmonary outcomes in chronic obstructive pulmonary disease: a randomized trial. Annals of Internal Medicine2009; Vol. 151, issue 8:517‐27. ">Lapperre 2009</a>, <a href="./references#CD006826-bbs2-0007" title="NCT00358358 . Trial SCO104925. See detailed description, 2006. http://clinicaltrials.gov/show/NCT00358358. [] ">NCT00358358</a> or <a href="./references#CD006826-bbs2-0001" title="BourbeauJ , ChristodoulopoulosP , MaltaisF , YamauchiY , OlivensteinR , HamidQ . Effect of salmeterol/fluticasone propionate on airway inflammation in COPD: a randomised controlled trial. Thorax2007; Vol. 62, issue 11:938‐43. ">Bourbeau 2007</a>. <a href="./references#CD006826-bbs2-0004" title="HananiaNA , DarkenP , HorstmanD , ReisnerC , LeeB , DavisS , et al. The efficacy and safety of fluticasone propionate (250 micro g)/salmeterol (50 micro g) combined in the diskus inhaler for the treatment of COPD. Chest2003;124(3):834‐43. HananiaNA , RamsdellJ , PayneK , DavisS , HorstmanD , LeeB , et al. Improvements in airflow and dyspnea in COPD patients following 24 weeks treatment with salmeterol 50mcg and fluticasone propionate 250mcg alone or in combination via the diskus. American Journal of Respiratory &amp; Critical Care Medicine2001;163(5 Suppl):A279. HorstmanD , DarkenP , DavisS , LeeB . Improvements in FEV1 and symptoms in poorly reversible COPD patients following treatment with salmeterol 50mcg/fluticasone propionate 250mcg combination [Abstract]. European Respiratory Journal2003;22 Suppl 45:P434. MahlerDA , DarkenP , BrownCP , KnobilK . Predicting lung function responses to combination therapy in chronic obstructive pulmonary disease (COPD) [Abstract]. National COPD Conference; November 14‐15, 2003; Arlington, Virginia. Abstract 1081. MahlerDA , DarkenP , BrownCP , KnobilK . Predicting lung function responses to salmeterol/fluticasone propionate combination therapy in COPD [Abstract]. European Respiratory Journal2003;22 Suppl 45:P429. SFCA3007 . A randomized, double‐blind, placebo‐controlled, parallel‐group trial evaluating the safety and efficacy of the DISKUS formulations of salmeterol (SAL) 50mcg BID and fluticasone propionate (FP) 250mcg BID individually and in combination as salmeterol 50mcg/fluticasone propionate 250mcg BID (SFC 50/250) compared to placebo in COPD subjects. GlaxoSmithKline Clinical Trials Register (http:ctr.gsk.co.uk)2005. SpencerM , WireP , LeeB , ChangCN , DarkenP , HorstmanD . Patients with COPD using salmeterol/fluticasone propionate combination therapy experience improved quality of life. European Respiratory Journal2003;22 Suppl 45:51s. SpencerMD , KariaN , AndersonJ . The clinical significance of treatment benefits with the salmeterol/fluticasone propionate 50/500mcg combination in COPD. European Respiratory Journal2004;24 Suppl 48:290s. ">Hanania 2003</a> and <a href="./references#CD006826-bbs2-0006" title="MahlerDA , DarkenP , BrownCP , KnobilK . Predicting lung function responses to combination therapy in chronic obstructive pulmonary disease (COPD), 2003. http://www.abstracts2view.com. MahlerDA , WireP , HorstmanD , ChangCN , YatesJ , FischerT , et al. Effectiveness of fluticasone propionate and salmeterol combination delivered via the diskus device in the treatment of chronic obstructive pulmonary disease. American Journal of Respiratory Critical Care Medicine2002;166(8):1084‐91. SFCA3006 . A randomized, double‐blind, placebo‐controlled, parallel‐group trial evaluating the safety and efficacy of the DISKUS formulations of salmeterol (SAL) 50mcg BID and fluticasone propionate (FP) 500mcg BID individually and in combination as salmeterol 50mcg/fluticasone propionate 500mcg BID (SFC 50/500) compared to placebo in COPD subjects. GlaxoSmithKline Clinical Trials Register (http:ctr.gsk.co.uk)2005. SpencerM , WireP , LeeB , ChangCN , DarkenP , HorstmanD . Patients with COPD using salmeterol/fluticasone propionate combination therapy experience improved quality of life. European Respiratory Journal2003;22 Suppl 45:51s. SpencerMD , AndersonJA . Salmeterol/fluticasone combination produces clinically important benefits in dyspnea and fatigue [Abstract]. American Thoracic Society 2005 International Conference; May 20‐25, 2005; San Diego, California. B93 [Poster 308]. SpencerMD , KariaN , AndersonJ . The clinical significance of treatment benefits with the salmeterol/fluticasone propionate 50/500mcg combination in COPD. European Respiratory Journal2004;24 Suppl 48:290s. ">Mahler 2002</a> withdrew participants whose condition was exacerbated. </p> <p>Lung function, if reported, was measured as FEV<sub>1</sub> or peak expiratory flow (PEF) in all studies. Quality of life assessments by the SGRQ or the CRDQ were available for <a href="./references#CD006826-bbs2-0002" title="AstraZenecaSD . A placebo‐controlled 12‐month efficacy study of the fixed combination budesonide/formoterol compared to budesonide and formoterol as monotherapies in patients with chronic obstructive pulmonary disease (COPD). AstraZeneca Clinical Trials2002. BorgstromL , AskingL , OlssonH , PetersonS . Lack of interaction between disease severity and therapeutic response with budesonide/formoterol in a single inhaler [Abstract]. American Thoracic Society 100th International Conference; May 21‐26; 2004, Orlando, Florida. C22 [Poster 505]. CalverleyPM , BonsawatW , CsekeZ , ZhongN , PetersonS , OlssonH . Maintenance therapy with budesonide and formoterol in chronic obstructive pulmonary disease. European Respiratory Journal2003;22(6):912‐9. CalverleyPMA , CsekeZ , PetersonS . Budesonide/formoterol reduces the use of oral corticosteroids in the treatment of COPD [Abstract]. European Respiratory Journal2003;22 Suppl 45:P436. CalverleyPMA , KunaP , OlssonH . COPD exacerbations are reduced by budesonide/formoterol in a single inhaler [Abstract]. European Respiratory Journal2003;22 Suppl 45:P1587. CalverleyPMA , OlssonH , Symbicort International COPD Study Group. Budesonide/formoterol ina single inhaler sustains improvements in lung function over 12 months compared with monocomponents and placebo in patients with COPD [abstract]. American Thoracic Society 99th International Conference; May 16‐21, 2003; Seattle, Washington. B024 [Poster 418]. CalverleyPMA , PetersonS . Combining budesonide/formoterol in a single inhale reduces exacerbation frequency in COPD [abstract]. American Thoracic Society 99th International Conference; May 16‐21, 2003; Seattle, Washington. D092 [Poster 211]. CalverleyPMA , StåhlE , JonesPW . Budesonide/formoterol improves the general health status of patients with COPD [Abstract]. American Thoracic Society 2005 International Conference; May 20‐25, 2005; San Diego, California. B93 [Poster 303]. CalverleyPMA , SzafranskiW , AnderssonA . Budesonide/formoterol is a well‐tolerated long term maintenance therapy for COPD. European Respiratory Journal2005;26 Suppl 49:Poster 1917. CalverleyPMA , ThompsonNC , OlssonH . Budesonide/formoterol in a single inhaler sustains lung function improvements in COPD [Abstract]. European Respiratory Journal2003;22 Suppl 45:P435. HalpinD , StåhlE , LundbackB , AndersonF , PetersonS . Treatment costs and number needed to treat (NNT) with budesonide/formoterol to avoid one exacerbation of COPD [Abstract]. American Thoracic Society 100th International Conference; May 21‐26, 2004; Orlando, Florida. D22 [Poster 525]. HalpinDMG , LarssonT , CalverleyPMA . How many patients with COPD must be treated with budesonide/formoterol compared with formoterol alone to avoid 1 day of oral steroid use? [Abstract]. American Thoracic Society 2005 International Conference; May 20‐25, 2005; San Diego, California. B93 [Poster 314]. JonesPW , StahlE . Budesonide/formoterol in a single inhaler improves health status in patients with COPD [abstract]. American Thoracic Society 99th International Conference; May 16‐21, 2003; Orlando, Florida. B024 [Poster 419]. JonesPW , StåhlE . Budesonide /formoterol sustains clinically relevant improvements in health status in COPD [Abstract]. European Respiratory Journal2005;26 Suppl 49:Abstract 1352. JonesPW , StåhlE . Reducing exacerbations leads to a better health‐related quality of life in patients with COPD. 13th ERS Annual Congress; September 27, 2003; Vienna, Austria. P1586. LofdahlCG . Reducing the impact of COPD exacerbations: Clinical efficacy of budesonide/formoterol. European Respiratory Review2004;13(88):14‐21. LofdahlCG , AndreassonE , SvenssonK , EricssonA . Budesonide/formoterol in a single inhaler improves health status in patients with COPD without increasing healthcare costs [Abstract]. European Respiratory Journal2003;22 Suppl 45:P433. LofdahlCG , EricssonA , SvenssonK , AndreassonE . Cost effectiveness of budesonide/formoterol in a single inhaler for COPD compared with each monocomponent used alone. Pharmacoeconomics2005;23(4):365‐75. ">Calverley 2003</a>; <a href="./references#CD006826-bbs2-0003" title="DohertyDE , KerwinE , TashkinDP , Matiz‐BuenoCE , ShekarT , BanerjeeS , et al. Combined mometasone furoate and formoterol in patients with moderate to very severe chronic obstructive pulmonary disease (COPD): phase 3 efficacy and safety study [Abstract]. Journal of Allergy and Clinical Immunology2012; Vol. 129, issue 2 Suppl:AB75 [283]. DohertyDE , TashkinDP , KerwinE , KnorrBA , ShekarT , BanerjeeS , et al. Effects of mometasone furoate/formoterol fumarate fixed‐dose combination formulation on chronic obstructive pulmonary disease (COPD): results from a 52‐week Phase III trial in subjects with moderate‐to‐very severe COPD. International Journal of Chronic Obstructive Pulmonary Disease2012; Vol. 7, issue 1178‐2005 (Electronic). 1176‐9106 (Linking):57‐71. NCT00383721 . A Randomized, 26‐Week, Placebo‐Controlled Efficacy and Safety Study With a 26‐Week Long‐Term Safety Extension, of High‐ and Medium‐Dose Inhaled Mometasone Furoate/Formoterol Fixed‐Dose Combination Formulation Compared With Formoterol and High‐Dose Inhaled Mometasone Furoate Monotherapy in Subjects With Moderate to Severe COPD, 2006. http://clinicaltrials.gov/show/NCT00383721. [] ">Doherty 2012</a>; <a href="./references#CD006826-bbs2-0004" title="HananiaNA , DarkenP , HorstmanD , ReisnerC , LeeB , DavisS , et al. The efficacy and safety of fluticasone propionate (250 micro g)/salmeterol (50 micro g) combined in the diskus inhaler for the treatment of COPD. Chest2003;124(3):834‐43. HananiaNA , RamsdellJ , PayneK , DavisS , HorstmanD , LeeB , et al. Improvements in airflow and dyspnea in COPD patients following 24 weeks treatment with salmeterol 50mcg and fluticasone propionate 250mcg alone or in combination via the diskus. American Journal of Respiratory &amp; Critical Care Medicine2001;163(5 Suppl):A279. HorstmanD , DarkenP , DavisS , LeeB . Improvements in FEV1 and symptoms in poorly reversible COPD patients following treatment with salmeterol 50mcg/fluticasone propionate 250mcg combination [Abstract]. European Respiratory Journal2003;22 Suppl 45:P434. MahlerDA , DarkenP , BrownCP , KnobilK . Predicting lung function responses to combination therapy in chronic obstructive pulmonary disease (COPD) [Abstract]. National COPD Conference; November 14‐15, 2003; Arlington, Virginia. Abstract 1081. MahlerDA , DarkenP , BrownCP , KnobilK . Predicting lung function responses to salmeterol/fluticasone propionate combination therapy in COPD [Abstract]. European Respiratory Journal2003;22 Suppl 45:P429. SFCA3007 . A randomized, double‐blind, placebo‐controlled, parallel‐group trial evaluating the safety and efficacy of the DISKUS formulations of salmeterol (SAL) 50mcg BID and fluticasone propionate (FP) 250mcg BID individually and in combination as salmeterol 50mcg/fluticasone propionate 250mcg BID (SFC 50/250) compared to placebo in COPD subjects. GlaxoSmithKline Clinical Trials Register (http:ctr.gsk.co.uk)2005. SpencerM , WireP , LeeB , ChangCN , DarkenP , HorstmanD . Patients with COPD using salmeterol/fluticasone propionate combination therapy experience improved quality of life. European Respiratory Journal2003;22 Suppl 45:51s. SpencerMD , KariaN , AndersonJ . The clinical significance of treatment benefits with the salmeterol/fluticasone propionate 50/500mcg combination in COPD. European Respiratory Journal2004;24 Suppl 48:290s. ">Hanania 2003</a>; <a href="./references#CD006826-bbs2-0005" title="LapperreTS , Snoeck‐StrobandJB , GosmanMM , JansenDF , vanSchadewijkA , ThiadensHA , et al. Effect of fluticasone with and without salmeterol on pulmonary outcomes in chronic obstructive pulmonary disease: a randomized trial. Annals of Internal Medicine2009; Vol. 151, issue 8:517‐27. ">Lapperre 2009</a>; <a href="./references#CD006826-bbs2-0006" title="MahlerDA , DarkenP , BrownCP , KnobilK . Predicting lung function responses to combination therapy in chronic obstructive pulmonary disease (COPD), 2003. http://www.abstracts2view.com. MahlerDA , WireP , HorstmanD , ChangCN , YatesJ , FischerT , et al. Effectiveness of fluticasone propionate and salmeterol combination delivered via the diskus device in the treatment of chronic obstructive pulmonary disease. American Journal of Respiratory Critical Care Medicine2002;166(8):1084‐91. SFCA3006 . A randomized, double‐blind, placebo‐controlled, parallel‐group trial evaluating the safety and efficacy of the DISKUS formulations of salmeterol (SAL) 50mcg BID and fluticasone propionate (FP) 500mcg BID individually and in combination as salmeterol 50mcg/fluticasone propionate 500mcg BID (SFC 50/500) compared to placebo in COPD subjects. GlaxoSmithKline Clinical Trials Register (http:ctr.gsk.co.uk)2005. SpencerM , WireP , LeeB , ChangCN , DarkenP , HorstmanD . Patients with COPD using salmeterol/fluticasone propionate combination therapy experience improved quality of life. European Respiratory Journal2003;22 Suppl 45:51s. SpencerMD , AndersonJA . Salmeterol/fluticasone combination produces clinically important benefits in dyspnea and fatigue [Abstract]. American Thoracic Society 2005 International Conference; May 20‐25, 2005; San Diego, California. B93 [Poster 308]. SpencerMD , KariaN , AndersonJ . The clinical significance of treatment benefits with the salmeterol/fluticasone propionate 50/500mcg combination in COPD. European Respiratory Journal2004;24 Suppl 48:290s. ">Mahler 2002</a>; <a href="./references#CD006826-bbs2-0008" title="SFCT01 . A Multicentre, Randomised, Double‐Blind, Parallel Group, Placebo‐Controlled Study to Compare the Efficacy and Safety of Inhaled Salmeterol/Fluticasone Propionate Combination Product 25/250 µg Two Puffs Bd and Fluticasone Propionate 250µg Two Puffs Bd Alone, All Administered Via Metered Dose Inhalers (MDI), in the Treatment of Subjects with Chronic Obstructive Pulmonary Disease (COPD) for 52 Weeks. GlaxoSmithKline Clinical Trials Register (http:ctr.gsk.co.uk)2005. ">SFCT01</a>; <a href="./references#CD006826-bbs2-0010" title="AndersonP . Budesonide/formoterol in a single inhaler (Symbicort) provides early and sustained improvement in lung function in moderate to severe COPD [Abstract]. Thorax2002;57(Suppl III):iii43. AstraZenecaSD . A placebo‐controlled 12 month efficacy study of the fixed combination budesonide/formoterol compared with budesonide and formoterol as monotherapies in patients with chronic obstructive pulmonary disease (COPD). AstraZeneca Clinical Trials2001. BorgstromL , AskingL , OlssonH , PetersonS . Lack of interaction between disease severity and therapeutic response with budesonide/formoterol in a single inhaler [Abstract]. American Thoracic Society 100th International Conference; May 21‐26, 2004; Orlando, Florida. C22 [Poster 505]. CalverleyP , PauwelsR , LofdahlCG , SvenssonK , HigenbottamT , et al. Relationship between respiratory symptoms and medical treatment in exacerbations of COPD. European Respiratory Journal2005;26(3):406‐13. CalverleyPMA . Effect of budesonide/formoterol on severe exacerbations and lung function in moderate to severe COPD. Thorax. BTS Winter Meeting 2002:S145. CalverleyPMA , SzafranskiW , AnderssonA . Budesonide/formoterol is a well‐tolerated long term maintenance therapy for COPD. European Respiratory Journal2005;26 Suppl 49:Poster 1917. CalverleyPMA , ThompsonNC , OlssonH . Budesonide/formoterol in a single inhaler sustains lung function improvements in COPD [Abstract]. European Respiratory Journal2003;22 Suppl 45:P435. CampbellLM , SzafranskiW . Budesonide/formoterol in a single inhaler (Symbicort) provides sustained relief from symptoms in moderate to severe COPD. Thorax. BTS Winter Meeting 2002:S143. CampellLW , SzafranskiW . Budesonide/Formoterol in a single inhaler (Symbicort) reduces severe exacerbations in patients with moderate‐severe COPD. Thorax. BTS Winter Meeting 2002:S141. DahlR , CukierA , OlssonH . Budesonide/formoterol in a single inhaler reduces severe and mild exacerbations in patients with moderate to severe COPD. European Respiratory Journal2002;20 Suppl 38:242 [P1575]. EgedeF , MengaG . Budesonide/formoterol in a single inhaler provides sustained relief from symptoms and night‐time awakenings in moderate‐severe COPD: results from symptoms and night‐time awakenings in moderate to severe COPD: results from a 1‐year study. European Respiratory Journal2002;20 Suppl 38:242 [P1574]. HalpinD , StahlE , LundbackB , AndersonF , PetersonS . Treatment costs and number needed to treat (NNT) with budesonide/formoterol to avoid one exacerbation of COPD [Abstract]. American Thoracic Society 100th International Conference; May 21‐26, 2004; Orlando, Florida. D22 [Poster 525]. JonesPW , StahlE , SvenssonK . Improvement in health status in patients with moderate to severe COPD after treatment with budesonide/formoterol in a single inhaler. European Respiratory Journal2002;20 Suppl 38:250 [P1613]. KorsgaardJ , SansoresR . Budesonide/formoterol (single inhaler) provides sustained relief from shortness of breath and chest tightness in a 1‐year study of patients with moderate to severe COPD. European Respiratory Journal2002;20 Suppl 38:242 [P1577]. LangeP , SaenzC . Budesonide/formoterol in a single inhaler is well tolerated in patients with moderate to severe COPD: results of a 1 year study. European Respiratory Journal2002;20 Suppl 38:242 [P1573]. LofdahlCG . Reducing the impact of COPD exacerbations: clinical efficacy of budesonide/formoterol. European Respiratory Review2004;13(88):14‐21. MilanowskiJ , NahabedianS . Budesonide/formoterol in a single inhaler acts rapidly to improve lung function and relieve symptoms in patients with moderate to severe COPD. European Respiratory Journal2002;20 Suppl 38:242 [P1576]. SzafranskiW , CukierA , RamirezA , MengaG , SansoresR , NahabedianS , et al. Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease. European Respiratory Journal2003;21(1):74‐81. ">Szafranski 2003</a>; <a href="./references#CD006826-bbs2-0011" title="Astrazeneca(D5899C00002) . A 6‐month double‐blind, double‐dummy, randomized, parallel group, multicenter efficacy &amp; safety study of Symbicort® pMDI 2 × 160/4.5mg &amp; 80/4.5mg bid compared to Formoterol TBH, Budesonide pMDI (&amp; the combination) &amp; placebo in COPD patients. www.astrazenecaclinicaltrials.com (accessed 8 April 2008). BleeckerER , MeyersDA , BaileyWC , SimsA‐M , BujacSR , GoldmanM , et al. ADRB2 polymorphisms and budesonide/formoterol responses in COPDADRB2 polymorphisms and treatment response in COPD. Chest2012;142(2):320‐8. TashkinDP , RennardSI , MartinP , GoldmanM , SilkoffPE . Efficacy of budesonide/formoterol administered via one pressurized metered‐dose inhaler over 6 months in patients with chronic obstructive pulmonary disease [Abstract]. Chest2008; Vol. 134, issue 4:105001s. TashkinDP , RennardSI , MartinP , RamachandranS , MartinUJ , SilkoffPE , et al. Efficacy and safety of budesonide and formoterol in one pressurized metered‐dose inhaler in patients with moderate to very severe chronic obstructive pulmonary disease : results of a 6‐month randomized clinical trial. Drugs2008; Vol. 68, issue 0012‐6667 (Print):1975‐2000. ">Tashkin 2008</a>; <a href="./references#CD006826-bbs2-0012" title="KerwinE , TashkinDP , Matiz‐BuenoCE , DohertyDE , ShekarT , BanerjeeS , et al. Clinical efficacy and safety of combined mometasone furoate and formoterol in patients with moderate to very severe chronic obstructive pulmonary disease (COPD) [Abstract]. Journal of Allergy and Clinical Immunology2012; Vol. 129, issue 2 Suppl:AB201 [759]. NCT00383435 . A Randomized, 26‐Week, Placebo‐Controlled Efficacy and Safety Study With a 26‐Week Long‐Term Safety Extension, of High‐ and Medium‐Dose Inhaled Mometasone Furoate/Formoterol Fixed‐Dose Combination Formulation Compared With Formoterol and High‐Dose Inhaled Mometasone Furoate Monotherapy in Subjects With Moderate to Severe COPD, 2006. http://clinicaltrials.gov/show/NCT00383435. [] TashkinDP , DohertyDE , KerwinE , Matiz‐BuenoCE , KnorrB , ShekarT , et al. Efficacy and safety of a fixed‐dose combination of mometasone furoate and formoterol fumarate in subjects with moderate to very severe COPD: results from a 52‐week Phase III trial. International Journal of Chronic Obstructive Pulmonary Disease2012; Vol. 7, issue 1178‐2005 (Electronic). 1176‐9106 (Linking):43‐55. ">Tashkin 2012</a>; <a href="./references#CD006826-bbs2-0013" title="BriggsAH , GlickHA , Lozano‐OrtegaG , SpencerM , CalverleyPM , JonesPW , et al. Is treatment with ICS and LABA cost‐effective for COPD? Multinational economic analysis of the TORCH study. European Respiratory Journal2010; Vol. 35, issue 3:532‐9. CalverleyPM , AndersonJA , CelliB , FergusonGT , JenkinsC , JonesPW , et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease.[see comment]. New England Journal of Medicine2007; Vol. 356, issue 8:775‐89. CalverleyPMA , AndersonJA , CelliB , FergusonGT , JenkinsC , JonesPW , et al. Cardiovascular events in patients with chronic obstructive pulmonary disease: TORCH study results. Thorax2010;65:719‐25. CalverleyPMA , AndersonJA , CelliB , FergusonGT , JenkinsC , JonesPW , et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. New England Journal of Medicine2007;356(8):775‐89. CalverleyPMA , CelliB , FergusonG , JenkinsC , JonesPW , PrideNB , et al. Baseline characteristics of the first 5,000 COPD patients enrolled in the TORCH survival study. European Respiratory Journal2003;22 Suppl 45:578s. CelliB , CalverleyPMA , AndersonJA , FergusonGT , JenkinsC , JonesPW , et al. The TORCH (TOwards a Revolution in COPD Health) study: salmeterol/fluticasone propionate (SFC) improves health status, reduces exacerbations and improves lung function over three years. European Respiratory Journal2006;28 Suppl 50:34s. CelliB , VestboJ , JenkinsCR , JonesPW , FergusonGT , CalverleyPM , et al. Sex differences in mortality and clinical expressions of patients with chronic obstructive pulmonary disease: the TORCH experience. American Journal of Respiratory and Critical Care Medicine2011;183(3):317‐22. CelliBR , ThomasNE , AndersonJA , FergusonGT , JenkinsCR , JonesPW , et al. Effect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease: results from the TORCH study. American Journal of Respiratory and Critical Care Medicine2008;174(4):332‐8. CrimC , CalverleyPM , AndersonJA , CelliB , FergusonGT , JenkinsC , et al. Pneumonia risk in COPD patients receiving inhaled corticosteroids alone or in combination: TORCH study results. European Respiratory Journal2009;34(3):641‐7. FergusonGT , CalverleyPM , AndersonJA , JenkinsCR , JonesPW , WillitsLR , et al. Prevalence and progression of osteoporosis in patients with COPD: results from the TOwards a Revolution in COPD Health study. Chest2009; Vol. 136, issue 0012‐3692:1456‐65. FergusonGT , CalverleyPMA , AndersonJA , et al. The TORCH (TOwards a Revolution in COPD Health) study: salmeterol/fluticasone propionate (SFC) improves survival in COPD over three years. European Respiratory Journal2006;28 Suppl 50:34s. GlaxoSmithKlineSCO30003 . A multicentre, randomised, double‐blind, parallel group, placebo‐controlled study to investigate the long‐term effects of salmeterol/fluticasone propionate (SERETIDE/VIANI/ADVAIR) 50/500mcg bd, salmeterol 50mcg bd and fluticasone propionate 500mcg bd, all delivered via the DISKUS/ACCUHALER inhaler, on the survival of subjects with chronic obstructive pulmonary disease (COPD) over 3 years of treatment. GlaxoSmithKline Clinical Trial Register2006. HoughtonCM , LawsonN , BorrillZL , WixonCL , YoxallS , LangleySJ , et al. Comparison of the effects of salmeterol/fluticasone propionate with fluticasone propionate on airway physiology in adults with mild persistent asthma. Respiratory Research2007;8:52. JenkinsCR , CalverleyPMA , CelliB , FergusonG , JonesPW , PrideN , et al. Seasonal patterns of exacerbation rates in the TORCH survival study, 2007. http://www.abstracts2view.comA839. JenkinsCR , CelliB , AndersonJA , FergusonGT , JonesPW , VestboJ , et al. Seasonality and determinants of moderate and severe COPD exacerbations in the TORCH study. European Respiratory Journal2012;39(1):38‐45. JenkinsCR , JonesPW , CalverleyPM , CelliB , AndersonJA , FergusonGT , et al. Efficacy of salmeterol/fluticasone propionate by GOLD stage of chronic obstructive pulmonary disease: analysis from the randomised, placebo‐controlled TORCH study. Respiratory Research2009;10:59. JohnsonM , AgustiAG , BarnesNC . Reflections on TORCH: potential mechanisms for the survival benefit of salmeterol/fluticasone propionate in COPD patients. COPD2008;5(6):369‐75. JonesPW , AndersonJA , CalverleyPM , CelliBR , FergusonGT , JenkinsC , et al. TORCH Investigators. Health status in the TORCH study of COPD: treatment efficacy and other determinants of change. Respiratory Research2011;12:71. JonesPW , CalverleyP , CelliB , FergusonG , JenkinsC , PrideN . Trans‐regional validity of the SGRQ in the TORCH survival study, 2007. http://www.abstracts2view.comA122. McGarveyLP , JohnM , AndersonJA , ZvarichMT , WiseRA . Ascertainment of cause‐specific mortality in COPD: operations of the TORCH Clinical Endpoint Committee. Thorax2007;62:411‐5. NCT00268216 . See detailed description, 2000. http://clinicaltrials.gov/show/NCT00268216. [] SCO30003 . A multicentre, randomised, double‐blind, parallel group, placebo‐controlled study to investigate the long‐term effects of salmeterol/fluticasone propionate (SERETIDE®/VIANI®/ADVAIR®) 50/500mcg bd, salmeterol 50mcg bd and fluticasone propionate 500mcg bd, all delivered via the DISKUS®/ACCUHALER® inhaler, on the survival of subjects with chronic obstructive pulmonary disease (COPD) over 3 years of treatment, 2006. www.ctr.gsk.co.uk. VestboJ , AndersonJA , CalverleyPM , CelliB , FergusonGT , JenkinsC , et al. Adherence to inhaled therapy, mortality and hospital admission in COPD. Thorax2009;64(11):939‐43. VestboJ , CalverleyP , CelliB , FergusonG , JenkinsC , JonesP , et al. The TORCH (TOwards a Revolution in COPD Health) survival study protocol. European Respiratory Journal2004;24(2):206‐10. WiseRA , McGarveyLP , JohnM , AndersonJA , ZvarichMT . Reliability of cause‐specific mortality adjudication in a COPD clinical trial, 2007. http://www.abstracts2view.comA120. ">TORCH</a>; <a href="./references#CD006826-bbs2-0014" title="CalverleyP , PauwelsR , VestboJ , JonesP , PrideN , GulsvikA , et al. Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial. Lancet2003;361(9356):449‐56. CalverleyPMA , PauwelsRA , VestboJ , JonesPW , PrideNB , GulsvikA , et al. Clinical improvements with salmeterol / fluticasone propionate combination in differing severities of COPD, 2003. http://www.abstracts2view.comA035 [Poster D50]. CalverleyPMA , PauwelsRA , VestboJ , JonesPW , PrideNB , GulsvikA , et al. Salmeterol/Fluticasone propionate combination for one year provides greater clinical benefit than its individual components. Proceedings of the 98th International American Thoracic Society Conference http://www.abstracts‐on‐line.com/abstracts/ATS; May 17‐22, 2002; Atlanta, Georgia. A98 [Poster 306]. CalverlyPMA , PauwelsR , VestboJ , JonesP , PrideN , GulsvikA , et al. Safety of salmeterol/fluticasone propionate combination in the treatment of chronic obstructive pulmonary disease. European Respiratory Journal2002;20 Suppl 38:242 [P1572]. HunjanMK , ChandlerF . Numbers needed to treat (NNT) to avoid an exacerbation in patients with chronic obstructive pulmonary disease (COPD) using salmeterol/fluticasone propionate combination (SFC) and associated costs [Abstract]. American Thoracic Society 100th International Conference; May 21‐26, 2004; Orlando, Florida. D22 [Poster 503]. HunjanMK , WilliamsDT . Costs of avoiding exacerbations in patients with chronic obstructive pulmonary disease (COPD) treated with salmeterol/ fluticasone propionate combination (seretide) and salmeterol. European Respiratory Journal2004;24 Suppl 48:291s. HunjanMK , WilliamsDT . Salmeterol/ fluticasone propionate combination is clinically effective in avoiding exacerbations in patients with moderate/severe COPD. European Respiratory Journal2004;24 Suppl 48:513s. JonesPW , EdinHM , AndersonJ . Salmeterol/fluticasone propionate combination improves health status in COPD patients. Proceedings of the 98th International American Thoracic Society Conference http://www.abstracts‐on‐line.com/abstracts/ATS; May 17‐22, 2002; Atlanta, Georgia. A39 [Poster K39]. JonesPW , StåhlE . Budesonide /formoterol sustains clinically relevant improvements in health status in COPD [Abstract]. European Respiratory Journal2005;26 Suppl 49:Abstract 1352. JonesPW , VestboJ , PauwelsRA , CalverleyPMA , AndersonJA , SpencerMD . Informative drop out in COPD studies: investigation of health status of withdrawals in the TRISTAN study. Proceedings of the 13th ERS Annual Congress; September 27, 2003; Vienna, Austria. P1593. NitschmannS . Inhalational combination therapy in chronic obstructive lung disease. Tristan study. German Internist2004;45(6):727‐8. PauwelsR , VestboJ , CalverleyPMA , JonesPW , PrideNB , GulsvikA . Characterization of exacerbations in the TRISTAN study of salmeterol / fluticasone propionate (SFC) combination in moderate to severe COPD, 2006. http://www.abstracts2view.com. PauwelsRA , CalverlyPMA , VestboJ , JonesPW , PrideN , GulsvikA , et al. Reduction of exacerbations with salmeterol/fluticasone combination 50/500 mcg bd in the treatment of chronic obstructive pulmonary disease. European Respiratory Journal2002;20 Suppl 38:240 [P1569]. SFCB3024 . A multicentre, randomised, double‐blind, parallel group, placebo‐controlled study to compare the efficacy and safety of the salmeterol/FP combination product at a strength of 50/500mcg bd with salmeterol 50mcg bd alone and FP 500mcg bd alone, delivered via the DISKUS™/ACCUHALER™, in the treatment of subjects with chronic obstructive pulmonary disease (COPD) for 12 months. GlaxoSmithKline Clinical Trials Register (http:ctr.gsk.co.uk)2005. SpencerM , BriggsAH , GrossmanRF , RanceL . Development of an economic model to assess the cost effectiveness of treatment interventions for chronic obstructive pulmonary disease. Pharmacoeconomics2005;23(6):619‐37. SpencerMD , KariaN , AndersonJ . The clinical significance of treatment benefits with the salmeterol/fluticasone propionate 50/500mcg combination in COPD. European Respiratory Journal2004;24 Suppl 48:290s. VestboJ , CalverleyPMA , PauwelsR , JonesP , PrideN , GulsvikA , et al. Absence of gender susceptibility to the combination of salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease. European Respiratory Journal2002;20 Suppl 38:240 [P1570]. VestboJ , PauwelsR , AndersonJA , JonesP , CalverleyP . Early onset of effect of salmeterol and fluticasone propionate in chronic obstructive pulmonary disease. Thorax2005;60(4):301‐4. VestboJ , PauwelsRS , CalverleyPMA , JonesPW , PrideNB , GulsvikA . Salmeterol / fluticasone propionate combination produces improvement in lung function detectable within 24 hours in moderate to severe COPD, 2003. http://www.abstracts2view.com. VestboJ , SorianoJB , AndersonJA , CalverleyP , PauwelsR , JonesP . Gender does not influence the response to the combination of salmeterol and fluticasone propionate in COPD. Respiratory Medicine2004;98(11):1045‐50. ">TRISTAN</a>; <a href="./references#CD006826-bbs2-0009" title="NCT00120978 . Advair－CRP Study. http://clinicaltrials.gov/show/NCT001209782004. [] SinDD , ManSF , MarciniukDD , FordG , FitzGeraldM , WongE , et al. Can inhaled fluticasone alone or in combination with salmeterol reduce systemic inflammation in chronic obstructive pulmonary disease? Study protocol for a randomized controlled trial [NCT00120978]. BMC Pulmonary Medicine2006;6(6):3. SinDD , ManSF , MarciniukDD , FordG , FitzGeraldM , WongE , et al. The effects of fluticasone with or without salmeterol on systemic biomarkers of inflammation in chronic obstructive pulmonary disease. American Journal of Respiratory and Critical Care Medicine2008; Vol. 177, issue 11:1207‐14. ">Sin 2008</a>; and <a href="./references#CD006826-bbs2-0015" title="ZhongN , ZhengJ , WenF , YangL , ChenP , XiuQ , et al. Efficacy and safety of budesonide/formoterol via a dry powder inhaler in Chinese patients with chronic obstructive pulmonary disease. Current Medical Research and Opinion2012; Vol. 28, issue 2:257‐65. ZhongN , ZhengJ , WenF , YangL , ChenP , XiuQ , et al. Efficacy and safety of inhalation of budesonide/formoterol via turbuhaler in Chinese patients with chronic obstructive pulmonary disease [Abstract]. Chest2011; Vol. 140, issue 4:5225A. ">Zhong 2012</a>. Quality of life assessment was not reported for <a href="./references#CD006826-bbs2-0007" title="NCT00358358 . Trial SCO104925. See detailed description, 2006. http://clinicaltrials.gov/show/NCT00358358. [] ">NCT00358358</a> or <a href="./references#CD006826-bbs2-0001" title="BourbeauJ , ChristodoulopoulosP , MaltaisF , YamauchiY , OlivensteinR , HamidQ . Effect of salmeterol/fluticasone propionate on airway inflammation in COPD: a randomised controlled trial. Thorax2007; Vol. 62, issue 11:938‐43. ">Bourbeau 2007</a>. All‐cause mortality was reported by <a href="./references#CD006826-bbs2-0013" title="BriggsAH , GlickHA , Lozano‐OrtegaG , SpencerM , CalverleyPM , JonesPW , et al. Is treatment with ICS and LABA cost‐effective for COPD? Multinational economic analysis of the TORCH study. European Respiratory Journal2010; Vol. 35, issue 3:532‐9. CalverleyPM , AndersonJA , CelliB , FergusonGT , JenkinsC , JonesPW , et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease.[see comment]. New England Journal of Medicine2007; Vol. 356, issue 8:775‐89. CalverleyPMA , AndersonJA , CelliB , FergusonGT , JenkinsC , JonesPW , et al. Cardiovascular events in patients with chronic obstructive pulmonary disease: TORCH study results. Thorax2010;65:719‐25. CalverleyPMA , AndersonJA , CelliB , FergusonGT , JenkinsC , JonesPW , et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. New England Journal of Medicine2007;356(8):775‐89. CalverleyPMA , CelliB , FergusonG , JenkinsC , JonesPW , PrideNB , et al. Baseline characteristics of the first 5,000 COPD patients enrolled in the TORCH survival study. European Respiratory Journal2003;22 Suppl 45:578s. CelliB , CalverleyPMA , AndersonJA , FergusonGT , JenkinsC , JonesPW , et al. The TORCH (TOwards a Revolution in COPD Health) study: salmeterol/fluticasone propionate (SFC) improves health status, reduces exacerbations and improves lung function over three years. European Respiratory Journal2006;28 Suppl 50:34s. CelliB , VestboJ , JenkinsCR , JonesPW , FergusonGT , CalverleyPM , et al. Sex differences in mortality and clinical expressions of patients with chronic obstructive pulmonary disease: the TORCH experience. American Journal of Respiratory and Critical Care Medicine2011;183(3):317‐22. CelliBR , ThomasNE , AndersonJA , FergusonGT , JenkinsCR , JonesPW , et al. Effect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease: results from the TORCH study. American Journal of Respiratory and Critical Care Medicine2008;174(4):332‐8. CrimC , CalverleyPM , AndersonJA , CelliB , FergusonGT , JenkinsC , et al. Pneumonia risk in COPD patients receiving inhaled corticosteroids alone or in combination: TORCH study results. European Respiratory Journal2009;34(3):641‐7. FergusonGT , CalverleyPM , AndersonJA , JenkinsCR , JonesPW , WillitsLR , et al. Prevalence and progression of osteoporosis in patients with COPD: results from the TOwards a Revolution in COPD Health study. Chest2009; Vol. 136, issue 0012‐3692:1456‐65. FergusonGT , CalverleyPMA , AndersonJA , et al. The TORCH (TOwards a Revolution in COPD Health) study: salmeterol/fluticasone propionate (SFC) improves survival in COPD over three years. European Respiratory Journal2006;28 Suppl 50:34s. GlaxoSmithKlineSCO30003 . A multicentre, randomised, double‐blind, parallel group, placebo‐controlled study to investigate the long‐term effects of salmeterol/fluticasone propionate (SERETIDE/VIANI/ADVAIR) 50/500mcg bd, salmeterol 50mcg bd and fluticasone propionate 500mcg bd, all delivered via the DISKUS/ACCUHALER inhaler, on the survival of subjects with chronic obstructive pulmonary disease (COPD) over 3 years of treatment. GlaxoSmithKline Clinical Trial Register2006. HoughtonCM , LawsonN , BorrillZL , WixonCL , YoxallS , LangleySJ , et al. Comparison of the effects of salmeterol/fluticasone propionate with fluticasone propionate on airway physiology in adults with mild persistent asthma. Respiratory Research2007;8:52. JenkinsCR , CalverleyPMA , CelliB , FergusonG , JonesPW , PrideN , et al. Seasonal patterns of exacerbation rates in the TORCH survival study, 2007. http://www.abstracts2view.comA839. JenkinsCR , CelliB , AndersonJA , FergusonGT , JonesPW , VestboJ , et al. Seasonality and determinants of moderate and severe COPD exacerbations in the TORCH study. European Respiratory Journal2012;39(1):38‐45. JenkinsCR , JonesPW , CalverleyPM , CelliB , AndersonJA , FergusonGT , et al. Efficacy of salmeterol/fluticasone propionate by GOLD stage of chronic obstructive pulmonary disease: analysis from the randomised, placebo‐controlled TORCH study. Respiratory Research2009;10:59. JohnsonM , AgustiAG , BarnesNC . Reflections on TORCH: potential mechanisms for the survival benefit of salmeterol/fluticasone propionate in COPD patients. COPD2008;5(6):369‐75. JonesPW , AndersonJA , CalverleyPM , CelliBR , FergusonGT , JenkinsC , et al. TORCH Investigators. Health status in the TORCH study of COPD: treatment efficacy and other determinants of change. Respiratory Research2011;12:71. JonesPW , CalverleyP , CelliB , FergusonG , JenkinsC , PrideN . Trans‐regional validity of the SGRQ in the TORCH survival study, 2007. http://www.abstracts2view.comA122. McGarveyLP , JohnM , AndersonJA , ZvarichMT , WiseRA . Ascertainment of cause‐specific mortality in COPD: operations of the TORCH Clinical Endpoint Committee. Thorax2007;62:411‐5. NCT00268216 . See detailed description, 2000. http://clinicaltrials.gov/show/NCT00268216. [] SCO30003 . A multicentre, randomised, double‐blind, parallel group, placebo‐controlled study to investigate the long‐term effects of salmeterol/fluticasone propionate (SERETIDE®/VIANI®/ADVAIR®) 50/500mcg bd, salmeterol 50mcg bd and fluticasone propionate 500mcg bd, all delivered via the DISKUS®/ACCUHALER® inhaler, on the survival of subjects with chronic obstructive pulmonary disease (COPD) over 3 years of treatment, 2006. www.ctr.gsk.co.uk. VestboJ , AndersonJA , CalverleyPM , CelliB , FergusonGT , JenkinsC , et al. Adherence to inhaled therapy, mortality and hospital admission in COPD. Thorax2009;64(11):939‐43. VestboJ , CalverleyP , CelliB , FergusonG , JenkinsC , JonesP , et al. The TORCH (TOwards a Revolution in COPD Health) survival study protocol. European Respiratory Journal2004;24(2):206‐10. WiseRA , McGarveyLP , JohnM , AndersonJA , ZvarichMT . Reliability of cause‐specific mortality adjudication in a COPD clinical trial, 2007. http://www.abstracts2view.comA120. ">TORCH</a>. Mortality data were also reported for <a href="./references#CD006826-bbs2-0003" title="DohertyDE , KerwinE , TashkinDP , Matiz‐BuenoCE , ShekarT , BanerjeeS , et al. Combined mometasone furoate and formoterol in patients with moderate to very severe chronic obstructive pulmonary disease (COPD): phase 3 efficacy and safety study [Abstract]. Journal of Allergy and Clinical Immunology2012; Vol. 129, issue 2 Suppl:AB75 [283]. DohertyDE , TashkinDP , KerwinE , KnorrBA , ShekarT , BanerjeeS , et al. Effects of mometasone furoate/formoterol fumarate fixed‐dose combination formulation on chronic obstructive pulmonary disease (COPD): results from a 52‐week Phase III trial in subjects with moderate‐to‐very severe COPD. International Journal of Chronic Obstructive Pulmonary Disease2012; Vol. 7, issue 1178‐2005 (Electronic). 1176‐9106 (Linking):57‐71. NCT00383721 . A Randomized, 26‐Week, Placebo‐Controlled Efficacy and Safety Study With a 26‐Week Long‐Term Safety Extension, of High‐ and Medium‐Dose Inhaled Mometasone Furoate/Formoterol Fixed‐Dose Combination Formulation Compared With Formoterol and High‐Dose Inhaled Mometasone Furoate Monotherapy in Subjects With Moderate to Severe COPD, 2006. http://clinicaltrials.gov/show/NCT00383721. [] ">Doherty 2012</a>; <a href="./references#CD006826-bbs2-0007" title="NCT00358358 . Trial SCO104925. See detailed description, 2006. http://clinicaltrials.gov/show/NCT00358358. [] ">NCT00358358</a>; <a href="./references#CD006826-bbs2-0011" title="Astrazeneca(D5899C00002) . A 6‐month double‐blind, double‐dummy, randomized, parallel group, multicenter efficacy &amp; safety study of Symbicort® pMDI 2 × 160/4.5mg &amp; 80/4.5mg bid compared to Formoterol TBH, Budesonide pMDI (&amp; the combination) &amp; placebo in COPD patients. www.astrazenecaclinicaltrials.com (accessed 8 April 2008). BleeckerER , MeyersDA , BaileyWC , SimsA‐M , BujacSR , GoldmanM , et al. ADRB2 polymorphisms and budesonide/formoterol responses in COPDADRB2 polymorphisms and treatment response in COPD. Chest2012;142(2):320‐8. TashkinDP , RennardSI , MartinP , GoldmanM , SilkoffPE . Efficacy of budesonide/formoterol administered via one pressurized metered‐dose inhaler over 6 months in patients with chronic obstructive pulmonary disease [Abstract]. Chest2008; Vol. 134, issue 4:105001s. TashkinDP , RennardSI , MartinP , RamachandranS , MartinUJ , SilkoffPE , et al. Efficacy and safety of budesonide and formoterol in one pressurized metered‐dose inhaler in patients with moderate to very severe chronic obstructive pulmonary disease : results of a 6‐month randomized clinical trial. Drugs2008; Vol. 68, issue 0012‐6667 (Print):1975‐2000. ">Tashkin 2008</a>; <a href="./references#CD006826-bbs2-0012" title="KerwinE , TashkinDP , Matiz‐BuenoCE , DohertyDE , ShekarT , BanerjeeS , et al. Clinical efficacy and safety of combined mometasone furoate and formoterol in patients with moderate to very severe chronic obstructive pulmonary disease (COPD) [Abstract]. Journal of Allergy and Clinical Immunology2012; Vol. 129, issue 2 Suppl:AB201 [759]. NCT00383435 . A Randomized, 26‐Week, Placebo‐Controlled Efficacy and Safety Study With a 26‐Week Long‐Term Safety Extension, of High‐ and Medium‐Dose Inhaled Mometasone Furoate/Formoterol Fixed‐Dose Combination Formulation Compared With Formoterol and High‐Dose Inhaled Mometasone Furoate Monotherapy in Subjects With Moderate to Severe COPD, 2006. http://clinicaltrials.gov/show/NCT00383435. [] TashkinDP , DohertyDE , KerwinE , Matiz‐BuenoCE , KnorrB , ShekarT , et al. Efficacy and safety of a fixed‐dose combination of mometasone furoate and formoterol fumarate in subjects with moderate to very severe COPD: results from a 52‐week Phase III trial. International Journal of Chronic Obstructive Pulmonary Disease2012; Vol. 7, issue 1178‐2005 (Electronic). 1176‐9106 (Linking):43‐55. ">Tashkin 2012</a>; and <a href="./references#CD006826-bbs2-0015" title="ZhongN , ZhengJ , WenF , YangL , ChenP , XiuQ , et al. Efficacy and safety of budesonide/formoterol via a dry powder inhaler in Chinese patients with chronic obstructive pulmonary disease. Current Medical Research and Opinion2012; Vol. 28, issue 2:257‐65. ZhongN , ZhengJ , WenF , YangL , ChenP , XiuQ , et al. Efficacy and safety of inhalation of budesonide/formoterol via turbuhaler in Chinese patients with chronic obstructive pulmonary disease [Abstract]. Chest2011; Vol. 140, issue 4:5225A. ">Zhong 2012</a>,, although death was not one of their pre‐defined outcomes. </p> </section> </section> <section id="CD006826-sec-0061"> <h4 class="title">Excluded studies</h4> <p>A total of 48 studies were excluded－36 (75%) because the comparison was not made between combined LABA/ICS versus ICS; 5 (10%) because participants were also randomly assigned to receive tiotropium as a co‐intervention; 2 (4%) because asthma patients were combined in the study; 2 (4%) because ICS dose in the ICS/LABA condition was less than 80% of the ICS dose in the ICS‐only condition; 1 (2%) because investigators provided an aggregated report of two studies; 1 (2%) because it examined the acute effect of combined LABA/ICS and 1 (2%) because the focus was on sleep quality in COPD. A list of excluded studies is provided in <a href="./references#CD006826-sec-0146" title="">Characteristics of excluded studies</a>. </p> </section> </section> <section id="CD006826-sec-0062"> <h3 class="title">Risk of bias in included studies</h3> <p>Intention‐to treat (ITT) analyses were reported in all studies for their primary outcomes. <a href="./references#CD006826-bbs2-0013" title="BriggsAH , GlickHA , Lozano‐OrtegaG , SpencerM , CalverleyPM , JonesPW , et al. Is treatment with ICS and LABA cost‐effective for COPD? Multinational economic analysis of the TORCH study. European Respiratory Journal2010; Vol. 35, issue 3:532‐9. CalverleyPM , AndersonJA , CelliB , FergusonGT , JenkinsC , JonesPW , et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease.[see comment]. New England Journal of Medicine2007; Vol. 356, issue 8:775‐89. CalverleyPMA , AndersonJA , CelliB , FergusonGT , JenkinsC , JonesPW , et al. Cardiovascular events in patients with chronic obstructive pulmonary disease: TORCH study results. Thorax2010;65:719‐25. CalverleyPMA , AndersonJA , CelliB , FergusonGT , JenkinsC , JonesPW , et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. New England Journal of Medicine2007;356(8):775‐89. CalverleyPMA , CelliB , FergusonG , JenkinsC , JonesPW , PrideNB , et al. Baseline characteristics of the first 5,000 COPD patients enrolled in the TORCH survival study. European Respiratory Journal2003;22 Suppl 45:578s. CelliB , CalverleyPMA , AndersonJA , FergusonGT , JenkinsC , JonesPW , et al. The TORCH (TOwards a Revolution in COPD Health) study: salmeterol/fluticasone propionate (SFC) improves health status, reduces exacerbations and improves lung function over three years. European Respiratory Journal2006;28 Suppl 50:34s. CelliB , VestboJ , JenkinsCR , JonesPW , FergusonGT , CalverleyPM , et al. Sex differences in mortality and clinical expressions of patients with chronic obstructive pulmonary disease: the TORCH experience. American Journal of Respiratory and Critical Care Medicine2011;183(3):317‐22. CelliBR , ThomasNE , AndersonJA , FergusonGT , JenkinsCR , JonesPW , et al. Effect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease: results from the TORCH study. American Journal of Respiratory and Critical Care Medicine2008;174(4):332‐8. CrimC , CalverleyPM , AndersonJA , CelliB , FergusonGT , JenkinsC , et al. Pneumonia risk in COPD patients receiving inhaled corticosteroids alone or in combination: TORCH study results. European Respiratory Journal2009;34(3):641‐7. FergusonGT , CalverleyPM , AndersonJA , JenkinsCR , JonesPW , WillitsLR , et al. Prevalence and progression of osteoporosis in patients with COPD: results from the TOwards a Revolution in COPD Health study. Chest2009; Vol. 136, issue 0012‐3692:1456‐65. FergusonGT , CalverleyPMA , AndersonJA , et al. The TORCH (TOwards a Revolution in COPD Health) study: salmeterol/fluticasone propionate (SFC) improves survival in COPD over three years. European Respiratory Journal2006;28 Suppl 50:34s. GlaxoSmithKlineSCO30003 . A multicentre, randomised, double‐blind, parallel group, placebo‐controlled study to investigate the long‐term effects of salmeterol/fluticasone propionate (SERETIDE/VIANI/ADVAIR) 50/500mcg bd, salmeterol 50mcg bd and fluticasone propionate 500mcg bd, all delivered via the DISKUS/ACCUHALER inhaler, on the survival of subjects with chronic obstructive pulmonary disease (COPD) over 3 years of treatment. GlaxoSmithKline Clinical Trial Register2006. HoughtonCM , LawsonN , BorrillZL , WixonCL , YoxallS , LangleySJ , et al. Comparison of the effects of salmeterol/fluticasone propionate with fluticasone propionate on airway physiology in adults with mild persistent asthma. Respiratory Research2007;8:52. JenkinsCR , CalverleyPMA , CelliB , FergusonG , JonesPW , PrideN , et al. Seasonal patterns of exacerbation rates in the TORCH survival study, 2007. http://www.abstracts2view.comA839. JenkinsCR , CelliB , AndersonJA , FergusonGT , JonesPW , VestboJ , et al. Seasonality and determinants of moderate and severe COPD exacerbations in the TORCH study. European Respiratory Journal2012;39(1):38‐45. JenkinsCR , JonesPW , CalverleyPM , CelliB , AndersonJA , FergusonGT , et al. Efficacy of salmeterol/fluticasone propionate by GOLD stage of chronic obstructive pulmonary disease: analysis from the randomised, placebo‐controlled TORCH study. Respiratory Research2009;10:59. JohnsonM , AgustiAG , BarnesNC . Reflections on TORCH: potential mechanisms for the survival benefit of salmeterol/fluticasone propionate in COPD patients. COPD2008;5(6):369‐75. JonesPW , AndersonJA , CalverleyPM , CelliBR , FergusonGT , JenkinsC , et al. TORCH Investigators. Health status in the TORCH study of COPD: treatment efficacy and other determinants of change. Respiratory Research2011;12:71. JonesPW , CalverleyP , CelliB , FergusonG , JenkinsC , PrideN . Trans‐regional validity of the SGRQ in the TORCH survival study, 2007. http://www.abstracts2view.comA122. McGarveyLP , JohnM , AndersonJA , ZvarichMT , WiseRA . Ascertainment of cause‐specific mortality in COPD: operations of the TORCH Clinical Endpoint Committee. Thorax2007;62:411‐5. NCT00268216 . See detailed description, 2000. http://clinicaltrials.gov/show/NCT00268216. [] SCO30003 . A multicentre, randomised, double‐blind, parallel group, placebo‐controlled study to investigate the long‐term effects of salmeterol/fluticasone propionate (SERETIDE®/VIANI®/ADVAIR®) 50/500mcg bd, salmeterol 50mcg bd and fluticasone propionate 500mcg bd, all delivered via the DISKUS®/ACCUHALER® inhaler, on the survival of subjects with chronic obstructive pulmonary disease (COPD) over 3 years of treatment, 2006. www.ctr.gsk.co.uk. VestboJ , AndersonJA , CalverleyPM , CelliB , FergusonGT , JenkinsC , et al. Adherence to inhaled therapy, mortality and hospital admission in COPD. Thorax2009;64(11):939‐43. VestboJ , CalverleyP , CelliB , FergusonG , JenkinsC , JonesP , et al. The TORCH (TOwards a Revolution in COPD Health) survival study protocol. European Respiratory Journal2004;24(2):206‐10. WiseRA , McGarveyLP , JohnM , AndersonJA , ZvarichMT . Reliability of cause‐specific mortality adjudication in a COPD clinical trial, 2007. http://www.abstracts2view.comA120. ">TORCH</a> reported incomplete data for FEV<sub>1</sub> and SGRQ scores. Concealment of allocation was reported in <a href="./references#CD006826-bbs2-0002" title="AstraZenecaSD . A placebo‐controlled 12‐month efficacy study of the fixed combination budesonide/formoterol compared to budesonide and formoterol as monotherapies in patients with chronic obstructive pulmonary disease (COPD). AstraZeneca Clinical Trials2002. BorgstromL , AskingL , OlssonH , PetersonS . Lack of interaction between disease severity and therapeutic response with budesonide/formoterol in a single inhaler [Abstract]. American Thoracic Society 100th International Conference; May 21‐26; 2004, Orlando, Florida. C22 [Poster 505]. CalverleyPM , BonsawatW , CsekeZ , ZhongN , PetersonS , OlssonH . Maintenance therapy with budesonide and formoterol in chronic obstructive pulmonary disease. European Respiratory Journal2003;22(6):912‐9. CalverleyPMA , CsekeZ , PetersonS . Budesonide/formoterol reduces the use of oral corticosteroids in the treatment of COPD [Abstract]. European Respiratory Journal2003;22 Suppl 45:P436. CalverleyPMA , KunaP , OlssonH . COPD exacerbations are reduced by budesonide/formoterol in a single inhaler [Abstract]. European Respiratory Journal2003;22 Suppl 45:P1587. CalverleyPMA , OlssonH , Symbicort International COPD Study Group. Budesonide/formoterol ina single inhaler sustains improvements in lung function over 12 months compared with monocomponents and placebo in patients with COPD [abstract]. American Thoracic Society 99th International Conference; May 16‐21, 2003; Seattle, Washington. B024 [Poster 418]. CalverleyPMA , PetersonS . Combining budesonide/formoterol in a single inhale reduces exacerbation frequency in COPD [abstract]. American Thoracic Society 99th International Conference; May 16‐21, 2003; Seattle, Washington. D092 [Poster 211]. CalverleyPMA , StåhlE , JonesPW . Budesonide/formoterol improves the general health status of patients with COPD [Abstract]. American Thoracic Society 2005 International Conference; May 20‐25, 2005; San Diego, California. B93 [Poster 303]. CalverleyPMA , SzafranskiW , AnderssonA . Budesonide/formoterol is a well‐tolerated long term maintenance therapy for COPD. European Respiratory Journal2005;26 Suppl 49:Poster 1917. CalverleyPMA , ThompsonNC , OlssonH . Budesonide/formoterol in a single inhaler sustains lung function improvements in COPD [Abstract]. European Respiratory Journal2003;22 Suppl 45:P435. HalpinD , StåhlE , LundbackB , AndersonF , PetersonS . Treatment costs and number needed to treat (NNT) with budesonide/formoterol to avoid one exacerbation of COPD [Abstract]. American Thoracic Society 100th International Conference; May 21‐26, 2004; Orlando, Florida. D22 [Poster 525]. HalpinDMG , LarssonT , CalverleyPMA . How many patients with COPD must be treated with budesonide/formoterol compared with formoterol alone to avoid 1 day of oral steroid use? [Abstract]. American Thoracic Society 2005 International Conference; May 20‐25, 2005; San Diego, California. B93 [Poster 314]. JonesPW , StahlE . Budesonide/formoterol in a single inhaler improves health status in patients with COPD [abstract]. American Thoracic Society 99th International Conference; May 16‐21, 2003; Orlando, Florida. B024 [Poster 419]. JonesPW , StåhlE . Budesonide /formoterol sustains clinically relevant improvements in health status in COPD [Abstract]. European Respiratory Journal2005;26 Suppl 49:Abstract 1352. JonesPW , StåhlE . Reducing exacerbations leads to a better health‐related quality of life in patients with COPD. 13th ERS Annual Congress; September 27, 2003; Vienna, Austria. P1586. LofdahlCG . Reducing the impact of COPD exacerbations: Clinical efficacy of budesonide/formoterol. European Respiratory Review2004;13(88):14‐21. LofdahlCG , AndreassonE , SvenssonK , EricssonA . Budesonide/formoterol in a single inhaler improves health status in patients with COPD without increasing healthcare costs [Abstract]. European Respiratory Journal2003;22 Suppl 45:P433. LofdahlCG , EricssonA , SvenssonK , AndreassonE . Cost effectiveness of budesonide/formoterol in a single inhaler for COPD compared with each monocomponent used alone. Pharmacoeconomics2005;23(4):365‐75. ">Calverley 2003</a>; <a href="./references#CD006826-bbs2-0010" title="AndersonP . Budesonide/formoterol in a single inhaler (Symbicort) provides early and sustained improvement in lung function in moderate to severe COPD [Abstract]. Thorax2002;57(Suppl III):iii43. AstraZenecaSD . A placebo‐controlled 12 month efficacy study of the fixed combination budesonide/formoterol compared with budesonide and formoterol as monotherapies in patients with chronic obstructive pulmonary disease (COPD). AstraZeneca Clinical Trials2001. BorgstromL , AskingL , OlssonH , PetersonS . Lack of interaction between disease severity and therapeutic response with budesonide/formoterol in a single inhaler [Abstract]. American Thoracic Society 100th International Conference; May 21‐26, 2004; Orlando, Florida. C22 [Poster 505]. CalverleyP , PauwelsR , LofdahlCG , SvenssonK , HigenbottamT , et al. Relationship between respiratory symptoms and medical treatment in exacerbations of COPD. European Respiratory Journal2005;26(3):406‐13. CalverleyPMA . Effect of budesonide/formoterol on severe exacerbations and lung function in moderate to severe COPD. Thorax. BTS Winter Meeting 2002:S145. CalverleyPMA , SzafranskiW , AnderssonA . Budesonide/formoterol is a well‐tolerated long term maintenance therapy for COPD. European Respiratory Journal2005;26 Suppl 49:Poster 1917. CalverleyPMA , ThompsonNC , OlssonH . Budesonide/formoterol in a single inhaler sustains lung function improvements in COPD [Abstract]. European Respiratory Journal2003;22 Suppl 45:P435. CampbellLM , SzafranskiW . Budesonide/formoterol in a single inhaler (Symbicort) provides sustained relief from symptoms in moderate to severe COPD. Thorax. BTS Winter Meeting 2002:S143. CampellLW , SzafranskiW . Budesonide/Formoterol in a single inhaler (Symbicort) reduces severe exacerbations in patients with moderate‐severe COPD. Thorax. BTS Winter Meeting 2002:S141. DahlR , CukierA , OlssonH . Budesonide/formoterol in a single inhaler reduces severe and mild exacerbations in patients with moderate to severe COPD. European Respiratory Journal2002;20 Suppl 38:242 [P1575]. EgedeF , MengaG . Budesonide/formoterol in a single inhaler provides sustained relief from symptoms and night‐time awakenings in moderate‐severe COPD: results from symptoms and night‐time awakenings in moderate to severe COPD: results from a 1‐year study. European Respiratory Journal2002;20 Suppl 38:242 [P1574]. HalpinD , StahlE , LundbackB , AndersonF , PetersonS . Treatment costs and number needed to treat (NNT) with budesonide/formoterol to avoid one exacerbation of COPD [Abstract]. American Thoracic Society 100th International Conference; May 21‐26, 2004; Orlando, Florida. D22 [Poster 525]. JonesPW , StahlE , SvenssonK . Improvement in health status in patients with moderate to severe COPD after treatment with budesonide/formoterol in a single inhaler. European Respiratory Journal2002;20 Suppl 38:250 [P1613]. KorsgaardJ , SansoresR . Budesonide/formoterol (single inhaler) provides sustained relief from shortness of breath and chest tightness in a 1‐year study of patients with moderate to severe COPD. European Respiratory Journal2002;20 Suppl 38:242 [P1577]. LangeP , SaenzC . Budesonide/formoterol in a single inhaler is well tolerated in patients with moderate to severe COPD: results of a 1 year study. European Respiratory Journal2002;20 Suppl 38:242 [P1573]. LofdahlCG . Reducing the impact of COPD exacerbations: clinical efficacy of budesonide/formoterol. European Respiratory Review2004;13(88):14‐21. MilanowskiJ , NahabedianS . Budesonide/formoterol in a single inhaler acts rapidly to improve lung function and relieve symptoms in patients with moderate to severe COPD. European Respiratory Journal2002;20 Suppl 38:242 [P1576]. SzafranskiW , CukierA , RamirezA , MengaG , SansoresR , NahabedianS , et al. Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease. European Respiratory Journal2003;21(1):74‐81. ">Szafranski 2003</a>; <a href="./references#CD006826-bbs2-0013" title="BriggsAH , GlickHA , Lozano‐OrtegaG , SpencerM , CalverleyPM , JonesPW , et al. Is treatment with ICS and LABA cost‐effective for COPD? Multinational economic analysis of the TORCH study. European Respiratory Journal2010; Vol. 35, issue 3:532‐9. CalverleyPM , AndersonJA , CelliB , FergusonGT , JenkinsC , JonesPW , et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease.[see comment]. New England Journal of Medicine2007; Vol. 356, issue 8:775‐89. CalverleyPMA , AndersonJA , CelliB , FergusonGT , JenkinsC , JonesPW , et al. Cardiovascular events in patients with chronic obstructive pulmonary disease: TORCH study results. Thorax2010;65:719‐25. CalverleyPMA , AndersonJA , CelliB , FergusonGT , JenkinsC , JonesPW , et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. New England Journal of Medicine2007;356(8):775‐89. CalverleyPMA , CelliB , FergusonG , JenkinsC , JonesPW , PrideNB , et al. Baseline characteristics of the first 5,000 COPD patients enrolled in the TORCH survival study. European Respiratory Journal2003;22 Suppl 45:578s. CelliB , CalverleyPMA , AndersonJA , FergusonGT , JenkinsC , JonesPW , et al. The TORCH (TOwards a Revolution in COPD Health) study: salmeterol/fluticasone propionate (SFC) improves health status, reduces exacerbations and improves lung function over three years. European Respiratory Journal2006;28 Suppl 50:34s. CelliB , VestboJ , JenkinsCR , JonesPW , FergusonGT , CalverleyPM , et al. Sex differences in mortality and clinical expressions of patients with chronic obstructive pulmonary disease: the TORCH experience. American Journal of Respiratory and Critical Care Medicine2011;183(3):317‐22. CelliBR , ThomasNE , AndersonJA , FergusonGT , JenkinsCR , JonesPW , et al. Effect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease: results from the TORCH study. American Journal of Respiratory and Critical Care Medicine2008;174(4):332‐8. CrimC , CalverleyPM , AndersonJA , CelliB , FergusonGT , JenkinsC , et al. Pneumonia risk in COPD patients receiving inhaled corticosteroids alone or in combination: TORCH study results. European Respiratory Journal2009;34(3):641‐7. FergusonGT , CalverleyPM , AndersonJA , JenkinsCR , JonesPW , WillitsLR , et al. Prevalence and progression of osteoporosis in patients with COPD: results from the TOwards a Revolution in COPD Health study. Chest2009; Vol. 136, issue 0012‐3692:1456‐65. FergusonGT , CalverleyPMA , AndersonJA , et al. The TORCH (TOwards a Revolution in COPD Health) study: salmeterol/fluticasone propionate (SFC) improves survival in COPD over three years. European Respiratory Journal2006;28 Suppl 50:34s. GlaxoSmithKlineSCO30003 . A multicentre, randomised, double‐blind, parallel group, placebo‐controlled study to investigate the long‐term effects of salmeterol/fluticasone propionate (SERETIDE/VIANI/ADVAIR) 50/500mcg bd, salmeterol 50mcg bd and fluticasone propionate 500mcg bd, all delivered via the DISKUS/ACCUHALER inhaler, on the survival of subjects with chronic obstructive pulmonary disease (COPD) over 3 years of treatment. GlaxoSmithKline Clinical Trial Register2006. HoughtonCM , LawsonN , BorrillZL , WixonCL , YoxallS , LangleySJ , et al. Comparison of the effects of salmeterol/fluticasone propionate with fluticasone propionate on airway physiology in adults with mild persistent asthma. Respiratory Research2007;8:52. JenkinsCR , CalverleyPMA , CelliB , FergusonG , JonesPW , PrideN , et al. Seasonal patterns of exacerbation rates in the TORCH survival study, 2007. http://www.abstracts2view.comA839. JenkinsCR , CelliB , AndersonJA , FergusonGT , JonesPW , VestboJ , et al. Seasonality and determinants of moderate and severe COPD exacerbations in the TORCH study. European Respiratory Journal2012;39(1):38‐45. JenkinsCR , JonesPW , CalverleyPM , CelliB , AndersonJA , FergusonGT , et al. Efficacy of salmeterol/fluticasone propionate by GOLD stage of chronic obstructive pulmonary disease: analysis from the randomised, placebo‐controlled TORCH study. Respiratory Research2009;10:59. JohnsonM , AgustiAG , BarnesNC . Reflections on TORCH: potential mechanisms for the survival benefit of salmeterol/fluticasone propionate in COPD patients. COPD2008;5(6):369‐75. JonesPW , AndersonJA , CalverleyPM , CelliBR , FergusonGT , JenkinsC , et al. TORCH Investigators. Health status in the TORCH study of COPD: treatment efficacy and other determinants of change. Respiratory Research2011;12:71. JonesPW , CalverleyP , CelliB , FergusonG , JenkinsC , PrideN . Trans‐regional validity of the SGRQ in the TORCH survival study, 2007. http://www.abstracts2view.comA122. McGarveyLP , JohnM , AndersonJA , ZvarichMT , WiseRA . Ascertainment of cause‐specific mortality in COPD: operations of the TORCH Clinical Endpoint Committee. Thorax2007;62:411‐5. NCT00268216 . See detailed description, 2000. http://clinicaltrials.gov/show/NCT00268216. [] SCO30003 . A multicentre, randomised, double‐blind, parallel group, placebo‐controlled study to investigate the long‐term effects of salmeterol/fluticasone propionate (SERETIDE®/VIANI®/ADVAIR®) 50/500mcg bd, salmeterol 50mcg bd and fluticasone propionate 500mcg bd, all delivered via the DISKUS®/ACCUHALER® inhaler, on the survival of subjects with chronic obstructive pulmonary disease (COPD) over 3 years of treatment, 2006. www.ctr.gsk.co.uk. VestboJ , AndersonJA , CalverleyPM , CelliB , FergusonGT , JenkinsC , et al. Adherence to inhaled therapy, mortality and hospital admission in COPD. Thorax2009;64(11):939‐43. VestboJ , CalverleyP , CelliB , FergusonG , JenkinsC , JonesP , et al. The TORCH (TOwards a Revolution in COPD Health) survival study protocol. European Respiratory Journal2004;24(2):206‐10. WiseRA , McGarveyLP , JohnM , AndersonJA , ZvarichMT . Reliability of cause‐specific mortality adjudication in a COPD clinical trial, 2007. http://www.abstracts2view.comA120. ">TORCH</a>; and <a href="./references#CD006826-bbs2-0014" title="CalverleyP , PauwelsR , VestboJ , JonesP , PrideN , GulsvikA , et al. Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial. Lancet2003;361(9356):449‐56. CalverleyPMA , PauwelsRA , VestboJ , JonesPW , PrideNB , GulsvikA , et al. Clinical improvements with salmeterol / fluticasone propionate combination in differing severities of COPD, 2003. http://www.abstracts2view.comA035 [Poster D50]. CalverleyPMA , PauwelsRA , VestboJ , JonesPW , PrideNB , GulsvikA , et al. Salmeterol/Fluticasone propionate combination for one year provides greater clinical benefit than its individual components. Proceedings of the 98th International American Thoracic Society Conference http://www.abstracts‐on‐line.com/abstracts/ATS; May 17‐22, 2002; Atlanta, Georgia. A98 [Poster 306]. CalverlyPMA , PauwelsR , VestboJ , JonesP , PrideN , GulsvikA , et al. Safety of salmeterol/fluticasone propionate combination in the treatment of chronic obstructive pulmonary disease. European Respiratory Journal2002;20 Suppl 38:242 [P1572]. HunjanMK , ChandlerF . Numbers needed to treat (NNT) to avoid an exacerbation in patients with chronic obstructive pulmonary disease (COPD) using salmeterol/fluticasone propionate combination (SFC) and associated costs [Abstract]. American Thoracic Society 100th International Conference; May 21‐26, 2004; Orlando, Florida. D22 [Poster 503]. HunjanMK , WilliamsDT . Costs of avoiding exacerbations in patients with chronic obstructive pulmonary disease (COPD) treated with salmeterol/ fluticasone propionate combination (seretide) and salmeterol. European Respiratory Journal2004;24 Suppl 48:291s. HunjanMK , WilliamsDT . Salmeterol/ fluticasone propionate combination is clinically effective in avoiding exacerbations in patients with moderate/severe COPD. European Respiratory Journal2004;24 Suppl 48:513s. JonesPW , EdinHM , AndersonJ . Salmeterol/fluticasone propionate combination improves health status in COPD patients. Proceedings of the 98th International American Thoracic Society Conference http://www.abstracts‐on‐line.com/abstracts/ATS; May 17‐22, 2002; Atlanta, Georgia. A39 [Poster K39]. JonesPW , StåhlE . Budesonide /formoterol sustains clinically relevant improvements in health status in COPD [Abstract]. European Respiratory Journal2005;26 Suppl 49:Abstract 1352. JonesPW , VestboJ , PauwelsRA , CalverleyPMA , AndersonJA , SpencerMD . Informative drop out in COPD studies: investigation of health status of withdrawals in the TRISTAN study. Proceedings of the 13th ERS Annual Congress; September 27, 2003; Vienna, Austria. P1593. NitschmannS . Inhalational combination therapy in chronic obstructive lung disease. Tristan study. German Internist2004;45(6):727‐8. PauwelsR , VestboJ , CalverleyPMA , JonesPW , PrideNB , GulsvikA . Characterization of exacerbations in the TRISTAN study of salmeterol / fluticasone propionate (SFC) combination in moderate to severe COPD, 2006. http://www.abstracts2view.com. PauwelsRA , CalverlyPMA , VestboJ , JonesPW , PrideN , GulsvikA , et al. Reduction of exacerbations with salmeterol/fluticasone combination 50/500 mcg bd in the treatment of chronic obstructive pulmonary disease. European Respiratory Journal2002;20 Suppl 38:240 [P1569]. SFCB3024 . A multicentre, randomised, double‐blind, parallel group, placebo‐controlled study to compare the efficacy and safety of the salmeterol/FP combination product at a strength of 50/500mcg bd with salmeterol 50mcg bd alone and FP 500mcg bd alone, delivered via the DISKUS™/ACCUHALER™, in the treatment of subjects with chronic obstructive pulmonary disease (COPD) for 12 months. GlaxoSmithKline Clinical Trials Register (http:ctr.gsk.co.uk)2005. SpencerM , BriggsAH , GrossmanRF , RanceL . Development of an economic model to assess the cost effectiveness of treatment interventions for chronic obstructive pulmonary disease. Pharmacoeconomics2005;23(6):619‐37. SpencerMD , KariaN , AndersonJ . The clinical significance of treatment benefits with the salmeterol/fluticasone propionate 50/500mcg combination in COPD. European Respiratory Journal2004;24 Suppl 48:290s. VestboJ , CalverleyPMA , PauwelsR , JonesP , PrideN , GulsvikA , et al. Absence of gender susceptibility to the combination of salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease. European Respiratory Journal2002;20 Suppl 38:240 [P1570]. VestboJ , PauwelsR , AndersonJA , JonesP , CalverleyP . Early onset of effect of salmeterol and fluticasone propionate in chronic obstructive pulmonary disease. Thorax2005;60(4):301‐4. VestboJ , PauwelsRS , CalverleyPMA , JonesPW , PrideNB , GulsvikA . Salmeterol / fluticasone propionate combination produces improvement in lung function detectable within 24 hours in moderate to severe COPD, 2003. http://www.abstracts2view.com. VestboJ , SorianoJB , AndersonJA , CalverleyP , PauwelsR , JonesP . Gender does not influence the response to the combination of salmeterol and fluticasone propionate in COPD. Respiratory Medicine2004;98(11):1045‐50. ">TRISTAN</a>. Blinding of treatment was reported for all studies. Identical delivery devices for treatment groups were reported in <a href="./references#CD006826-bbs2-0002" title="AstraZenecaSD . A placebo‐controlled 12‐month efficacy study of the fixed combination budesonide/formoterol compared to budesonide and formoterol as monotherapies in patients with chronic obstructive pulmonary disease (COPD). AstraZeneca Clinical Trials2002. BorgstromL , AskingL , OlssonH , PetersonS . Lack of interaction between disease severity and therapeutic response with budesonide/formoterol in a single inhaler [Abstract]. American Thoracic Society 100th International Conference; May 21‐26; 2004, Orlando, Florida. C22 [Poster 505]. CalverleyPM , BonsawatW , CsekeZ , ZhongN , PetersonS , OlssonH . Maintenance therapy with budesonide and formoterol in chronic obstructive pulmonary disease. European Respiratory Journal2003;22(6):912‐9. CalverleyPMA , CsekeZ , PetersonS . Budesonide/formoterol reduces the use of oral corticosteroids in the treatment of COPD [Abstract]. European Respiratory Journal2003;22 Suppl 45:P436. CalverleyPMA , KunaP , OlssonH . COPD exacerbations are reduced by budesonide/formoterol in a single inhaler [Abstract]. European Respiratory Journal2003;22 Suppl 45:P1587. CalverleyPMA , OlssonH , Symbicort International COPD Study Group. Budesonide/formoterol ina single inhaler sustains improvements in lung function over 12 months compared with monocomponents and placebo in patients with COPD [abstract]. American Thoracic Society 99th International Conference; May 16‐21, 2003; Seattle, Washington. B024 [Poster 418]. CalverleyPMA , PetersonS . Combining budesonide/formoterol in a single inhale reduces exacerbation frequency in COPD [abstract]. American Thoracic Society 99th International Conference; May 16‐21, 2003; Seattle, Washington. D092 [Poster 211]. CalverleyPMA , StåhlE , JonesPW . Budesonide/formoterol improves the general health status of patients with COPD [Abstract]. American Thoracic Society 2005 International Conference; May 20‐25, 2005; San Diego, California. B93 [Poster 303]. CalverleyPMA , SzafranskiW , AnderssonA . Budesonide/formoterol is a well‐tolerated long term maintenance therapy for COPD. European Respiratory Journal2005;26 Suppl 49:Poster 1917. CalverleyPMA , ThompsonNC , OlssonH . Budesonide/formoterol in a single inhaler sustains lung function improvements in COPD [Abstract]. European Respiratory Journal2003;22 Suppl 45:P435. HalpinD , StåhlE , LundbackB , AndersonF , PetersonS . Treatment costs and number needed to treat (NNT) with budesonide/formoterol to avoid one exacerbation of COPD [Abstract]. American Thoracic Society 100th International Conference; May 21‐26, 2004; Orlando, Florida. D22 [Poster 525]. HalpinDMG , LarssonT , CalverleyPMA . How many patients with COPD must be treated with budesonide/formoterol compared with formoterol alone to avoid 1 day of oral steroid use? [Abstract]. American Thoracic Society 2005 International Conference; May 20‐25, 2005; San Diego, California. B93 [Poster 314]. JonesPW , StahlE . Budesonide/formoterol in a single inhaler improves health status in patients with COPD [abstract]. American Thoracic Society 99th International Conference; May 16‐21, 2003; Orlando, Florida. B024 [Poster 419]. JonesPW , StåhlE . Budesonide /formoterol sustains clinically relevant improvements in health status in COPD [Abstract]. European Respiratory Journal2005;26 Suppl 49:Abstract 1352. JonesPW , StåhlE . Reducing exacerbations leads to a better health‐related quality of life in patients with COPD. 13th ERS Annual Congress; September 27, 2003; Vienna, Austria. P1586. LofdahlCG . Reducing the impact of COPD exacerbations: Clinical efficacy of budesonide/formoterol. European Respiratory Review2004;13(88):14‐21. LofdahlCG , AndreassonE , SvenssonK , EricssonA . Budesonide/formoterol in a single inhaler improves health status in patients with COPD without increasing healthcare costs [Abstract]. European Respiratory Journal2003;22 Suppl 45:P433. LofdahlCG , EricssonA , SvenssonK , AndreassonE . Cost effectiveness of budesonide/formoterol in a single inhaler for COPD compared with each monocomponent used alone. Pharmacoeconomics2005;23(4):365‐75. ">Calverley 2003</a>; <a href="./references#CD006826-bbs2-0010" title="AndersonP . Budesonide/formoterol in a single inhaler (Symbicort) provides early and sustained improvement in lung function in moderate to severe COPD [Abstract]. Thorax2002;57(Suppl III):iii43. AstraZenecaSD . A placebo‐controlled 12 month efficacy study of the fixed combination budesonide/formoterol compared with budesonide and formoterol as monotherapies in patients with chronic obstructive pulmonary disease (COPD). AstraZeneca Clinical Trials2001. BorgstromL , AskingL , OlssonH , PetersonS . Lack of interaction between disease severity and therapeutic response with budesonide/formoterol in a single inhaler [Abstract]. American Thoracic Society 100th International Conference; May 21‐26, 2004; Orlando, Florida. C22 [Poster 505]. CalverleyP , PauwelsR , LofdahlCG , SvenssonK , HigenbottamT , et al. Relationship between respiratory symptoms and medical treatment in exacerbations of COPD. European Respiratory Journal2005;26(3):406‐13. CalverleyPMA . Effect of budesonide/formoterol on severe exacerbations and lung function in moderate to severe COPD. Thorax. BTS Winter Meeting 2002:S145. CalverleyPMA , SzafranskiW , AnderssonA . Budesonide/formoterol is a well‐tolerated long term maintenance therapy for COPD. European Respiratory Journal2005;26 Suppl 49:Poster 1917. CalverleyPMA , ThompsonNC , OlssonH . Budesonide/formoterol in a single inhaler sustains lung function improvements in COPD [Abstract]. European Respiratory Journal2003;22 Suppl 45:P435. CampbellLM , SzafranskiW . Budesonide/formoterol in a single inhaler (Symbicort) provides sustained relief from symptoms in moderate to severe COPD. Thorax. BTS Winter Meeting 2002:S143. CampellLW , SzafranskiW . Budesonide/Formoterol in a single inhaler (Symbicort) reduces severe exacerbations in patients with moderate‐severe COPD. Thorax. BTS Winter Meeting 2002:S141. DahlR , CukierA , OlssonH . Budesonide/formoterol in a single inhaler reduces severe and mild exacerbations in patients with moderate to severe COPD. European Respiratory Journal2002;20 Suppl 38:242 [P1575]. EgedeF , MengaG . Budesonide/formoterol in a single inhaler provides sustained relief from symptoms and night‐time awakenings in moderate‐severe COPD: results from symptoms and night‐time awakenings in moderate to severe COPD: results from a 1‐year study. European Respiratory Journal2002;20 Suppl 38:242 [P1574]. HalpinD , StahlE , LundbackB , AndersonF , PetersonS . Treatment costs and number needed to treat (NNT) with budesonide/formoterol to avoid one exacerbation of COPD [Abstract]. American Thoracic Society 100th International Conference; May 21‐26, 2004; Orlando, Florida. D22 [Poster 525]. JonesPW , StahlE , SvenssonK . Improvement in health status in patients with moderate to severe COPD after treatment with budesonide/formoterol in a single inhaler. European Respiratory Journal2002;20 Suppl 38:250 [P1613]. KorsgaardJ , SansoresR . Budesonide/formoterol (single inhaler) provides sustained relief from shortness of breath and chest tightness in a 1‐year study of patients with moderate to severe COPD. European Respiratory Journal2002;20 Suppl 38:242 [P1577]. LangeP , SaenzC . Budesonide/formoterol in a single inhaler is well tolerated in patients with moderate to severe COPD: results of a 1 year study. European Respiratory Journal2002;20 Suppl 38:242 [P1573]. LofdahlCG . Reducing the impact of COPD exacerbations: clinical efficacy of budesonide/formoterol. European Respiratory Review2004;13(88):14‐21. MilanowskiJ , NahabedianS . Budesonide/formoterol in a single inhaler acts rapidly to improve lung function and relieve symptoms in patients with moderate to severe COPD. European Respiratory Journal2002;20 Suppl 38:242 [P1576]. SzafranskiW , CukierA , RamirezA , MengaG , SansoresR , NahabedianS , et al. Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease. European Respiratory Journal2003;21(1):74‐81. ">Szafranski 2003</a>; <a href="./references#CD006826-bbs2-0013" title="BriggsAH , GlickHA , Lozano‐OrtegaG , SpencerM , CalverleyPM , JonesPW , et al. Is treatment with ICS and LABA cost‐effective for COPD? Multinational economic analysis of the TORCH study. European Respiratory Journal2010; Vol. 35, issue 3:532‐9. CalverleyPM , AndersonJA , CelliB , FergusonGT , JenkinsC , JonesPW , et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease.[see comment]. New England Journal of Medicine2007; Vol. 356, issue 8:775‐89. CalverleyPMA , AndersonJA , CelliB , FergusonGT , JenkinsC , JonesPW , et al. Cardiovascular events in patients with chronic obstructive pulmonary disease: TORCH study results. Thorax2010;65:719‐25. CalverleyPMA , AndersonJA , CelliB , FergusonGT , JenkinsC , JonesPW , et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. New England Journal of Medicine2007;356(8):775‐89. CalverleyPMA , CelliB , FergusonG , JenkinsC , JonesPW , PrideNB , et al. Baseline characteristics of the first 5,000 COPD patients enrolled in the TORCH survival study. European Respiratory Journal2003;22 Suppl 45:578s. CelliB , CalverleyPMA , AndersonJA , FergusonGT , JenkinsC , JonesPW , et al. The TORCH (TOwards a Revolution in COPD Health) study: salmeterol/fluticasone propionate (SFC) improves health status, reduces exacerbations and improves lung function over three years. European Respiratory Journal2006;28 Suppl 50:34s. CelliB , VestboJ , JenkinsCR , JonesPW , FergusonGT , CalverleyPM , et al. Sex differences in mortality and clinical expressions of patients with chronic obstructive pulmonary disease: the TORCH experience. American Journal of Respiratory and Critical Care Medicine2011;183(3):317‐22. CelliBR , ThomasNE , AndersonJA , FergusonGT , JenkinsCR , JonesPW , et al. Effect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease: results from the TORCH study. American Journal of Respiratory and Critical Care Medicine2008;174(4):332‐8. CrimC , CalverleyPM , AndersonJA , CelliB , FergusonGT , JenkinsC , et al. Pneumonia risk in COPD patients receiving inhaled corticosteroids alone or in combination: TORCH study results. European Respiratory Journal2009;34(3):641‐7. FergusonGT , CalverleyPM , AndersonJA , JenkinsCR , JonesPW , WillitsLR , et al. Prevalence and progression of osteoporosis in patients with COPD: results from the TOwards a Revolution in COPD Health study. Chest2009; Vol. 136, issue 0012‐3692:1456‐65. FergusonGT , CalverleyPMA , AndersonJA , et al. The TORCH (TOwards a Revolution in COPD Health) study: salmeterol/fluticasone propionate (SFC) improves survival in COPD over three years. European Respiratory Journal2006;28 Suppl 50:34s. GlaxoSmithKlineSCO30003 . A multicentre, randomised, double‐blind, parallel group, placebo‐controlled study to investigate the long‐term effects of salmeterol/fluticasone propionate (SERETIDE/VIANI/ADVAIR) 50/500mcg bd, salmeterol 50mcg bd and fluticasone propionate 500mcg bd, all delivered via the DISKUS/ACCUHALER inhaler, on the survival of subjects with chronic obstructive pulmonary disease (COPD) over 3 years of treatment. GlaxoSmithKline Clinical Trial Register2006. HoughtonCM , LawsonN , BorrillZL , WixonCL , YoxallS , LangleySJ , et al. Comparison of the effects of salmeterol/fluticasone propionate with fluticasone propionate on airway physiology in adults with mild persistent asthma. Respiratory Research2007;8:52. JenkinsCR , CalverleyPMA , CelliB , FergusonG , JonesPW , PrideN , et al. Seasonal patterns of exacerbation rates in the TORCH survival study, 2007. http://www.abstracts2view.comA839. JenkinsCR , CelliB , AndersonJA , FergusonGT , JonesPW , VestboJ , et al. Seasonality and determinants of moderate and severe COPD exacerbations in the TORCH study. European Respiratory Journal2012;39(1):38‐45. JenkinsCR , JonesPW , CalverleyPM , CelliB , AndersonJA , FergusonGT , et al. Efficacy of salmeterol/fluticasone propionate by GOLD stage of chronic obstructive pulmonary disease: analysis from the randomised, placebo‐controlled TORCH study. Respiratory Research2009;10:59. JohnsonM , AgustiAG , BarnesNC . Reflections on TORCH: potential mechanisms for the survival benefit of salmeterol/fluticasone propionate in COPD patients. COPD2008;5(6):369‐75. JonesPW , AndersonJA , CalverleyPM , CelliBR , FergusonGT , JenkinsC , et al. TORCH Investigators. Health status in the TORCH study of COPD: treatment efficacy and other determinants of change. Respiratory Research2011;12:71. JonesPW , CalverleyP , CelliB , FergusonG , JenkinsC , PrideN . Trans‐regional validity of the SGRQ in the TORCH survival study, 2007. http://www.abstracts2view.comA122. McGarveyLP , JohnM , AndersonJA , ZvarichMT , WiseRA . Ascertainment of cause‐specific mortality in COPD: operations of the TORCH Clinical Endpoint Committee. Thorax2007;62:411‐5. NCT00268216 . See detailed description, 2000. http://clinicaltrials.gov/show/NCT00268216. [] SCO30003 . A multicentre, randomised, double‐blind, parallel group, placebo‐controlled study to investigate the long‐term effects of salmeterol/fluticasone propionate (SERETIDE®/VIANI®/ADVAIR®) 50/500mcg bd, salmeterol 50mcg bd and fluticasone propionate 500mcg bd, all delivered via the DISKUS®/ACCUHALER® inhaler, on the survival of subjects with chronic obstructive pulmonary disease (COPD) over 3 years of treatment, 2006. www.ctr.gsk.co.uk. VestboJ , AndersonJA , CalverleyPM , CelliB , FergusonGT , JenkinsC , et al. Adherence to inhaled therapy, mortality and hospital admission in COPD. Thorax2009;64(11):939‐43. VestboJ , CalverleyP , CelliB , FergusonG , JenkinsC , JonesP , et al. The TORCH (TOwards a Revolution in COPD Health) survival study protocol. European Respiratory Journal2004;24(2):206‐10. WiseRA , McGarveyLP , JohnM , AndersonJA , ZvarichMT . Reliability of cause‐specific mortality adjudication in a COPD clinical trial, 2007. http://www.abstracts2view.comA120. ">TORCH</a>; and <a href="./references#CD006826-bbs2-0014" title="CalverleyP , PauwelsR , VestboJ , JonesP , PrideN , GulsvikA , et al. Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial. Lancet2003;361(9356):449‐56. CalverleyPMA , PauwelsRA , VestboJ , JonesPW , PrideNB , GulsvikA , et al. Clinical improvements with salmeterol / fluticasone propionate combination in differing severities of COPD, 2003. http://www.abstracts2view.comA035 [Poster D50]. CalverleyPMA , PauwelsRA , VestboJ , JonesPW , PrideNB , GulsvikA , et al. Salmeterol/Fluticasone propionate combination for one year provides greater clinical benefit than its individual components. Proceedings of the 98th International American Thoracic Society Conference http://www.abstracts‐on‐line.com/abstracts/ATS; May 17‐22, 2002; Atlanta, Georgia. A98 [Poster 306]. CalverlyPMA , PauwelsR , VestboJ , JonesP , PrideN , GulsvikA , et al. Safety of salmeterol/fluticasone propionate combination in the treatment of chronic obstructive pulmonary disease. European Respiratory Journal2002;20 Suppl 38:242 [P1572]. HunjanMK , ChandlerF . Numbers needed to treat (NNT) to avoid an exacerbation in patients with chronic obstructive pulmonary disease (COPD) using salmeterol/fluticasone propionate combination (SFC) and associated costs [Abstract]. American Thoracic Society 100th International Conference; May 21‐26, 2004; Orlando, Florida. D22 [Poster 503]. HunjanMK , WilliamsDT . Costs of avoiding exacerbations in patients with chronic obstructive pulmonary disease (COPD) treated with salmeterol/ fluticasone propionate combination (seretide) and salmeterol. European Respiratory Journal2004;24 Suppl 48:291s. HunjanMK , WilliamsDT . Salmeterol/ fluticasone propionate combination is clinically effective in avoiding exacerbations in patients with moderate/severe COPD. European Respiratory Journal2004;24 Suppl 48:513s. JonesPW , EdinHM , AndersonJ . Salmeterol/fluticasone propionate combination improves health status in COPD patients. Proceedings of the 98th International American Thoracic Society Conference http://www.abstracts‐on‐line.com/abstracts/ATS; May 17‐22, 2002; Atlanta, Georgia. A39 [Poster K39]. JonesPW , StåhlE . Budesonide /formoterol sustains clinically relevant improvements in health status in COPD [Abstract]. European Respiratory Journal2005;26 Suppl 49:Abstract 1352. JonesPW , VestboJ , PauwelsRA , CalverleyPMA , AndersonJA , SpencerMD . Informative drop out in COPD studies: investigation of health status of withdrawals in the TRISTAN study. Proceedings of the 13th ERS Annual Congress; September 27, 2003; Vienna, Austria. P1593. NitschmannS . Inhalational combination therapy in chronic obstructive lung disease. Tristan study. German Internist2004;45(6):727‐8. PauwelsR , VestboJ , CalverleyPMA , JonesPW , PrideNB , GulsvikA . Characterization of exacerbations in the TRISTAN study of salmeterol / fluticasone propionate (SFC) combination in moderate to severe COPD, 2006. http://www.abstracts2view.com. PauwelsRA , CalverlyPMA , VestboJ , JonesPW , PrideN , GulsvikA , et al. Reduction of exacerbations with salmeterol/fluticasone combination 50/500 mcg bd in the treatment of chronic obstructive pulmonary disease. European Respiratory Journal2002;20 Suppl 38:240 [P1569]. SFCB3024 . A multicentre, randomised, double‐blind, parallel group, placebo‐controlled study to compare the efficacy and safety of the salmeterol/FP combination product at a strength of 50/500mcg bd with salmeterol 50mcg bd alone and FP 500mcg bd alone, delivered via the DISKUS™/ACCUHALER™, in the treatment of subjects with chronic obstructive pulmonary disease (COPD) for 12 months. GlaxoSmithKline Clinical Trials Register (http:ctr.gsk.co.uk)2005. SpencerM , BriggsAH , GrossmanRF , RanceL . Development of an economic model to assess the cost effectiveness of treatment interventions for chronic obstructive pulmonary disease. Pharmacoeconomics2005;23(6):619‐37. SpencerMD , KariaN , AndersonJ . The clinical significance of treatment benefits with the salmeterol/fluticasone propionate 50/500mcg combination in COPD. European Respiratory Journal2004;24 Suppl 48:290s. VestboJ , CalverleyPMA , PauwelsR , JonesP , PrideN , GulsvikA , et al. Absence of gender susceptibility to the combination of salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease. European Respiratory Journal2002;20 Suppl 38:240 [P1570]. VestboJ , PauwelsR , AndersonJA , JonesP , CalverleyP . Early onset of effect of salmeterol and fluticasone propionate in chronic obstructive pulmonary disease. Thorax2005;60(4):301‐4. VestboJ , PauwelsRS , CalverleyPMA , JonesPW , PrideNB , GulsvikA . Salmeterol / fluticasone propionate combination produces improvement in lung function detectable within 24 hours in moderate to severe COPD, 2003. http://www.abstracts2view.com. VestboJ , SorianoJB , AndersonJA , CalverleyP , PauwelsR , JonesP . Gender does not influence the response to the combination of salmeterol and fluticasone propionate in COPD. Respiratory Medicine2004;98(11):1045‐50. ">TRISTAN</a>. </p> <p>An overview of the judgements we have made regarding the risk of bias for each study is given in <a href="#CD006826-fig-0002">Figure 2</a>. </p> <div class="figure" id="CD006826-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD006826-fig-0002" src="/cdsr/doi/10.1002/14651858.CD006826.pub2/media/CDSR/CD006826/image_n/nCD006826-AFig-FIG02.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> </div> <section id="CD006826-sec-0063"> <h4 class="title">Allocation</h4> <p>In nine of the fifteen studies, the risk of selection bias was judged as low, and in the remaining six, the risk was viewed as unclear. Among the FPS versus fluticasone trials (9 studies, 5132 participants), five (<a href="./references#CD006826-bbs2-0001" title="BourbeauJ , ChristodoulopoulosP , MaltaisF , YamauchiY , OlivensteinR , HamidQ . Effect of salmeterol/fluticasone propionate on airway inflammation in COPD: a randomised controlled trial. Thorax2007; Vol. 62, issue 11:938‐43. ">Bourbeau 2007</a>; <a href="./references#CD006826-bbs2-0005" title="LapperreTS , Snoeck‐StrobandJB , GosmanMM , JansenDF , vanSchadewijkA , ThiadensHA , et al. Effect of fluticasone with and without salmeterol on pulmonary outcomes in chronic obstructive pulmonary disease: a randomized trial. Annals of Internal Medicine2009; Vol. 151, issue 8:517‐27. ">Lapperre 2009</a>; <a href="./references#CD006826-bbs2-0009" title="NCT00120978 . Advair－CRP Study. http://clinicaltrials.gov/show/NCT001209782004. [] SinDD , ManSF , MarciniukDD , FordG , FitzGeraldM , WongE , et al. Can inhaled fluticasone alone or in combination with salmeterol reduce systemic inflammation in chronic obstructive pulmonary disease? Study protocol for a randomized controlled trial [NCT00120978]. BMC Pulmonary Medicine2006;6(6):3. SinDD , ManSF , MarciniukDD , FordG , FitzGeraldM , WongE , et al. The effects of fluticasone with or without salmeterol on systemic biomarkers of inflammation in chronic obstructive pulmonary disease. American Journal of Respiratory and Critical Care Medicine2008; Vol. 177, issue 11:1207‐14. ">Sin 2008</a>; <a href="./references#CD006826-bbs2-0013" title="BriggsAH , GlickHA , Lozano‐OrtegaG , SpencerM , CalverleyPM , JonesPW , et al. Is treatment with ICS and LABA cost‐effective for COPD? Multinational economic analysis of the TORCH study. European Respiratory Journal2010; Vol. 35, issue 3:532‐9. CalverleyPM , AndersonJA , CelliB , FergusonGT , JenkinsC , JonesPW , et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease.[see comment]. New England Journal of Medicine2007; Vol. 356, issue 8:775‐89. CalverleyPMA , AndersonJA , CelliB , FergusonGT , JenkinsC , JonesPW , et al. Cardiovascular events in patients with chronic obstructive pulmonary disease: TORCH study results. Thorax2010;65:719‐25. CalverleyPMA , AndersonJA , CelliB , FergusonGT , JenkinsC , JonesPW , et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. New England Journal of Medicine2007;356(8):775‐89. CalverleyPMA , CelliB , FergusonG , JenkinsC , JonesPW , PrideNB , et al. Baseline characteristics of the first 5,000 COPD patients enrolled in the TORCH survival study. European Respiratory Journal2003;22 Suppl 45:578s. CelliB , CalverleyPMA , AndersonJA , FergusonGT , JenkinsC , JonesPW , et al. The TORCH (TOwards a Revolution in COPD Health) study: salmeterol/fluticasone propionate (SFC) improves health status, reduces exacerbations and improves lung function over three years. European Respiratory Journal2006;28 Suppl 50:34s. CelliB , VestboJ , JenkinsCR , JonesPW , FergusonGT , CalverleyPM , et al. Sex differences in mortality and clinical expressions of patients with chronic obstructive pulmonary disease: the TORCH experience. American Journal of Respiratory and Critical Care Medicine2011;183(3):317‐22. CelliBR , ThomasNE , AndersonJA , FergusonGT , JenkinsCR , JonesPW , et al. Effect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease: results from the TORCH study. American Journal of Respiratory and Critical Care Medicine2008;174(4):332‐8. CrimC , CalverleyPM , AndersonJA , CelliB , FergusonGT , JenkinsC , et al. Pneumonia risk in COPD patients receiving inhaled corticosteroids alone or in combination: TORCH study results. European Respiratory Journal2009;34(3):641‐7. FergusonGT , CalverleyPM , AndersonJA , JenkinsCR , JonesPW , WillitsLR , et al. Prevalence and progression of osteoporosis in patients with COPD: results from the TOwards a Revolution in COPD Health study. Chest2009; Vol. 136, issue 0012‐3692:1456‐65. FergusonGT , CalverleyPMA , AndersonJA , et al. The TORCH (TOwards a Revolution in COPD Health) study: salmeterol/fluticasone propionate (SFC) improves survival in COPD over three years. European Respiratory Journal2006;28 Suppl 50:34s. GlaxoSmithKlineSCO30003 . A multicentre, randomised, double‐blind, parallel group, placebo‐controlled study to investigate the long‐term effects of salmeterol/fluticasone propionate (SERETIDE/VIANI/ADVAIR) 50/500mcg bd, salmeterol 50mcg bd and fluticasone propionate 500mcg bd, all delivered via the DISKUS/ACCUHALER inhaler, on the survival of subjects with chronic obstructive pulmonary disease (COPD) over 3 years of treatment. GlaxoSmithKline Clinical Trial Register2006. HoughtonCM , LawsonN , BorrillZL , WixonCL , YoxallS , LangleySJ , et al. Comparison of the effects of salmeterol/fluticasone propionate with fluticasone propionate on airway physiology in adults with mild persistent asthma. Respiratory Research2007;8:52. JenkinsCR , CalverleyPMA , CelliB , FergusonG , JonesPW , PrideN , et al. Seasonal patterns of exacerbation rates in the TORCH survival study, 2007. http://www.abstracts2view.comA839. JenkinsCR , CelliB , AndersonJA , FergusonGT , JonesPW , VestboJ , et al. Seasonality and determinants of moderate and severe COPD exacerbations in the TORCH study. European Respiratory Journal2012;39(1):38‐45. JenkinsCR , JonesPW , CalverleyPM , CelliB , AndersonJA , FergusonGT , et al. Efficacy of salmeterol/fluticasone propionate by GOLD stage of chronic obstructive pulmonary disease: analysis from the randomised, placebo‐controlled TORCH study. Respiratory Research2009;10:59. JohnsonM , AgustiAG , BarnesNC . Reflections on TORCH: potential mechanisms for the survival benefit of salmeterol/fluticasone propionate in COPD patients. COPD2008;5(6):369‐75. JonesPW , AndersonJA , CalverleyPM , CelliBR , FergusonGT , JenkinsC , et al. TORCH Investigators. Health status in the TORCH study of COPD: treatment efficacy and other determinants of change. Respiratory Research2011;12:71. JonesPW , CalverleyP , CelliB , FergusonG , JenkinsC , PrideN . Trans‐regional validity of the SGRQ in the TORCH survival study, 2007. http://www.abstracts2view.comA122. McGarveyLP , JohnM , AndersonJA , ZvarichMT , WiseRA . Ascertainment of cause‐specific mortality in COPD: operations of the TORCH Clinical Endpoint Committee. Thorax2007;62:411‐5. NCT00268216 . See detailed description, 2000. http://clinicaltrials.gov/show/NCT00268216. [] SCO30003 . A multicentre, randomised, double‐blind, parallel group, placebo‐controlled study to investigate the long‐term effects of salmeterol/fluticasone propionate (SERETIDE®/VIANI®/ADVAIR®) 50/500mcg bd, salmeterol 50mcg bd and fluticasone propionate 500mcg bd, all delivered via the DISKUS®/ACCUHALER® inhaler, on the survival of subjects with chronic obstructive pulmonary disease (COPD) over 3 years of treatment, 2006. www.ctr.gsk.co.uk. VestboJ , AndersonJA , CalverleyPM , CelliB , FergusonGT , JenkinsC , et al. Adherence to inhaled therapy, mortality and hospital admission in COPD. Thorax2009;64(11):939‐43. VestboJ , CalverleyP , CelliB , FergusonG , JenkinsC , JonesP , et al. The TORCH (TOwards a Revolution in COPD Health) survival study protocol. European Respiratory Journal2004;24(2):206‐10. WiseRA , McGarveyLP , JohnM , AndersonJA , ZvarichMT . Reliability of cause‐specific mortality adjudication in a COPD clinical trial, 2007. http://www.abstracts2view.comA120. ">TORCH</a>; <a href="./references#CD006826-bbs2-0014" title="CalverleyP , PauwelsR , VestboJ , JonesP , PrideN , GulsvikA , et al. Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial. Lancet2003;361(9356):449‐56. CalverleyPMA , PauwelsRA , VestboJ , JonesPW , PrideNB , GulsvikA , et al. Clinical improvements with salmeterol / fluticasone propionate combination in differing severities of COPD, 2003. http://www.abstracts2view.comA035 [Poster D50]. CalverleyPMA , PauwelsRA , VestboJ , JonesPW , PrideNB , GulsvikA , et al. Salmeterol/Fluticasone propionate combination for one year provides greater clinical benefit than its individual components. Proceedings of the 98th International American Thoracic Society Conference http://www.abstracts‐on‐line.com/abstracts/ATS; May 17‐22, 2002; Atlanta, Georgia. A98 [Poster 306]. CalverlyPMA , PauwelsR , VestboJ , JonesP , PrideN , GulsvikA , et al. Safety of salmeterol/fluticasone propionate combination in the treatment of chronic obstructive pulmonary disease. European Respiratory Journal2002;20 Suppl 38:242 [P1572]. HunjanMK , ChandlerF . Numbers needed to treat (NNT) to avoid an exacerbation in patients with chronic obstructive pulmonary disease (COPD) using salmeterol/fluticasone propionate combination (SFC) and associated costs [Abstract]. American Thoracic Society 100th International Conference; May 21‐26, 2004; Orlando, Florida. D22 [Poster 503]. HunjanMK , WilliamsDT . Costs of avoiding exacerbations in patients with chronic obstructive pulmonary disease (COPD) treated with salmeterol/ fluticasone propionate combination (seretide) and salmeterol. European Respiratory Journal2004;24 Suppl 48:291s. HunjanMK , WilliamsDT . Salmeterol/ fluticasone propionate combination is clinically effective in avoiding exacerbations in patients with moderate/severe COPD. European Respiratory Journal2004;24 Suppl 48:513s. JonesPW , EdinHM , AndersonJ . Salmeterol/fluticasone propionate combination improves health status in COPD patients. Proceedings of the 98th International American Thoracic Society Conference http://www.abstracts‐on‐line.com/abstracts/ATS; May 17‐22, 2002; Atlanta, Georgia. A39 [Poster K39]. JonesPW , StåhlE . Budesonide /formoterol sustains clinically relevant improvements in health status in COPD [Abstract]. European Respiratory Journal2005;26 Suppl 49:Abstract 1352. JonesPW , VestboJ , PauwelsRA , CalverleyPMA , AndersonJA , SpencerMD . Informative drop out in COPD studies: investigation of health status of withdrawals in the TRISTAN study. Proceedings of the 13th ERS Annual Congress; September 27, 2003; Vienna, Austria. P1593. NitschmannS . Inhalational combination therapy in chronic obstructive lung disease. Tristan study. German Internist2004;45(6):727‐8. PauwelsR , VestboJ , CalverleyPMA , JonesPW , PrideNB , GulsvikA . Characterization of exacerbations in the TRISTAN study of salmeterol / fluticasone propionate (SFC) combination in moderate to severe COPD, 2006. http://www.abstracts2view.com. PauwelsRA , CalverlyPMA , VestboJ , JonesPW , PrideN , GulsvikA , et al. Reduction of exacerbations with salmeterol/fluticasone combination 50/500 mcg bd in the treatment of chronic obstructive pulmonary disease. European Respiratory Journal2002;20 Suppl 38:240 [P1569]. SFCB3024 . A multicentre, randomised, double‐blind, parallel group, placebo‐controlled study to compare the efficacy and safety of the salmeterol/FP combination product at a strength of 50/500mcg bd with salmeterol 50mcg bd alone and FP 500mcg bd alone, delivered via the DISKUS™/ACCUHALER™, in the treatment of subjects with chronic obstructive pulmonary disease (COPD) for 12 months. GlaxoSmithKline Clinical Trials Register (http:ctr.gsk.co.uk)2005. SpencerM , BriggsAH , GrossmanRF , RanceL . Development of an economic model to assess the cost effectiveness of treatment interventions for chronic obstructive pulmonary disease. Pharmacoeconomics2005;23(6):619‐37. SpencerMD , KariaN , AndersonJ . The clinical significance of treatment benefits with the salmeterol/fluticasone propionate 50/500mcg combination in COPD. European Respiratory Journal2004;24 Suppl 48:290s. VestboJ , CalverleyPMA , PauwelsR , JonesP , PrideN , GulsvikA , et al. Absence of gender susceptibility to the combination of salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease. European Respiratory Journal2002;20 Suppl 38:240 [P1570]. VestboJ , PauwelsR , AndersonJA , JonesP , CalverleyP . Early onset of effect of salmeterol and fluticasone propionate in chronic obstructive pulmonary disease. Thorax2005;60(4):301‐4. VestboJ , PauwelsRS , CalverleyPMA , JonesPW , PrideNB , GulsvikA . Salmeterol / fluticasone propionate combination produces improvement in lung function detectable within 24 hours in moderate to severe COPD, 2003. http://www.abstracts2view.com. VestboJ , SorianoJB , AndersonJA , CalverleyP , PauwelsR , JonesP . Gender does not influence the response to the combination of salmeterol and fluticasone propionate in COPD. Respiratory Medicine2004;98(11):1045‐50. ">TRISTAN</a>) were judged to be at low risk of selection bias, and in the remaining four (<a href="./references#CD006826-bbs2-0004" title="HananiaNA , DarkenP , HorstmanD , ReisnerC , LeeB , DavisS , et al. The efficacy and safety of fluticasone propionate (250 micro g)/salmeterol (50 micro g) combined in the diskus inhaler for the treatment of COPD. Chest2003;124(3):834‐43. HananiaNA , RamsdellJ , PayneK , DavisS , HorstmanD , LeeB , et al. Improvements in airflow and dyspnea in COPD patients following 24 weeks treatment with salmeterol 50mcg and fluticasone propionate 250mcg alone or in combination via the diskus. American Journal of Respiratory &amp; Critical Care Medicine2001;163(5 Suppl):A279. HorstmanD , DarkenP , DavisS , LeeB . Improvements in FEV1 and symptoms in poorly reversible COPD patients following treatment with salmeterol 50mcg/fluticasone propionate 250mcg combination [Abstract]. European Respiratory Journal2003;22 Suppl 45:P434. MahlerDA , DarkenP , BrownCP , KnobilK . Predicting lung function responses to combination therapy in chronic obstructive pulmonary disease (COPD) [Abstract]. National COPD Conference; November 14‐15, 2003; Arlington, Virginia. Abstract 1081. MahlerDA , DarkenP , BrownCP , KnobilK . Predicting lung function responses to salmeterol/fluticasone propionate combination therapy in COPD [Abstract]. European Respiratory Journal2003;22 Suppl 45:P429. SFCA3007 . A randomized, double‐blind, placebo‐controlled, parallel‐group trial evaluating the safety and efficacy of the DISKUS formulations of salmeterol (SAL) 50mcg BID and fluticasone propionate (FP) 250mcg BID individually and in combination as salmeterol 50mcg/fluticasone propionate 250mcg BID (SFC 50/250) compared to placebo in COPD subjects. GlaxoSmithKline Clinical Trials Register (http:ctr.gsk.co.uk)2005. SpencerM , WireP , LeeB , ChangCN , DarkenP , HorstmanD . Patients with COPD using salmeterol/fluticasone propionate combination therapy experience improved quality of life. European Respiratory Journal2003;22 Suppl 45:51s. SpencerMD , KariaN , AndersonJ . The clinical significance of treatment benefits with the salmeterol/fluticasone propionate 50/500mcg combination in COPD. European Respiratory Journal2004;24 Suppl 48:290s. ">Hanania 2003</a>; <a href="./references#CD006826-bbs2-0006" title="MahlerDA , DarkenP , BrownCP , KnobilK . Predicting lung function responses to combination therapy in chronic obstructive pulmonary disease (COPD), 2003. http://www.abstracts2view.com. MahlerDA , WireP , HorstmanD , ChangCN , YatesJ , FischerT , et al. Effectiveness of fluticasone propionate and salmeterol combination delivered via the diskus device in the treatment of chronic obstructive pulmonary disease. American Journal of Respiratory Critical Care Medicine2002;166(8):1084‐91. SFCA3006 . A randomized, double‐blind, placebo‐controlled, parallel‐group trial evaluating the safety and efficacy of the DISKUS formulations of salmeterol (SAL) 50mcg BID and fluticasone propionate (FP) 500mcg BID individually and in combination as salmeterol 50mcg/fluticasone propionate 500mcg BID (SFC 50/500) compared to placebo in COPD subjects. GlaxoSmithKline Clinical Trials Register (http:ctr.gsk.co.uk)2005. SpencerM , WireP , LeeB , ChangCN , DarkenP , HorstmanD . Patients with COPD using salmeterol/fluticasone propionate combination therapy experience improved quality of life. European Respiratory Journal2003;22 Suppl 45:51s. SpencerMD , AndersonJA . Salmeterol/fluticasone combination produces clinically important benefits in dyspnea and fatigue [Abstract]. American Thoracic Society 2005 International Conference; May 20‐25, 2005; San Diego, California. B93 [Poster 308]. SpencerMD , KariaN , AndersonJ . The clinical significance of treatment benefits with the salmeterol/fluticasone propionate 50/500mcg combination in COPD. European Respiratory Journal2004;24 Suppl 48:290s. ">Mahler 2002</a><a href="./references#CD006826-bbs2-0008" title="SFCT01 . A Multicentre, Randomised, Double‐Blind, Parallel Group, Placebo‐Controlled Study to Compare the Efficacy and Safety of Inhaled Salmeterol/Fluticasone Propionate Combination Product 25/250 µg Two Puffs Bd and Fluticasone Propionate 250µg Two Puffs Bd Alone, All Administered Via Metered Dose Inhalers (MDI), in the Treatment of Subjects with Chronic Obstructive Pulmonary Disease (COPD) for 52 Weeks. GlaxoSmithKline Clinical Trials Register (http:ctr.gsk.co.uk)2005. ">SFCT01</a>; <a href="./references#CD006826-bbs2-0007" title="NCT00358358 . Trial SCO104925. See detailed description, 2006. http://clinicaltrials.gov/show/NCT00358358. [] ">NCT00358358</a>), the risk was considered to be unclear. Three of the four BDF versus BD studies (1777 participants; <a href="./references#CD006826-bbs2-0010" title="AndersonP . Budesonide/formoterol in a single inhaler (Symbicort) provides early and sustained improvement in lung function in moderate to severe COPD [Abstract]. Thorax2002;57(Suppl III):iii43. AstraZenecaSD . A placebo‐controlled 12 month efficacy study of the fixed combination budesonide/formoterol compared with budesonide and formoterol as monotherapies in patients with chronic obstructive pulmonary disease (COPD). AstraZeneca Clinical Trials2001. BorgstromL , AskingL , OlssonH , PetersonS . Lack of interaction between disease severity and therapeutic response with budesonide/formoterol in a single inhaler [Abstract]. American Thoracic Society 100th International Conference; May 21‐26, 2004; Orlando, Florida. C22 [Poster 505]. CalverleyP , PauwelsR , LofdahlCG , SvenssonK , HigenbottamT , et al. Relationship between respiratory symptoms and medical treatment in exacerbations of COPD. European Respiratory Journal2005;26(3):406‐13. CalverleyPMA . Effect of budesonide/formoterol on severe exacerbations and lung function in moderate to severe COPD. Thorax. BTS Winter Meeting 2002:S145. CalverleyPMA , SzafranskiW , AnderssonA . Budesonide/formoterol is a well‐tolerated long term maintenance therapy for COPD. European Respiratory Journal2005;26 Suppl 49:Poster 1917. CalverleyPMA , ThompsonNC , OlssonH . Budesonide/formoterol in a single inhaler sustains lung function improvements in COPD [Abstract]. European Respiratory Journal2003;22 Suppl 45:P435. CampbellLM , SzafranskiW . Budesonide/formoterol in a single inhaler (Symbicort) provides sustained relief from symptoms in moderate to severe COPD. Thorax. BTS Winter Meeting 2002:S143. CampellLW , SzafranskiW . Budesonide/Formoterol in a single inhaler (Symbicort) reduces severe exacerbations in patients with moderate‐severe COPD. Thorax. BTS Winter Meeting 2002:S141. DahlR , CukierA , OlssonH . Budesonide/formoterol in a single inhaler reduces severe and mild exacerbations in patients with moderate to severe COPD. European Respiratory Journal2002;20 Suppl 38:242 [P1575]. EgedeF , MengaG . Budesonide/formoterol in a single inhaler provides sustained relief from symptoms and night‐time awakenings in moderate‐severe COPD: results from symptoms and night‐time awakenings in moderate to severe COPD: results from a 1‐year study. European Respiratory Journal2002;20 Suppl 38:242 [P1574]. HalpinD , StahlE , LundbackB , AndersonF , PetersonS . Treatment costs and number needed to treat (NNT) with budesonide/formoterol to avoid one exacerbation of COPD [Abstract]. American Thoracic Society 100th International Conference; May 21‐26, 2004; Orlando, Florida. D22 [Poster 525]. JonesPW , StahlE , SvenssonK . Improvement in health status in patients with moderate to severe COPD after treatment with budesonide/formoterol in a single inhaler. European Respiratory Journal2002;20 Suppl 38:250 [P1613]. KorsgaardJ , SansoresR . Budesonide/formoterol (single inhaler) provides sustained relief from shortness of breath and chest tightness in a 1‐year study of patients with moderate to severe COPD. European Respiratory Journal2002;20 Suppl 38:242 [P1577]. LangeP , SaenzC . Budesonide/formoterol in a single inhaler is well tolerated in patients with moderate to severe COPD: results of a 1 year study. European Respiratory Journal2002;20 Suppl 38:242 [P1573]. LofdahlCG . Reducing the impact of COPD exacerbations: clinical efficacy of budesonide/formoterol. European Respiratory Review2004;13(88):14‐21. MilanowskiJ , NahabedianS . Budesonide/formoterol in a single inhaler acts rapidly to improve lung function and relieve symptoms in patients with moderate to severe COPD. European Respiratory Journal2002;20 Suppl 38:242 [P1576]. SzafranskiW , CukierA , RamirezA , MengaG , SansoresR , NahabedianS , et al. Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease. European Respiratory Journal2003;21(1):74‐81. ">Szafranski 2003</a>; <a href="./references#CD006826-bbs2-0011" title="Astrazeneca(D5899C00002) . A 6‐month double‐blind, double‐dummy, randomized, parallel group, multicenter efficacy &amp; safety study of Symbicort® pMDI 2 × 160/4.5mg &amp; 80/4.5mg bid compared to Formoterol TBH, Budesonide pMDI (&amp; the combination) &amp; placebo in COPD patients. www.astrazenecaclinicaltrials.com (accessed 8 April 2008). BleeckerER , MeyersDA , BaileyWC , SimsA‐M , BujacSR , GoldmanM , et al. ADRB2 polymorphisms and budesonide/formoterol responses in COPDADRB2 polymorphisms and treatment response in COPD. Chest2012;142(2):320‐8. TashkinDP , RennardSI , MartinP , GoldmanM , SilkoffPE . Efficacy of budesonide/formoterol administered via one pressurized metered‐dose inhaler over 6 months in patients with chronic obstructive pulmonary disease [Abstract]. Chest2008; Vol. 134, issue 4:105001s. TashkinDP , RennardSI , MartinP , RamachandranS , MartinUJ , SilkoffPE , et al. Efficacy and safety of budesonide and formoterol in one pressurized metered‐dose inhaler in patients with moderate to very severe chronic obstructive pulmonary disease : results of a 6‐month randomized clinical trial. Drugs2008; Vol. 68, issue 0012‐6667 (Print):1975‐2000. ">Tashkin 2008</a>; <a href="./references#CD006826-bbs2-0015" title="ZhongN , ZhengJ , WenF , YangL , ChenP , XiuQ , et al. Efficacy and safety of budesonide/formoterol via a dry powder inhaler in Chinese patients with chronic obstructive pulmonary disease. Current Medical Research and Opinion2012; Vol. 28, issue 2:257‐65. ZhongN , ZhengJ , WenF , YangL , ChenP , XiuQ , et al. Efficacy and safety of inhalation of budesonide/formoterol via turbuhaler in Chinese patients with chronic obstructive pulmonary disease [Abstract]. Chest2011; Vol. 140, issue 4:5225A. ">Zhong 2012</a>) were regarded as having low risk of selection bias in terms of sequence generation, although the issue of allocation concealment in <a href="./references#CD006826-bbs2-0011" title="Astrazeneca(D5899C00002) . A 6‐month double‐blind, double‐dummy, randomized, parallel group, multicenter efficacy &amp; safety study of Symbicort® pMDI 2 × 160/4.5mg &amp; 80/4.5mg bid compared to Formoterol TBH, Budesonide pMDI (&amp; the combination) &amp; placebo in COPD patients. www.astrazenecaclinicaltrials.com (accessed 8 April 2008). BleeckerER , MeyersDA , BaileyWC , SimsA‐M , BujacSR , GoldmanM , et al. ADRB2 polymorphisms and budesonide/formoterol responses in COPDADRB2 polymorphisms and treatment response in COPD. Chest2012;142(2):320‐8. TashkinDP , RennardSI , MartinP , GoldmanM , SilkoffPE . Efficacy of budesonide/formoterol administered via one pressurized metered‐dose inhaler over 6 months in patients with chronic obstructive pulmonary disease [Abstract]. Chest2008; Vol. 134, issue 4:105001s. TashkinDP , RennardSI , MartinP , RamachandranS , MartinUJ , SilkoffPE , et al. Efficacy and safety of budesonide and formoterol in one pressurized metered‐dose inhaler in patients with moderate to very severe chronic obstructive pulmonary disease : results of a 6‐month randomized clinical trial. Drugs2008; Vol. 68, issue 0012‐6667 (Print):1975‐2000. ">Tashkin 2008</a> was unclear; in <a href="./references#CD006826-bbs2-0002" title="AstraZenecaSD . A placebo‐controlled 12‐month efficacy study of the fixed combination budesonide/formoterol compared to budesonide and formoterol as monotherapies in patients with chronic obstructive pulmonary disease (COPD). AstraZeneca Clinical Trials2002. BorgstromL , AskingL , OlssonH , PetersonS . Lack of interaction between disease severity and therapeutic response with budesonide/formoterol in a single inhaler [Abstract]. American Thoracic Society 100th International Conference; May 21‐26; 2004, Orlando, Florida. C22 [Poster 505]. CalverleyPM , BonsawatW , CsekeZ , ZhongN , PetersonS , OlssonH . Maintenance therapy with budesonide and formoterol in chronic obstructive pulmonary disease. European Respiratory Journal2003;22(6):912‐9. CalverleyPMA , CsekeZ , PetersonS . Budesonide/formoterol reduces the use of oral corticosteroids in the treatment of COPD [Abstract]. European Respiratory Journal2003;22 Suppl 45:P436. CalverleyPMA , KunaP , OlssonH . COPD exacerbations are reduced by budesonide/formoterol in a single inhaler [Abstract]. European Respiratory Journal2003;22 Suppl 45:P1587. CalverleyPMA , OlssonH , Symbicort International COPD Study Group. Budesonide/formoterol ina single inhaler sustains improvements in lung function over 12 months compared with monocomponents and placebo in patients with COPD [abstract]. American Thoracic Society 99th International Conference; May 16‐21, 2003; Seattle, Washington. B024 [Poster 418]. CalverleyPMA , PetersonS . Combining budesonide/formoterol in a single inhale reduces exacerbation frequency in COPD [abstract]. American Thoracic Society 99th International Conference; May 16‐21, 2003; Seattle, Washington. D092 [Poster 211]. CalverleyPMA , StåhlE , JonesPW . Budesonide/formoterol improves the general health status of patients with COPD [Abstract]. American Thoracic Society 2005 International Conference; May 20‐25, 2005; San Diego, California. B93 [Poster 303]. CalverleyPMA , SzafranskiW , AnderssonA . Budesonide/formoterol is a well‐tolerated long term maintenance therapy for COPD. European Respiratory Journal2005;26 Suppl 49:Poster 1917. CalverleyPMA , ThompsonNC , OlssonH . Budesonide/formoterol in a single inhaler sustains lung function improvements in COPD [Abstract]. European Respiratory Journal2003;22 Suppl 45:P435. HalpinD , StåhlE , LundbackB , AndersonF , PetersonS . Treatment costs and number needed to treat (NNT) with budesonide/formoterol to avoid one exacerbation of COPD [Abstract]. American Thoracic Society 100th International Conference; May 21‐26, 2004; Orlando, Florida. D22 [Poster 525]. HalpinDMG , LarssonT , CalverleyPMA . How many patients with COPD must be treated with budesonide/formoterol compared with formoterol alone to avoid 1 day of oral steroid use? [Abstract]. American Thoracic Society 2005 International Conference; May 20‐25, 2005; San Diego, California. B93 [Poster 314]. JonesPW , StahlE . Budesonide/formoterol in a single inhaler improves health status in patients with COPD [abstract]. American Thoracic Society 99th International Conference; May 16‐21, 2003; Orlando, Florida. B024 [Poster 419]. JonesPW , StåhlE . Budesonide /formoterol sustains clinically relevant improvements in health status in COPD [Abstract]. European Respiratory Journal2005;26 Suppl 49:Abstract 1352. JonesPW , StåhlE . Reducing exacerbations leads to a better health‐related quality of life in patients with COPD. 13th ERS Annual Congress; September 27, 2003; Vienna, Austria. P1586. LofdahlCG . Reducing the impact of COPD exacerbations: Clinical efficacy of budesonide/formoterol. European Respiratory Review2004;13(88):14‐21. LofdahlCG , AndreassonE , SvenssonK , EricssonA . Budesonide/formoterol in a single inhaler improves health status in patients with COPD without increasing healthcare costs [Abstract]. European Respiratory Journal2003;22 Suppl 45:P433. LofdahlCG , EricssonA , SvenssonK , AndreassonE . Cost effectiveness of budesonide/formoterol in a single inhaler for COPD compared with each monocomponent used alone. Pharmacoeconomics2005;23(4):365‐75. ">Calverley 2003</a>, the risk of selection bias in terms of sequence generation and allocation concealment was regarded as unclear. </p> <p>Of the two MF/F versus MF trials (905 participants), <a href="./references#CD006826-bbs2-0012" title="KerwinE , TashkinDP , Matiz‐BuenoCE , DohertyDE , ShekarT , BanerjeeS , et al. Clinical efficacy and safety of combined mometasone furoate and formoterol in patients with moderate to very severe chronic obstructive pulmonary disease (COPD) [Abstract]. Journal of Allergy and Clinical Immunology2012; Vol. 129, issue 2 Suppl:AB201 [759]. NCT00383435 . A Randomized, 26‐Week, Placebo‐Controlled Efficacy and Safety Study With a 26‐Week Long‐Term Safety Extension, of High‐ and Medium‐Dose Inhaled Mometasone Furoate/Formoterol Fixed‐Dose Combination Formulation Compared With Formoterol and High‐Dose Inhaled Mometasone Furoate Monotherapy in Subjects With Moderate to Severe COPD, 2006. http://clinicaltrials.gov/show/NCT00383435. [] TashkinDP , DohertyDE , KerwinE , Matiz‐BuenoCE , KnorrB , ShekarT , et al. Efficacy and safety of a fixed‐dose combination of mometasone furoate and formoterol fumarate in subjects with moderate to very severe COPD: results from a 52‐week Phase III trial. International Journal of Chronic Obstructive Pulmonary Disease2012; Vol. 7, issue 1178‐2005 (Electronic). 1176‐9106 (Linking):43‐55. ">Tashkin 2012</a> was judged to be at low risk of selection bias, and for <a href="./references#CD006826-bbs2-0003" title="DohertyDE , KerwinE , TashkinDP , Matiz‐BuenoCE , ShekarT , BanerjeeS , et al. Combined mometasone furoate and formoterol in patients with moderate to very severe chronic obstructive pulmonary disease (COPD): phase 3 efficacy and safety study [Abstract]. Journal of Allergy and Clinical Immunology2012; Vol. 129, issue 2 Suppl:AB75 [283]. DohertyDE , TashkinDP , KerwinE , KnorrBA , ShekarT , BanerjeeS , et al. Effects of mometasone furoate/formoterol fumarate fixed‐dose combination formulation on chronic obstructive pulmonary disease (COPD): results from a 52‐week Phase III trial in subjects with moderate‐to‐very severe COPD. International Journal of Chronic Obstructive Pulmonary Disease2012; Vol. 7, issue 1178‐2005 (Electronic). 1176‐9106 (Linking):57‐71. NCT00383721 . A Randomized, 26‐Week, Placebo‐Controlled Efficacy and Safety Study With a 26‐Week Long‐Term Safety Extension, of High‐ and Medium‐Dose Inhaled Mometasone Furoate/Formoterol Fixed‐Dose Combination Formulation Compared With Formoterol and High‐Dose Inhaled Mometasone Furoate Monotherapy in Subjects With Moderate to Severe COPD, 2006. http://clinicaltrials.gov/show/NCT00383721. [] ">Doherty 2012</a>, the risk was considered to be unclear. A summary of the selection bias is provided in <a href="#CD006826-fig-0002">Figure 2</a>. </p> </section> <section id="CD006826-sec-0064"> <h4 class="title">Blinding</h4> <p>The risk of performance and detection bias was judged to be low in all fifteen trials.</p> </section> <section id="CD006826-sec-0065"> <h4 class="title">Incomplete outcome data</h4> <p>Dropout rates were uniformly high (&gt; 20%) in the long‐term (longer than 6 months) studies, and most studies were judged to be at high risk of attrition bias, whereas the shorter‐term studies (<a href="./references#CD006826-bbs2-0001" title="BourbeauJ , ChristodoulopoulosP , MaltaisF , YamauchiY , OlivensteinR , HamidQ . Effect of salmeterol/fluticasone propionate on airway inflammation in COPD: a randomised controlled trial. Thorax2007; Vol. 62, issue 11:938‐43. ">Bourbeau 2007</a>; <a href="./references#CD006826-bbs2-0003" title="DohertyDE , KerwinE , TashkinDP , Matiz‐BuenoCE , ShekarT , BanerjeeS , et al. Combined mometasone furoate and formoterol in patients with moderate to very severe chronic obstructive pulmonary disease (COPD): phase 3 efficacy and safety study [Abstract]. Journal of Allergy and Clinical Immunology2012; Vol. 129, issue 2 Suppl:AB75 [283]. DohertyDE , TashkinDP , KerwinE , KnorrBA , ShekarT , BanerjeeS , et al. Effects of mometasone furoate/formoterol fumarate fixed‐dose combination formulation on chronic obstructive pulmonary disease (COPD): results from a 52‐week Phase III trial in subjects with moderate‐to‐very severe COPD. International Journal of Chronic Obstructive Pulmonary Disease2012; Vol. 7, issue 1178‐2005 (Electronic). 1176‐9106 (Linking):57‐71. NCT00383721 . A Randomized, 26‐Week, Placebo‐Controlled Efficacy and Safety Study With a 26‐Week Long‐Term Safety Extension, of High‐ and Medium‐Dose Inhaled Mometasone Furoate/Formoterol Fixed‐Dose Combination Formulation Compared With Formoterol and High‐Dose Inhaled Mometasone Furoate Monotherapy in Subjects With Moderate to Severe COPD, 2006. http://clinicaltrials.gov/show/NCT00383721. [] ">Doherty 2012</a>; <a href="./references#CD006826-bbs2-0007" title="NCT00358358 . Trial SCO104925. See detailed description, 2006. http://clinicaltrials.gov/show/NCT00358358. [] ">NCT00358358</a>; <a href="./references#CD006826-bbs2-0009" title="NCT00120978 . Advair－CRP Study. http://clinicaltrials.gov/show/NCT001209782004. [] SinDD , ManSF , MarciniukDD , FordG , FitzGeraldM , WongE , et al. Can inhaled fluticasone alone or in combination with salmeterol reduce systemic inflammation in chronic obstructive pulmonary disease? Study protocol for a randomized controlled trial [NCT00120978]. BMC Pulmonary Medicine2006;6(6):3. SinDD , ManSF , MarciniukDD , FordG , FitzGeraldM , WongE , et al. The effects of fluticasone with or without salmeterol on systemic biomarkers of inflammation in chronic obstructive pulmonary disease. American Journal of Respiratory and Critical Care Medicine2008; Vol. 177, issue 11:1207‐14. ">Sin 2008</a>) had lower dropout rates and were judged to be at low (dropout rate &lt; 10%) or unclear (dropout rate 10% to 20%) risk of attrition bias. The <a href="./references#CD006826-bbs2-0013" title="BriggsAH , GlickHA , Lozano‐OrtegaG , SpencerM , CalverleyPM , JonesPW , et al. Is treatment with ICS and LABA cost‐effective for COPD? Multinational economic analysis of the TORCH study. European Respiratory Journal2010; Vol. 35, issue 3:532‐9. CalverleyPM , AndersonJA , CelliB , FergusonGT , JenkinsC , JonesPW , et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease.[see comment]. New England Journal of Medicine2007; Vol. 356, issue 8:775‐89. CalverleyPMA , AndersonJA , CelliB , FergusonGT , JenkinsC , JonesPW , et al. Cardiovascular events in patients with chronic obstructive pulmonary disease: TORCH study results. Thorax2010;65:719‐25. CalverleyPMA , AndersonJA , CelliB , FergusonGT , JenkinsC , JonesPW , et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. New England Journal of Medicine2007;356(8):775‐89. CalverleyPMA , CelliB , FergusonG , JenkinsC , JonesPW , PrideNB , et al. Baseline characteristics of the first 5,000 COPD patients enrolled in the TORCH survival study. European Respiratory Journal2003;22 Suppl 45:578s. CelliB , CalverleyPMA , AndersonJA , FergusonGT , JenkinsC , JonesPW , et al. The TORCH (TOwards a Revolution in COPD Health) study: salmeterol/fluticasone propionate (SFC) improves health status, reduces exacerbations and improves lung function over three years. European Respiratory Journal2006;28 Suppl 50:34s. CelliB , VestboJ , JenkinsCR , JonesPW , FergusonGT , CalverleyPM , et al. Sex differences in mortality and clinical expressions of patients with chronic obstructive pulmonary disease: the TORCH experience. American Journal of Respiratory and Critical Care Medicine2011;183(3):317‐22. CelliBR , ThomasNE , AndersonJA , FergusonGT , JenkinsCR , JonesPW , et al. Effect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease: results from the TORCH study. American Journal of Respiratory and Critical Care Medicine2008;174(4):332‐8. CrimC , CalverleyPM , AndersonJA , CelliB , FergusonGT , JenkinsC , et al. Pneumonia risk in COPD patients receiving inhaled corticosteroids alone or in combination: TORCH study results. European Respiratory Journal2009;34(3):641‐7. FergusonGT , CalverleyPM , AndersonJA , JenkinsCR , JonesPW , WillitsLR , et al. Prevalence and progression of osteoporosis in patients with COPD: results from the TOwards a Revolution in COPD Health study. Chest2009; Vol. 136, issue 0012‐3692:1456‐65. FergusonGT , CalverleyPMA , AndersonJA , et al. The TORCH (TOwards a Revolution in COPD Health) study: salmeterol/fluticasone propionate (SFC) improves survival in COPD over three years. European Respiratory Journal2006;28 Suppl 50:34s. GlaxoSmithKlineSCO30003 . A multicentre, randomised, double‐blind, parallel group, placebo‐controlled study to investigate the long‐term effects of salmeterol/fluticasone propionate (SERETIDE/VIANI/ADVAIR) 50/500mcg bd, salmeterol 50mcg bd and fluticasone propionate 500mcg bd, all delivered via the DISKUS/ACCUHALER inhaler, on the survival of subjects with chronic obstructive pulmonary disease (COPD) over 3 years of treatment. GlaxoSmithKline Clinical Trial Register2006. HoughtonCM , LawsonN , BorrillZL , WixonCL , YoxallS , LangleySJ , et al. Comparison of the effects of salmeterol/fluticasone propionate with fluticasone propionate on airway physiology in adults with mild persistent asthma. Respiratory Research2007;8:52. JenkinsCR , CalverleyPMA , CelliB , FergusonG , JonesPW , PrideN , et al. Seasonal patterns of exacerbation rates in the TORCH survival study, 2007. http://www.abstracts2view.comA839. JenkinsCR , CelliB , AndersonJA , FergusonGT , JonesPW , VestboJ , et al. Seasonality and determinants of moderate and severe COPD exacerbations in the TORCH study. European Respiratory Journal2012;39(1):38‐45. JenkinsCR , JonesPW , CalverleyPM , CelliB , AndersonJA , FergusonGT , et al. Efficacy of salmeterol/fluticasone propionate by GOLD stage of chronic obstructive pulmonary disease: analysis from the randomised, placebo‐controlled TORCH study. Respiratory Research2009;10:59. JohnsonM , AgustiAG , BarnesNC . Reflections on TORCH: potential mechanisms for the survival benefit of salmeterol/fluticasone propionate in COPD patients. COPD2008;5(6):369‐75. JonesPW , AndersonJA , CalverleyPM , CelliBR , FergusonGT , JenkinsC , et al. TORCH Investigators. Health status in the TORCH study of COPD: treatment efficacy and other determinants of change. Respiratory Research2011;12:71. JonesPW , CalverleyP , CelliB , FergusonG , JenkinsC , PrideN . Trans‐regional validity of the SGRQ in the TORCH survival study, 2007. http://www.abstracts2view.comA122. McGarveyLP , JohnM , AndersonJA , ZvarichMT , WiseRA . Ascertainment of cause‐specific mortality in COPD: operations of the TORCH Clinical Endpoint Committee. Thorax2007;62:411‐5. NCT00268216 . See detailed description, 2000. http://clinicaltrials.gov/show/NCT00268216. [] SCO30003 . A multicentre, randomised, double‐blind, parallel group, placebo‐controlled study to investigate the long‐term effects of salmeterol/fluticasone propionate (SERETIDE®/VIANI®/ADVAIR®) 50/500mcg bd, salmeterol 50mcg bd and fluticasone propionate 500mcg bd, all delivered via the DISKUS®/ACCUHALER® inhaler, on the survival of subjects with chronic obstructive pulmonary disease (COPD) over 3 years of treatment, 2006. www.ctr.gsk.co.uk. VestboJ , AndersonJA , CalverleyPM , CelliB , FergusonGT , JenkinsC , et al. Adherence to inhaled therapy, mortality and hospital admission in COPD. Thorax2009;64(11):939‐43. VestboJ , CalverleyP , CelliB , FergusonG , JenkinsC , JonesP , et al. The TORCH (TOwards a Revolution in COPD Health) survival study protocol. European Respiratory Journal2004;24(2):206‐10. WiseRA , McGarveyLP , JohnM , AndersonJA , ZvarichMT . Reliability of cause‐specific mortality adjudication in a COPD clinical trial, 2007. http://www.abstracts2view.comA120. ">TORCH</a> study, however, ascertained the mortality results for those participants who withdrew from the study and so was judged to have low risk of attrition bias for mortality (<a href="#CD006826-fig-0002">Figure 2</a>). </p> </section> <section id="CD006826-sec-0066"> <h4 class="title">Selective reporting</h4> <p>In only one trial was the risk of reporting bias considered unclear: <a href="./references#CD006826-bbs2-0001" title="BourbeauJ , ChristodoulopoulosP , MaltaisF , YamauchiY , OlivensteinR , HamidQ . Effect of salmeterol/fluticasone propionate on airway inflammation in COPD: a randomised controlled trial. Thorax2007; Vol. 62, issue 11:938‐43. ">Bourbeau 2007</a>. In all other cases, the risk of reporting bias was judged to be low. </p> </section> </section> <section id="CD006826-sec-0067"> <h3 class="title" id="CD006826-sec-0067">Effects of interventions</h3> <p>See: <a href="./full#CD006826-tbl-0001"><b>Summary of findings for the main comparison</b> All combined inhalers－participants with one or more exacerbations</a> </p> <section id="CD006826-sec-0068"> <h4 class="title">Primary outcomes</h4> <section id="CD006826-sec-0069"> <h5 class="title">Exacerbation rates</h5> <section id="CD006826-sec-0070"> <h6 class="title">Pooled results for FPS, BDF and MF/F versus ICS alone</h6> <p>A significant reduction was noted in the rate of exacerbations requiring oral corticosteroids with combination therapy when compared with ICS (6 studies: N = 5601; rate ratio (RR) 0.87; 95% CI 0.80 to 0.94; <a href="./references#CD006826-fig-0009" title="">Analysis 1.1</a>; <a href="#CD006826-fig-0003">Figure 3</a>)<i>.</i> A summary of definitions of exacerbations in the included studies is provided in <a href="#CD006826-tbl-0003">Table 2</a>. The mean exacerbation rate in the ICS‐only arms of the included studies was 1.21 exacerbations per patient per year (range 0.88 to 1.60), and we would expect an equivalent rate of 1.05 (95% CI 0.97 to 1.14) with combination therapy (see <a href="./full#CD006826-tbl-0001">summary of findings Table for the main comparison</a>). </p> <div class="figure" id="CD006826-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 1 All Combined Inhalers－Primary Outcomes, outcome: 1.1 Exacerbation rates (exacerbations requiring oral corticosteroids)." data-id="CD006826-fig-0003" src="/cdsr/doi/10.1002/14651858.CD006826.pub2/media/CDSR/CD006826/image_n/nCD006826-AFig-FIG03.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 1 All Combined Inhalers－Primary Outcomes, outcome: 1.1 Exacerbation rates (exacerbations requiring oral corticosteroids). </p> </div> </div> </div> <div class="table" id="CD006826-tbl-0003"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Exacerbations</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Trial</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> COPD exacerbation definition</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006826-bbs2-0001" title="BourbeauJ , ChristodoulopoulosP , MaltaisF , YamauchiY , OlivensteinR , HamidQ . Effect of salmeterol/fluticasone propionate on airway inflammation in COPD: a randomised controlled trial. Thorax2007; Vol. 62, issue 11:938‐43. ">Bourbeau 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Exacerbations not reported</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006826-bbs2-0002" title="AstraZenecaSD . A placebo‐controlled 12‐month efficacy study of the fixed combination budesonide/formoterol compared to budesonide and formoterol as monotherapies in patients with chronic obstructive pulmonary disease (COPD). AstraZeneca Clinical Trials2002. BorgstromL , AskingL , OlssonH , PetersonS . Lack of interaction between disease severity and therapeutic response with budesonide/formoterol in a single inhaler [Abstract]. American Thoracic Society 100th International Conference; May 21‐26; 2004, Orlando, Florida. C22 [Poster 505]. CalverleyPM , BonsawatW , CsekeZ , ZhongN , PetersonS , OlssonH . Maintenance therapy with budesonide and formoterol in chronic obstructive pulmonary disease. European Respiratory Journal2003;22(6):912‐9. CalverleyPMA , CsekeZ , PetersonS . Budesonide/formoterol reduces the use of oral corticosteroids in the treatment of COPD [Abstract]. European Respiratory Journal2003;22 Suppl 45:P436. CalverleyPMA , KunaP , OlssonH . COPD exacerbations are reduced by budesonide/formoterol in a single inhaler [Abstract]. European Respiratory Journal2003;22 Suppl 45:P1587. CalverleyPMA , OlssonH , Symbicort International COPD Study Group. Budesonide/formoterol ina single inhaler sustains improvements in lung function over 12 months compared with monocomponents and placebo in patients with COPD [abstract]. American Thoracic Society 99th International Conference; May 16‐21, 2003; Seattle, Washington. B024 [Poster 418]. CalverleyPMA , PetersonS . Combining budesonide/formoterol in a single inhale reduces exacerbation frequency in COPD [abstract]. American Thoracic Society 99th International Conference; May 16‐21, 2003; Seattle, Washington. D092 [Poster 211]. CalverleyPMA , StåhlE , JonesPW . Budesonide/formoterol improves the general health status of patients with COPD [Abstract]. American Thoracic Society 2005 International Conference; May 20‐25, 2005; San Diego, California. B93 [Poster 303]. CalverleyPMA , SzafranskiW , AnderssonA . Budesonide/formoterol is a well‐tolerated long term maintenance therapy for COPD. European Respiratory Journal2005;26 Suppl 49:Poster 1917. CalverleyPMA , ThompsonNC , OlssonH . Budesonide/formoterol in a single inhaler sustains lung function improvements in COPD [Abstract]. European Respiratory Journal2003;22 Suppl 45:P435. HalpinD , StåhlE , LundbackB , AndersonF , PetersonS . Treatment costs and number needed to treat (NNT) with budesonide/formoterol to avoid one exacerbation of COPD [Abstract]. American Thoracic Society 100th International Conference; May 21‐26, 2004; Orlando, Florida. D22 [Poster 525]. HalpinDMG , LarssonT , CalverleyPMA . How many patients with COPD must be treated with budesonide/formoterol compared with formoterol alone to avoid 1 day of oral steroid use? [Abstract]. American Thoracic Society 2005 International Conference; May 20‐25, 2005; San Diego, California. B93 [Poster 314]. JonesPW , StahlE . Budesonide/formoterol in a single inhaler improves health status in patients with COPD [abstract]. American Thoracic Society 99th International Conference; May 16‐21, 2003; Orlando, Florida. B024 [Poster 419]. JonesPW , StåhlE . Budesonide /formoterol sustains clinically relevant improvements in health status in COPD [Abstract]. European Respiratory Journal2005;26 Suppl 49:Abstract 1352. JonesPW , StåhlE . Reducing exacerbations leads to a better health‐related quality of life in patients with COPD. 13th ERS Annual Congress; September 27, 2003; Vienna, Austria. P1586. LofdahlCG . Reducing the impact of COPD exacerbations: Clinical efficacy of budesonide/formoterol. European Respiratory Review2004;13(88):14‐21. LofdahlCG , AndreassonE , SvenssonK , EricssonA . Budesonide/formoterol in a single inhaler improves health status in patients with COPD without increasing healthcare costs [Abstract]. European Respiratory Journal2003;22 Suppl 45:P433. LofdahlCG , EricssonA , SvenssonK , AndreassonE . Cost effectiveness of budesonide/formoterol in a single inhaler for COPD compared with each monocomponent used alone. Pharmacoeconomics2005;23(4):365‐75. ">Calverley 2003</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mild exacerbations</b> = number of days with intake of 4 or more puffs of rescue medication </p> <p><b>Severe exacerbation</b> = intake of a course of oral steroids and/or antibiotics and/or hospitalisation due to respiratory symptoms </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006826-bbs2-0003" title="DohertyDE , KerwinE , TashkinDP , Matiz‐BuenoCE , ShekarT , BanerjeeS , et al. Combined mometasone furoate and formoterol in patients with moderate to very severe chronic obstructive pulmonary disease (COPD): phase 3 efficacy and safety study [Abstract]. Journal of Allergy and Clinical Immunology2012; Vol. 129, issue 2 Suppl:AB75 [283]. DohertyDE , TashkinDP , KerwinE , KnorrBA , ShekarT , BanerjeeS , et al. Effects of mometasone furoate/formoterol fumarate fixed‐dose combination formulation on chronic obstructive pulmonary disease (COPD): results from a 52‐week Phase III trial in subjects with moderate‐to‐very severe COPD. International Journal of Chronic Obstructive Pulmonary Disease2012; Vol. 7, issue 1178‐2005 (Electronic). 1176‐9106 (Linking):57‐71. NCT00383721 . A Randomized, 26‐Week, Placebo‐Controlled Efficacy and Safety Study With a 26‐Week Long‐Term Safety Extension, of High‐ and Medium‐Dose Inhaled Mometasone Furoate/Formoterol Fixed‐Dose Combination Formulation Compared With Formoterol and High‐Dose Inhaled Mometasone Furoate Monotherapy in Subjects With Moderate to Severe COPD, 2006. http://clinicaltrials.gov/show/NCT00383721. [] ">Doherty 2012</a><b>/</b> </p> <p><a href="./references#CD006826-bbs2-0012" title="KerwinE , TashkinDP , Matiz‐BuenoCE , DohertyDE , ShekarT , BanerjeeS , et al. Clinical efficacy and safety of combined mometasone furoate and formoterol in patients with moderate to very severe chronic obstructive pulmonary disease (COPD) [Abstract]. Journal of Allergy and Clinical Immunology2012; Vol. 129, issue 2 Suppl:AB201 [759]. NCT00383435 . A Randomized, 26‐Week, Placebo‐Controlled Efficacy and Safety Study With a 26‐Week Long‐Term Safety Extension, of High‐ and Medium‐Dose Inhaled Mometasone Furoate/Formoterol Fixed‐Dose Combination Formulation Compared With Formoterol and High‐Dose Inhaled Mometasone Furoate Monotherapy in Subjects With Moderate to Severe COPD, 2006. http://clinicaltrials.gov/show/NCT00383435. [] TashkinDP , DohertyDE , KerwinE , Matiz‐BuenoCE , KnorrB , ShekarT , et al. Efficacy and safety of a fixed‐dose combination of mometasone furoate and formoterol fumarate in subjects with moderate to very severe COPD: results from a 52‐week Phase III trial. International Journal of Chronic Obstructive Pulmonary Disease2012; Vol. 7, issue 1178‐2005 (Electronic). 1176‐9106 (Linking):43‐55. ">Tashkin 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mild exacerbation</b> = clinically judged deterioration of COPD symptoms (managed with increased short‐acting bronchodilator use: ≥ 12 inhalations/d of SABA/short‐acting anticholinergic, or ≥ 2 nebulised treatments/d of 2.5 mg SABA/short‐acting anticholinergic) on any two consecutive days </p> <p><b>Moderate exacerbation</b> = clinically judged deterioration of COPD with an acute change in symptoms that required antibiotic and/or oral steroid treatment for lower airway disease </p> <p><b>Severe exacerbation</b> = deterioration of COPD that resulted in emergency treatment or hospitalisation due to COPD </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006826-bbs2-0005" title="LapperreTS , Snoeck‐StrobandJB , GosmanMM , JansenDF , vanSchadewijkA , ThiadensHA , et al. Effect of fluticasone with and without salmeterol on pulmonary outcomes in chronic obstructive pulmonary disease: a randomized trial. Annals of Internal Medicine2009; Vol. 151, issue 8:517‐27. ">Lapperre 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Exacerbations not reported</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006826-bbs2-0007" title="NCT00358358 . Trial SCO104925. See detailed description, 2006. http://clinicaltrials.gov/show/NCT00358358. [] ">NCT00358358</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Exacerbations not reported</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006826-bbs2-0008" title="SFCT01 . A Multicentre, Randomised, Double‐Blind, Parallel Group, Placebo‐Controlled Study to Compare the Efficacy and Safety of Inhaled Salmeterol/Fluticasone Propionate Combination Product 25/250 µg Two Puffs Bd and Fluticasone Propionate 250µg Two Puffs Bd Alone, All Administered Via Metered Dose Inhalers (MDI), in the Treatment of Subjects with Chronic Obstructive Pulmonary Disease (COPD) for 52 Weeks. GlaxoSmithKline Clinical Trials Register (http:ctr.gsk.co.uk)2005. ">SFCT01</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No definition found</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006826-bbs2-0009" title="NCT00120978 . Advair－CRP Study. http://clinicaltrials.gov/show/NCT001209782004. [] SinDD , ManSF , MarciniukDD , FordG , FitzGeraldM , WongE , et al. Can inhaled fluticasone alone or in combination with salmeterol reduce systemic inflammation in chronic obstructive pulmonary disease? Study protocol for a randomized controlled trial [NCT00120978]. BMC Pulmonary Medicine2006;6(6):3. SinDD , ManSF , MarciniukDD , FordG , FitzGeraldM , WongE , et al. The effects of fluticasone with or without salmeterol on systemic biomarkers of inflammation in chronic obstructive pulmonary disease. American Journal of Respiratory and Critical Care Medicine2008; Vol. 177, issue 11:1207‐14. ">Sin 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>“Exacerbations were defined as worsening of COPD symptoms leading to hospitalisation, a visit to the emergency room, or use of an antimicrobial agent and/or systemic corticosteroids as an outpatient” </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006826-bbs2-0010" title="AndersonP . Budesonide/formoterol in a single inhaler (Symbicort) provides early and sustained improvement in lung function in moderate to severe COPD [Abstract]. Thorax2002;57(Suppl III):iii43. AstraZenecaSD . A placebo‐controlled 12 month efficacy study of the fixed combination budesonide/formoterol compared with budesonide and formoterol as monotherapies in patients with chronic obstructive pulmonary disease (COPD). AstraZeneca Clinical Trials2001. BorgstromL , AskingL , OlssonH , PetersonS . Lack of interaction between disease severity and therapeutic response with budesonide/formoterol in a single inhaler [Abstract]. American Thoracic Society 100th International Conference; May 21‐26, 2004; Orlando, Florida. C22 [Poster 505]. CalverleyP , PauwelsR , LofdahlCG , SvenssonK , HigenbottamT , et al. Relationship between respiratory symptoms and medical treatment in exacerbations of COPD. European Respiratory Journal2005;26(3):406‐13. CalverleyPMA . Effect of budesonide/formoterol on severe exacerbations and lung function in moderate to severe COPD. Thorax. BTS Winter Meeting 2002:S145. CalverleyPMA , SzafranskiW , AnderssonA . Budesonide/formoterol is a well‐tolerated long term maintenance therapy for COPD. European Respiratory Journal2005;26 Suppl 49:Poster 1917. CalverleyPMA , ThompsonNC , OlssonH . Budesonide/formoterol in a single inhaler sustains lung function improvements in COPD [Abstract]. European Respiratory Journal2003;22 Suppl 45:P435. CampbellLM , SzafranskiW . Budesonide/formoterol in a single inhaler (Symbicort) provides sustained relief from symptoms in moderate to severe COPD. Thorax. BTS Winter Meeting 2002:S143. CampellLW , SzafranskiW . Budesonide/Formoterol in a single inhaler (Symbicort) reduces severe exacerbations in patients with moderate‐severe COPD. Thorax. BTS Winter Meeting 2002:S141. DahlR , CukierA , OlssonH . Budesonide/formoterol in a single inhaler reduces severe and mild exacerbations in patients with moderate to severe COPD. European Respiratory Journal2002;20 Suppl 38:242 [P1575]. EgedeF , MengaG . Budesonide/formoterol in a single inhaler provides sustained relief from symptoms and night‐time awakenings in moderate‐severe COPD: results from symptoms and night‐time awakenings in moderate to severe COPD: results from a 1‐year study. European Respiratory Journal2002;20 Suppl 38:242 [P1574]. HalpinD , StahlE , LundbackB , AndersonF , PetersonS . Treatment costs and number needed to treat (NNT) with budesonide/formoterol to avoid one exacerbation of COPD [Abstract]. American Thoracic Society 100th International Conference; May 21‐26, 2004; Orlando, Florida. D22 [Poster 525]. JonesPW , StahlE , SvenssonK . Improvement in health status in patients with moderate to severe COPD after treatment with budesonide/formoterol in a single inhaler. European Respiratory Journal2002;20 Suppl 38:250 [P1613]. KorsgaardJ , SansoresR . Budesonide/formoterol (single inhaler) provides sustained relief from shortness of breath and chest tightness in a 1‐year study of patients with moderate to severe COPD. European Respiratory Journal2002;20 Suppl 38:242 [P1577]. LangeP , SaenzC . Budesonide/formoterol in a single inhaler is well tolerated in patients with moderate to severe COPD: results of a 1 year study. European Respiratory Journal2002;20 Suppl 38:242 [P1573]. LofdahlCG . Reducing the impact of COPD exacerbations: clinical efficacy of budesonide/formoterol. European Respiratory Review2004;13(88):14‐21. MilanowskiJ , NahabedianS . Budesonide/formoterol in a single inhaler acts rapidly to improve lung function and relieve symptoms in patients with moderate to severe COPD. European Respiratory Journal2002;20 Suppl 38:242 [P1576]. SzafranskiW , CukierA , RamirezA , MengaG , SansoresR , NahabedianS , et al. Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease. European Respiratory Journal2003;21(1):74‐81. ">Szafranski 2003</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mild exacerbations</b> = a day with ≥ 4 inhalations of reliever medication above the mean run‐in use </p> <p><b>Severe exacerbation</b> = use of oral steroids and/or antibiotics and/or hospitalisation due to respiratory symptoms </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006826-bbs2-0011" title="Astrazeneca(D5899C00002) . A 6‐month double‐blind, double‐dummy, randomized, parallel group, multicenter efficacy &amp; safety study of Symbicort® pMDI 2 × 160/4.5mg &amp; 80/4.5mg bid compared to Formoterol TBH, Budesonide pMDI (&amp; the combination) &amp; placebo in COPD patients. www.astrazenecaclinicaltrials.com (accessed 8 April 2008). BleeckerER , MeyersDA , BaileyWC , SimsA‐M , BujacSR , GoldmanM , et al. ADRB2 polymorphisms and budesonide/formoterol responses in COPDADRB2 polymorphisms and treatment response in COPD. Chest2012;142(2):320‐8. TashkinDP , RennardSI , MartinP , GoldmanM , SilkoffPE . Efficacy of budesonide/formoterol administered via one pressurized metered‐dose inhaler over 6 months in patients with chronic obstructive pulmonary disease [Abstract]. Chest2008; Vol. 134, issue 4:105001s. TashkinDP , RennardSI , MartinP , RamachandranS , MartinUJ , SilkoffPE , et al. Efficacy and safety of budesonide and formoterol in one pressurized metered‐dose inhaler in patients with moderate to very severe chronic obstructive pulmonary disease : results of a 6‐month randomized clinical trial. Drugs2008; Vol. 68, issue 0012‐6667 (Print):1975‐2000. ">Tashkin 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>“Worsening of COPD symptoms that required treatment with</p> <p>oral corticosteroids and/or hospitalisation”</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006826-bbs2-0013" title="BriggsAH , GlickHA , Lozano‐OrtegaG , SpencerM , CalverleyPM , JonesPW , et al. Is treatment with ICS and LABA cost‐effective for COPD? Multinational economic analysis of the TORCH study. European Respiratory Journal2010; Vol. 35, issue 3:532‐9. CalverleyPM , AndersonJA , CelliB , FergusonGT , JenkinsC , JonesPW , et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease.[see comment]. New England Journal of Medicine2007; Vol. 356, issue 8:775‐89. CalverleyPMA , AndersonJA , CelliB , FergusonGT , JenkinsC , JonesPW , et al. Cardiovascular events in patients with chronic obstructive pulmonary disease: TORCH study results. Thorax2010;65:719‐25. CalverleyPMA , AndersonJA , CelliB , FergusonGT , JenkinsC , JonesPW , et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. New England Journal of Medicine2007;356(8):775‐89. CalverleyPMA , CelliB , FergusonG , JenkinsC , JonesPW , PrideNB , et al. Baseline characteristics of the first 5,000 COPD patients enrolled in the TORCH survival study. European Respiratory Journal2003;22 Suppl 45:578s. CelliB , CalverleyPMA , AndersonJA , FergusonGT , JenkinsC , JonesPW , et al. The TORCH (TOwards a Revolution in COPD Health) study: salmeterol/fluticasone propionate (SFC) improves health status, reduces exacerbations and improves lung function over three years. European Respiratory Journal2006;28 Suppl 50:34s. CelliB , VestboJ , JenkinsCR , JonesPW , FergusonGT , CalverleyPM , et al. Sex differences in mortality and clinical expressions of patients with chronic obstructive pulmonary disease: the TORCH experience. American Journal of Respiratory and Critical Care Medicine2011;183(3):317‐22. CelliBR , ThomasNE , AndersonJA , FergusonGT , JenkinsCR , JonesPW , et al. Effect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease: results from the TORCH study. American Journal of Respiratory and Critical Care Medicine2008;174(4):332‐8. CrimC , CalverleyPM , AndersonJA , CelliB , FergusonGT , JenkinsC , et al. Pneumonia risk in COPD patients receiving inhaled corticosteroids alone or in combination: TORCH study results. European Respiratory Journal2009;34(3):641‐7. FergusonGT , CalverleyPM , AndersonJA , JenkinsCR , JonesPW , WillitsLR , et al. Prevalence and progression of osteoporosis in patients with COPD: results from the TOwards a Revolution in COPD Health study. Chest2009; Vol. 136, issue 0012‐3692:1456‐65. FergusonGT , CalverleyPMA , AndersonJA , et al. The TORCH (TOwards a Revolution in COPD Health) study: salmeterol/fluticasone propionate (SFC) improves survival in COPD over three years. European Respiratory Journal2006;28 Suppl 50:34s. GlaxoSmithKlineSCO30003 . A multicentre, randomised, double‐blind, parallel group, placebo‐controlled study to investigate the long‐term effects of salmeterol/fluticasone propionate (SERETIDE/VIANI/ADVAIR) 50/500mcg bd, salmeterol 50mcg bd and fluticasone propionate 500mcg bd, all delivered via the DISKUS/ACCUHALER inhaler, on the survival of subjects with chronic obstructive pulmonary disease (COPD) over 3 years of treatment. GlaxoSmithKline Clinical Trial Register2006. HoughtonCM , LawsonN , BorrillZL , WixonCL , YoxallS , LangleySJ , et al. Comparison of the effects of salmeterol/fluticasone propionate with fluticasone propionate on airway physiology in adults with mild persistent asthma. Respiratory Research2007;8:52. JenkinsCR , CalverleyPMA , CelliB , FergusonG , JonesPW , PrideN , et al. Seasonal patterns of exacerbation rates in the TORCH survival study, 2007. http://www.abstracts2view.comA839. JenkinsCR , CelliB , AndersonJA , FergusonGT , JonesPW , VestboJ , et al. Seasonality and determinants of moderate and severe COPD exacerbations in the TORCH study. European Respiratory Journal2012;39(1):38‐45. JenkinsCR , JonesPW , CalverleyPM , CelliB , AndersonJA , FergusonGT , et al. Efficacy of salmeterol/fluticasone propionate by GOLD stage of chronic obstructive pulmonary disease: analysis from the randomised, placebo‐controlled TORCH study. Respiratory Research2009;10:59. JohnsonM , AgustiAG , BarnesNC . Reflections on TORCH: potential mechanisms for the survival benefit of salmeterol/fluticasone propionate in COPD patients. COPD2008;5(6):369‐75. JonesPW , AndersonJA , CalverleyPM , CelliBR , FergusonGT , JenkinsC , et al. TORCH Investigators. Health status in the TORCH study of COPD: treatment efficacy and other determinants of change. Respiratory Research2011;12:71. JonesPW , CalverleyP , CelliB , FergusonG , JenkinsC , PrideN . Trans‐regional validity of the SGRQ in the TORCH survival study, 2007. http://www.abstracts2view.comA122. McGarveyLP , JohnM , AndersonJA , ZvarichMT , WiseRA . Ascertainment of cause‐specific mortality in COPD: operations of the TORCH Clinical Endpoint Committee. Thorax2007;62:411‐5. NCT00268216 . See detailed description, 2000. http://clinicaltrials.gov/show/NCT00268216. [] SCO30003 . A multicentre, randomised, double‐blind, parallel group, placebo‐controlled study to investigate the long‐term effects of salmeterol/fluticasone propionate (SERETIDE®/VIANI®/ADVAIR®) 50/500mcg bd, salmeterol 50mcg bd and fluticasone propionate 500mcg bd, all delivered via the DISKUS®/ACCUHALER® inhaler, on the survival of subjects with chronic obstructive pulmonary disease (COPD) over 3 years of treatment, 2006. www.ctr.gsk.co.uk. VestboJ , AndersonJA , CalverleyPM , CelliB , FergusonGT , JenkinsC , et al. Adherence to inhaled therapy, mortality and hospital admission in COPD. Thorax2009;64(11):939‐43. VestboJ , CalverleyP , CelliB , FergusonG , JenkinsC , JonesP , et al. The TORCH (TOwards a Revolution in COPD Health) survival study protocol. European Respiratory Journal2004;24(2):206‐10. WiseRA , McGarveyLP , JohnM , AndersonJA , ZvarichMT . Reliability of cause‐specific mortality adjudication in a COPD clinical trial, 2007. http://www.abstracts2view.comA120. ">TORCH</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>“A symptomatic deterioration requiring treatment with antibiotic agents,</p> <p>systemic corticosteroids, hospitalisation, or a combination of these”</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006826-bbs2-0014" title="CalverleyP , PauwelsR , VestboJ , JonesP , PrideN , GulsvikA , et al. Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial. Lancet2003;361(9356):449‐56. CalverleyPMA , PauwelsRA , VestboJ , JonesPW , PrideNB , GulsvikA , et al. Clinical improvements with salmeterol / fluticasone propionate combination in differing severities of COPD, 2003. http://www.abstracts2view.comA035 [Poster D50]. CalverleyPMA , PauwelsRA , VestboJ , JonesPW , PrideNB , GulsvikA , et al. Salmeterol/Fluticasone propionate combination for one year provides greater clinical benefit than its individual components. Proceedings of the 98th International American Thoracic Society Conference http://www.abstracts‐on‐line.com/abstracts/ATS; May 17‐22, 2002; Atlanta, Georgia. A98 [Poster 306]. CalverlyPMA , PauwelsR , VestboJ , JonesP , PrideN , GulsvikA , et al. Safety of salmeterol/fluticasone propionate combination in the treatment of chronic obstructive pulmonary disease. European Respiratory Journal2002;20 Suppl 38:242 [P1572]. HunjanMK , ChandlerF . Numbers needed to treat (NNT) to avoid an exacerbation in patients with chronic obstructive pulmonary disease (COPD) using salmeterol/fluticasone propionate combination (SFC) and associated costs [Abstract]. American Thoracic Society 100th International Conference; May 21‐26, 2004; Orlando, Florida. D22 [Poster 503]. HunjanMK , WilliamsDT . Costs of avoiding exacerbations in patients with chronic obstructive pulmonary disease (COPD) treated with salmeterol/ fluticasone propionate combination (seretide) and salmeterol. European Respiratory Journal2004;24 Suppl 48:291s. HunjanMK , WilliamsDT . Salmeterol/ fluticasone propionate combination is clinically effective in avoiding exacerbations in patients with moderate/severe COPD. European Respiratory Journal2004;24 Suppl 48:513s. JonesPW , EdinHM , AndersonJ . Salmeterol/fluticasone propionate combination improves health status in COPD patients. Proceedings of the 98th International American Thoracic Society Conference http://www.abstracts‐on‐line.com/abstracts/ATS; May 17‐22, 2002; Atlanta, Georgia. A39 [Poster K39]. JonesPW , StåhlE . Budesonide /formoterol sustains clinically relevant improvements in health status in COPD [Abstract]. European Respiratory Journal2005;26 Suppl 49:Abstract 1352. JonesPW , VestboJ , PauwelsRA , CalverleyPMA , AndersonJA , SpencerMD . Informative drop out in COPD studies: investigation of health status of withdrawals in the TRISTAN study. Proceedings of the 13th ERS Annual Congress; September 27, 2003; Vienna, Austria. P1593. NitschmannS . Inhalational combination therapy in chronic obstructive lung disease. Tristan study. German Internist2004;45(6):727‐8. PauwelsR , VestboJ , CalverleyPMA , JonesPW , PrideNB , GulsvikA . Characterization of exacerbations in the TRISTAN study of salmeterol / fluticasone propionate (SFC) combination in moderate to severe COPD, 2006. http://www.abstracts2view.com. PauwelsRA , CalverlyPMA , VestboJ , JonesPW , PrideN , GulsvikA , et al. Reduction of exacerbations with salmeterol/fluticasone combination 50/500 mcg bd in the treatment of chronic obstructive pulmonary disease. European Respiratory Journal2002;20 Suppl 38:240 [P1569]. SFCB3024 . A multicentre, randomised, double‐blind, parallel group, placebo‐controlled study to compare the efficacy and safety of the salmeterol/FP combination product at a strength of 50/500mcg bd with salmeterol 50mcg bd alone and FP 500mcg bd alone, delivered via the DISKUS™/ACCUHALER™, in the treatment of subjects with chronic obstructive pulmonary disease (COPD) for 12 months. GlaxoSmithKline Clinical Trials Register (http:ctr.gsk.co.uk)2005. SpencerM , BriggsAH , GrossmanRF , RanceL . Development of an economic model to assess the cost effectiveness of treatment interventions for chronic obstructive pulmonary disease. Pharmacoeconomics2005;23(6):619‐37. SpencerMD , KariaN , AndersonJ . The clinical significance of treatment benefits with the salmeterol/fluticasone propionate 50/500mcg combination in COPD. European Respiratory Journal2004;24 Suppl 48:290s. VestboJ , CalverleyPMA , PauwelsR , JonesP , PrideN , GulsvikA , et al. Absence of gender susceptibility to the combination of salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease. European Respiratory Journal2002;20 Suppl 38:240 [P1570]. VestboJ , PauwelsR , AndersonJA , JonesP , CalverleyP . Early onset of effect of salmeterol and fluticasone propionate in chronic obstructive pulmonary disease. Thorax2005;60(4):301‐4. VestboJ , PauwelsRS , CalverleyPMA , JonesPW , PrideNB , GulsvikA . Salmeterol / fluticasone propionate combination produces improvement in lung function detectable within 24 hours in moderate to severe COPD, 2003. http://www.abstracts2view.com. VestboJ , SorianoJB , AndersonJA , CalverleyP , PauwelsR , JonesP . Gender does not influence the response to the combination of salmeterol and fluticasone propionate in COPD. Respiratory Medicine2004;98(11):1045‐50. ">TRISTAN</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>“Exacerbations were defined a priori as a worsening of COPD symptoms that required treatment with antibiotics, oral corticosteroids, or both. Episodes that </p> <p>required corticosteroid treatment or hospital admission were noted separately”</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006826-bbs2-0015" title="ZhongN , ZhengJ , WenF , YangL , ChenP , XiuQ , et al. Efficacy and safety of budesonide/formoterol via a dry powder inhaler in Chinese patients with chronic obstructive pulmonary disease. Current Medical Research and Opinion2012; Vol. 28, issue 2:257‐65. ZhongN , ZhengJ , WenF , YangL , ChenP , XiuQ , et al. Efficacy and safety of inhalation of budesonide/formoterol via turbuhaler in Chinese patients with chronic obstructive pulmonary disease [Abstract]. Chest2011; Vol. 140, issue 4:5225A. ">Zhong 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>“An exacerbation was defined as use of oral/IV corticosteroids and/or antibiotics and/or emergency room treatment/hospitalisation due to respiratory symptoms” </p> </td> </tr> </tbody> </table> </div> </section> <section id="CD006826-sec-0071"> <h6 class="title">FPS versus FP</h6> <p>Two studies compared FPS versus FP (<a href="./references#CD006826-bbs2-0013" title="BriggsAH , GlickHA , Lozano‐OrtegaG , SpencerM , CalverleyPM , JonesPW , et al. Is treatment with ICS and LABA cost‐effective for COPD? Multinational economic analysis of the TORCH study. European Respiratory Journal2010; Vol. 35, issue 3:532‐9. CalverleyPM , AndersonJA , CelliB , FergusonGT , JenkinsC , JonesPW , et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease.[see comment]. New England Journal of Medicine2007; Vol. 356, issue 8:775‐89. CalverleyPMA , AndersonJA , CelliB , FergusonGT , JenkinsC , JonesPW , et al. Cardiovascular events in patients with chronic obstructive pulmonary disease: TORCH study results. Thorax2010;65:719‐25. CalverleyPMA , AndersonJA , CelliB , FergusonGT , JenkinsC , JonesPW , et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. New England Journal of Medicine2007;356(8):775‐89. CalverleyPMA , CelliB , FergusonG , JenkinsC , JonesPW , PrideNB , et al. Baseline characteristics of the first 5,000 COPD patients enrolled in the TORCH survival study. European Respiratory Journal2003;22 Suppl 45:578s. CelliB , CalverleyPMA , AndersonJA , FergusonGT , JenkinsC , JonesPW , et al. The TORCH (TOwards a Revolution in COPD Health) study: salmeterol/fluticasone propionate (SFC) improves health status, reduces exacerbations and improves lung function over three years. European Respiratory Journal2006;28 Suppl 50:34s. CelliB , VestboJ , JenkinsCR , JonesPW , FergusonGT , CalverleyPM , et al. Sex differences in mortality and clinical expressions of patients with chronic obstructive pulmonary disease: the TORCH experience. American Journal of Respiratory and Critical Care Medicine2011;183(3):317‐22. CelliBR , ThomasNE , AndersonJA , FergusonGT , JenkinsCR , JonesPW , et al. Effect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease: results from the TORCH study. American Journal of Respiratory and Critical Care Medicine2008;174(4):332‐8. CrimC , CalverleyPM , AndersonJA , CelliB , FergusonGT , JenkinsC , et al. Pneumonia risk in COPD patients receiving inhaled corticosteroids alone or in combination: TORCH study results. European Respiratory Journal2009;34(3):641‐7. FergusonGT , CalverleyPM , AndersonJA , JenkinsCR , JonesPW , WillitsLR , et al. Prevalence and progression of osteoporosis in patients with COPD: results from the TOwards a Revolution in COPD Health study. Chest2009; Vol. 136, issue 0012‐3692:1456‐65. FergusonGT , CalverleyPMA , AndersonJA , et al. The TORCH (TOwards a Revolution in COPD Health) study: salmeterol/fluticasone propionate (SFC) improves survival in COPD over three years. European Respiratory Journal2006;28 Suppl 50:34s. GlaxoSmithKlineSCO30003 . A multicentre, randomised, double‐blind, parallel group, placebo‐controlled study to investigate the long‐term effects of salmeterol/fluticasone propionate (SERETIDE/VIANI/ADVAIR) 50/500mcg bd, salmeterol 50mcg bd and fluticasone propionate 500mcg bd, all delivered via the DISKUS/ACCUHALER inhaler, on the survival of subjects with chronic obstructive pulmonary disease (COPD) over 3 years of treatment. GlaxoSmithKline Clinical Trial Register2006. HoughtonCM , LawsonN , BorrillZL , WixonCL , YoxallS , LangleySJ , et al. Comparison of the effects of salmeterol/fluticasone propionate with fluticasone propionate on airway physiology in adults with mild persistent asthma. Respiratory Research2007;8:52. JenkinsCR , CalverleyPMA , CelliB , FergusonG , JonesPW , PrideN , et al. Seasonal patterns of exacerbation rates in the TORCH survival study, 2007. http://www.abstracts2view.comA839. JenkinsCR , CelliB , AndersonJA , FergusonGT , JonesPW , VestboJ , et al. Seasonality and determinants of moderate and severe COPD exacerbations in the TORCH study. European Respiratory Journal2012;39(1):38‐45. JenkinsCR , JonesPW , CalverleyPM , CelliB , AndersonJA , FergusonGT , et al. Efficacy of salmeterol/fluticasone propionate by GOLD stage of chronic obstructive pulmonary disease: analysis from the randomised, placebo‐controlled TORCH study. Respiratory Research2009;10:59. JohnsonM , AgustiAG , BarnesNC . Reflections on TORCH: potential mechanisms for the survival benefit of salmeterol/fluticasone propionate in COPD patients. COPD2008;5(6):369‐75. JonesPW , AndersonJA , CalverleyPM , CelliBR , FergusonGT , JenkinsC , et al. TORCH Investigators. Health status in the TORCH study of COPD: treatment efficacy and other determinants of change. Respiratory Research2011;12:71. JonesPW , CalverleyP , CelliB , FergusonG , JenkinsC , PrideN . Trans‐regional validity of the SGRQ in the TORCH survival study, 2007. http://www.abstracts2view.comA122. McGarveyLP , JohnM , AndersonJA , ZvarichMT , WiseRA . Ascertainment of cause‐specific mortality in COPD: operations of the TORCH Clinical Endpoint Committee. Thorax2007;62:411‐5. NCT00268216 . See detailed description, 2000. http://clinicaltrials.gov/show/NCT00268216. [] SCO30003 . A multicentre, randomised, double‐blind, parallel group, placebo‐controlled study to investigate the long‐term effects of salmeterol/fluticasone propionate (SERETIDE®/VIANI®/ADVAIR®) 50/500mcg bd, salmeterol 50mcg bd and fluticasone propionate 500mcg bd, all delivered via the DISKUS®/ACCUHALER® inhaler, on the survival of subjects with chronic obstructive pulmonary disease (COPD) over 3 years of treatment, 2006. www.ctr.gsk.co.uk. VestboJ , AndersonJA , CalverleyPM , CelliB , FergusonGT , JenkinsC , et al. Adherence to inhaled therapy, mortality and hospital admission in COPD. Thorax2009;64(11):939‐43. VestboJ , CalverleyP , CelliB , FergusonG , JenkinsC , JonesP , et al. The TORCH (TOwards a Revolution in COPD Health) survival study protocol. European Respiratory Journal2004;24(2):206‐10. WiseRA , McGarveyLP , JohnM , AndersonJA , ZvarichMT . Reliability of cause‐specific mortality adjudication in a COPD clinical trial, 2007. http://www.abstracts2view.comA120. ">TORCH</a>; <a href="./references#CD006826-bbs2-0014" title="CalverleyP , PauwelsR , VestboJ , JonesP , PrideN , GulsvikA , et al. Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial. Lancet2003;361(9356):449‐56. CalverleyPMA , PauwelsRA , VestboJ , JonesPW , PrideNB , GulsvikA , et al. Clinical improvements with salmeterol / fluticasone propionate combination in differing severities of COPD, 2003. http://www.abstracts2view.comA035 [Poster D50]. CalverleyPMA , PauwelsRA , VestboJ , JonesPW , PrideNB , GulsvikA , et al. Salmeterol/Fluticasone propionate combination for one year provides greater clinical benefit than its individual components. Proceedings of the 98th International American Thoracic Society Conference http://www.abstracts‐on‐line.com/abstracts/ATS; May 17‐22, 2002; Atlanta, Georgia. A98 [Poster 306]. CalverlyPMA , PauwelsR , VestboJ , JonesP , PrideN , GulsvikA , et al. Safety of salmeterol/fluticasone propionate combination in the treatment of chronic obstructive pulmonary disease. European Respiratory Journal2002;20 Suppl 38:242 [P1572]. HunjanMK , ChandlerF . Numbers needed to treat (NNT) to avoid an exacerbation in patients with chronic obstructive pulmonary disease (COPD) using salmeterol/fluticasone propionate combination (SFC) and associated costs [Abstract]. American Thoracic Society 100th International Conference; May 21‐26, 2004; Orlando, Florida. D22 [Poster 503]. HunjanMK , WilliamsDT . Costs of avoiding exacerbations in patients with chronic obstructive pulmonary disease (COPD) treated with salmeterol/ fluticasone propionate combination (seretide) and salmeterol. European Respiratory Journal2004;24 Suppl 48:291s. HunjanMK , WilliamsDT . Salmeterol/ fluticasone propionate combination is clinically effective in avoiding exacerbations in patients with moderate/severe COPD. European Respiratory Journal2004;24 Suppl 48:513s. JonesPW , EdinHM , AndersonJ . Salmeterol/fluticasone propionate combination improves health status in COPD patients. Proceedings of the 98th International American Thoracic Society Conference http://www.abstracts‐on‐line.com/abstracts/ATS; May 17‐22, 2002; Atlanta, Georgia. A39 [Poster K39]. JonesPW , StåhlE . Budesonide /formoterol sustains clinically relevant improvements in health status in COPD [Abstract]. European Respiratory Journal2005;26 Suppl 49:Abstract 1352. JonesPW , VestboJ , PauwelsRA , CalverleyPMA , AndersonJA , SpencerMD . Informative drop out in COPD studies: investigation of health status of withdrawals in the TRISTAN study. Proceedings of the 13th ERS Annual Congress; September 27, 2003; Vienna, Austria. P1593. NitschmannS . Inhalational combination therapy in chronic obstructive lung disease. Tristan study. German Internist2004;45(6):727‐8. PauwelsR , VestboJ , CalverleyPMA , JonesPW , PrideNB , GulsvikA . Characterization of exacerbations in the TRISTAN study of salmeterol / fluticasone propionate (SFC) combination in moderate to severe COPD, 2006. http://www.abstracts2view.com. PauwelsRA , CalverlyPMA , VestboJ , JonesPW , PrideN , GulsvikA , et al. Reduction of exacerbations with salmeterol/fluticasone combination 50/500 mcg bd in the treatment of chronic obstructive pulmonary disease. European Respiratory Journal2002;20 Suppl 38:240 [P1569]. SFCB3024 . A multicentre, randomised, double‐blind, parallel group, placebo‐controlled study to compare the efficacy and safety of the salmeterol/FP combination product at a strength of 50/500mcg bd with salmeterol 50mcg bd alone and FP 500mcg bd alone, delivered via the DISKUS™/ACCUHALER™, in the treatment of subjects with chronic obstructive pulmonary disease (COPD) for 12 months. GlaxoSmithKline Clinical Trials Register (http:ctr.gsk.co.uk)2005. SpencerM , BriggsAH , GrossmanRF , RanceL . Development of an economic model to assess the cost effectiveness of treatment interventions for chronic obstructive pulmonary disease. Pharmacoeconomics2005;23(6):619‐37. SpencerMD , KariaN , AndersonJ . The clinical significance of treatment benefits with the salmeterol/fluticasone propionate 50/500mcg combination in COPD. European Respiratory Journal2004;24 Suppl 48:290s. VestboJ , CalverleyPMA , PauwelsR , JonesP , PrideN , GulsvikA , et al. Absence of gender susceptibility to the combination of salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease. European Respiratory Journal2002;20 Suppl 38:240 [P1570]. VestboJ , PauwelsR , AndersonJA , JonesP , CalverleyP . Early onset of effect of salmeterol and fluticasone propionate in chronic obstructive pulmonary disease. Thorax2005;60(4):301‐4. VestboJ , PauwelsRS , CalverleyPMA , JonesPW , PrideNB , GulsvikA . Salmeterol / fluticasone propionate combination produces improvement in lung function detectable within 24 hours in moderate to severe COPD, 2003. http://www.abstracts2view.com. VestboJ , SorianoJB , AndersonJA , CalverleyP , PauwelsR , JonesP . Gender does not influence the response to the combination of salmeterol and fluticasone propionate in COPD. Respiratory Medicine2004;98(11):1045‐50. ">TRISTAN</a>). A significant reduction was noted in the rate of exacerbations with combination therapy when compared with FP (2 studies; N = 3789; RR 0.88; 95% CI 0.80 to 0.98; <a href="./references#CD006826-fig-0009" title="">Analysis 1.1</a>). </p> </section> <section id="CD006826-sec-0072"> <h6 class="title">BDF versus BD</h6> <p>Four studies compared BDF versus BD (<a href="./references#CD006826-bbs2-0002" title="AstraZenecaSD . A placebo‐controlled 12‐month efficacy study of the fixed combination budesonide/formoterol compared to budesonide and formoterol as monotherapies in patients with chronic obstructive pulmonary disease (COPD). AstraZeneca Clinical Trials2002. BorgstromL , AskingL , OlssonH , PetersonS . Lack of interaction between disease severity and therapeutic response with budesonide/formoterol in a single inhaler [Abstract]. American Thoracic Society 100th International Conference; May 21‐26; 2004, Orlando, Florida. C22 [Poster 505]. CalverleyPM , BonsawatW , CsekeZ , ZhongN , PetersonS , OlssonH . Maintenance therapy with budesonide and formoterol in chronic obstructive pulmonary disease. European Respiratory Journal2003;22(6):912‐9. CalverleyPMA , CsekeZ , PetersonS . Budesonide/formoterol reduces the use of oral corticosteroids in the treatment of COPD [Abstract]. European Respiratory Journal2003;22 Suppl 45:P436. CalverleyPMA , KunaP , OlssonH . COPD exacerbations are reduced by budesonide/formoterol in a single inhaler [Abstract]. European Respiratory Journal2003;22 Suppl 45:P1587. CalverleyPMA , OlssonH , Symbicort International COPD Study Group. Budesonide/formoterol ina single inhaler sustains improvements in lung function over 12 months compared with monocomponents and placebo in patients with COPD [abstract]. American Thoracic Society 99th International Conference; May 16‐21, 2003; Seattle, Washington. B024 [Poster 418]. CalverleyPMA , PetersonS . Combining budesonide/formoterol in a single inhale reduces exacerbation frequency in COPD [abstract]. American Thoracic Society 99th International Conference; May 16‐21, 2003; Seattle, Washington. D092 [Poster 211]. CalverleyPMA , StåhlE , JonesPW . Budesonide/formoterol improves the general health status of patients with COPD [Abstract]. American Thoracic Society 2005 International Conference; May 20‐25, 2005; San Diego, California. B93 [Poster 303]. CalverleyPMA , SzafranskiW , AnderssonA . Budesonide/formoterol is a well‐tolerated long term maintenance therapy for COPD. European Respiratory Journal2005;26 Suppl 49:Poster 1917. CalverleyPMA , ThompsonNC , OlssonH . Budesonide/formoterol in a single inhaler sustains lung function improvements in COPD [Abstract]. European Respiratory Journal2003;22 Suppl 45:P435. HalpinD , StåhlE , LundbackB , AndersonF , PetersonS . Treatment costs and number needed to treat (NNT) with budesonide/formoterol to avoid one exacerbation of COPD [Abstract]. American Thoracic Society 100th International Conference; May 21‐26, 2004; Orlando, Florida. D22 [Poster 525]. HalpinDMG , LarssonT , CalverleyPMA . How many patients with COPD must be treated with budesonide/formoterol compared with formoterol alone to avoid 1 day of oral steroid use? [Abstract]. American Thoracic Society 2005 International Conference; May 20‐25, 2005; San Diego, California. B93 [Poster 314]. JonesPW , StahlE . Budesonide/formoterol in a single inhaler improves health status in patients with COPD [abstract]. American Thoracic Society 99th International Conference; May 16‐21, 2003; Orlando, Florida. B024 [Poster 419]. JonesPW , StåhlE . Budesonide /formoterol sustains clinically relevant improvements in health status in COPD [Abstract]. European Respiratory Journal2005;26 Suppl 49:Abstract 1352. JonesPW , StåhlE . Reducing exacerbations leads to a better health‐related quality of life in patients with COPD. 13th ERS Annual Congress; September 27, 2003; Vienna, Austria. P1586. LofdahlCG . Reducing the impact of COPD exacerbations: Clinical efficacy of budesonide/formoterol. European Respiratory Review2004;13(88):14‐21. LofdahlCG , AndreassonE , SvenssonK , EricssonA . Budesonide/formoterol in a single inhaler improves health status in patients with COPD without increasing healthcare costs [Abstract]. European Respiratory Journal2003;22 Suppl 45:P433. LofdahlCG , EricssonA , SvenssonK , AndreassonE . Cost effectiveness of budesonide/formoterol in a single inhaler for COPD compared with each monocomponent used alone. Pharmacoeconomics2005;23(4):365‐75. ">Calverley 2003</a>, <a href="./references#CD006826-bbs2-0010" title="AndersonP . Budesonide/formoterol in a single inhaler (Symbicort) provides early and sustained improvement in lung function in moderate to severe COPD [Abstract]. Thorax2002;57(Suppl III):iii43. AstraZenecaSD . A placebo‐controlled 12 month efficacy study of the fixed combination budesonide/formoterol compared with budesonide and formoterol as monotherapies in patients with chronic obstructive pulmonary disease (COPD). AstraZeneca Clinical Trials2001. BorgstromL , AskingL , OlssonH , PetersonS . Lack of interaction between disease severity and therapeutic response with budesonide/formoterol in a single inhaler [Abstract]. American Thoracic Society 100th International Conference; May 21‐26, 2004; Orlando, Florida. C22 [Poster 505]. CalverleyP , PauwelsR , LofdahlCG , SvenssonK , HigenbottamT , et al. Relationship between respiratory symptoms and medical treatment in exacerbations of COPD. European Respiratory Journal2005;26(3):406‐13. CalverleyPMA . Effect of budesonide/formoterol on severe exacerbations and lung function in moderate to severe COPD. Thorax. BTS Winter Meeting 2002:S145. CalverleyPMA , SzafranskiW , AnderssonA . Budesonide/formoterol is a well‐tolerated long term maintenance therapy for COPD. European Respiratory Journal2005;26 Suppl 49:Poster 1917. CalverleyPMA , ThompsonNC , OlssonH . Budesonide/formoterol in a single inhaler sustains lung function improvements in COPD [Abstract]. European Respiratory Journal2003;22 Suppl 45:P435. CampbellLM , SzafranskiW . Budesonide/formoterol in a single inhaler (Symbicort) provides sustained relief from symptoms in moderate to severe COPD. Thorax. BTS Winter Meeting 2002:S143. CampellLW , SzafranskiW . Budesonide/Formoterol in a single inhaler (Symbicort) reduces severe exacerbations in patients with moderate‐severe COPD. Thorax. BTS Winter Meeting 2002:S141. DahlR , CukierA , OlssonH . Budesonide/formoterol in a single inhaler reduces severe and mild exacerbations in patients with moderate to severe COPD. European Respiratory Journal2002;20 Suppl 38:242 [P1575]. EgedeF , MengaG . Budesonide/formoterol in a single inhaler provides sustained relief from symptoms and night‐time awakenings in moderate‐severe COPD: results from symptoms and night‐time awakenings in moderate to severe COPD: results from a 1‐year study. European Respiratory Journal2002;20 Suppl 38:242 [P1574]. HalpinD , StahlE , LundbackB , AndersonF , PetersonS . Treatment costs and number needed to treat (NNT) with budesonide/formoterol to avoid one exacerbation of COPD [Abstract]. American Thoracic Society 100th International Conference; May 21‐26, 2004; Orlando, Florida. D22 [Poster 525]. JonesPW , StahlE , SvenssonK . Improvement in health status in patients with moderate to severe COPD after treatment with budesonide/formoterol in a single inhaler. European Respiratory Journal2002;20 Suppl 38:250 [P1613]. KorsgaardJ , SansoresR . Budesonide/formoterol (single inhaler) provides sustained relief from shortness of breath and chest tightness in a 1‐year study of patients with moderate to severe COPD. European Respiratory Journal2002;20 Suppl 38:242 [P1577]. LangeP , SaenzC . Budesonide/formoterol in a single inhaler is well tolerated in patients with moderate to severe COPD: results of a 1 year study. European Respiratory Journal2002;20 Suppl 38:242 [P1573]. LofdahlCG . Reducing the impact of COPD exacerbations: clinical efficacy of budesonide/formoterol. European Respiratory Review2004;13(88):14‐21. MilanowskiJ , NahabedianS . Budesonide/formoterol in a single inhaler acts rapidly to improve lung function and relieve symptoms in patients with moderate to severe COPD. European Respiratory Journal2002;20 Suppl 38:242 [P1576]. SzafranskiW , CukierA , RamirezA , MengaG , SansoresR , NahabedianS , et al. Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease. European Respiratory Journal2003;21(1):74‐81. ">Szafranski 2003</a>; <a href="./references#CD006826-bbs2-0011" title="Astrazeneca(D5899C00002) . A 6‐month double‐blind, double‐dummy, randomized, parallel group, multicenter efficacy &amp; safety study of Symbicort® pMDI 2 × 160/4.5mg &amp; 80/4.5mg bid compared to Formoterol TBH, Budesonide pMDI (&amp; the combination) &amp; placebo in COPD patients. www.astrazenecaclinicaltrials.com (accessed 8 April 2008). BleeckerER , MeyersDA , BaileyWC , SimsA‐M , BujacSR , GoldmanM , et al. ADRB2 polymorphisms and budesonide/formoterol responses in COPDADRB2 polymorphisms and treatment response in COPD. Chest2012;142(2):320‐8. TashkinDP , RennardSI , MartinP , GoldmanM , SilkoffPE . Efficacy of budesonide/formoterol administered via one pressurized metered‐dose inhaler over 6 months in patients with chronic obstructive pulmonary disease [Abstract]. Chest2008; Vol. 134, issue 4:105001s. TashkinDP , RennardSI , MartinP , RamachandranS , MartinUJ , SilkoffPE , et al. Efficacy and safety of budesonide and formoterol in one pressurized metered‐dose inhaler in patients with moderate to very severe chronic obstructive pulmonary disease : results of a 6‐month randomized clinical trial. Drugs2008; Vol. 68, issue 0012‐6667 (Print):1975‐2000. ">Tashkin 2008</a>; <a href="./references#CD006826-bbs2-0015" title="ZhongN , ZhengJ , WenF , YangL , ChenP , XiuQ , et al. Efficacy and safety of budesonide/formoterol via a dry powder inhaler in Chinese patients with chronic obstructive pulmonary disease. Current Medical Research and Opinion2012; Vol. 28, issue 2:257‐65. ZhongN , ZhengJ , WenF , YangL , ChenP , XiuQ , et al. Efficacy and safety of inhalation of budesonide/formoterol via turbuhaler in Chinese patients with chronic obstructive pulmonary disease [Abstract]. Chest2011; Vol. 140, issue 4:5225A. ">Zhong 2012</a>). A significant effect on pooled exacerbation rates was seen with BDF versus BD (4 studies; N = 1777; RR 0.84; 95% CI 0.73 to 0.97; <a href="./references#CD006826-fig-0009" title="">Analysis 1.1</a>). </p> </section> <section id="CD006826-sec-0073"> <h6 class="title">MF/F versus MF</h6> <p>The two studies comparing MF/F versus MF did not report rate data for exacerbations.</p> </section> </section> <section id="CD006826-sec-0074"> <h5 class="title">Number of participants with one or more exacerbation</h5> <p>No significant difference was seen with combination therapy when compared with ICS (7 studies: N = 2781, OR 0.87, 95% CI 0.70 to 1.09; <a href="./references#CD006826-fig-0010" title="">Analysis 1.2</a>; <a href="#CD006826-fig-0004">Figure 4</a>). </p> <div class="figure" id="CD006826-fig-0004"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 4</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 1 All Combined Inhalers－Primary Outcomes, outcome: 1.2 Number of participants with one or more exacerbation." data-id="CD006826-fig-0004" src="/cdsr/doi/10.1002/14651858.CD006826.pub2/media/CDSR/CD006826/image_n/nCD006826-AFig-FIG04.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 1 All Combined Inhalers－Primary Outcomes, outcome: 1.2 Number of participants with one or more exacerbation. </p> </div> </div> </div> <section id="CD006826-sec-0075"> <h6 class="title">FPS versus FP</h6> <p>No significant difference was observed between FPS and FP in the reports of participants with one or more exacerbations (3 studies (<a href="./references#CD006826-bbs2-0008" title="SFCT01 . A Multicentre, Randomised, Double‐Blind, Parallel Group, Placebo‐Controlled Study to Compare the Efficacy and Safety of Inhaled Salmeterol/Fluticasone Propionate Combination Product 25/250 µg Two Puffs Bd and Fluticasone Propionate 250µg Two Puffs Bd Alone, All Administered Via Metered Dose Inhalers (MDI), in the Treatment of Subjects with Chronic Obstructive Pulmonary Disease (COPD) for 52 Weeks. GlaxoSmithKline Clinical Trials Register (http:ctr.gsk.co.uk)2005. ">SFCT01</a>; <a href="./references#CD006826-bbs2-0009" title="NCT00120978 . Advair－CRP Study. http://clinicaltrials.gov/show/NCT001209782004. [] SinDD , ManSF , MarciniukDD , FordG , FitzGeraldM , WongE , et al. Can inhaled fluticasone alone or in combination with salmeterol reduce systemic inflammation in chronic obstructive pulmonary disease? Study protocol for a randomized controlled trial [NCT00120978]. BMC Pulmonary Medicine2006;6(6):3. SinDD , ManSF , MarciniukDD , FordG , FitzGeraldM , WongE , et al. The effects of fluticasone with or without salmeterol on systemic biomarkers of inflammation in chronic obstructive pulmonary disease. American Journal of Respiratory and Critical Care Medicine2008; Vol. 177, issue 11:1207‐14. ">Sin 2008</a>; <a href="./references#CD006826-bbs2-0014" title="CalverleyP , PauwelsR , VestboJ , JonesP , PrideN , GulsvikA , et al. Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial. Lancet2003;361(9356):449‐56. CalverleyPMA , PauwelsRA , VestboJ , JonesPW , PrideNB , GulsvikA , et al. Clinical improvements with salmeterol / fluticasone propionate combination in differing severities of COPD, 2003. http://www.abstracts2view.comA035 [Poster D50]. CalverleyPMA , PauwelsRA , VestboJ , JonesPW , PrideNB , GulsvikA , et al. Salmeterol/Fluticasone propionate combination for one year provides greater clinical benefit than its individual components. Proceedings of the 98th International American Thoracic Society Conference http://www.abstracts‐on‐line.com/abstracts/ATS; May 17‐22, 2002; Atlanta, Georgia. A98 [Poster 306]. CalverlyPMA , PauwelsR , VestboJ , JonesP , PrideN , GulsvikA , et al. Safety of salmeterol/fluticasone propionate combination in the treatment of chronic obstructive pulmonary disease. European Respiratory Journal2002;20 Suppl 38:242 [P1572]. HunjanMK , ChandlerF . Numbers needed to treat (NNT) to avoid an exacerbation in patients with chronic obstructive pulmonary disease (COPD) using salmeterol/fluticasone propionate combination (SFC) and associated costs [Abstract]. American Thoracic Society 100th International Conference; May 21‐26, 2004; Orlando, Florida. D22 [Poster 503]. HunjanMK , WilliamsDT . Costs of avoiding exacerbations in patients with chronic obstructive pulmonary disease (COPD) treated with salmeterol/ fluticasone propionate combination (seretide) and salmeterol. European Respiratory Journal2004;24 Suppl 48:291s. HunjanMK , WilliamsDT . Salmeterol/ fluticasone propionate combination is clinically effective in avoiding exacerbations in patients with moderate/severe COPD. European Respiratory Journal2004;24 Suppl 48:513s. JonesPW , EdinHM , AndersonJ . Salmeterol/fluticasone propionate combination improves health status in COPD patients. Proceedings of the 98th International American Thoracic Society Conference http://www.abstracts‐on‐line.com/abstracts/ATS; May 17‐22, 2002; Atlanta, Georgia. A39 [Poster K39]. JonesPW , StåhlE . Budesonide /formoterol sustains clinically relevant improvements in health status in COPD [Abstract]. European Respiratory Journal2005;26 Suppl 49:Abstract 1352. JonesPW , VestboJ , PauwelsRA , CalverleyPMA , AndersonJA , SpencerMD . Informative drop out in COPD studies: investigation of health status of withdrawals in the TRISTAN study. Proceedings of the 13th ERS Annual Congress; September 27, 2003; Vienna, Austria. P1593. NitschmannS . Inhalational combination therapy in chronic obstructive lung disease. Tristan study. German Internist2004;45(6):727‐8. PauwelsR , VestboJ , CalverleyPMA , JonesPW , PrideNB , GulsvikA . Characterization of exacerbations in the TRISTAN study of salmeterol / fluticasone propionate (SFC) combination in moderate to severe COPD, 2006. http://www.abstracts2view.com. PauwelsRA , CalverlyPMA , VestboJ , JonesPW , PrideN , GulsvikA , et al. Reduction of exacerbations with salmeterol/fluticasone combination 50/500 mcg bd in the treatment of chronic obstructive pulmonary disease. European Respiratory Journal2002;20 Suppl 38:240 [P1569]. SFCB3024 . A multicentre, randomised, double‐blind, parallel group, placebo‐controlled study to compare the efficacy and safety of the salmeterol/FP combination product at a strength of 50/500mcg bd with salmeterol 50mcg bd alone and FP 500mcg bd alone, delivered via the DISKUS™/ACCUHALER™, in the treatment of subjects with chronic obstructive pulmonary disease (COPD) for 12 months. GlaxoSmithKline Clinical Trials Register (http:ctr.gsk.co.uk)2005. SpencerM , BriggsAH , GrossmanRF , RanceL . Development of an economic model to assess the cost effectiveness of treatment interventions for chronic obstructive pulmonary disease. Pharmacoeconomics2005;23(6):619‐37. SpencerMD , KariaN , AndersonJ . The clinical significance of treatment benefits with the salmeterol/fluticasone propionate 50/500mcg combination in COPD. European Respiratory Journal2004;24 Suppl 48:290s. VestboJ , CalverleyPMA , PauwelsR , JonesP , PrideN , GulsvikA , et al. Absence of gender susceptibility to the combination of salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease. European Respiratory Journal2002;20 Suppl 38:240 [P1570]. VestboJ , PauwelsR , AndersonJA , JonesP , CalverleyP . Early onset of effect of salmeterol and fluticasone propionate in chronic obstructive pulmonary disease. Thorax2005;60(4):301‐4. VestboJ , PauwelsRS , CalverleyPMA , JonesPW , PrideNB , GulsvikA . Salmeterol / fluticasone propionate combination produces improvement in lung function detectable within 24 hours in moderate to severe COPD, 2003. http://www.abstracts2view.com. VestboJ , SorianoJB , AndersonJA , CalverleyP , PauwelsR , JonesP . Gender does not influence the response to the combination of salmeterol and fluticasone propionate in COPD. Respiratory Medicine2004;98(11):1045‐50. ">TRISTAN</a>); N = 1173, OR 1.22, 95% CI 0.81 to 1.84); this outcome was not reported in <a href="./references#CD006826-bbs2-0013" title="BriggsAH , GlickHA , Lozano‐OrtegaG , SpencerM , CalverleyPM , JonesPW , et al. Is treatment with ICS and LABA cost‐effective for COPD? Multinational economic analysis of the TORCH study. European Respiratory Journal2010; Vol. 35, issue 3:532‐9. CalverleyPM , AndersonJA , CelliB , FergusonGT , JenkinsC , JonesPW , et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease.[see comment]. New England Journal of Medicine2007; Vol. 356, issue 8:775‐89. CalverleyPMA , AndersonJA , CelliB , FergusonGT , JenkinsC , JonesPW , et al. Cardiovascular events in patients with chronic obstructive pulmonary disease: TORCH study results. Thorax2010;65:719‐25. CalverleyPMA , AndersonJA , CelliB , FergusonGT , JenkinsC , JonesPW , et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. New England Journal of Medicine2007;356(8):775‐89. CalverleyPMA , CelliB , FergusonG , JenkinsC , JonesPW , PrideNB , et al. Baseline characteristics of the first 5,000 COPD patients enrolled in the TORCH survival study. European Respiratory Journal2003;22 Suppl 45:578s. CelliB , CalverleyPMA , AndersonJA , FergusonGT , JenkinsC , JonesPW , et al. The TORCH (TOwards a Revolution in COPD Health) study: salmeterol/fluticasone propionate (SFC) improves health status, reduces exacerbations and improves lung function over three years. European Respiratory Journal2006;28 Suppl 50:34s. CelliB , VestboJ , JenkinsCR , JonesPW , FergusonGT , CalverleyPM , et al. Sex differences in mortality and clinical expressions of patients with chronic obstructive pulmonary disease: the TORCH experience. American Journal of Respiratory and Critical Care Medicine2011;183(3):317‐22. CelliBR , ThomasNE , AndersonJA , FergusonGT , JenkinsCR , JonesPW , et al. Effect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease: results from the TORCH study. American Journal of Respiratory and Critical Care Medicine2008;174(4):332‐8. CrimC , CalverleyPM , AndersonJA , CelliB , FergusonGT , JenkinsC , et al. Pneumonia risk in COPD patients receiving inhaled corticosteroids alone or in combination: TORCH study results. European Respiratory Journal2009;34(3):641‐7. FergusonGT , CalverleyPM , AndersonJA , JenkinsCR , JonesPW , WillitsLR , et al. Prevalence and progression of osteoporosis in patients with COPD: results from the TOwards a Revolution in COPD Health study. Chest2009; Vol. 136, issue 0012‐3692:1456‐65. FergusonGT , CalverleyPMA , AndersonJA , et al. The TORCH (TOwards a Revolution in COPD Health) study: salmeterol/fluticasone propionate (SFC) improves survival in COPD over three years. European Respiratory Journal2006;28 Suppl 50:34s. GlaxoSmithKlineSCO30003 . A multicentre, randomised, double‐blind, parallel group, placebo‐controlled study to investigate the long‐term effects of salmeterol/fluticasone propionate (SERETIDE/VIANI/ADVAIR) 50/500mcg bd, salmeterol 50mcg bd and fluticasone propionate 500mcg bd, all delivered via the DISKUS/ACCUHALER inhaler, on the survival of subjects with chronic obstructive pulmonary disease (COPD) over 3 years of treatment. GlaxoSmithKline Clinical Trial Register2006. HoughtonCM , LawsonN , BorrillZL , WixonCL , YoxallS , LangleySJ , et al. Comparison of the effects of salmeterol/fluticasone propionate with fluticasone propionate on airway physiology in adults with mild persistent asthma. Respiratory Research2007;8:52. JenkinsCR , CalverleyPMA , CelliB , FergusonG , JonesPW , PrideN , et al. Seasonal patterns of exacerbation rates in the TORCH survival study, 2007. http://www.abstracts2view.comA839. JenkinsCR , CelliB , AndersonJA , FergusonGT , JonesPW , VestboJ , et al. Seasonality and determinants of moderate and severe COPD exacerbations in the TORCH study. European Respiratory Journal2012;39(1):38‐45. JenkinsCR , JonesPW , CalverleyPM , CelliB , AndersonJA , FergusonGT , et al. Efficacy of salmeterol/fluticasone propionate by GOLD stage of chronic obstructive pulmonary disease: analysis from the randomised, placebo‐controlled TORCH study. Respiratory Research2009;10:59. JohnsonM , AgustiAG , BarnesNC . Reflections on TORCH: potential mechanisms for the survival benefit of salmeterol/fluticasone propionate in COPD patients. COPD2008;5(6):369‐75. JonesPW , AndersonJA , CalverleyPM , CelliBR , FergusonGT , JenkinsC , et al. TORCH Investigators. Health status in the TORCH study of COPD: treatment efficacy and other determinants of change. Respiratory Research2011;12:71. JonesPW , CalverleyP , CelliB , FergusonG , JenkinsC , PrideN . Trans‐regional validity of the SGRQ in the TORCH survival study, 2007. http://www.abstracts2view.comA122. McGarveyLP , JohnM , AndersonJA , ZvarichMT , WiseRA . Ascertainment of cause‐specific mortality in COPD: operations of the TORCH Clinical Endpoint Committee. Thorax2007;62:411‐5. NCT00268216 . See detailed description, 2000. http://clinicaltrials.gov/show/NCT00268216. [] SCO30003 . A multicentre, randomised, double‐blind, parallel group, placebo‐controlled study to investigate the long‐term effects of salmeterol/fluticasone propionate (SERETIDE®/VIANI®/ADVAIR®) 50/500mcg bd, salmeterol 50mcg bd and fluticasone propionate 500mcg bd, all delivered via the DISKUS®/ACCUHALER® inhaler, on the survival of subjects with chronic obstructive pulmonary disease (COPD) over 3 years of treatment, 2006. www.ctr.gsk.co.uk. VestboJ , AndersonJA , CalverleyPM , CelliB , FergusonGT , JenkinsC , et al. Adherence to inhaled therapy, mortality and hospital admission in COPD. Thorax2009;64(11):939‐43. VestboJ , CalverleyP , CelliB , FergusonG , JenkinsC , JonesP , et al. The TORCH (TOwards a Revolution in COPD Health) survival study protocol. European Respiratory Journal2004;24(2):206‐10. WiseRA , McGarveyLP , JohnM , AndersonJA , ZvarichMT . Reliability of cause‐specific mortality adjudication in a COPD clinical trial, 2007. http://www.abstracts2view.comA120. ">TORCH</a>. However, some evidence suggests that FPS leads to a lower rate of exacerbations requiring oral steroids (2 studies (<a href="./references#CD006826-bbs2-0013" title="BriggsAH , GlickHA , Lozano‐OrtegaG , SpencerM , CalverleyPM , JonesPW , et al. Is treatment with ICS and LABA cost‐effective for COPD? Multinational economic analysis of the TORCH study. European Respiratory Journal2010; Vol. 35, issue 3:532‐9. CalverleyPM , AndersonJA , CelliB , FergusonGT , JenkinsC , JonesPW , et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease.[see comment]. New England Journal of Medicine2007; Vol. 356, issue 8:775‐89. CalverleyPMA , AndersonJA , CelliB , FergusonGT , JenkinsC , JonesPW , et al. Cardiovascular events in patients with chronic obstructive pulmonary disease: TORCH study results. Thorax2010;65:719‐25. CalverleyPMA , AndersonJA , CelliB , FergusonGT , JenkinsC , JonesPW , et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. New England Journal of Medicine2007;356(8):775‐89. CalverleyPMA , CelliB , FergusonG , JenkinsC , JonesPW , PrideNB , et al. Baseline characteristics of the first 5,000 COPD patients enrolled in the TORCH survival study. European Respiratory Journal2003;22 Suppl 45:578s. CelliB , CalverleyPMA , AndersonJA , FergusonGT , JenkinsC , JonesPW , et al. The TORCH (TOwards a Revolution in COPD Health) study: salmeterol/fluticasone propionate (SFC) improves health status, reduces exacerbations and improves lung function over three years. European Respiratory Journal2006;28 Suppl 50:34s. CelliB , VestboJ , JenkinsCR , JonesPW , FergusonGT , CalverleyPM , et al. Sex differences in mortality and clinical expressions of patients with chronic obstructive pulmonary disease: the TORCH experience. American Journal of Respiratory and Critical Care Medicine2011;183(3):317‐22. CelliBR , ThomasNE , AndersonJA , FergusonGT , JenkinsCR , JonesPW , et al. Effect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease: results from the TORCH study. American Journal of Respiratory and Critical Care Medicine2008;174(4):332‐8. CrimC , CalverleyPM , AndersonJA , CelliB , FergusonGT , JenkinsC , et al. Pneumonia risk in COPD patients receiving inhaled corticosteroids alone or in combination: TORCH study results. European Respiratory Journal2009;34(3):641‐7. FergusonGT , CalverleyPM , AndersonJA , JenkinsCR , JonesPW , WillitsLR , et al. Prevalence and progression of osteoporosis in patients with COPD: results from the TOwards a Revolution in COPD Health study. Chest2009; Vol. 136, issue 0012‐3692:1456‐65. FergusonGT , CalverleyPMA , AndersonJA , et al. The TORCH (TOwards a Revolution in COPD Health) study: salmeterol/fluticasone propionate (SFC) improves survival in COPD over three years. European Respiratory Journal2006;28 Suppl 50:34s. GlaxoSmithKlineSCO30003 . A multicentre, randomised, double‐blind, parallel group, placebo‐controlled study to investigate the long‐term effects of salmeterol/fluticasone propionate (SERETIDE/VIANI/ADVAIR) 50/500mcg bd, salmeterol 50mcg bd and fluticasone propionate 500mcg bd, all delivered via the DISKUS/ACCUHALER inhaler, on the survival of subjects with chronic obstructive pulmonary disease (COPD) over 3 years of treatment. GlaxoSmithKline Clinical Trial Register2006. HoughtonCM , LawsonN , BorrillZL , WixonCL , YoxallS , LangleySJ , et al. Comparison of the effects of salmeterol/fluticasone propionate with fluticasone propionate on airway physiology in adults with mild persistent asthma. Respiratory Research2007;8:52. JenkinsCR , CalverleyPMA , CelliB , FergusonG , JonesPW , PrideN , et al. Seasonal patterns of exacerbation rates in the TORCH survival study, 2007. http://www.abstracts2view.comA839. JenkinsCR , CelliB , AndersonJA , FergusonGT , JonesPW , VestboJ , et al. Seasonality and determinants of moderate and severe COPD exacerbations in the TORCH study. European Respiratory Journal2012;39(1):38‐45. JenkinsCR , JonesPW , CalverleyPM , CelliB , AndersonJA , FergusonGT , et al. Efficacy of salmeterol/fluticasone propionate by GOLD stage of chronic obstructive pulmonary disease: analysis from the randomised, placebo‐controlled TORCH study. Respiratory Research2009;10:59. JohnsonM , AgustiAG , BarnesNC . Reflections on TORCH: potential mechanisms for the survival benefit of salmeterol/fluticasone propionate in COPD patients. COPD2008;5(6):369‐75. JonesPW , AndersonJA , CalverleyPM , CelliBR , FergusonGT , JenkinsC , et al. TORCH Investigators. Health status in the TORCH study of COPD: treatment efficacy and other determinants of change. Respiratory Research2011;12:71. JonesPW , CalverleyP , CelliB , FergusonG , JenkinsC , PrideN . Trans‐regional validity of the SGRQ in the TORCH survival study, 2007. http://www.abstracts2view.comA122. McGarveyLP , JohnM , AndersonJA , ZvarichMT , WiseRA . Ascertainment of cause‐specific mortality in COPD: operations of the TORCH Clinical Endpoint Committee. Thorax2007;62:411‐5. NCT00268216 . See detailed description, 2000. http://clinicaltrials.gov/show/NCT00268216. [] SCO30003 . A multicentre, randomised, double‐blind, parallel group, placebo‐controlled study to investigate the long‐term effects of salmeterol/fluticasone propionate (SERETIDE®/VIANI®/ADVAIR®) 50/500mcg bd, salmeterol 50mcg bd and fluticasone propionate 500mcg bd, all delivered via the DISKUS®/ACCUHALER® inhaler, on the survival of subjects with chronic obstructive pulmonary disease (COPD) over 3 years of treatment, 2006. www.ctr.gsk.co.uk. VestboJ , AndersonJA , CalverleyPM , CelliB , FergusonGT , JenkinsC , et al. Adherence to inhaled therapy, mortality and hospital admission in COPD. Thorax2009;64(11):939‐43. VestboJ , CalverleyP , CelliB , FergusonG , JenkinsC , JonesP , et al. The TORCH (TOwards a Revolution in COPD Health) survival study protocol. European Respiratory Journal2004;24(2):206‐10. WiseRA , McGarveyLP , JohnM , AndersonJA , ZvarichMT . Reliability of cause‐specific mortality adjudication in a COPD clinical trial, 2007. http://www.abstracts2view.comA120. ">TORCH</a>; <a href="./references#CD006826-bbs2-0014" title="CalverleyP , PauwelsR , VestboJ , JonesP , PrideN , GulsvikA , et al. Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial. Lancet2003;361(9356):449‐56. CalverleyPMA , PauwelsRA , VestboJ , JonesPW , PrideNB , GulsvikA , et al. Clinical improvements with salmeterol / fluticasone propionate combination in differing severities of COPD, 2003. http://www.abstracts2view.comA035 [Poster D50]. CalverleyPMA , PauwelsRA , VestboJ , JonesPW , PrideNB , GulsvikA , et al. Salmeterol/Fluticasone propionate combination for one year provides greater clinical benefit than its individual components. Proceedings of the 98th International American Thoracic Society Conference http://www.abstracts‐on‐line.com/abstracts/ATS; May 17‐22, 2002; Atlanta, Georgia. A98 [Poster 306]. CalverlyPMA , PauwelsR , VestboJ , JonesP , PrideN , GulsvikA , et al. Safety of salmeterol/fluticasone propionate combination in the treatment of chronic obstructive pulmonary disease. European Respiratory Journal2002;20 Suppl 38:242 [P1572]. HunjanMK , ChandlerF . Numbers needed to treat (NNT) to avoid an exacerbation in patients with chronic obstructive pulmonary disease (COPD) using salmeterol/fluticasone propionate combination (SFC) and associated costs [Abstract]. American Thoracic Society 100th International Conference; May 21‐26, 2004; Orlando, Florida. D22 [Poster 503]. HunjanMK , WilliamsDT . Costs of avoiding exacerbations in patients with chronic obstructive pulmonary disease (COPD) treated with salmeterol/ fluticasone propionate combination (seretide) and salmeterol. European Respiratory Journal2004;24 Suppl 48:291s. HunjanMK , WilliamsDT . Salmeterol/ fluticasone propionate combination is clinically effective in avoiding exacerbations in patients with moderate/severe COPD. European Respiratory Journal2004;24 Suppl 48:513s. JonesPW , EdinHM , AndersonJ . Salmeterol/fluticasone propionate combination improves health status in COPD patients. Proceedings of the 98th International American Thoracic Society Conference http://www.abstracts‐on‐line.com/abstracts/ATS; May 17‐22, 2002; Atlanta, Georgia. A39 [Poster K39]. JonesPW , StåhlE . Budesonide /formoterol sustains clinically relevant improvements in health status in COPD [Abstract]. European Respiratory Journal2005;26 Suppl 49:Abstract 1352. JonesPW , VestboJ , PauwelsRA , CalverleyPMA , AndersonJA , SpencerMD . Informative drop out in COPD studies: investigation of health status of withdrawals in the TRISTAN study. Proceedings of the 13th ERS Annual Congress; September 27, 2003; Vienna, Austria. P1593. NitschmannS . Inhalational combination therapy in chronic obstructive lung disease. Tristan study. German Internist2004;45(6):727‐8. PauwelsR , VestboJ , CalverleyPMA , JonesPW , PrideNB , GulsvikA . Characterization of exacerbations in the TRISTAN study of salmeterol / fluticasone propionate (SFC) combination in moderate to severe COPD, 2006. http://www.abstracts2view.com. PauwelsRA , CalverlyPMA , VestboJ , JonesPW , PrideN , GulsvikA , et al. Reduction of exacerbations with salmeterol/fluticasone combination 50/500 mcg bd in the treatment of chronic obstructive pulmonary disease. European Respiratory Journal2002;20 Suppl 38:240 [P1569]. SFCB3024 . A multicentre, randomised, double‐blind, parallel group, placebo‐controlled study to compare the efficacy and safety of the salmeterol/FP combination product at a strength of 50/500mcg bd with salmeterol 50mcg bd alone and FP 500mcg bd alone, delivered via the DISKUS™/ACCUHALER™, in the treatment of subjects with chronic obstructive pulmonary disease (COPD) for 12 months. GlaxoSmithKline Clinical Trials Register (http:ctr.gsk.co.uk)2005. SpencerM , BriggsAH , GrossmanRF , RanceL . Development of an economic model to assess the cost effectiveness of treatment interventions for chronic obstructive pulmonary disease. Pharmacoeconomics2005;23(6):619‐37. SpencerMD , KariaN , AndersonJ . The clinical significance of treatment benefits with the salmeterol/fluticasone propionate 50/500mcg combination in COPD. European Respiratory Journal2004;24 Suppl 48:290s. VestboJ , CalverleyPMA , PauwelsR , JonesP , PrideN , GulsvikA , et al. Absence of gender susceptibility to the combination of salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease. European Respiratory Journal2002;20 Suppl 38:240 [P1570]. VestboJ , PauwelsR , AndersonJA , JonesP , CalverleyP . Early onset of effect of salmeterol and fluticasone propionate in chronic obstructive pulmonary disease. Thorax2005;60(4):301‐4. VestboJ , PauwelsRS , CalverleyPMA , JonesPW , PrideNB , GulsvikA . Salmeterol / fluticasone propionate combination produces improvement in lung function detectable within 24 hours in moderate to severe COPD, 2003. http://www.abstracts2view.com. VestboJ , SorianoJB , AndersonJA , CalverleyP , PauwelsR , JonesP . Gender does not influence the response to the combination of salmeterol and fluticasone propionate in COPD. Respiratory Medicine2004;98(11):1045‐50. ">TRISTAN</a>); N = 3824; RR 0.89, 95% CI 0.81 to 0.98; <a href="./references#CD006826-fig-0018" title="">Analysis 2.5</a>). </p> </section> <section id="CD006826-sec-0076"> <h6 class="title">BDF versus BD</h6> <p>No studies that compared BDF versus BD reported this outcome.</p> </section> <section id="CD006826-sec-0077"> <h6 class="title">MF/F versus MF</h6> <p>A significant difference was noted between MF/F and MF with respect to the numbers of participants with moderate and severe exacerbations (2 studies (<a href="./references#CD006826-bbs2-0003" title="DohertyDE , KerwinE , TashkinDP , Matiz‐BuenoCE , ShekarT , BanerjeeS , et al. Combined mometasone furoate and formoterol in patients with moderate to very severe chronic obstructive pulmonary disease (COPD): phase 3 efficacy and safety study [Abstract]. Journal of Allergy and Clinical Immunology2012; Vol. 129, issue 2 Suppl:AB75 [283]. DohertyDE , TashkinDP , KerwinE , KnorrBA , ShekarT , BanerjeeS , et al. Effects of mometasone furoate/formoterol fumarate fixed‐dose combination formulation on chronic obstructive pulmonary disease (COPD): results from a 52‐week Phase III trial in subjects with moderate‐to‐very severe COPD. International Journal of Chronic Obstructive Pulmonary Disease2012; Vol. 7, issue 1178‐2005 (Electronic). 1176‐9106 (Linking):57‐71. NCT00383721 . A Randomized, 26‐Week, Placebo‐Controlled Efficacy and Safety Study With a 26‐Week Long‐Term Safety Extension, of High‐ and Medium‐Dose Inhaled Mometasone Furoate/Formoterol Fixed‐Dose Combination Formulation Compared With Formoterol and High‐Dose Inhaled Mometasone Furoate Monotherapy in Subjects With Moderate to Severe COPD, 2006. http://clinicaltrials.gov/show/NCT00383721. [] ">Doherty 2012</a>; <a href="./references#CD006826-bbs2-0012" title="KerwinE , TashkinDP , Matiz‐BuenoCE , DohertyDE , ShekarT , BanerjeeS , et al. Clinical efficacy and safety of combined mometasone furoate and formoterol in patients with moderate to very severe chronic obstructive pulmonary disease (COPD) [Abstract]. Journal of Allergy and Clinical Immunology2012; Vol. 129, issue 2 Suppl:AB201 [759]. NCT00383435 . A Randomized, 26‐Week, Placebo‐Controlled Efficacy and Safety Study With a 26‐Week Long‐Term Safety Extension, of High‐ and Medium‐Dose Inhaled Mometasone Furoate/Formoterol Fixed‐Dose Combination Formulation Compared With Formoterol and High‐Dose Inhaled Mometasone Furoate Monotherapy in Subjects With Moderate to Severe COPD, 2006. http://clinicaltrials.gov/show/NCT00383435. [] TashkinDP , DohertyDE , KerwinE , Matiz‐BuenoCE , KnorrB , ShekarT , et al. Efficacy and safety of a fixed‐dose combination of mometasone furoate and formoterol fumarate in subjects with moderate to very severe COPD: results from a 52‐week Phase III trial. International Journal of Chronic Obstructive Pulmonary Disease2012; Vol. 7, issue 1178‐2005 (Electronic). 1176‐9106 (Linking):43‐55. ">Tashkin 2012</a>); N = 905, OR 0.67, 95% CI 0.45 to 0.98; <a href="./references#CD006826-fig-0057" title="">Analysis 4.1</a>). </p> </section> </section> <section id="CD006826-sec-0078"> <h5 class="title">Hospitalisations due to COPD exacerbations</h5> <section id="CD006826-sec-0079"> <h6 class="title">Pooled results for FPS, BDF and MF/F versus ICS alone</h6> <p>No significant difference was described between combined LABA/ICS and ICS‐alone treatments in hospitalisations due to COPD exacerbations (10 studies: <a href="./references#CD006826-bbs2-0002" title="AstraZenecaSD . A placebo‐controlled 12‐month efficacy study of the fixed combination budesonide/formoterol compared to budesonide and formoterol as monotherapies in patients with chronic obstructive pulmonary disease (COPD). AstraZeneca Clinical Trials2002. BorgstromL , AskingL , OlssonH , PetersonS . Lack of interaction between disease severity and therapeutic response with budesonide/formoterol in a single inhaler [Abstract]. American Thoracic Society 100th International Conference; May 21‐26; 2004, Orlando, Florida. C22 [Poster 505]. CalverleyPM , BonsawatW , CsekeZ , ZhongN , PetersonS , OlssonH . Maintenance therapy with budesonide and formoterol in chronic obstructive pulmonary disease. European Respiratory Journal2003;22(6):912‐9. CalverleyPMA , CsekeZ , PetersonS . Budesonide/formoterol reduces the use of oral corticosteroids in the treatment of COPD [Abstract]. European Respiratory Journal2003;22 Suppl 45:P436. CalverleyPMA , KunaP , OlssonH . COPD exacerbations are reduced by budesonide/formoterol in a single inhaler [Abstract]. European Respiratory Journal2003;22 Suppl 45:P1587. CalverleyPMA , OlssonH , Symbicort International COPD Study Group. Budesonide/formoterol ina single inhaler sustains improvements in lung function over 12 months compared with monocomponents and placebo in patients with COPD [abstract]. American Thoracic Society 99th International Conference; May 16‐21, 2003; Seattle, Washington. B024 [Poster 418]. CalverleyPMA , PetersonS . Combining budesonide/formoterol in a single inhale reduces exacerbation frequency in COPD [abstract]. American Thoracic Society 99th International Conference; May 16‐21, 2003; Seattle, Washington. D092 [Poster 211]. CalverleyPMA , StåhlE , JonesPW . Budesonide/formoterol improves the general health status of patients with COPD [Abstract]. American Thoracic Society 2005 International Conference; May 20‐25, 2005; San Diego, California. B93 [Poster 303]. CalverleyPMA , SzafranskiW , AnderssonA . Budesonide/formoterol is a well‐tolerated long term maintenance therapy for COPD. European Respiratory Journal2005;26 Suppl 49:Poster 1917. CalverleyPMA , ThompsonNC , OlssonH . Budesonide/formoterol in a single inhaler sustains lung function improvements in COPD [Abstract]. European Respiratory Journal2003;22 Suppl 45:P435. HalpinD , StåhlE , LundbackB , AndersonF , PetersonS . Treatment costs and number needed to treat (NNT) with budesonide/formoterol to avoid one exacerbation of COPD [Abstract]. American Thoracic Society 100th International Conference; May 21‐26, 2004; Orlando, Florida. D22 [Poster 525]. HalpinDMG , LarssonT , CalverleyPMA . How many patients with COPD must be treated with budesonide/formoterol compared with formoterol alone to avoid 1 day of oral steroid use? [Abstract]. American Thoracic Society 2005 International Conference; May 20‐25, 2005; San Diego, California. B93 [Poster 314]. JonesPW , StahlE . Budesonide/formoterol in a single inhaler improves health status in patients with COPD [abstract]. American Thoracic Society 99th International Conference; May 16‐21, 2003; Orlando, Florida. B024 [Poster 419]. JonesPW , StåhlE . Budesonide /formoterol sustains clinically relevant improvements in health status in COPD [Abstract]. European Respiratory Journal2005;26 Suppl 49:Abstract 1352. JonesPW , StåhlE . Reducing exacerbations leads to a better health‐related quality of life in patients with COPD. 13th ERS Annual Congress; September 27, 2003; Vienna, Austria. P1586. LofdahlCG . Reducing the impact of COPD exacerbations: Clinical efficacy of budesonide/formoterol. European Respiratory Review2004;13(88):14‐21. LofdahlCG , AndreassonE , SvenssonK , EricssonA . Budesonide/formoterol in a single inhaler improves health status in patients with COPD without increasing healthcare costs [Abstract]. European Respiratory Journal2003;22 Suppl 45:P433. LofdahlCG , EricssonA , SvenssonK , AndreassonE . Cost effectiveness of budesonide/formoterol in a single inhaler for COPD compared with each monocomponent used alone. Pharmacoeconomics2005;23(4):365‐75. ">Calverley 2003</a>; <a href="./references#CD006826-bbs2-0003" title="DohertyDE , KerwinE , TashkinDP , Matiz‐BuenoCE , ShekarT , BanerjeeS , et al. Combined mometasone furoate and formoterol in patients with moderate to very severe chronic obstructive pulmonary disease (COPD): phase 3 efficacy and safety study [Abstract]. Journal of Allergy and Clinical Immunology2012; Vol. 129, issue 2 Suppl:AB75 [283]. DohertyDE , TashkinDP , KerwinE , KnorrBA , ShekarT , BanerjeeS , et al. Effects of mometasone furoate/formoterol fumarate fixed‐dose combination formulation on chronic obstructive pulmonary disease (COPD): results from a 52‐week Phase III trial in subjects with moderate‐to‐very severe COPD. International Journal of Chronic Obstructive Pulmonary Disease2012; Vol. 7, issue 1178‐2005 (Electronic). 1176‐9106 (Linking):57‐71. NCT00383721 . A Randomized, 26‐Week, Placebo‐Controlled Efficacy and Safety Study With a 26‐Week Long‐Term Safety Extension, of High‐ and Medium‐Dose Inhaled Mometasone Furoate/Formoterol Fixed‐Dose Combination Formulation Compared With Formoterol and High‐Dose Inhaled Mometasone Furoate Monotherapy in Subjects With Moderate to Severe COPD, 2006. http://clinicaltrials.gov/show/NCT00383721. [] ">Doherty 2012</a>; <a href="./references#CD006826-bbs2-0004" title="HananiaNA , DarkenP , HorstmanD , ReisnerC , LeeB , DavisS , et al. The efficacy and safety of fluticasone propionate (250 micro g)/salmeterol (50 micro g) combined in the diskus inhaler for the treatment of COPD. Chest2003;124(3):834‐43. HananiaNA , RamsdellJ , PayneK , DavisS , HorstmanD , LeeB , et al. Improvements in airflow and dyspnea in COPD patients following 24 weeks treatment with salmeterol 50mcg and fluticasone propionate 250mcg alone or in combination via the diskus. American Journal of Respiratory &amp; Critical Care Medicine2001;163(5 Suppl):A279. HorstmanD , DarkenP , DavisS , LeeB . Improvements in FEV1 and symptoms in poorly reversible COPD patients following treatment with salmeterol 50mcg/fluticasone propionate 250mcg combination [Abstract]. European Respiratory Journal2003;22 Suppl 45:P434. MahlerDA , DarkenP , BrownCP , KnobilK . Predicting lung function responses to combination therapy in chronic obstructive pulmonary disease (COPD) [Abstract]. National COPD Conference; November 14‐15, 2003; Arlington, Virginia. Abstract 1081. MahlerDA , DarkenP , BrownCP , KnobilK . Predicting lung function responses to salmeterol/fluticasone propionate combination therapy in COPD [Abstract]. European Respiratory Journal2003;22 Suppl 45:P429. SFCA3007 . A randomized, double‐blind, placebo‐controlled, parallel‐group trial evaluating the safety and efficacy of the DISKUS formulations of salmeterol (SAL) 50mcg BID and fluticasone propionate (FP) 250mcg BID individually and in combination as salmeterol 50mcg/fluticasone propionate 250mcg BID (SFC 50/250) compared to placebo in COPD subjects. GlaxoSmithKline Clinical Trials Register (http:ctr.gsk.co.uk)2005. SpencerM , WireP , LeeB , ChangCN , DarkenP , HorstmanD . Patients with COPD using salmeterol/fluticasone propionate combination therapy experience improved quality of life. European Respiratory Journal2003;22 Suppl 45:51s. SpencerMD , KariaN , AndersonJ . The clinical significance of treatment benefits with the salmeterol/fluticasone propionate 50/500mcg combination in COPD. European Respiratory Journal2004;24 Suppl 48:290s. ">Hanania 2003</a>; <a href="./references#CD006826-bbs2-0006" title="MahlerDA , DarkenP , BrownCP , KnobilK . Predicting lung function responses to combination therapy in chronic obstructive pulmonary disease (COPD), 2003. http://www.abstracts2view.com. MahlerDA , WireP , HorstmanD , ChangCN , YatesJ , FischerT , et al. Effectiveness of fluticasone propionate and salmeterol combination delivered via the diskus device in the treatment of chronic obstructive pulmonary disease. American Journal of Respiratory Critical Care Medicine2002;166(8):1084‐91. SFCA3006 . A randomized, double‐blind, placebo‐controlled, parallel‐group trial evaluating the safety and efficacy of the DISKUS formulations of salmeterol (SAL) 50mcg BID and fluticasone propionate (FP) 500mcg BID individually and in combination as salmeterol 50mcg/fluticasone propionate 500mcg BID (SFC 50/500) compared to placebo in COPD subjects. GlaxoSmithKline Clinical Trials Register (http:ctr.gsk.co.uk)2005. SpencerM , WireP , LeeB , ChangCN , DarkenP , HorstmanD . Patients with COPD using salmeterol/fluticasone propionate combination therapy experience improved quality of life. European Respiratory Journal2003;22 Suppl 45:51s. SpencerMD , AndersonJA . Salmeterol/fluticasone combination produces clinically important benefits in dyspnea and fatigue [Abstract]. American Thoracic Society 2005 International Conference; May 20‐25, 2005; San Diego, California. B93 [Poster 308]. SpencerMD , KariaN , AndersonJ . The clinical significance of treatment benefits with the salmeterol/fluticasone propionate 50/500mcg combination in COPD. European Respiratory Journal2004;24 Suppl 48:290s. ">Mahler 2002</a>; <a href="./references#CD006826-bbs2-0008" title="SFCT01 . A Multicentre, Randomised, Double‐Blind, Parallel Group, Placebo‐Controlled Study to Compare the Efficacy and Safety of Inhaled Salmeterol/Fluticasone Propionate Combination Product 25/250 µg Two Puffs Bd and Fluticasone Propionate 250µg Two Puffs Bd Alone, All Administered Via Metered Dose Inhalers (MDI), in the Treatment of Subjects with Chronic Obstructive Pulmonary Disease (COPD) for 52 Weeks. GlaxoSmithKline Clinical Trials Register (http:ctr.gsk.co.uk)2005. ">SFCT01</a>; <a href="./references#CD006826-bbs2-0011" title="Astrazeneca(D5899C00002) . A 6‐month double‐blind, double‐dummy, randomized, parallel group, multicenter efficacy &amp; safety study of Symbicort® pMDI 2 × 160/4.5mg &amp; 80/4.5mg bid compared to Formoterol TBH, Budesonide pMDI (&amp; the combination) &amp; placebo in COPD patients. www.astrazenecaclinicaltrials.com (accessed 8 April 2008). BleeckerER , MeyersDA , BaileyWC , SimsA‐M , BujacSR , GoldmanM , et al. ADRB2 polymorphisms and budesonide/formoterol responses in COPDADRB2 polymorphisms and treatment response in COPD. Chest2012;142(2):320‐8. TashkinDP , RennardSI , MartinP , GoldmanM , SilkoffPE . Efficacy of budesonide/formoterol administered via one pressurized metered‐dose inhaler over 6 months in patients with chronic obstructive pulmonary disease [Abstract]. Chest2008; Vol. 134, issue 4:105001s. TashkinDP , RennardSI , MartinP , RamachandranS , MartinUJ , SilkoffPE , et al. Efficacy and safety of budesonide and formoterol in one pressurized metered‐dose inhaler in patients with moderate to very severe chronic obstructive pulmonary disease : results of a 6‐month randomized clinical trial. Drugs2008; Vol. 68, issue 0012‐6667 (Print):1975‐2000. ">Tashkin 2008</a>; <a href="./references#CD006826-bbs2-0012" title="KerwinE , TashkinDP , Matiz‐BuenoCE , DohertyDE , ShekarT , BanerjeeS , et al. Clinical efficacy and safety of combined mometasone furoate and formoterol in patients with moderate to very severe chronic obstructive pulmonary disease (COPD) [Abstract]. Journal of Allergy and Clinical Immunology2012; Vol. 129, issue 2 Suppl:AB201 [759]. NCT00383435 . A Randomized, 26‐Week, Placebo‐Controlled Efficacy and Safety Study With a 26‐Week Long‐Term Safety Extension, of High‐ and Medium‐Dose Inhaled Mometasone Furoate/Formoterol Fixed‐Dose Combination Formulation Compared With Formoterol and High‐Dose Inhaled Mometasone Furoate Monotherapy in Subjects With Moderate to Severe COPD, 2006. http://clinicaltrials.gov/show/NCT00383435. [] TashkinDP , DohertyDE , KerwinE , Matiz‐BuenoCE , KnorrB , ShekarT , et al. Efficacy and safety of a fixed‐dose combination of mometasone furoate and formoterol fumarate in subjects with moderate to very severe COPD: results from a 52‐week Phase III trial. International Journal of Chronic Obstructive Pulmonary Disease2012; Vol. 7, issue 1178‐2005 (Electronic). 1176‐9106 (Linking):43‐55. ">Tashkin 2012</a>; <a href="./references#CD006826-bbs2-0013" title="BriggsAH , GlickHA , Lozano‐OrtegaG , SpencerM , CalverleyPM , JonesPW , et al. Is treatment with ICS and LABA cost‐effective for COPD? Multinational economic analysis of the TORCH study. European Respiratory Journal2010; Vol. 35, issue 3:532‐9. CalverleyPM , AndersonJA , CelliB , FergusonGT , JenkinsC , JonesPW , et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease.[see comment]. New England Journal of Medicine2007; Vol. 356, issue 8:775‐89. CalverleyPMA , AndersonJA , CelliB , FergusonGT , JenkinsC , JonesPW , et al. Cardiovascular events in patients with chronic obstructive pulmonary disease: TORCH study results. Thorax2010;65:719‐25. CalverleyPMA , AndersonJA , CelliB , FergusonGT , JenkinsC , JonesPW , et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. New England Journal of Medicine2007;356(8):775‐89. CalverleyPMA , CelliB , FergusonG , JenkinsC , JonesPW , PrideNB , et al. Baseline characteristics of the first 5,000 COPD patients enrolled in the TORCH survival study. European Respiratory Journal2003;22 Suppl 45:578s. CelliB , CalverleyPMA , AndersonJA , FergusonGT , JenkinsC , JonesPW , et al. The TORCH (TOwards a Revolution in COPD Health) study: salmeterol/fluticasone propionate (SFC) improves health status, reduces exacerbations and improves lung function over three years. European Respiratory Journal2006;28 Suppl 50:34s. CelliB , VestboJ , JenkinsCR , JonesPW , FergusonGT , CalverleyPM , et al. Sex differences in mortality and clinical expressions of patients with chronic obstructive pulmonary disease: the TORCH experience. American Journal of Respiratory and Critical Care Medicine2011;183(3):317‐22. CelliBR , ThomasNE , AndersonJA , FergusonGT , JenkinsCR , JonesPW , et al. Effect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease: results from the TORCH study. American Journal of Respiratory and Critical Care Medicine2008;174(4):332‐8. CrimC , CalverleyPM , AndersonJA , CelliB , FergusonGT , JenkinsC , et al. Pneumonia risk in COPD patients receiving inhaled corticosteroids alone or in combination: TORCH study results. European Respiratory Journal2009;34(3):641‐7. FergusonGT , CalverleyPM , AndersonJA , JenkinsCR , JonesPW , WillitsLR , et al. Prevalence and progression of osteoporosis in patients with COPD: results from the TOwards a Revolution in COPD Health study. Chest2009; Vol. 136, issue 0012‐3692:1456‐65. FergusonGT , CalverleyPMA , AndersonJA , et al. The TORCH (TOwards a Revolution in COPD Health) study: salmeterol/fluticasone propionate (SFC) improves survival in COPD over three years. European Respiratory Journal2006;28 Suppl 50:34s. GlaxoSmithKlineSCO30003 . A multicentre, randomised, double‐blind, parallel group, placebo‐controlled study to investigate the long‐term effects of salmeterol/fluticasone propionate (SERETIDE/VIANI/ADVAIR) 50/500mcg bd, salmeterol 50mcg bd and fluticasone propionate 500mcg bd, all delivered via the DISKUS/ACCUHALER inhaler, on the survival of subjects with chronic obstructive pulmonary disease (COPD) over 3 years of treatment. GlaxoSmithKline Clinical Trial Register2006. HoughtonCM , LawsonN , BorrillZL , WixonCL , YoxallS , LangleySJ , et al. Comparison of the effects of salmeterol/fluticasone propionate with fluticasone propionate on airway physiology in adults with mild persistent asthma. Respiratory Research2007;8:52. JenkinsCR , CalverleyPMA , CelliB , FergusonG , JonesPW , PrideN , et al. Seasonal patterns of exacerbation rates in the TORCH survival study, 2007. http://www.abstracts2view.comA839. JenkinsCR , CelliB , AndersonJA , FergusonGT , JonesPW , VestboJ , et al. Seasonality and determinants of moderate and severe COPD exacerbations in the TORCH study. European Respiratory Journal2012;39(1):38‐45. JenkinsCR , JonesPW , CalverleyPM , CelliB , AndersonJA , FergusonGT , et al. Efficacy of salmeterol/fluticasone propionate by GOLD stage of chronic obstructive pulmonary disease: analysis from the randomised, placebo‐controlled TORCH study. Respiratory Research2009;10:59. JohnsonM , AgustiAG , BarnesNC . Reflections on TORCH: potential mechanisms for the survival benefit of salmeterol/fluticasone propionate in COPD patients. COPD2008;5(6):369‐75. JonesPW , AndersonJA , CalverleyPM , CelliBR , FergusonGT , JenkinsC , et al. TORCH Investigators. Health status in the TORCH study of COPD: treatment efficacy and other determinants of change. Respiratory Research2011;12:71. JonesPW , CalverleyP , CelliB , FergusonG , JenkinsC , PrideN . Trans‐regional validity of the SGRQ in the TORCH survival study, 2007. http://www.abstracts2view.comA122. McGarveyLP , JohnM , AndersonJA , ZvarichMT , WiseRA . Ascertainment of cause‐specific mortality in COPD: operations of the TORCH Clinical Endpoint Committee. Thorax2007;62:411‐5. NCT00268216 . See detailed description, 2000. http://clinicaltrials.gov/show/NCT00268216. [] SCO30003 . A multicentre, randomised, double‐blind, parallel group, placebo‐controlled study to investigate the long‐term effects of salmeterol/fluticasone propionate (SERETIDE®/VIANI®/ADVAIR®) 50/500mcg bd, salmeterol 50mcg bd and fluticasone propionate 500mcg bd, all delivered via the DISKUS®/ACCUHALER® inhaler, on the survival of subjects with chronic obstructive pulmonary disease (COPD) over 3 years of treatment, 2006. www.ctr.gsk.co.uk. VestboJ , AndersonJA , CalverleyPM , CelliB , FergusonGT , JenkinsC , et al. Adherence to inhaled therapy, mortality and hospital admission in COPD. Thorax2009;64(11):939‐43. VestboJ , CalverleyP , CelliB , FergusonG , JenkinsC , JonesP , et al. The TORCH (TOwards a Revolution in COPD Health) survival study protocol. European Respiratory Journal2004;24(2):206‐10. WiseRA , McGarveyLP , JohnM , AndersonJA , ZvarichMT . Reliability of cause‐specific mortality adjudication in a COPD clinical trial, 2007. http://www.abstracts2view.comA120. ">TORCH</a>; <a href="./references#CD006826-bbs2-0014" title="CalverleyP , PauwelsR , VestboJ , JonesP , PrideN , GulsvikA , et al. Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial. Lancet2003;361(9356):449‐56. CalverleyPMA , PauwelsRA , VestboJ , JonesPW , PrideNB , GulsvikA , et al. Clinical improvements with salmeterol / fluticasone propionate combination in differing severities of COPD, 2003. http://www.abstracts2view.comA035 [Poster D50]. CalverleyPMA , PauwelsRA , VestboJ , JonesPW , PrideNB , GulsvikA , et al. Salmeterol/Fluticasone propionate combination for one year provides greater clinical benefit than its individual components. Proceedings of the 98th International American Thoracic Society Conference http://www.abstracts‐on‐line.com/abstracts/ATS; May 17‐22, 2002; Atlanta, Georgia. A98 [Poster 306]. CalverlyPMA , PauwelsR , VestboJ , JonesP , PrideN , GulsvikA , et al. Safety of salmeterol/fluticasone propionate combination in the treatment of chronic obstructive pulmonary disease. European Respiratory Journal2002;20 Suppl 38:242 [P1572]. HunjanMK , ChandlerF . Numbers needed to treat (NNT) to avoid an exacerbation in patients with chronic obstructive pulmonary disease (COPD) using salmeterol/fluticasone propionate combination (SFC) and associated costs [Abstract]. American Thoracic Society 100th International Conference; May 21‐26, 2004; Orlando, Florida. D22 [Poster 503]. HunjanMK , WilliamsDT . Costs of avoiding exacerbations in patients with chronic obstructive pulmonary disease (COPD) treated with salmeterol/ fluticasone propionate combination (seretide) and salmeterol. European Respiratory Journal2004;24 Suppl 48:291s. HunjanMK , WilliamsDT . Salmeterol/ fluticasone propionate combination is clinically effective in avoiding exacerbations in patients with moderate/severe COPD. European Respiratory Journal2004;24 Suppl 48:513s. JonesPW , EdinHM , AndersonJ . Salmeterol/fluticasone propionate combination improves health status in COPD patients. Proceedings of the 98th International American Thoracic Society Conference http://www.abstracts‐on‐line.com/abstracts/ATS; May 17‐22, 2002; Atlanta, Georgia. A39 [Poster K39]. JonesPW , StåhlE . Budesonide /formoterol sustains clinically relevant improvements in health status in COPD [Abstract]. European Respiratory Journal2005;26 Suppl 49:Abstract 1352. JonesPW , VestboJ , PauwelsRA , CalverleyPMA , AndersonJA , SpencerMD . Informative drop out in COPD studies: investigation of health status of withdrawals in the TRISTAN study. Proceedings of the 13th ERS Annual Congress; September 27, 2003; Vienna, Austria. P1593. NitschmannS . Inhalational combination therapy in chronic obstructive lung disease. Tristan study. German Internist2004;45(6):727‐8. PauwelsR , VestboJ , CalverleyPMA , JonesPW , PrideNB , GulsvikA . Characterization of exacerbations in the TRISTAN study of salmeterol / fluticasone propionate (SFC) combination in moderate to severe COPD, 2006. http://www.abstracts2view.com. PauwelsRA , CalverlyPMA , VestboJ , JonesPW , PrideN , GulsvikA , et al. Reduction of exacerbations with salmeterol/fluticasone combination 50/500 mcg bd in the treatment of chronic obstructive pulmonary disease. European Respiratory Journal2002;20 Suppl 38:240 [P1569]. SFCB3024 . A multicentre, randomised, double‐blind, parallel group, placebo‐controlled study to compare the efficacy and safety of the salmeterol/FP combination product at a strength of 50/500mcg bd with salmeterol 50mcg bd alone and FP 500mcg bd alone, delivered via the DISKUS™/ACCUHALER™, in the treatment of subjects with chronic obstructive pulmonary disease (COPD) for 12 months. GlaxoSmithKline Clinical Trials Register (http:ctr.gsk.co.uk)2005. SpencerM , BriggsAH , GrossmanRF , RanceL . Development of an economic model to assess the cost effectiveness of treatment interventions for chronic obstructive pulmonary disease. Pharmacoeconomics2005;23(6):619‐37. SpencerMD , KariaN , AndersonJ . The clinical significance of treatment benefits with the salmeterol/fluticasone propionate 50/500mcg combination in COPD. European Respiratory Journal2004;24 Suppl 48:290s. VestboJ , CalverleyPMA , PauwelsR , JonesP , PrideN , GulsvikA , et al. Absence of gender susceptibility to the combination of salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease. European Respiratory Journal2002;20 Suppl 38:240 [P1570]. VestboJ , PauwelsR , AndersonJA , JonesP , CalverleyP . Early onset of effect of salmeterol and fluticasone propionate in chronic obstructive pulmonary disease. Thorax2005;60(4):301‐4. VestboJ , PauwelsRS , CalverleyPMA , JonesPW , PrideNB , GulsvikA . Salmeterol / fluticasone propionate combination produces improvement in lung function detectable within 24 hours in moderate to severe COPD, 2003. http://www.abstracts2view.com. VestboJ , SorianoJB , AndersonJA , CalverleyP , PauwelsR , JonesP . Gender does not influence the response to the combination of salmeterol and fluticasone propionate in COPD. Respiratory Medicine2004;98(11):1045‐50. ">TRISTAN</a>; <a href="./references#CD006826-bbs2-0015" title="ZhongN , ZhengJ , WenF , YangL , ChenP , XiuQ , et al. Efficacy and safety of budesonide/formoterol via a dry powder inhaler in Chinese patients with chronic obstructive pulmonary disease. Current Medical Research and Opinion2012; Vol. 28, issue 2:257‐65. ZhongN , ZhengJ , WenF , YangL , ChenP , XiuQ , et al. Efficacy and safety of inhalation of budesonide/formoterol via turbuhaler in Chinese patients with chronic obstructive pulmonary disease [Abstract]. Chest2011; Vol. 140, issue 4:5225A. ">Zhong 2012</a>; N = 7060, OR 0.93, 95% CI 0.80 to 1.07; <a href="./references#CD006826-fig-0011" title="">Analysis 1.3</a>; <a href="#CD006826-fig-0005">Figure 5</a>). </p> <div class="figure" id="CD006826-fig-0005"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 5</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 1 All Combined Inhalers－Primary Outcomes, outcome: 1.3 Hospitalisations due to COPD exacerbations." data-id="CD006826-fig-0005" src="/cdsr/doi/10.1002/14651858.CD006826.pub2/media/CDSR/CD006826/image_n/nCD006826-AFig-FIG05.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 1 All Combined Inhalers－Primary Outcomes, outcome: 1.3 Hospitalisations due to COPD exacerbations. </p> </div> </div> </div> </section> <section id="CD006826-sec-0080"> <h6 class="title">FPS versus FP</h6> <p>Data related to this outcome were obtained from five studies for the comparison of FPS versus FP (<a href="./references#CD006826-bbs2-0004" title="HananiaNA , DarkenP , HorstmanD , ReisnerC , LeeB , DavisS , et al. The efficacy and safety of fluticasone propionate (250 micro g)/salmeterol (50 micro g) combined in the diskus inhaler for the treatment of COPD. Chest2003;124(3):834‐43. HananiaNA , RamsdellJ , PayneK , DavisS , HorstmanD , LeeB , et al. Improvements in airflow and dyspnea in COPD patients following 24 weeks treatment with salmeterol 50mcg and fluticasone propionate 250mcg alone or in combination via the diskus. American Journal of Respiratory &amp; Critical Care Medicine2001;163(5 Suppl):A279. HorstmanD , DarkenP , DavisS , LeeB . Improvements in FEV1 and symptoms in poorly reversible COPD patients following treatment with salmeterol 50mcg/fluticasone propionate 250mcg combination [Abstract]. European Respiratory Journal2003;22 Suppl 45:P434. MahlerDA , DarkenP , BrownCP , KnobilK . Predicting lung function responses to combination therapy in chronic obstructive pulmonary disease (COPD) [Abstract]. National COPD Conference; November 14‐15, 2003; Arlington, Virginia. Abstract 1081. MahlerDA , DarkenP , BrownCP , KnobilK . Predicting lung function responses to salmeterol/fluticasone propionate combination therapy in COPD [Abstract]. European Respiratory Journal2003;22 Suppl 45:P429. SFCA3007 . A randomized, double‐blind, placebo‐controlled, parallel‐group trial evaluating the safety and efficacy of the DISKUS formulations of salmeterol (SAL) 50mcg BID and fluticasone propionate (FP) 250mcg BID individually and in combination as salmeterol 50mcg/fluticasone propionate 250mcg BID (SFC 50/250) compared to placebo in COPD subjects. GlaxoSmithKline Clinical Trials Register (http:ctr.gsk.co.uk)2005. SpencerM , WireP , LeeB , ChangCN , DarkenP , HorstmanD . Patients with COPD using salmeterol/fluticasone propionate combination therapy experience improved quality of life. European Respiratory Journal2003;22 Suppl 45:51s. SpencerMD , KariaN , AndersonJ . The clinical significance of treatment benefits with the salmeterol/fluticasone propionate 50/500mcg combination in COPD. European Respiratory Journal2004;24 Suppl 48:290s. ">Hanania 2003</a>; <a href="./references#CD006826-bbs2-0006" title="MahlerDA , DarkenP , BrownCP , KnobilK . Predicting lung function responses to combination therapy in chronic obstructive pulmonary disease (COPD), 2003. http://www.abstracts2view.com. MahlerDA , WireP , HorstmanD , ChangCN , YatesJ , FischerT , et al. Effectiveness of fluticasone propionate and salmeterol combination delivered via the diskus device in the treatment of chronic obstructive pulmonary disease. American Journal of Respiratory Critical Care Medicine2002;166(8):1084‐91. SFCA3006 . A randomized, double‐blind, placebo‐controlled, parallel‐group trial evaluating the safety and efficacy of the DISKUS formulations of salmeterol (SAL) 50mcg BID and fluticasone propionate (FP) 500mcg BID individually and in combination as salmeterol 50mcg/fluticasone propionate 500mcg BID (SFC 50/500) compared to placebo in COPD subjects. GlaxoSmithKline Clinical Trials Register (http:ctr.gsk.co.uk)2005. SpencerM , WireP , LeeB , ChangCN , DarkenP , HorstmanD . Patients with COPD using salmeterol/fluticasone propionate combination therapy experience improved quality of life. European Respiratory Journal2003;22 Suppl 45:51s. SpencerMD , AndersonJA . Salmeterol/fluticasone combination produces clinically important benefits in dyspnea and fatigue [Abstract]. American Thoracic Society 2005 International Conference; May 20‐25, 2005; San Diego, California. B93 [Poster 308]. SpencerMD , KariaN , AndersonJ . The clinical significance of treatment benefits with the salmeterol/fluticasone propionate 50/500mcg combination in COPD. European Respiratory Journal2004;24 Suppl 48:290s. ">Mahler 2002</a>; <a href="./references#CD006826-bbs2-0008" title="SFCT01 . A Multicentre, Randomised, Double‐Blind, Parallel Group, Placebo‐Controlled Study to Compare the Efficacy and Safety of Inhaled Salmeterol/Fluticasone Propionate Combination Product 25/250 µg Two Puffs Bd and Fluticasone Propionate 250µg Two Puffs Bd Alone, All Administered Via Metered Dose Inhalers (MDI), in the Treatment of Subjects with Chronic Obstructive Pulmonary Disease (COPD) for 52 Weeks. GlaxoSmithKline Clinical Trials Register (http:ctr.gsk.co.uk)2005. ">SFCT01</a>; <a href="./references#CD006826-bbs2-0013" title="BriggsAH , GlickHA , Lozano‐OrtegaG , SpencerM , CalverleyPM , JonesPW , et al. Is treatment with ICS and LABA cost‐effective for COPD? Multinational economic analysis of the TORCH study. European Respiratory Journal2010; Vol. 35, issue 3:532‐9. CalverleyPM , AndersonJA , CelliB , FergusonGT , JenkinsC , JonesPW , et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease.[see comment]. New England Journal of Medicine2007; Vol. 356, issue 8:775‐89. CalverleyPMA , AndersonJA , CelliB , FergusonGT , JenkinsC , JonesPW , et al. Cardiovascular events in patients with chronic obstructive pulmonary disease: TORCH study results. Thorax2010;65:719‐25. CalverleyPMA , AndersonJA , CelliB , FergusonGT , JenkinsC , JonesPW , et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. New England Journal of Medicine2007;356(8):775‐89. CalverleyPMA , CelliB , FergusonG , JenkinsC , JonesPW , PrideNB , et al. Baseline characteristics of the first 5,000 COPD patients enrolled in the TORCH survival study. European Respiratory Journal2003;22 Suppl 45:578s. CelliB , CalverleyPMA , AndersonJA , FergusonGT , JenkinsC , JonesPW , et al. The TORCH (TOwards a Revolution in COPD Health) study: salmeterol/fluticasone propionate (SFC) improves health status, reduces exacerbations and improves lung function over three years. European Respiratory Journal2006;28 Suppl 50:34s. CelliB , VestboJ , JenkinsCR , JonesPW , FergusonGT , CalverleyPM , et al. Sex differences in mortality and clinical expressions of patients with chronic obstructive pulmonary disease: the TORCH experience. American Journal of Respiratory and Critical Care Medicine2011;183(3):317‐22. CelliBR , ThomasNE , AndersonJA , FergusonGT , JenkinsCR , JonesPW , et al. Effect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease: results from the TORCH study. American Journal of Respiratory and Critical Care Medicine2008;174(4):332‐8. CrimC , CalverleyPM , AndersonJA , CelliB , FergusonGT , JenkinsC , et al. Pneumonia risk in COPD patients receiving inhaled corticosteroids alone or in combination: TORCH study results. European Respiratory Journal2009;34(3):641‐7. FergusonGT , CalverleyPM , AndersonJA , JenkinsCR , JonesPW , WillitsLR , et al. Prevalence and progression of osteoporosis in patients with COPD: results from the TOwards a Revolution in COPD Health study. Chest2009; Vol. 136, issue 0012‐3692:1456‐65. FergusonGT , CalverleyPMA , AndersonJA , et al. The TORCH (TOwards a Revolution in COPD Health) study: salmeterol/fluticasone propionate (SFC) improves survival in COPD over three years. European Respiratory Journal2006;28 Suppl 50:34s. GlaxoSmithKlineSCO30003 . A multicentre, randomised, double‐blind, parallel group, placebo‐controlled study to investigate the long‐term effects of salmeterol/fluticasone propionate (SERETIDE/VIANI/ADVAIR) 50/500mcg bd, salmeterol 50mcg bd and fluticasone propionate 500mcg bd, all delivered via the DISKUS/ACCUHALER inhaler, on the survival of subjects with chronic obstructive pulmonary disease (COPD) over 3 years of treatment. GlaxoSmithKline Clinical Trial Register2006. HoughtonCM , LawsonN , BorrillZL , WixonCL , YoxallS , LangleySJ , et al. Comparison of the effects of salmeterol/fluticasone propionate with fluticasone propionate on airway physiology in adults with mild persistent asthma. Respiratory Research2007;8:52. JenkinsCR , CalverleyPMA , CelliB , FergusonG , JonesPW , PrideN , et al. Seasonal patterns of exacerbation rates in the TORCH survival study, 2007. http://www.abstracts2view.comA839. JenkinsCR , CelliB , AndersonJA , FergusonGT , JonesPW , VestboJ , et al. Seasonality and determinants of moderate and severe COPD exacerbations in the TORCH study. European Respiratory Journal2012;39(1):38‐45. JenkinsCR , JonesPW , CalverleyPM , CelliB , AndersonJA , FergusonGT , et al. Efficacy of salmeterol/fluticasone propionate by GOLD stage of chronic obstructive pulmonary disease: analysis from the randomised, placebo‐controlled TORCH study. Respiratory Research2009;10:59. JohnsonM , AgustiAG , BarnesNC . Reflections on TORCH: potential mechanisms for the survival benefit of salmeterol/fluticasone propionate in COPD patients. COPD2008;5(6):369‐75. JonesPW , AndersonJA , CalverleyPM , CelliBR , FergusonGT , JenkinsC , et al. TORCH Investigators. Health status in the TORCH study of COPD: treatment efficacy and other determinants of change. Respiratory Research2011;12:71. JonesPW , CalverleyP , CelliB , FergusonG , JenkinsC , PrideN . Trans‐regional validity of the SGRQ in the TORCH survival study, 2007. http://www.abstracts2view.comA122. McGarveyLP , JohnM , AndersonJA , ZvarichMT , WiseRA . Ascertainment of cause‐specific mortality in COPD: operations of the TORCH Clinical Endpoint Committee. Thorax2007;62:411‐5. NCT00268216 . See detailed description, 2000. http://clinicaltrials.gov/show/NCT00268216. [] SCO30003 . A multicentre, randomised, double‐blind, parallel group, placebo‐controlled study to investigate the long‐term effects of salmeterol/fluticasone propionate (SERETIDE®/VIANI®/ADVAIR®) 50/500mcg bd, salmeterol 50mcg bd and fluticasone propionate 500mcg bd, all delivered via the DISKUS®/ACCUHALER® inhaler, on the survival of subjects with chronic obstructive pulmonary disease (COPD) over 3 years of treatment, 2006. www.ctr.gsk.co.uk. VestboJ , AndersonJA , CalverleyPM , CelliB , FergusonGT , JenkinsC , et al. Adherence to inhaled therapy, mortality and hospital admission in COPD. Thorax2009;64(11):939‐43. VestboJ , CalverleyP , CelliB , FergusonG , JenkinsC , JonesP , et al. The TORCH (TOwards a Revolution in COPD Health) survival study protocol. European Respiratory Journal2004;24(2):206‐10. WiseRA , McGarveyLP , JohnM , AndersonJA , ZvarichMT . Reliability of cause‐specific mortality adjudication in a COPD clinical trial, 2007. http://www.abstracts2view.comA120. ">TORCH</a>; <a href="./references#CD006826-bbs2-0014" title="CalverleyP , PauwelsR , VestboJ , JonesP , PrideN , GulsvikA , et al. Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial. Lancet2003;361(9356):449‐56. CalverleyPMA , PauwelsRA , VestboJ , JonesPW , PrideNB , GulsvikA , et al. Clinical improvements with salmeterol / fluticasone propionate combination in differing severities of COPD, 2003. http://www.abstracts2view.comA035 [Poster D50]. CalverleyPMA , PauwelsRA , VestboJ , JonesPW , PrideNB , GulsvikA , et al. Salmeterol/Fluticasone propionate combination for one year provides greater clinical benefit than its individual components. Proceedings of the 98th International American Thoracic Society Conference http://www.abstracts‐on‐line.com/abstracts/ATS; May 17‐22, 2002; Atlanta, Georgia. A98 [Poster 306]. CalverlyPMA , PauwelsR , VestboJ , JonesP , PrideN , GulsvikA , et al. Safety of salmeterol/fluticasone propionate combination in the treatment of chronic obstructive pulmonary disease. European Respiratory Journal2002;20 Suppl 38:242 [P1572]. HunjanMK , ChandlerF . Numbers needed to treat (NNT) to avoid an exacerbation in patients with chronic obstructive pulmonary disease (COPD) using salmeterol/fluticasone propionate combination (SFC) and associated costs [Abstract]. American Thoracic Society 100th International Conference; May 21‐26, 2004; Orlando, Florida. D22 [Poster 503]. HunjanMK , WilliamsDT . Costs of avoiding exacerbations in patients with chronic obstructive pulmonary disease (COPD) treated with salmeterol/ fluticasone propionate combination (seretide) and salmeterol. European Respiratory Journal2004;24 Suppl 48:291s. HunjanMK , WilliamsDT . Salmeterol/ fluticasone propionate combination is clinically effective in avoiding exacerbations in patients with moderate/severe COPD. European Respiratory Journal2004;24 Suppl 48:513s. JonesPW , EdinHM , AndersonJ . Salmeterol/fluticasone propionate combination improves health status in COPD patients. Proceedings of the 98th International American Thoracic Society Conference http://www.abstracts‐on‐line.com/abstracts/ATS; May 17‐22, 2002; Atlanta, Georgia. A39 [Poster K39]. JonesPW , StåhlE . Budesonide /formoterol sustains clinically relevant improvements in health status in COPD [Abstract]. European Respiratory Journal2005;26 Suppl 49:Abstract 1352. JonesPW , VestboJ , PauwelsRA , CalverleyPMA , AndersonJA , SpencerMD . Informative drop out in COPD studies: investigation of health status of withdrawals in the TRISTAN study. Proceedings of the 13th ERS Annual Congress; September 27, 2003; Vienna, Austria. P1593. NitschmannS . Inhalational combination therapy in chronic obstructive lung disease. Tristan study. German Internist2004;45(6):727‐8. PauwelsR , VestboJ , CalverleyPMA , JonesPW , PrideNB , GulsvikA . Characterization of exacerbations in the TRISTAN study of salmeterol / fluticasone propionate (SFC) combination in moderate to severe COPD, 2006. http://www.abstracts2view.com. PauwelsRA , CalverlyPMA , VestboJ , JonesPW , PrideN , GulsvikA , et al. Reduction of exacerbations with salmeterol/fluticasone combination 50/500 mcg bd in the treatment of chronic obstructive pulmonary disease. European Respiratory Journal2002;20 Suppl 38:240 [P1569]. SFCB3024 . A multicentre, randomised, double‐blind, parallel group, placebo‐controlled study to compare the efficacy and safety of the salmeterol/FP combination product at a strength of 50/500mcg bd with salmeterol 50mcg bd alone and FP 500mcg bd alone, delivered via the DISKUS™/ACCUHALER™, in the treatment of subjects with chronic obstructive pulmonary disease (COPD) for 12 months. GlaxoSmithKline Clinical Trials Register (http:ctr.gsk.co.uk)2005. SpencerM , BriggsAH , GrossmanRF , RanceL . Development of an economic model to assess the cost effectiveness of treatment interventions for chronic obstructive pulmonary disease. Pharmacoeconomics2005;23(6):619‐37. SpencerMD , KariaN , AndersonJ . The clinical significance of treatment benefits with the salmeterol/fluticasone propionate 50/500mcg combination in COPD. European Respiratory Journal2004;24 Suppl 48:290s. VestboJ , CalverleyPMA , PauwelsR , JonesP , PrideN , GulsvikA , et al. Absence of gender susceptibility to the combination of salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease. European Respiratory Journal2002;20 Suppl 38:240 [P1570]. VestboJ , PauwelsR , AndersonJA , JonesP , CalverleyP . Early onset of effect of salmeterol and fluticasone propionate in chronic obstructive pulmonary disease. Thorax2005;60(4):301‐4. VestboJ , PauwelsRS , CalverleyPMA , JonesPW , PrideNB , GulsvikA . Salmeterol / fluticasone propionate combination produces improvement in lung function detectable within 24 hours in moderate to severe COPD, 2003. http://www.abstracts2view.com. VestboJ , SorianoJB , AndersonJA , CalverleyP , PauwelsR , JonesP . Gender does not influence the response to the combination of salmeterol and fluticasone propionate in COPD. Respiratory Medicine2004;98(11):1045‐50. ">TRISTAN</a>; N = 4799, OR 0.93, 95% CI 0.79 to 1.10), and no significant difference was noted between combined LABA/ICS and ICS alone. </p> </section> <section id="CD006826-sec-0081"> <h6 class="title">BDF versus BD</h6> <p>Three studies (<a href="./references#CD006826-bbs2-0002" title="AstraZenecaSD . A placebo‐controlled 12‐month efficacy study of the fixed combination budesonide/formoterol compared to budesonide and formoterol as monotherapies in patients with chronic obstructive pulmonary disease (COPD). AstraZeneca Clinical Trials2002. BorgstromL , AskingL , OlssonH , PetersonS . Lack of interaction between disease severity and therapeutic response with budesonide/formoterol in a single inhaler [Abstract]. American Thoracic Society 100th International Conference; May 21‐26; 2004, Orlando, Florida. C22 [Poster 505]. CalverleyPM , BonsawatW , CsekeZ , ZhongN , PetersonS , OlssonH . Maintenance therapy with budesonide and formoterol in chronic obstructive pulmonary disease. European Respiratory Journal2003;22(6):912‐9. CalverleyPMA , CsekeZ , PetersonS . Budesonide/formoterol reduces the use of oral corticosteroids in the treatment of COPD [Abstract]. European Respiratory Journal2003;22 Suppl 45:P436. CalverleyPMA , KunaP , OlssonH . COPD exacerbations are reduced by budesonide/formoterol in a single inhaler [Abstract]. European Respiratory Journal2003;22 Suppl 45:P1587. CalverleyPMA , OlssonH , Symbicort International COPD Study Group. Budesonide/formoterol ina single inhaler sustains improvements in lung function over 12 months compared with monocomponents and placebo in patients with COPD [abstract]. American Thoracic Society 99th International Conference; May 16‐21, 2003; Seattle, Washington. B024 [Poster 418]. CalverleyPMA , PetersonS . Combining budesonide/formoterol in a single inhale reduces exacerbation frequency in COPD [abstract]. American Thoracic Society 99th International Conference; May 16‐21, 2003; Seattle, Washington. D092 [Poster 211]. CalverleyPMA , StåhlE , JonesPW . Budesonide/formoterol improves the general health status of patients with COPD [Abstract]. American Thoracic Society 2005 International Conference; May 20‐25, 2005; San Diego, California. B93 [Poster 303]. CalverleyPMA , SzafranskiW , AnderssonA . Budesonide/formoterol is a well‐tolerated long term maintenance therapy for COPD. European Respiratory Journal2005;26 Suppl 49:Poster 1917. CalverleyPMA , ThompsonNC , OlssonH . Budesonide/formoterol in a single inhaler sustains lung function improvements in COPD [Abstract]. European Respiratory Journal2003;22 Suppl 45:P435. HalpinD , StåhlE , LundbackB , AndersonF , PetersonS . Treatment costs and number needed to treat (NNT) with budesonide/formoterol to avoid one exacerbation of COPD [Abstract]. American Thoracic Society 100th International Conference; May 21‐26, 2004; Orlando, Florida. D22 [Poster 525]. HalpinDMG , LarssonT , CalverleyPMA . How many patients with COPD must be treated with budesonide/formoterol compared with formoterol alone to avoid 1 day of oral steroid use? [Abstract]. American Thoracic Society 2005 International Conference; May 20‐25, 2005; San Diego, California. B93 [Poster 314]. JonesPW , StahlE . Budesonide/formoterol in a single inhaler improves health status in patients with COPD [abstract]. American Thoracic Society 99th International Conference; May 16‐21, 2003; Orlando, Florida. B024 [Poster 419]. JonesPW , StåhlE . Budesonide /formoterol sustains clinically relevant improvements in health status in COPD [Abstract]. European Respiratory Journal2005;26 Suppl 49:Abstract 1352. JonesPW , StåhlE . Reducing exacerbations leads to a better health‐related quality of life in patients with COPD. 13th ERS Annual Congress; September 27, 2003; Vienna, Austria. P1586. LofdahlCG . Reducing the impact of COPD exacerbations: Clinical efficacy of budesonide/formoterol. European Respiratory Review2004;13(88):14‐21. LofdahlCG , AndreassonE , SvenssonK , EricssonA . Budesonide/formoterol in a single inhaler improves health status in patients with COPD without increasing healthcare costs [Abstract]. European Respiratory Journal2003;22 Suppl 45:P433. LofdahlCG , EricssonA , SvenssonK , AndreassonE . Cost effectiveness of budesonide/formoterol in a single inhaler for COPD compared with each monocomponent used alone. Pharmacoeconomics2005;23(4):365‐75. ">Calverley 2003</a>; <a href="./references#CD006826-bbs2-0011" title="Astrazeneca(D5899C00002) . A 6‐month double‐blind, double‐dummy, randomized, parallel group, multicenter efficacy &amp; safety study of Symbicort® pMDI 2 × 160/4.5mg &amp; 80/4.5mg bid compared to Formoterol TBH, Budesonide pMDI (&amp; the combination) &amp; placebo in COPD patients. www.astrazenecaclinicaltrials.com (accessed 8 April 2008). BleeckerER , MeyersDA , BaileyWC , SimsA‐M , BujacSR , GoldmanM , et al. ADRB2 polymorphisms and budesonide/formoterol responses in COPDADRB2 polymorphisms and treatment response in COPD. Chest2012;142(2):320‐8. TashkinDP , RennardSI , MartinP , GoldmanM , SilkoffPE . Efficacy of budesonide/formoterol administered via one pressurized metered‐dose inhaler over 6 months in patients with chronic obstructive pulmonary disease [Abstract]. Chest2008; Vol. 134, issue 4:105001s. TashkinDP , RennardSI , MartinP , RamachandranS , MartinUJ , SilkoffPE , et al. Efficacy and safety of budesonide and formoterol in one pressurized metered‐dose inhaler in patients with moderate to very severe chronic obstructive pulmonary disease : results of a 6‐month randomized clinical trial. Drugs2008; Vol. 68, issue 0012‐6667 (Print):1975‐2000. ">Tashkin 2008</a>; <a href="./references#CD006826-bbs2-0015" title="ZhongN , ZhengJ , WenF , YangL , ChenP , XiuQ , et al. Efficacy and safety of budesonide/formoterol via a dry powder inhaler in Chinese patients with chronic obstructive pulmonary disease. Current Medical Research and Opinion2012; Vol. 28, issue 2:257‐65. ZhongN , ZhengJ , WenF , YangL , ChenP , XiuQ , et al. Efficacy and safety of inhalation of budesonide/formoterol via turbuhaler in Chinese patients with chronic obstructive pulmonary disease [Abstract]. Chest2011; Vol. 140, issue 4:5225A. ">Zhong 2012</a>) provided relevant data (N = 1371, OR 0.85, 95% CI 0.60 to 1.20), and no significant difference was described between BDF and BD in hospitalisations due to COPD exacerbations. </p> </section> <section id="CD006826-sec-0082"> <h6 class="title">MF/F versus MF</h6> <p>Similarly, the two studies comparing MF/F versus MF (<a href="./references#CD006826-bbs2-0003" title="DohertyDE , KerwinE , TashkinDP , Matiz‐BuenoCE , ShekarT , BanerjeeS , et al. Combined mometasone furoate and formoterol in patients with moderate to very severe chronic obstructive pulmonary disease (COPD): phase 3 efficacy and safety study [Abstract]. Journal of Allergy and Clinical Immunology2012; Vol. 129, issue 2 Suppl:AB75 [283]. DohertyDE , TashkinDP , KerwinE , KnorrBA , ShekarT , BanerjeeS , et al. Effects of mometasone furoate/formoterol fumarate fixed‐dose combination formulation on chronic obstructive pulmonary disease (COPD): results from a 52‐week Phase III trial in subjects with moderate‐to‐very severe COPD. International Journal of Chronic Obstructive Pulmonary Disease2012; Vol. 7, issue 1178‐2005 (Electronic). 1176‐9106 (Linking):57‐71. NCT00383721 . A Randomized, 26‐Week, Placebo‐Controlled Efficacy and Safety Study With a 26‐Week Long‐Term Safety Extension, of High‐ and Medium‐Dose Inhaled Mometasone Furoate/Formoterol Fixed‐Dose Combination Formulation Compared With Formoterol and High‐Dose Inhaled Mometasone Furoate Monotherapy in Subjects With Moderate to Severe COPD, 2006. http://clinicaltrials.gov/show/NCT00383721. [] ">Doherty 2012</a>; <a href="./references#CD006826-bbs2-0012" title="KerwinE , TashkinDP , Matiz‐BuenoCE , DohertyDE , ShekarT , BanerjeeS , et al. Clinical efficacy and safety of combined mometasone furoate and formoterol in patients with moderate to very severe chronic obstructive pulmonary disease (COPD) [Abstract]. Journal of Allergy and Clinical Immunology2012; Vol. 129, issue 2 Suppl:AB201 [759]. NCT00383435 . A Randomized, 26‐Week, Placebo‐Controlled Efficacy and Safety Study With a 26‐Week Long‐Term Safety Extension, of High‐ and Medium‐Dose Inhaled Mometasone Furoate/Formoterol Fixed‐Dose Combination Formulation Compared With Formoterol and High‐Dose Inhaled Mometasone Furoate Monotherapy in Subjects With Moderate to Severe COPD, 2006. http://clinicaltrials.gov/show/NCT00383435. [] TashkinDP , DohertyDE , KerwinE , Matiz‐BuenoCE , KnorrB , ShekarT , et al. Efficacy and safety of a fixed‐dose combination of mometasone furoate and formoterol fumarate in subjects with moderate to very severe COPD: results from a 52‐week Phase III trial. International Journal of Chronic Obstructive Pulmonary Disease2012; Vol. 7, issue 1178‐2005 (Electronic). 1176‐9106 (Linking):43‐55. ">Tashkin 2012</a>) reported no significant benefit derived from the LABA with respect to hospitalisations due to COPD exacerbations (N = 905, OR 1.46, 95% CI 0.66 to 3.21). </p> </section> </section> <section id="CD006826-sec-0083"> <h5 class="title">Mortality</h5> <section id="CD006826-sec-0084"> <h6 class="title">Pooled results for FPS, BDF and MF/F versus ICS alone</h6> <p>When data were combined for both treatments and their respective comparators, the odds of death were significantly lower after combination treatment than after mono‐component steroid (12 studies; N = 7518, OR 0.78, 95% CI 0.64 to 0.94; <a href="./references#CD006826-fig-0012" title="">Analysis 1.4</a>; <a href="#CD006826-fig-0006">Figure 6</a>). Because differing lengths of follow‐up across studies and differing event rates in the control arm hinder the calculation of pooled NNTB values, we have tabulated this for each study individually (see <a href="#CD006826-tbl-0004">Table 3</a>). The three‐year NNTB (using the baseline risk of 16% in the ICS arm of <a href="./references#CD006826-bbs2-0013" title="BriggsAH , GlickHA , Lozano‐OrtegaG , SpencerM , CalverleyPM , JonesPW , et al. Is treatment with ICS and LABA cost‐effective for COPD? Multinational economic analysis of the TORCH study. European Respiratory Journal2010; Vol. 35, issue 3:532‐9. CalverleyPM , AndersonJA , CelliB , FergusonGT , JenkinsC , JonesPW , et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease.[see comment]. New England Journal of Medicine2007; Vol. 356, issue 8:775‐89. CalverleyPMA , AndersonJA , CelliB , FergusonGT , JenkinsC , JonesPW , et al. Cardiovascular events in patients with chronic obstructive pulmonary disease: TORCH study results. Thorax2010;65:719‐25. CalverleyPMA , AndersonJA , CelliB , FergusonGT , JenkinsC , JonesPW , et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. New England Journal of Medicine2007;356(8):775‐89. CalverleyPMA , CelliB , FergusonG , JenkinsC , JonesPW , PrideNB , et al. Baseline characteristics of the first 5,000 COPD patients enrolled in the TORCH survival study. European Respiratory Journal2003;22 Suppl 45:578s. CelliB , CalverleyPMA , AndersonJA , FergusonGT , JenkinsC , JonesPW , et al. The TORCH (TOwards a Revolution in COPD Health) study: salmeterol/fluticasone propionate (SFC) improves health status, reduces exacerbations and improves lung function over three years. European Respiratory Journal2006;28 Suppl 50:34s. CelliB , VestboJ , JenkinsCR , JonesPW , FergusonGT , CalverleyPM , et al. Sex differences in mortality and clinical expressions of patients with chronic obstructive pulmonary disease: the TORCH experience. American Journal of Respiratory and Critical Care Medicine2011;183(3):317‐22. CelliBR , ThomasNE , AndersonJA , FergusonGT , JenkinsCR , JonesPW , et al. Effect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease: results from the TORCH study. American Journal of Respiratory and Critical Care Medicine2008;174(4):332‐8. CrimC , CalverleyPM , AndersonJA , CelliB , FergusonGT , JenkinsC , et al. Pneumonia risk in COPD patients receiving inhaled corticosteroids alone or in combination: TORCH study results. European Respiratory Journal2009;34(3):641‐7. FergusonGT , CalverleyPM , AndersonJA , JenkinsCR , JonesPW , WillitsLR , et al. Prevalence and progression of osteoporosis in patients with COPD: results from the TOwards a Revolution in COPD Health study. Chest2009; Vol. 136, issue 0012‐3692:1456‐65. FergusonGT , CalverleyPMA , AndersonJA , et al. The TORCH (TOwards a Revolution in COPD Health) study: salmeterol/fluticasone propionate (SFC) improves survival in COPD over three years. European Respiratory Journal2006;28 Suppl 50:34s. GlaxoSmithKlineSCO30003 . A multicentre, randomised, double‐blind, parallel group, placebo‐controlled study to investigate the long‐term effects of salmeterol/fluticasone propionate (SERETIDE/VIANI/ADVAIR) 50/500mcg bd, salmeterol 50mcg bd and fluticasone propionate 500mcg bd, all delivered via the DISKUS/ACCUHALER inhaler, on the survival of subjects with chronic obstructive pulmonary disease (COPD) over 3 years of treatment. GlaxoSmithKline Clinical Trial Register2006. HoughtonCM , LawsonN , BorrillZL , WixonCL , YoxallS , LangleySJ , et al. Comparison of the effects of salmeterol/fluticasone propionate with fluticasone propionate on airway physiology in adults with mild persistent asthma. Respiratory Research2007;8:52. JenkinsCR , CalverleyPMA , CelliB , FergusonG , JonesPW , PrideN , et al. Seasonal patterns of exacerbation rates in the TORCH survival study, 2007. http://www.abstracts2view.comA839. JenkinsCR , CelliB , AndersonJA , FergusonGT , JonesPW , VestboJ , et al. Seasonality and determinants of moderate and severe COPD exacerbations in the TORCH study. European Respiratory Journal2012;39(1):38‐45. JenkinsCR , JonesPW , CalverleyPM , CelliB , AndersonJA , FergusonGT , et al. Efficacy of salmeterol/fluticasone propionate by GOLD stage of chronic obstructive pulmonary disease: analysis from the randomised, placebo‐controlled TORCH study. Respiratory Research2009;10:59. JohnsonM , AgustiAG , BarnesNC . Reflections on TORCH: potential mechanisms for the survival benefit of salmeterol/fluticasone propionate in COPD patients. COPD2008;5(6):369‐75. JonesPW , AndersonJA , CalverleyPM , CelliBR , FergusonGT , JenkinsC , et al. TORCH Investigators. Health status in the TORCH study of COPD: treatment efficacy and other determinants of change. Respiratory Research2011;12:71. JonesPW , CalverleyP , CelliB , FergusonG , JenkinsC , PrideN . Trans‐regional validity of the SGRQ in the TORCH survival study, 2007. http://www.abstracts2view.comA122. McGarveyLP , JohnM , AndersonJA , ZvarichMT , WiseRA . Ascertainment of cause‐specific mortality in COPD: operations of the TORCH Clinical Endpoint Committee. Thorax2007;62:411‐5. NCT00268216 . See detailed description, 2000. http://clinicaltrials.gov/show/NCT00268216. [] SCO30003 . A multicentre, randomised, double‐blind, parallel group, placebo‐controlled study to investigate the long‐term effects of salmeterol/fluticasone propionate (SERETIDE®/VIANI®/ADVAIR®) 50/500mcg bd, salmeterol 50mcg bd and fluticasone propionate 500mcg bd, all delivered via the DISKUS®/ACCUHALER® inhaler, on the survival of subjects with chronic obstructive pulmonary disease (COPD) over 3 years of treatment, 2006. www.ctr.gsk.co.uk. VestboJ , AndersonJA , CalverleyPM , CelliB , FergusonGT , JenkinsC , et al. Adherence to inhaled therapy, mortality and hospital admission in COPD. Thorax2009;64(11):939‐43. VestboJ , CalverleyP , CelliB , FergusonG , JenkinsC , JonesP , et al. The TORCH (TOwards a Revolution in COPD Health) survival study protocol. European Respiratory Journal2004;24(2):206‐10. WiseRA , McGarveyLP , JohnM , AndersonJA , ZvarichMT . Reliability of cause‐specific mortality adjudication in a COPD clinical trial, 2007. http://www.abstracts2view.comA120. ">TORCH</a>) to prevent one extra death is 32 (95% CI 19 to 123). In contrast, in lower‐risk participants (using the baseline risk of 0.8% in the ICS arm of <a href="./references#CD006826-bbs2-0014" title="CalverleyP , PauwelsR , VestboJ , JonesP , PrideN , GulsvikA , et al. Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial. Lancet2003;361(9356):449‐56. CalverleyPMA , PauwelsRA , VestboJ , JonesPW , PrideNB , GulsvikA , et al. Clinical improvements with salmeterol / fluticasone propionate combination in differing severities of COPD, 2003. http://www.abstracts2view.comA035 [Poster D50]. CalverleyPMA , PauwelsRA , VestboJ , JonesPW , PrideNB , GulsvikA , et al. Salmeterol/Fluticasone propionate combination for one year provides greater clinical benefit than its individual components. Proceedings of the 98th International American Thoracic Society Conference http://www.abstracts‐on‐line.com/abstracts/ATS; May 17‐22, 2002; Atlanta, Georgia. A98 [Poster 306]. CalverlyPMA , PauwelsR , VestboJ , JonesP , PrideN , GulsvikA , et al. Safety of salmeterol/fluticasone propionate combination in the treatment of chronic obstructive pulmonary disease. European Respiratory Journal2002;20 Suppl 38:242 [P1572]. HunjanMK , ChandlerF . Numbers needed to treat (NNT) to avoid an exacerbation in patients with chronic obstructive pulmonary disease (COPD) using salmeterol/fluticasone propionate combination (SFC) and associated costs [Abstract]. American Thoracic Society 100th International Conference; May 21‐26, 2004; Orlando, Florida. D22 [Poster 503]. HunjanMK , WilliamsDT . Costs of avoiding exacerbations in patients with chronic obstructive pulmonary disease (COPD) treated with salmeterol/ fluticasone propionate combination (seretide) and salmeterol. European Respiratory Journal2004;24 Suppl 48:291s. HunjanMK , WilliamsDT . Salmeterol/ fluticasone propionate combination is clinically effective in avoiding exacerbations in patients with moderate/severe COPD. European Respiratory Journal2004;24 Suppl 48:513s. JonesPW , EdinHM , AndersonJ . Salmeterol/fluticasone propionate combination improves health status in COPD patients. Proceedings of the 98th International American Thoracic Society Conference http://www.abstracts‐on‐line.com/abstracts/ATS; May 17‐22, 2002; Atlanta, Georgia. A39 [Poster K39]. JonesPW , StåhlE . Budesonide /formoterol sustains clinically relevant improvements in health status in COPD [Abstract]. European Respiratory Journal2005;26 Suppl 49:Abstract 1352. JonesPW , VestboJ , PauwelsRA , CalverleyPMA , AndersonJA , SpencerMD . Informative drop out in COPD studies: investigation of health status of withdrawals in the TRISTAN study. Proceedings of the 13th ERS Annual Congress; September 27, 2003; Vienna, Austria. P1593. NitschmannS . Inhalational combination therapy in chronic obstructive lung disease. Tristan study. German Internist2004;45(6):727‐8. PauwelsR , VestboJ , CalverleyPMA , JonesPW , PrideNB , GulsvikA . Characterization of exacerbations in the TRISTAN study of salmeterol / fluticasone propionate (SFC) combination in moderate to severe COPD, 2006. http://www.abstracts2view.com. PauwelsRA , CalverlyPMA , VestboJ , JonesPW , PrideN , GulsvikA , et al. Reduction of exacerbations with salmeterol/fluticasone combination 50/500 mcg bd in the treatment of chronic obstructive pulmonary disease. European Respiratory Journal2002;20 Suppl 38:240 [P1569]. SFCB3024 . A multicentre, randomised, double‐blind, parallel group, placebo‐controlled study to compare the efficacy and safety of the salmeterol/FP combination product at a strength of 50/500mcg bd with salmeterol 50mcg bd alone and FP 500mcg bd alone, delivered via the DISKUS™/ACCUHALER™, in the treatment of subjects with chronic obstructive pulmonary disease (COPD) for 12 months. GlaxoSmithKline Clinical Trials Register (http:ctr.gsk.co.uk)2005. SpencerM , BriggsAH , GrossmanRF , RanceL . Development of an economic model to assess the cost effectiveness of treatment interventions for chronic obstructive pulmonary disease. Pharmacoeconomics2005;23(6):619‐37. SpencerMD , KariaN , AndersonJ . The clinical significance of treatment benefits with the salmeterol/fluticasone propionate 50/500mcg combination in COPD. European Respiratory Journal2004;24 Suppl 48:290s. VestboJ , CalverleyPMA , PauwelsR , JonesP , PrideN , GulsvikA , et al. Absence of gender susceptibility to the combination of salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease. European Respiratory Journal2002;20 Suppl 38:240 [P1570]. VestboJ , PauwelsR , AndersonJA , JonesP , CalverleyP . Early onset of effect of salmeterol and fluticasone propionate in chronic obstructive pulmonary disease. Thorax2005;60(4):301‐4. VestboJ , PauwelsRS , CalverleyPMA , JonesPW , PrideNB , GulsvikA . Salmeterol / fluticasone propionate combination produces improvement in lung function detectable within 24 hours in moderate to severe COPD, 2003. http://www.abstracts2view.com. VestboJ , SorianoJB , AndersonJA , CalverleyP , PauwelsR , JonesP . Gender does not influence the response to the combination of salmeterol and fluticasone propionate in COPD. Respiratory Medicine2004;98(11):1045‐50. ">TRISTAN</a>), the one‐year NNTB is much higher at 547 to prevent one extra death (95% CI 340 to 2100). </p> <div class="figure" id="CD006826-fig-0006"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 6</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 1 All Combined Inhalers－Primary Outcomes, outcome: 1.4 Mortality." data-id="CD006826-fig-0006" src="/cdsr/doi/10.1002/14651858.CD006826.pub2/media/CDSR/CD006826/image_n/nCD006826-AFig-FIG06.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 1 All Combined Inhalers－Primary Outcomes, outcome: 1.4 Mortality. </p> </div> </div> </div> <div class="table" id="CD006826-tbl-0004"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Rates of NNT and mortality</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b> Study ID</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b> Study duration</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b> ICS rate (%)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b> NNT *</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD006826-bbs2-0002" title="AstraZenecaSD . A placebo‐controlled 12‐month efficacy study of the fixed combination budesonide/formoterol compared to budesonide and formoterol as monotherapies in patients with chronic obstructive pulmonary disease (COPD). AstraZeneca Clinical Trials2002. BorgstromL , AskingL , OlssonH , PetersonS . Lack of interaction between disease severity and therapeutic response with budesonide/formoterol in a single inhaler [Abstract]. American Thoracic Society 100th International Conference; May 21‐26; 2004, Orlando, Florida. C22 [Poster 505]. CalverleyPM , BonsawatW , CsekeZ , ZhongN , PetersonS , OlssonH . Maintenance therapy with budesonide and formoterol in chronic obstructive pulmonary disease. European Respiratory Journal2003;22(6):912‐9. CalverleyPMA , CsekeZ , PetersonS . Budesonide/formoterol reduces the use of oral corticosteroids in the treatment of COPD [Abstract]. European Respiratory Journal2003;22 Suppl 45:P436. CalverleyPMA , KunaP , OlssonH . COPD exacerbations are reduced by budesonide/formoterol in a single inhaler [Abstract]. European Respiratory Journal2003;22 Suppl 45:P1587. CalverleyPMA , OlssonH , Symbicort International COPD Study Group. Budesonide/formoterol ina single inhaler sustains improvements in lung function over 12 months compared with monocomponents and placebo in patients with COPD [abstract]. American Thoracic Society 99th International Conference; May 16‐21, 2003; Seattle, Washington. B024 [Poster 418]. CalverleyPMA , PetersonS . Combining budesonide/formoterol in a single inhale reduces exacerbation frequency in COPD [abstract]. American Thoracic Society 99th International Conference; May 16‐21, 2003; Seattle, Washington. D092 [Poster 211]. CalverleyPMA , StåhlE , JonesPW . Budesonide/formoterol improves the general health status of patients with COPD [Abstract]. American Thoracic Society 2005 International Conference; May 20‐25, 2005; San Diego, California. B93 [Poster 303]. CalverleyPMA , SzafranskiW , AnderssonA . Budesonide/formoterol is a well‐tolerated long term maintenance therapy for COPD. European Respiratory Journal2005;26 Suppl 49:Poster 1917. CalverleyPMA , ThompsonNC , OlssonH . Budesonide/formoterol in a single inhaler sustains lung function improvements in COPD [Abstract]. European Respiratory Journal2003;22 Suppl 45:P435. HalpinD , StåhlE , LundbackB , AndersonF , PetersonS . Treatment costs and number needed to treat (NNT) with budesonide/formoterol to avoid one exacerbation of COPD [Abstract]. American Thoracic Society 100th International Conference; May 21‐26, 2004; Orlando, Florida. D22 [Poster 525]. HalpinDMG , LarssonT , CalverleyPMA . How many patients with COPD must be treated with budesonide/formoterol compared with formoterol alone to avoid 1 day of oral steroid use? [Abstract]. American Thoracic Society 2005 International Conference; May 20‐25, 2005; San Diego, California. B93 [Poster 314]. JonesPW , StahlE . Budesonide/formoterol in a single inhaler improves health status in patients with COPD [abstract]. American Thoracic Society 99th International Conference; May 16‐21, 2003; Orlando, Florida. B024 [Poster 419]. JonesPW , StåhlE . Budesonide /formoterol sustains clinically relevant improvements in health status in COPD [Abstract]. European Respiratory Journal2005;26 Suppl 49:Abstract 1352. JonesPW , StåhlE . Reducing exacerbations leads to a better health‐related quality of life in patients with COPD. 13th ERS Annual Congress; September 27, 2003; Vienna, Austria. P1586. LofdahlCG . Reducing the impact of COPD exacerbations: Clinical efficacy of budesonide/formoterol. European Respiratory Review2004;13(88):14‐21. LofdahlCG , AndreassonE , SvenssonK , EricssonA . Budesonide/formoterol in a single inhaler improves health status in patients with COPD without increasing healthcare costs [Abstract]. European Respiratory Journal2003;22 Suppl 45:P433. LofdahlCG , EricssonA , SvenssonK , AndreassonE . Cost effectiveness of budesonide/formoterol in a single inhaler for COPD compared with each monocomponent used alone. Pharmacoeconomics2005;23(4):365‐75. ">Calverley 2003</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>52 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>202 (123 to 741)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD006826-bbs2-0008" title="SFCT01 . A Multicentre, Randomised, Double‐Blind, Parallel Group, Placebo‐Controlled Study to Compare the Efficacy and Safety of Inhaled Salmeterol/Fluticasone Propionate Combination Product 25/250 µg Two Puffs Bd and Fluticasone Propionate 250µg Two Puffs Bd Alone, All Administered Via Metered Dose Inhalers (MDI), in the Treatment of Subjects with Chronic Obstructive Pulmonary Disease (COPD) for 52 Weeks. GlaxoSmithKline Clinical Trials Register (http:ctr.gsk.co.uk)2005. ">SFCT01</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>52 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD006826-bbs2-0007" title="NCT00358358 . Trial SCO104925. See detailed description, 2006. http://clinicaltrials.gov/show/NCT00358358. [] ">NCT00358358</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.38</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>195 (119 to 717)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD006826-bbs2-0004" title="HananiaNA , DarkenP , HorstmanD , ReisnerC , LeeB , DavisS , et al. The efficacy and safety of fluticasone propionate (250 micro g)/salmeterol (50 micro g) combined in the diskus inhaler for the treatment of COPD. Chest2003;124(3):834‐43. HananiaNA , RamsdellJ , PayneK , DavisS , HorstmanD , LeeB , et al. Improvements in airflow and dyspnea in COPD patients following 24 weeks treatment with salmeterol 50mcg and fluticasone propionate 250mcg alone or in combination via the diskus. American Journal of Respiratory &amp; Critical Care Medicine2001;163(5 Suppl):A279. HorstmanD , DarkenP , DavisS , LeeB . Improvements in FEV1 and symptoms in poorly reversible COPD patients following treatment with salmeterol 50mcg/fluticasone propionate 250mcg combination [Abstract]. European Respiratory Journal2003;22 Suppl 45:P434. MahlerDA , DarkenP , BrownCP , KnobilK . Predicting lung function responses to combination therapy in chronic obstructive pulmonary disease (COPD) [Abstract]. National COPD Conference; November 14‐15, 2003; Arlington, Virginia. Abstract 1081. MahlerDA , DarkenP , BrownCP , KnobilK . Predicting lung function responses to salmeterol/fluticasone propionate combination therapy in COPD [Abstract]. European Respiratory Journal2003;22 Suppl 45:P429. SFCA3007 . A randomized, double‐blind, placebo‐controlled, parallel‐group trial evaluating the safety and efficacy of the DISKUS formulations of salmeterol (SAL) 50mcg BID and fluticasone propionate (FP) 250mcg BID individually and in combination as salmeterol 50mcg/fluticasone propionate 250mcg BID (SFC 50/250) compared to placebo in COPD subjects. GlaxoSmithKline Clinical Trials Register (http:ctr.gsk.co.uk)2005. SpencerM , WireP , LeeB , ChangCN , DarkenP , HorstmanD . Patients with COPD using salmeterol/fluticasone propionate combination therapy experience improved quality of life. European Respiratory Journal2003;22 Suppl 45:51s. SpencerMD , KariaN , AndersonJ . The clinical significance of treatment benefits with the salmeterol/fluticasone propionate 50/500mcg combination in COPD. European Respiratory Journal2004;24 Suppl 48:290s. ">Hanania 2003</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD006826-bbs2-0006" title="MahlerDA , DarkenP , BrownCP , KnobilK . Predicting lung function responses to combination therapy in chronic obstructive pulmonary disease (COPD), 2003. http://www.abstracts2view.com. MahlerDA , WireP , HorstmanD , ChangCN , YatesJ , FischerT , et al. Effectiveness of fluticasone propionate and salmeterol combination delivered via the diskus device in the treatment of chronic obstructive pulmonary disease. American Journal of Respiratory Critical Care Medicine2002;166(8):1084‐91. SFCA3006 . A randomized, double‐blind, placebo‐controlled, parallel‐group trial evaluating the safety and efficacy of the DISKUS formulations of salmeterol (SAL) 50mcg BID and fluticasone propionate (FP) 500mcg BID individually and in combination as salmeterol 50mcg/fluticasone propionate 500mcg BID (SFC 50/500) compared to placebo in COPD subjects. GlaxoSmithKline Clinical Trials Register (http:ctr.gsk.co.uk)2005. SpencerM , WireP , LeeB , ChangCN , DarkenP , HorstmanD . Patients with COPD using salmeterol/fluticasone propionate combination therapy experience improved quality of life. European Respiratory Journal2003;22 Suppl 45:51s. SpencerMD , AndersonJA . Salmeterol/fluticasone combination produces clinically important benefits in dyspnea and fatigue [Abstract]. American Thoracic Society 2005 International Conference; May 20‐25, 2005; San Diego, California. B93 [Poster 308]. SpencerMD , KariaN , AndersonJ . The clinical significance of treatment benefits with the salmeterol/fluticasone propionate 50/500mcg combination in COPD. European Respiratory Journal2004;24 Suppl 48:290s. ">Mahler 2002</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD006826-bbs2-0015" title="ZhongN , ZhengJ , WenF , YangL , ChenP , XiuQ , et al. Efficacy and safety of budesonide/formoterol via a dry powder inhaler in Chinese patients with chronic obstructive pulmonary disease. Current Medical Research and Opinion2012; Vol. 28, issue 2:257‐65. ZhongN , ZhengJ , WenF , YangL , ChenP , XiuQ , et al. Efficacy and safety of inhalation of budesonide/formoterol via turbuhaler in Chinese patients with chronic obstructive pulmonary disease [Abstract]. Chest2011; Vol. 140, issue 4:5225A. ">Zhong 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD006826-bbs2-0010" title="AndersonP . Budesonide/formoterol in a single inhaler (Symbicort) provides early and sustained improvement in lung function in moderate to severe COPD [Abstract]. Thorax2002;57(Suppl III):iii43. AstraZenecaSD . A placebo‐controlled 12 month efficacy study of the fixed combination budesonide/formoterol compared with budesonide and formoterol as monotherapies in patients with chronic obstructive pulmonary disease (COPD). AstraZeneca Clinical Trials2001. BorgstromL , AskingL , OlssonH , PetersonS . Lack of interaction between disease severity and therapeutic response with budesonide/formoterol in a single inhaler [Abstract]. American Thoracic Society 100th International Conference; May 21‐26, 2004; Orlando, Florida. C22 [Poster 505]. CalverleyP , PauwelsR , LofdahlCG , SvenssonK , HigenbottamT , et al. Relationship between respiratory symptoms and medical treatment in exacerbations of COPD. European Respiratory Journal2005;26(3):406‐13. CalverleyPMA . Effect of budesonide/formoterol on severe exacerbations and lung function in moderate to severe COPD. Thorax. BTS Winter Meeting 2002:S145. CalverleyPMA , SzafranskiW , AnderssonA . Budesonide/formoterol is a well‐tolerated long term maintenance therapy for COPD. European Respiratory Journal2005;26 Suppl 49:Poster 1917. CalverleyPMA , ThompsonNC , OlssonH . Budesonide/formoterol in a single inhaler sustains lung function improvements in COPD [Abstract]. European Respiratory Journal2003;22 Suppl 45:P435. CampbellLM , SzafranskiW . Budesonide/formoterol in a single inhaler (Symbicort) provides sustained relief from symptoms in moderate to severe COPD. Thorax. BTS Winter Meeting 2002:S143. CampellLW , SzafranskiW . Budesonide/Formoterol in a single inhaler (Symbicort) reduces severe exacerbations in patients with moderate‐severe COPD. Thorax. BTS Winter Meeting 2002:S141. DahlR , CukierA , OlssonH . Budesonide/formoterol in a single inhaler reduces severe and mild exacerbations in patients with moderate to severe COPD. European Respiratory Journal2002;20 Suppl 38:242 [P1575]. EgedeF , MengaG . Budesonide/formoterol in a single inhaler provides sustained relief from symptoms and night‐time awakenings in moderate‐severe COPD: results from symptoms and night‐time awakenings in moderate to severe COPD: results from a 1‐year study. European Respiratory Journal2002;20 Suppl 38:242 [P1574]. HalpinD , StahlE , LundbackB , AndersonF , PetersonS . Treatment costs and number needed to treat (NNT) with budesonide/formoterol to avoid one exacerbation of COPD [Abstract]. American Thoracic Society 100th International Conference; May 21‐26, 2004; Orlando, Florida. D22 [Poster 525]. JonesPW , StahlE , SvenssonK . Improvement in health status in patients with moderate to severe COPD after treatment with budesonide/formoterol in a single inhaler. European Respiratory Journal2002;20 Suppl 38:250 [P1613]. KorsgaardJ , SansoresR . Budesonide/formoterol (single inhaler) provides sustained relief from shortness of breath and chest tightness in a 1‐year study of patients with moderate to severe COPD. European Respiratory Journal2002;20 Suppl 38:242 [P1577]. LangeP , SaenzC . Budesonide/formoterol in a single inhaler is well tolerated in patients with moderate to severe COPD: results of a 1 year study. European Respiratory Journal2002;20 Suppl 38:242 [P1573]. LofdahlCG . Reducing the impact of COPD exacerbations: clinical efficacy of budesonide/formoterol. European Respiratory Review2004;13(88):14‐21. MilanowskiJ , NahabedianS . Budesonide/formoterol in a single inhaler acts rapidly to improve lung function and relieve symptoms in patients with moderate to severe COPD. European Respiratory Journal2002;20 Suppl 38:242 [P1576]. SzafranskiW , CukierA , RamirezA , MengaG , SansoresR , NahabedianS , et al. Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease. European Respiratory Journal2003;21(1):74‐81. ">Szafranski 2003</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>52 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>186 (113 to 683)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD006826-bbs2-0013" title="BriggsAH , GlickHA , Lozano‐OrtegaG , SpencerM , CalverleyPM , JonesPW , et al. Is treatment with ICS and LABA cost‐effective for COPD? Multinational economic analysis of the TORCH study. European Respiratory Journal2010; Vol. 35, issue 3:532‐9. CalverleyPM , AndersonJA , CelliB , FergusonGT , JenkinsC , JonesPW , et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease.[see comment]. New England Journal of Medicine2007; Vol. 356, issue 8:775‐89. CalverleyPMA , AndersonJA , CelliB , FergusonGT , JenkinsC , JonesPW , et al. Cardiovascular events in patients with chronic obstructive pulmonary disease: TORCH study results. Thorax2010;65:719‐25. CalverleyPMA , AndersonJA , CelliB , FergusonGT , JenkinsC , JonesPW , et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. New England Journal of Medicine2007;356(8):775‐89. CalverleyPMA , CelliB , FergusonG , JenkinsC , JonesPW , PrideNB , et al. Baseline characteristics of the first 5,000 COPD patients enrolled in the TORCH survival study. European Respiratory Journal2003;22 Suppl 45:578s. CelliB , CalverleyPMA , AndersonJA , FergusonGT , JenkinsC , JonesPW , et al. The TORCH (TOwards a Revolution in COPD Health) study: salmeterol/fluticasone propionate (SFC) improves health status, reduces exacerbations and improves lung function over three years. European Respiratory Journal2006;28 Suppl 50:34s. CelliB , VestboJ , JenkinsCR , JonesPW , FergusonGT , CalverleyPM , et al. Sex differences in mortality and clinical expressions of patients with chronic obstructive pulmonary disease: the TORCH experience. American Journal of Respiratory and Critical Care Medicine2011;183(3):317‐22. CelliBR , ThomasNE , AndersonJA , FergusonGT , JenkinsCR , JonesPW , et al. Effect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease: results from the TORCH study. American Journal of Respiratory and Critical Care Medicine2008;174(4):332‐8. CrimC , CalverleyPM , AndersonJA , CelliB , FergusonGT , JenkinsC , et al. Pneumonia risk in COPD patients receiving inhaled corticosteroids alone or in combination: TORCH study results. European Respiratory Journal2009;34(3):641‐7. FergusonGT , CalverleyPM , AndersonJA , JenkinsCR , JonesPW , WillitsLR , et al. Prevalence and progression of osteoporosis in patients with COPD: results from the TOwards a Revolution in COPD Health study. Chest2009; Vol. 136, issue 0012‐3692:1456‐65. FergusonGT , CalverleyPMA , AndersonJA , et al. The TORCH (TOwards a Revolution in COPD Health) study: salmeterol/fluticasone propionate (SFC) improves survival in COPD over three years. European Respiratory Journal2006;28 Suppl 50:34s. GlaxoSmithKlineSCO30003 . A multicentre, randomised, double‐blind, parallel group, placebo‐controlled study to investigate the long‐term effects of salmeterol/fluticasone propionate (SERETIDE/VIANI/ADVAIR) 50/500mcg bd, salmeterol 50mcg bd and fluticasone propionate 500mcg bd, all delivered via the DISKUS/ACCUHALER inhaler, on the survival of subjects with chronic obstructive pulmonary disease (COPD) over 3 years of treatment. GlaxoSmithKline Clinical Trial Register2006. HoughtonCM , LawsonN , BorrillZL , WixonCL , YoxallS , LangleySJ , et al. Comparison of the effects of salmeterol/fluticasone propionate with fluticasone propionate on airway physiology in adults with mild persistent asthma. Respiratory Research2007;8:52. JenkinsCR , CalverleyPMA , CelliB , FergusonG , JonesPW , PrideN , et al. Seasonal patterns of exacerbation rates in the TORCH survival study, 2007. http://www.abstracts2view.comA839. JenkinsCR , CelliB , AndersonJA , FergusonGT , JonesPW , VestboJ , et al. Seasonality and determinants of moderate and severe COPD exacerbations in the TORCH study. European Respiratory Journal2012;39(1):38‐45. JenkinsCR , JonesPW , CalverleyPM , CelliB , AndersonJA , FergusonGT , et al. Efficacy of salmeterol/fluticasone propionate by GOLD stage of chronic obstructive pulmonary disease: analysis from the randomised, placebo‐controlled TORCH study. Respiratory Research2009;10:59. JohnsonM , AgustiAG , BarnesNC . Reflections on TORCH: potential mechanisms for the survival benefit of salmeterol/fluticasone propionate in COPD patients. COPD2008;5(6):369‐75. JonesPW , AndersonJA , CalverleyPM , CelliBR , FergusonGT , JenkinsC , et al. TORCH Investigators. Health status in the TORCH study of COPD: treatment efficacy and other determinants of change. Respiratory Research2011;12:71. JonesPW , CalverleyP , CelliB , FergusonG , JenkinsC , PrideN . Trans‐regional validity of the SGRQ in the TORCH survival study, 2007. http://www.abstracts2view.comA122. McGarveyLP , JohnM , AndersonJA , ZvarichMT , WiseRA . Ascertainment of cause‐specific mortality in COPD: operations of the TORCH Clinical Endpoint Committee. Thorax2007;62:411‐5. NCT00268216 . See detailed description, 2000. http://clinicaltrials.gov/show/NCT00268216. [] SCO30003 . A multicentre, randomised, double‐blind, parallel group, placebo‐controlled study to investigate the long‐term effects of salmeterol/fluticasone propionate (SERETIDE®/VIANI®/ADVAIR®) 50/500mcg bd, salmeterol 50mcg bd and fluticasone propionate 500mcg bd, all delivered via the DISKUS®/ACCUHALER® inhaler, on the survival of subjects with chronic obstructive pulmonary disease (COPD) over 3 years of treatment, 2006. www.ctr.gsk.co.uk. VestboJ , AndersonJA , CalverleyPM , CelliB , FergusonGT , JenkinsC , et al. Adherence to inhaled therapy, mortality and hospital admission in COPD. Thorax2009;64(11):939‐43. VestboJ , CalverleyP , CelliB , FergusonG , JenkinsC , JonesP , et al. The TORCH (TOwards a Revolution in COPD Health) survival study protocol. European Respiratory Journal2004;24(2):206‐10. WiseRA , McGarveyLP , JohnM , AndersonJA , ZvarichMT . Reliability of cause‐specific mortality adjudication in a COPD clinical trial, 2007. http://www.abstracts2view.comA120. ">TORCH</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>156 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>33 (20 to 123)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD006826-bbs2-0003" title="DohertyDE , KerwinE , TashkinDP , Matiz‐BuenoCE , ShekarT , BanerjeeS , et al. Combined mometasone furoate and formoterol in patients with moderate to very severe chronic obstructive pulmonary disease (COPD): phase 3 efficacy and safety study [Abstract]. Journal of Allergy and Clinical Immunology2012; Vol. 129, issue 2 Suppl:AB75 [283]. DohertyDE , TashkinDP , KerwinE , KnorrBA , ShekarT , BanerjeeS , et al. Effects of mometasone furoate/formoterol fumarate fixed‐dose combination formulation on chronic obstructive pulmonary disease (COPD): results from a 52‐week Phase III trial in subjects with moderate‐to‐very severe COPD. International Journal of Chronic Obstructive Pulmonary Disease2012; Vol. 7, issue 1178‐2005 (Electronic). 1176‐9106 (Linking):57‐71. NCT00383721 . A Randomized, 26‐Week, Placebo‐Controlled Efficacy and Safety Study With a 26‐Week Long‐Term Safety Extension, of High‐ and Medium‐Dose Inhaled Mometasone Furoate/Formoterol Fixed‐Dose Combination Formulation Compared With Formoterol and High‐Dose Inhaled Mometasone Furoate Monotherapy in Subjects With Moderate to Severe COPD, 2006. http://clinicaltrials.gov/show/NCT00383721. [] ">Doherty 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>52 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>386 (236 to 1417)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD006826-bbs2-0014" title="CalverleyP , PauwelsR , VestboJ , JonesP , PrideN , GulsvikA , et al. Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial. Lancet2003;361(9356):449‐56. CalverleyPMA , PauwelsRA , VestboJ , JonesPW , PrideNB , GulsvikA , et al. Clinical improvements with salmeterol / fluticasone propionate combination in differing severities of COPD, 2003. http://www.abstracts2view.comA035 [Poster D50]. CalverleyPMA , PauwelsRA , VestboJ , JonesPW , PrideNB , GulsvikA , et al. Salmeterol/Fluticasone propionate combination for one year provides greater clinical benefit than its individual components. Proceedings of the 98th International American Thoracic Society Conference http://www.abstracts‐on‐line.com/abstracts/ATS; May 17‐22, 2002; Atlanta, Georgia. A98 [Poster 306]. CalverlyPMA , PauwelsR , VestboJ , JonesP , PrideN , GulsvikA , et al. Safety of salmeterol/fluticasone propionate combination in the treatment of chronic obstructive pulmonary disease. European Respiratory Journal2002;20 Suppl 38:242 [P1572]. HunjanMK , ChandlerF . Numbers needed to treat (NNT) to avoid an exacerbation in patients with chronic obstructive pulmonary disease (COPD) using salmeterol/fluticasone propionate combination (SFC) and associated costs [Abstract]. American Thoracic Society 100th International Conference; May 21‐26, 2004; Orlando, Florida. D22 [Poster 503]. HunjanMK , WilliamsDT . Costs of avoiding exacerbations in patients with chronic obstructive pulmonary disease (COPD) treated with salmeterol/ fluticasone propionate combination (seretide) and salmeterol. European Respiratory Journal2004;24 Suppl 48:291s. HunjanMK , WilliamsDT . Salmeterol/ fluticasone propionate combination is clinically effective in avoiding exacerbations in patients with moderate/severe COPD. European Respiratory Journal2004;24 Suppl 48:513s. JonesPW , EdinHM , AndersonJ . Salmeterol/fluticasone propionate combination improves health status in COPD patients. Proceedings of the 98th International American Thoracic Society Conference http://www.abstracts‐on‐line.com/abstracts/ATS; May 17‐22, 2002; Atlanta, Georgia. A39 [Poster K39]. JonesPW , StåhlE . Budesonide /formoterol sustains clinically relevant improvements in health status in COPD [Abstract]. European Respiratory Journal2005;26 Suppl 49:Abstract 1352. JonesPW , VestboJ , PauwelsRA , CalverleyPMA , AndersonJA , SpencerMD . Informative drop out in COPD studies: investigation of health status of withdrawals in the TRISTAN study. Proceedings of the 13th ERS Annual Congress; September 27, 2003; Vienna, Austria. P1593. NitschmannS . Inhalational combination therapy in chronic obstructive lung disease. Tristan study. German Internist2004;45(6):727‐8. PauwelsR , VestboJ , CalverleyPMA , JonesPW , PrideNB , GulsvikA . Characterization of exacerbations in the TRISTAN study of salmeterol / fluticasone propionate (SFC) combination in moderate to severe COPD, 2006. http://www.abstracts2view.com. PauwelsRA , CalverlyPMA , VestboJ , JonesPW , PrideN , GulsvikA , et al. Reduction of exacerbations with salmeterol/fluticasone combination 50/500 mcg bd in the treatment of chronic obstructive pulmonary disease. European Respiratory Journal2002;20 Suppl 38:240 [P1569]. SFCB3024 . A multicentre, randomised, double‐blind, parallel group, placebo‐controlled study to compare the efficacy and safety of the salmeterol/FP combination product at a strength of 50/500mcg bd with salmeterol 50mcg bd alone and FP 500mcg bd alone, delivered via the DISKUS™/ACCUHALER™, in the treatment of subjects with chronic obstructive pulmonary disease (COPD) for 12 months. GlaxoSmithKline Clinical Trials Register (http:ctr.gsk.co.uk)2005. SpencerM , BriggsAH , GrossmanRF , RanceL . Development of an economic model to assess the cost effectiveness of treatment interventions for chronic obstructive pulmonary disease. Pharmacoeconomics2005;23(6):619‐37. SpencerMD , KariaN , AndersonJ . The clinical significance of treatment benefits with the salmeterol/fluticasone propionate 50/500mcg combination in COPD. European Respiratory Journal2004;24 Suppl 48:290s. VestboJ , CalverleyPMA , PauwelsR , JonesP , PrideN , GulsvikA , et al. Absence of gender susceptibility to the combination of salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease. European Respiratory Journal2002;20 Suppl 38:240 [P1570]. VestboJ , PauwelsR , AndersonJA , JonesP , CalverleyP . Early onset of effect of salmeterol and fluticasone propionate in chronic obstructive pulmonary disease. Thorax2005;60(4):301‐4. VestboJ , PauwelsRS , CalverleyPMA , JonesPW , PrideNB , GulsvikA . Salmeterol / fluticasone propionate combination produces improvement in lung function detectable within 24 hours in moderate to severe COPD, 2003. http://www.abstracts2view.com. VestboJ , SorianoJB , AndersonJA , CalverleyP , PauwelsR , JonesP . Gender does not influence the response to the combination of salmeterol and fluticasone propionate in COPD. Respiratory Medicine2004;98(11):1045‐50. ">TRISTAN</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>52 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>572 (350 to 2100)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD006826-bbs2-0011" title="Astrazeneca(D5899C00002) . A 6‐month double‐blind, double‐dummy, randomized, parallel group, multicenter efficacy &amp; safety study of Symbicort® pMDI 2 × 160/4.5mg &amp; 80/4.5mg bid compared to Formoterol TBH, Budesonide pMDI (&amp; the combination) &amp; placebo in COPD patients. www.astrazenecaclinicaltrials.com (accessed 8 April 2008). BleeckerER , MeyersDA , BaileyWC , SimsA‐M , BujacSR , GoldmanM , et al. ADRB2 polymorphisms and budesonide/formoterol responses in COPDADRB2 polymorphisms and treatment response in COPD. Chest2012;142(2):320‐8. TashkinDP , RennardSI , MartinP , GoldmanM , SilkoffPE . Efficacy of budesonide/formoterol administered via one pressurized metered‐dose inhaler over 6 months in patients with chronic obstructive pulmonary disease [Abstract]. Chest2008; Vol. 134, issue 4:105001s. TashkinDP , RennardSI , MartinP , RamachandranS , MartinUJ , SilkoffPE , et al. Efficacy and safety of budesonide and formoterol in one pressurized metered‐dose inhaler in patients with moderate to very severe chronic obstructive pulmonary disease : results of a 6‐month randomized clinical trial. Drugs2008; Vol. 68, issue 0012‐6667 (Print):1975‐2000. ">Tashkin 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.73</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>627 (383 to 2299)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD006826-bbs2-0012" title="KerwinE , TashkinDP , Matiz‐BuenoCE , DohertyDE , ShekarT , BanerjeeS , et al. Clinical efficacy and safety of combined mometasone furoate and formoterol in patients with moderate to very severe chronic obstructive pulmonary disease (COPD) [Abstract]. Journal of Allergy and Clinical Immunology2012; Vol. 129, issue 2 Suppl:AB201 [759]. NCT00383435 . A Randomized, 26‐Week, Placebo‐Controlled Efficacy and Safety Study With a 26‐Week Long‐Term Safety Extension, of High‐ and Medium‐Dose Inhaled Mometasone Furoate/Formoterol Fixed‐Dose Combination Formulation Compared With Formoterol and High‐Dose Inhaled Mometasone Furoate Monotherapy in Subjects With Moderate to Severe COPD, 2006. http://clinicaltrials.gov/show/NCT00383435. [] TashkinDP , DohertyDE , KerwinE , Matiz‐BuenoCE , KnorrB , ShekarT , et al. Efficacy and safety of a fixed‐dose combination of mometasone furoate and formoterol fumarate in subjects with moderate to very severe COPD: results from a 52‐week Phase III trial. International Journal of Chronic Obstructive Pulmonary Disease2012; Vol. 7, issue 1178‐2005 (Electronic). 1176‐9106 (Linking):43‐55. ">Tashkin 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.43</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>322 (197 to 1182)</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>*Number needed to treat to prevent one death.</p> </div> </div> </section> <section id="CD006826-sec-0085"> <h6 class="title">FPS versus FP</h6> <p>Trials varied in length from 12 to 156 weeks. Compared with FP, a significant reduction was noted in the odds of death at the end of treatment (6 studies; <a href="./references#CD006826-bbs2-0004" title="HananiaNA , DarkenP , HorstmanD , ReisnerC , LeeB , DavisS , et al. The efficacy and safety of fluticasone propionate (250 micro g)/salmeterol (50 micro g) combined in the diskus inhaler for the treatment of COPD. Chest2003;124(3):834‐43. HananiaNA , RamsdellJ , PayneK , DavisS , HorstmanD , LeeB , et al. Improvements in airflow and dyspnea in COPD patients following 24 weeks treatment with salmeterol 50mcg and fluticasone propionate 250mcg alone or in combination via the diskus. American Journal of Respiratory &amp; Critical Care Medicine2001;163(5 Suppl):A279. HorstmanD , DarkenP , DavisS , LeeB . Improvements in FEV1 and symptoms in poorly reversible COPD patients following treatment with salmeterol 50mcg/fluticasone propionate 250mcg combination [Abstract]. European Respiratory Journal2003;22 Suppl 45:P434. MahlerDA , DarkenP , BrownCP , KnobilK . Predicting lung function responses to combination therapy in chronic obstructive pulmonary disease (COPD) [Abstract]. National COPD Conference; November 14‐15, 2003; Arlington, Virginia. Abstract 1081. MahlerDA , DarkenP , BrownCP , KnobilK . Predicting lung function responses to salmeterol/fluticasone propionate combination therapy in COPD [Abstract]. European Respiratory Journal2003;22 Suppl 45:P429. SFCA3007 . A randomized, double‐blind, placebo‐controlled, parallel‐group trial evaluating the safety and efficacy of the DISKUS formulations of salmeterol (SAL) 50mcg BID and fluticasone propionate (FP) 250mcg BID individually and in combination as salmeterol 50mcg/fluticasone propionate 250mcg BID (SFC 50/250) compared to placebo in COPD subjects. GlaxoSmithKline Clinical Trials Register (http:ctr.gsk.co.uk)2005. SpencerM , WireP , LeeB , ChangCN , DarkenP , HorstmanD . Patients with COPD using salmeterol/fluticasone propionate combination therapy experience improved quality of life. European Respiratory Journal2003;22 Suppl 45:51s. SpencerMD , KariaN , AndersonJ . The clinical significance of treatment benefits with the salmeterol/fluticasone propionate 50/500mcg combination in COPD. European Respiratory Journal2004;24 Suppl 48:290s. ">Hanania 2003</a>; <a href="./references#CD006826-bbs2-0006" title="MahlerDA , DarkenP , BrownCP , KnobilK . Predicting lung function responses to combination therapy in chronic obstructive pulmonary disease (COPD), 2003. http://www.abstracts2view.com. MahlerDA , WireP , HorstmanD , ChangCN , YatesJ , FischerT , et al. Effectiveness of fluticasone propionate and salmeterol combination delivered via the diskus device in the treatment of chronic obstructive pulmonary disease. American Journal of Respiratory Critical Care Medicine2002;166(8):1084‐91. SFCA3006 . A randomized, double‐blind, placebo‐controlled, parallel‐group trial evaluating the safety and efficacy of the DISKUS formulations of salmeterol (SAL) 50mcg BID and fluticasone propionate (FP) 500mcg BID individually and in combination as salmeterol 50mcg/fluticasone propionate 500mcg BID (SFC 50/500) compared to placebo in COPD subjects. GlaxoSmithKline Clinical Trials Register (http:ctr.gsk.co.uk)2005. SpencerM , WireP , LeeB , ChangCN , DarkenP , HorstmanD . Patients with COPD using salmeterol/fluticasone propionate combination therapy experience improved quality of life. European Respiratory Journal2003;22 Suppl 45:51s. SpencerMD , AndersonJA . Salmeterol/fluticasone combination produces clinically important benefits in dyspnea and fatigue [Abstract]. American Thoracic Society 2005 International Conference; May 20‐25, 2005; San Diego, California. B93 [Poster 308]. SpencerMD , KariaN , AndersonJ . The clinical significance of treatment benefits with the salmeterol/fluticasone propionate 50/500mcg combination in COPD. European Respiratory Journal2004;24 Suppl 48:290s. ">Mahler 2002</a>; <a href="./references#CD006826-bbs2-0007" title="NCT00358358 . Trial SCO104925. See detailed description, 2006. http://clinicaltrials.gov/show/NCT00358358. [] ">NCT00358358</a>; <a href="./references#CD006826-bbs2-0008" title="SFCT01 . A Multicentre, Randomised, Double‐Blind, Parallel Group, Placebo‐Controlled Study to Compare the Efficacy and Safety of Inhaled Salmeterol/Fluticasone Propionate Combination Product 25/250 µg Two Puffs Bd and Fluticasone Propionate 250µg Two Puffs Bd Alone, All Administered Via Metered Dose Inhalers (MDI), in the Treatment of Subjects with Chronic Obstructive Pulmonary Disease (COPD) for 52 Weeks. GlaxoSmithKline Clinical Trials Register (http:ctr.gsk.co.uk)2005. ">SFCT01</a>; <a href="./references#CD006826-bbs2-0013" title="BriggsAH , GlickHA , Lozano‐OrtegaG , SpencerM , CalverleyPM , JonesPW , et al. Is treatment with ICS and LABA cost‐effective for COPD? Multinational economic analysis of the TORCH study. European Respiratory Journal2010; Vol. 35, issue 3:532‐9. CalverleyPM , AndersonJA , CelliB , FergusonGT , JenkinsC , JonesPW , et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease.[see comment]. New England Journal of Medicine2007; Vol. 356, issue 8:775‐89. CalverleyPMA , AndersonJA , CelliB , FergusonGT , JenkinsC , JonesPW , et al. Cardiovascular events in patients with chronic obstructive pulmonary disease: TORCH study results. Thorax2010;65:719‐25. CalverleyPMA , AndersonJA , CelliB , FergusonGT , JenkinsC , JonesPW , et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. New England Journal of Medicine2007;356(8):775‐89. CalverleyPMA , CelliB , FergusonG , JenkinsC , JonesPW , PrideNB , et al. Baseline characteristics of the first 5,000 COPD patients enrolled in the TORCH survival study. European Respiratory Journal2003;22 Suppl 45:578s. CelliB , CalverleyPMA , AndersonJA , FergusonGT , JenkinsC , JonesPW , et al. The TORCH (TOwards a Revolution in COPD Health) study: salmeterol/fluticasone propionate (SFC) improves health status, reduces exacerbations and improves lung function over three years. European Respiratory Journal2006;28 Suppl 50:34s. CelliB , VestboJ , JenkinsCR , JonesPW , FergusonGT , CalverleyPM , et al. Sex differences in mortality and clinical expressions of patients with chronic obstructive pulmonary disease: the TORCH experience. American Journal of Respiratory and Critical Care Medicine2011;183(3):317‐22. CelliBR , ThomasNE , AndersonJA , FergusonGT , JenkinsCR , JonesPW , et al. Effect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease: results from the TORCH study. American Journal of Respiratory and Critical Care Medicine2008;174(4):332‐8. CrimC , CalverleyPM , AndersonJA , CelliB , FergusonGT , JenkinsC , et al. Pneumonia risk in COPD patients receiving inhaled corticosteroids alone or in combination: TORCH study results. European Respiratory Journal2009;34(3):641‐7. FergusonGT , CalverleyPM , AndersonJA , JenkinsCR , JonesPW , WillitsLR , et al. Prevalence and progression of osteoporosis in patients with COPD: results from the TOwards a Revolution in COPD Health study. Chest2009; Vol. 136, issue 0012‐3692:1456‐65. FergusonGT , CalverleyPMA , AndersonJA , et al. The TORCH (TOwards a Revolution in COPD Health) study: salmeterol/fluticasone propionate (SFC) improves survival in COPD over three years. European Respiratory Journal2006;28 Suppl 50:34s. GlaxoSmithKlineSCO30003 . A multicentre, randomised, double‐blind, parallel group, placebo‐controlled study to investigate the long‐term effects of salmeterol/fluticasone propionate (SERETIDE/VIANI/ADVAIR) 50/500mcg bd, salmeterol 50mcg bd and fluticasone propionate 500mcg bd, all delivered via the DISKUS/ACCUHALER inhaler, on the survival of subjects with chronic obstructive pulmonary disease (COPD) over 3 years of treatment. GlaxoSmithKline Clinical Trial Register2006. HoughtonCM , LawsonN , BorrillZL , WixonCL , YoxallS , LangleySJ , et al. Comparison of the effects of salmeterol/fluticasone propionate with fluticasone propionate on airway physiology in adults with mild persistent asthma. Respiratory Research2007;8:52. JenkinsCR , CalverleyPMA , CelliB , FergusonG , JonesPW , PrideN , et al. Seasonal patterns of exacerbation rates in the TORCH survival study, 2007. http://www.abstracts2view.comA839. JenkinsCR , CelliB , AndersonJA , FergusonGT , JonesPW , VestboJ , et al. Seasonality and determinants of moderate and severe COPD exacerbations in the TORCH study. European Respiratory Journal2012;39(1):38‐45. JenkinsCR , JonesPW , CalverleyPM , CelliB , AndersonJA , FergusonGT , et al. Efficacy of salmeterol/fluticasone propionate by GOLD stage of chronic obstructive pulmonary disease: analysis from the randomised, placebo‐controlled TORCH study. Respiratory Research2009;10:59. JohnsonM , AgustiAG , BarnesNC . Reflections on TORCH: potential mechanisms for the survival benefit of salmeterol/fluticasone propionate in COPD patients. COPD2008;5(6):369‐75. JonesPW , AndersonJA , CalverleyPM , CelliBR , FergusonGT , JenkinsC , et al. TORCH Investigators. Health status in the TORCH study of COPD: treatment efficacy and other determinants of change. Respiratory Research2011;12:71. JonesPW , CalverleyP , CelliB , FergusonG , JenkinsC , PrideN . Trans‐regional validity of the SGRQ in the TORCH survival study, 2007. http://www.abstracts2view.comA122. McGarveyLP , JohnM , AndersonJA , ZvarichMT , WiseRA . Ascertainment of cause‐specific mortality in COPD: operations of the TORCH Clinical Endpoint Committee. Thorax2007;62:411‐5. NCT00268216 . See detailed description, 2000. http://clinicaltrials.gov/show/NCT00268216. [] SCO30003 . A multicentre, randomised, double‐blind, parallel group, placebo‐controlled study to investigate the long‐term effects of salmeterol/fluticasone propionate (SERETIDE®/VIANI®/ADVAIR®) 50/500mcg bd, salmeterol 50mcg bd and fluticasone propionate 500mcg bd, all delivered via the DISKUS®/ACCUHALER® inhaler, on the survival of subjects with chronic obstructive pulmonary disease (COPD) over 3 years of treatment, 2006. www.ctr.gsk.co.uk. VestboJ , AndersonJA , CalverleyPM , CelliB , FergusonGT , JenkinsC , et al. Adherence to inhaled therapy, mortality and hospital admission in COPD. Thorax2009;64(11):939‐43. VestboJ , CalverleyP , CelliB , FergusonG , JenkinsC , JonesP , et al. The TORCH (TOwards a Revolution in COPD Health) survival study protocol. European Respiratory Journal2004;24(2):206‐10. WiseRA , McGarveyLP , JohnM , AndersonJA , ZvarichMT . Reliability of cause‐specific mortality adjudication in a COPD clinical trial, 2007. http://www.abstracts2view.comA120. ">TORCH</a>; <a href="./references#CD006826-bbs2-0014" title="CalverleyP , PauwelsR , VestboJ , JonesP , PrideN , GulsvikA , et al. Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial. Lancet2003;361(9356):449‐56. CalverleyPMA , PauwelsRA , VestboJ , JonesPW , PrideNB , GulsvikA , et al. Clinical improvements with salmeterol / fluticasone propionate combination in differing severities of COPD, 2003. http://www.abstracts2view.comA035 [Poster D50]. CalverleyPMA , PauwelsRA , VestboJ , JonesPW , PrideNB , GulsvikA , et al. Salmeterol/Fluticasone propionate combination for one year provides greater clinical benefit than its individual components. Proceedings of the 98th International American Thoracic Society Conference http://www.abstracts‐on‐line.com/abstracts/ATS; May 17‐22, 2002; Atlanta, Georgia. A98 [Poster 306]. CalverlyPMA , PauwelsR , VestboJ , JonesP , PrideN , GulsvikA , et al. Safety of salmeterol/fluticasone propionate combination in the treatment of chronic obstructive pulmonary disease. European Respiratory Journal2002;20 Suppl 38:242 [P1572]. HunjanMK , ChandlerF . Numbers needed to treat (NNT) to avoid an exacerbation in patients with chronic obstructive pulmonary disease (COPD) using salmeterol/fluticasone propionate combination (SFC) and associated costs [Abstract]. American Thoracic Society 100th International Conference; May 21‐26, 2004; Orlando, Florida. D22 [Poster 503]. HunjanMK , WilliamsDT . Costs of avoiding exacerbations in patients with chronic obstructive pulmonary disease (COPD) treated with salmeterol/ fluticasone propionate combination (seretide) and salmeterol. European Respiratory Journal2004;24 Suppl 48:291s. HunjanMK , WilliamsDT . Salmeterol/ fluticasone propionate combination is clinically effective in avoiding exacerbations in patients with moderate/severe COPD. European Respiratory Journal2004;24 Suppl 48:513s. JonesPW , EdinHM , AndersonJ . Salmeterol/fluticasone propionate combination improves health status in COPD patients. Proceedings of the 98th International American Thoracic Society Conference http://www.abstracts‐on‐line.com/abstracts/ATS; May 17‐22, 2002; Atlanta, Georgia. A39 [Poster K39]. JonesPW , StåhlE . Budesonide /formoterol sustains clinically relevant improvements in health status in COPD [Abstract]. European Respiratory Journal2005;26 Suppl 49:Abstract 1352. JonesPW , VestboJ , PauwelsRA , CalverleyPMA , AndersonJA , SpencerMD . Informative drop out in COPD studies: investigation of health status of withdrawals in the TRISTAN study. Proceedings of the 13th ERS Annual Congress; September 27, 2003; Vienna, Austria. P1593. NitschmannS . Inhalational combination therapy in chronic obstructive lung disease. Tristan study. German Internist2004;45(6):727‐8. PauwelsR , VestboJ , CalverleyPMA , JonesPW , PrideNB , GulsvikA . Characterization of exacerbations in the TRISTAN study of salmeterol / fluticasone propionate (SFC) combination in moderate to severe COPD, 2006. http://www.abstracts2view.com. PauwelsRA , CalverlyPMA , VestboJ , JonesPW , PrideN , GulsvikA , et al. Reduction of exacerbations with salmeterol/fluticasone combination 50/500 mcg bd in the treatment of chronic obstructive pulmonary disease. European Respiratory Journal2002;20 Suppl 38:240 [P1569]. SFCB3024 . A multicentre, randomised, double‐blind, parallel group, placebo‐controlled study to compare the efficacy and safety of the salmeterol/FP combination product at a strength of 50/500mcg bd with salmeterol 50mcg bd alone and FP 500mcg bd alone, delivered via the DISKUS™/ACCUHALER™, in the treatment of subjects with chronic obstructive pulmonary disease (COPD) for 12 months. GlaxoSmithKline Clinical Trials Register (http:ctr.gsk.co.uk)2005. SpencerM , BriggsAH , GrossmanRF , RanceL . Development of an economic model to assess the cost effectiveness of treatment interventions for chronic obstructive pulmonary disease. Pharmacoeconomics2005;23(6):619‐37. SpencerMD , KariaN , AndersonJ . The clinical significance of treatment benefits with the salmeterol/fluticasone propionate 50/500mcg combination in COPD. European Respiratory Journal2004;24 Suppl 48:290s. VestboJ , CalverleyPMA , PauwelsR , JonesP , PrideN , GulsvikA , et al. Absence of gender susceptibility to the combination of salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease. European Respiratory Journal2002;20 Suppl 38:240 [P1570]. VestboJ , PauwelsR , AndersonJA , JonesP , CalverleyP . Early onset of effect of salmeterol and fluticasone propionate in chronic obstructive pulmonary disease. Thorax2005;60(4):301‐4. VestboJ , PauwelsRS , CalverleyPMA , JonesPW , PrideNB , GulsvikA . Salmeterol / fluticasone propionate combination produces improvement in lung function detectable within 24 hours in moderate to severe COPD, 2003. http://www.abstracts2view.com. VestboJ , SorianoJB , AndersonJA , CalverleyP , PauwelsR , JonesP . Gender does not influence the response to the combination of salmeterol and fluticasone propionate in COPD. Respiratory Medicine2004;98(11):1045‐50. ">TRISTAN</a>; N = 4836, OR 0.76, 95% CI 0.62 to 0.92). </p> </section> <section id="CD006826-sec-0086"> <h6 class="title">BDF versus BD</h6> <p>The length of studies ranged from 24 to 52 weeks. Investigators did not identify a significant difference between BDF and BD with regard to mortality (4 studies; <a href="./references#CD006826-bbs2-0002" title="AstraZenecaSD . A placebo‐controlled 12‐month efficacy study of the fixed combination budesonide/formoterol compared to budesonide and formoterol as monotherapies in patients with chronic obstructive pulmonary disease (COPD). AstraZeneca Clinical Trials2002. BorgstromL , AskingL , OlssonH , PetersonS . Lack of interaction between disease severity and therapeutic response with budesonide/formoterol in a single inhaler [Abstract]. American Thoracic Society 100th International Conference; May 21‐26; 2004, Orlando, Florida. C22 [Poster 505]. CalverleyPM , BonsawatW , CsekeZ , ZhongN , PetersonS , OlssonH . Maintenance therapy with budesonide and formoterol in chronic obstructive pulmonary disease. European Respiratory Journal2003;22(6):912‐9. CalverleyPMA , CsekeZ , PetersonS . Budesonide/formoterol reduces the use of oral corticosteroids in the treatment of COPD [Abstract]. European Respiratory Journal2003;22 Suppl 45:P436. CalverleyPMA , KunaP , OlssonH . COPD exacerbations are reduced by budesonide/formoterol in a single inhaler [Abstract]. European Respiratory Journal2003;22 Suppl 45:P1587. CalverleyPMA , OlssonH , Symbicort International COPD Study Group. Budesonide/formoterol ina single inhaler sustains improvements in lung function over 12 months compared with monocomponents and placebo in patients with COPD [abstract]. American Thoracic Society 99th International Conference; May 16‐21, 2003; Seattle, Washington. B024 [Poster 418]. CalverleyPMA , PetersonS . Combining budesonide/formoterol in a single inhale reduces exacerbation frequency in COPD [abstract]. American Thoracic Society 99th International Conference; May 16‐21, 2003; Seattle, Washington. D092 [Poster 211]. CalverleyPMA , StåhlE , JonesPW . Budesonide/formoterol improves the general health status of patients with COPD [Abstract]. American Thoracic Society 2005 International Conference; May 20‐25, 2005; San Diego, California. B93 [Poster 303]. CalverleyPMA , SzafranskiW , AnderssonA . Budesonide/formoterol is a well‐tolerated long term maintenance therapy for COPD. European Respiratory Journal2005;26 Suppl 49:Poster 1917. CalverleyPMA , ThompsonNC , OlssonH . Budesonide/formoterol in a single inhaler sustains lung function improvements in COPD [Abstract]. European Respiratory Journal2003;22 Suppl 45:P435. HalpinD , StåhlE , LundbackB , AndersonF , PetersonS . Treatment costs and number needed to treat (NNT) with budesonide/formoterol to avoid one exacerbation of COPD [Abstract]. American Thoracic Society 100th International Conference; May 21‐26, 2004; Orlando, Florida. D22 [Poster 525]. HalpinDMG , LarssonT , CalverleyPMA . How many patients with COPD must be treated with budesonide/formoterol compared with formoterol alone to avoid 1 day of oral steroid use? [Abstract]. American Thoracic Society 2005 International Conference; May 20‐25, 2005; San Diego, California. B93 [Poster 314]. JonesPW , StahlE . Budesonide/formoterol in a single inhaler improves health status in patients with COPD [abstract]. American Thoracic Society 99th International Conference; May 16‐21, 2003; Orlando, Florida. B024 [Poster 419]. JonesPW , StåhlE . Budesonide /formoterol sustains clinically relevant improvements in health status in COPD [Abstract]. European Respiratory Journal2005;26 Suppl 49:Abstract 1352. JonesPW , StåhlE . Reducing exacerbations leads to a better health‐related quality of life in patients with COPD. 13th ERS Annual Congress; September 27, 2003; Vienna, Austria. P1586. LofdahlCG . Reducing the impact of COPD exacerbations: Clinical efficacy of budesonide/formoterol. European Respiratory Review2004;13(88):14‐21. LofdahlCG , AndreassonE , SvenssonK , EricssonA . Budesonide/formoterol in a single inhaler improves health status in patients with COPD without increasing healthcare costs [Abstract]. European Respiratory Journal2003;22 Suppl 45:P433. LofdahlCG , EricssonA , SvenssonK , AndreassonE . Cost effectiveness of budesonide/formoterol in a single inhaler for COPD compared with each monocomponent used alone. Pharmacoeconomics2005;23(4):365‐75. ">Calverley 2003</a>; <a href="./references#CD006826-bbs2-0010" title="AndersonP . Budesonide/formoterol in a single inhaler (Symbicort) provides early and sustained improvement in lung function in moderate to severe COPD [Abstract]. Thorax2002;57(Suppl III):iii43. AstraZenecaSD . A placebo‐controlled 12 month efficacy study of the fixed combination budesonide/formoterol compared with budesonide and formoterol as monotherapies in patients with chronic obstructive pulmonary disease (COPD). AstraZeneca Clinical Trials2001. BorgstromL , AskingL , OlssonH , PetersonS . Lack of interaction between disease severity and therapeutic response with budesonide/formoterol in a single inhaler [Abstract]. American Thoracic Society 100th International Conference; May 21‐26, 2004; Orlando, Florida. C22 [Poster 505]. CalverleyP , PauwelsR , LofdahlCG , SvenssonK , HigenbottamT , et al. Relationship between respiratory symptoms and medical treatment in exacerbations of COPD. European Respiratory Journal2005;26(3):406‐13. CalverleyPMA . Effect of budesonide/formoterol on severe exacerbations and lung function in moderate to severe COPD. Thorax. BTS Winter Meeting 2002:S145. CalverleyPMA , SzafranskiW , AnderssonA . Budesonide/formoterol is a well‐tolerated long term maintenance therapy for COPD. European Respiratory Journal2005;26 Suppl 49:Poster 1917. CalverleyPMA , ThompsonNC , OlssonH . Budesonide/formoterol in a single inhaler sustains lung function improvements in COPD [Abstract]. European Respiratory Journal2003;22 Suppl 45:P435. CampbellLM , SzafranskiW . Budesonide/formoterol in a single inhaler (Symbicort) provides sustained relief from symptoms in moderate to severe COPD. Thorax. BTS Winter Meeting 2002:S143. CampellLW , SzafranskiW . Budesonide/Formoterol in a single inhaler (Symbicort) reduces severe exacerbations in patients with moderate‐severe COPD. Thorax. BTS Winter Meeting 2002:S141. DahlR , CukierA , OlssonH . Budesonide/formoterol in a single inhaler reduces severe and mild exacerbations in patients with moderate to severe COPD. European Respiratory Journal2002;20 Suppl 38:242 [P1575]. EgedeF , MengaG . Budesonide/formoterol in a single inhaler provides sustained relief from symptoms and night‐time awakenings in moderate‐severe COPD: results from symptoms and night‐time awakenings in moderate to severe COPD: results from a 1‐year study. European Respiratory Journal2002;20 Suppl 38:242 [P1574]. HalpinD , StahlE , LundbackB , AndersonF , PetersonS . Treatment costs and number needed to treat (NNT) with budesonide/formoterol to avoid one exacerbation of COPD [Abstract]. American Thoracic Society 100th International Conference; May 21‐26, 2004; Orlando, Florida. D22 [Poster 525]. JonesPW , StahlE , SvenssonK . Improvement in health status in patients with moderate to severe COPD after treatment with budesonide/formoterol in a single inhaler. European Respiratory Journal2002;20 Suppl 38:250 [P1613]. KorsgaardJ , SansoresR . Budesonide/formoterol (single inhaler) provides sustained relief from shortness of breath and chest tightness in a 1‐year study of patients with moderate to severe COPD. European Respiratory Journal2002;20 Suppl 38:242 [P1577]. LangeP , SaenzC . Budesonide/formoterol in a single inhaler is well tolerated in patients with moderate to severe COPD: results of a 1 year study. European Respiratory Journal2002;20 Suppl 38:242 [P1573]. LofdahlCG . Reducing the impact of COPD exacerbations: clinical efficacy of budesonide/formoterol. European Respiratory Review2004;13(88):14‐21. MilanowskiJ , NahabedianS . Budesonide/formoterol in a single inhaler acts rapidly to improve lung function and relieve symptoms in patients with moderate to severe COPD. European Respiratory Journal2002;20 Suppl 38:242 [P1576]. SzafranskiW , CukierA , RamirezA , MengaG , SansoresR , NahabedianS , et al. Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease. European Respiratory Journal2003;21(1):74‐81. ">Szafranski 2003</a>; <a href="./references#CD006826-bbs2-0011" title="Astrazeneca(D5899C00002) . A 6‐month double‐blind, double‐dummy, randomized, parallel group, multicenter efficacy &amp; safety study of Symbicort® pMDI 2 × 160/4.5mg &amp; 80/4.5mg bid compared to Formoterol TBH, Budesonide pMDI (&amp; the combination) &amp; placebo in COPD patients. www.astrazenecaclinicaltrials.com (accessed 8 April 2008). BleeckerER , MeyersDA , BaileyWC , SimsA‐M , BujacSR , GoldmanM , et al. ADRB2 polymorphisms and budesonide/formoterol responses in COPDADRB2 polymorphisms and treatment response in COPD. Chest2012;142(2):320‐8. TashkinDP , RennardSI , MartinP , GoldmanM , SilkoffPE . Efficacy of budesonide/formoterol administered via one pressurized metered‐dose inhaler over 6 months in patients with chronic obstructive pulmonary disease [Abstract]. Chest2008; Vol. 134, issue 4:105001s. TashkinDP , RennardSI , MartinP , RamachandranS , MartinUJ , SilkoffPE , et al. Efficacy and safety of budesonide and formoterol in one pressurized metered‐dose inhaler in patients with moderate to very severe chronic obstructive pulmonary disease : results of a 6‐month randomized clinical trial. Drugs2008; Vol. 68, issue 0012‐6667 (Print):1975‐2000. ">Tashkin 2008</a>; <a href="./references#CD006826-bbs2-0015" title="ZhongN , ZhengJ , WenF , YangL , ChenP , XiuQ , et al. Efficacy and safety of budesonide/formoterol via a dry powder inhaler in Chinese patients with chronic obstructive pulmonary disease. Current Medical Research and Opinion2012; Vol. 28, issue 2:257‐65. ZhongN , ZhengJ , WenF , YangL , ChenP , XiuQ , et al. Efficacy and safety of inhalation of budesonide/formoterol via turbuhaler in Chinese patients with chronic obstructive pulmonary disease [Abstract]. Chest2011; Vol. 140, issue 4:5225A. ">Zhong 2012</a>; N = 1777, OR 1.13, 95% CI 0.54 to 2.37). </p> </section> <section id="CD006826-sec-0087"> <h6 class="title">MF/F versus MF</h6> <p>Two trials were identified: one 26 weeks in duration (<a href="./references#CD006826-bbs2-0012" title="KerwinE , TashkinDP , Matiz‐BuenoCE , DohertyDE , ShekarT , BanerjeeS , et al. Clinical efficacy and safety of combined mometasone furoate and formoterol in patients with moderate to very severe chronic obstructive pulmonary disease (COPD) [Abstract]. Journal of Allergy and Clinical Immunology2012; Vol. 129, issue 2 Suppl:AB201 [759]. NCT00383435 . A Randomized, 26‐Week, Placebo‐Controlled Efficacy and Safety Study With a 26‐Week Long‐Term Safety Extension, of High‐ and Medium‐Dose Inhaled Mometasone Furoate/Formoterol Fixed‐Dose Combination Formulation Compared With Formoterol and High‐Dose Inhaled Mometasone Furoate Monotherapy in Subjects With Moderate to Severe COPD, 2006. http://clinicaltrials.gov/show/NCT00383435. [] TashkinDP , DohertyDE , KerwinE , Matiz‐BuenoCE , KnorrB , ShekarT , et al. Efficacy and safety of a fixed‐dose combination of mometasone furoate and formoterol fumarate in subjects with moderate to very severe COPD: results from a 52‐week Phase III trial. International Journal of Chronic Obstructive Pulmonary Disease2012; Vol. 7, issue 1178‐2005 (Electronic). 1176‐9106 (Linking):43‐55. ">Tashkin 2012</a>) and the other 52 weeks (<a href="./references#CD006826-bbs2-0003" title="DohertyDE , KerwinE , TashkinDP , Matiz‐BuenoCE , ShekarT , BanerjeeS , et al. Combined mometasone furoate and formoterol in patients with moderate to very severe chronic obstructive pulmonary disease (COPD): phase 3 efficacy and safety study [Abstract]. Journal of Allergy and Clinical Immunology2012; Vol. 129, issue 2 Suppl:AB75 [283]. DohertyDE , TashkinDP , KerwinE , KnorrBA , ShekarT , BanerjeeS , et al. Effects of mometasone furoate/formoterol fumarate fixed‐dose combination formulation on chronic obstructive pulmonary disease (COPD): results from a 52‐week Phase III trial in subjects with moderate‐to‐very severe COPD. International Journal of Chronic Obstructive Pulmonary Disease2012; Vol. 7, issue 1178‐2005 (Electronic). 1176‐9106 (Linking):57‐71. NCT00383721 . A Randomized, 26‐Week, Placebo‐Controlled Efficacy and Safety Study With a 26‐Week Long‐Term Safety Extension, of High‐ and Medium‐Dose Inhaled Mometasone Furoate/Formoterol Fixed‐Dose Combination Formulation Compared With Formoterol and High‐Dose Inhaled Mometasone Furoate Monotherapy in Subjects With Moderate to Severe COPD, 2006. http://clinicaltrials.gov/show/NCT00383721. [] ">Doherty 2012</a>). No significant difference was reported between MF/F and MF on this outcome (N = 905, OR 0.89, 95% CI 0.27 to 2.91). </p> </section> </section> <section id="CD006826-sec-0088"> <h5 class="title">Pneumonia</h5> <section id="CD006826-sec-0089"> <h6 class="title">Pooled results for FPS, BDF and MF/F versus ICS alone</h6> <p>When data were combined for both treatments and their respective comparators, the odds of pneumonia were not significantly different after combination treatment than after mono‐component steroid (12 studies; N = 7315, OR 1.08, 95% CI 0.91 to 1.28; <a href="./references#CD006826-fig-0013" title="">Analysis 1.5</a>; <a href="#CD006826-fig-0007">Figure 7</a>). </p> <div class="figure" id="CD006826-fig-0007"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 7</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 1 All Combined Inhalers－Primary Outcomes, outcome: 1.5 Pneumonia." data-id="CD006826-fig-0007" src="/cdsr/doi/10.1002/14651858.CD006826.pub2/media/CDSR/CD006826/image_n/nCD006826-AFig-FIG07.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 1 All Combined Inhalers－Primary Outcomes, outcome: 1.5 Pneumonia. </p> </div> </div> </div> </section> <section id="CD006826-sec-0090"> <h6 class="title">FPS versus FP</h6> <p>No significant difference between FPS and FP was observed in the number of participants with pneumonia at the end of treatment (7 studies; <a href="./references#CD006826-bbs2-0004" title="HananiaNA , DarkenP , HorstmanD , ReisnerC , LeeB , DavisS , et al. The efficacy and safety of fluticasone propionate (250 micro g)/salmeterol (50 micro g) combined in the diskus inhaler for the treatment of COPD. Chest2003;124(3):834‐43. HananiaNA , RamsdellJ , PayneK , DavisS , HorstmanD , LeeB , et al. Improvements in airflow and dyspnea in COPD patients following 24 weeks treatment with salmeterol 50mcg and fluticasone propionate 250mcg alone or in combination via the diskus. American Journal of Respiratory &amp; Critical Care Medicine2001;163(5 Suppl):A279. HorstmanD , DarkenP , DavisS , LeeB . Improvements in FEV1 and symptoms in poorly reversible COPD patients following treatment with salmeterol 50mcg/fluticasone propionate 250mcg combination [Abstract]. European Respiratory Journal2003;22 Suppl 45:P434. MahlerDA , DarkenP , BrownCP , KnobilK . Predicting lung function responses to combination therapy in chronic obstructive pulmonary disease (COPD) [Abstract]. National COPD Conference; November 14‐15, 2003; Arlington, Virginia. Abstract 1081. MahlerDA , DarkenP , BrownCP , KnobilK . Predicting lung function responses to salmeterol/fluticasone propionate combination therapy in COPD [Abstract]. European Respiratory Journal2003;22 Suppl 45:P429. SFCA3007 . A randomized, double‐blind, placebo‐controlled, parallel‐group trial evaluating the safety and efficacy of the DISKUS formulations of salmeterol (SAL) 50mcg BID and fluticasone propionate (FP) 250mcg BID individually and in combination as salmeterol 50mcg/fluticasone propionate 250mcg BID (SFC 50/250) compared to placebo in COPD subjects. GlaxoSmithKline Clinical Trials Register (http:ctr.gsk.co.uk)2005. SpencerM , WireP , LeeB , ChangCN , DarkenP , HorstmanD . Patients with COPD using salmeterol/fluticasone propionate combination therapy experience improved quality of life. European Respiratory Journal2003;22 Suppl 45:51s. SpencerMD , KariaN , AndersonJ . The clinical significance of treatment benefits with the salmeterol/fluticasone propionate 50/500mcg combination in COPD. European Respiratory Journal2004;24 Suppl 48:290s. ">Hanania 2003</a>; <a href="./references#CD006826-bbs2-0006" title="MahlerDA , DarkenP , BrownCP , KnobilK . Predicting lung function responses to combination therapy in chronic obstructive pulmonary disease (COPD), 2003. http://www.abstracts2view.com. MahlerDA , WireP , HorstmanD , ChangCN , YatesJ , FischerT , et al. Effectiveness of fluticasone propionate and salmeterol combination delivered via the diskus device in the treatment of chronic obstructive pulmonary disease. American Journal of Respiratory Critical Care Medicine2002;166(8):1084‐91. SFCA3006 . A randomized, double‐blind, placebo‐controlled, parallel‐group trial evaluating the safety and efficacy of the DISKUS formulations of salmeterol (SAL) 50mcg BID and fluticasone propionate (FP) 500mcg BID individually and in combination as salmeterol 50mcg/fluticasone propionate 500mcg BID (SFC 50/500) compared to placebo in COPD subjects. GlaxoSmithKline Clinical Trials Register (http:ctr.gsk.co.uk)2005. SpencerM , WireP , LeeB , ChangCN , DarkenP , HorstmanD . Patients with COPD using salmeterol/fluticasone propionate combination therapy experience improved quality of life. European Respiratory Journal2003;22 Suppl 45:51s. SpencerMD , AndersonJA . Salmeterol/fluticasone combination produces clinically important benefits in dyspnea and fatigue [Abstract]. American Thoracic Society 2005 International Conference; May 20‐25, 2005; San Diego, California. B93 [Poster 308]. SpencerMD , KariaN , AndersonJ . The clinical significance of treatment benefits with the salmeterol/fluticasone propionate 50/500mcg combination in COPD. European Respiratory Journal2004;24 Suppl 48:290s. ">Mahler 2002</a>; <a href="./references#CD006826-bbs2-0007" title="NCT00358358 . Trial SCO104925. See detailed description, 2006. http://clinicaltrials.gov/show/NCT00358358. [] ">NCT00358358</a>; <a href="./references#CD006826-bbs2-0008" title="SFCT01 . A Multicentre, Randomised, Double‐Blind, Parallel Group, Placebo‐Controlled Study to Compare the Efficacy and Safety of Inhaled Salmeterol/Fluticasone Propionate Combination Product 25/250 µg Two Puffs Bd and Fluticasone Propionate 250µg Two Puffs Bd Alone, All Administered Via Metered Dose Inhalers (MDI), in the Treatment of Subjects with Chronic Obstructive Pulmonary Disease (COPD) for 52 Weeks. GlaxoSmithKline Clinical Trials Register (http:ctr.gsk.co.uk)2005. ">SFCT01</a>; <a href="./references#CD006826-bbs2-0009" title="NCT00120978 . Advair－CRP Study. http://clinicaltrials.gov/show/NCT001209782004. [] SinDD , ManSF , MarciniukDD , FordG , FitzGeraldM , WongE , et al. Can inhaled fluticasone alone or in combination with salmeterol reduce systemic inflammation in chronic obstructive pulmonary disease? Study protocol for a randomized controlled trial [NCT00120978]. BMC Pulmonary Medicine2006;6(6):3. SinDD , ManSF , MarciniukDD , FordG , FitzGeraldM , WongE , et al. The effects of fluticasone with or without salmeterol on systemic biomarkers of inflammation in chronic obstructive pulmonary disease. American Journal of Respiratory and Critical Care Medicine2008; Vol. 177, issue 11:1207‐14. ">Sin 2008</a>; <a href="./references#CD006826-bbs2-0013" title="BriggsAH , GlickHA , Lozano‐OrtegaG , SpencerM , CalverleyPM , JonesPW , et al. Is treatment with ICS and LABA cost‐effective for COPD? Multinational economic analysis of the TORCH study. European Respiratory Journal2010; Vol. 35, issue 3:532‐9. CalverleyPM , AndersonJA , CelliB , FergusonGT , JenkinsC , JonesPW , et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease.[see comment]. New England Journal of Medicine2007; Vol. 356, issue 8:775‐89. CalverleyPMA , AndersonJA , CelliB , FergusonGT , JenkinsC , JonesPW , et al. Cardiovascular events in patients with chronic obstructive pulmonary disease: TORCH study results. Thorax2010;65:719‐25. CalverleyPMA , AndersonJA , CelliB , FergusonGT , JenkinsC , JonesPW , et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. New England Journal of Medicine2007;356(8):775‐89. CalverleyPMA , CelliB , FergusonG , JenkinsC , JonesPW , PrideNB , et al. Baseline characteristics of the first 5,000 COPD patients enrolled in the TORCH survival study. European Respiratory Journal2003;22 Suppl 45:578s. CelliB , CalverleyPMA , AndersonJA , FergusonGT , JenkinsC , JonesPW , et al. The TORCH (TOwards a Revolution in COPD Health) study: salmeterol/fluticasone propionate (SFC) improves health status, reduces exacerbations and improves lung function over three years. European Respiratory Journal2006;28 Suppl 50:34s. CelliB , VestboJ , JenkinsCR , JonesPW , FergusonGT , CalverleyPM , et al. Sex differences in mortality and clinical expressions of patients with chronic obstructive pulmonary disease: the TORCH experience. American Journal of Respiratory and Critical Care Medicine2011;183(3):317‐22. CelliBR , ThomasNE , AndersonJA , FergusonGT , JenkinsCR , JonesPW , et al. Effect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease: results from the TORCH study. American Journal of Respiratory and Critical Care Medicine2008;174(4):332‐8. CrimC , CalverleyPM , AndersonJA , CelliB , FergusonGT , JenkinsC , et al. Pneumonia risk in COPD patients receiving inhaled corticosteroids alone or in combination: TORCH study results. European Respiratory Journal2009;34(3):641‐7. FergusonGT , CalverleyPM , AndersonJA , JenkinsCR , JonesPW , WillitsLR , et al. Prevalence and progression of osteoporosis in patients with COPD: results from the TOwards a Revolution in COPD Health study. Chest2009; Vol. 136, issue 0012‐3692:1456‐65. FergusonGT , CalverleyPMA , AndersonJA , et al. The TORCH (TOwards a Revolution in COPD Health) study: salmeterol/fluticasone propionate (SFC) improves survival in COPD over three years. European Respiratory Journal2006;28 Suppl 50:34s. GlaxoSmithKlineSCO30003 . A multicentre, randomised, double‐blind, parallel group, placebo‐controlled study to investigate the long‐term effects of salmeterol/fluticasone propionate (SERETIDE/VIANI/ADVAIR) 50/500mcg bd, salmeterol 50mcg bd and fluticasone propionate 500mcg bd, all delivered via the DISKUS/ACCUHALER inhaler, on the survival of subjects with chronic obstructive pulmonary disease (COPD) over 3 years of treatment. GlaxoSmithKline Clinical Trial Register2006. HoughtonCM , LawsonN , BorrillZL , WixonCL , YoxallS , LangleySJ , et al. Comparison of the effects of salmeterol/fluticasone propionate with fluticasone propionate on airway physiology in adults with mild persistent asthma. Respiratory Research2007;8:52. JenkinsCR , CalverleyPMA , CelliB , FergusonG , JonesPW , PrideN , et al. Seasonal patterns of exacerbation rates in the TORCH survival study, 2007. http://www.abstracts2view.comA839. JenkinsCR , CelliB , AndersonJA , FergusonGT , JonesPW , VestboJ , et al. Seasonality and determinants of moderate and severe COPD exacerbations in the TORCH study. European Respiratory Journal2012;39(1):38‐45. JenkinsCR , JonesPW , CalverleyPM , CelliB , AndersonJA , FergusonGT , et al. Efficacy of salmeterol/fluticasone propionate by GOLD stage of chronic obstructive pulmonary disease: analysis from the randomised, placebo‐controlled TORCH study. Respiratory Research2009;10:59. JohnsonM , AgustiAG , BarnesNC . Reflections on TORCH: potential mechanisms for the survival benefit of salmeterol/fluticasone propionate in COPD patients. COPD2008;5(6):369‐75. JonesPW , AndersonJA , CalverleyPM , CelliBR , FergusonGT , JenkinsC , et al. TORCH Investigators. Health status in the TORCH study of COPD: treatment efficacy and other determinants of change. Respiratory Research2011;12:71. JonesPW , CalverleyP , CelliB , FergusonG , JenkinsC , PrideN . Trans‐regional validity of the SGRQ in the TORCH survival study, 2007. http://www.abstracts2view.comA122. McGarveyLP , JohnM , AndersonJA , ZvarichMT , WiseRA . Ascertainment of cause‐specific mortality in COPD: operations of the TORCH Clinical Endpoint Committee. Thorax2007;62:411‐5. NCT00268216 . See detailed description, 2000. http://clinicaltrials.gov/show/NCT00268216. [] SCO30003 . A multicentre, randomised, double‐blind, parallel group, placebo‐controlled study to investigate the long‐term effects of salmeterol/fluticasone propionate (SERETIDE®/VIANI®/ADVAIR®) 50/500mcg bd, salmeterol 50mcg bd and fluticasone propionate 500mcg bd, all delivered via the DISKUS®/ACCUHALER® inhaler, on the survival of subjects with chronic obstructive pulmonary disease (COPD) over 3 years of treatment, 2006. www.ctr.gsk.co.uk. VestboJ , AndersonJA , CalverleyPM , CelliB , FergusonGT , JenkinsC , et al. Adherence to inhaled therapy, mortality and hospital admission in COPD. Thorax2009;64(11):939‐43. VestboJ , CalverleyP , CelliB , FergusonG , JenkinsC , JonesP , et al. The TORCH (TOwards a Revolution in COPD Health) survival study protocol. European Respiratory Journal2004;24(2):206‐10. WiseRA , McGarveyLP , JohnM , AndersonJA , ZvarichMT . Reliability of cause‐specific mortality adjudication in a COPD clinical trial, 2007. http://www.abstracts2view.comA120. ">TORCH</a>; <a href="./references#CD006826-bbs2-0014" title="CalverleyP , PauwelsR , VestboJ , JonesP , PrideN , GulsvikA , et al. Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial. Lancet2003;361(9356):449‐56. CalverleyPMA , PauwelsRA , VestboJ , JonesPW , PrideNB , GulsvikA , et al. Clinical improvements with salmeterol / fluticasone propionate combination in differing severities of COPD, 2003. http://www.abstracts2view.comA035 [Poster D50]. CalverleyPMA , PauwelsRA , VestboJ , JonesPW , PrideNB , GulsvikA , et al. Salmeterol/Fluticasone propionate combination for one year provides greater clinical benefit than its individual components. Proceedings of the 98th International American Thoracic Society Conference http://www.abstracts‐on‐line.com/abstracts/ATS; May 17‐22, 2002; Atlanta, Georgia. A98 [Poster 306]. CalverlyPMA , PauwelsR , VestboJ , JonesP , PrideN , GulsvikA , et al. Safety of salmeterol/fluticasone propionate combination in the treatment of chronic obstructive pulmonary disease. European Respiratory Journal2002;20 Suppl 38:242 [P1572]. HunjanMK , ChandlerF . Numbers needed to treat (NNT) to avoid an exacerbation in patients with chronic obstructive pulmonary disease (COPD) using salmeterol/fluticasone propionate combination (SFC) and associated costs [Abstract]. American Thoracic Society 100th International Conference; May 21‐26, 2004; Orlando, Florida. D22 [Poster 503]. HunjanMK , WilliamsDT . Costs of avoiding exacerbations in patients with chronic obstructive pulmonary disease (COPD) treated with salmeterol/ fluticasone propionate combination (seretide) and salmeterol. European Respiratory Journal2004;24 Suppl 48:291s. HunjanMK , WilliamsDT . Salmeterol/ fluticasone propionate combination is clinically effective in avoiding exacerbations in patients with moderate/severe COPD. European Respiratory Journal2004;24 Suppl 48:513s. JonesPW , EdinHM , AndersonJ . Salmeterol/fluticasone propionate combination improves health status in COPD patients. Proceedings of the 98th International American Thoracic Society Conference http://www.abstracts‐on‐line.com/abstracts/ATS; May 17‐22, 2002; Atlanta, Georgia. A39 [Poster K39]. JonesPW , StåhlE . Budesonide /formoterol sustains clinically relevant improvements in health status in COPD [Abstract]. European Respiratory Journal2005;26 Suppl 49:Abstract 1352. JonesPW , VestboJ , PauwelsRA , CalverleyPMA , AndersonJA , SpencerMD . Informative drop out in COPD studies: investigation of health status of withdrawals in the TRISTAN study. Proceedings of the 13th ERS Annual Congress; September 27, 2003; Vienna, Austria. P1593. NitschmannS . Inhalational combination therapy in chronic obstructive lung disease. Tristan study. German Internist2004;45(6):727‐8. PauwelsR , VestboJ , CalverleyPMA , JonesPW , PrideNB , GulsvikA . Characterization of exacerbations in the TRISTAN study of salmeterol / fluticasone propionate (SFC) combination in moderate to severe COPD, 2006. http://www.abstracts2view.com. PauwelsRA , CalverlyPMA , VestboJ , JonesPW , PrideN , GulsvikA , et al. Reduction of exacerbations with salmeterol/fluticasone combination 50/500 mcg bd in the treatment of chronic obstructive pulmonary disease. European Respiratory Journal2002;20 Suppl 38:240 [P1569]. SFCB3024 . A multicentre, randomised, double‐blind, parallel group, placebo‐controlled study to compare the efficacy and safety of the salmeterol/FP combination product at a strength of 50/500mcg bd with salmeterol 50mcg bd alone and FP 500mcg bd alone, delivered via the DISKUS™/ACCUHALER™, in the treatment of subjects with chronic obstructive pulmonary disease (COPD) for 12 months. GlaxoSmithKline Clinical Trials Register (http:ctr.gsk.co.uk)2005. SpencerM , BriggsAH , GrossmanRF , RanceL . Development of an economic model to assess the cost effectiveness of treatment interventions for chronic obstructive pulmonary disease. Pharmacoeconomics2005;23(6):619‐37. SpencerMD , KariaN , AndersonJ . The clinical significance of treatment benefits with the salmeterol/fluticasone propionate 50/500mcg combination in COPD. European Respiratory Journal2004;24 Suppl 48:290s. VestboJ , CalverleyPMA , PauwelsR , JonesP , PrideN , GulsvikA , et al. Absence of gender susceptibility to the combination of salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease. European Respiratory Journal2002;20 Suppl 38:240 [P1570]. VestboJ , PauwelsR , AndersonJA , JonesP , CalverleyP . Early onset of effect of salmeterol and fluticasone propionate in chronic obstructive pulmonary disease. Thorax2005;60(4):301‐4. VestboJ , PauwelsRS , CalverleyPMA , JonesPW , PrideNB , GulsvikA . Salmeterol / fluticasone propionate combination produces improvement in lung function detectable within 24 hours in moderate to severe COPD, 2003. http://www.abstracts2view.com. VestboJ , SorianoJB , AndersonJA , CalverleyP , PauwelsR , JonesP . Gender does not influence the response to the combination of salmeterol and fluticasone propionate in COPD. Respiratory Medicine2004;98(11):1045‐50. ">TRISTAN</a>; N = 5015, OR 1.06, 95% CI 0.89 to 1.27). </p> </section> <section id="CD006826-sec-0091"> <h6 class="title">BDF versus BD</h6> <p>The three studies that reported pneumonia (<a href="./references#CD006826-bbs2-0002" title="AstraZenecaSD . A placebo‐controlled 12‐month efficacy study of the fixed combination budesonide/formoterol compared to budesonide and formoterol as monotherapies in patients with chronic obstructive pulmonary disease (COPD). AstraZeneca Clinical Trials2002. BorgstromL , AskingL , OlssonH , PetersonS . Lack of interaction between disease severity and therapeutic response with budesonide/formoterol in a single inhaler [Abstract]. American Thoracic Society 100th International Conference; May 21‐26; 2004, Orlando, Florida. C22 [Poster 505]. CalverleyPM , BonsawatW , CsekeZ , ZhongN , PetersonS , OlssonH . Maintenance therapy with budesonide and formoterol in chronic obstructive pulmonary disease. European Respiratory Journal2003;22(6):912‐9. CalverleyPMA , CsekeZ , PetersonS . Budesonide/formoterol reduces the use of oral corticosteroids in the treatment of COPD [Abstract]. European Respiratory Journal2003;22 Suppl 45:P436. CalverleyPMA , KunaP , OlssonH . COPD exacerbations are reduced by budesonide/formoterol in a single inhaler [Abstract]. European Respiratory Journal2003;22 Suppl 45:P1587. CalverleyPMA , OlssonH , Symbicort International COPD Study Group. Budesonide/formoterol ina single inhaler sustains improvements in lung function over 12 months compared with monocomponents and placebo in patients with COPD [abstract]. American Thoracic Society 99th International Conference; May 16‐21, 2003; Seattle, Washington. B024 [Poster 418]. CalverleyPMA , PetersonS . Combining budesonide/formoterol in a single inhale reduces exacerbation frequency in COPD [abstract]. American Thoracic Society 99th International Conference; May 16‐21, 2003; Seattle, Washington. D092 [Poster 211]. CalverleyPMA , StåhlE , JonesPW . Budesonide/formoterol improves the general health status of patients with COPD [Abstract]. American Thoracic Society 2005 International Conference; May 20‐25, 2005; San Diego, California. B93 [Poster 303]. CalverleyPMA , SzafranskiW , AnderssonA . Budesonide/formoterol is a well‐tolerated long term maintenance therapy for COPD. European Respiratory Journal2005;26 Suppl 49:Poster 1917. CalverleyPMA , ThompsonNC , OlssonH . Budesonide/formoterol in a single inhaler sustains lung function improvements in COPD [Abstract]. European Respiratory Journal2003;22 Suppl 45:P435. HalpinD , StåhlE , LundbackB , AndersonF , PetersonS . Treatment costs and number needed to treat (NNT) with budesonide/formoterol to avoid one exacerbation of COPD [Abstract]. American Thoracic Society 100th International Conference; May 21‐26, 2004; Orlando, Florida. D22 [Poster 525]. HalpinDMG , LarssonT , CalverleyPMA . How many patients with COPD must be treated with budesonide/formoterol compared with formoterol alone to avoid 1 day of oral steroid use? [Abstract]. American Thoracic Society 2005 International Conference; May 20‐25, 2005; San Diego, California. B93 [Poster 314]. JonesPW , StahlE . Budesonide/formoterol in a single inhaler improves health status in patients with COPD [abstract]. American Thoracic Society 99th International Conference; May 16‐21, 2003; Orlando, Florida. B024 [Poster 419]. JonesPW , StåhlE . Budesonide /formoterol sustains clinically relevant improvements in health status in COPD [Abstract]. European Respiratory Journal2005;26 Suppl 49:Abstract 1352. JonesPW , StåhlE . Reducing exacerbations leads to a better health‐related quality of life in patients with COPD. 13th ERS Annual Congress; September 27, 2003; Vienna, Austria. P1586. LofdahlCG . Reducing the impact of COPD exacerbations: Clinical efficacy of budesonide/formoterol. European Respiratory Review2004;13(88):14‐21. LofdahlCG , AndreassonE , SvenssonK , EricssonA . Budesonide/formoterol in a single inhaler improves health status in patients with COPD without increasing healthcare costs [Abstract]. European Respiratory Journal2003;22 Suppl 45:P433. LofdahlCG , EricssonA , SvenssonK , AndreassonE . Cost effectiveness of budesonide/formoterol in a single inhaler for COPD compared with each monocomponent used alone. Pharmacoeconomics2005;23(4):365‐75. ">Calverley 2003</a>; <a href="./references#CD006826-bbs2-0011" title="Astrazeneca(D5899C00002) . A 6‐month double‐blind, double‐dummy, randomized, parallel group, multicenter efficacy &amp; safety study of Symbicort® pMDI 2 × 160/4.5mg &amp; 80/4.5mg bid compared to Formoterol TBH, Budesonide pMDI (&amp; the combination) &amp; placebo in COPD patients. www.astrazenecaclinicaltrials.com (accessed 8 April 2008). BleeckerER , MeyersDA , BaileyWC , SimsA‐M , BujacSR , GoldmanM , et al. ADRB2 polymorphisms and budesonide/formoterol responses in COPDADRB2 polymorphisms and treatment response in COPD. Chest2012;142(2):320‐8. TashkinDP , RennardSI , MartinP , GoldmanM , SilkoffPE . Efficacy of budesonide/formoterol administered via one pressurized metered‐dose inhaler over 6 months in patients with chronic obstructive pulmonary disease [Abstract]. Chest2008; Vol. 134, issue 4:105001s. TashkinDP , RennardSI , MartinP , RamachandranS , MartinUJ , SilkoffPE , et al. Efficacy and safety of budesonide and formoterol in one pressurized metered‐dose inhaler in patients with moderate to very severe chronic obstructive pulmonary disease : results of a 6‐month randomized clinical trial. Drugs2008; Vol. 68, issue 0012‐6667 (Print):1975‐2000. ">Tashkin 2008</a>; <a href="./references#CD006826-bbs2-0015" title="ZhongN , ZhengJ , WenF , YangL , ChenP , XiuQ , et al. Efficacy and safety of budesonide/formoterol via a dry powder inhaler in Chinese patients with chronic obstructive pulmonary disease. Current Medical Research and Opinion2012; Vol. 28, issue 2:257‐65. ZhongN , ZhengJ , WenF , YangL , ChenP , XiuQ , et al. Efficacy and safety of inhalation of budesonide/formoterol via turbuhaler in Chinese patients with chronic obstructive pulmonary disease [Abstract]. Chest2011; Vol. 140, issue 4:5225A. ">Zhong 2012</a>) did not identify a significant difference between BDF and BD (N = 1371, OR 1.11, 95% CI 0.47 to 2.63). </p> </section> <section id="CD006826-sec-0092"> <h6 class="title">MF/F versus MF</h6> <p>Both studies (<a href="./references#CD006826-bbs2-0012" title="KerwinE , TashkinDP , Matiz‐BuenoCE , DohertyDE , ShekarT , BanerjeeS , et al. Clinical efficacy and safety of combined mometasone furoate and formoterol in patients with moderate to very severe chronic obstructive pulmonary disease (COPD) [Abstract]. Journal of Allergy and Clinical Immunology2012; Vol. 129, issue 2 Suppl:AB201 [759]. NCT00383435 . A Randomized, 26‐Week, Placebo‐Controlled Efficacy and Safety Study With a 26‐Week Long‐Term Safety Extension, of High‐ and Medium‐Dose Inhaled Mometasone Furoate/Formoterol Fixed‐Dose Combination Formulation Compared With Formoterol and High‐Dose Inhaled Mometasone Furoate Monotherapy in Subjects With Moderate to Severe COPD, 2006. http://clinicaltrials.gov/show/NCT00383435. [] TashkinDP , DohertyDE , KerwinE , Matiz‐BuenoCE , KnorrB , ShekarT , et al. Efficacy and safety of a fixed‐dose combination of mometasone furoate and formoterol fumarate in subjects with moderate to very severe COPD: results from a 52‐week Phase III trial. International Journal of Chronic Obstructive Pulmonary Disease2012; Vol. 7, issue 1178‐2005 (Electronic). 1176‐9106 (Linking):43‐55. ">Tashkin 2012</a> and <a href="./references#CD006826-bbs2-0003" title="DohertyDE , KerwinE , TashkinDP , Matiz‐BuenoCE , ShekarT , BanerjeeS , et al. Combined mometasone furoate and formoterol in patients with moderate to very severe chronic obstructive pulmonary disease (COPD): phase 3 efficacy and safety study [Abstract]. Journal of Allergy and Clinical Immunology2012; Vol. 129, issue 2 Suppl:AB75 [283]. DohertyDE , TashkinDP , KerwinE , KnorrBA , ShekarT , BanerjeeS , et al. Effects of mometasone furoate/formoterol fumarate fixed‐dose combination formulation on chronic obstructive pulmonary disease (COPD): results from a 52‐week Phase III trial in subjects with moderate‐to‐very severe COPD. International Journal of Chronic Obstructive Pulmonary Disease2012; Vol. 7, issue 1178‐2005 (Electronic). 1176‐9106 (Linking):57‐71. NCT00383721 . A Randomized, 26‐Week, Placebo‐Controlled Efficacy and Safety Study With a 26‐Week Long‐Term Safety Extension, of High‐ and Medium‐Dose Inhaled Mometasone Furoate/Formoterol Fixed‐Dose Combination Formulation Compared With Formoterol and High‐Dose Inhaled Mometasone Furoate Monotherapy in Subjects With Moderate to Severe COPD, 2006. http://clinicaltrials.gov/show/NCT00383721. [] ">Doherty 2012</a>) included pneumonia in their range of outcomes. No significant difference between MF/F and MF was noted in the number of participants with pneumonia at the end of treatment (N = 905, OR 1.92, 95% CI 0.66 to 5.57). </p> </section> </section> </section> <section id="CD006826-sec-0093"> <h4 class="title">Secondary outcomes</h4> <section id="CD006826-sec-0094"> <h5 class="title">Change in lung function (FEV<sub>1</sub>) </h5> <section id="CD006826-sec-0095"> <h6 class="title">FPS versus FP</h6> <p>A significant difference in pre‐dose FEV<sub>1</sub> change from baseline favoured FPS (2 studies; <a href="./references#CD006826-bbs2-0004" title="HananiaNA , DarkenP , HorstmanD , ReisnerC , LeeB , DavisS , et al. The efficacy and safety of fluticasone propionate (250 micro g)/salmeterol (50 micro g) combined in the diskus inhaler for the treatment of COPD. Chest2003;124(3):834‐43. HananiaNA , RamsdellJ , PayneK , DavisS , HorstmanD , LeeB , et al. Improvements in airflow and dyspnea in COPD patients following 24 weeks treatment with salmeterol 50mcg and fluticasone propionate 250mcg alone or in combination via the diskus. American Journal of Respiratory &amp; Critical Care Medicine2001;163(5 Suppl):A279. HorstmanD , DarkenP , DavisS , LeeB . Improvements in FEV1 and symptoms in poorly reversible COPD patients following treatment with salmeterol 50mcg/fluticasone propionate 250mcg combination [Abstract]. European Respiratory Journal2003;22 Suppl 45:P434. MahlerDA , DarkenP , BrownCP , KnobilK . Predicting lung function responses to combination therapy in chronic obstructive pulmonary disease (COPD) [Abstract]. National COPD Conference; November 14‐15, 2003; Arlington, Virginia. Abstract 1081. MahlerDA , DarkenP , BrownCP , KnobilK . Predicting lung function responses to salmeterol/fluticasone propionate combination therapy in COPD [Abstract]. European Respiratory Journal2003;22 Suppl 45:P429. SFCA3007 . A randomized, double‐blind, placebo‐controlled, parallel‐group trial evaluating the safety and efficacy of the DISKUS formulations of salmeterol (SAL) 50mcg BID and fluticasone propionate (FP) 250mcg BID individually and in combination as salmeterol 50mcg/fluticasone propionate 250mcg BID (SFC 50/250) compared to placebo in COPD subjects. GlaxoSmithKline Clinical Trials Register (http:ctr.gsk.co.uk)2005. SpencerM , WireP , LeeB , ChangCN , DarkenP , HorstmanD . Patients with COPD using salmeterol/fluticasone propionate combination therapy experience improved quality of life. European Respiratory Journal2003;22 Suppl 45:51s. SpencerMD , KariaN , AndersonJ . The clinical significance of treatment benefits with the salmeterol/fluticasone propionate 50/500mcg combination in COPD. European Respiratory Journal2004;24 Suppl 48:290s. ">Hanania 2003</a>; <a href="./references#CD006826-bbs2-0006" title="MahlerDA , DarkenP , BrownCP , KnobilK . Predicting lung function responses to combination therapy in chronic obstructive pulmonary disease (COPD), 2003. http://www.abstracts2view.com. MahlerDA , WireP , HorstmanD , ChangCN , YatesJ , FischerT , et al. Effectiveness of fluticasone propionate and salmeterol combination delivered via the diskus device in the treatment of chronic obstructive pulmonary disease. American Journal of Respiratory Critical Care Medicine2002;166(8):1084‐91. SFCA3006 . A randomized, double‐blind, placebo‐controlled, parallel‐group trial evaluating the safety and efficacy of the DISKUS formulations of salmeterol (SAL) 50mcg BID and fluticasone propionate (FP) 500mcg BID individually and in combination as salmeterol 50mcg/fluticasone propionate 500mcg BID (SFC 50/500) compared to placebo in COPD subjects. GlaxoSmithKline Clinical Trials Register (http:ctr.gsk.co.uk)2005. SpencerM , WireP , LeeB , ChangCN , DarkenP , HorstmanD . Patients with COPD using salmeterol/fluticasone propionate combination therapy experience improved quality of life. European Respiratory Journal2003;22 Suppl 45:51s. SpencerMD , AndersonJA . Salmeterol/fluticasone combination produces clinically important benefits in dyspnea and fatigue [Abstract]. American Thoracic Society 2005 International Conference; May 20‐25, 2005; San Diego, California. B93 [Poster 308]. SpencerMD , KariaN , AndersonJ . The clinical significance of treatment benefits with the salmeterol/fluticasone propionate 50/500mcg combination in COPD. European Respiratory Journal2004;24 Suppl 48:290s. ">Mahler 2002</a>; N = 699, MD 0.05 L, 95% CI 0.02 to 0.09; <a href="./references#CD006826-fig-0024" title="">Analysis 2.11</a>). </p> <p>Similarly, a significant difference in post‐dose FEV<sub>1</sub> change from baseline favoured FPS (6 studies; <a href="./references#CD006826-bbs2-0004" title="HananiaNA , DarkenP , HorstmanD , ReisnerC , LeeB , DavisS , et al. The efficacy and safety of fluticasone propionate (250 micro g)/salmeterol (50 micro g) combined in the diskus inhaler for the treatment of COPD. Chest2003;124(3):834‐43. HananiaNA , RamsdellJ , PayneK , DavisS , HorstmanD , LeeB , et al. Improvements in airflow and dyspnea in COPD patients following 24 weeks treatment with salmeterol 50mcg and fluticasone propionate 250mcg alone or in combination via the diskus. American Journal of Respiratory &amp; Critical Care Medicine2001;163(5 Suppl):A279. HorstmanD , DarkenP , DavisS , LeeB . Improvements in FEV1 and symptoms in poorly reversible COPD patients following treatment with salmeterol 50mcg/fluticasone propionate 250mcg combination [Abstract]. European Respiratory Journal2003;22 Suppl 45:P434. MahlerDA , DarkenP , BrownCP , KnobilK . Predicting lung function responses to combination therapy in chronic obstructive pulmonary disease (COPD) [Abstract]. National COPD Conference; November 14‐15, 2003; Arlington, Virginia. Abstract 1081. MahlerDA , DarkenP , BrownCP , KnobilK . Predicting lung function responses to salmeterol/fluticasone propionate combination therapy in COPD [Abstract]. European Respiratory Journal2003;22 Suppl 45:P429. SFCA3007 . A randomized, double‐blind, placebo‐controlled, parallel‐group trial evaluating the safety and efficacy of the DISKUS formulations of salmeterol (SAL) 50mcg BID and fluticasone propionate (FP) 250mcg BID individually and in combination as salmeterol 50mcg/fluticasone propionate 250mcg BID (SFC 50/250) compared to placebo in COPD subjects. GlaxoSmithKline Clinical Trials Register (http:ctr.gsk.co.uk)2005. SpencerM , WireP , LeeB , ChangCN , DarkenP , HorstmanD . Patients with COPD using salmeterol/fluticasone propionate combination therapy experience improved quality of life. European Respiratory Journal2003;22 Suppl 45:51s. SpencerMD , KariaN , AndersonJ . The clinical significance of treatment benefits with the salmeterol/fluticasone propionate 50/500mcg combination in COPD. European Respiratory Journal2004;24 Suppl 48:290s. ">Hanania 2003</a>; <a href="./references#CD006826-bbs2-0005" title="LapperreTS , Snoeck‐StrobandJB , GosmanMM , JansenDF , vanSchadewijkA , ThiadensHA , et al. Effect of fluticasone with and without salmeterol on pulmonary outcomes in chronic obstructive pulmonary disease: a randomized trial. Annals of Internal Medicine2009; Vol. 151, issue 8:517‐27. ">Lapperre 2009</a>; <a href="./references#CD006826-bbs2-0006" title="MahlerDA , DarkenP , BrownCP , KnobilK . Predicting lung function responses to combination therapy in chronic obstructive pulmonary disease (COPD), 2003. http://www.abstracts2view.com. MahlerDA , WireP , HorstmanD , ChangCN , YatesJ , FischerT , et al. Effectiveness of fluticasone propionate and salmeterol combination delivered via the diskus device in the treatment of chronic obstructive pulmonary disease. American Journal of Respiratory Critical Care Medicine2002;166(8):1084‐91. SFCA3006 . A randomized, double‐blind, placebo‐controlled, parallel‐group trial evaluating the safety and efficacy of the DISKUS formulations of salmeterol (SAL) 50mcg BID and fluticasone propionate (FP) 500mcg BID individually and in combination as salmeterol 50mcg/fluticasone propionate 500mcg BID (SFC 50/500) compared to placebo in COPD subjects. GlaxoSmithKline Clinical Trials Register (http:ctr.gsk.co.uk)2005. SpencerM , WireP , LeeB , ChangCN , DarkenP , HorstmanD . Patients with COPD using salmeterol/fluticasone propionate combination therapy experience improved quality of life. European Respiratory Journal2003;22 Suppl 45:51s. SpencerMD , AndersonJA . Salmeterol/fluticasone combination produces clinically important benefits in dyspnea and fatigue [Abstract]. American Thoracic Society 2005 International Conference; May 20‐25, 2005; San Diego, California. B93 [Poster 308]. SpencerMD , KariaN , AndersonJ . The clinical significance of treatment benefits with the salmeterol/fluticasone propionate 50/500mcg combination in COPD. European Respiratory Journal2004;24 Suppl 48:290s. ">Mahler 2002</a>; <a href="./references#CD006826-bbs2-0008" title="SFCT01 . A Multicentre, Randomised, Double‐Blind, Parallel Group, Placebo‐Controlled Study to Compare the Efficacy and Safety of Inhaled Salmeterol/Fluticasone Propionate Combination Product 25/250 µg Two Puffs Bd and Fluticasone Propionate 250µg Two Puffs Bd Alone, All Administered Via Metered Dose Inhalers (MDI), in the Treatment of Subjects with Chronic Obstructive Pulmonary Disease (COPD) for 52 Weeks. GlaxoSmithKline Clinical Trials Register (http:ctr.gsk.co.uk)2005. ">SFCT01</a>; <a href="./references#CD006826-bbs2-0013" title="BriggsAH , GlickHA , Lozano‐OrtegaG , SpencerM , CalverleyPM , JonesPW , et al. Is treatment with ICS and LABA cost‐effective for COPD? Multinational economic analysis of the TORCH study. European Respiratory Journal2010; Vol. 35, issue 3:532‐9. CalverleyPM , AndersonJA , CelliB , FergusonGT , JenkinsC , JonesPW , et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease.[see comment]. New England Journal of Medicine2007; Vol. 356, issue 8:775‐89. CalverleyPMA , AndersonJA , CelliB , FergusonGT , JenkinsC , JonesPW , et al. Cardiovascular events in patients with chronic obstructive pulmonary disease: TORCH study results. Thorax2010;65:719‐25. CalverleyPMA , AndersonJA , CelliB , FergusonGT , JenkinsC , JonesPW , et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. New England Journal of Medicine2007;356(8):775‐89. CalverleyPMA , CelliB , FergusonG , JenkinsC , JonesPW , PrideNB , et al. Baseline characteristics of the first 5,000 COPD patients enrolled in the TORCH survival study. European Respiratory Journal2003;22 Suppl 45:578s. CelliB , CalverleyPMA , AndersonJA , FergusonGT , JenkinsC , JonesPW , et al. The TORCH (TOwards a Revolution in COPD Health) study: salmeterol/fluticasone propionate (SFC) improves health status, reduces exacerbations and improves lung function over three years. European Respiratory Journal2006;28 Suppl 50:34s. CelliB , VestboJ , JenkinsCR , JonesPW , FergusonGT , CalverleyPM , et al. Sex differences in mortality and clinical expressions of patients with chronic obstructive pulmonary disease: the TORCH experience. American Journal of Respiratory and Critical Care Medicine2011;183(3):317‐22. CelliBR , ThomasNE , AndersonJA , FergusonGT , JenkinsCR , JonesPW , et al. Effect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease: results from the TORCH study. American Journal of Respiratory and Critical Care Medicine2008;174(4):332‐8. CrimC , CalverleyPM , AndersonJA , CelliB , FergusonGT , JenkinsC , et al. Pneumonia risk in COPD patients receiving inhaled corticosteroids alone or in combination: TORCH study results. European Respiratory Journal2009;34(3):641‐7. FergusonGT , CalverleyPM , AndersonJA , JenkinsCR , JonesPW , WillitsLR , et al. Prevalence and progression of osteoporosis in patients with COPD: results from the TOwards a Revolution in COPD Health study. Chest2009; Vol. 136, issue 0012‐3692:1456‐65. FergusonGT , CalverleyPMA , AndersonJA , et al. The TORCH (TOwards a Revolution in COPD Health) study: salmeterol/fluticasone propionate (SFC) improves survival in COPD over three years. European Respiratory Journal2006;28 Suppl 50:34s. GlaxoSmithKlineSCO30003 . A multicentre, randomised, double‐blind, parallel group, placebo‐controlled study to investigate the long‐term effects of salmeterol/fluticasone propionate (SERETIDE/VIANI/ADVAIR) 50/500mcg bd, salmeterol 50mcg bd and fluticasone propionate 500mcg bd, all delivered via the DISKUS/ACCUHALER inhaler, on the survival of subjects with chronic obstructive pulmonary disease (COPD) over 3 years of treatment. GlaxoSmithKline Clinical Trial Register2006. HoughtonCM , LawsonN , BorrillZL , WixonCL , YoxallS , LangleySJ , et al. Comparison of the effects of salmeterol/fluticasone propionate with fluticasone propionate on airway physiology in adults with mild persistent asthma. Respiratory Research2007;8:52. JenkinsCR , CalverleyPMA , CelliB , FergusonG , JonesPW , PrideN , et al. Seasonal patterns of exacerbation rates in the TORCH survival study, 2007. http://www.abstracts2view.comA839. JenkinsCR , CelliB , AndersonJA , FergusonGT , JonesPW , VestboJ , et al. Seasonality and determinants of moderate and severe COPD exacerbations in the TORCH study. European Respiratory Journal2012;39(1):38‐45. JenkinsCR , JonesPW , CalverleyPM , CelliB , AndersonJA , FergusonGT , et al. Efficacy of salmeterol/fluticasone propionate by GOLD stage of chronic obstructive pulmonary disease: analysis from the randomised, placebo‐controlled TORCH study. Respiratory Research2009;10:59. JohnsonM , AgustiAG , BarnesNC . Reflections on TORCH: potential mechanisms for the survival benefit of salmeterol/fluticasone propionate in COPD patients. COPD2008;5(6):369‐75. JonesPW , AndersonJA , CalverleyPM , CelliBR , FergusonGT , JenkinsC , et al. TORCH Investigators. Health status in the TORCH study of COPD: treatment efficacy and other determinants of change. Respiratory Research2011;12:71. JonesPW , CalverleyP , CelliB , FergusonG , JenkinsC , PrideN . Trans‐regional validity of the SGRQ in the TORCH survival study, 2007. http://www.abstracts2view.comA122. McGarveyLP , JohnM , AndersonJA , ZvarichMT , WiseRA . Ascertainment of cause‐specific mortality in COPD: operations of the TORCH Clinical Endpoint Committee. Thorax2007;62:411‐5. NCT00268216 . See detailed description, 2000. http://clinicaltrials.gov/show/NCT00268216. [] SCO30003 . A multicentre, randomised, double‐blind, parallel group, placebo‐controlled study to investigate the long‐term effects of salmeterol/fluticasone propionate (SERETIDE®/VIANI®/ADVAIR®) 50/500mcg bd, salmeterol 50mcg bd and fluticasone propionate 500mcg bd, all delivered via the DISKUS®/ACCUHALER® inhaler, on the survival of subjects with chronic obstructive pulmonary disease (COPD) over 3 years of treatment, 2006. www.ctr.gsk.co.uk. VestboJ , AndersonJA , CalverleyPM , CelliB , FergusonGT , JenkinsC , et al. Adherence to inhaled therapy, mortality and hospital admission in COPD. Thorax2009;64(11):939‐43. VestboJ , CalverleyP , CelliB , FergusonG , JenkinsC , JonesP , et al. The TORCH (TOwards a Revolution in COPD Health) survival study protocol. European Respiratory Journal2004;24(2):206‐10. WiseRA , McGarveyLP , JohnM , AndersonJA , ZvarichMT . Reliability of cause‐specific mortality adjudication in a COPD clinical trial, 2007. http://www.abstracts2view.comA120. ">TORCH</a>; <a href="./references#CD006826-bbs2-0014" title="CalverleyP , PauwelsR , VestboJ , JonesP , PrideN , GulsvikA , et al. Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial. Lancet2003;361(9356):449‐56. CalverleyPMA , PauwelsRA , VestboJ , JonesPW , PrideNB , GulsvikA , et al. Clinical improvements with salmeterol / fluticasone propionate combination in differing severities of COPD, 2003. http://www.abstracts2view.comA035 [Poster D50]. CalverleyPMA , PauwelsRA , VestboJ , JonesPW , PrideNB , GulsvikA , et al. Salmeterol/Fluticasone propionate combination for one year provides greater clinical benefit than its individual components. Proceedings of the 98th International American Thoracic Society Conference http://www.abstracts‐on‐line.com/abstracts/ATS; May 17‐22, 2002; Atlanta, Georgia. A98 [Poster 306]. CalverlyPMA , PauwelsR , VestboJ , JonesP , PrideN , GulsvikA , et al. Safety of salmeterol/fluticasone propionate combination in the treatment of chronic obstructive pulmonary disease. European Respiratory Journal2002;20 Suppl 38:242 [P1572]. HunjanMK , ChandlerF . Numbers needed to treat (NNT) to avoid an exacerbation in patients with chronic obstructive pulmonary disease (COPD) using salmeterol/fluticasone propionate combination (SFC) and associated costs [Abstract]. American Thoracic Society 100th International Conference; May 21‐26, 2004; Orlando, Florida. D22 [Poster 503]. HunjanMK , WilliamsDT . Costs of avoiding exacerbations in patients with chronic obstructive pulmonary disease (COPD) treated with salmeterol/ fluticasone propionate combination (seretide) and salmeterol. European Respiratory Journal2004;24 Suppl 48:291s. HunjanMK , WilliamsDT . Salmeterol/ fluticasone propionate combination is clinically effective in avoiding exacerbations in patients with moderate/severe COPD. European Respiratory Journal2004;24 Suppl 48:513s. JonesPW , EdinHM , AndersonJ . Salmeterol/fluticasone propionate combination improves health status in COPD patients. Proceedings of the 98th International American Thoracic Society Conference http://www.abstracts‐on‐line.com/abstracts/ATS; May 17‐22, 2002; Atlanta, Georgia. A39 [Poster K39]. JonesPW , StåhlE . Budesonide /formoterol sustains clinically relevant improvements in health status in COPD [Abstract]. European Respiratory Journal2005;26 Suppl 49:Abstract 1352. JonesPW , VestboJ , PauwelsRA , CalverleyPMA , AndersonJA , SpencerMD . Informative drop out in COPD studies: investigation of health status of withdrawals in the TRISTAN study. Proceedings of the 13th ERS Annual Congress; September 27, 2003; Vienna, Austria. P1593. NitschmannS . Inhalational combination therapy in chronic obstructive lung disease. Tristan study. German Internist2004;45(6):727‐8. PauwelsR , VestboJ , CalverleyPMA , JonesPW , PrideNB , GulsvikA . Characterization of exacerbations in the TRISTAN study of salmeterol / fluticasone propionate (SFC) combination in moderate to severe COPD, 2006. http://www.abstracts2view.com. PauwelsRA , CalverlyPMA , VestboJ , JonesPW , PrideN , GulsvikA , et al. Reduction of exacerbations with salmeterol/fluticasone combination 50/500 mcg bd in the treatment of chronic obstructive pulmonary disease. European Respiratory Journal2002;20 Suppl 38:240 [P1569]. SFCB3024 . A multicentre, randomised, double‐blind, parallel group, placebo‐controlled study to compare the efficacy and safety of the salmeterol/FP combination product at a strength of 50/500mcg bd with salmeterol 50mcg bd alone and FP 500mcg bd alone, delivered via the DISKUS™/ACCUHALER™, in the treatment of subjects with chronic obstructive pulmonary disease (COPD) for 12 months. GlaxoSmithKline Clinical Trials Register (http:ctr.gsk.co.uk)2005. SpencerM , BriggsAH , GrossmanRF , RanceL . Development of an economic model to assess the cost effectiveness of treatment interventions for chronic obstructive pulmonary disease. Pharmacoeconomics2005;23(6):619‐37. SpencerMD , KariaN , AndersonJ . The clinical significance of treatment benefits with the salmeterol/fluticasone propionate 50/500mcg combination in COPD. European Respiratory Journal2004;24 Suppl 48:290s. VestboJ , CalverleyPMA , PauwelsR , JonesP , PrideN , GulsvikA , et al. Absence of gender susceptibility to the combination of salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease. European Respiratory Journal2002;20 Suppl 38:240 [P1570]. VestboJ , PauwelsR , AndersonJA , JonesP , CalverleyP . Early onset of effect of salmeterol and fluticasone propionate in chronic obstructive pulmonary disease. Thorax2005;60(4):301‐4. VestboJ , PauwelsRS , CalverleyPMA , JonesPW , PrideNB , GulsvikA . Salmeterol / fluticasone propionate combination produces improvement in lung function detectable within 24 hours in moderate to severe COPD, 2003. http://www.abstracts2view.com. VestboJ , SorianoJB , AndersonJA , CalverleyP , PauwelsR , JonesP . Gender does not influence the response to the combination of salmeterol and fluticasone propionate in COPD. Respiratory Medicine2004;98(11):1045‐50. ">TRISTAN</a>; N = 4833, MD 0.05 L, 95% CI 0.04 to 0.06; <a href="./references#CD006826-fig-0025" title="">Analysis 2.12</a>). </p> <p>Data incorporated in this analysis from <a href="./references#CD006826-bbs2-0008" title="SFCT01 . A Multicentre, Randomised, Double‐Blind, Parallel Group, Placebo‐Controlled Study to Compare the Efficacy and Safety of Inhaled Salmeterol/Fluticasone Propionate Combination Product 25/250 µg Two Puffs Bd and Fluticasone Propionate 250µg Two Puffs Bd Alone, All Administered Via Metered Dose Inhalers (MDI), in the Treatment of Subjects with Chronic Obstructive Pulmonary Disease (COPD) for 52 Weeks. GlaxoSmithKline Clinical Trials Register (http:ctr.gsk.co.uk)2005. ">SFCT01</a> and <a href="./references#CD006826-bbs2-0014" title="CalverleyP , PauwelsR , VestboJ , JonesP , PrideN , GulsvikA , et al. Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial. Lancet2003;361(9356):449‐56. CalverleyPMA , PauwelsRA , VestboJ , JonesPW , PrideNB , GulsvikA , et al. Clinical improvements with salmeterol / fluticasone propionate combination in differing severities of COPD, 2003. http://www.abstracts2view.comA035 [Poster D50]. CalverleyPMA , PauwelsRA , VestboJ , JonesPW , PrideNB , GulsvikA , et al. Salmeterol/Fluticasone propionate combination for one year provides greater clinical benefit than its individual components. Proceedings of the 98th International American Thoracic Society Conference http://www.abstracts‐on‐line.com/abstracts/ATS; May 17‐22, 2002; Atlanta, Georgia. A98 [Poster 306]. CalverlyPMA , PauwelsR , VestboJ , JonesP , PrideN , GulsvikA , et al. Safety of salmeterol/fluticasone propionate combination in the treatment of chronic obstructive pulmonary disease. European Respiratory Journal2002;20 Suppl 38:242 [P1572]. HunjanMK , ChandlerF . Numbers needed to treat (NNT) to avoid an exacerbation in patients with chronic obstructive pulmonary disease (COPD) using salmeterol/fluticasone propionate combination (SFC) and associated costs [Abstract]. American Thoracic Society 100th International Conference; May 21‐26, 2004; Orlando, Florida. D22 [Poster 503]. HunjanMK , WilliamsDT . Costs of avoiding exacerbations in patients with chronic obstructive pulmonary disease (COPD) treated with salmeterol/ fluticasone propionate combination (seretide) and salmeterol. European Respiratory Journal2004;24 Suppl 48:291s. HunjanMK , WilliamsDT . Salmeterol/ fluticasone propionate combination is clinically effective in avoiding exacerbations in patients with moderate/severe COPD. European Respiratory Journal2004;24 Suppl 48:513s. JonesPW , EdinHM , AndersonJ . Salmeterol/fluticasone propionate combination improves health status in COPD patients. Proceedings of the 98th International American Thoracic Society Conference http://www.abstracts‐on‐line.com/abstracts/ATS; May 17‐22, 2002; Atlanta, Georgia. A39 [Poster K39]. JonesPW , StåhlE . Budesonide /formoterol sustains clinically relevant improvements in health status in COPD [Abstract]. European Respiratory Journal2005;26 Suppl 49:Abstract 1352. JonesPW , VestboJ , PauwelsRA , CalverleyPMA , AndersonJA , SpencerMD . Informative drop out in COPD studies: investigation of health status of withdrawals in the TRISTAN study. Proceedings of the 13th ERS Annual Congress; September 27, 2003; Vienna, Austria. P1593. NitschmannS . Inhalational combination therapy in chronic obstructive lung disease. Tristan study. German Internist2004;45(6):727‐8. PauwelsR , VestboJ , CalverleyPMA , JonesPW , PrideNB , GulsvikA . Characterization of exacerbations in the TRISTAN study of salmeterol / fluticasone propionate (SFC) combination in moderate to severe COPD, 2006. http://www.abstracts2view.com. PauwelsRA , CalverlyPMA , VestboJ , JonesPW , PrideN , GulsvikA , et al. Reduction of exacerbations with salmeterol/fluticasone combination 50/500 mcg bd in the treatment of chronic obstructive pulmonary disease. European Respiratory Journal2002;20 Suppl 38:240 [P1569]. SFCB3024 . A multicentre, randomised, double‐blind, parallel group, placebo‐controlled study to compare the efficacy and safety of the salmeterol/FP combination product at a strength of 50/500mcg bd with salmeterol 50mcg bd alone and FP 500mcg bd alone, delivered via the DISKUS™/ACCUHALER™, in the treatment of subjects with chronic obstructive pulmonary disease (COPD) for 12 months. GlaxoSmithKline Clinical Trials Register (http:ctr.gsk.co.uk)2005. SpencerM , BriggsAH , GrossmanRF , RanceL . Development of an economic model to assess the cost effectiveness of treatment interventions for chronic obstructive pulmonary disease. Pharmacoeconomics2005;23(6):619‐37. SpencerMD , KariaN , AndersonJ . The clinical significance of treatment benefits with the salmeterol/fluticasone propionate 50/500mcg combination in COPD. European Respiratory Journal2004;24 Suppl 48:290s. VestboJ , CalverleyPMA , PauwelsR , JonesP , PrideN , GulsvikA , et al. Absence of gender susceptibility to the combination of salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease. European Respiratory Journal2002;20 Suppl 38:240 [P1570]. VestboJ , PauwelsR , AndersonJA , JonesP , CalverleyP . Early onset of effect of salmeterol and fluticasone propionate in chronic obstructive pulmonary disease. Thorax2005;60(4):301‐4. VestboJ , PauwelsRS , CalverleyPMA , JonesPW , PrideNB , GulsvikA . Salmeterol / fluticasone propionate combination produces improvement in lung function detectable within 24 hours in moderate to severe COPD, 2003. http://www.abstracts2view.com. VestboJ , SorianoJB , AndersonJA , CalverleyP , PauwelsR , JonesP . Gender does not influence the response to the combination of salmeterol and fluticasone propionate in COPD. Respiratory Medicine2004;98(11):1045‐50. ">TRISTAN</a> were end of treatment data rather than change from baseline data. </p> </section> <section id="CD006826-sec-0096"> <h6 class="title">BDF versus BD</h6> <p>The pre‐dose FEV<sub>1</sub> change from baseline to the average over the randomised treatment period (1 study; N = 552, MD 0.08 L, 95% CI 0.05 to 0.11; <a href="./references#CD006826-fig-0043" title="">Analysis 3.9</a>) was significant. Only one study (<a href="./references#CD006826-bbs2-0011" title="Astrazeneca(D5899C00002) . A 6‐month double‐blind, double‐dummy, randomized, parallel group, multicenter efficacy &amp; safety study of Symbicort® pMDI 2 × 160/4.5mg &amp; 80/4.5mg bid compared to Formoterol TBH, Budesonide pMDI (&amp; the combination) &amp; placebo in COPD patients. www.astrazenecaclinicaltrials.com (accessed 8 April 2008). BleeckerER , MeyersDA , BaileyWC , SimsA‐M , BujacSR , GoldmanM , et al. ADRB2 polymorphisms and budesonide/formoterol responses in COPDADRB2 polymorphisms and treatment response in COPD. Chest2012;142(2):320‐8. TashkinDP , RennardSI , MartinP , GoldmanM , SilkoffPE . Efficacy of budesonide/formoterol administered via one pressurized metered‐dose inhaler over 6 months in patients with chronic obstructive pulmonary disease [Abstract]. Chest2008; Vol. 134, issue 4:105001s. TashkinDP , RennardSI , MartinP , RamachandranS , MartinUJ , SilkoffPE , et al. Efficacy and safety of budesonide and formoterol in one pressurized metered‐dose inhaler in patients with moderate to very severe chronic obstructive pulmonary disease : results of a 6‐month randomized clinical trial. Drugs2008; Vol. 68, issue 0012‐6667 (Print):1975‐2000. ">Tashkin 2008</a>) contributed to this outcome, and it included a partially reversible population (a mixed population). </p> <p>The 1‐hour post‐dose FEV<sub>1</sub> change from baseline to the average over the randomised treatment period (1 study; N = 552, MD 0.17 L, 95% CI 0.14 to 0.20; <a href="./references#CD006826-fig-0044" title="">Analysis 3.10</a>) was also significant. Again, only one study (<a href="./references#CD006826-bbs2-0011" title="Astrazeneca(D5899C00002) . A 6‐month double‐blind, double‐dummy, randomized, parallel group, multicenter efficacy &amp; safety study of Symbicort® pMDI 2 × 160/4.5mg &amp; 80/4.5mg bid compared to Formoterol TBH, Budesonide pMDI (&amp; the combination) &amp; placebo in COPD patients. www.astrazenecaclinicaltrials.com (accessed 8 April 2008). BleeckerER , MeyersDA , BaileyWC , SimsA‐M , BujacSR , GoldmanM , et al. ADRB2 polymorphisms and budesonide/formoterol responses in COPDADRB2 polymorphisms and treatment response in COPD. Chest2012;142(2):320‐8. TashkinDP , RennardSI , MartinP , GoldmanM , SilkoffPE . Efficacy of budesonide/formoterol administered via one pressurized metered‐dose inhaler over 6 months in patients with chronic obstructive pulmonary disease [Abstract]. Chest2008; Vol. 134, issue 4:105001s. TashkinDP , RennardSI , MartinP , RamachandranS , MartinUJ , SilkoffPE , et al. Efficacy and safety of budesonide and formoterol in one pressurized metered‐dose inhaler in patients with moderate to very severe chronic obstructive pulmonary disease : results of a 6‐month randomized clinical trial. Drugs2008; Vol. 68, issue 0012‐6667 (Print):1975‐2000. ">Tashkin 2008</a>) contributed to this outcome, and it included a partially reversible population (a mixed population). </p> </section> <section id="CD006826-sec-0097"> <h6 class="title">MF/F versus MF</h6> <p>We analysed change from baseline in FEV<sub>1</sub> AUC<sub>0‐12 h</sub> at week 13 (2 studies; <a href="./references#CD006826-bbs2-0003" title="DohertyDE , KerwinE , TashkinDP , Matiz‐BuenoCE , ShekarT , BanerjeeS , et al. Combined mometasone furoate and formoterol in patients with moderate to very severe chronic obstructive pulmonary disease (COPD): phase 3 efficacy and safety study [Abstract]. Journal of Allergy and Clinical Immunology2012; Vol. 129, issue 2 Suppl:AB75 [283]. DohertyDE , TashkinDP , KerwinE , KnorrBA , ShekarT , BanerjeeS , et al. Effects of mometasone furoate/formoterol fumarate fixed‐dose combination formulation on chronic obstructive pulmonary disease (COPD): results from a 52‐week Phase III trial in subjects with moderate‐to‐very severe COPD. International Journal of Chronic Obstructive Pulmonary Disease2012; Vol. 7, issue 1178‐2005 (Electronic). 1176‐9106 (Linking):57‐71. NCT00383721 . A Randomized, 26‐Week, Placebo‐Controlled Efficacy and Safety Study With a 26‐Week Long‐Term Safety Extension, of High‐ and Medium‐Dose Inhaled Mometasone Furoate/Formoterol Fixed‐Dose Combination Formulation Compared With Formoterol and High‐Dose Inhaled Mometasone Furoate Monotherapy in Subjects With Moderate to Severe COPD, 2006. http://clinicaltrials.gov/show/NCT00383721. [] ">Doherty 2012</a>; <a href="./references#CD006826-bbs2-0012" title="KerwinE , TashkinDP , Matiz‐BuenoCE , DohertyDE , ShekarT , BanerjeeS , et al. Clinical efficacy and safety of combined mometasone furoate and formoterol in patients with moderate to very severe chronic obstructive pulmonary disease (COPD) [Abstract]. Journal of Allergy and Clinical Immunology2012; Vol. 129, issue 2 Suppl:AB201 [759]. NCT00383435 . A Randomized, 26‐Week, Placebo‐Controlled Efficacy and Safety Study With a 26‐Week Long‐Term Safety Extension, of High‐ and Medium‐Dose Inhaled Mometasone Furoate/Formoterol Fixed‐Dose Combination Formulation Compared With Formoterol and High‐Dose Inhaled Mometasone Furoate Monotherapy in Subjects With Moderate to Severe COPD, 2006. http://clinicaltrials.gov/show/NCT00383435. [] TashkinDP , DohertyDE , KerwinE , Matiz‐BuenoCE , KnorrB , ShekarT , et al. Efficacy and safety of a fixed‐dose combination of mometasone furoate and formoterol fumarate in subjects with moderate to very severe COPD: results from a 52‐week Phase III trial. International Journal of Chronic Obstructive Pulmonary Disease2012; Vol. 7, issue 1178‐2005 (Electronic). 1176‐9106 (Linking):43‐55. ">Tashkin 2012</a>; N = 905, MD 116.59 mL, 95% CI 68.59 to 164.59; <a href="./references#CD006826-fig-0061" title="">Analysis 4.5</a>) and at week 26 (same two studies; MD 109.34 mL, 95% CI 57.87 to 160.81; <a href="./references#CD006826-fig-0060" title="">Analysis 4.4</a>). In both cases, a significant benefit favoured MF/F. An effect in favour of MF/F was also observed in mean change from baseline in morning pre‐dose FEV<sub>1</sub> at 13 weeks (MD 0.08 L, 95% CI 0.04 to 0.11; <a href="./references#CD006826-fig-0062" title="">Analysis 4.6</a>). </p> </section> </section> <section id="CD006826-sec-0098"> <h5 class="title">Quality of life</h5> <section id="CD006826-sec-0099"> <h6 class="title">FPS versus FP</h6> <p>A significant improvement favoured FPS over FP: ‐1.30 units on the SGRQ (3 studies; <a href="./references#CD006826-bbs2-0008" title="SFCT01 . A Multicentre, Randomised, Double‐Blind, Parallel Group, Placebo‐Controlled Study to Compare the Efficacy and Safety of Inhaled Salmeterol/Fluticasone Propionate Combination Product 25/250 µg Two Puffs Bd and Fluticasone Propionate 250µg Two Puffs Bd Alone, All Administered Via Metered Dose Inhalers (MDI), in the Treatment of Subjects with Chronic Obstructive Pulmonary Disease (COPD) for 52 Weeks. GlaxoSmithKline Clinical Trials Register (http:ctr.gsk.co.uk)2005. ">SFCT01</a>; <a href="./references#CD006826-bbs2-0013" title="BriggsAH , GlickHA , Lozano‐OrtegaG , SpencerM , CalverleyPM , JonesPW , et al. Is treatment with ICS and LABA cost‐effective for COPD? Multinational economic analysis of the TORCH study. European Respiratory Journal2010; Vol. 35, issue 3:532‐9. CalverleyPM , AndersonJA , CelliB , FergusonGT , JenkinsC , JonesPW , et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease.[see comment]. New England Journal of Medicine2007; Vol. 356, issue 8:775‐89. CalverleyPMA , AndersonJA , CelliB , FergusonGT , JenkinsC , JonesPW , et al. Cardiovascular events in patients with chronic obstructive pulmonary disease: TORCH study results. Thorax2010;65:719‐25. CalverleyPMA , AndersonJA , CelliB , FergusonGT , JenkinsC , JonesPW , et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. New England Journal of Medicine2007;356(8):775‐89. CalverleyPMA , CelliB , FergusonG , JenkinsC , JonesPW , PrideNB , et al. Baseline characteristics of the first 5,000 COPD patients enrolled in the TORCH survival study. European Respiratory Journal2003;22 Suppl 45:578s. CelliB , CalverleyPMA , AndersonJA , FergusonGT , JenkinsC , JonesPW , et al. The TORCH (TOwards a Revolution in COPD Health) study: salmeterol/fluticasone propionate (SFC) improves health status, reduces exacerbations and improves lung function over three years. European Respiratory Journal2006;28 Suppl 50:34s. CelliB , VestboJ , JenkinsCR , JonesPW , FergusonGT , CalverleyPM , et al. Sex differences in mortality and clinical expressions of patients with chronic obstructive pulmonary disease: the TORCH experience. American Journal of Respiratory and Critical Care Medicine2011;183(3):317‐22. CelliBR , ThomasNE , AndersonJA , FergusonGT , JenkinsCR , JonesPW , et al. Effect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease: results from the TORCH study. American Journal of Respiratory and Critical Care Medicine2008;174(4):332‐8. CrimC , CalverleyPM , AndersonJA , CelliB , FergusonGT , JenkinsC , et al. Pneumonia risk in COPD patients receiving inhaled corticosteroids alone or in combination: TORCH study results. European Respiratory Journal2009;34(3):641‐7. FergusonGT , CalverleyPM , AndersonJA , JenkinsCR , JonesPW , WillitsLR , et al. Prevalence and progression of osteoporosis in patients with COPD: results from the TOwards a Revolution in COPD Health study. Chest2009; Vol. 136, issue 0012‐3692:1456‐65. FergusonGT , CalverleyPMA , AndersonJA , et al. The TORCH (TOwards a Revolution in COPD Health) study: salmeterol/fluticasone propionate (SFC) improves survival in COPD over three years. European Respiratory Journal2006;28 Suppl 50:34s. GlaxoSmithKlineSCO30003 . A multicentre, randomised, double‐blind, parallel group, placebo‐controlled study to investigate the long‐term effects of salmeterol/fluticasone propionate (SERETIDE/VIANI/ADVAIR) 50/500mcg bd, salmeterol 50mcg bd and fluticasone propionate 500mcg bd, all delivered via the DISKUS/ACCUHALER inhaler, on the survival of subjects with chronic obstructive pulmonary disease (COPD) over 3 years of treatment. GlaxoSmithKline Clinical Trial Register2006. HoughtonCM , LawsonN , BorrillZL , WixonCL , YoxallS , LangleySJ , et al. Comparison of the effects of salmeterol/fluticasone propionate with fluticasone propionate on airway physiology in adults with mild persistent asthma. Respiratory Research2007;8:52. JenkinsCR , CalverleyPMA , CelliB , FergusonG , JonesPW , PrideN , et al. Seasonal patterns of exacerbation rates in the TORCH survival study, 2007. http://www.abstracts2view.comA839. JenkinsCR , CelliB , AndersonJA , FergusonGT , JonesPW , VestboJ , et al. Seasonality and determinants of moderate and severe COPD exacerbations in the TORCH study. European Respiratory Journal2012;39(1):38‐45. JenkinsCR , JonesPW , CalverleyPM , CelliB , AndersonJA , FergusonGT , et al. Efficacy of salmeterol/fluticasone propionate by GOLD stage of chronic obstructive pulmonary disease: analysis from the randomised, placebo‐controlled TORCH study. Respiratory Research2009;10:59. JohnsonM , AgustiAG , BarnesNC . Reflections on TORCH: potential mechanisms for the survival benefit of salmeterol/fluticasone propionate in COPD patients. COPD2008;5(6):369‐75. JonesPW , AndersonJA , CalverleyPM , CelliBR , FergusonGT , JenkinsC , et al. TORCH Investigators. Health status in the TORCH study of COPD: treatment efficacy and other determinants of change. Respiratory Research2011;12:71. JonesPW , CalverleyP , CelliB , FergusonG , JenkinsC , PrideN . Trans‐regional validity of the SGRQ in the TORCH survival study, 2007. http://www.abstracts2view.comA122. McGarveyLP , JohnM , AndersonJA , ZvarichMT , WiseRA . Ascertainment of cause‐specific mortality in COPD: operations of the TORCH Clinical Endpoint Committee. Thorax2007;62:411‐5. NCT00268216 . See detailed description, 2000. http://clinicaltrials.gov/show/NCT00268216. [] SCO30003 . A multicentre, randomised, double‐blind, parallel group, placebo‐controlled study to investigate the long‐term effects of salmeterol/fluticasone propionate (SERETIDE®/VIANI®/ADVAIR®) 50/500mcg bd, salmeterol 50mcg bd and fluticasone propionate 500mcg bd, all delivered via the DISKUS®/ACCUHALER® inhaler, on the survival of subjects with chronic obstructive pulmonary disease (COPD) over 3 years of treatment, 2006. www.ctr.gsk.co.uk. VestboJ , AndersonJA , CalverleyPM , CelliB , FergusonGT , JenkinsC , et al. Adherence to inhaled therapy, mortality and hospital admission in COPD. Thorax2009;64(11):939‐43. VestboJ , CalverleyP , CelliB , FergusonG , JenkinsC , JonesP , et al. The TORCH (TOwards a Revolution in COPD Health) survival study protocol. European Respiratory Journal2004;24(2):206‐10. WiseRA , McGarveyLP , JohnM , AndersonJA , ZvarichMT . Reliability of cause‐specific mortality adjudication in a COPD clinical trial, 2007. http://www.abstracts2view.comA120. ">TORCH</a>; <a href="./references#CD006826-bbs2-0014" title="CalverleyP , PauwelsR , VestboJ , JonesP , PrideN , GulsvikA , et al. Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial. Lancet2003;361(9356):449‐56. CalverleyPMA , PauwelsRA , VestboJ , JonesPW , PrideNB , GulsvikA , et al. Clinical improvements with salmeterol / fluticasone propionate combination in differing severities of COPD, 2003. http://www.abstracts2view.comA035 [Poster D50]. CalverleyPMA , PauwelsRA , VestboJ , JonesPW , PrideNB , GulsvikA , et al. Salmeterol/Fluticasone propionate combination for one year provides greater clinical benefit than its individual components. Proceedings of the 98th International American Thoracic Society Conference http://www.abstracts‐on‐line.com/abstracts/ATS; May 17‐22, 2002; Atlanta, Georgia. A98 [Poster 306]. CalverlyPMA , PauwelsR , VestboJ , JonesP , PrideN , GulsvikA , et al. Safety of salmeterol/fluticasone propionate combination in the treatment of chronic obstructive pulmonary disease. European Respiratory Journal2002;20 Suppl 38:242 [P1572]. HunjanMK , ChandlerF . Numbers needed to treat (NNT) to avoid an exacerbation in patients with chronic obstructive pulmonary disease (COPD) using salmeterol/fluticasone propionate combination (SFC) and associated costs [Abstract]. American Thoracic Society 100th International Conference; May 21‐26, 2004; Orlando, Florida. D22 [Poster 503]. HunjanMK , WilliamsDT . Costs of avoiding exacerbations in patients with chronic obstructive pulmonary disease (COPD) treated with salmeterol/ fluticasone propionate combination (seretide) and salmeterol. European Respiratory Journal2004;24 Suppl 48:291s. HunjanMK , WilliamsDT . Salmeterol/ fluticasone propionate combination is clinically effective in avoiding exacerbations in patients with moderate/severe COPD. European Respiratory Journal2004;24 Suppl 48:513s. JonesPW , EdinHM , AndersonJ . Salmeterol/fluticasone propionate combination improves health status in COPD patients. Proceedings of the 98th International American Thoracic Society Conference http://www.abstracts‐on‐line.com/abstracts/ATS; May 17‐22, 2002; Atlanta, Georgia. A39 [Poster K39]. JonesPW , StåhlE . Budesonide /formoterol sustains clinically relevant improvements in health status in COPD [Abstract]. European Respiratory Journal2005;26 Suppl 49:Abstract 1352. JonesPW , VestboJ , PauwelsRA , CalverleyPMA , AndersonJA , SpencerMD . Informative drop out in COPD studies: investigation of health status of withdrawals in the TRISTAN study. Proceedings of the 13th ERS Annual Congress; September 27, 2003; Vienna, Austria. P1593. NitschmannS . Inhalational combination therapy in chronic obstructive lung disease. Tristan study. German Internist2004;45(6):727‐8. PauwelsR , VestboJ , CalverleyPMA , JonesPW , PrideNB , GulsvikA . Characterization of exacerbations in the TRISTAN study of salmeterol / fluticasone propionate (SFC) combination in moderate to severe COPD, 2006. http://www.abstracts2view.com. PauwelsRA , CalverlyPMA , VestboJ , JonesPW , PrideN , GulsvikA , et al. Reduction of exacerbations with salmeterol/fluticasone combination 50/500 mcg bd in the treatment of chronic obstructive pulmonary disease. European Respiratory Journal2002;20 Suppl 38:240 [P1569]. SFCB3024 . A multicentre, randomised, double‐blind, parallel group, placebo‐controlled study to compare the efficacy and safety of the salmeterol/FP combination product at a strength of 50/500mcg bd with salmeterol 50mcg bd alone and FP 500mcg bd alone, delivered via the DISKUS™/ACCUHALER™, in the treatment of subjects with chronic obstructive pulmonary disease (COPD) for 12 months. GlaxoSmithKline Clinical Trials Register (http:ctr.gsk.co.uk)2005. SpencerM , BriggsAH , GrossmanRF , RanceL . Development of an economic model to assess the cost effectiveness of treatment interventions for chronic obstructive pulmonary disease. Pharmacoeconomics2005;23(6):619‐37. SpencerMD , KariaN , AndersonJ . The clinical significance of treatment benefits with the salmeterol/fluticasone propionate 50/500mcg combination in COPD. European Respiratory Journal2004;24 Suppl 48:290s. VestboJ , CalverleyPMA , PauwelsR , JonesP , PrideN , GulsvikA , et al. Absence of gender susceptibility to the combination of salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease. European Respiratory Journal2002;20 Suppl 38:240 [P1570]. VestboJ , PauwelsR , AndersonJA , JonesP , CalverleyP . Early onset of effect of salmeterol and fluticasone propionate in chronic obstructive pulmonary disease. Thorax2005;60(4):301‐4. VestboJ , PauwelsRS , CalverleyPMA , JonesPW , PrideNB , GulsvikA . Salmeterol / fluticasone propionate combination produces improvement in lung function detectable within 24 hours in moderate to severe COPD, 2003. http://www.abstracts2view.com. VestboJ , SorianoJB , AndersonJA , CalverleyP , PauwelsR , JonesP . Gender does not influence the response to the combination of salmeterol and fluticasone propionate in COPD. Respiratory Medicine2004;98(11):1045‐50. ">TRISTAN</a>; N = 3001, SGRQ units ‐1.30, 95% CI ‐2.04 to ‐0.57; <a href="./references#CD006826-fig-0021" title="">Analysis 2.8</a>). Because of the high rate of attrition in <a href="./references#CD006826-bbs2-0013" title="BriggsAH , GlickHA , Lozano‐OrtegaG , SpencerM , CalverleyPM , JonesPW , et al. Is treatment with ICS and LABA cost‐effective for COPD? Multinational economic analysis of the TORCH study. European Respiratory Journal2010; Vol. 35, issue 3:532‐9. CalverleyPM , AndersonJA , CelliB , FergusonGT , JenkinsC , JonesPW , et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease.[see comment]. New England Journal of Medicine2007; Vol. 356, issue 8:775‐89. CalverleyPMA , AndersonJA , CelliB , FergusonGT , JenkinsC , JonesPW , et al. Cardiovascular events in patients with chronic obstructive pulmonary disease: TORCH study results. Thorax2010;65:719‐25. CalverleyPMA , AndersonJA , CelliB , FergusonGT , JenkinsC , JonesPW , et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. New England Journal of Medicine2007;356(8):775‐89. CalverleyPMA , CelliB , FergusonG , JenkinsC , JonesPW , PrideNB , et al. Baseline characteristics of the first 5,000 COPD patients enrolled in the TORCH survival study. European Respiratory Journal2003;22 Suppl 45:578s. CelliB , CalverleyPMA , AndersonJA , FergusonGT , JenkinsC , JonesPW , et al. The TORCH (TOwards a Revolution in COPD Health) study: salmeterol/fluticasone propionate (SFC) improves health status, reduces exacerbations and improves lung function over three years. European Respiratory Journal2006;28 Suppl 50:34s. CelliB , VestboJ , JenkinsCR , JonesPW , FergusonGT , CalverleyPM , et al. Sex differences in mortality and clinical expressions of patients with chronic obstructive pulmonary disease: the TORCH experience. American Journal of Respiratory and Critical Care Medicine2011;183(3):317‐22. CelliBR , ThomasNE , AndersonJA , FergusonGT , JenkinsCR , JonesPW , et al. Effect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease: results from the TORCH study. American Journal of Respiratory and Critical Care Medicine2008;174(4):332‐8. CrimC , CalverleyPM , AndersonJA , CelliB , FergusonGT , JenkinsC , et al. Pneumonia risk in COPD patients receiving inhaled corticosteroids alone or in combination: TORCH study results. European Respiratory Journal2009;34(3):641‐7. FergusonGT , CalverleyPM , AndersonJA , JenkinsCR , JonesPW , WillitsLR , et al. Prevalence and progression of osteoporosis in patients with COPD: results from the TOwards a Revolution in COPD Health study. Chest2009; Vol. 136, issue 0012‐3692:1456‐65. FergusonGT , CalverleyPMA , AndersonJA , et al. The TORCH (TOwards a Revolution in COPD Health) study: salmeterol/fluticasone propionate (SFC) improves survival in COPD over three years. European Respiratory Journal2006;28 Suppl 50:34s. GlaxoSmithKlineSCO30003 . A multicentre, randomised, double‐blind, parallel group, placebo‐controlled study to investigate the long‐term effects of salmeterol/fluticasone propionate (SERETIDE/VIANI/ADVAIR) 50/500mcg bd, salmeterol 50mcg bd and fluticasone propionate 500mcg bd, all delivered via the DISKUS/ACCUHALER inhaler, on the survival of subjects with chronic obstructive pulmonary disease (COPD) over 3 years of treatment. GlaxoSmithKline Clinical Trial Register2006. HoughtonCM , LawsonN , BorrillZL , WixonCL , YoxallS , LangleySJ , et al. Comparison of the effects of salmeterol/fluticasone propionate with fluticasone propionate on airway physiology in adults with mild persistent asthma. Respiratory Research2007;8:52. JenkinsCR , CalverleyPMA , CelliB , FergusonG , JonesPW , PrideN , et al. Seasonal patterns of exacerbation rates in the TORCH survival study, 2007. http://www.abstracts2view.comA839. JenkinsCR , CelliB , AndersonJA , FergusonGT , JonesPW , VestboJ , et al. Seasonality and determinants of moderate and severe COPD exacerbations in the TORCH study. European Respiratory Journal2012;39(1):38‐45. JenkinsCR , JonesPW , CalverleyPM , CelliB , AndersonJA , FergusonGT , et al. Efficacy of salmeterol/fluticasone propionate by GOLD stage of chronic obstructive pulmonary disease: analysis from the randomised, placebo‐controlled TORCH study. Respiratory Research2009;10:59. JohnsonM , AgustiAG , BarnesNC . Reflections on TORCH: potential mechanisms for the survival benefit of salmeterol/fluticasone propionate in COPD patients. COPD2008;5(6):369‐75. JonesPW , AndersonJA , CalverleyPM , CelliBR , FergusonGT , JenkinsC , et al. TORCH Investigators. Health status in the TORCH study of COPD: treatment efficacy and other determinants of change. Respiratory Research2011;12:71. JonesPW , CalverleyP , CelliB , FergusonG , JenkinsC , PrideN . Trans‐regional validity of the SGRQ in the TORCH survival study, 2007. http://www.abstracts2view.comA122. McGarveyLP , JohnM , AndersonJA , ZvarichMT , WiseRA . Ascertainment of cause‐specific mortality in COPD: operations of the TORCH Clinical Endpoint Committee. Thorax2007;62:411‐5. NCT00268216 . See detailed description, 2000. http://clinicaltrials.gov/show/NCT00268216. [] SCO30003 . A multicentre, randomised, double‐blind, parallel group, placebo‐controlled study to investigate the long‐term effects of salmeterol/fluticasone propionate (SERETIDE®/VIANI®/ADVAIR®) 50/500mcg bd, salmeterol 50mcg bd and fluticasone propionate 500mcg bd, all delivered via the DISKUS®/ACCUHALER® inhaler, on the survival of subjects with chronic obstructive pulmonary disease (COPD) over 3 years of treatment, 2006. www.ctr.gsk.co.uk. VestboJ , AndersonJA , CalverleyPM , CelliB , FergusonGT , JenkinsC , et al. Adherence to inhaled therapy, mortality and hospital admission in COPD. Thorax2009;64(11):939‐43. VestboJ , CalverleyP , CelliB , FergusonG , JenkinsC , JonesP , et al. The TORCH (TOwards a Revolution in COPD Health) survival study protocol. European Respiratory Journal2004;24(2):206‐10. WiseRA , McGarveyLP , JohnM , AndersonJA , ZvarichMT . Reliability of cause‐specific mortality adjudication in a COPD clinical trial, 2007. http://www.abstracts2view.comA120. ">TORCH</a>, the data were presented for only a subset of those who were randomly assigned (2007/3091). Removing this study from the analysis resulted in a similar effect estimate (SGRQ units ‐1.56, 95% CI ‐2.66 to ‐0.46). </p> <p>Data from two studies reporting quality of life as mean change in CRDQ suggested high levels of statistical variation (I<sup>2</sup> = 77%). Neither fixed‐effect nor random‐effects modelling revealed significant differences (2.12 units, 95% CI ‐0.50 to 4.75; and 2.34 units, 95% CI ‐3.15 to 7.82, respectively). </p> </section> <section id="CD006826-sec-0100"> <h6 class="title">BDF versus BD</h6> <p>A significant effect favoured BDF versus BD on the SGRQ (change from baseline). Four studies contributed data (<a href="./references#CD006826-bbs2-0002" title="AstraZenecaSD . A placebo‐controlled 12‐month efficacy study of the fixed combination budesonide/formoterol compared to budesonide and formoterol as monotherapies in patients with chronic obstructive pulmonary disease (COPD). AstraZeneca Clinical Trials2002. BorgstromL , AskingL , OlssonH , PetersonS . Lack of interaction between disease severity and therapeutic response with budesonide/formoterol in a single inhaler [Abstract]. American Thoracic Society 100th International Conference; May 21‐26; 2004, Orlando, Florida. C22 [Poster 505]. CalverleyPM , BonsawatW , CsekeZ , ZhongN , PetersonS , OlssonH . Maintenance therapy with budesonide and formoterol in chronic obstructive pulmonary disease. European Respiratory Journal2003;22(6):912‐9. CalverleyPMA , CsekeZ , PetersonS . Budesonide/formoterol reduces the use of oral corticosteroids in the treatment of COPD [Abstract]. European Respiratory Journal2003;22 Suppl 45:P436. CalverleyPMA , KunaP , OlssonH . COPD exacerbations are reduced by budesonide/formoterol in a single inhaler [Abstract]. European Respiratory Journal2003;22 Suppl 45:P1587. CalverleyPMA , OlssonH , Symbicort International COPD Study Group. Budesonide/formoterol ina single inhaler sustains improvements in lung function over 12 months compared with monocomponents and placebo in patients with COPD [abstract]. American Thoracic Society 99th International Conference; May 16‐21, 2003; Seattle, Washington. B024 [Poster 418]. CalverleyPMA , PetersonS . Combining budesonide/formoterol in a single inhale reduces exacerbation frequency in COPD [abstract]. American Thoracic Society 99th International Conference; May 16‐21, 2003; Seattle, Washington. D092 [Poster 211]. CalverleyPMA , StåhlE , JonesPW . Budesonide/formoterol improves the general health status of patients with COPD [Abstract]. American Thoracic Society 2005 International Conference; May 20‐25, 2005; San Diego, California. B93 [Poster 303]. CalverleyPMA , SzafranskiW , AnderssonA . Budesonide/formoterol is a well‐tolerated long term maintenance therapy for COPD. European Respiratory Journal2005;26 Suppl 49:Poster 1917. CalverleyPMA , ThompsonNC , OlssonH . Budesonide/formoterol in a single inhaler sustains lung function improvements in COPD [Abstract]. European Respiratory Journal2003;22 Suppl 45:P435. HalpinD , StåhlE , LundbackB , AndersonF , PetersonS . Treatment costs and number needed to treat (NNT) with budesonide/formoterol to avoid one exacerbation of COPD [Abstract]. American Thoracic Society 100th International Conference; May 21‐26, 2004; Orlando, Florida. D22 [Poster 525]. HalpinDMG , LarssonT , CalverleyPMA . How many patients with COPD must be treated with budesonide/formoterol compared with formoterol alone to avoid 1 day of oral steroid use? [Abstract]. American Thoracic Society 2005 International Conference; May 20‐25, 2005; San Diego, California. B93 [Poster 314]. JonesPW , StahlE . Budesonide/formoterol in a single inhaler improves health status in patients with COPD [abstract]. American Thoracic Society 99th International Conference; May 16‐21, 2003; Orlando, Florida. B024 [Poster 419]. JonesPW , StåhlE . Budesonide /formoterol sustains clinically relevant improvements in health status in COPD [Abstract]. European Respiratory Journal2005;26 Suppl 49:Abstract 1352. JonesPW , StåhlE . Reducing exacerbations leads to a better health‐related quality of life in patients with COPD. 13th ERS Annual Congress; September 27, 2003; Vienna, Austria. P1586. LofdahlCG . Reducing the impact of COPD exacerbations: Clinical efficacy of budesonide/formoterol. European Respiratory Review2004;13(88):14‐21. LofdahlCG , AndreassonE , SvenssonK , EricssonA . Budesonide/formoterol in a single inhaler improves health status in patients with COPD without increasing healthcare costs [Abstract]. European Respiratory Journal2003;22 Suppl 45:P433. LofdahlCG , EricssonA , SvenssonK , AndreassonE . Cost effectiveness of budesonide/formoterol in a single inhaler for COPD compared with each monocomponent used alone. Pharmacoeconomics2005;23(4):365‐75. ">Calverley 2003</a>; <a href="./references#CD006826-bbs2-0010" title="AndersonP . Budesonide/formoterol in a single inhaler (Symbicort) provides early and sustained improvement in lung function in moderate to severe COPD [Abstract]. Thorax2002;57(Suppl III):iii43. AstraZenecaSD . A placebo‐controlled 12 month efficacy study of the fixed combination budesonide/formoterol compared with budesonide and formoterol as monotherapies in patients with chronic obstructive pulmonary disease (COPD). AstraZeneca Clinical Trials2001. BorgstromL , AskingL , OlssonH , PetersonS . Lack of interaction between disease severity and therapeutic response with budesonide/formoterol in a single inhaler [Abstract]. American Thoracic Society 100th International Conference; May 21‐26, 2004; Orlando, Florida. C22 [Poster 505]. CalverleyP , PauwelsR , LofdahlCG , SvenssonK , HigenbottamT , et al. Relationship between respiratory symptoms and medical treatment in exacerbations of COPD. European Respiratory Journal2005;26(3):406‐13. CalverleyPMA . Effect of budesonide/formoterol on severe exacerbations and lung function in moderate to severe COPD. Thorax. BTS Winter Meeting 2002:S145. CalverleyPMA , SzafranskiW , AnderssonA . Budesonide/formoterol is a well‐tolerated long term maintenance therapy for COPD. European Respiratory Journal2005;26 Suppl 49:Poster 1917. CalverleyPMA , ThompsonNC , OlssonH . Budesonide/formoterol in a single inhaler sustains lung function improvements in COPD [Abstract]. European Respiratory Journal2003;22 Suppl 45:P435. CampbellLM , SzafranskiW . Budesonide/formoterol in a single inhaler (Symbicort) provides sustained relief from symptoms in moderate to severe COPD. Thorax. BTS Winter Meeting 2002:S143. CampellLW , SzafranskiW . Budesonide/Formoterol in a single inhaler (Symbicort) reduces severe exacerbations in patients with moderate‐severe COPD. Thorax. BTS Winter Meeting 2002:S141. DahlR , CukierA , OlssonH . Budesonide/formoterol in a single inhaler reduces severe and mild exacerbations in patients with moderate to severe COPD. European Respiratory Journal2002;20 Suppl 38:242 [P1575]. EgedeF , MengaG . Budesonide/formoterol in a single inhaler provides sustained relief from symptoms and night‐time awakenings in moderate‐severe COPD: results from symptoms and night‐time awakenings in moderate to severe COPD: results from a 1‐year study. European Respiratory Journal2002;20 Suppl 38:242 [P1574]. HalpinD , StahlE , LundbackB , AndersonF , PetersonS . Treatment costs and number needed to treat (NNT) with budesonide/formoterol to avoid one exacerbation of COPD [Abstract]. American Thoracic Society 100th International Conference; May 21‐26, 2004; Orlando, Florida. D22 [Poster 525]. JonesPW , StahlE , SvenssonK . Improvement in health status in patients with moderate to severe COPD after treatment with budesonide/formoterol in a single inhaler. European Respiratory Journal2002;20 Suppl 38:250 [P1613]. KorsgaardJ , SansoresR . Budesonide/formoterol (single inhaler) provides sustained relief from shortness of breath and chest tightness in a 1‐year study of patients with moderate to severe COPD. European Respiratory Journal2002;20 Suppl 38:242 [P1577]. LangeP , SaenzC . Budesonide/formoterol in a single inhaler is well tolerated in patients with moderate to severe COPD: results of a 1 year study. European Respiratory Journal2002;20 Suppl 38:242 [P1573]. LofdahlCG . Reducing the impact of COPD exacerbations: clinical efficacy of budesonide/formoterol. European Respiratory Review2004;13(88):14‐21. MilanowskiJ , NahabedianS . Budesonide/formoterol in a single inhaler acts rapidly to improve lung function and relieve symptoms in patients with moderate to severe COPD. European Respiratory Journal2002;20 Suppl 38:242 [P1576]. SzafranskiW , CukierA , RamirezA , MengaG , SansoresR , NahabedianS , et al. Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease. European Respiratory Journal2003;21(1):74‐81. ">Szafranski 2003</a>; <a href="./references#CD006826-bbs2-0011" title="Astrazeneca(D5899C00002) . A 6‐month double‐blind, double‐dummy, randomized, parallel group, multicenter efficacy &amp; safety study of Symbicort® pMDI 2 × 160/4.5mg &amp; 80/4.5mg bid compared to Formoterol TBH, Budesonide pMDI (&amp; the combination) &amp; placebo in COPD patients. www.astrazenecaclinicaltrials.com (accessed 8 April 2008). BleeckerER , MeyersDA , BaileyWC , SimsA‐M , BujacSR , GoldmanM , et al. ADRB2 polymorphisms and budesonide/formoterol responses in COPDADRB2 polymorphisms and treatment response in COPD. Chest2012;142(2):320‐8. TashkinDP , RennardSI , MartinP , GoldmanM , SilkoffPE . Efficacy of budesonide/formoterol administered via one pressurized metered‐dose inhaler over 6 months in patients with chronic obstructive pulmonary disease [Abstract]. Chest2008; Vol. 134, issue 4:105001s. TashkinDP , RennardSI , MartinP , RamachandranS , MartinUJ , SilkoffPE , et al. Efficacy and safety of budesonide and formoterol in one pressurized metered‐dose inhaler in patients with moderate to very severe chronic obstructive pulmonary disease : results of a 6‐month randomized clinical trial. Drugs2008; Vol. 68, issue 0012‐6667 (Print):1975‐2000. ">Tashkin 2008</a>; <a href="./references#CD006826-bbs2-0015" title="ZhongN , ZhengJ , WenF , YangL , ChenP , XiuQ , et al. Efficacy and safety of budesonide/formoterol via a dry powder inhaler in Chinese patients with chronic obstructive pulmonary disease. Current Medical Research and Opinion2012; Vol. 28, issue 2:257‐65. ZhongN , ZhengJ , WenF , YangL , ChenP , XiuQ , et al. Efficacy and safety of inhalation of budesonide/formoterol via turbuhaler in Chinese patients with chronic obstructive pulmonary disease [Abstract]. Chest2011; Vol. 140, issue 4:5225A. ">Zhong 2012</a>; N = 1777, MD ‐2.80, 95% CI ‐3.99 to ‐1.61; <a href="./references#CD006826-fig-0038" title="">Analysis 3.4</a>). The effect was observed in a partially reversible population (mixed population) (1 study; <a href="./references#CD006826-bbs2-0011" title="Astrazeneca(D5899C00002) . A 6‐month double‐blind, double‐dummy, randomized, parallel group, multicenter efficacy &amp; safety study of Symbicort® pMDI 2 × 160/4.5mg &amp; 80/4.5mg bid compared to Formoterol TBH, Budesonide pMDI (&amp; the combination) &amp; placebo in COPD patients. www.astrazenecaclinicaltrials.com (accessed 8 April 2008). BleeckerER , MeyersDA , BaileyWC , SimsA‐M , BujacSR , GoldmanM , et al. ADRB2 polymorphisms and budesonide/formoterol responses in COPDADRB2 polymorphisms and treatment response in COPD. Chest2012;142(2):320‐8. TashkinDP , RennardSI , MartinP , GoldmanM , SilkoffPE . Efficacy of budesonide/formoterol administered via one pressurized metered‐dose inhaler over 6 months in patients with chronic obstructive pulmonary disease [Abstract]. Chest2008; Vol. 134, issue 4:105001s. TashkinDP , RennardSI , MartinP , RamachandranS , MartinUJ , SilkoffPE , et al. Efficacy and safety of budesonide and formoterol in one pressurized metered‐dose inhaler in patients with moderate to very severe chronic obstructive pulmonary disease : results of a 6‐month randomized clinical trial. Drugs2008; Vol. 68, issue 0012‐6667 (Print):1975‐2000. ">Tashkin 2008</a>; N = 552, MD ‐2.57, 95% CI ‐4.68 to ‐0.46) and in a poorly reversible population (3 studies; <a href="./references#CD006826-bbs2-0002" title="AstraZenecaSD . A placebo‐controlled 12‐month efficacy study of the fixed combination budesonide/formoterol compared to budesonide and formoterol as monotherapies in patients with chronic obstructive pulmonary disease (COPD). AstraZeneca Clinical Trials2002. BorgstromL , AskingL , OlssonH , PetersonS . Lack of interaction between disease severity and therapeutic response with budesonide/formoterol in a single inhaler [Abstract]. American Thoracic Society 100th International Conference; May 21‐26; 2004, Orlando, Florida. C22 [Poster 505]. CalverleyPM , BonsawatW , CsekeZ , ZhongN , PetersonS , OlssonH . Maintenance therapy with budesonide and formoterol in chronic obstructive pulmonary disease. European Respiratory Journal2003;22(6):912‐9. CalverleyPMA , CsekeZ , PetersonS . Budesonide/formoterol reduces the use of oral corticosteroids in the treatment of COPD [Abstract]. European Respiratory Journal2003;22 Suppl 45:P436. CalverleyPMA , KunaP , OlssonH . COPD exacerbations are reduced by budesonide/formoterol in a single inhaler [Abstract]. European Respiratory Journal2003;22 Suppl 45:P1587. CalverleyPMA , OlssonH , Symbicort International COPD Study Group. Budesonide/formoterol ina single inhaler sustains improvements in lung function over 12 months compared with monocomponents and placebo in patients with COPD [abstract]. American Thoracic Society 99th International Conference; May 16‐21, 2003; Seattle, Washington. B024 [Poster 418]. CalverleyPMA , PetersonS . Combining budesonide/formoterol in a single inhale reduces exacerbation frequency in COPD [abstract]. American Thoracic Society 99th International Conference; May 16‐21, 2003; Seattle, Washington. D092 [Poster 211]. CalverleyPMA , StåhlE , JonesPW . Budesonide/formoterol improves the general health status of patients with COPD [Abstract]. American Thoracic Society 2005 International Conference; May 20‐25, 2005; San Diego, California. B93 [Poster 303]. CalverleyPMA , SzafranskiW , AnderssonA . Budesonide/formoterol is a well‐tolerated long term maintenance therapy for COPD. European Respiratory Journal2005;26 Suppl 49:Poster 1917. CalverleyPMA , ThompsonNC , OlssonH . Budesonide/formoterol in a single inhaler sustains lung function improvements in COPD [Abstract]. European Respiratory Journal2003;22 Suppl 45:P435. HalpinD , StåhlE , LundbackB , AndersonF , PetersonS . Treatment costs and number needed to treat (NNT) with budesonide/formoterol to avoid one exacerbation of COPD [Abstract]. American Thoracic Society 100th International Conference; May 21‐26, 2004; Orlando, Florida. D22 [Poster 525]. HalpinDMG , LarssonT , CalverleyPMA . How many patients with COPD must be treated with budesonide/formoterol compared with formoterol alone to avoid 1 day of oral steroid use? [Abstract]. American Thoracic Society 2005 International Conference; May 20‐25, 2005; San Diego, California. B93 [Poster 314]. JonesPW , StahlE . Budesonide/formoterol in a single inhaler improves health status in patients with COPD [abstract]. American Thoracic Society 99th International Conference; May 16‐21, 2003; Orlando, Florida. B024 [Poster 419]. JonesPW , StåhlE . Budesonide /formoterol sustains clinically relevant improvements in health status in COPD [Abstract]. European Respiratory Journal2005;26 Suppl 49:Abstract 1352. JonesPW , StåhlE . Reducing exacerbations leads to a better health‐related quality of life in patients with COPD. 13th ERS Annual Congress; September 27, 2003; Vienna, Austria. P1586. LofdahlCG . Reducing the impact of COPD exacerbations: Clinical efficacy of budesonide/formoterol. European Respiratory Review2004;13(88):14‐21. LofdahlCG , AndreassonE , SvenssonK , EricssonA . Budesonide/formoterol in a single inhaler improves health status in patients with COPD without increasing healthcare costs [Abstract]. European Respiratory Journal2003;22 Suppl 45:P433. LofdahlCG , EricssonA , SvenssonK , AndreassonE . Cost effectiveness of budesonide/formoterol in a single inhaler for COPD compared with each monocomponent used alone. Pharmacoeconomics2005;23(4):365‐75. ">Calverley 2003</a>; <a href="./references#CD006826-bbs2-0010" title="AndersonP . Budesonide/formoterol in a single inhaler (Symbicort) provides early and sustained improvement in lung function in moderate to severe COPD [Abstract]. Thorax2002;57(Suppl III):iii43. AstraZenecaSD . A placebo‐controlled 12 month efficacy study of the fixed combination budesonide/formoterol compared with budesonide and formoterol as monotherapies in patients with chronic obstructive pulmonary disease (COPD). AstraZeneca Clinical Trials2001. BorgstromL , AskingL , OlssonH , PetersonS . Lack of interaction between disease severity and therapeutic response with budesonide/formoterol in a single inhaler [Abstract]. American Thoracic Society 100th International Conference; May 21‐26, 2004; Orlando, Florida. C22 [Poster 505]. CalverleyP , PauwelsR , LofdahlCG , SvenssonK , HigenbottamT , et al. Relationship between respiratory symptoms and medical treatment in exacerbations of COPD. European Respiratory Journal2005;26(3):406‐13. CalverleyPMA . Effect of budesonide/formoterol on severe exacerbations and lung function in moderate to severe COPD. Thorax. BTS Winter Meeting 2002:S145. CalverleyPMA , SzafranskiW , AnderssonA . Budesonide/formoterol is a well‐tolerated long term maintenance therapy for COPD. European Respiratory Journal2005;26 Suppl 49:Poster 1917. CalverleyPMA , ThompsonNC , OlssonH . Budesonide/formoterol in a single inhaler sustains lung function improvements in COPD [Abstract]. European Respiratory Journal2003;22 Suppl 45:P435. CampbellLM , SzafranskiW . Budesonide/formoterol in a single inhaler (Symbicort) provides sustained relief from symptoms in moderate to severe COPD. Thorax. BTS Winter Meeting 2002:S143. CampellLW , SzafranskiW . Budesonide/Formoterol in a single inhaler (Symbicort) reduces severe exacerbations in patients with moderate‐severe COPD. Thorax. BTS Winter Meeting 2002:S141. DahlR , CukierA , OlssonH . Budesonide/formoterol in a single inhaler reduces severe and mild exacerbations in patients with moderate to severe COPD. European Respiratory Journal2002;20 Suppl 38:242 [P1575]. EgedeF , MengaG . Budesonide/formoterol in a single inhaler provides sustained relief from symptoms and night‐time awakenings in moderate‐severe COPD: results from symptoms and night‐time awakenings in moderate to severe COPD: results from a 1‐year study. European Respiratory Journal2002;20 Suppl 38:242 [P1574]. HalpinD , StahlE , LundbackB , AndersonF , PetersonS . Treatment costs and number needed to treat (NNT) with budesonide/formoterol to avoid one exacerbation of COPD [Abstract]. American Thoracic Society 100th International Conference; May 21‐26, 2004; Orlando, Florida. D22 [Poster 525]. JonesPW , StahlE , SvenssonK . Improvement in health status in patients with moderate to severe COPD after treatment with budesonide/formoterol in a single inhaler. European Respiratory Journal2002;20 Suppl 38:250 [P1613]. KorsgaardJ , SansoresR . Budesonide/formoterol (single inhaler) provides sustained relief from shortness of breath and chest tightness in a 1‐year study of patients with moderate to severe COPD. European Respiratory Journal2002;20 Suppl 38:242 [P1577]. LangeP , SaenzC . Budesonide/formoterol in a single inhaler is well tolerated in patients with moderate to severe COPD: results of a 1 year study. European Respiratory Journal2002;20 Suppl 38:242 [P1573]. LofdahlCG . Reducing the impact of COPD exacerbations: clinical efficacy of budesonide/formoterol. European Respiratory Review2004;13(88):14‐21. MilanowskiJ , NahabedianS . Budesonide/formoterol in a single inhaler acts rapidly to improve lung function and relieve symptoms in patients with moderate to severe COPD. European Respiratory Journal2002;20 Suppl 38:242 [P1576]. SzafranskiW , CukierA , RamirezA , MengaG , SansoresR , NahabedianS , et al. Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease. European Respiratory Journal2003;21(1):74‐81. ">Szafranski 2003</a>; <a href="./references#CD006826-bbs2-0015" title="ZhongN , ZhengJ , WenF , YangL , ChenP , XiuQ , et al. Efficacy and safety of budesonide/formoterol via a dry powder inhaler in Chinese patients with chronic obstructive pulmonary disease. Current Medical Research and Opinion2012; Vol. 28, issue 2:257‐65. ZhongN , ZhengJ , WenF , YangL , ChenP , XiuQ , et al. Efficacy and safety of inhalation of budesonide/formoterol via turbuhaler in Chinese patients with chronic obstructive pulmonary disease [Abstract]. Chest2011; Vol. 140, issue 4:5225A. ">Zhong 2012</a>; N = 1225, MD ‐2.91, 95% CI ‐4.35 to ‐1.47). </p> </section> <section id="CD006826-sec-0101"> <h6 class="title">MF/F versus MF</h6> <p>No significant effect difference was reported for MF/F versus MF on the SGRQ (change from baseline), with data contributed by both <a href="./references#CD006826-bbs2-0003" title="DohertyDE , KerwinE , TashkinDP , Matiz‐BuenoCE , ShekarT , BanerjeeS , et al. Combined mometasone furoate and formoterol in patients with moderate to very severe chronic obstructive pulmonary disease (COPD): phase 3 efficacy and safety study [Abstract]. Journal of Allergy and Clinical Immunology2012; Vol. 129, issue 2 Suppl:AB75 [283]. DohertyDE , TashkinDP , KerwinE , KnorrBA , ShekarT , BanerjeeS , et al. Effects of mometasone furoate/formoterol fumarate fixed‐dose combination formulation on chronic obstructive pulmonary disease (COPD): results from a 52‐week Phase III trial in subjects with moderate‐to‐very severe COPD. International Journal of Chronic Obstructive Pulmonary Disease2012; Vol. 7, issue 1178‐2005 (Electronic). 1176‐9106 (Linking):57‐71. NCT00383721 . A Randomized, 26‐Week, Placebo‐Controlled Efficacy and Safety Study With a 26‐Week Long‐Term Safety Extension, of High‐ and Medium‐Dose Inhaled Mometasone Furoate/Formoterol Fixed‐Dose Combination Formulation Compared With Formoterol and High‐Dose Inhaled Mometasone Furoate Monotherapy in Subjects With Moderate to Severe COPD, 2006. http://clinicaltrials.gov/show/NCT00383721. [] ">Doherty 2012</a> and <a href="./references#CD006826-bbs2-0012" title="KerwinE , TashkinDP , Matiz‐BuenoCE , DohertyDE , ShekarT , BanerjeeS , et al. Clinical efficacy and safety of combined mometasone furoate and formoterol in patients with moderate to very severe chronic obstructive pulmonary disease (COPD) [Abstract]. Journal of Allergy and Clinical Immunology2012; Vol. 129, issue 2 Suppl:AB201 [759]. NCT00383435 . A Randomized, 26‐Week, Placebo‐Controlled Efficacy and Safety Study With a 26‐Week Long‐Term Safety Extension, of High‐ and Medium‐Dose Inhaled Mometasone Furoate/Formoterol Fixed‐Dose Combination Formulation Compared With Formoterol and High‐Dose Inhaled Mometasone Furoate Monotherapy in Subjects With Moderate to Severe COPD, 2006. http://clinicaltrials.gov/show/NCT00383435. [] TashkinDP , DohertyDE , KerwinE , Matiz‐BuenoCE , KnorrB , ShekarT , et al. Efficacy and safety of a fixed‐dose combination of mometasone furoate and formoterol fumarate in subjects with moderate to very severe COPD: results from a 52‐week Phase III trial. International Journal of Chronic Obstructive Pulmonary Disease2012; Vol. 7, issue 1178‐2005 (Electronic). 1176‐9106 (Linking):43‐55. ">Tashkin 2012</a> (2 studies; N = 905, MD ‐0.29, 95% CI ‐2.16 to 1.57; <a href="./references#CD006826-fig-0059" title="">Analysis 4.3</a>). </p> </section> </section> <section id="CD006826-sec-0102"> <h5 class="title">Symptom score</h5> <section id="CD006826-sec-0103"> <h6 class="title">FPS versus FP</h6> <p>Pooled data from <a href="./references#CD006826-bbs2-0006" title="MahlerDA , DarkenP , BrownCP , KnobilK . Predicting lung function responses to combination therapy in chronic obstructive pulmonary disease (COPD), 2003. http://www.abstracts2view.com. MahlerDA , WireP , HorstmanD , ChangCN , YatesJ , FischerT , et al. Effectiveness of fluticasone propionate and salmeterol combination delivered via the diskus device in the treatment of chronic obstructive pulmonary disease. American Journal of Respiratory Critical Care Medicine2002;166(8):1084‐91. SFCA3006 . A randomized, double‐blind, placebo‐controlled, parallel‐group trial evaluating the safety and efficacy of the DISKUS formulations of salmeterol (SAL) 50mcg BID and fluticasone propionate (FP) 500mcg BID individually and in combination as salmeterol 50mcg/fluticasone propionate 500mcg BID (SFC 50/500) compared to placebo in COPD subjects. GlaxoSmithKline Clinical Trials Register (http:ctr.gsk.co.uk)2005. SpencerM , WireP , LeeB , ChangCN , DarkenP , HorstmanD . Patients with COPD using salmeterol/fluticasone propionate combination therapy experience improved quality of life. European Respiratory Journal2003;22 Suppl 45:51s. SpencerMD , AndersonJA . Salmeterol/fluticasone combination produces clinically important benefits in dyspnea and fatigue [Abstract]. American Thoracic Society 2005 International Conference; May 20‐25, 2005; San Diego, California. B93 [Poster 308]. SpencerMD , KariaN , AndersonJ . The clinical significance of treatment benefits with the salmeterol/fluticasone propionate 50/500mcg combination in COPD. European Respiratory Journal2004;24 Suppl 48:290s. ">Mahler 2002</a> and <a href="./references#CD006826-bbs2-0004" title="HananiaNA , DarkenP , HorstmanD , ReisnerC , LeeB , DavisS , et al. The efficacy and safety of fluticasone propionate (250 micro g)/salmeterol (50 micro g) combined in the diskus inhaler for the treatment of COPD. Chest2003;124(3):834‐43. HananiaNA , RamsdellJ , PayneK , DavisS , HorstmanD , LeeB , et al. Improvements in airflow and dyspnea in COPD patients following 24 weeks treatment with salmeterol 50mcg and fluticasone propionate 250mcg alone or in combination via the diskus. American Journal of Respiratory &amp; Critical Care Medicine2001;163(5 Suppl):A279. HorstmanD , DarkenP , DavisS , LeeB . Improvements in FEV1 and symptoms in poorly reversible COPD patients following treatment with salmeterol 50mcg/fluticasone propionate 250mcg combination [Abstract]. European Respiratory Journal2003;22 Suppl 45:P434. MahlerDA , DarkenP , BrownCP , KnobilK . Predicting lung function responses to combination therapy in chronic obstructive pulmonary disease (COPD) [Abstract]. National COPD Conference; November 14‐15, 2003; Arlington, Virginia. Abstract 1081. MahlerDA , DarkenP , BrownCP , KnobilK . Predicting lung function responses to salmeterol/fluticasone propionate combination therapy in COPD [Abstract]. European Respiratory Journal2003;22 Suppl 45:P429. SFCA3007 . A randomized, double‐blind, placebo‐controlled, parallel‐group trial evaluating the safety and efficacy of the DISKUS formulations of salmeterol (SAL) 50mcg BID and fluticasone propionate (FP) 250mcg BID individually and in combination as salmeterol 50mcg/fluticasone propionate 250mcg BID (SFC 50/250) compared to placebo in COPD subjects. GlaxoSmithKline Clinical Trials Register (http:ctr.gsk.co.uk)2005. SpencerM , WireP , LeeB , ChangCN , DarkenP , HorstmanD . Patients with COPD using salmeterol/fluticasone propionate combination therapy experience improved quality of life. European Respiratory Journal2003;22 Suppl 45:51s. SpencerMD , KariaN , AndersonJ . The clinical significance of treatment benefits with the salmeterol/fluticasone propionate 50/500mcg combination in COPD. European Respiratory Journal2004;24 Suppl 48:290s. ">Hanania 2003</a> indicated no significant difference between FPS and FP in TDI scores (2 studies; N = 690, MD 0.31, 95% CI ‐0.45 to 1.08; <a href="./references#CD006826-fig-0022" title="">Analysis 2.9</a>). </p> </section> <section id="CD006826-sec-0104"> <h6 class="title">BDF versus BD</h6> <p>A significant benefit for BDF versus BD was observed in symptom change scores (3 studies; <a href="./references#CD006826-bbs2-0002" title="AstraZenecaSD . A placebo‐controlled 12‐month efficacy study of the fixed combination budesonide/formoterol compared to budesonide and formoterol as monotherapies in patients with chronic obstructive pulmonary disease (COPD). AstraZeneca Clinical Trials2002. BorgstromL , AskingL , OlssonH , PetersonS . Lack of interaction between disease severity and therapeutic response with budesonide/formoterol in a single inhaler [Abstract]. American Thoracic Society 100th International Conference; May 21‐26; 2004, Orlando, Florida. C22 [Poster 505]. CalverleyPM , BonsawatW , CsekeZ , ZhongN , PetersonS , OlssonH . Maintenance therapy with budesonide and formoterol in chronic obstructive pulmonary disease. European Respiratory Journal2003;22(6):912‐9. CalverleyPMA , CsekeZ , PetersonS . Budesonide/formoterol reduces the use of oral corticosteroids in the treatment of COPD [Abstract]. European Respiratory Journal2003;22 Suppl 45:P436. CalverleyPMA , KunaP , OlssonH . COPD exacerbations are reduced by budesonide/formoterol in a single inhaler [Abstract]. European Respiratory Journal2003;22 Suppl 45:P1587. CalverleyPMA , OlssonH , Symbicort International COPD Study Group. Budesonide/formoterol ina single inhaler sustains improvements in lung function over 12 months compared with monocomponents and placebo in patients with COPD [abstract]. American Thoracic Society 99th International Conference; May 16‐21, 2003; Seattle, Washington. B024 [Poster 418]. CalverleyPMA , PetersonS . Combining budesonide/formoterol in a single inhale reduces exacerbation frequency in COPD [abstract]. American Thoracic Society 99th International Conference; May 16‐21, 2003; Seattle, Washington. D092 [Poster 211]. CalverleyPMA , StåhlE , JonesPW . Budesonide/formoterol improves the general health status of patients with COPD [Abstract]. American Thoracic Society 2005 International Conference; May 20‐25, 2005; San Diego, California. B93 [Poster 303]. CalverleyPMA , SzafranskiW , AnderssonA . Budesonide/formoterol is a well‐tolerated long term maintenance therapy for COPD. European Respiratory Journal2005;26 Suppl 49:Poster 1917. CalverleyPMA , ThompsonNC , OlssonH . Budesonide/formoterol in a single inhaler sustains lung function improvements in COPD [Abstract]. European Respiratory Journal2003;22 Suppl 45:P435. HalpinD , StåhlE , LundbackB , AndersonF , PetersonS . Treatment costs and number needed to treat (NNT) with budesonide/formoterol to avoid one exacerbation of COPD [Abstract]. American Thoracic Society 100th International Conference; May 21‐26, 2004; Orlando, Florida. D22 [Poster 525]. HalpinDMG , LarssonT , CalverleyPMA . How many patients with COPD must be treated with budesonide/formoterol compared with formoterol alone to avoid 1 day of oral steroid use? [Abstract]. American Thoracic Society 2005 International Conference; May 20‐25, 2005; San Diego, California. B93 [Poster 314]. JonesPW , StahlE . Budesonide/formoterol in a single inhaler improves health status in patients with COPD [abstract]. American Thoracic Society 99th International Conference; May 16‐21, 2003; Orlando, Florida. B024 [Poster 419]. JonesPW , StåhlE . Budesonide /formoterol sustains clinically relevant improvements in health status in COPD [Abstract]. European Respiratory Journal2005;26 Suppl 49:Abstract 1352. JonesPW , StåhlE . Reducing exacerbations leads to a better health‐related quality of life in patients with COPD. 13th ERS Annual Congress; September 27, 2003; Vienna, Austria. P1586. LofdahlCG . Reducing the impact of COPD exacerbations: Clinical efficacy of budesonide/formoterol. European Respiratory Review2004;13(88):14‐21. LofdahlCG , AndreassonE , SvenssonK , EricssonA . Budesonide/formoterol in a single inhaler improves health status in patients with COPD without increasing healthcare costs [Abstract]. European Respiratory Journal2003;22 Suppl 45:P433. LofdahlCG , EricssonA , SvenssonK , AndreassonE . Cost effectiveness of budesonide/formoterol in a single inhaler for COPD compared with each monocomponent used alone. Pharmacoeconomics2005;23(4):365‐75. ">Calverley 2003</a>; <a href="./references#CD006826-bbs2-0010" title="AndersonP . Budesonide/formoterol in a single inhaler (Symbicort) provides early and sustained improvement in lung function in moderate to severe COPD [Abstract]. Thorax2002;57(Suppl III):iii43. AstraZenecaSD . A placebo‐controlled 12 month efficacy study of the fixed combination budesonide/formoterol compared with budesonide and formoterol as monotherapies in patients with chronic obstructive pulmonary disease (COPD). AstraZeneca Clinical Trials2001. BorgstromL , AskingL , OlssonH , PetersonS . Lack of interaction between disease severity and therapeutic response with budesonide/formoterol in a single inhaler [Abstract]. American Thoracic Society 100th International Conference; May 21‐26, 2004; Orlando, Florida. C22 [Poster 505]. CalverleyP , PauwelsR , LofdahlCG , SvenssonK , HigenbottamT , et al. Relationship between respiratory symptoms and medical treatment in exacerbations of COPD. European Respiratory Journal2005;26(3):406‐13. CalverleyPMA . Effect of budesonide/formoterol on severe exacerbations and lung function in moderate to severe COPD. Thorax. BTS Winter Meeting 2002:S145. CalverleyPMA , SzafranskiW , AnderssonA . Budesonide/formoterol is a well‐tolerated long term maintenance therapy for COPD. European Respiratory Journal2005;26 Suppl 49:Poster 1917. CalverleyPMA , ThompsonNC , OlssonH . Budesonide/formoterol in a single inhaler sustains lung function improvements in COPD [Abstract]. European Respiratory Journal2003;22 Suppl 45:P435. CampbellLM , SzafranskiW . Budesonide/formoterol in a single inhaler (Symbicort) provides sustained relief from symptoms in moderate to severe COPD. Thorax. BTS Winter Meeting 2002:S143. CampellLW , SzafranskiW . Budesonide/Formoterol in a single inhaler (Symbicort) reduces severe exacerbations in patients with moderate‐severe COPD. Thorax. BTS Winter Meeting 2002:S141. DahlR , CukierA , OlssonH . Budesonide/formoterol in a single inhaler reduces severe and mild exacerbations in patients with moderate to severe COPD. European Respiratory Journal2002;20 Suppl 38:242 [P1575]. EgedeF , MengaG . Budesonide/formoterol in a single inhaler provides sustained relief from symptoms and night‐time awakenings in moderate‐severe COPD: results from symptoms and night‐time awakenings in moderate to severe COPD: results from a 1‐year study. European Respiratory Journal2002;20 Suppl 38:242 [P1574]. HalpinD , StahlE , LundbackB , AndersonF , PetersonS . Treatment costs and number needed to treat (NNT) with budesonide/formoterol to avoid one exacerbation of COPD [Abstract]. American Thoracic Society 100th International Conference; May 21‐26, 2004; Orlando, Florida. D22 [Poster 525]. JonesPW , StahlE , SvenssonK . Improvement in health status in patients with moderate to severe COPD after treatment with budesonide/formoterol in a single inhaler. European Respiratory Journal2002;20 Suppl 38:250 [P1613]. KorsgaardJ , SansoresR . Budesonide/formoterol (single inhaler) provides sustained relief from shortness of breath and chest tightness in a 1‐year study of patients with moderate to severe COPD. European Respiratory Journal2002;20 Suppl 38:242 [P1577]. LangeP , SaenzC . Budesonide/formoterol in a single inhaler is well tolerated in patients with moderate to severe COPD: results of a 1 year study. European Respiratory Journal2002;20 Suppl 38:242 [P1573]. LofdahlCG . Reducing the impact of COPD exacerbations: clinical efficacy of budesonide/formoterol. European Respiratory Review2004;13(88):14‐21. MilanowskiJ , NahabedianS . Budesonide/formoterol in a single inhaler acts rapidly to improve lung function and relieve symptoms in patients with moderate to severe COPD. European Respiratory Journal2002;20 Suppl 38:242 [P1576]. SzafranskiW , CukierA , RamirezA , MengaG , SansoresR , NahabedianS , et al. Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease. European Respiratory Journal2003;21(1):74‐81. ">Szafranski 2003</a>; <a href="./references#CD006826-bbs2-0015" title="ZhongN , ZhengJ , WenF , YangL , ChenP , XiuQ , et al. Efficacy and safety of budesonide/formoterol via a dry powder inhaler in Chinese patients with chronic obstructive pulmonary disease. Current Medical Research and Opinion2012; Vol. 28, issue 2:257‐65. ZhongN , ZhengJ , WenF , YangL , ChenP , XiuQ , et al. Efficacy and safety of inhalation of budesonide/formoterol via turbuhaler in Chinese patients with chronic obstructive pulmonary disease [Abstract]. Chest2011; Vol. 140, issue 4:5225A. ">Zhong 2012</a>; N = 1225, MD ‐0.45, 95% CI ‐0.67 to ‐0.22; <a href="./references#CD006826-fig-0039" title="">Analysis 3.5</a>). </p> </section> <section id="CD006826-sec-0105"> <h6 class="title">MF/F versus MF</h6> <p>Symptoms were considered in <a href="./references#CD006826-bbs2-0003" title="DohertyDE , KerwinE , TashkinDP , Matiz‐BuenoCE , ShekarT , BanerjeeS , et al. Combined mometasone furoate and formoterol in patients with moderate to very severe chronic obstructive pulmonary disease (COPD): phase 3 efficacy and safety study [Abstract]. Journal of Allergy and Clinical Immunology2012; Vol. 129, issue 2 Suppl:AB75 [283]. DohertyDE , TashkinDP , KerwinE , KnorrBA , ShekarT , BanerjeeS , et al. Effects of mometasone furoate/formoterol fumarate fixed‐dose combination formulation on chronic obstructive pulmonary disease (COPD): results from a 52‐week Phase III trial in subjects with moderate‐to‐very severe COPD. International Journal of Chronic Obstructive Pulmonary Disease2012; Vol. 7, issue 1178‐2005 (Electronic). 1176‐9106 (Linking):57‐71. NCT00383721 . A Randomized, 26‐Week, Placebo‐Controlled Efficacy and Safety Study With a 26‐Week Long‐Term Safety Extension, of High‐ and Medium‐Dose Inhaled Mometasone Furoate/Formoterol Fixed‐Dose Combination Formulation Compared With Formoterol and High‐Dose Inhaled Mometasone Furoate Monotherapy in Subjects With Moderate to Severe COPD, 2006. http://clinicaltrials.gov/show/NCT00383721. [] ">Doherty 2012</a> and <a href="./references#CD006826-bbs2-0012" title="KerwinE , TashkinDP , Matiz‐BuenoCE , DohertyDE , ShekarT , BanerjeeS , et al. Clinical efficacy and safety of combined mometasone furoate and formoterol in patients with moderate to very severe chronic obstructive pulmonary disease (COPD) [Abstract]. Journal of Allergy and Clinical Immunology2012; Vol. 129, issue 2 Suppl:AB201 [759]. NCT00383435 . A Randomized, 26‐Week, Placebo‐Controlled Efficacy and Safety Study With a 26‐Week Long‐Term Safety Extension, of High‐ and Medium‐Dose Inhaled Mometasone Furoate/Formoterol Fixed‐Dose Combination Formulation Compared With Formoterol and High‐Dose Inhaled Mometasone Furoate Monotherapy in Subjects With Moderate to Severe COPD, 2006. http://clinicaltrials.gov/show/NCT00383435. [] TashkinDP , DohertyDE , KerwinE , Matiz‐BuenoCE , KnorrB , ShekarT , et al. Efficacy and safety of a fixed‐dose combination of mometasone furoate and formoterol fumarate in subjects with moderate to very severe COPD: results from a 52‐week Phase III trial. International Journal of Chronic Obstructive Pulmonary Disease2012; Vol. 7, issue 1178‐2005 (Electronic). 1176‐9106 (Linking):43‐55. ">Tashkin 2012</a> in terms of COPD symptom‐free nights. In both studies, no significant difference was noted between MF/F and MF with respect to this outcome, although insufficient data were recorded to allow a meta‐analysis. </p> </section> </section> <section id="CD006826-sec-0106"> <h5 class="title">Rescue medication</h5> <section id="CD006826-sec-0107"> <h6 class="title">FPS versus FP</h6> <p>Pooled data from <a href="./references#CD006826-bbs2-0006" title="MahlerDA , DarkenP , BrownCP , KnobilK . Predicting lung function responses to combination therapy in chronic obstructive pulmonary disease (COPD), 2003. http://www.abstracts2view.com. MahlerDA , WireP , HorstmanD , ChangCN , YatesJ , FischerT , et al. Effectiveness of fluticasone propionate and salmeterol combination delivered via the diskus device in the treatment of chronic obstructive pulmonary disease. American Journal of Respiratory Critical Care Medicine2002;166(8):1084‐91. SFCA3006 . A randomized, double‐blind, placebo‐controlled, parallel‐group trial evaluating the safety and efficacy of the DISKUS formulations of salmeterol (SAL) 50mcg BID and fluticasone propionate (FP) 500mcg BID individually and in combination as salmeterol 50mcg/fluticasone propionate 500mcg BID (SFC 50/500) compared to placebo in COPD subjects. GlaxoSmithKline Clinical Trials Register (http:ctr.gsk.co.uk)2005. SpencerM , WireP , LeeB , ChangCN , DarkenP , HorstmanD . Patients with COPD using salmeterol/fluticasone propionate combination therapy experience improved quality of life. European Respiratory Journal2003;22 Suppl 45:51s. SpencerMD , AndersonJA . Salmeterol/fluticasone combination produces clinically important benefits in dyspnea and fatigue [Abstract]. American Thoracic Society 2005 International Conference; May 20‐25, 2005; San Diego, California. B93 [Poster 308]. SpencerMD , KariaN , AndersonJ . The clinical significance of treatment benefits with the salmeterol/fluticasone propionate 50/500mcg combination in COPD. European Respiratory Journal2004;24 Suppl 48:290s. ">Mahler 2002</a> and <a href="./references#CD006826-bbs2-0004" title="HananiaNA , DarkenP , HorstmanD , ReisnerC , LeeB , DavisS , et al. The efficacy and safety of fluticasone propionate (250 micro g)/salmeterol (50 micro g) combined in the diskus inhaler for the treatment of COPD. Chest2003;124(3):834‐43. HananiaNA , RamsdellJ , PayneK , DavisS , HorstmanD , LeeB , et al. Improvements in airflow and dyspnea in COPD patients following 24 weeks treatment with salmeterol 50mcg and fluticasone propionate 250mcg alone or in combination via the diskus. American Journal of Respiratory &amp; Critical Care Medicine2001;163(5 Suppl):A279. HorstmanD , DarkenP , DavisS , LeeB . Improvements in FEV1 and symptoms in poorly reversible COPD patients following treatment with salmeterol 50mcg/fluticasone propionate 250mcg combination [Abstract]. European Respiratory Journal2003;22 Suppl 45:P434. MahlerDA , DarkenP , BrownCP , KnobilK . Predicting lung function responses to combination therapy in chronic obstructive pulmonary disease (COPD) [Abstract]. National COPD Conference; November 14‐15, 2003; Arlington, Virginia. Abstract 1081. MahlerDA , DarkenP , BrownCP , KnobilK . Predicting lung function responses to salmeterol/fluticasone propionate combination therapy in COPD [Abstract]. European Respiratory Journal2003;22 Suppl 45:P429. SFCA3007 . A randomized, double‐blind, placebo‐controlled, parallel‐group trial evaluating the safety and efficacy of the DISKUS formulations of salmeterol (SAL) 50mcg BID and fluticasone propionate (FP) 250mcg BID individually and in combination as salmeterol 50mcg/fluticasone propionate 250mcg BID (SFC 50/250) compared to placebo in COPD subjects. GlaxoSmithKline Clinical Trials Register (http:ctr.gsk.co.uk)2005. SpencerM , WireP , LeeB , ChangCN , DarkenP , HorstmanD . Patients with COPD using salmeterol/fluticasone propionate combination therapy experience improved quality of life. European Respiratory Journal2003;22 Suppl 45:51s. SpencerMD , KariaN , AndersonJ . The clinical significance of treatment benefits with the salmeterol/fluticasone propionate 50/500mcg combination in COPD. European Respiratory Journal2004;24 Suppl 48:290s. ">Hanania 2003</a> indicated a significant reduction in mean puffs per day of short‐acting beta<sub>2</sub>‐agonist usage in favour of FPS over FP (2 studies; N = 686, MD ‐0.80, 95% CI ‐1.31 to ‐0.29; <a href="./references#CD006826-fig-0028" title="">Analysis 2.15</a>). </p> <p><a href="./references#CD006826-bbs2-0014" title="CalverleyP , PauwelsR , VestboJ , JonesP , PrideN , GulsvikA , et al. Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial. Lancet2003;361(9356):449‐56. CalverleyPMA , PauwelsRA , VestboJ , JonesPW , PrideNB , GulsvikA , et al. Clinical improvements with salmeterol / fluticasone propionate combination in differing severities of COPD, 2003. http://www.abstracts2view.comA035 [Poster D50]. CalverleyPMA , PauwelsRA , VestboJ , JonesPW , PrideNB , GulsvikA , et al. Salmeterol/Fluticasone propionate combination for one year provides greater clinical benefit than its individual components. Proceedings of the 98th International American Thoracic Society Conference http://www.abstracts‐on‐line.com/abstracts/ATS; May 17‐22, 2002; Atlanta, Georgia. A98 [Poster 306]. CalverlyPMA , PauwelsR , VestboJ , JonesP , PrideN , GulsvikA , et al. Safety of salmeterol/fluticasone propionate combination in the treatment of chronic obstructive pulmonary disease. European Respiratory Journal2002;20 Suppl 38:242 [P1572]. HunjanMK , ChandlerF . Numbers needed to treat (NNT) to avoid an exacerbation in patients with chronic obstructive pulmonary disease (COPD) using salmeterol/fluticasone propionate combination (SFC) and associated costs [Abstract]. American Thoracic Society 100th International Conference; May 21‐26, 2004; Orlando, Florida. D22 [Poster 503]. HunjanMK , WilliamsDT . Costs of avoiding exacerbations in patients with chronic obstructive pulmonary disease (COPD) treated with salmeterol/ fluticasone propionate combination (seretide) and salmeterol. European Respiratory Journal2004;24 Suppl 48:291s. HunjanMK , WilliamsDT . Salmeterol/ fluticasone propionate combination is clinically effective in avoiding exacerbations in patients with moderate/severe COPD. European Respiratory Journal2004;24 Suppl 48:513s. JonesPW , EdinHM , AndersonJ . Salmeterol/fluticasone propionate combination improves health status in COPD patients. Proceedings of the 98th International American Thoracic Society Conference http://www.abstracts‐on‐line.com/abstracts/ATS; May 17‐22, 2002; Atlanta, Georgia. A39 [Poster K39]. JonesPW , StåhlE . Budesonide /formoterol sustains clinically relevant improvements in health status in COPD [Abstract]. European Respiratory Journal2005;26 Suppl 49:Abstract 1352. JonesPW , VestboJ , PauwelsRA , CalverleyPMA , AndersonJA , SpencerMD . Informative drop out in COPD studies: investigation of health status of withdrawals in the TRISTAN study. Proceedings of the 13th ERS Annual Congress; September 27, 2003; Vienna, Austria. P1593. NitschmannS . Inhalational combination therapy in chronic obstructive lung disease. Tristan study. German Internist2004;45(6):727‐8. PauwelsR , VestboJ , CalverleyPMA , JonesPW , PrideNB , GulsvikA . Characterization of exacerbations in the TRISTAN study of salmeterol / fluticasone propionate (SFC) combination in moderate to severe COPD, 2006. http://www.abstracts2view.com. PauwelsRA , CalverlyPMA , VestboJ , JonesPW , PrideN , GulsvikA , et al. Reduction of exacerbations with salmeterol/fluticasone combination 50/500 mcg bd in the treatment of chronic obstructive pulmonary disease. European Respiratory Journal2002;20 Suppl 38:240 [P1569]. SFCB3024 . A multicentre, randomised, double‐blind, parallel group, placebo‐controlled study to compare the efficacy and safety of the salmeterol/FP combination product at a strength of 50/500mcg bd with salmeterol 50mcg bd alone and FP 500mcg bd alone, delivered via the DISKUS™/ACCUHALER™, in the treatment of subjects with chronic obstructive pulmonary disease (COPD) for 12 months. GlaxoSmithKline Clinical Trials Register (http:ctr.gsk.co.uk)2005. SpencerM , BriggsAH , GrossmanRF , RanceL . Development of an economic model to assess the cost effectiveness of treatment interventions for chronic obstructive pulmonary disease. Pharmacoeconomics2005;23(6):619‐37. SpencerMD , KariaN , AndersonJ . The clinical significance of treatment benefits with the salmeterol/fluticasone propionate 50/500mcg combination in COPD. European Respiratory Journal2004;24 Suppl 48:290s. VestboJ , CalverleyPMA , PauwelsR , JonesP , PrideN , GulsvikA , et al. Absence of gender susceptibility to the combination of salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease. European Respiratory Journal2002;20 Suppl 38:240 [P1570]. VestboJ , PauwelsR , AndersonJA , JonesP , CalverleyP . Early onset of effect of salmeterol and fluticasone propionate in chronic obstructive pulmonary disease. Thorax2005;60(4):301‐4. VestboJ , PauwelsRS , CalverleyPMA , JonesPW , PrideNB , GulsvikA . Salmeterol / fluticasone propionate combination produces improvement in lung function detectable within 24 hours in moderate to severe COPD, 2003. http://www.abstracts2view.com. VestboJ , SorianoJB , AndersonJA , CalverleyP , PauwelsR , JonesP . Gender does not influence the response to the combination of salmeterol and fluticasone propionate in COPD. Respiratory Medicine2004;98(11):1045‐50. ">TRISTAN</a> reported a significant difference in median % of days without use of relief medication in favour of FPS over FP (P &lt; 0.001). </p> </section> <section id="CD006826-sec-0108"> <h6 class="title">BDF versus BD</h6> <p>BDF treatment reduced the requirement for reliever medication when compared with BD (4 studies; <a href="./references#CD006826-bbs2-0002" title="AstraZenecaSD . A placebo‐controlled 12‐month efficacy study of the fixed combination budesonide/formoterol compared to budesonide and formoterol as monotherapies in patients with chronic obstructive pulmonary disease (COPD). AstraZeneca Clinical Trials2002. BorgstromL , AskingL , OlssonH , PetersonS . Lack of interaction between disease severity and therapeutic response with budesonide/formoterol in a single inhaler [Abstract]. American Thoracic Society 100th International Conference; May 21‐26; 2004, Orlando, Florida. C22 [Poster 505]. CalverleyPM , BonsawatW , CsekeZ , ZhongN , PetersonS , OlssonH . Maintenance therapy with budesonide and formoterol in chronic obstructive pulmonary disease. European Respiratory Journal2003;22(6):912‐9. CalverleyPMA , CsekeZ , PetersonS . Budesonide/formoterol reduces the use of oral corticosteroids in the treatment of COPD [Abstract]. European Respiratory Journal2003;22 Suppl 45:P436. CalverleyPMA , KunaP , OlssonH . COPD exacerbations are reduced by budesonide/formoterol in a single inhaler [Abstract]. European Respiratory Journal2003;22 Suppl 45:P1587. CalverleyPMA , OlssonH , Symbicort International COPD Study Group. Budesonide/formoterol ina single inhaler sustains improvements in lung function over 12 months compared with monocomponents and placebo in patients with COPD [abstract]. American Thoracic Society 99th International Conference; May 16‐21, 2003; Seattle, Washington. B024 [Poster 418]. CalverleyPMA , PetersonS . Combining budesonide/formoterol in a single inhale reduces exacerbation frequency in COPD [abstract]. American Thoracic Society 99th International Conference; May 16‐21, 2003; Seattle, Washington. D092 [Poster 211]. CalverleyPMA , StåhlE , JonesPW . Budesonide/formoterol improves the general health status of patients with COPD [Abstract]. American Thoracic Society 2005 International Conference; May 20‐25, 2005; San Diego, California. B93 [Poster 303]. CalverleyPMA , SzafranskiW , AnderssonA . Budesonide/formoterol is a well‐tolerated long term maintenance therapy for COPD. European Respiratory Journal2005;26 Suppl 49:Poster 1917. CalverleyPMA , ThompsonNC , OlssonH . Budesonide/formoterol in a single inhaler sustains lung function improvements in COPD [Abstract]. European Respiratory Journal2003;22 Suppl 45:P435. HalpinD , StåhlE , LundbackB , AndersonF , PetersonS . Treatment costs and number needed to treat (NNT) with budesonide/formoterol to avoid one exacerbation of COPD [Abstract]. American Thoracic Society 100th International Conference; May 21‐26, 2004; Orlando, Florida. D22 [Poster 525]. HalpinDMG , LarssonT , CalverleyPMA . How many patients with COPD must be treated with budesonide/formoterol compared with formoterol alone to avoid 1 day of oral steroid use? [Abstract]. American Thoracic Society 2005 International Conference; May 20‐25, 2005; San Diego, California. B93 [Poster 314]. JonesPW , StahlE . Budesonide/formoterol in a single inhaler improves health status in patients with COPD [abstract]. American Thoracic Society 99th International Conference; May 16‐21, 2003; Orlando, Florida. B024 [Poster 419]. JonesPW , StåhlE . Budesonide /formoterol sustains clinically relevant improvements in health status in COPD [Abstract]. European Respiratory Journal2005;26 Suppl 49:Abstract 1352. JonesPW , StåhlE . Reducing exacerbations leads to a better health‐related quality of life in patients with COPD. 13th ERS Annual Congress; September 27, 2003; Vienna, Austria. P1586. LofdahlCG . Reducing the impact of COPD exacerbations: Clinical efficacy of budesonide/formoterol. European Respiratory Review2004;13(88):14‐21. LofdahlCG , AndreassonE , SvenssonK , EricssonA . Budesonide/formoterol in a single inhaler improves health status in patients with COPD without increasing healthcare costs [Abstract]. European Respiratory Journal2003;22 Suppl 45:P433. LofdahlCG , EricssonA , SvenssonK , AndreassonE . Cost effectiveness of budesonide/formoterol in a single inhaler for COPD compared with each monocomponent used alone. Pharmacoeconomics2005;23(4):365‐75. ">Calverley 2003</a>; <a href="./references#CD006826-bbs2-0010" title="AndersonP . Budesonide/formoterol in a single inhaler (Symbicort) provides early and sustained improvement in lung function in moderate to severe COPD [Abstract]. Thorax2002;57(Suppl III):iii43. AstraZenecaSD . A placebo‐controlled 12 month efficacy study of the fixed combination budesonide/formoterol compared with budesonide and formoterol as monotherapies in patients with chronic obstructive pulmonary disease (COPD). AstraZeneca Clinical Trials2001. BorgstromL , AskingL , OlssonH , PetersonS . Lack of interaction between disease severity and therapeutic response with budesonide/formoterol in a single inhaler [Abstract]. American Thoracic Society 100th International Conference; May 21‐26, 2004; Orlando, Florida. C22 [Poster 505]. CalverleyP , PauwelsR , LofdahlCG , SvenssonK , HigenbottamT , et al. Relationship between respiratory symptoms and medical treatment in exacerbations of COPD. European Respiratory Journal2005;26(3):406‐13. CalverleyPMA . Effect of budesonide/formoterol on severe exacerbations and lung function in moderate to severe COPD. Thorax. BTS Winter Meeting 2002:S145. CalverleyPMA , SzafranskiW , AnderssonA . Budesonide/formoterol is a well‐tolerated long term maintenance therapy for COPD. European Respiratory Journal2005;26 Suppl 49:Poster 1917. CalverleyPMA , ThompsonNC , OlssonH . Budesonide/formoterol in a single inhaler sustains lung function improvements in COPD [Abstract]. European Respiratory Journal2003;22 Suppl 45:P435. CampbellLM , SzafranskiW . Budesonide/formoterol in a single inhaler (Symbicort) provides sustained relief from symptoms in moderate to severe COPD. Thorax. BTS Winter Meeting 2002:S143. CampellLW , SzafranskiW . Budesonide/Formoterol in a single inhaler (Symbicort) reduces severe exacerbations in patients with moderate‐severe COPD. Thorax. BTS Winter Meeting 2002:S141. DahlR , CukierA , OlssonH . Budesonide/formoterol in a single inhaler reduces severe and mild exacerbations in patients with moderate to severe COPD. European Respiratory Journal2002;20 Suppl 38:242 [P1575]. EgedeF , MengaG . Budesonide/formoterol in a single inhaler provides sustained relief from symptoms and night‐time awakenings in moderate‐severe COPD: results from symptoms and night‐time awakenings in moderate to severe COPD: results from a 1‐year study. European Respiratory Journal2002;20 Suppl 38:242 [P1574]. HalpinD , StahlE , LundbackB , AndersonF , PetersonS . Treatment costs and number needed to treat (NNT) with budesonide/formoterol to avoid one exacerbation of COPD [Abstract]. American Thoracic Society 100th International Conference; May 21‐26, 2004; Orlando, Florida. D22 [Poster 525]. JonesPW , StahlE , SvenssonK . Improvement in health status in patients with moderate to severe COPD after treatment with budesonide/formoterol in a single inhaler. European Respiratory Journal2002;20 Suppl 38:250 [P1613]. KorsgaardJ , SansoresR . Budesonide/formoterol (single inhaler) provides sustained relief from shortness of breath and chest tightness in a 1‐year study of patients with moderate to severe COPD. European Respiratory Journal2002;20 Suppl 38:242 [P1577]. LangeP , SaenzC . Budesonide/formoterol in a single inhaler is well tolerated in patients with moderate to severe COPD: results of a 1 year study. European Respiratory Journal2002;20 Suppl 38:242 [P1573]. LofdahlCG . Reducing the impact of COPD exacerbations: clinical efficacy of budesonide/formoterol. European Respiratory Review2004;13(88):14‐21. MilanowskiJ , NahabedianS . Budesonide/formoterol in a single inhaler acts rapidly to improve lung function and relieve symptoms in patients with moderate to severe COPD. European Respiratory Journal2002;20 Suppl 38:242 [P1576]. SzafranskiW , CukierA , RamirezA , MengaG , SansoresR , NahabedianS , et al. Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease. European Respiratory Journal2003;21(1):74‐81. ">Szafranski 2003</a>; <a href="./references#CD006826-bbs2-0011" title="Astrazeneca(D5899C00002) . A 6‐month double‐blind, double‐dummy, randomized, parallel group, multicenter efficacy &amp; safety study of Symbicort® pMDI 2 × 160/4.5mg &amp; 80/4.5mg bid compared to Formoterol TBH, Budesonide pMDI (&amp; the combination) &amp; placebo in COPD patients. www.astrazenecaclinicaltrials.com (accessed 8 April 2008). BleeckerER , MeyersDA , BaileyWC , SimsA‐M , BujacSR , GoldmanM , et al. ADRB2 polymorphisms and budesonide/formoterol responses in COPDADRB2 polymorphisms and treatment response in COPD. Chest2012;142(2):320‐8. TashkinDP , RennardSI , MartinP , GoldmanM , SilkoffPE . Efficacy of budesonide/formoterol administered via one pressurized metered‐dose inhaler over 6 months in patients with chronic obstructive pulmonary disease [Abstract]. Chest2008; Vol. 134, issue 4:105001s. TashkinDP , RennardSI , MartinP , RamachandranS , MartinUJ , SilkoffPE , et al. Efficacy and safety of budesonide and formoterol in one pressurized metered‐dose inhaler in patients with moderate to very severe chronic obstructive pulmonary disease : results of a 6‐month randomized clinical trial. Drugs2008; Vol. 68, issue 0012‐6667 (Print):1975‐2000. ">Tashkin 2008</a>; <a href="./references#CD006826-bbs2-0015" title="ZhongN , ZhengJ , WenF , YangL , ChenP , XiuQ , et al. Efficacy and safety of budesonide/formoterol via a dry powder inhaler in Chinese patients with chronic obstructive pulmonary disease. Current Medical Research and Opinion2012; Vol. 28, issue 2:257‐65. ZhongN , ZhengJ , WenF , YangL , ChenP , XiuQ , et al. Efficacy and safety of inhalation of budesonide/formoterol via turbuhaler in Chinese patients with chronic obstructive pulmonary disease [Abstract]. Chest2011; Vol. 140, issue 4:5225A. ">Zhong 2012</a>; N = 1777, MD ‐0.72, 95% CI ‐0.92 to ‐0.52; <a href="./references#CD006826-fig-0047" title="">Analysis 3.13</a>). </p> </section> <section id="CD006826-sec-0109"> <h6 class="title">MF/F versus MF</h6> <p>No data were reported for this outcome.</p> </section> </section> <section id="CD006826-sec-0110"> <h5 class="title">Safety and tolerability</h5> <section id="CD006826-sec-0111"> <h6 class="title">FPS versus FP</h6> <p>No significant difference was noted between FPS and FP in the odds of any adverse event (<a href="./references#CD006826-fig-0032" title="">Analysis 2.19</a> through to <a href="./references#CD006826-fig-0034" title="">Analysis 2.21</a>). </p> </section> <section id="CD006826-sec-0112"> <h6 class="title">BDF versus BD</h6> <p>A significant difference between BDF and BD was observed in the adverse events included in this review for nasopharyngitis (1 study; <a href="./references#CD006826-bbs2-0011" title="Astrazeneca(D5899C00002) . A 6‐month double‐blind, double‐dummy, randomized, parallel group, multicenter efficacy &amp; safety study of Symbicort® pMDI 2 × 160/4.5mg &amp; 80/4.5mg bid compared to Formoterol TBH, Budesonide pMDI (&amp; the combination) &amp; placebo in COPD patients. www.astrazenecaclinicaltrials.com (accessed 8 April 2008). BleeckerER , MeyersDA , BaileyWC , SimsA‐M , BujacSR , GoldmanM , et al. ADRB2 polymorphisms and budesonide/formoterol responses in COPDADRB2 polymorphisms and treatment response in COPD. Chest2012;142(2):320‐8. TashkinDP , RennardSI , MartinP , GoldmanM , SilkoffPE . Efficacy of budesonide/formoterol administered via one pressurized metered‐dose inhaler over 6 months in patients with chronic obstructive pulmonary disease [Abstract]. Chest2008; Vol. 134, issue 4:105001s. TashkinDP , RennardSI , MartinP , RamachandranS , MartinUJ , SilkoffPE , et al. Efficacy and safety of budesonide and formoterol in one pressurized metered‐dose inhaler in patients with moderate to very severe chronic obstructive pulmonary disease : results of a 6‐month randomized clinical trial. Drugs2008; Vol. 68, issue 0012‐6667 (Print):1975‐2000. ">Tashkin 2008</a>; N = 552, OR 2.42, 95% CI 1.09 to 5.39; <a href="./references#CD006826-fig-0056" title="">Analysis 3.22</a>), with fewer cases in the BD group. Because this finding is provided by only one study, and because the level of significance (P = 0.03) is marginal, any evaluation of this outcome should be cautious until additional data become available. No significant difference between BDF and BD was reported for any other adverse event considered in the review for this comparison (<a href="./references#CD006826-fig-0056" title="">Analysis 3.22</a>). </p> </section> <section id="CD006826-sec-0113"> <h6 class="title">MF/F versus MF</h6> <p>No significant difference was observed between MF/F and MF in the odds of any adverse event (<a href="./references#CD006826-fig-0066" title="">Analysis 4.10</a> through to <a href="./references#CD006826-fig-0068" title="">Analysis 4.12</a>). </p> </section> </section> <section id="CD006826-sec-0114"> <h5 class="title">Withdrawals</h5> <section id="CD006826-sec-0115"> <h6 class="title">FPS versus FP</h6> <p>Study withdrawal occurred significantly less frequently on FPS than on FP (9 studies; <a href="./references#CD006826-bbs2-0001" title="BourbeauJ , ChristodoulopoulosP , MaltaisF , YamauchiY , OlivensteinR , HamidQ . Effect of salmeterol/fluticasone propionate on airway inflammation in COPD: a randomised controlled trial. Thorax2007; Vol. 62, issue 11:938‐43. ">Bourbeau 2007</a>; <a href="./references#CD006826-bbs2-0004" title="HananiaNA , DarkenP , HorstmanD , ReisnerC , LeeB , DavisS , et al. The efficacy and safety of fluticasone propionate (250 micro g)/salmeterol (50 micro g) combined in the diskus inhaler for the treatment of COPD. Chest2003;124(3):834‐43. HananiaNA , RamsdellJ , PayneK , DavisS , HorstmanD , LeeB , et al. Improvements in airflow and dyspnea in COPD patients following 24 weeks treatment with salmeterol 50mcg and fluticasone propionate 250mcg alone or in combination via the diskus. American Journal of Respiratory &amp; Critical Care Medicine2001;163(5 Suppl):A279. HorstmanD , DarkenP , DavisS , LeeB . Improvements in FEV1 and symptoms in poorly reversible COPD patients following treatment with salmeterol 50mcg/fluticasone propionate 250mcg combination [Abstract]. European Respiratory Journal2003;22 Suppl 45:P434. MahlerDA , DarkenP , BrownCP , KnobilK . Predicting lung function responses to combination therapy in chronic obstructive pulmonary disease (COPD) [Abstract]. National COPD Conference; November 14‐15, 2003; Arlington, Virginia. Abstract 1081. MahlerDA , DarkenP , BrownCP , KnobilK . Predicting lung function responses to salmeterol/fluticasone propionate combination therapy in COPD [Abstract]. European Respiratory Journal2003;22 Suppl 45:P429. SFCA3007 . A randomized, double‐blind, placebo‐controlled, parallel‐group trial evaluating the safety and efficacy of the DISKUS formulations of salmeterol (SAL) 50mcg BID and fluticasone propionate (FP) 250mcg BID individually and in combination as salmeterol 50mcg/fluticasone propionate 250mcg BID (SFC 50/250) compared to placebo in COPD subjects. GlaxoSmithKline Clinical Trials Register (http:ctr.gsk.co.uk)2005. SpencerM , WireP , LeeB , ChangCN , DarkenP , HorstmanD . Patients with COPD using salmeterol/fluticasone propionate combination therapy experience improved quality of life. European Respiratory Journal2003;22 Suppl 45:51s. SpencerMD , KariaN , AndersonJ . The clinical significance of treatment benefits with the salmeterol/fluticasone propionate 50/500mcg combination in COPD. European Respiratory Journal2004;24 Suppl 48:290s. ">Hanania 2003</a>; <a href="./references#CD006826-bbs2-0005" title="LapperreTS , Snoeck‐StrobandJB , GosmanMM , JansenDF , vanSchadewijkA , ThiadensHA , et al. Effect of fluticasone with and without salmeterol on pulmonary outcomes in chronic obstructive pulmonary disease: a randomized trial. Annals of Internal Medicine2009; Vol. 151, issue 8:517‐27. ">Lapperre 2009</a>; <a href="./references#CD006826-bbs2-0006" title="MahlerDA , DarkenP , BrownCP , KnobilK . Predicting lung function responses to combination therapy in chronic obstructive pulmonary disease (COPD), 2003. http://www.abstracts2view.com. MahlerDA , WireP , HorstmanD , ChangCN , YatesJ , FischerT , et al. Effectiveness of fluticasone propionate and salmeterol combination delivered via the diskus device in the treatment of chronic obstructive pulmonary disease. American Journal of Respiratory Critical Care Medicine2002;166(8):1084‐91. SFCA3006 . A randomized, double‐blind, placebo‐controlled, parallel‐group trial evaluating the safety and efficacy of the DISKUS formulations of salmeterol (SAL) 50mcg BID and fluticasone propionate (FP) 500mcg BID individually and in combination as salmeterol 50mcg/fluticasone propionate 500mcg BID (SFC 50/500) compared to placebo in COPD subjects. GlaxoSmithKline Clinical Trials Register (http:ctr.gsk.co.uk)2005. SpencerM , WireP , LeeB , ChangCN , DarkenP , HorstmanD . Patients with COPD using salmeterol/fluticasone propionate combination therapy experience improved quality of life. European Respiratory Journal2003;22 Suppl 45:51s. SpencerMD , AndersonJA . Salmeterol/fluticasone combination produces clinically important benefits in dyspnea and fatigue [Abstract]. American Thoracic Society 2005 International Conference; May 20‐25, 2005; San Diego, California. B93 [Poster 308]. SpencerMD , KariaN , AndersonJ . The clinical significance of treatment benefits with the salmeterol/fluticasone propionate 50/500mcg combination in COPD. European Respiratory Journal2004;24 Suppl 48:290s. ">Mahler 2002</a>; <a href="./references#CD006826-bbs2-0007" title="NCT00358358 . Trial SCO104925. See detailed description, 2006. http://clinicaltrials.gov/show/NCT00358358. [] ">NCT00358358</a>; <a href="./references#CD006826-bbs2-0008" title="SFCT01 . A Multicentre, Randomised, Double‐Blind, Parallel Group, Placebo‐Controlled Study to Compare the Efficacy and Safety of Inhaled Salmeterol/Fluticasone Propionate Combination Product 25/250 µg Two Puffs Bd and Fluticasone Propionate 250µg Two Puffs Bd Alone, All Administered Via Metered Dose Inhalers (MDI), in the Treatment of Subjects with Chronic Obstructive Pulmonary Disease (COPD) for 52 Weeks. GlaxoSmithKline Clinical Trials Register (http:ctr.gsk.co.uk)2005. ">SFCT01</a>; <a href="./references#CD006826-bbs2-0009" title="NCT00120978 . Advair－CRP Study. http://clinicaltrials.gov/show/NCT001209782004. [] SinDD , ManSF , MarciniukDD , FordG , FitzGeraldM , WongE , et al. Can inhaled fluticasone alone or in combination with salmeterol reduce systemic inflammation in chronic obstructive pulmonary disease? Study protocol for a randomized controlled trial [NCT00120978]. BMC Pulmonary Medicine2006;6(6):3. SinDD , ManSF , MarciniukDD , FordG , FitzGeraldM , WongE , et al. The effects of fluticasone with or without salmeterol on systemic biomarkers of inflammation in chronic obstructive pulmonary disease. American Journal of Respiratory and Critical Care Medicine2008; Vol. 177, issue 11:1207‐14. ">Sin 2008</a>; <a href="./references#CD006826-bbs2-0013" title="BriggsAH , GlickHA , Lozano‐OrtegaG , SpencerM , CalverleyPM , JonesPW , et al. Is treatment with ICS and LABA cost‐effective for COPD? Multinational economic analysis of the TORCH study. European Respiratory Journal2010; Vol. 35, issue 3:532‐9. CalverleyPM , AndersonJA , CelliB , FergusonGT , JenkinsC , JonesPW , et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease.[see comment]. New England Journal of Medicine2007; Vol. 356, issue 8:775‐89. CalverleyPMA , AndersonJA , CelliB , FergusonGT , JenkinsC , JonesPW , et al. Cardiovascular events in patients with chronic obstructive pulmonary disease: TORCH study results. Thorax2010;65:719‐25. CalverleyPMA , AndersonJA , CelliB , FergusonGT , JenkinsC , JonesPW , et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. New England Journal of Medicine2007;356(8):775‐89. CalverleyPMA , CelliB , FergusonG , JenkinsC , JonesPW , PrideNB , et al. Baseline characteristics of the first 5,000 COPD patients enrolled in the TORCH survival study. European Respiratory Journal2003;22 Suppl 45:578s. CelliB , CalverleyPMA , AndersonJA , FergusonGT , JenkinsC , JonesPW , et al. The TORCH (TOwards a Revolution in COPD Health) study: salmeterol/fluticasone propionate (SFC) improves health status, reduces exacerbations and improves lung function over three years. European Respiratory Journal2006;28 Suppl 50:34s. CelliB , VestboJ , JenkinsCR , JonesPW , FergusonGT , CalverleyPM , et al. Sex differences in mortality and clinical expressions of patients with chronic obstructive pulmonary disease: the TORCH experience. American Journal of Respiratory and Critical Care Medicine2011;183(3):317‐22. CelliBR , ThomasNE , AndersonJA , FergusonGT , JenkinsCR , JonesPW , et al. Effect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease: results from the TORCH study. American Journal of Respiratory and Critical Care Medicine2008;174(4):332‐8. CrimC , CalverleyPM , AndersonJA , CelliB , FergusonGT , JenkinsC , et al. Pneumonia risk in COPD patients receiving inhaled corticosteroids alone or in combination: TORCH study results. European Respiratory Journal2009;34(3):641‐7. FergusonGT , CalverleyPM , AndersonJA , JenkinsCR , JonesPW , WillitsLR , et al. Prevalence and progression of osteoporosis in patients with COPD: results from the TOwards a Revolution in COPD Health study. Chest2009; Vol. 136, issue 0012‐3692:1456‐65. FergusonGT , CalverleyPMA , AndersonJA , et al. The TORCH (TOwards a Revolution in COPD Health) study: salmeterol/fluticasone propionate (SFC) improves survival in COPD over three years. European Respiratory Journal2006;28 Suppl 50:34s. GlaxoSmithKlineSCO30003 . A multicentre, randomised, double‐blind, parallel group, placebo‐controlled study to investigate the long‐term effects of salmeterol/fluticasone propionate (SERETIDE/VIANI/ADVAIR) 50/500mcg bd, salmeterol 50mcg bd and fluticasone propionate 500mcg bd, all delivered via the DISKUS/ACCUHALER inhaler, on the survival of subjects with chronic obstructive pulmonary disease (COPD) over 3 years of treatment. GlaxoSmithKline Clinical Trial Register2006. HoughtonCM , LawsonN , BorrillZL , WixonCL , YoxallS , LangleySJ , et al. Comparison of the effects of salmeterol/fluticasone propionate with fluticasone propionate on airway physiology in adults with mild persistent asthma. Respiratory Research2007;8:52. JenkinsCR , CalverleyPMA , CelliB , FergusonG , JonesPW , PrideN , et al. Seasonal patterns of exacerbation rates in the TORCH survival study, 2007. http://www.abstracts2view.comA839. JenkinsCR , CelliB , AndersonJA , FergusonGT , JonesPW , VestboJ , et al. Seasonality and determinants of moderate and severe COPD exacerbations in the TORCH study. European Respiratory Journal2012;39(1):38‐45. JenkinsCR , JonesPW , CalverleyPM , CelliB , AndersonJA , FergusonGT , et al. Efficacy of salmeterol/fluticasone propionate by GOLD stage of chronic obstructive pulmonary disease: analysis from the randomised, placebo‐controlled TORCH study. Respiratory Research2009;10:59. JohnsonM , AgustiAG , BarnesNC . Reflections on TORCH: potential mechanisms for the survival benefit of salmeterol/fluticasone propionate in COPD patients. COPD2008;5(6):369‐75. JonesPW , AndersonJA , CalverleyPM , CelliBR , FergusonGT , JenkinsC , et al. TORCH Investigators. Health status in the TORCH study of COPD: treatment efficacy and other determinants of change. Respiratory Research2011;12:71. JonesPW , CalverleyP , CelliB , FergusonG , JenkinsC , PrideN . Trans‐regional validity of the SGRQ in the TORCH survival study, 2007. http://www.abstracts2view.comA122. McGarveyLP , JohnM , AndersonJA , ZvarichMT , WiseRA . Ascertainment of cause‐specific mortality in COPD: operations of the TORCH Clinical Endpoint Committee. Thorax2007;62:411‐5. NCT00268216 . See detailed description, 2000. http://clinicaltrials.gov/show/NCT00268216. [] SCO30003 . A multicentre, randomised, double‐blind, parallel group, placebo‐controlled study to investigate the long‐term effects of salmeterol/fluticasone propionate (SERETIDE®/VIANI®/ADVAIR®) 50/500mcg bd, salmeterol 50mcg bd and fluticasone propionate 500mcg bd, all delivered via the DISKUS®/ACCUHALER® inhaler, on the survival of subjects with chronic obstructive pulmonary disease (COPD) over 3 years of treatment, 2006. www.ctr.gsk.co.uk. VestboJ , AndersonJA , CalverleyPM , CelliB , FergusonGT , JenkinsC , et al. Adherence to inhaled therapy, mortality and hospital admission in COPD. Thorax2009;64(11):939‐43. VestboJ , CalverleyP , CelliB , FergusonG , JenkinsC , JonesP , et al. The TORCH (TOwards a Revolution in COPD Health) survival study protocol. European Respiratory Journal2004;24(2):206‐10. WiseRA , McGarveyLP , JohnM , AndersonJA , ZvarichMT . Reliability of cause‐specific mortality adjudication in a COPD clinical trial, 2007. http://www.abstracts2view.comA120. ">TORCH</a>; <a href="./references#CD006826-bbs2-0014" title="CalverleyP , PauwelsR , VestboJ , JonesP , PrideN , GulsvikA , et al. Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial. Lancet2003;361(9356):449‐56. CalverleyPMA , PauwelsRA , VestboJ , JonesPW , PrideNB , GulsvikA , et al. Clinical improvements with salmeterol / fluticasone propionate combination in differing severities of COPD, 2003. http://www.abstracts2view.comA035 [Poster D50]. CalverleyPMA , PauwelsRA , VestboJ , JonesPW , PrideNB , GulsvikA , et al. Salmeterol/Fluticasone propionate combination for one year provides greater clinical benefit than its individual components. Proceedings of the 98th International American Thoracic Society Conference http://www.abstracts‐on‐line.com/abstracts/ATS; May 17‐22, 2002; Atlanta, Georgia. A98 [Poster 306]. CalverlyPMA , PauwelsR , VestboJ , JonesP , PrideN , GulsvikA , et al. Safety of salmeterol/fluticasone propionate combination in the treatment of chronic obstructive pulmonary disease. European Respiratory Journal2002;20 Suppl 38:242 [P1572]. HunjanMK , ChandlerF . Numbers needed to treat (NNT) to avoid an exacerbation in patients with chronic obstructive pulmonary disease (COPD) using salmeterol/fluticasone propionate combination (SFC) and associated costs [Abstract]. American Thoracic Society 100th International Conference; May 21‐26, 2004; Orlando, Florida. D22 [Poster 503]. HunjanMK , WilliamsDT . Costs of avoiding exacerbations in patients with chronic obstructive pulmonary disease (COPD) treated with salmeterol/ fluticasone propionate combination (seretide) and salmeterol. European Respiratory Journal2004;24 Suppl 48:291s. HunjanMK , WilliamsDT . Salmeterol/ fluticasone propionate combination is clinically effective in avoiding exacerbations in patients with moderate/severe COPD. European Respiratory Journal2004;24 Suppl 48:513s. JonesPW , EdinHM , AndersonJ . Salmeterol/fluticasone propionate combination improves health status in COPD patients. Proceedings of the 98th International American Thoracic Society Conference http://www.abstracts‐on‐line.com/abstracts/ATS; May 17‐22, 2002; Atlanta, Georgia. A39 [Poster K39]. JonesPW , StåhlE . Budesonide /formoterol sustains clinically relevant improvements in health status in COPD [Abstract]. European Respiratory Journal2005;26 Suppl 49:Abstract 1352. JonesPW , VestboJ , PauwelsRA , CalverleyPMA , AndersonJA , SpencerMD . Informative drop out in COPD studies: investigation of health status of withdrawals in the TRISTAN study. Proceedings of the 13th ERS Annual Congress; September 27, 2003; Vienna, Austria. P1593. NitschmannS . Inhalational combination therapy in chronic obstructive lung disease. Tristan study. German Internist2004;45(6):727‐8. PauwelsR , VestboJ , CalverleyPMA , JonesPW , PrideNB , GulsvikA . Characterization of exacerbations in the TRISTAN study of salmeterol / fluticasone propionate (SFC) combination in moderate to severe COPD, 2006. http://www.abstracts2view.com. PauwelsRA , CalverlyPMA , VestboJ , JonesPW , PrideN , GulsvikA , et al. Reduction of exacerbations with salmeterol/fluticasone combination 50/500 mcg bd in the treatment of chronic obstructive pulmonary disease. European Respiratory Journal2002;20 Suppl 38:240 [P1569]. SFCB3024 . A multicentre, randomised, double‐blind, parallel group, placebo‐controlled study to compare the efficacy and safety of the salmeterol/FP combination product at a strength of 50/500mcg bd with salmeterol 50mcg bd alone and FP 500mcg bd alone, delivered via the DISKUS™/ACCUHALER™, in the treatment of subjects with chronic obstructive pulmonary disease (COPD) for 12 months. GlaxoSmithKline Clinical Trials Register (http:ctr.gsk.co.uk)2005. SpencerM , BriggsAH , GrossmanRF , RanceL . Development of an economic model to assess the cost effectiveness of treatment interventions for chronic obstructive pulmonary disease. Pharmacoeconomics2005;23(6):619‐37. SpencerMD , KariaN , AndersonJ . The clinical significance of treatment benefits with the salmeterol/fluticasone propionate 50/500mcg combination in COPD. European Respiratory Journal2004;24 Suppl 48:290s. VestboJ , CalverleyPMA , PauwelsR , JonesP , PrideN , GulsvikA , et al. Absence of gender susceptibility to the combination of salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease. European Respiratory Journal2002;20 Suppl 38:240 [P1570]. VestboJ , PauwelsR , AndersonJA , JonesP , CalverleyP . Early onset of effect of salmeterol and fluticasone propionate in chronic obstructive pulmonary disease. Thorax2005;60(4):301‐4. VestboJ , PauwelsRS , CalverleyPMA , JonesPW , PrideNB , GulsvikA . Salmeterol / fluticasone propionate combination produces improvement in lung function detectable within 24 hours in moderate to severe COPD, 2003. http://www.abstracts2view.com. VestboJ , SorianoJB , AndersonJA , CalverleyP , PauwelsR , JonesP . Gender does not influence the response to the combination of salmeterol and fluticasone propionate in COPD. Respiratory Medicine2004;98(11):1045‐50. ">TRISTAN</a>; N = 5132, OR 0.86, 95% CI 0.76 to 0.97; <a href="./references#CD006826-fig-0029" title="">Analysis 2.16</a>). When expressed as withdrawal due to lack of efficacy, no significant difference between treatments was described (5 studies; <a href="./references#CD006826-bbs2-0006" title="MahlerDA , DarkenP , BrownCP , KnobilK . Predicting lung function responses to combination therapy in chronic obstructive pulmonary disease (COPD), 2003. http://www.abstracts2view.com. MahlerDA , WireP , HorstmanD , ChangCN , YatesJ , FischerT , et al. Effectiveness of fluticasone propionate and salmeterol combination delivered via the diskus device in the treatment of chronic obstructive pulmonary disease. American Journal of Respiratory Critical Care Medicine2002;166(8):1084‐91. SFCA3006 . A randomized, double‐blind, placebo‐controlled, parallel‐group trial evaluating the safety and efficacy of the DISKUS formulations of salmeterol (SAL) 50mcg BID and fluticasone propionate (FP) 500mcg BID individually and in combination as salmeterol 50mcg/fluticasone propionate 500mcg BID (SFC 50/500) compared to placebo in COPD subjects. GlaxoSmithKline Clinical Trials Register (http:ctr.gsk.co.uk)2005. SpencerM , WireP , LeeB , ChangCN , DarkenP , HorstmanD . Patients with COPD using salmeterol/fluticasone propionate combination therapy experience improved quality of life. European Respiratory Journal2003;22 Suppl 45:51s. SpencerMD , AndersonJA . Salmeterol/fluticasone combination produces clinically important benefits in dyspnea and fatigue [Abstract]. American Thoracic Society 2005 International Conference; May 20‐25, 2005; San Diego, California. B93 [Poster 308]. SpencerMD , KariaN , AndersonJ . The clinical significance of treatment benefits with the salmeterol/fluticasone propionate 50/500mcg combination in COPD. European Respiratory Journal2004;24 Suppl 48:290s. ">Mahler 2002</a>; <a href="./references#CD006826-bbs2-0008" title="SFCT01 . A Multicentre, Randomised, Double‐Blind, Parallel Group, Placebo‐Controlled Study to Compare the Efficacy and Safety of Inhaled Salmeterol/Fluticasone Propionate Combination Product 25/250 µg Two Puffs Bd and Fluticasone Propionate 250µg Two Puffs Bd Alone, All Administered Via Metered Dose Inhalers (MDI), in the Treatment of Subjects with Chronic Obstructive Pulmonary Disease (COPD) for 52 Weeks. GlaxoSmithKline Clinical Trials Register (http:ctr.gsk.co.uk)2005. ">SFCT01</a>; <a href="./references#CD006826-bbs2-0009" title="NCT00120978 . Advair－CRP Study. http://clinicaltrials.gov/show/NCT001209782004. [] SinDD , ManSF , MarciniukDD , FordG , FitzGeraldM , WongE , et al. Can inhaled fluticasone alone or in combination with salmeterol reduce systemic inflammation in chronic obstructive pulmonary disease? Study protocol for a randomized controlled trial [NCT00120978]. BMC Pulmonary Medicine2006;6(6):3. SinDD , ManSF , MarciniukDD , FordG , FitzGeraldM , WongE , et al. The effects of fluticasone with or without salmeterol on systemic biomarkers of inflammation in chronic obstructive pulmonary disease. American Journal of Respiratory and Critical Care Medicine2008; Vol. 177, issue 11:1207‐14. ">Sin 2008</a>; <a href="./references#CD006826-bbs2-0013" title="BriggsAH , GlickHA , Lozano‐OrtegaG , SpencerM , CalverleyPM , JonesPW , et al. Is treatment with ICS and LABA cost‐effective for COPD? Multinational economic analysis of the TORCH study. European Respiratory Journal2010; Vol. 35, issue 3:532‐9. CalverleyPM , AndersonJA , CelliB , FergusonGT , JenkinsC , JonesPW , et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease.[see comment]. New England Journal of Medicine2007; Vol. 356, issue 8:775‐89. CalverleyPMA , AndersonJA , CelliB , FergusonGT , JenkinsC , JonesPW , et al. Cardiovascular events in patients with chronic obstructive pulmonary disease: TORCH study results. Thorax2010;65:719‐25. CalverleyPMA , AndersonJA , CelliB , FergusonGT , JenkinsC , JonesPW , et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. New England Journal of Medicine2007;356(8):775‐89. CalverleyPMA , CelliB , FergusonG , JenkinsC , JonesPW , PrideNB , et al. Baseline characteristics of the first 5,000 COPD patients enrolled in the TORCH survival study. European Respiratory Journal2003;22 Suppl 45:578s. CelliB , CalverleyPMA , AndersonJA , FergusonGT , JenkinsC , JonesPW , et al. The TORCH (TOwards a Revolution in COPD Health) study: salmeterol/fluticasone propionate (SFC) improves health status, reduces exacerbations and improves lung function over three years. European Respiratory Journal2006;28 Suppl 50:34s. CelliB , VestboJ , JenkinsCR , JonesPW , FergusonGT , CalverleyPM , et al. Sex differences in mortality and clinical expressions of patients with chronic obstructive pulmonary disease: the TORCH experience. American Journal of Respiratory and Critical Care Medicine2011;183(3):317‐22. CelliBR , ThomasNE , AndersonJA , FergusonGT , JenkinsCR , JonesPW , et al. Effect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease: results from the TORCH study. American Journal of Respiratory and Critical Care Medicine2008;174(4):332‐8. CrimC , CalverleyPM , AndersonJA , CelliB , FergusonGT , JenkinsC , et al. Pneumonia risk in COPD patients receiving inhaled corticosteroids alone or in combination: TORCH study results. European Respiratory Journal2009;34(3):641‐7. FergusonGT , CalverleyPM , AndersonJA , JenkinsCR , JonesPW , WillitsLR , et al. Prevalence and progression of osteoporosis in patients with COPD: results from the TOwards a Revolution in COPD Health study. Chest2009; Vol. 136, issue 0012‐3692:1456‐65. FergusonGT , CalverleyPMA , AndersonJA , et al. The TORCH (TOwards a Revolution in COPD Health) study: salmeterol/fluticasone propionate (SFC) improves survival in COPD over three years. European Respiratory Journal2006;28 Suppl 50:34s. GlaxoSmithKlineSCO30003 . A multicentre, randomised, double‐blind, parallel group, placebo‐controlled study to investigate the long‐term effects of salmeterol/fluticasone propionate (SERETIDE/VIANI/ADVAIR) 50/500mcg bd, salmeterol 50mcg bd and fluticasone propionate 500mcg bd, all delivered via the DISKUS/ACCUHALER inhaler, on the survival of subjects with chronic obstructive pulmonary disease (COPD) over 3 years of treatment. GlaxoSmithKline Clinical Trial Register2006. HoughtonCM , LawsonN , BorrillZL , WixonCL , YoxallS , LangleySJ , et al. Comparison of the effects of salmeterol/fluticasone propionate with fluticasone propionate on airway physiology in adults with mild persistent asthma. Respiratory Research2007;8:52. JenkinsCR , CalverleyPMA , CelliB , FergusonG , JonesPW , PrideN , et al. Seasonal patterns of exacerbation rates in the TORCH survival study, 2007. http://www.abstracts2view.comA839. JenkinsCR , CelliB , AndersonJA , FergusonGT , JonesPW , VestboJ , et al. Seasonality and determinants of moderate and severe COPD exacerbations in the TORCH study. European Respiratory Journal2012;39(1):38‐45. JenkinsCR , JonesPW , CalverleyPM , CelliB , AndersonJA , FergusonGT , et al. Efficacy of salmeterol/fluticasone propionate by GOLD stage of chronic obstructive pulmonary disease: analysis from the randomised, placebo‐controlled TORCH study. Respiratory Research2009;10:59. JohnsonM , AgustiAG , BarnesNC . Reflections on TORCH: potential mechanisms for the survival benefit of salmeterol/fluticasone propionate in COPD patients. COPD2008;5(6):369‐75. JonesPW , AndersonJA , CalverleyPM , CelliBR , FergusonGT , JenkinsC , et al. TORCH Investigators. Health status in the TORCH study of COPD: treatment efficacy and other determinants of change. Respiratory Research2011;12:71. JonesPW , CalverleyP , CelliB , FergusonG , JenkinsC , PrideN . Trans‐regional validity of the SGRQ in the TORCH survival study, 2007. http://www.abstracts2view.comA122. McGarveyLP , JohnM , AndersonJA , ZvarichMT , WiseRA . Ascertainment of cause‐specific mortality in COPD: operations of the TORCH Clinical Endpoint Committee. Thorax2007;62:411‐5. NCT00268216 . See detailed description, 2000. http://clinicaltrials.gov/show/NCT00268216. [] SCO30003 . A multicentre, randomised, double‐blind, parallel group, placebo‐controlled study to investigate the long‐term effects of salmeterol/fluticasone propionate (SERETIDE®/VIANI®/ADVAIR®) 50/500mcg bd, salmeterol 50mcg bd and fluticasone propionate 500mcg bd, all delivered via the DISKUS®/ACCUHALER® inhaler, on the survival of subjects with chronic obstructive pulmonary disease (COPD) over 3 years of treatment, 2006. www.ctr.gsk.co.uk. VestboJ , AndersonJA , CalverleyPM , CelliB , FergusonGT , JenkinsC , et al. Adherence to inhaled therapy, mortality and hospital admission in COPD. Thorax2009;64(11):939‐43. VestboJ , CalverleyP , CelliB , FergusonG , JenkinsC , JonesP , et al. The TORCH (TOwards a Revolution in COPD Health) survival study protocol. European Respiratory Journal2004;24(2):206‐10. WiseRA , McGarveyLP , JohnM , AndersonJA , ZvarichMT . Reliability of cause‐specific mortality adjudication in a COPD clinical trial, 2007. http://www.abstracts2view.comA120. ">TORCH</a>; <a href="./references#CD006826-bbs2-0014" title="CalverleyP , PauwelsR , VestboJ , JonesP , PrideN , GulsvikA , et al. Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial. Lancet2003;361(9356):449‐56. CalverleyPMA , PauwelsRA , VestboJ , JonesPW , PrideNB , GulsvikA , et al. Clinical improvements with salmeterol / fluticasone propionate combination in differing severities of COPD, 2003. http://www.abstracts2view.comA035 [Poster D50]. CalverleyPMA , PauwelsRA , VestboJ , JonesPW , PrideNB , GulsvikA , et al. Salmeterol/Fluticasone propionate combination for one year provides greater clinical benefit than its individual components. Proceedings of the 98th International American Thoracic Society Conference http://www.abstracts‐on‐line.com/abstracts/ATS; May 17‐22, 2002; Atlanta, Georgia. A98 [Poster 306]. CalverlyPMA , PauwelsR , VestboJ , JonesP , PrideN , GulsvikA , et al. Safety of salmeterol/fluticasone propionate combination in the treatment of chronic obstructive pulmonary disease. European Respiratory Journal2002;20 Suppl 38:242 [P1572]. HunjanMK , ChandlerF . Numbers needed to treat (NNT) to avoid an exacerbation in patients with chronic obstructive pulmonary disease (COPD) using salmeterol/fluticasone propionate combination (SFC) and associated costs [Abstract]. American Thoracic Society 100th International Conference; May 21‐26, 2004; Orlando, Florida. D22 [Poster 503]. HunjanMK , WilliamsDT . Costs of avoiding exacerbations in patients with chronic obstructive pulmonary disease (COPD) treated with salmeterol/ fluticasone propionate combination (seretide) and salmeterol. European Respiratory Journal2004;24 Suppl 48:291s. HunjanMK , WilliamsDT . Salmeterol/ fluticasone propionate combination is clinically effective in avoiding exacerbations in patients with moderate/severe COPD. European Respiratory Journal2004;24 Suppl 48:513s. JonesPW , EdinHM , AndersonJ . Salmeterol/fluticasone propionate combination improves health status in COPD patients. Proceedings of the 98th International American Thoracic Society Conference http://www.abstracts‐on‐line.com/abstracts/ATS; May 17‐22, 2002; Atlanta, Georgia. A39 [Poster K39]. JonesPW , StåhlE . Budesonide /formoterol sustains clinically relevant improvements in health status in COPD [Abstract]. European Respiratory Journal2005;26 Suppl 49:Abstract 1352. JonesPW , VestboJ , PauwelsRA , CalverleyPMA , AndersonJA , SpencerMD . Informative drop out in COPD studies: investigation of health status of withdrawals in the TRISTAN study. Proceedings of the 13th ERS Annual Congress; September 27, 2003; Vienna, Austria. P1593. NitschmannS . Inhalational combination therapy in chronic obstructive lung disease. Tristan study. German Internist2004;45(6):727‐8. PauwelsR , VestboJ , CalverleyPMA , JonesPW , PrideNB , GulsvikA . Characterization of exacerbations in the TRISTAN study of salmeterol / fluticasone propionate (SFC) combination in moderate to severe COPD, 2006. http://www.abstracts2view.com. PauwelsRA , CalverlyPMA , VestboJ , JonesPW , PrideN , GulsvikA , et al. Reduction of exacerbations with salmeterol/fluticasone combination 50/500 mcg bd in the treatment of chronic obstructive pulmonary disease. European Respiratory Journal2002;20 Suppl 38:240 [P1569]. SFCB3024 . A multicentre, randomised, double‐blind, parallel group, placebo‐controlled study to compare the efficacy and safety of the salmeterol/FP combination product at a strength of 50/500mcg bd with salmeterol 50mcg bd alone and FP 500mcg bd alone, delivered via the DISKUS™/ACCUHALER™, in the treatment of subjects with chronic obstructive pulmonary disease (COPD) for 12 months. GlaxoSmithKline Clinical Trials Register (http:ctr.gsk.co.uk)2005. SpencerM , BriggsAH , GrossmanRF , RanceL . Development of an economic model to assess the cost effectiveness of treatment interventions for chronic obstructive pulmonary disease. Pharmacoeconomics2005;23(6):619‐37. SpencerMD , KariaN , AndersonJ . The clinical significance of treatment benefits with the salmeterol/fluticasone propionate 50/500mcg combination in COPD. European Respiratory Journal2004;24 Suppl 48:290s. VestboJ , CalverleyPMA , PauwelsR , JonesP , PrideN , GulsvikA , et al. Absence of gender susceptibility to the combination of salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease. European Respiratory Journal2002;20 Suppl 38:240 [P1570]. VestboJ , PauwelsR , AndersonJA , JonesP , CalverleyP . Early onset of effect of salmeterol and fluticasone propionate in chronic obstructive pulmonary disease. Thorax2005;60(4):301‐4. VestboJ , PauwelsRS , CalverleyPMA , JonesPW , PrideNB , GulsvikA . Salmeterol / fluticasone propionate combination produces improvement in lung function detectable within 24 hours in moderate to severe COPD, 2003. http://www.abstracts2view.com. VestboJ , SorianoJB , AndersonJA , CalverleyP , PauwelsR , JonesP . Gender does not influence the response to the combination of salmeterol and fluticasone propionate in COPD. Respiratory Medicine2004;98(11):1045‐50. ">TRISTAN</a>; N = 4592, OR 0.77, 95% CI 0.53 to 1.13; <a href="./references#CD006826-fig-0030" title="">Analysis 2.17</a>). However, fewer withdrawals resulted from adverse events among FPS‐treated participants than among those treated with FP (7 studies; <a href="./references#CD006826-bbs2-0001" title="BourbeauJ , ChristodoulopoulosP , MaltaisF , YamauchiY , OlivensteinR , HamidQ . Effect of salmeterol/fluticasone propionate on airway inflammation in COPD: a randomised controlled trial. Thorax2007; Vol. 62, issue 11:938‐43. ">Bourbeau 2007</a>; <a href="./references#CD006826-bbs2-0006" title="MahlerDA , DarkenP , BrownCP , KnobilK . Predicting lung function responses to combination therapy in chronic obstructive pulmonary disease (COPD), 2003. http://www.abstracts2view.com. MahlerDA , WireP , HorstmanD , ChangCN , YatesJ , FischerT , et al. Effectiveness of fluticasone propionate and salmeterol combination delivered via the diskus device in the treatment of chronic obstructive pulmonary disease. American Journal of Respiratory Critical Care Medicine2002;166(8):1084‐91. SFCA3006 . A randomized, double‐blind, placebo‐controlled, parallel‐group trial evaluating the safety and efficacy of the DISKUS formulations of salmeterol (SAL) 50mcg BID and fluticasone propionate (FP) 500mcg BID individually and in combination as salmeterol 50mcg/fluticasone propionate 500mcg BID (SFC 50/500) compared to placebo in COPD subjects. GlaxoSmithKline Clinical Trials Register (http:ctr.gsk.co.uk)2005. SpencerM , WireP , LeeB , ChangCN , DarkenP , HorstmanD . Patients with COPD using salmeterol/fluticasone propionate combination therapy experience improved quality of life. European Respiratory Journal2003;22 Suppl 45:51s. SpencerMD , AndersonJA . Salmeterol/fluticasone combination produces clinically important benefits in dyspnea and fatigue [Abstract]. American Thoracic Society 2005 International Conference; May 20‐25, 2005; San Diego, California. B93 [Poster 308]. SpencerMD , KariaN , AndersonJ . The clinical significance of treatment benefits with the salmeterol/fluticasone propionate 50/500mcg combination in COPD. European Respiratory Journal2004;24 Suppl 48:290s. ">Mahler 2002</a>; <a href="./references#CD006826-bbs2-0007" title="NCT00358358 . Trial SCO104925. See detailed description, 2006. http://clinicaltrials.gov/show/NCT00358358. [] ">NCT00358358</a>; <a href="./references#CD006826-bbs2-0008" title="SFCT01 . A Multicentre, Randomised, Double‐Blind, Parallel Group, Placebo‐Controlled Study to Compare the Efficacy and Safety of Inhaled Salmeterol/Fluticasone Propionate Combination Product 25/250 µg Two Puffs Bd and Fluticasone Propionate 250µg Two Puffs Bd Alone, All Administered Via Metered Dose Inhalers (MDI), in the Treatment of Subjects with Chronic Obstructive Pulmonary Disease (COPD) for 52 Weeks. GlaxoSmithKline Clinical Trials Register (http:ctr.gsk.co.uk)2005. ">SFCT01</a>; <a href="./references#CD006826-bbs2-0009" title="NCT00120978 . Advair－CRP Study. http://clinicaltrials.gov/show/NCT001209782004. [] SinDD , ManSF , MarciniukDD , FordG , FitzGeraldM , WongE , et al. Can inhaled fluticasone alone or in combination with salmeterol reduce systemic inflammation in chronic obstructive pulmonary disease? Study protocol for a randomized controlled trial [NCT00120978]. BMC Pulmonary Medicine2006;6(6):3. SinDD , ManSF , MarciniukDD , FordG , FitzGeraldM , WongE , et al. The effects of fluticasone with or without salmeterol on systemic biomarkers of inflammation in chronic obstructive pulmonary disease. American Journal of Respiratory and Critical Care Medicine2008; Vol. 177, issue 11:1207‐14. ">Sin 2008</a>; <a href="./references#CD006826-bbs2-0013" title="BriggsAH , GlickHA , Lozano‐OrtegaG , SpencerM , CalverleyPM , JonesPW , et al. Is treatment with ICS and LABA cost‐effective for COPD? Multinational economic analysis of the TORCH study. European Respiratory Journal2010; Vol. 35, issue 3:532‐9. CalverleyPM , AndersonJA , CelliB , FergusonGT , JenkinsC , JonesPW , et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease.[see comment]. New England Journal of Medicine2007; Vol. 356, issue 8:775‐89. CalverleyPMA , AndersonJA , CelliB , FergusonGT , JenkinsC , JonesPW , et al. Cardiovascular events in patients with chronic obstructive pulmonary disease: TORCH study results. Thorax2010;65:719‐25. CalverleyPMA , AndersonJA , CelliB , FergusonGT , JenkinsC , JonesPW , et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. New England Journal of Medicine2007;356(8):775‐89. CalverleyPMA , CelliB , FergusonG , JenkinsC , JonesPW , PrideNB , et al. Baseline characteristics of the first 5,000 COPD patients enrolled in the TORCH survival study. European Respiratory Journal2003;22 Suppl 45:578s. CelliB , CalverleyPMA , AndersonJA , FergusonGT , JenkinsC , JonesPW , et al. The TORCH (TOwards a Revolution in COPD Health) study: salmeterol/fluticasone propionate (SFC) improves health status, reduces exacerbations and improves lung function over three years. European Respiratory Journal2006;28 Suppl 50:34s. CelliB , VestboJ , JenkinsCR , JonesPW , FergusonGT , CalverleyPM , et al. Sex differences in mortality and clinical expressions of patients with chronic obstructive pulmonary disease: the TORCH experience. American Journal of Respiratory and Critical Care Medicine2011;183(3):317‐22. CelliBR , ThomasNE , AndersonJA , FergusonGT , JenkinsCR , JonesPW , et al. Effect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease: results from the TORCH study. American Journal of Respiratory and Critical Care Medicine2008;174(4):332‐8. CrimC , CalverleyPM , AndersonJA , CelliB , FergusonGT , JenkinsC , et al. Pneumonia risk in COPD patients receiving inhaled corticosteroids alone or in combination: TORCH study results. European Respiratory Journal2009;34(3):641‐7. FergusonGT , CalverleyPM , AndersonJA , JenkinsCR , JonesPW , WillitsLR , et al. Prevalence and progression of osteoporosis in patients with COPD: results from the TOwards a Revolution in COPD Health study. Chest2009; Vol. 136, issue 0012‐3692:1456‐65. FergusonGT , CalverleyPMA , AndersonJA , et al. The TORCH (TOwards a Revolution in COPD Health) study: salmeterol/fluticasone propionate (SFC) improves survival in COPD over three years. European Respiratory Journal2006;28 Suppl 50:34s. GlaxoSmithKlineSCO30003 . A multicentre, randomised, double‐blind, parallel group, placebo‐controlled study to investigate the long‐term effects of salmeterol/fluticasone propionate (SERETIDE/VIANI/ADVAIR) 50/500mcg bd, salmeterol 50mcg bd and fluticasone propionate 500mcg bd, all delivered via the DISKUS/ACCUHALER inhaler, on the survival of subjects with chronic obstructive pulmonary disease (COPD) over 3 years of treatment. GlaxoSmithKline Clinical Trial Register2006. HoughtonCM , LawsonN , BorrillZL , WixonCL , YoxallS , LangleySJ , et al. Comparison of the effects of salmeterol/fluticasone propionate with fluticasone propionate on airway physiology in adults with mild persistent asthma. Respiratory Research2007;8:52. JenkinsCR , CalverleyPMA , CelliB , FergusonG , JonesPW , PrideN , et al. Seasonal patterns of exacerbation rates in the TORCH survival study, 2007. http://www.abstracts2view.comA839. JenkinsCR , CelliB , AndersonJA , FergusonGT , JonesPW , VestboJ , et al. Seasonality and determinants of moderate and severe COPD exacerbations in the TORCH study. European Respiratory Journal2012;39(1):38‐45. JenkinsCR , JonesPW , CalverleyPM , CelliB , AndersonJA , FergusonGT , et al. Efficacy of salmeterol/fluticasone propionate by GOLD stage of chronic obstructive pulmonary disease: analysis from the randomised, placebo‐controlled TORCH study. Respiratory Research2009;10:59. JohnsonM , AgustiAG , BarnesNC . Reflections on TORCH: potential mechanisms for the survival benefit of salmeterol/fluticasone propionate in COPD patients. COPD2008;5(6):369‐75. JonesPW , AndersonJA , CalverleyPM , CelliBR , FergusonGT , JenkinsC , et al. TORCH Investigators. Health status in the TORCH study of COPD: treatment efficacy and other determinants of change. Respiratory Research2011;12:71. JonesPW , CalverleyP , CelliB , FergusonG , JenkinsC , PrideN . Trans‐regional validity of the SGRQ in the TORCH survival study, 2007. http://www.abstracts2view.comA122. McGarveyLP , JohnM , AndersonJA , ZvarichMT , WiseRA . Ascertainment of cause‐specific mortality in COPD: operations of the TORCH Clinical Endpoint Committee. Thorax2007;62:411‐5. NCT00268216 . See detailed description, 2000. http://clinicaltrials.gov/show/NCT00268216. [] SCO30003 . A multicentre, randomised, double‐blind, parallel group, placebo‐controlled study to investigate the long‐term effects of salmeterol/fluticasone propionate (SERETIDE®/VIANI®/ADVAIR®) 50/500mcg bd, salmeterol 50mcg bd and fluticasone propionate 500mcg bd, all delivered via the DISKUS®/ACCUHALER® inhaler, on the survival of subjects with chronic obstructive pulmonary disease (COPD) over 3 years of treatment, 2006. www.ctr.gsk.co.uk. VestboJ , AndersonJA , CalverleyPM , CelliB , FergusonGT , JenkinsC , et al. Adherence to inhaled therapy, mortality and hospital admission in COPD. Thorax2009;64(11):939‐43. VestboJ , CalverleyP , CelliB , FergusonG , JenkinsC , JonesP , et al. The TORCH (TOwards a Revolution in COPD Health) survival study protocol. European Respiratory Journal2004;24(2):206‐10. WiseRA , McGarveyLP , JohnM , AndersonJA , ZvarichMT . Reliability of cause‐specific mortality adjudication in a COPD clinical trial, 2007. http://www.abstracts2view.comA120. ">TORCH</a>; <a href="./references#CD006826-bbs2-0014" title="CalverleyP , PauwelsR , VestboJ , JonesP , PrideN , GulsvikA , et al. Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial. Lancet2003;361(9356):449‐56. CalverleyPMA , PauwelsRA , VestboJ , JonesPW , PrideNB , GulsvikA , et al. Clinical improvements with salmeterol / fluticasone propionate combination in differing severities of COPD, 2003. http://www.abstracts2view.comA035 [Poster D50]. CalverleyPMA , PauwelsRA , VestboJ , JonesPW , PrideNB , GulsvikA , et al. Salmeterol/Fluticasone propionate combination for one year provides greater clinical benefit than its individual components. Proceedings of the 98th International American Thoracic Society Conference http://www.abstracts‐on‐line.com/abstracts/ATS; May 17‐22, 2002; Atlanta, Georgia. A98 [Poster 306]. CalverlyPMA , PauwelsR , VestboJ , JonesP , PrideN , GulsvikA , et al. Safety of salmeterol/fluticasone propionate combination in the treatment of chronic obstructive pulmonary disease. European Respiratory Journal2002;20 Suppl 38:242 [P1572]. HunjanMK , ChandlerF . Numbers needed to treat (NNT) to avoid an exacerbation in patients with chronic obstructive pulmonary disease (COPD) using salmeterol/fluticasone propionate combination (SFC) and associated costs [Abstract]. American Thoracic Society 100th International Conference; May 21‐26, 2004; Orlando, Florida. D22 [Poster 503]. HunjanMK , WilliamsDT . Costs of avoiding exacerbations in patients with chronic obstructive pulmonary disease (COPD) treated with salmeterol/ fluticasone propionate combination (seretide) and salmeterol. European Respiratory Journal2004;24 Suppl 48:291s. HunjanMK , WilliamsDT . Salmeterol/ fluticasone propionate combination is clinically effective in avoiding exacerbations in patients with moderate/severe COPD. European Respiratory Journal2004;24 Suppl 48:513s. JonesPW , EdinHM , AndersonJ . Salmeterol/fluticasone propionate combination improves health status in COPD patients. Proceedings of the 98th International American Thoracic Society Conference http://www.abstracts‐on‐line.com/abstracts/ATS; May 17‐22, 2002; Atlanta, Georgia. A39 [Poster K39]. JonesPW , StåhlE . Budesonide /formoterol sustains clinically relevant improvements in health status in COPD [Abstract]. European Respiratory Journal2005;26 Suppl 49:Abstract 1352. JonesPW , VestboJ , PauwelsRA , CalverleyPMA , AndersonJA , SpencerMD . Informative drop out in COPD studies: investigation of health status of withdrawals in the TRISTAN study. Proceedings of the 13th ERS Annual Congress; September 27, 2003; Vienna, Austria. P1593. NitschmannS . Inhalational combination therapy in chronic obstructive lung disease. Tristan study. German Internist2004;45(6):727‐8. PauwelsR , VestboJ , CalverleyPMA , JonesPW , PrideNB , GulsvikA . Characterization of exacerbations in the TRISTAN study of salmeterol / fluticasone propionate (SFC) combination in moderate to severe COPD, 2006. http://www.abstracts2view.com. PauwelsRA , CalverlyPMA , VestboJ , JonesPW , PrideN , GulsvikA , et al. Reduction of exacerbations with salmeterol/fluticasone combination 50/500 mcg bd in the treatment of chronic obstructive pulmonary disease. European Respiratory Journal2002;20 Suppl 38:240 [P1569]. SFCB3024 . A multicentre, randomised, double‐blind, parallel group, placebo‐controlled study to compare the efficacy and safety of the salmeterol/FP combination product at a strength of 50/500mcg bd with salmeterol 50mcg bd alone and FP 500mcg bd alone, delivered via the DISKUS™/ACCUHALER™, in the treatment of subjects with chronic obstructive pulmonary disease (COPD) for 12 months. GlaxoSmithKline Clinical Trials Register (http:ctr.gsk.co.uk)2005. SpencerM , BriggsAH , GrossmanRF , RanceL . Development of an economic model to assess the cost effectiveness of treatment interventions for chronic obstructive pulmonary disease. Pharmacoeconomics2005;23(6):619‐37. SpencerMD , KariaN , AndersonJ . The clinical significance of treatment benefits with the salmeterol/fluticasone propionate 50/500mcg combination in COPD. European Respiratory Journal2004;24 Suppl 48:290s. VestboJ , CalverleyPMA , PauwelsR , JonesP , PrideN , GulsvikA , et al. Absence of gender susceptibility to the combination of salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease. European Respiratory Journal2002;20 Suppl 38:240 [P1570]. VestboJ , PauwelsR , AndersonJA , JonesP , CalverleyP . Early onset of effect of salmeterol and fluticasone propionate in chronic obstructive pulmonary disease. Thorax2005;60(4):301‐4. VestboJ , PauwelsRS , CalverleyPMA , JonesPW , PrideNB , GulsvikA . Salmeterol / fluticasone propionate combination produces improvement in lung function detectable within 24 hours in moderate to severe COPD, 2003. http://www.abstracts2view.com. VestboJ , SorianoJB , AndersonJA , CalverleyP , PauwelsR , JonesP . Gender does not influence the response to the combination of salmeterol and fluticasone propionate in COPD. Respiratory Medicine2004;98(11):1045‐50. ">TRISTAN</a>; N = 4712, OR 0.75, 95% CI 0.64 to 0.87; <a href="./references#CD006826-fig-0031" title="">Analysis 2.18</a>). </p> </section> <section id="CD006826-sec-0116"> <h6 class="title">BDF versus BD</h6> <p>Data were pooled from <a href="./references#CD006826-bbs2-0002" title="AstraZenecaSD . A placebo‐controlled 12‐month efficacy study of the fixed combination budesonide/formoterol compared to budesonide and formoterol as monotherapies in patients with chronic obstructive pulmonary disease (COPD). AstraZeneca Clinical Trials2002. BorgstromL , AskingL , OlssonH , PetersonS . Lack of interaction between disease severity and therapeutic response with budesonide/formoterol in a single inhaler [Abstract]. American Thoracic Society 100th International Conference; May 21‐26; 2004, Orlando, Florida. C22 [Poster 505]. CalverleyPM , BonsawatW , CsekeZ , ZhongN , PetersonS , OlssonH . Maintenance therapy with budesonide and formoterol in chronic obstructive pulmonary disease. European Respiratory Journal2003;22(6):912‐9. CalverleyPMA , CsekeZ , PetersonS . Budesonide/formoterol reduces the use of oral corticosteroids in the treatment of COPD [Abstract]. European Respiratory Journal2003;22 Suppl 45:P436. CalverleyPMA , KunaP , OlssonH . COPD exacerbations are reduced by budesonide/formoterol in a single inhaler [Abstract]. European Respiratory Journal2003;22 Suppl 45:P1587. CalverleyPMA , OlssonH , Symbicort International COPD Study Group. Budesonide/formoterol ina single inhaler sustains improvements in lung function over 12 months compared with monocomponents and placebo in patients with COPD [abstract]. American Thoracic Society 99th International Conference; May 16‐21, 2003; Seattle, Washington. B024 [Poster 418]. CalverleyPMA , PetersonS . Combining budesonide/formoterol in a single inhale reduces exacerbation frequency in COPD [abstract]. American Thoracic Society 99th International Conference; May 16‐21, 2003; Seattle, Washington. D092 [Poster 211]. CalverleyPMA , StåhlE , JonesPW . Budesonide/formoterol improves the general health status of patients with COPD [Abstract]. American Thoracic Society 2005 International Conference; May 20‐25, 2005; San Diego, California. B93 [Poster 303]. CalverleyPMA , SzafranskiW , AnderssonA . Budesonide/formoterol is a well‐tolerated long term maintenance therapy for COPD. European Respiratory Journal2005;26 Suppl 49:Poster 1917. CalverleyPMA , ThompsonNC , OlssonH . Budesonide/formoterol in a single inhaler sustains lung function improvements in COPD [Abstract]. European Respiratory Journal2003;22 Suppl 45:P435. HalpinD , StåhlE , LundbackB , AndersonF , PetersonS . Treatment costs and number needed to treat (NNT) with budesonide/formoterol to avoid one exacerbation of COPD [Abstract]. American Thoracic Society 100th International Conference; May 21‐26, 2004; Orlando, Florida. D22 [Poster 525]. HalpinDMG , LarssonT , CalverleyPMA . How many patients with COPD must be treated with budesonide/formoterol compared with formoterol alone to avoid 1 day of oral steroid use? [Abstract]. American Thoracic Society 2005 International Conference; May 20‐25, 2005; San Diego, California. B93 [Poster 314]. JonesPW , StahlE . Budesonide/formoterol in a single inhaler improves health status in patients with COPD [abstract]. American Thoracic Society 99th International Conference; May 16‐21, 2003; Orlando, Florida. B024 [Poster 419]. JonesPW , StåhlE . Budesonide /formoterol sustains clinically relevant improvements in health status in COPD [Abstract]. European Respiratory Journal2005;26 Suppl 49:Abstract 1352. JonesPW , StåhlE . Reducing exacerbations leads to a better health‐related quality of life in patients with COPD. 13th ERS Annual Congress; September 27, 2003; Vienna, Austria. P1586. LofdahlCG . Reducing the impact of COPD exacerbations: Clinical efficacy of budesonide/formoterol. European Respiratory Review2004;13(88):14‐21. LofdahlCG , AndreassonE , SvenssonK , EricssonA . Budesonide/formoterol in a single inhaler improves health status in patients with COPD without increasing healthcare costs [Abstract]. European Respiratory Journal2003;22 Suppl 45:P433. LofdahlCG , EricssonA , SvenssonK , AndreassonE . Cost effectiveness of budesonide/formoterol in a single inhaler for COPD compared with each monocomponent used alone. Pharmacoeconomics2005;23(4):365‐75. ">Calverley 2003</a>, <a href="./references#CD006826-bbs2-0010" title="AndersonP . Budesonide/formoterol in a single inhaler (Symbicort) provides early and sustained improvement in lung function in moderate to severe COPD [Abstract]. Thorax2002;57(Suppl III):iii43. AstraZenecaSD . A placebo‐controlled 12 month efficacy study of the fixed combination budesonide/formoterol compared with budesonide and formoterol as monotherapies in patients with chronic obstructive pulmonary disease (COPD). AstraZeneca Clinical Trials2001. BorgstromL , AskingL , OlssonH , PetersonS . Lack of interaction between disease severity and therapeutic response with budesonide/formoterol in a single inhaler [Abstract]. American Thoracic Society 100th International Conference; May 21‐26, 2004; Orlando, Florida. C22 [Poster 505]. CalverleyP , PauwelsR , LofdahlCG , SvenssonK , HigenbottamT , et al. Relationship between respiratory symptoms and medical treatment in exacerbations of COPD. European Respiratory Journal2005;26(3):406‐13. CalverleyPMA . Effect of budesonide/formoterol on severe exacerbations and lung function in moderate to severe COPD. Thorax. BTS Winter Meeting 2002:S145. CalverleyPMA , SzafranskiW , AnderssonA . Budesonide/formoterol is a well‐tolerated long term maintenance therapy for COPD. European Respiratory Journal2005;26 Suppl 49:Poster 1917. CalverleyPMA , ThompsonNC , OlssonH . Budesonide/formoterol in a single inhaler sustains lung function improvements in COPD [Abstract]. European Respiratory Journal2003;22 Suppl 45:P435. CampbellLM , SzafranskiW . Budesonide/formoterol in a single inhaler (Symbicort) provides sustained relief from symptoms in moderate to severe COPD. Thorax. BTS Winter Meeting 2002:S143. CampellLW , SzafranskiW . Budesonide/Formoterol in a single inhaler (Symbicort) reduces severe exacerbations in patients with moderate‐severe COPD. Thorax. BTS Winter Meeting 2002:S141. DahlR , CukierA , OlssonH . Budesonide/formoterol in a single inhaler reduces severe and mild exacerbations in patients with moderate to severe COPD. European Respiratory Journal2002;20 Suppl 38:242 [P1575]. EgedeF , MengaG . Budesonide/formoterol in a single inhaler provides sustained relief from symptoms and night‐time awakenings in moderate‐severe COPD: results from symptoms and night‐time awakenings in moderate to severe COPD: results from a 1‐year study. European Respiratory Journal2002;20 Suppl 38:242 [P1574]. HalpinD , StahlE , LundbackB , AndersonF , PetersonS . Treatment costs and number needed to treat (NNT) with budesonide/formoterol to avoid one exacerbation of COPD [Abstract]. American Thoracic Society 100th International Conference; May 21‐26, 2004; Orlando, Florida. D22 [Poster 525]. JonesPW , StahlE , SvenssonK . Improvement in health status in patients with moderate to severe COPD after treatment with budesonide/formoterol in a single inhaler. European Respiratory Journal2002;20 Suppl 38:250 [P1613]. KorsgaardJ , SansoresR . Budesonide/formoterol (single inhaler) provides sustained relief from shortness of breath and chest tightness in a 1‐year study of patients with moderate to severe COPD. European Respiratory Journal2002;20 Suppl 38:242 [P1577]. LangeP , SaenzC . Budesonide/formoterol in a single inhaler is well tolerated in patients with moderate to severe COPD: results of a 1 year study. European Respiratory Journal2002;20 Suppl 38:242 [P1573]. LofdahlCG . Reducing the impact of COPD exacerbations: clinical efficacy of budesonide/formoterol. European Respiratory Review2004;13(88):14‐21. MilanowskiJ , NahabedianS . Budesonide/formoterol in a single inhaler acts rapidly to improve lung function and relieve symptoms in patients with moderate to severe COPD. European Respiratory Journal2002;20 Suppl 38:242 [P1576]. SzafranskiW , CukierA , RamirezA , MengaG , SansoresR , NahabedianS , et al. Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease. European Respiratory Journal2003;21(1):74‐81. ">Szafranski 2003</a> and <a href="./references#CD006826-bbs2-0015" title="ZhongN , ZhengJ , WenF , YangL , ChenP , XiuQ , et al. Efficacy and safety of budesonide/formoterol via a dry powder inhaler in Chinese patients with chronic obstructive pulmonary disease. Current Medical Research and Opinion2012; Vol. 28, issue 2:257‐65. ZhongN , ZhengJ , WenF , YangL , ChenP , XiuQ , et al. Efficacy and safety of inhalation of budesonide/formoterol via turbuhaler in Chinese patients with chronic obstructive pulmonary disease [Abstract]. Chest2011; Vol. 140, issue 4:5225A. ">Zhong 2012</a> for withdrawals due to worsening COPD symptoms and adverse events, and a very marginal significant difference in withdrawals due to worsening of COPD symptoms was noted when BDF was compared with BD (3 studies; N = 1225, OR 0.68, 95% CI 0.46 to 0.99; <a href="./references#CD006826-fig-0052" title="">Analysis 3.18</a>). Because the statistical significance of this effect is so very marginal, any evaluation of this finding should await the availability of additional data. </p> <p>No significant difference was noted between BDF and BD in the likelihood of withdrawal due to adverse events other than COPD deterioration (4 studies; <a href="./references#CD006826-bbs2-0002" title="AstraZenecaSD . A placebo‐controlled 12‐month efficacy study of the fixed combination budesonide/formoterol compared to budesonide and formoterol as monotherapies in patients with chronic obstructive pulmonary disease (COPD). AstraZeneca Clinical Trials2002. BorgstromL , AskingL , OlssonH , PetersonS . Lack of interaction between disease severity and therapeutic response with budesonide/formoterol in a single inhaler [Abstract]. American Thoracic Society 100th International Conference; May 21‐26; 2004, Orlando, Florida. C22 [Poster 505]. CalverleyPM , BonsawatW , CsekeZ , ZhongN , PetersonS , OlssonH . Maintenance therapy with budesonide and formoterol in chronic obstructive pulmonary disease. European Respiratory Journal2003;22(6):912‐9. CalverleyPMA , CsekeZ , PetersonS . Budesonide/formoterol reduces the use of oral corticosteroids in the treatment of COPD [Abstract]. European Respiratory Journal2003;22 Suppl 45:P436. CalverleyPMA , KunaP , OlssonH . COPD exacerbations are reduced by budesonide/formoterol in a single inhaler [Abstract]. European Respiratory Journal2003;22 Suppl 45:P1587. CalverleyPMA , OlssonH , Symbicort International COPD Study Group. Budesonide/formoterol ina single inhaler sustains improvements in lung function over 12 months compared with monocomponents and placebo in patients with COPD [abstract]. American Thoracic Society 99th International Conference; May 16‐21, 2003; Seattle, Washington. B024 [Poster 418]. CalverleyPMA , PetersonS . Combining budesonide/formoterol in a single inhale reduces exacerbation frequency in COPD [abstract]. American Thoracic Society 99th International Conference; May 16‐21, 2003; Seattle, Washington. D092 [Poster 211]. CalverleyPMA , StåhlE , JonesPW . Budesonide/formoterol improves the general health status of patients with COPD [Abstract]. American Thoracic Society 2005 International Conference; May 20‐25, 2005; San Diego, California. B93 [Poster 303]. CalverleyPMA , SzafranskiW , AnderssonA . Budesonide/formoterol is a well‐tolerated long term maintenance therapy for COPD. European Respiratory Journal2005;26 Suppl 49:Poster 1917. CalverleyPMA , ThompsonNC , OlssonH . Budesonide/formoterol in a single inhaler sustains lung function improvements in COPD [Abstract]. European Respiratory Journal2003;22 Suppl 45:P435. HalpinD , StåhlE , LundbackB , AndersonF , PetersonS . Treatment costs and number needed to treat (NNT) with budesonide/formoterol to avoid one exacerbation of COPD [Abstract]. American Thoracic Society 100th International Conference; May 21‐26, 2004; Orlando, Florida. D22 [Poster 525]. HalpinDMG , LarssonT , CalverleyPMA . How many patients with COPD must be treated with budesonide/formoterol compared with formoterol alone to avoid 1 day of oral steroid use? [Abstract]. American Thoracic Society 2005 International Conference; May 20‐25, 2005; San Diego, California. B93 [Poster 314]. JonesPW , StahlE . Budesonide/formoterol in a single inhaler improves health status in patients with COPD [abstract]. American Thoracic Society 99th International Conference; May 16‐21, 2003; Orlando, Florida. B024 [Poster 419]. JonesPW , StåhlE . Budesonide /formoterol sustains clinically relevant improvements in health status in COPD [Abstract]. European Respiratory Journal2005;26 Suppl 49:Abstract 1352. JonesPW , StåhlE . Reducing exacerbations leads to a better health‐related quality of life in patients with COPD. 13th ERS Annual Congress; September 27, 2003; Vienna, Austria. P1586. LofdahlCG . Reducing the impact of COPD exacerbations: Clinical efficacy of budesonide/formoterol. European Respiratory Review2004;13(88):14‐21. LofdahlCG , AndreassonE , SvenssonK , EricssonA . Budesonide/formoterol in a single inhaler improves health status in patients with COPD without increasing healthcare costs [Abstract]. European Respiratory Journal2003;22 Suppl 45:P433. LofdahlCG , EricssonA , SvenssonK , AndreassonE . Cost effectiveness of budesonide/formoterol in a single inhaler for COPD compared with each monocomponent used alone. Pharmacoeconomics2005;23(4):365‐75. ">Calverley 2003</a>, <a href="./references#CD006826-bbs2-0010" title="AndersonP . Budesonide/formoterol in a single inhaler (Symbicort) provides early and sustained improvement in lung function in moderate to severe COPD [Abstract]. Thorax2002;57(Suppl III):iii43. AstraZenecaSD . A placebo‐controlled 12 month efficacy study of the fixed combination budesonide/formoterol compared with budesonide and formoterol as monotherapies in patients with chronic obstructive pulmonary disease (COPD). AstraZeneca Clinical Trials2001. BorgstromL , AskingL , OlssonH , PetersonS . Lack of interaction between disease severity and therapeutic response with budesonide/formoterol in a single inhaler [Abstract]. American Thoracic Society 100th International Conference; May 21‐26, 2004; Orlando, Florida. C22 [Poster 505]. CalverleyP , PauwelsR , LofdahlCG , SvenssonK , HigenbottamT , et al. Relationship between respiratory symptoms and medical treatment in exacerbations of COPD. European Respiratory Journal2005;26(3):406‐13. CalverleyPMA . Effect of budesonide/formoterol on severe exacerbations and lung function in moderate to severe COPD. Thorax. BTS Winter Meeting 2002:S145. CalverleyPMA , SzafranskiW , AnderssonA . Budesonide/formoterol is a well‐tolerated long term maintenance therapy for COPD. European Respiratory Journal2005;26 Suppl 49:Poster 1917. CalverleyPMA , ThompsonNC , OlssonH . Budesonide/formoterol in a single inhaler sustains lung function improvements in COPD [Abstract]. European Respiratory Journal2003;22 Suppl 45:P435. CampbellLM , SzafranskiW . Budesonide/formoterol in a single inhaler (Symbicort) provides sustained relief from symptoms in moderate to severe COPD. Thorax. BTS Winter Meeting 2002:S143. CampellLW , SzafranskiW . Budesonide/Formoterol in a single inhaler (Symbicort) reduces severe exacerbations in patients with moderate‐severe COPD. Thorax. BTS Winter Meeting 2002:S141. DahlR , CukierA , OlssonH . Budesonide/formoterol in a single inhaler reduces severe and mild exacerbations in patients with moderate to severe COPD. European Respiratory Journal2002;20 Suppl 38:242 [P1575]. EgedeF , MengaG . Budesonide/formoterol in a single inhaler provides sustained relief from symptoms and night‐time awakenings in moderate‐severe COPD: results from symptoms and night‐time awakenings in moderate to severe COPD: results from a 1‐year study. European Respiratory Journal2002;20 Suppl 38:242 [P1574]. HalpinD , StahlE , LundbackB , AndersonF , PetersonS . Treatment costs and number needed to treat (NNT) with budesonide/formoterol to avoid one exacerbation of COPD [Abstract]. American Thoracic Society 100th International Conference; May 21‐26, 2004; Orlando, Florida. D22 [Poster 525]. JonesPW , StahlE , SvenssonK . Improvement in health status in patients with moderate to severe COPD after treatment with budesonide/formoterol in a single inhaler. European Respiratory Journal2002;20 Suppl 38:250 [P1613]. KorsgaardJ , SansoresR . Budesonide/formoterol (single inhaler) provides sustained relief from shortness of breath and chest tightness in a 1‐year study of patients with moderate to severe COPD. European Respiratory Journal2002;20 Suppl 38:242 [P1577]. LangeP , SaenzC . Budesonide/formoterol in a single inhaler is well tolerated in patients with moderate to severe COPD: results of a 1 year study. European Respiratory Journal2002;20 Suppl 38:242 [P1573]. LofdahlCG . Reducing the impact of COPD exacerbations: clinical efficacy of budesonide/formoterol. European Respiratory Review2004;13(88):14‐21. MilanowskiJ , NahabedianS . Budesonide/formoterol in a single inhaler acts rapidly to improve lung function and relieve symptoms in patients with moderate to severe COPD. European Respiratory Journal2002;20 Suppl 38:242 [P1576]. SzafranskiW , CukierA , RamirezA , MengaG , SansoresR , NahabedianS , et al. Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease. European Respiratory Journal2003;21(1):74‐81. ">Szafranski 2003</a>; <a href="./references#CD006826-bbs2-0011" title="Astrazeneca(D5899C00002) . A 6‐month double‐blind, double‐dummy, randomized, parallel group, multicenter efficacy &amp; safety study of Symbicort® pMDI 2 × 160/4.5mg &amp; 80/4.5mg bid compared to Formoterol TBH, Budesonide pMDI (&amp; the combination) &amp; placebo in COPD patients. www.astrazenecaclinicaltrials.com (accessed 8 April 2008). BleeckerER , MeyersDA , BaileyWC , SimsA‐M , BujacSR , GoldmanM , et al. ADRB2 polymorphisms and budesonide/formoterol responses in COPDADRB2 polymorphisms and treatment response in COPD. Chest2012;142(2):320‐8. TashkinDP , RennardSI , MartinP , GoldmanM , SilkoffPE . Efficacy of budesonide/formoterol administered via one pressurized metered‐dose inhaler over 6 months in patients with chronic obstructive pulmonary disease [Abstract]. Chest2008; Vol. 134, issue 4:105001s. TashkinDP , RennardSI , MartinP , RamachandranS , MartinUJ , SilkoffPE , et al. Efficacy and safety of budesonide and formoterol in one pressurized metered‐dose inhaler in patients with moderate to very severe chronic obstructive pulmonary disease : results of a 6‐month randomized clinical trial. Drugs2008; Vol. 68, issue 0012‐6667 (Print):1975‐2000. ">Tashkin 2008</a>; <a href="./references#CD006826-bbs2-0015" title="ZhongN , ZhengJ , WenF , YangL , ChenP , XiuQ , et al. Efficacy and safety of budesonide/formoterol via a dry powder inhaler in Chinese patients with chronic obstructive pulmonary disease. Current Medical Research and Opinion2012; Vol. 28, issue 2:257‐65. ZhongN , ZhengJ , WenF , YangL , ChenP , XiuQ , et al. Efficacy and safety of inhalation of budesonide/formoterol via turbuhaler in Chinese patients with chronic obstructive pulmonary disease [Abstract]. Chest2011; Vol. 140, issue 4:5225A. ">Zhong 2012</a>; N = 1777, OR 0.95, 95% CI 0.66 to 1.37; <a href="./references#CD006826-fig-0053" title="">Analysis 3.19</a>). </p> </section> <section id="CD006826-sec-0117"> <h6 class="title">MF/F versus MF</h6> <p>No significant difference regarding withdrawals was observed in the comparison between MF/F and MF (2 studies; <a href="./references#CD006826-bbs2-0003" title="DohertyDE , KerwinE , TashkinDP , Matiz‐BuenoCE , ShekarT , BanerjeeS , et al. Combined mometasone furoate and formoterol in patients with moderate to very severe chronic obstructive pulmonary disease (COPD): phase 3 efficacy and safety study [Abstract]. Journal of Allergy and Clinical Immunology2012; Vol. 129, issue 2 Suppl:AB75 [283]. DohertyDE , TashkinDP , KerwinE , KnorrBA , ShekarT , BanerjeeS , et al. Effects of mometasone furoate/formoterol fumarate fixed‐dose combination formulation on chronic obstructive pulmonary disease (COPD): results from a 52‐week Phase III trial in subjects with moderate‐to‐very severe COPD. International Journal of Chronic Obstructive Pulmonary Disease2012; Vol. 7, issue 1178‐2005 (Electronic). 1176‐9106 (Linking):57‐71. NCT00383721 . A Randomized, 26‐Week, Placebo‐Controlled Efficacy and Safety Study With a 26‐Week Long‐Term Safety Extension, of High‐ and Medium‐Dose Inhaled Mometasone Furoate/Formoterol Fixed‐Dose Combination Formulation Compared With Formoterol and High‐Dose Inhaled Mometasone Furoate Monotherapy in Subjects With Moderate to Severe COPD, 2006. http://clinicaltrials.gov/show/NCT00383721. [] ">Doherty 2012</a>; <a href="./references#CD006826-bbs2-0012" title="KerwinE , TashkinDP , Matiz‐BuenoCE , DohertyDE , ShekarT , BanerjeeS , et al. Clinical efficacy and safety of combined mometasone furoate and formoterol in patients with moderate to very severe chronic obstructive pulmonary disease (COPD) [Abstract]. Journal of Allergy and Clinical Immunology2012; Vol. 129, issue 2 Suppl:AB201 [759]. NCT00383435 . A Randomized, 26‐Week, Placebo‐Controlled Efficacy and Safety Study With a 26‐Week Long‐Term Safety Extension, of High‐ and Medium‐Dose Inhaled Mometasone Furoate/Formoterol Fixed‐Dose Combination Formulation Compared With Formoterol and High‐Dose Inhaled Mometasone Furoate Monotherapy in Subjects With Moderate to Severe COPD, 2006. http://clinicaltrials.gov/show/NCT00383435. [] TashkinDP , DohertyDE , KerwinE , Matiz‐BuenoCE , KnorrB , ShekarT , et al. Efficacy and safety of a fixed‐dose combination of mometasone furoate and formoterol fumarate in subjects with moderate to very severe COPD: results from a 52‐week Phase III trial. International Journal of Chronic Obstructive Pulmonary Disease2012; Vol. 7, issue 1178‐2005 (Electronic). 1176‐9106 (Linking):43‐55. ">Tashkin 2012</a>; N = 905, OR 0.78, 95% CI 0.56 to 1.09; <a href="./references#CD006826-fig-0063" title="">Analysis 4.7</a>), and no significant difference was noted regarding withdrawals due to adverse events (2 studies; <a href="./references#CD006826-bbs2-0003" title="DohertyDE , KerwinE , TashkinDP , Matiz‐BuenoCE , ShekarT , BanerjeeS , et al. Combined mometasone furoate and formoterol in patients with moderate to very severe chronic obstructive pulmonary disease (COPD): phase 3 efficacy and safety study [Abstract]. Journal of Allergy and Clinical Immunology2012; Vol. 129, issue 2 Suppl:AB75 [283]. DohertyDE , TashkinDP , KerwinE , KnorrBA , ShekarT , BanerjeeS , et al. Effects of mometasone furoate/formoterol fumarate fixed‐dose combination formulation on chronic obstructive pulmonary disease (COPD): results from a 52‐week Phase III trial in subjects with moderate‐to‐very severe COPD. International Journal of Chronic Obstructive Pulmonary Disease2012; Vol. 7, issue 1178‐2005 (Electronic). 1176‐9106 (Linking):57‐71. NCT00383721 . A Randomized, 26‐Week, Placebo‐Controlled Efficacy and Safety Study With a 26‐Week Long‐Term Safety Extension, of High‐ and Medium‐Dose Inhaled Mometasone Furoate/Formoterol Fixed‐Dose Combination Formulation Compared With Formoterol and High‐Dose Inhaled Mometasone Furoate Monotherapy in Subjects With Moderate to Severe COPD, 2006. http://clinicaltrials.gov/show/NCT00383721. [] ">Doherty 2012</a>; <a href="./references#CD006826-bbs2-0012" title="KerwinE , TashkinDP , Matiz‐BuenoCE , DohertyDE , ShekarT , BanerjeeS , et al. Clinical efficacy and safety of combined mometasone furoate and formoterol in patients with moderate to very severe chronic obstructive pulmonary disease (COPD) [Abstract]. Journal of Allergy and Clinical Immunology2012; Vol. 129, issue 2 Suppl:AB201 [759]. NCT00383435 . A Randomized, 26‐Week, Placebo‐Controlled Efficacy and Safety Study With a 26‐Week Long‐Term Safety Extension, of High‐ and Medium‐Dose Inhaled Mometasone Furoate/Formoterol Fixed‐Dose Combination Formulation Compared With Formoterol and High‐Dose Inhaled Mometasone Furoate Monotherapy in Subjects With Moderate to Severe COPD, 2006. http://clinicaltrials.gov/show/NCT00383435. [] TashkinDP , DohertyDE , KerwinE , Matiz‐BuenoCE , KnorrB , ShekarT , et al. Efficacy and safety of a fixed‐dose combination of mometasone furoate and formoterol fumarate in subjects with moderate to very severe COPD: results from a 52‐week Phase III trial. International Journal of Chronic Obstructive Pulmonary Disease2012; Vol. 7, issue 1178‐2005 (Electronic). 1176‐9106 (Linking):43‐55. ">Tashkin 2012</a>; N = 905, OR 1.38, 95% CI 0.71 to 2.68; <a href="./references#CD006826-fig-0064" title="">Analysis 4.8</a>) or withdrawals due to treatment failure (2 studies; <a href="./references#CD006826-bbs2-0003" title="DohertyDE , KerwinE , TashkinDP , Matiz‐BuenoCE , ShekarT , BanerjeeS , et al. Combined mometasone furoate and formoterol in patients with moderate to very severe chronic obstructive pulmonary disease (COPD): phase 3 efficacy and safety study [Abstract]. Journal of Allergy and Clinical Immunology2012; Vol. 129, issue 2 Suppl:AB75 [283]. DohertyDE , TashkinDP , KerwinE , KnorrBA , ShekarT , BanerjeeS , et al. Effects of mometasone furoate/formoterol fumarate fixed‐dose combination formulation on chronic obstructive pulmonary disease (COPD): results from a 52‐week Phase III trial in subjects with moderate‐to‐very severe COPD. International Journal of Chronic Obstructive Pulmonary Disease2012; Vol. 7, issue 1178‐2005 (Electronic). 1176‐9106 (Linking):57‐71. NCT00383721 . A Randomized, 26‐Week, Placebo‐Controlled Efficacy and Safety Study With a 26‐Week Long‐Term Safety Extension, of High‐ and Medium‐Dose Inhaled Mometasone Furoate/Formoterol Fixed‐Dose Combination Formulation Compared With Formoterol and High‐Dose Inhaled Mometasone Furoate Monotherapy in Subjects With Moderate to Severe COPD, 2006. http://clinicaltrials.gov/show/NCT00383721. [] ">Doherty 2012</a>; <a href="./references#CD006826-bbs2-0012" title="KerwinE , TashkinDP , Matiz‐BuenoCE , DohertyDE , ShekarT , BanerjeeS , et al. Clinical efficacy and safety of combined mometasone furoate and formoterol in patients with moderate to very severe chronic obstructive pulmonary disease (COPD) [Abstract]. Journal of Allergy and Clinical Immunology2012; Vol. 129, issue 2 Suppl:AB201 [759]. NCT00383435 . A Randomized, 26‐Week, Placebo‐Controlled Efficacy and Safety Study With a 26‐Week Long‐Term Safety Extension, of High‐ and Medium‐Dose Inhaled Mometasone Furoate/Formoterol Fixed‐Dose Combination Formulation Compared With Formoterol and High‐Dose Inhaled Mometasone Furoate Monotherapy in Subjects With Moderate to Severe COPD, 2006. http://clinicaltrials.gov/show/NCT00383435. [] TashkinDP , DohertyDE , KerwinE , Matiz‐BuenoCE , KnorrB , ShekarT , et al. Efficacy and safety of a fixed‐dose combination of mometasone furoate and formoterol fumarate in subjects with moderate to very severe COPD: results from a 52‐week Phase III trial. International Journal of Chronic Obstructive Pulmonary Disease2012; Vol. 7, issue 1178‐2005 (Electronic). 1176‐9106 (Linking):43‐55. ">Tashkin 2012</a>; N = 905, OR 0.68, 95% CI 0.19 to 2.44; <a href="./references#CD006826-fig-0065" title="">Analysis 4.9</a>). </p> </section> </section> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD006826-sec-0118" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD006826-sec-0118"></div> <section id="CD006826-sec-0119"> <h3 class="title" id="CD006826-sec-0119">Summary of main results</h3> <p>We reviewed data from 15 randomised controlled trials (7814 participants; <a href="#CD006826-tbl-0005">Table 4</a>) assessing the effectiveness and safety of combined inhaled corticosteroid and long‐acting beta<sub>2</sub>‐agonist in the treatment of chronic obstructive pulmonary disease (COPD) versus ICS alone for the clinically important primary outcomes of exacerbations, mortality, hospitalisation and pneumonia. Overall, available evidence suggests that combination therapy with ICS and LABA shows an advantage over ICS alone in reducing exacerbations and mortality throughout the study period, with no significant effect on hospitalisation or pneumonia. The greatest quantity of evidence comes from populations of poorly reversible participants who have more severe COPD. It should be noted that most of the evidence for a reduction in mortality (weighting of 90%) comes from the TORCH study, which compared FPS and FP in participants with an FEV<sub>1</sub> &lt; 60% predicted. Furthermore, the mortality benefit is confined to the FPS combination only and is not seen in the others. If we remove the TORCH study, mortality rates are not significantly different between combination treatment and ICS alone. Furthermore, the TORCH study did not show any statistically significant mortality benefit at 2 years, only at 3 years, so we can only be sure that benefit would accrue over the longer period. Finally, about 14% of those in the TORCH study died, whereas mortality rates in the other studies reporting this outcome were in the order of 3%, and all were less than 12 months in duration. The TORCH study was the only study in this review that showed significantly fewer withdrawals in the combination group than in the ICS group, but it was also the only study that ascertained the vital status of all participants, including those who withdrew from the study. </p> <div class="table" id="CD006826-tbl-0005"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">Included studies</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Study ID</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No. of participants randomised</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Study duration (weeks)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Control</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bourbeau 2007</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>39</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>FPS (50/500 mcg bid)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>FP (500 mg bid)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Calverley 2003</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>511</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>52</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>BDF (320/9 mcg bid)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>BUD (400 mcg bid)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Doherty 2012</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>478</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MF/F (200/5 mcg bid)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MF (200 mcg bid)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Hanania 2003</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>366</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>FPS (50/250 mcg bid)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>FP (250 mcg bid)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Lapperre 2009</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>54</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>130</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>FPS (50/500 mcg bid)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>FP (500 mcg bid)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mahler 2002</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>333</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>FPS (50/500 mcg bid)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>FP (500 mcg bid)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NCT00358358</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>81</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>FPS (50/500 mcg bid)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>FP (500 mcg bid)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>SFCT01</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>256</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>52</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>FPS (50/500 mcg bid)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>FP (500 mcg bid)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sin 2008</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>179</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>FPS (50/500 mcg bid)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>FP (500 mcg bid)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Szafranski 2003</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>406</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>52</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>BDF (320/9 mcg bid)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>BUD (400 mcg bid)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tashkin 2008</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>552</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>BDF (160/4.5 mcg) 2 inhalations bid</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>BUD (160 mcg) 2 inhalations bid</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tashkin 2012</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>427</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MF/F (400/10 mcg bid)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MF (400 mcg bid)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>TORCH</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3091</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>156</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>FPS (50/500 mcg bid)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>FP (500 mcg bid)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>TRISTAN</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>733</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>52</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>FPS (50/500 mcg bid)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>FP (500 mcg bid)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Zhong 2012</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>308</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>BDF (160/4.5 mcg) 2 inhalations bid</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>BUD (200 mcg) 2 inhalations bid</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>FPS = fluticasone/salmeterol;</p> <p>FP = fluticasone;</p> <p>BDF = budesonide/formoterol;</p> <p>BUD = budesonide;</p> <p>MF/F = mometasone/formoterol;</p> <p>MF =  mometasone.</p> </div> </div> <p>If the mortality benefit seen in this review in association with the combined inhaler is confirmed in other three‐year studies, the mechanism needs elucidation, and this is likely to be important. The TORCH investigators did find a significant difference between LABA/ICS and ICS alone, but not between LABA/ICS and placebo, although the P value for this comparison was 0.052. To date, the only approaches used in COPD to reduce mortality rates are smoking cessation and long‐term oxygen therapy (LTOT) in hypoxic patients. On the basis of our findings, at best, 33 people with moderate to severe COPD need to be treated with a combination FPS inhaler for three years to prevent one excess death, compared with those treated with ICS alone. This reduction appears to involve COPD‐related deaths. On the other hand, no evidence of a mortality benefit has been obtained for the other combination inhalers over their component ICS. From this review, we can conclude that combination treatment is related to fewer exacerbations, and probably to fewer severe exacerbations, than ICS alone, as is discussed later. Exacerbations are risky times for death; therefore this is a plausible explanation, but to be sure, we would need to use individual participant data to gather additional details on the causes and timing of death and modelling of the amount of variance in mortality that is explained by the reduced exacerbations. In contrast, the small change in lung function seems insufficient to account for a mortality benefit, but this needs to be tested in other, longer‐term trials. It is interesting to contrast the finding of a possible mortality benefit of LABA/ICS combinations in COPD with the situation in asthma. In that disease, use of a LABA alone is associated with an increased death rate, but when combined with ICS, this is no longer the case (<a href="./references#CD006826-bbs2-0080" title="Rodrigo GJ. Castro‐RodríguezJA . Safety of long‐acting beta agonists for the treatment of asthma: clearing the air. Thorax 2012 21 April 2011;67:342‐9. ">Rodrigo 2012</a>). </p> <p>Greater consistency was seen with the interventions for exacerbations, and the number of exacerbations was reduced by both FPS and BDF as was the proportion of participants with an exacerbation that was reduced by MF/F, compared with the component ICS alone. It is interesting to note that for the FPS studies, the reduction in the proportion of participants with an exacerbation was not significant, but those who experienced exacerbations had fewer of them, and fewer of these participants needed treatment with oral steroids. Yet, the differences in exacerbations with combination therapy did not translate to fewer hospitalisations for COPD, and this is difficult to explain. Hospitalisations are among the most costly aspects of COPD management, causing a negative impact on expectancy and quality of life. It is plausible that the hospital stays were shorter. Most studies clearly defined hospitalisation as a stay of at least 24 hours. Moreover, hospitalisations are relatively rare events that can be quantified only by larger and longer studies. To exemplify this point, on average about 7% of patients per year were hospitalised for COPD in the TORCH study, in part because of the lack of the inclusion criterion of a moderate to severe exacerbation 52 weeks before enrolment, as was required in more recent trials. </p> <p>This review was unable to shed light on the debate as to whether or not ICS increase pneumonia in COPD, as it was administered in both intervention arms. This can be tested only when the comparator does not contain ICS. We found no significant difference, with one interpretation being that LABAs do not reduce the risk of pneumonia with ICS. However, we also found that pneumonia was not a frequent adverse event when it was defined by chest x‐ray. The shorter studies in <a href="./references#CD006826-fig-0013" title="">Analysis 1.5</a> identified only 60 cases of pneumonia among 4222 participants (1.4%), in contrast to the three‐year <a href="./references#CD006826-bbs2-0013" title="BriggsAH , GlickHA , Lozano‐OrtegaG , SpencerM , CalverleyPM , JonesPW , et al. Is treatment with ICS and LABA cost‐effective for COPD? Multinational economic analysis of the TORCH study. European Respiratory Journal2010; Vol. 35, issue 3:532‐9. CalverleyPM , AndersonJA , CelliB , FergusonGT , JenkinsC , JonesPW , et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease.[see comment]. New England Journal of Medicine2007; Vol. 356, issue 8:775‐89. CalverleyPMA , AndersonJA , CelliB , FergusonGT , JenkinsC , JonesPW , et al. Cardiovascular events in patients with chronic obstructive pulmonary disease: TORCH study results. Thorax2010;65:719‐25. CalverleyPMA , AndersonJA , CelliB , FergusonGT , JenkinsC , JonesPW , et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. New England Journal of Medicine2007;356(8):775‐89. CalverleyPMA , CelliB , FergusonG , JenkinsC , JonesPW , PrideNB , et al. Baseline characteristics of the first 5,000 COPD patients enrolled in the TORCH survival study. European Respiratory Journal2003;22 Suppl 45:578s. CelliB , CalverleyPMA , AndersonJA , FergusonGT , JenkinsC , JonesPW , et al. The TORCH (TOwards a Revolution in COPD Health) study: salmeterol/fluticasone propionate (SFC) improves health status, reduces exacerbations and improves lung function over three years. European Respiratory Journal2006;28 Suppl 50:34s. CelliB , VestboJ , JenkinsCR , JonesPW , FergusonGT , CalverleyPM , et al. Sex differences in mortality and clinical expressions of patients with chronic obstructive pulmonary disease: the TORCH experience. American Journal of Respiratory and Critical Care Medicine2011;183(3):317‐22. CelliBR , ThomasNE , AndersonJA , FergusonGT , JenkinsCR , JonesPW , et al. Effect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease: results from the TORCH study. American Journal of Respiratory and Critical Care Medicine2008;174(4):332‐8. CrimC , CalverleyPM , AndersonJA , CelliB , FergusonGT , JenkinsC , et al. Pneumonia risk in COPD patients receiving inhaled corticosteroids alone or in combination: TORCH study results. European Respiratory Journal2009;34(3):641‐7. FergusonGT , CalverleyPM , AndersonJA , JenkinsCR , JonesPW , WillitsLR , et al. Prevalence and progression of osteoporosis in patients with COPD: results from the TOwards a Revolution in COPD Health study. Chest2009; Vol. 136, issue 0012‐3692:1456‐65. FergusonGT , CalverleyPMA , AndersonJA , et al. The TORCH (TOwards a Revolution in COPD Health) study: salmeterol/fluticasone propionate (SFC) improves survival in COPD over three years. European Respiratory Journal2006;28 Suppl 50:34s. GlaxoSmithKlineSCO30003 . A multicentre, randomised, double‐blind, parallel group, placebo‐controlled study to investigate the long‐term effects of salmeterol/fluticasone propionate (SERETIDE/VIANI/ADVAIR) 50/500mcg bd, salmeterol 50mcg bd and fluticasone propionate 500mcg bd, all delivered via the DISKUS/ACCUHALER inhaler, on the survival of subjects with chronic obstructive pulmonary disease (COPD) over 3 years of treatment. GlaxoSmithKline Clinical Trial Register2006. HoughtonCM , LawsonN , BorrillZL , WixonCL , YoxallS , LangleySJ , et al. Comparison of the effects of salmeterol/fluticasone propionate with fluticasone propionate on airway physiology in adults with mild persistent asthma. Respiratory Research2007;8:52. JenkinsCR , CalverleyPMA , CelliB , FergusonG , JonesPW , PrideN , et al. Seasonal patterns of exacerbation rates in the TORCH survival study, 2007. http://www.abstracts2view.comA839. JenkinsCR , CelliB , AndersonJA , FergusonGT , JonesPW , VestboJ , et al. Seasonality and determinants of moderate and severe COPD exacerbations in the TORCH study. European Respiratory Journal2012;39(1):38‐45. JenkinsCR , JonesPW , CalverleyPM , CelliB , AndersonJA , FergusonGT , et al. Efficacy of salmeterol/fluticasone propionate by GOLD stage of chronic obstructive pulmonary disease: analysis from the randomised, placebo‐controlled TORCH study. Respiratory Research2009;10:59. JohnsonM , AgustiAG , BarnesNC . Reflections on TORCH: potential mechanisms for the survival benefit of salmeterol/fluticasone propionate in COPD patients. COPD2008;5(6):369‐75. JonesPW , AndersonJA , CalverleyPM , CelliBR , FergusonGT , JenkinsC , et al. TORCH Investigators. Health status in the TORCH study of COPD: treatment efficacy and other determinants of change. Respiratory Research2011;12:71. JonesPW , CalverleyP , CelliB , FergusonG , JenkinsC , PrideN . Trans‐regional validity of the SGRQ in the TORCH survival study, 2007. http://www.abstracts2view.comA122. McGarveyLP , JohnM , AndersonJA , ZvarichMT , WiseRA . Ascertainment of cause‐specific mortality in COPD: operations of the TORCH Clinical Endpoint Committee. Thorax2007;62:411‐5. NCT00268216 . See detailed description, 2000. http://clinicaltrials.gov/show/NCT00268216. [] SCO30003 . A multicentre, randomised, double‐blind, parallel group, placebo‐controlled study to investigate the long‐term effects of salmeterol/fluticasone propionate (SERETIDE®/VIANI®/ADVAIR®) 50/500mcg bd, salmeterol 50mcg bd and fluticasone propionate 500mcg bd, all delivered via the DISKUS®/ACCUHALER® inhaler, on the survival of subjects with chronic obstructive pulmonary disease (COPD) over 3 years of treatment, 2006. www.ctr.gsk.co.uk. VestboJ , AndersonJA , CalverleyPM , CelliB , FergusonGT , JenkinsC , et al. Adherence to inhaled therapy, mortality and hospital admission in COPD. Thorax2009;64(11):939‐43. VestboJ , CalverleyP , CelliB , FergusonG , JenkinsC , JonesP , et al. The TORCH (TOwards a Revolution in COPD Health) survival study protocol. European Respiratory Journal2004;24(2):206‐10. WiseRA , McGarveyLP , JohnM , AndersonJA , ZvarichMT . Reliability of cause‐specific mortality adjudication in a COPD clinical trial, 2007. http://www.abstracts2view.comA120. ">TORCH</a> study, which reported 587 episodes of pneumonia from a sample of 3098 participants who received ICS treatment (19%). The results of <a href="./references#CD006826-fig-0012" title="">Analysis 1.4</a> were the same, whether or not the TORCH study was included. </p> <p>An internal consistency of the findings for primary outcomes and secondary outcomes was evident. All combination inhalers were associated with better lung function at the end of the study than was their ICS component, but this difference was relatively small. Two combinations (BDF and FPS) were associated with better quality of life, decreased use of rescue medication and withdrawals due to adverse events, but not with withdrawals due to lack of efficacy. The causes for withdrawals and for adverse events were coded slightly differently among the trials and thus were not combined, although this will be considered for future reviews. Improvement in quality of life was seen only when measured with the SGRQ, not with the CDRQ. The differences were small and were much less than a minimum clinically important difference (<a href="./references#CD006826-bbs2-0074" title="JonesPW . Interpreting thresholds for a clinically significant change in health status in asthma and COPD. European Respiratory Journal2002;19:398‐404. ">Jones 2002</a>). This suggests that the clinical effects may be imperceptible to patients, or that any benefits may be offset by other harms. Fewer exacerbations may result in lower healthcare costs; although this review does not show a reduction in costly hospitalisations, bed days could still be reduced. </p> </section> <section id="CD006826-sec-0120"> <h3 class="title" id="CD006826-sec-0120">Overall completeness and applicability of evidence</h3> <p>In the review are fifteen studies, with a total of 7814 participants. All eligible studies addressed at least one of the primary outcomes. The participants and outcomes were typical of COPD patients. The most plentiful data are available for the FPS combination, which was the only one to show a mortality benefit. Fewer data are available for the MF/F combination, but no evidence suggests that it behaves differently from the other inhalers. A sufficient number of trials in the analysis provided the opportunity to include funnel plots for the primary analyses; they are presented in <a href="#CD006826-fig-0008">Figure 8</a>. </p> <div class="figure" id="CD006826-fig-0008"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 8</div> </div> <hr class="top"/><img alt="Funnel plot of comparison: 1 All Combined Inhalers－Primary Outcomes, outcome: 1.4 Mortality." data-id="CD006826-fig-0008" src="/cdsr/doi/10.1002/14651858.CD006826.pub2/media/CDSR/CD006826/image_n/nCD006826-AFig-FIG08.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Funnel plot of comparison: 1 All Combined Inhalers－Primary Outcomes, outcome: 1.4 Mortality. </p> </div> </div> </div> <p>We did not compare the efficacy and safety of combination therapy with the same treatment delivered in two separate inhalers, so we cannot comment on the relative effectiveness of a combination inhaler in comparison with the individual components delivered separately. Whilst we recognise that inhaled corticosteroids are rarely likely to be used as monotherapy in COPD, the trials in this review provide the best evidence for assessing the additional benefit of adding LABA to ICS. </p> </section> <section id="CD006826-sec-0121"> <h3 class="title" id="CD006826-sec-0121">Quality of the evidence</h3> <p>According to the results section, the risks of bias in allocation, blinding, attrition and selective reporting were judged to be low. </p> </section> <section id="CD006826-sec-0122"> <h3 class="title" id="CD006826-sec-0122">Potential biases in the review process</h3> <p>The Cochrane Airways Group provides an excellent level of support in the identification of potentially relevant trials. However, concern with respect to study selection bias or publication bias in this process is inevitable. A matter of concern is that failure to identify unpublished trials may lead to an incomplete estimation of the effects of combined therapy versus ICS alone. However, an exhaustive search of the published literature, without language restrictions, for potentially relevant clinical trials was underpinned by a systematic search strategy to minimise the likelihood of bias. Of the 15 included studies, 13 were identified through the Cochrane Airways Group Register, an additional study (<a href="./references#CD006826-bbs2-0007" title="NCT00358358 . Trial SCO104925. See detailed description, 2006. http://clinicaltrials.gov/show/NCT00358358. [] ">NCT00358358</a>) was identified by the group from www.clinicaltrials.gov and <a href="./references#CD006826-bbs2-0008" title="SFCT01 . A Multicentre, Randomised, Double‐Blind, Parallel Group, Placebo‐Controlled Study to Compare the Efficacy and Safety of Inhaled Salmeterol/Fluticasone Propionate Combination Product 25/250 µg Two Puffs Bd and Fluticasone Propionate 250µg Two Puffs Bd Alone, All Administered Via Metered Dose Inhalers (MDI), in the Treatment of Subjects with Chronic Obstructive Pulmonary Disease (COPD) for 52 Weeks. GlaxoSmithKline Clinical Trials Register (http:ctr.gsk.co.uk)2005. ">SFCT01</a> was obtained via the GlaxoSmithKline Clinical Trials Register. Trial selection and data extraction followed a prespecified protocol, and the process was independently conducted by two investigators. Nevertheless, we acknowledge that additional unidentified trials may exist. </p> </section> <section id="CD006826-sec-0123"> <h3 class="title" id="CD006826-sec-0123">Agreements and disagreements with other studies or reviews</h3> <p>This Cochrane review confirms and builds upon an earlier one (<a href="./references#CD006826-bbs2-0085" title="NanniniL , CatesCJ , LassersonTJ , PooleP . Combined corticosteroid and long‐acting beta‐agonist in one inhaler versus inhaled steroids for chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews2007, Issue 4. [DOI: 10.1002/14651858.CD006826] ">Nannini 2007</a>) In terms of exacerbations; reduction in moderate COPD exacerbation rates with combined therapy is now shown for three LABA/ICS combinations over ICS alone. A recent publication describing all inhaled medications in COPD concluded that LABA/ICS was associated with the lowest risk of death among all treatments (<a href="./references#CD006826-bbs2-0068" title="DongYH , LinHH , ShauWY , WuYC , ChangCH , LaiMS . Comparative safety of inhaled medications inpatients with chronic obstructive pulmonary disease: systematic review and mixed treatment comparison meta‐analysis of randomised controlled trials. Thorax2013;68(2):48‐56. ">Dong 2013</a>). Another systematic review (<a href="./references#CD006826-bbs2-0069" title="DrummondMB , DasenbrookEC , PitzMW , MurphyDJ , FanE . Inhaled corticosteroids in patients with stable chronic obstructive pulmonary disease: a systematic review and meta‐analysis. JAMA2008;26;300(20):2407‐16. ">Drummond 2008</a>) found in subgroup analyses that the highest risks of pneumonia were seen in those treated with the highest ICS dose (RR 1.46, 95% CI 1.10 to 1.92), a shorter duration of ICS use (RR 2.12, 95% CI 1.47 to 3.05) and combined ICS and bronchodilator therapy (RR 1.57, 95% CI 1.35 to 1.82), which does not disagree with our findings. We found a lower rate of pneumonia than was found by other studies when diagnosis was obtained by chest x‐ray. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD006826-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006826.pub2/media/CDSR/CD006826/urn:x-wiley:14651858:media:CD006826:CD006826-AFig-FIG01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006826.pub2/media/CDSR/CD006826/image_t/tCD006826-AFig-FIG01.png" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram." data-id="CD006826-fig-0001" src="/cdsr/doi/10.1002/14651858.CD006826.pub2/media/CDSR/CD006826/image_n/nCD006826-AFig-FIG01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006826.pub2/full#CD006826-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006826.pub2/media/CDSR/CD006826/image_n/nCD006826-AFig-FIG01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006826-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006826.pub2/media/CDSR/CD006826/urn:x-wiley:14651858:media:CD006826:CD006826-AFig-FIG02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006826.pub2/media/CDSR/CD006826/image_t/tCD006826-AFig-FIG02.png" target="_blank"><b></b></a></p> </div><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD006826-fig-0002" src="/cdsr/doi/10.1002/14651858.CD006826.pub2/media/CDSR/CD006826/image_n/nCD006826-AFig-FIG02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006826.pub2/full#CD006826-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006826.pub2/media/CDSR/CD006826/image_n/nCD006826-AFig-FIG02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006826-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006826.pub2/media/CDSR/CD006826/urn:x-wiley:14651858:media:CD006826:CD006826-AFig-FIG03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006826.pub2/media/CDSR/CD006826/image_t/tCD006826-AFig-FIG03.png" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 1 All Combined Inhalers－Primary Outcomes, outcome: 1.1 Exacerbation rates (exacerbations requiring oral corticosteroids)." data-id="CD006826-fig-0003" src="/cdsr/doi/10.1002/14651858.CD006826.pub2/media/CDSR/CD006826/image_n/nCD006826-AFig-FIG03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Forest plot of comparison: 1 All Combined Inhalers－Primary Outcomes, outcome: 1.1 Exacerbation rates (exacerbations requiring oral corticosteroids). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006826.pub2/full#CD006826-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006826.pub2/media/CDSR/CD006826/image_n/nCD006826-AFig-FIG03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006826-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006826.pub2/media/CDSR/CD006826/urn:x-wiley:14651858:media:CD006826:CD006826-AFig-FIG04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006826.pub2/media/CDSR/CD006826/image_t/tCD006826-AFig-FIG04.png" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 1 All Combined Inhalers－Primary Outcomes, outcome: 1.2 Number of participants with one or more exacerbation." data-id="CD006826-fig-0004" src="/cdsr/doi/10.1002/14651858.CD006826.pub2/media/CDSR/CD006826/image_n/nCD006826-AFig-FIG04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 4</div> <div class="figure-caption"> <p>Forest plot of comparison: 1 All Combined Inhalers－Primary Outcomes, outcome: 1.2 Number of participants with one or more exacerbation. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006826.pub2/full#CD006826-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006826.pub2/media/CDSR/CD006826/image_n/nCD006826-AFig-FIG04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006826-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006826.pub2/media/CDSR/CD006826/urn:x-wiley:14651858:media:CD006826:CD006826-AFig-FIG05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006826.pub2/media/CDSR/CD006826/image_t/tCD006826-AFig-FIG05.png" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 1 All Combined Inhalers－Primary Outcomes, outcome: 1.3 Hospitalisations due to COPD exacerbations." data-id="CD006826-fig-0005" src="/cdsr/doi/10.1002/14651858.CD006826.pub2/media/CDSR/CD006826/image_n/nCD006826-AFig-FIG05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 5</div> <div class="figure-caption"> <p>Forest plot of comparison: 1 All Combined Inhalers－Primary Outcomes, outcome: 1.3 Hospitalisations due to COPD exacerbations. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006826.pub2/full#CD006826-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006826.pub2/media/CDSR/CD006826/image_n/nCD006826-AFig-FIG05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006826-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006826.pub2/media/CDSR/CD006826/urn:x-wiley:14651858:media:CD006826:CD006826-AFig-FIG06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006826.pub2/media/CDSR/CD006826/image_t/tCD006826-AFig-FIG06.png" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 1 All Combined Inhalers－Primary Outcomes, outcome: 1.4 Mortality." data-id="CD006826-fig-0006" src="/cdsr/doi/10.1002/14651858.CD006826.pub2/media/CDSR/CD006826/image_n/nCD006826-AFig-FIG06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 6</div> <div class="figure-caption"> <p>Forest plot of comparison: 1 All Combined Inhalers－Primary Outcomes, outcome: 1.4 Mortality. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006826.pub2/full#CD006826-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006826.pub2/media/CDSR/CD006826/image_n/nCD006826-AFig-FIG06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006826-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006826.pub2/media/CDSR/CD006826/urn:x-wiley:14651858:media:CD006826:CD006826-AFig-FIG07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006826.pub2/media/CDSR/CD006826/image_t/tCD006826-AFig-FIG07.png" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 1 All Combined Inhalers－Primary Outcomes, outcome: 1.5 Pneumonia." data-id="CD006826-fig-0007" src="/cdsr/doi/10.1002/14651858.CD006826.pub2/media/CDSR/CD006826/image_n/nCD006826-AFig-FIG07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 7</div> <div class="figure-caption"> <p>Forest plot of comparison: 1 All Combined Inhalers－Primary Outcomes, outcome: 1.5 Pneumonia. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006826.pub2/full#CD006826-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006826.pub2/media/CDSR/CD006826/image_n/nCD006826-AFig-FIG07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006826-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006826.pub2/media/CDSR/CD006826/urn:x-wiley:14651858:media:CD006826:CD006826-AFig-FIG08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006826.pub2/media/CDSR/CD006826/image_t/tCD006826-AFig-FIG08.png" target="_blank"><b></b></a></p> </div><img alt="Funnel plot of comparison: 1 All Combined Inhalers－Primary Outcomes, outcome: 1.4 Mortality." data-id="CD006826-fig-0008" src="/cdsr/doi/10.1002/14651858.CD006826.pub2/media/CDSR/CD006826/image_n/nCD006826-AFig-FIG08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 8</div> <div class="figure-caption"> <p>Funnel plot of comparison: 1 All Combined Inhalers－Primary Outcomes, outcome: 1.4 Mortality. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006826.pub2/full#CD006826-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006826.pub2/media/CDSR/CD006826/image_n/nCD006826-AFig-FIG08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006826-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006826.pub2/media/CDSR/CD006826/urn:x-wiley:14651858:media:CD006826:CD006826-CMP-001-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006826.pub2/media/CDSR/CD006826/image_t/tCD006826-CMP-001-01.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 All Combined Inhalers ‐ Primary Outcomes, Outcome 1 Exacerbation rates (exacerbations requiring oral corticosteroids)." data-id="CD006826-fig-0009" src="/cdsr/doi/10.1002/14651858.CD006826.pub2/media/CDSR/CD006826/image_n/nCD006826-CMP-001-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1 All Combined Inhalers ‐ Primary Outcomes, Outcome 1 Exacerbation rates (exacerbations requiring oral corticosteroids). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006826.pub2/references#CD006826-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006826.pub2/media/CDSR/CD006826/image_n/nCD006826-CMP-001-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006826-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006826.pub2/media/CDSR/CD006826/urn:x-wiley:14651858:media:CD006826:CD006826-CMP-001-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006826.pub2/media/CDSR/CD006826/image_t/tCD006826-CMP-001-02.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 All Combined Inhalers ‐ Primary Outcomes, Outcome 2 Number of participants with one or more exacerbation." data-id="CD006826-fig-0010" src="/cdsr/doi/10.1002/14651858.CD006826.pub2/media/CDSR/CD006826/image_n/nCD006826-CMP-001-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1 All Combined Inhalers ‐ Primary Outcomes, Outcome 2 Number of participants with one or more exacerbation. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006826.pub2/references#CD006826-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006826.pub2/media/CDSR/CD006826/image_n/nCD006826-CMP-001-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006826-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006826.pub2/media/CDSR/CD006826/urn:x-wiley:14651858:media:CD006826:CD006826-CMP-001-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006826.pub2/media/CDSR/CD006826/image_t/tCD006826-CMP-001-03.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 All Combined Inhalers ‐ Primary Outcomes, Outcome 3 Hospitalisations due to COPD exacerbations." data-id="CD006826-fig-0011" src="/cdsr/doi/10.1002/14651858.CD006826.pub2/media/CDSR/CD006826/image_n/nCD006826-CMP-001-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1 All Combined Inhalers ‐ Primary Outcomes, Outcome 3 Hospitalisations due to COPD exacerbations. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006826.pub2/references#CD006826-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006826.pub2/media/CDSR/CD006826/image_n/nCD006826-CMP-001-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006826-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006826.pub2/media/CDSR/CD006826/urn:x-wiley:14651858:media:CD006826:CD006826-CMP-001-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006826.pub2/media/CDSR/CD006826/image_t/tCD006826-CMP-001-04.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 All Combined Inhalers ‐ Primary Outcomes, Outcome 4 Mortality." data-id="CD006826-fig-0012" src="/cdsr/doi/10.1002/14651858.CD006826.pub2/media/CDSR/CD006826/image_n/nCD006826-CMP-001-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1 All Combined Inhalers ‐ Primary Outcomes, Outcome 4 Mortality.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006826.pub2/references#CD006826-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006826.pub2/media/CDSR/CD006826/image_n/nCD006826-CMP-001-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006826-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006826.pub2/media/CDSR/CD006826/urn:x-wiley:14651858:media:CD006826:CD006826-CMP-001-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006826.pub2/media/CDSR/CD006826/image_t/tCD006826-CMP-001-05.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 All Combined Inhalers ‐ Primary Outcomes, Outcome 5 Pneumonia." data-id="CD006826-fig-0013" src="/cdsr/doi/10.1002/14651858.CD006826.pub2/media/CDSR/CD006826/image_n/nCD006826-CMP-001-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1 All Combined Inhalers ‐ Primary Outcomes, Outcome 5 Pneumonia.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006826.pub2/references#CD006826-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006826.pub2/media/CDSR/CD006826/image_n/nCD006826-CMP-001-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006826-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006826.pub2/media/CDSR/CD006826/urn:x-wiley:14651858:media:CD006826:CD006826-CMP-002-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006826.pub2/media/CDSR/CD006826/image_t/tCD006826-CMP-002-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Fluticasone/salmeterol (FPS) versus fluticasone (FP), Outcome 1 Exacerbation rates." data-id="CD006826-fig-0014" src="/cdsr/doi/10.1002/14651858.CD006826.pub2/media/CDSR/CD006826/image_n/nCD006826-CMP-002-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2 Fluticasone/salmeterol (FPS) versus fluticasone (FP), Outcome 1 Exacerbation rates. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006826.pub2/references#CD006826-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006826.pub2/media/CDSR/CD006826/image_n/nCD006826-CMP-002-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006826-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006826.pub2/media/CDSR/CD006826/urn:x-wiley:14651858:media:CD006826:CD006826-CMP-002-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006826.pub2/media/CDSR/CD006826/image_t/tCD006826-CMP-002-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Fluticasone/salmeterol (FPS) versus fluticasone (FP), Outcome 2 Number of participants with one or more exacerbation." data-id="CD006826-fig-0015" src="/cdsr/doi/10.1002/14651858.CD006826.pub2/media/CDSR/CD006826/image_n/nCD006826-CMP-002-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2 Fluticasone/salmeterol (FPS) versus fluticasone (FP), Outcome 2 Number of participants with one or more exacerbation. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006826.pub2/references#CD006826-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006826.pub2/media/CDSR/CD006826/image_n/nCD006826-CMP-002-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006826-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006826.pub2/media/CDSR/CD006826/urn:x-wiley:14651858:media:CD006826:CD006826-CMP-002-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006826.pub2/media/CDSR/CD006826/image_t/tCD006826-CMP-002-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Fluticasone/salmeterol (FPS) versus fluticasone (FP), Outcome 3 End of treatment mean number of exacerbations per participant." data-id="CD006826-fig-0016" src="/cdsr/doi/10.1002/14651858.CD006826.pub2/media/CDSR/CD006826/image_n/nCD006826-CMP-002-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.3</div> <div class="figure-caption"> <p>Comparison 2 Fluticasone/salmeterol (FPS) versus fluticasone (FP), Outcome 3 End of treatment mean number of exacerbations per participant. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006826.pub2/references#CD006826-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006826.pub2/media/CDSR/CD006826/image_n/nCD006826-CMP-002-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006826-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006826.pub2/media/CDSR/CD006826/urn:x-wiley:14651858:media:CD006826:CD006826-CMP-002-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006826.pub2/media/CDSR/CD006826/image_t/tCD006826-CMP-002-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Fluticasone/salmeterol (FPS) versus fluticasone (FP), Outcome 4 Number of participants with one or more exacerbations by type." data-id="CD006826-fig-0017" src="/cdsr/doi/10.1002/14651858.CD006826.pub2/media/CDSR/CD006826/image_n/nCD006826-CMP-002-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.4</div> <div class="figure-caption"> <p>Comparison 2 Fluticasone/salmeterol (FPS) versus fluticasone (FP), Outcome 4 Number of participants with one or more exacerbations by type. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006826.pub2/references#CD006826-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006826.pub2/media/CDSR/CD006826/image_n/nCD006826-CMP-002-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006826-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006826.pub2/media/CDSR/CD006826/urn:x-wiley:14651858:media:CD006826:CD006826-CMP-002-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006826.pub2/media/CDSR/CD006826/image_t/tCD006826-CMP-002-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Fluticasone/salmeterol (FPS) versus fluticasone (FP), Outcome 5 Exacerbations by type." data-id="CD006826-fig-0018" src="/cdsr/doi/10.1002/14651858.CD006826.pub2/media/CDSR/CD006826/image_n/nCD006826-CMP-002-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.5</div> <div class="figure-caption"> <p>Comparison 2 Fluticasone/salmeterol (FPS) versus fluticasone (FP), Outcome 5 Exacerbations by type. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006826.pub2/references#CD006826-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006826.pub2/media/CDSR/CD006826/image_n/nCD006826-CMP-002-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006826-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006826.pub2/media/CDSR/CD006826/urn:x-wiley:14651858:media:CD006826:CD006826-CMP-002-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006826.pub2/media/CDSR/CD006826/image_t/tCD006826-CMP-002-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Fluticasone/salmeterol (FPS) versus fluticasone (FP), Outcome 6 Mortality." data-id="CD006826-fig-0019" src="/cdsr/doi/10.1002/14651858.CD006826.pub2/media/CDSR/CD006826/image_n/nCD006826-CMP-002-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.6</div> <div class="figure-caption"> <p>Comparison 2 Fluticasone/salmeterol (FPS) versus fluticasone (FP), Outcome 6 Mortality.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006826.pub2/references#CD006826-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006826.pub2/media/CDSR/CD006826/image_n/nCD006826-CMP-002-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006826-fig-0020"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006826.pub2/media/CDSR/CD006826/urn:x-wiley:14651858:media:CD006826:CD006826-CMP-002-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006826.pub2/media/CDSR/CD006826/image_t/tCD006826-CMP-002-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Fluticasone/salmeterol (FPS) versus fluticasone (FP), Outcome 7 Mortality－cause specific." data-id="CD006826-fig-0020" src="/cdsr/doi/10.1002/14651858.CD006826.pub2/media/CDSR/CD006826/image_n/nCD006826-CMP-002-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.7</div> <div class="figure-caption"> <p>Comparison 2 Fluticasone/salmeterol (FPS) versus fluticasone (FP), Outcome 7 Mortality－cause specific. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006826.pub2/references#CD006826-fig-0020">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006826.pub2/media/CDSR/CD006826/image_n/nCD006826-CMP-002-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006826-fig-0021"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006826.pub2/media/CDSR/CD006826/urn:x-wiley:14651858:media:CD006826:CD006826-CMP-002-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006826.pub2/media/CDSR/CD006826/image_t/tCD006826-CMP-002-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Fluticasone/salmeterol (FPS) versus fluticasone (FP), Outcome 8 Change from baseline in St George's Respiratory Questionnaire (total score)." data-id="CD006826-fig-0021" src="/cdsr/doi/10.1002/14651858.CD006826.pub2/media/CDSR/CD006826/image_n/nCD006826-CMP-002-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.8</div> <div class="figure-caption"> <p>Comparison 2 Fluticasone/salmeterol (FPS) versus fluticasone (FP), Outcome 8 Change from baseline in St George's Respiratory Questionnaire (total score). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006826.pub2/references#CD006826-fig-0021">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006826.pub2/media/CDSR/CD006826/image_n/nCD006826-CMP-002-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006826-fig-0022"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006826.pub2/media/CDSR/CD006826/urn:x-wiley:14651858:media:CD006826:CD006826-CMP-002-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006826.pub2/media/CDSR/CD006826/image_t/tCD006826-CMP-002-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Fluticasone/salmeterol (FPS) versus fluticasone (FP), Outcome 9 Change from baseline in Transitional Dyspnoea Index (TDI)." data-id="CD006826-fig-0022" src="/cdsr/doi/10.1002/14651858.CD006826.pub2/media/CDSR/CD006826/image_n/nCD006826-CMP-002-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.9</div> <div class="figure-caption"> <p>Comparison 2 Fluticasone/salmeterol (FPS) versus fluticasone (FP), Outcome 9 Change from baseline in Transitional Dyspnoea Index (TDI). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006826.pub2/references#CD006826-fig-0022">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006826.pub2/media/CDSR/CD006826/image_n/nCD006826-CMP-002-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006826-fig-0023"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006826.pub2/media/CDSR/CD006826/urn:x-wiley:14651858:media:CD006826:CD006826-CMP-002-10" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006826.pub2/media/CDSR/CD006826/image_t/tCD006826-CMP-002-10.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Fluticasone/salmeterol (FPS) versus fluticasone (FP), Outcome 10 Change from baseline in Chronic Respiratory Disease Questionnaire scores." data-id="CD006826-fig-0023" src="/cdsr/doi/10.1002/14651858.CD006826.pub2/media/CDSR/CD006826/image_n/nCD006826-CMP-002-10.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.10</div> <div class="figure-caption"> <p>Comparison 2 Fluticasone/salmeterol (FPS) versus fluticasone (FP), Outcome 10 Change from baseline in Chronic Respiratory Disease Questionnaire scores. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006826.pub2/references#CD006826-fig-0023">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006826.pub2/media/CDSR/CD006826/image_n/nCD006826-CMP-002-10.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006826-fig-0024"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006826.pub2/media/CDSR/CD006826/urn:x-wiley:14651858:media:CD006826:CD006826-CMP-002-11" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006826.pub2/media/CDSR/CD006826/image_t/tCD006826-CMP-002-11.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Fluticasone/salmeterol (FPS) versus fluticasone (FP), Outcome 11 Change from baseline in predose FEV1." data-id="CD006826-fig-0024" src="/cdsr/doi/10.1002/14651858.CD006826.pub2/media/CDSR/CD006826/image_n/nCD006826-CMP-002-11.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.11</div> <div class="figure-caption"> <p>Comparison 2 Fluticasone/salmeterol (FPS) versus fluticasone (FP), Outcome 11 Change from baseline in predose FEV<sub>1</sub>. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006826.pub2/references#CD006826-fig-0024">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006826.pub2/media/CDSR/CD006826/image_n/nCD006826-CMP-002-11.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006826-fig-0025"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006826.pub2/media/CDSR/CD006826/urn:x-wiley:14651858:media:CD006826:CD006826-CMP-002-12" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006826.pub2/media/CDSR/CD006826/image_t/tCD006826-CMP-002-12.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Fluticasone/salmeterol (FPS) versus fluticasone (FP), Outcome 12 Change from baseline in post‐dose FEV1." data-id="CD006826-fig-0025" src="/cdsr/doi/10.1002/14651858.CD006826.pub2/media/CDSR/CD006826/image_n/nCD006826-CMP-002-12.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.12</div> <div class="figure-caption"> <p>Comparison 2 Fluticasone/salmeterol (FPS) versus fluticasone (FP), Outcome 12 Change from baseline in post‐dose FEV<sub>1</sub>. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006826.pub2/references#CD006826-fig-0025">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006826.pub2/media/CDSR/CD006826/image_n/nCD006826-CMP-002-12.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006826-fig-0026"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006826.pub2/media/CDSR/CD006826/urn:x-wiley:14651858:media:CD006826:CD006826-CMP-002-13" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006826.pub2/media/CDSR/CD006826/image_t/tCD006826-CMP-002-13.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Fluticasone/salmeterol (FPS) versus fluticasone (FP), Outcome 13 End of treatment am PEF (L/min)." data-id="CD006826-fig-0026" src="/cdsr/doi/10.1002/14651858.CD006826.pub2/media/CDSR/CD006826/image_n/nCD006826-CMP-002-13.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.13</div> <div class="figure-caption"> <p>Comparison 2 Fluticasone/salmeterol (FPS) versus fluticasone (FP), Outcome 13 End of treatment am PEF (L/min). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006826.pub2/references#CD006826-fig-0026">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006826.pub2/media/CDSR/CD006826/image_n/nCD006826-CMP-002-13.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006826-fig-0027"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006826.pub2/media/CDSR/CD006826/urn:x-wiley:14651858:media:CD006826:CD006826-CMP-002-14" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006826.pub2/media/CDSR/CD006826/image_t/tCD006826-CMP-002-14.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Fluticasone/salmeterol (FPS) versus fluticasone (FP), Outcome 14 Absolute shuttle walk test." data-id="CD006826-fig-0027" src="/cdsr/doi/10.1002/14651858.CD006826.pub2/media/CDSR/CD006826/image_n/nCD006826-CMP-002-14.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.14</div> <div class="figure-caption"> <p>Comparison 2 Fluticasone/salmeterol (FPS) versus fluticasone (FP), Outcome 14 Absolute shuttle walk test. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006826.pub2/references#CD006826-fig-0027">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006826.pub2/media/CDSR/CD006826/image_n/nCD006826-CMP-002-14.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006826-fig-0028"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006826.pub2/media/CDSR/CD006826/urn:x-wiley:14651858:media:CD006826:CD006826-CMP-002-15" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006826.pub2/media/CDSR/CD006826/image_t/tCD006826-CMP-002-15.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Fluticasone/salmeterol (FPS) versus fluticasone (FP), Outcome 15 Change from baseline in rescue medication usage (puffs/d)." data-id="CD006826-fig-0028" src="/cdsr/doi/10.1002/14651858.CD006826.pub2/media/CDSR/CD006826/image_n/nCD006826-CMP-002-15.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.15</div> <div class="figure-caption"> <p>Comparison 2 Fluticasone/salmeterol (FPS) versus fluticasone (FP), Outcome 15 Change from baseline in rescue medication usage (puffs/d). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006826.pub2/references#CD006826-fig-0028">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006826.pub2/media/CDSR/CD006826/image_n/nCD006826-CMP-002-15.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006826-fig-0029"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006826.pub2/media/CDSR/CD006826/urn:x-wiley:14651858:media:CD006826:CD006826-CMP-002-16" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006826.pub2/media/CDSR/CD006826/image_t/tCD006826-CMP-002-16.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Fluticasone/salmeterol (FPS) versus fluticasone (FP), Outcome 16 Withdrawals." data-id="CD006826-fig-0029" src="/cdsr/doi/10.1002/14651858.CD006826.pub2/media/CDSR/CD006826/image_n/nCD006826-CMP-002-16.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.16</div> <div class="figure-caption"> <p>Comparison 2 Fluticasone/salmeterol (FPS) versus fluticasone (FP), Outcome 16 Withdrawals.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006826.pub2/references#CD006826-fig-0029">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006826.pub2/media/CDSR/CD006826/image_n/nCD006826-CMP-002-16.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006826-fig-0030"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006826.pub2/media/CDSR/CD006826/urn:x-wiley:14651858:media:CD006826:CD006826-CMP-002-17" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006826.pub2/media/CDSR/CD006826/image_t/tCD006826-CMP-002-17.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Fluticasone/salmeterol (FPS) versus fluticasone (FP), Outcome 17 Withdrawal due to lack of efficacy/exacerbation." data-id="CD006826-fig-0030" src="/cdsr/doi/10.1002/14651858.CD006826.pub2/media/CDSR/CD006826/image_n/nCD006826-CMP-002-17.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.17</div> <div class="figure-caption"> <p>Comparison 2 Fluticasone/salmeterol (FPS) versus fluticasone (FP), Outcome 17 Withdrawal due to lack of efficacy/exacerbation. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006826.pub2/references#CD006826-fig-0030">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006826.pub2/media/CDSR/CD006826/image_n/nCD006826-CMP-002-17.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006826-fig-0031"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006826.pub2/media/CDSR/CD006826/urn:x-wiley:14651858:media:CD006826:CD006826-CMP-002-18" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006826.pub2/media/CDSR/CD006826/image_t/tCD006826-CMP-002-18.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Fluticasone/salmeterol (FPS) versus fluticasone (FP), Outcome 18 Withdrawals due to adverse events." data-id="CD006826-fig-0031" src="/cdsr/doi/10.1002/14651858.CD006826.pub2/media/CDSR/CD006826/image_n/nCD006826-CMP-002-18.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.18</div> <div class="figure-caption"> <p>Comparison 2 Fluticasone/salmeterol (FPS) versus fluticasone (FP), Outcome 18 Withdrawals due to adverse events. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006826.pub2/references#CD006826-fig-0031">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006826.pub2/media/CDSR/CD006826/image_n/nCD006826-CMP-002-18.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006826-fig-0032"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006826.pub2/media/CDSR/CD006826/urn:x-wiley:14651858:media:CD006826:CD006826-CMP-002-19" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006826.pub2/media/CDSR/CD006826/image_t/tCD006826-CMP-002-19.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Fluticasone/salmeterol (FPS) versus fluticasone (FP), Outcome 19 Adverse events－any event." data-id="CD006826-fig-0032" src="/cdsr/doi/10.1002/14651858.CD006826.pub2/media/CDSR/CD006826/image_n/nCD006826-CMP-002-19.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.19</div> <div class="figure-caption"> <p>Comparison 2 Fluticasone/salmeterol (FPS) versus fluticasone (FP), Outcome 19 Adverse events－any event. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006826.pub2/references#CD006826-fig-0032">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006826.pub2/media/CDSR/CD006826/image_n/nCD006826-CMP-002-19.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006826-fig-0033"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006826.pub2/media/CDSR/CD006826/urn:x-wiley:14651858:media:CD006826:CD006826-CMP-002-20" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006826.pub2/media/CDSR/CD006826/image_t/tCD006826-CMP-002-20.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Fluticasone/salmeterol (FPS) versus fluticasone (FP), Outcome 20 Adverse events－serious." data-id="CD006826-fig-0033" src="/cdsr/doi/10.1002/14651858.CD006826.pub2/media/CDSR/CD006826/image_n/nCD006826-CMP-002-20.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.20</div> <div class="figure-caption"> <p>Comparison 2 Fluticasone/salmeterol (FPS) versus fluticasone (FP), Outcome 20 Adverse events－serious. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006826.pub2/references#CD006826-fig-0033">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006826.pub2/media/CDSR/CD006826/image_n/nCD006826-CMP-002-20.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006826-fig-0034"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006826.pub2/media/CDSR/CD006826/urn:x-wiley:14651858:media:CD006826:CD006826-CMP-002-21" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006826.pub2/media/CDSR/CD006826/image_t/tCD006826-CMP-002-21.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Fluticasone/salmeterol (FPS) versus fluticasone (FP), Outcome 21 Adverse events (specific adverse events)." data-id="CD006826-fig-0034" src="/cdsr/doi/10.1002/14651858.CD006826.pub2/media/CDSR/CD006826/image_n/nCD006826-CMP-002-21.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.21</div> <div class="figure-caption"> <p>Comparison 2 Fluticasone/salmeterol (FPS) versus fluticasone (FP), Outcome 21 Adverse events (specific adverse events). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006826.pub2/references#CD006826-fig-0034">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006826.pub2/media/CDSR/CD006826/image_n/nCD006826-CMP-002-21.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006826-fig-0035"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006826.pub2/media/CDSR/CD006826/urn:x-wiley:14651858:media:CD006826:CD006826-CMP-003-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006826.pub2/media/CDSR/CD006826/image_t/tCD006826-CMP-003-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Budesonide/formoterol (BDF) versus budesonide (BD), Outcome 1 Exacerbations." data-id="CD006826-fig-0035" src="/cdsr/doi/10.1002/14651858.CD006826.pub2/media/CDSR/CD006826/image_n/nCD006826-CMP-003-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.1</div> <div class="figure-caption"> <p>Comparison 3 Budesonide/formoterol (BDF) versus budesonide (BD), Outcome 1 Exacerbations.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006826.pub2/references#CD006826-fig-0035">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006826.pub2/media/CDSR/CD006826/image_n/nCD006826-CMP-003-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006826-fig-0036"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006826.pub2/media/CDSR/CD006826/urn:x-wiley:14651858:media:CD006826:CD006826-CMP-003-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006826.pub2/media/CDSR/CD006826/image_t/tCD006826-CMP-003-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Budesonide/formoterol (BDF) versus budesonide (BD), Outcome 2 Mean exacerbation rates per participant per year." data-id="CD006826-fig-0036" src="/cdsr/doi/10.1002/14651858.CD006826.pub2/media/CDSR/CD006826/image_n/nCD006826-CMP-003-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.2</div> <div class="figure-caption"> <p>Comparison 3 Budesonide/formoterol (BDF) versus budesonide (BD), Outcome 2 Mean exacerbation rates per participant per year. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006826.pub2/references#CD006826-fig-0036">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006826.pub2/media/CDSR/CD006826/image_n/nCD006826-CMP-003-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006826-fig-0037"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006826.pub2/media/CDSR/CD006826/urn:x-wiley:14651858:media:CD006826:CD006826-CMP-003-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006826.pub2/media/CDSR/CD006826/image_t/tCD006826-CMP-003-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Budesonide/formoterol (BDF) versus budesonide (BD), Outcome 3 Mortality." data-id="CD006826-fig-0037" src="/cdsr/doi/10.1002/14651858.CD006826.pub2/media/CDSR/CD006826/image_n/nCD006826-CMP-003-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.3</div> <div class="figure-caption"> <p>Comparison 3 Budesonide/formoterol (BDF) versus budesonide (BD), Outcome 3 Mortality.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006826.pub2/references#CD006826-fig-0037">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006826.pub2/media/CDSR/CD006826/image_n/nCD006826-CMP-003-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006826-fig-0038"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006826.pub2/media/CDSR/CD006826/urn:x-wiley:14651858:media:CD006826:CD006826-CMP-003-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006826.pub2/media/CDSR/CD006826/image_t/tCD006826-CMP-003-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Budesonide/formoterol (BDF) versus budesonide (BD), Outcome 4 Quality of life－SGRQ total (change scores)." data-id="CD006826-fig-0038" src="/cdsr/doi/10.1002/14651858.CD006826.pub2/media/CDSR/CD006826/image_n/nCD006826-CMP-003-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.4</div> <div class="figure-caption"> <p>Comparison 3 Budesonide/formoterol (BDF) versus budesonide (BD), Outcome 4 Quality of life－SGRQ total (change scores). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006826.pub2/references#CD006826-fig-0038">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006826.pub2/media/CDSR/CD006826/image_n/nCD006826-CMP-003-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006826-fig-0039"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006826.pub2/media/CDSR/CD006826/urn:x-wiley:14651858:media:CD006826:CD006826-CMP-003-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006826.pub2/media/CDSR/CD006826/image_t/tCD006826-CMP-003-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Budesonide/formoterol (BDF) versus budesonide (BD), Outcome 5 Symptoms (change scores)." data-id="CD006826-fig-0039" src="/cdsr/doi/10.1002/14651858.CD006826.pub2/media/CDSR/CD006826/image_n/nCD006826-CMP-003-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.5</div> <div class="figure-caption"> <p>Comparison 3 Budesonide/formoterol (BDF) versus budesonide (BD), Outcome 5 Symptoms (change scores). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006826.pub2/references#CD006826-fig-0039">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006826.pub2/media/CDSR/CD006826/image_n/nCD006826-CMP-003-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006826-fig-0040"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006826.pub2/media/CDSR/CD006826/urn:x-wiley:14651858:media:CD006826:CD006826-CMP-003-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006826.pub2/media/CDSR/CD006826/image_t/tCD006826-CMP-003-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Budesonide/formoterol (BDF) versus budesonide (BD), Outcome 6 Breathlessness, cough and sputum score (BCSS) change from baseline－average over treatment period." data-id="CD006826-fig-0040" src="/cdsr/doi/10.1002/14651858.CD006826.pub2/media/CDSR/CD006826/image_n/nCD006826-CMP-003-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.6</div> <div class="figure-caption"> <p>Comparison 3 Budesonide/formoterol (BDF) versus budesonide (BD), Outcome 6 Breathlessness, cough and sputum score (BCSS) change from baseline－average over treatment period. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006826.pub2/references#CD006826-fig-0040">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006826.pub2/media/CDSR/CD006826/image_n/nCD006826-CMP-003-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006826-fig-0041"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006826.pub2/media/CDSR/CD006826/urn:x-wiley:14651858:media:CD006826:CD006826-CMP-003-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006826.pub2/media/CDSR/CD006826/image_t/tCD006826-CMP-003-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Budesonide/formoterol (BDF) versus budesonide (BD), Outcome 7 Awakening‐free nights, percentage change from baseline." data-id="CD006826-fig-0041" src="/cdsr/doi/10.1002/14651858.CD006826.pub2/media/CDSR/CD006826/image_n/nCD006826-CMP-003-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.7</div> <div class="figure-caption"> <p>Comparison 3 Budesonide/formoterol (BDF) versus budesonide (BD), Outcome 7 Awakening‐free nights, percentage change from baseline. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006826.pub2/references#CD006826-fig-0041">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006826.pub2/media/CDSR/CD006826/image_n/nCD006826-CMP-003-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006826-fig-0042"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006826.pub2/media/CDSR/CD006826/urn:x-wiley:14651858:media:CD006826:CD006826-CMP-003-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006826.pub2/media/CDSR/CD006826/image_t/tCD006826-CMP-003-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Budesonide/formoterol (BDF) versus budesonide (BD), Outcome 8 Mean FEV1 (% increase from baseline)." data-id="CD006826-fig-0042" src="/cdsr/doi/10.1002/14651858.CD006826.pub2/media/CDSR/CD006826/image_n/nCD006826-CMP-003-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.8</div> <div class="figure-caption"> <p>Comparison 3 Budesonide/formoterol (BDF) versus budesonide (BD), Outcome 8 Mean FEV<sub>1</sub> (% increase from baseline). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006826.pub2/references#CD006826-fig-0042">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006826.pub2/media/CDSR/CD006826/image_n/nCD006826-CMP-003-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006826-fig-0043"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006826.pub2/media/CDSR/CD006826/urn:x-wiley:14651858:media:CD006826:CD006826-CMP-003-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006826.pub2/media/CDSR/CD006826/image_t/tCD006826-CMP-003-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Budesonide/formoterol (BDF) versus budesonide (BD), Outcome 9 Pre‐dose FEV1 [L] change from baseline to the average over the randomised treatment period." data-id="CD006826-fig-0043" src="/cdsr/doi/10.1002/14651858.CD006826.pub2/media/CDSR/CD006826/image_n/nCD006826-CMP-003-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.9</div> <div class="figure-caption"> <p>Comparison 3 Budesonide/formoterol (BDF) versus budesonide (BD), Outcome 9 Pre‐dose FEV<sub>1</sub> [L] change from baseline to the average over the randomised treatment period. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006826.pub2/references#CD006826-fig-0043">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006826.pub2/media/CDSR/CD006826/image_n/nCD006826-CMP-003-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006826-fig-0044"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006826.pub2/media/CDSR/CD006826/urn:x-wiley:14651858:media:CD006826:CD006826-CMP-003-10" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006826.pub2/media/CDSR/CD006826/image_t/tCD006826-CMP-003-10.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Budesonide/formoterol (BDF) versus budesonide (BD), Outcome 10 1‐Hour post‐dose FEV1 [L] change from baseline to the average over the randomised treatment period." data-id="CD006826-fig-0044" src="/cdsr/doi/10.1002/14651858.CD006826.pub2/media/CDSR/CD006826/image_n/nCD006826-CMP-003-10.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.10</div> <div class="figure-caption"> <p>Comparison 3 Budesonide/formoterol (BDF) versus budesonide (BD), Outcome 10 1‐Hour post‐dose FEV<sub>1</sub> [L] change from baseline to the average over the randomised treatment period. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006826.pub2/references#CD006826-fig-0044">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006826.pub2/media/CDSR/CD006826/image_n/nCD006826-CMP-003-10.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006826-fig-0045"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006826.pub2/media/CDSR/CD006826/urn:x-wiley:14651858:media:CD006826:CD006826-CMP-003-11" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006826.pub2/media/CDSR/CD006826/image_t/tCD006826-CMP-003-11.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Budesonide/formoterol (BDF) versus budesonide (BD), Outcome 11 Morning PEFR change from baseline, average over treatment period (L/min)." data-id="CD006826-fig-0045" src="/cdsr/doi/10.1002/14651858.CD006826.pub2/media/CDSR/CD006826/image_n/nCD006826-CMP-003-11.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.11</div> <div class="figure-caption"> <p>Comparison 3 Budesonide/formoterol (BDF) versus budesonide (BD), Outcome 11 Morning PEFR change from baseline, average over treatment period (L/min). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006826.pub2/references#CD006826-fig-0045">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006826.pub2/media/CDSR/CD006826/image_n/nCD006826-CMP-003-11.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006826-fig-0046"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006826.pub2/media/CDSR/CD006826/urn:x-wiley:14651858:media:CD006826:CD006826-CMP-003-12" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006826.pub2/media/CDSR/CD006826/image_t/tCD006826-CMP-003-12.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Budesonide/formoterol (BDF) versus budesonide (BD), Outcome 12 Evening PEFR mean change from baseline, average over treatment period (L/min)." data-id="CD006826-fig-0046" src="/cdsr/doi/10.1002/14651858.CD006826.pub2/media/CDSR/CD006826/image_n/nCD006826-CMP-003-12.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.12</div> <div class="figure-caption"> <p>Comparison 3 Budesonide/formoterol (BDF) versus budesonide (BD), Outcome 12 Evening PEFR mean change from baseline, average over treatment period (L/min). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006826.pub2/references#CD006826-fig-0046">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006826.pub2/media/CDSR/CD006826/image_n/nCD006826-CMP-003-12.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006826-fig-0047"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006826.pub2/media/CDSR/CD006826/urn:x-wiley:14651858:media:CD006826:CD006826-CMP-003-13" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006826.pub2/media/CDSR/CD006826/image_t/tCD006826-CMP-003-13.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Budesonide/formoterol (BDF) versus budesonide (BD), Outcome 13 Rescue medication use." data-id="CD006826-fig-0047" src="/cdsr/doi/10.1002/14651858.CD006826.pub2/media/CDSR/CD006826/image_n/nCD006826-CMP-003-13.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.13</div> <div class="figure-caption"> <p>Comparison 3 Budesonide/formoterol (BDF) versus budesonide (BD), Outcome 13 Rescue medication use. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006826.pub2/references#CD006826-fig-0047">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006826.pub2/media/CDSR/CD006826/image_n/nCD006826-CMP-003-13.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006826-fig-0048"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006826.pub2/media/CDSR/CD006826/urn:x-wiley:14651858:media:CD006826:CD006826-CMP-003-14" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006826.pub2/media/CDSR/CD006826/image_t/tCD006826-CMP-003-14.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Budesonide/formoterol (BDF) versus budesonide (BD), Outcome 14 Sleep score (0 to 4)－change from baseline." data-id="CD006826-fig-0048" src="/cdsr/doi/10.1002/14651858.CD006826.pub2/media/CDSR/CD006826/image_n/nCD006826-CMP-003-14.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.14</div> <div class="figure-caption"> <p>Comparison 3 Budesonide/formoterol (BDF) versus budesonide (BD), Outcome 14 Sleep score (0 to 4)－change from baseline. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006826.pub2/references#CD006826-fig-0048">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006826.pub2/media/CDSR/CD006826/image_n/nCD006826-CMP-003-14.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006826-fig-0049"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006826.pub2/media/CDSR/CD006826/urn:x-wiley:14651858:media:CD006826:CD006826-CMP-003-15" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006826.pub2/media/CDSR/CD006826/image_t/tCD006826-CMP-003-15.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Budesonide/formoterol (BDF) versus budesonide (BD), Outcome 15 Dyspnoea score (0 to 4)－change from baseline." data-id="CD006826-fig-0049" src="/cdsr/doi/10.1002/14651858.CD006826.pub2/media/CDSR/CD006826/image_n/nCD006826-CMP-003-15.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.15</div> <div class="figure-caption"> <p>Comparison 3 Budesonide/formoterol (BDF) versus budesonide (BD), Outcome 15 Dyspnoea score (0 to 4)－change from baseline. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006826.pub2/references#CD006826-fig-0049">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006826.pub2/media/CDSR/CD006826/image_n/nCD006826-CMP-003-15.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006826-fig-0050"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006826.pub2/media/CDSR/CD006826/urn:x-wiley:14651858:media:CD006826:CD006826-CMP-003-16" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006826.pub2/media/CDSR/CD006826/image_t/tCD006826-CMP-003-16.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Budesonide/formoterol (BDF) versus budesonide (BD), Outcome 16 Cough score (0 to 4)－change from baseline." data-id="CD006826-fig-0050" src="/cdsr/doi/10.1002/14651858.CD006826.pub2/media/CDSR/CD006826/image_n/nCD006826-CMP-003-16.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.16</div> <div class="figure-caption"> <p>Comparison 3 Budesonide/formoterol (BDF) versus budesonide (BD), Outcome 16 Cough score (0 to 4)－change from baseline. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006826.pub2/references#CD006826-fig-0050">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006826.pub2/media/CDSR/CD006826/image_n/nCD006826-CMP-003-16.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006826-fig-0051"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006826.pub2/media/CDSR/CD006826/urn:x-wiley:14651858:media:CD006826:CD006826-CMP-003-17" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006826.pub2/media/CDSR/CD006826/image_t/tCD006826-CMP-003-17.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Budesonide/formoterol (BDF) versus budesonide (BD), Outcome 17 Sputum score (0 to 4)－change from baseline." data-id="CD006826-fig-0051" src="/cdsr/doi/10.1002/14651858.CD006826.pub2/media/CDSR/CD006826/image_n/nCD006826-CMP-003-17.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.17</div> <div class="figure-caption"> <p>Comparison 3 Budesonide/formoterol (BDF) versus budesonide (BD), Outcome 17 Sputum score (0 to 4)－change from baseline. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006826.pub2/references#CD006826-fig-0051">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006826.pub2/media/CDSR/CD006826/image_n/nCD006826-CMP-003-17.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006826-fig-0052"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006826.pub2/media/CDSR/CD006826/urn:x-wiley:14651858:media:CD006826:CD006826-CMP-003-18" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006826.pub2/media/CDSR/CD006826/image_t/tCD006826-CMP-003-18.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Budesonide/formoterol (BDF) versus budesonide (BD), Outcome 18 Withdrawals due to worsening COPD symptoms." data-id="CD006826-fig-0052" src="/cdsr/doi/10.1002/14651858.CD006826.pub2/media/CDSR/CD006826/image_n/nCD006826-CMP-003-18.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.18</div> <div class="figure-caption"> <p>Comparison 3 Budesonide/formoterol (BDF) versus budesonide (BD), Outcome 18 Withdrawals due to worsening COPD symptoms. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006826.pub2/references#CD006826-fig-0052">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006826.pub2/media/CDSR/CD006826/image_n/nCD006826-CMP-003-18.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006826-fig-0053"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006826.pub2/media/CDSR/CD006826/urn:x-wiley:14651858:media:CD006826:CD006826-CMP-003-19" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006826.pub2/media/CDSR/CD006826/image_t/tCD006826-CMP-003-19.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Budesonide/formoterol (BDF) versus budesonide (BD), Outcome 19 Withdrawals due to adverse events." data-id="CD006826-fig-0053" src="/cdsr/doi/10.1002/14651858.CD006826.pub2/media/CDSR/CD006826/image_n/nCD006826-CMP-003-19.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.19</div> <div class="figure-caption"> <p>Comparison 3 Budesonide/formoterol (BDF) versus budesonide (BD), Outcome 19 Withdrawals due to adverse events. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006826.pub2/references#CD006826-fig-0053">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006826.pub2/media/CDSR/CD006826/image_n/nCD006826-CMP-003-19.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006826-fig-0054"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006826.pub2/media/CDSR/CD006826/urn:x-wiley:14651858:media:CD006826:CD006826-CMP-003-20" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006826.pub2/media/CDSR/CD006826/image_t/tCD006826-CMP-003-20.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Budesonide/formoterol (BDF) versus budesonide (BD), Outcome 20 Adverse event－any (one or more)." data-id="CD006826-fig-0054" src="/cdsr/doi/10.1002/14651858.CD006826.pub2/media/CDSR/CD006826/image_n/nCD006826-CMP-003-20.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.20</div> <div class="figure-caption"> <p>Comparison 3 Budesonide/formoterol (BDF) versus budesonide (BD), Outcome 20 Adverse event－any (one or more). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006826.pub2/references#CD006826-fig-0054">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006826.pub2/media/CDSR/CD006826/image_n/nCD006826-CMP-003-20.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006826-fig-0055"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006826.pub2/media/CDSR/CD006826/urn:x-wiley:14651858:media:CD006826:CD006826-CMP-003-21" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006826.pub2/media/CDSR/CD006826/image_t/tCD006826-CMP-003-21.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Budesonide/formoterol (BDF) versus budesonide (BD), Outcome 21 Adverse events－serious events." data-id="CD006826-fig-0055" src="/cdsr/doi/10.1002/14651858.CD006826.pub2/media/CDSR/CD006826/image_n/nCD006826-CMP-003-21.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.21</div> <div class="figure-caption"> <p>Comparison 3 Budesonide/formoterol (BDF) versus budesonide (BD), Outcome 21 Adverse events－serious events. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006826.pub2/references#CD006826-fig-0055">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006826.pub2/media/CDSR/CD006826/image_n/nCD006826-CMP-003-21.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006826-fig-0056"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006826.pub2/media/CDSR/CD006826/urn:x-wiley:14651858:media:CD006826:CD006826-CMP-003-22" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006826.pub2/media/CDSR/CD006826/image_t/tCD006826-CMP-003-22.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Budesonide/formoterol (BDF) versus budesonide (BD), Outcome 22 Adverse events (specific adverse events)." data-id="CD006826-fig-0056" src="/cdsr/doi/10.1002/14651858.CD006826.pub2/media/CDSR/CD006826/image_n/nCD006826-CMP-003-22.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.22</div> <div class="figure-caption"> <p>Comparison 3 Budesonide/formoterol (BDF) versus budesonide (BD), Outcome 22 Adverse events (specific adverse events). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006826.pub2/references#CD006826-fig-0056">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006826.pub2/media/CDSR/CD006826/image_n/nCD006826-CMP-003-22.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006826-fig-0057"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006826.pub2/media/CDSR/CD006826/urn:x-wiley:14651858:media:CD006826:CD006826-CMP-004-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006826.pub2/media/CDSR/CD006826/image_t/tCD006826-CMP-004-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Mometasone/formoterol (MF/F) versus Mometasone (MF), Outcome 1 Patients with one or more exacerbation." data-id="CD006826-fig-0057" src="/cdsr/doi/10.1002/14651858.CD006826.pub2/media/CDSR/CD006826/image_n/nCD006826-CMP-004-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.1</div> <div class="figure-caption"> <p>Comparison 4 Mometasone/formoterol (MF/F) versus Mometasone (MF), Outcome 1 Patients with one or more exacerbation. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006826.pub2/references#CD006826-fig-0057">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006826.pub2/media/CDSR/CD006826/image_n/nCD006826-CMP-004-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006826-fig-0058"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006826.pub2/media/CDSR/CD006826/urn:x-wiley:14651858:media:CD006826:CD006826-CMP-004-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006826.pub2/media/CDSR/CD006826/image_t/tCD006826-CMP-004-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Mometasone/formoterol (MF/F) versus Mometasone (MF), Outcome 2 Mortality." data-id="CD006826-fig-0058" src="/cdsr/doi/10.1002/14651858.CD006826.pub2/media/CDSR/CD006826/image_n/nCD006826-CMP-004-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.2</div> <div class="figure-caption"> <p>Comparison 4 Mometasone/formoterol (MF/F) versus Mometasone (MF), Outcome 2 Mortality.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006826.pub2/references#CD006826-fig-0058">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006826.pub2/media/CDSR/CD006826/image_n/nCD006826-CMP-004-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006826-fig-0059"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006826.pub2/media/CDSR/CD006826/urn:x-wiley:14651858:media:CD006826:CD006826-CMP-004-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006826.pub2/media/CDSR/CD006826/image_t/tCD006826-CMP-004-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Mometasone/formoterol (MF/F) versus Mometasone (MF), Outcome 3 Change from baseline in SGRQ (total score)." data-id="CD006826-fig-0059" src="/cdsr/doi/10.1002/14651858.CD006826.pub2/media/CDSR/CD006826/image_n/nCD006826-CMP-004-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.3</div> <div class="figure-caption"> <p>Comparison 4 Mometasone/formoterol (MF/F) versus Mometasone (MF), Outcome 3 Change from baseline in SGRQ (total score). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006826.pub2/references#CD006826-fig-0059">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006826.pub2/media/CDSR/CD006826/image_n/nCD006826-CMP-004-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006826-fig-0060"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006826.pub2/media/CDSR/CD006826/urn:x-wiley:14651858:media:CD006826:CD006826-CMP-004-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006826.pub2/media/CDSR/CD006826/image_t/tCD006826-CMP-004-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Mometasone/formoterol (MF/F) versus Mometasone (MF), Outcome 4 Change from baseline in FEV1 AUC0‐12 h (mL) week 26." data-id="CD006826-fig-0060" src="/cdsr/doi/10.1002/14651858.CD006826.pub2/media/CDSR/CD006826/image_n/nCD006826-CMP-004-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.4</div> <div class="figure-caption"> <p>Comparison 4 Mometasone/formoterol (MF/F) versus Mometasone (MF), Outcome 4 Change from baseline in FEV<sub>1</sub> AUC<sub>0‐12 h</sub> (mL) week 26. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006826.pub2/references#CD006826-fig-0060">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006826.pub2/media/CDSR/CD006826/image_n/nCD006826-CMP-004-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006826-fig-0061"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006826.pub2/media/CDSR/CD006826/urn:x-wiley:14651858:media:CD006826:CD006826-CMP-004-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006826.pub2/media/CDSR/CD006826/image_t/tCD006826-CMP-004-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Mometasone/formoterol (MF/F) versus Mometasone (MF), Outcome 5 Change from baseline in FEV1 AUC0‐12 h (mL) week 13." data-id="CD006826-fig-0061" src="/cdsr/doi/10.1002/14651858.CD006826.pub2/media/CDSR/CD006826/image_n/nCD006826-CMP-004-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.5</div> <div class="figure-caption"> <p>Comparison 4 Mometasone/formoterol (MF/F) versus Mometasone (MF), Outcome 5 Change from baseline in FEV<sub>1</sub> AUC<sub>0‐12 h</sub> (mL) week 13. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006826.pub2/references#CD006826-fig-0061">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006826.pub2/media/CDSR/CD006826/image_n/nCD006826-CMP-004-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006826-fig-0062"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006826.pub2/media/CDSR/CD006826/urn:x-wiley:14651858:media:CD006826:CD006826-CMP-004-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006826.pub2/media/CDSR/CD006826/image_t/tCD006826-CMP-004-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Mometasone/formoterol (MF/F) versus Mometasone (MF), Outcome 6 Mean change from baseline AM pre‐dose FEV1 at 13 weeks (mL)." data-id="CD006826-fig-0062" src="/cdsr/doi/10.1002/14651858.CD006826.pub2/media/CDSR/CD006826/image_n/nCD006826-CMP-004-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.6</div> <div class="figure-caption"> <p>Comparison 4 Mometasone/formoterol (MF/F) versus Mometasone (MF), Outcome 6 Mean change from baseline AM pre‐dose FEV<sub>1</sub> at 13 weeks (mL). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006826.pub2/references#CD006826-fig-0062">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006826.pub2/media/CDSR/CD006826/image_n/nCD006826-CMP-004-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006826-fig-0063"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006826.pub2/media/CDSR/CD006826/urn:x-wiley:14651858:media:CD006826:CD006826-CMP-004-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006826.pub2/media/CDSR/CD006826/image_t/tCD006826-CMP-004-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Mometasone/formoterol (MF/F) versus Mometasone (MF), Outcome 7 Withdrawals－total." data-id="CD006826-fig-0063" src="/cdsr/doi/10.1002/14651858.CD006826.pub2/media/CDSR/CD006826/image_n/nCD006826-CMP-004-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.7</div> <div class="figure-caption"> <p>Comparison 4 Mometasone/formoterol (MF/F) versus Mometasone (MF), Outcome 7 Withdrawals－total.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006826.pub2/references#CD006826-fig-0063">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006826.pub2/media/CDSR/CD006826/image_n/nCD006826-CMP-004-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006826-fig-0064"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006826.pub2/media/CDSR/CD006826/urn:x-wiley:14651858:media:CD006826:CD006826-CMP-004-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006826.pub2/media/CDSR/CD006826/image_t/tCD006826-CMP-004-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Mometasone/formoterol (MF/F) versus Mometasone (MF), Outcome 8 Withdrawals due to adverse event." data-id="CD006826-fig-0064" src="/cdsr/doi/10.1002/14651858.CD006826.pub2/media/CDSR/CD006826/image_n/nCD006826-CMP-004-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.8</div> <div class="figure-caption"> <p>Comparison 4 Mometasone/formoterol (MF/F) versus Mometasone (MF), Outcome 8 Withdrawals due to adverse event. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006826.pub2/references#CD006826-fig-0064">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006826.pub2/media/CDSR/CD006826/image_n/nCD006826-CMP-004-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006826-fig-0065"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006826.pub2/media/CDSR/CD006826/urn:x-wiley:14651858:media:CD006826:CD006826-CMP-004-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006826.pub2/media/CDSR/CD006826/image_t/tCD006826-CMP-004-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Mometasone/formoterol (MF/F) versus Mometasone (MF), Outcome 9 Withdrawal due to treatment failure." data-id="CD006826-fig-0065" src="/cdsr/doi/10.1002/14651858.CD006826.pub2/media/CDSR/CD006826/image_n/nCD006826-CMP-004-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.9</div> <div class="figure-caption"> <p>Comparison 4 Mometasone/formoterol (MF/F) versus Mometasone (MF), Outcome 9 Withdrawal due to treatment failure. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006826.pub2/references#CD006826-fig-0065">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006826.pub2/media/CDSR/CD006826/image_n/nCD006826-CMP-004-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006826-fig-0066"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006826.pub2/media/CDSR/CD006826/urn:x-wiley:14651858:media:CD006826:CD006826-CMP-004-10" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006826.pub2/media/CDSR/CD006826/image_t/tCD006826-CMP-004-10.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Mometasone/formoterol (MF/F) versus Mometasone (MF), Outcome 10 Adverse event－any." data-id="CD006826-fig-0066" src="/cdsr/doi/10.1002/14651858.CD006826.pub2/media/CDSR/CD006826/image_n/nCD006826-CMP-004-10.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.10</div> <div class="figure-caption"> <p>Comparison 4 Mometasone/formoterol (MF/F) versus Mometasone (MF), Outcome 10 Adverse event－any. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006826.pub2/references#CD006826-fig-0066">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006826.pub2/media/CDSR/CD006826/image_n/nCD006826-CMP-004-10.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006826-fig-0067"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006826.pub2/media/CDSR/CD006826/urn:x-wiley:14651858:media:CD006826:CD006826-CMP-004-11" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006826.pub2/media/CDSR/CD006826/image_t/tCD006826-CMP-004-11.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Mometasone/formoterol (MF/F) versus Mometasone (MF), Outcome 11 Adverse event－serious." data-id="CD006826-fig-0067" src="/cdsr/doi/10.1002/14651858.CD006826.pub2/media/CDSR/CD006826/image_n/nCD006826-CMP-004-11.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.11</div> <div class="figure-caption"> <p>Comparison 4 Mometasone/formoterol (MF/F) versus Mometasone (MF), Outcome 11 Adverse event－serious. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006826.pub2/references#CD006826-fig-0067">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006826.pub2/media/CDSR/CD006826/image_n/nCD006826-CMP-004-11.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006826-fig-0068"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006826.pub2/media/CDSR/CD006826/urn:x-wiley:14651858:media:CD006826:CD006826-CMP-004-12" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006826.pub2/media/CDSR/CD006826/image_t/tCD006826-CMP-004-12.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Mometasone/formoterol (MF/F) versus Mometasone (MF), Outcome 12 Adverse events (specific adverse events)." data-id="CD006826-fig-0068" src="/cdsr/doi/10.1002/14651858.CD006826.pub2/media/CDSR/CD006826/image_n/nCD006826-CMP-004-12.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.12</div> <div class="figure-caption"> <p>Comparison 4 Mometasone/formoterol (MF/F) versus Mometasone (MF), Outcome 12 Adverse events (specific adverse events). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006826.pub2/references#CD006826-fig-0068">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006826.pub2/media/CDSR/CD006826/image_n/nCD006826-CMP-004-12.png" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD006826-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">All combined inhalers－participants with one or more exacerbations</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Combined steroid/LABA inhalers versus LABA alone for people with COPD</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> patients with COPD<br/> <b>Settings:</b> community<br/> <b>Intervention:</b> All combined inhalers－primary outcomes </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No. of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Control</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> All combined inhalers－primary outcomes</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Exacerbation rates per participant per year</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>1.21<sup>1</sup> </b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>1.05</b> </p> <p>(0.97 to 1.14)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Rate ratio 0.87</b> (0.80 to 0.94) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5601<br/> (6 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊝<br/> <b>moderate<sup>2</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Mortality</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>71 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>56 per 1000</b> <br/> (47 to 67) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>OR 0.78</b> <br/> (0.64 to 0.94) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7518<br/> (12 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊕<br/> <b>high<sup>3</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Pneumonia</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>85 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>91 per 1000</b> <br/> (78 to 107) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>OR 1.08</b> <br/> (0.91 to 1.28) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7320<br/> (12 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊝⊝<br/> <b>low<sup>2,4</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Hospitalisations due to COPD exacerbations</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>127 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>119 per 1000</b> <br/> (104 to 134) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 0.93</b> <br/> (0.8 to 1.07) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7060<br/> (10 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low<sup>2,4</sup> </b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Adverse events</b> －<b>serious</b> </p> <p>Fluticasone/salmeterol (FPS) versus fluticasone (FP)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>54 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>57 per 1000</b> <br/> (45 to 71) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>OR 1.05</b> <br/> (0.82 to 1.34) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5055<br/> (7 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊝⊝<br/> <b>low<sup>2,4</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Adverse events</b> －<b>serious events</b> Budesonide/formoterol (BDF) versus budesonide (BD) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>207 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>195 per 1000</b> <br/> (158 to 240) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>OR 0.93</b> <br/> (0.72 to 1.21) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1469<br/> (3 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊝⊝⊝<br/> <b>very low<sup>2,4,5</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Adverse events</b> －<b>serious</b> Mometasone/formoterol (MF/F) versus Mometasone (MF) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>78 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>80 per 1000</b> <br/> (50 to 123) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>OR 1.03</b> <br/> (0.63 to 1.67) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>905<br/> (2 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊝⊝<br/> <b>low<sup>2,4</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>OR:</b> Odds ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence:<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Mean exacerbation rate in the ICS arms of the included studies (range 0.88 to 1.60 per participant per year). </p> <p><sup>2</sup>(‐1 limitations) due to high risk of attrition bias. </p> <p><sup>3</sup>We did not deduct a point for attrition bias because most of the data on mortality were derived from TORCH. </p> <p><sup>4</sup>(‐1 imprecision) confidence interval cannot rule out differences in either direction. </p> <p><sup>5</sup>A point is deducted to reflect the considerable heterogeneity in this analysis (I<sup>2</sup> = 66%). </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">All combined inhalers－participants with one or more exacerbations</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD006826.pub2/full#CD006826-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD006826-tbl-0002"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Search history</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Version</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Detail</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1st published version－Issue 4, 2003 (all years to April 2002)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>References identified: 34<br/> References retrieved: 7<br/> Studies excluded: 3 (Cazzola 2000; Chapman 2002; Soriano 2002)<br/> Studies identified from supplementary searching: 4 (Dal Negro 2003; <a href="./references#CD006826-bbs2-0004" title="HananiaNA , DarkenP , HorstmanD , ReisnerC , LeeB , DavisS , et al. The efficacy and safety of fluticasone propionate (250 micro g)/salmeterol (50 micro g) combined in the diskus inhaler for the treatment of COPD. Chest2003;124(3):834‐43. HananiaNA , RamsdellJ , PayneK , DavisS , HorstmanD , LeeB , et al. Improvements in airflow and dyspnea in COPD patients following 24 weeks treatment with salmeterol 50mcg and fluticasone propionate 250mcg alone or in combination via the diskus. American Journal of Respiratory &amp; Critical Care Medicine2001;163(5 Suppl):A279. HorstmanD , DarkenP , DavisS , LeeB . Improvements in FEV1 and symptoms in poorly reversible COPD patients following treatment with salmeterol 50mcg/fluticasone propionate 250mcg combination [Abstract]. European Respiratory Journal2003;22 Suppl 45:P434. MahlerDA , DarkenP , BrownCP , KnobilK . Predicting lung function responses to combination therapy in chronic obstructive pulmonary disease (COPD) [Abstract]. National COPD Conference; November 14‐15, 2003; Arlington, Virginia. Abstract 1081. MahlerDA , DarkenP , BrownCP , KnobilK . Predicting lung function responses to salmeterol/fluticasone propionate combination therapy in COPD [Abstract]. European Respiratory Journal2003;22 Suppl 45:P429. SFCA3007 . A randomized, double‐blind, placebo‐controlled, parallel‐group trial evaluating the safety and efficacy of the DISKUS formulations of salmeterol (SAL) 50mcg BID and fluticasone propionate (FP) 250mcg BID individually and in combination as salmeterol 50mcg/fluticasone propionate 250mcg BID (SFC 50/250) compared to placebo in COPD subjects. GlaxoSmithKline Clinical Trials Register (http:ctr.gsk.co.uk)2005. SpencerM , WireP , LeeB , ChangCN , DarkenP , HorstmanD . Patients with COPD using salmeterol/fluticasone propionate combination therapy experience improved quality of life. European Respiratory Journal2003;22 Suppl 45:51s. SpencerMD , KariaN , AndersonJ . The clinical significance of treatment benefits with the salmeterol/fluticasone propionate 50/500mcg combination in COPD. European Respiratory Journal2004;24 Suppl 48:290s. ">Hanania 2003</a>－both included; Cazzola 2002a; Cazzola 2004－both excluded)<br/> Studies included: 4 </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2nd published version－Issue 3, 2004 (April 2003 to April 2004)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>References identified: 12<br/> References retrieved: 3 (2 papers full publication of a previously included or cited studies study (Dal Negro 2003; <a href="./references#CD006826-bbs2-0004" title="HananiaNA , DarkenP , HorstmanD , ReisnerC , LeeB , DavisS , et al. The efficacy and safety of fluticasone propionate (250 micro g)/salmeterol (50 micro g) combined in the diskus inhaler for the treatment of COPD. Chest2003;124(3):834‐43. HananiaNA , RamsdellJ , PayneK , DavisS , HorstmanD , LeeB , et al. Improvements in airflow and dyspnea in COPD patients following 24 weeks treatment with salmeterol 50mcg and fluticasone propionate 250mcg alone or in combination via the diskus. American Journal of Respiratory &amp; Critical Care Medicine2001;163(5 Suppl):A279. HorstmanD , DarkenP , DavisS , LeeB . Improvements in FEV1 and symptoms in poorly reversible COPD patients following treatment with salmeterol 50mcg/fluticasone propionate 250mcg combination [Abstract]. European Respiratory Journal2003;22 Suppl 45:P434. MahlerDA , DarkenP , BrownCP , KnobilK . Predicting lung function responses to combination therapy in chronic obstructive pulmonary disease (COPD) [Abstract]. National COPD Conference; November 14‐15, 2003; Arlington, Virginia. Abstract 1081. MahlerDA , DarkenP , BrownCP , KnobilK . Predicting lung function responses to salmeterol/fluticasone propionate combination therapy in COPD [Abstract]. European Respiratory Journal2003;22 Suppl 45:P429. SFCA3007 . A randomized, double‐blind, placebo‐controlled, parallel‐group trial evaluating the safety and efficacy of the DISKUS formulations of salmeterol (SAL) 50mcg BID and fluticasone propionate (FP) 250mcg BID individually and in combination as salmeterol 50mcg/fluticasone propionate 250mcg BID (SFC 50/250) compared to placebo in COPD subjects. GlaxoSmithKline Clinical Trials Register (http:ctr.gsk.co.uk)2005. SpencerM , WireP , LeeB , ChangCN , DarkenP , HorstmanD . Patients with COPD using salmeterol/fluticasone propionate combination therapy experience improved quality of life. European Respiratory Journal2003;22 Suppl 45:51s. SpencerMD , KariaN , AndersonJ . The clinical significance of treatment benefits with the salmeterol/fluticasone propionate 50/500mcg combination in COPD. European Respiratory Journal2004;24 Suppl 48:290s. ">Hanania 2003</a>)). Handsearching identified two further references to the COSMIC 2003 study<br/> Studies identified from supplementary searching: 1 (<a href="./references#CD006826-bbs2-0014" title="CalverleyP , PauwelsR , VestboJ , JonesP , PrideN , GulsvikA , et al. Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial. Lancet2003;361(9356):449‐56. CalverleyPMA , PauwelsRA , VestboJ , JonesPW , PrideNB , GulsvikA , et al. Clinical improvements with salmeterol / fluticasone propionate combination in differing severities of COPD, 2003. http://www.abstracts2view.comA035 [Poster D50]. CalverleyPMA , PauwelsRA , VestboJ , JonesPW , PrideNB , GulsvikA , et al. Salmeterol/Fluticasone propionate combination for one year provides greater clinical benefit than its individual components. Proceedings of the 98th International American Thoracic Society Conference http://www.abstracts‐on‐line.com/abstracts/ATS; May 17‐22, 2002; Atlanta, Georgia. A98 [Poster 306]. CalverlyPMA , PauwelsR , VestboJ , JonesP , PrideN , GulsvikA , et al. Safety of salmeterol/fluticasone propionate combination in the treatment of chronic obstructive pulmonary disease. European Respiratory Journal2002;20 Suppl 38:242 [P1572]. HunjanMK , ChandlerF . Numbers needed to treat (NNT) to avoid an exacerbation in patients with chronic obstructive pulmonary disease (COPD) using salmeterol/fluticasone propionate combination (SFC) and associated costs [Abstract]. American Thoracic Society 100th International Conference; May 21‐26, 2004; Orlando, Florida. D22 [Poster 503]. HunjanMK , WilliamsDT . Costs of avoiding exacerbations in patients with chronic obstructive pulmonary disease (COPD) treated with salmeterol/ fluticasone propionate combination (seretide) and salmeterol. European Respiratory Journal2004;24 Suppl 48:291s. HunjanMK , WilliamsDT . Salmeterol/ fluticasone propionate combination is clinically effective in avoiding exacerbations in patients with moderate/severe COPD. European Respiratory Journal2004;24 Suppl 48:513s. JonesPW , EdinHM , AndersonJ . Salmeterol/fluticasone propionate combination improves health status in COPD patients. Proceedings of the 98th International American Thoracic Society Conference http://www.abstracts‐on‐line.com/abstracts/ATS; May 17‐22, 2002; Atlanta, Georgia. A39 [Poster K39]. JonesPW , StåhlE . Budesonide /formoterol sustains clinically relevant improvements in health status in COPD [Abstract]. European Respiratory Journal2005;26 Suppl 49:Abstract 1352. JonesPW , VestboJ , PauwelsRA , CalverleyPMA , AndersonJA , SpencerMD . Informative drop out in COPD studies: investigation of health status of withdrawals in the TRISTAN study. Proceedings of the 13th ERS Annual Congress; September 27, 2003; Vienna, Austria. P1593. NitschmannS . Inhalational combination therapy in chronic obstructive lung disease. Tristan study. German Internist2004;45(6):727‐8. PauwelsR , VestboJ , CalverleyPMA , JonesPW , PrideNB , GulsvikA . Characterization of exacerbations in the TRISTAN study of salmeterol / fluticasone propionate (SFC) combination in moderate to severe COPD, 2006. http://www.abstracts2view.com. PauwelsRA , CalverlyPMA , VestboJ , JonesPW , PrideN , GulsvikA , et al. Reduction of exacerbations with salmeterol/fluticasone combination 50/500 mcg bd in the treatment of chronic obstructive pulmonary disease. European Respiratory Journal2002;20 Suppl 38:240 [P1569]. SFCB3024 . A multicentre, randomised, double‐blind, parallel group, placebo‐controlled study to compare the efficacy and safety of the salmeterol/FP combination product at a strength of 50/500mcg bd with salmeterol 50mcg bd alone and FP 500mcg bd alone, delivered via the DISKUS™/ACCUHALER™, in the treatment of subjects with chronic obstructive pulmonary disease (COPD) for 12 months. GlaxoSmithKline Clinical Trials Register (http:ctr.gsk.co.uk)2005. SpencerM , BriggsAH , GrossmanRF , RanceL . Development of an economic model to assess the cost effectiveness of treatment interventions for chronic obstructive pulmonary disease. Pharmacoeconomics2005;23(6):619‐37. SpencerMD , KariaN , AndersonJ . The clinical significance of treatment benefits with the salmeterol/fluticasone propionate 50/500mcg combination in COPD. European Respiratory Journal2004;24 Suppl 48:290s. VestboJ , CalverleyPMA , PauwelsR , JonesP , PrideN , GulsvikA , et al. Absence of gender susceptibility to the combination of salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease. European Respiratory Journal2002;20 Suppl 38:240 [P1570]. VestboJ , PauwelsR , AndersonJA , JonesP , CalverleyP . Early onset of effect of salmeterol and fluticasone propionate in chronic obstructive pulmonary disease. Thorax2005;60(4):301‐4. VestboJ , PauwelsRS , CalverleyPMA , JonesPW , PrideNB , GulsvikA . Salmeterol / fluticasone propionate combination produces improvement in lung function detectable within 24 hours in moderate to severe COPD, 2003. http://www.abstracts2view.com. VestboJ , SorianoJB , AndersonJA , CalverleyP , PauwelsR , JonesP . Gender does not influence the response to the combination of salmeterol and fluticasone propionate in COPD. Respiratory Medicine2004;98(11):1045‐50. ">TRISTAN</a>)<br/> New studies included: 2<br/> Total studies included: 6 </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3rd published version－Issue 3, 2005 (April 2004 to April 2005)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>References identified: 52<br/> References retrieved: 46 (references to studies already included/excluded/ongoing: 24)<br/> New unique studies identified: 10 (ongoing studies: 2)<br/> New studies included: 0<br/> Total studies included: 6 </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4th published version－April 2005 to April 2007</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>References identified: 66<br/> References retrieved: 27 (references to studies already included/excluded/ongoing)<br/> New unique studies identified: 8 (ongoing studies: 0)<br/> New studies included: 1<br/> Total studies included: 7 </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Present version－April 2007 to June 2013</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>References identified: 209<br/> References retrieved: 63 (references to studies already included/excluded/ongoing: 6)<br/> New unique studies identified: 57 (ongoing studies: 0)<br/> New studies included: 8<br/> Total studies included: 15 </p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Search history</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD006826.pub2/full#CD006826-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD006826-tbl-0003"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Exacerbations</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Trial</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> COPD exacerbation definition</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006826-bbs2-0001" title="BourbeauJ , ChristodoulopoulosP , MaltaisF , YamauchiY , OlivensteinR , HamidQ . Effect of salmeterol/fluticasone propionate on airway inflammation in COPD: a randomised controlled trial. Thorax2007; Vol. 62, issue 11:938‐43. ">Bourbeau 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Exacerbations not reported</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006826-bbs2-0002" title="AstraZenecaSD . A placebo‐controlled 12‐month efficacy study of the fixed combination budesonide/formoterol compared to budesonide and formoterol as monotherapies in patients with chronic obstructive pulmonary disease (COPD). AstraZeneca Clinical Trials2002. BorgstromL , AskingL , OlssonH , PetersonS . Lack of interaction between disease severity and therapeutic response with budesonide/formoterol in a single inhaler [Abstract]. American Thoracic Society 100th International Conference; May 21‐26; 2004, Orlando, Florida. C22 [Poster 505]. CalverleyPM , BonsawatW , CsekeZ , ZhongN , PetersonS , OlssonH . Maintenance therapy with budesonide and formoterol in chronic obstructive pulmonary disease. European Respiratory Journal2003;22(6):912‐9. CalverleyPMA , CsekeZ , PetersonS . Budesonide/formoterol reduces the use of oral corticosteroids in the treatment of COPD [Abstract]. European Respiratory Journal2003;22 Suppl 45:P436. CalverleyPMA , KunaP , OlssonH . COPD exacerbations are reduced by budesonide/formoterol in a single inhaler [Abstract]. European Respiratory Journal2003;22 Suppl 45:P1587. CalverleyPMA , OlssonH , Symbicort International COPD Study Group. Budesonide/formoterol ina single inhaler sustains improvements in lung function over 12 months compared with monocomponents and placebo in patients with COPD [abstract]. American Thoracic Society 99th International Conference; May 16‐21, 2003; Seattle, Washington. B024 [Poster 418]. CalverleyPMA , PetersonS . Combining budesonide/formoterol in a single inhale reduces exacerbation frequency in COPD [abstract]. American Thoracic Society 99th International Conference; May 16‐21, 2003; Seattle, Washington. D092 [Poster 211]. CalverleyPMA , StåhlE , JonesPW . Budesonide/formoterol improves the general health status of patients with COPD [Abstract]. American Thoracic Society 2005 International Conference; May 20‐25, 2005; San Diego, California. B93 [Poster 303]. CalverleyPMA , SzafranskiW , AnderssonA . Budesonide/formoterol is a well‐tolerated long term maintenance therapy for COPD. European Respiratory Journal2005;26 Suppl 49:Poster 1917. CalverleyPMA , ThompsonNC , OlssonH . Budesonide/formoterol in a single inhaler sustains lung function improvements in COPD [Abstract]. European Respiratory Journal2003;22 Suppl 45:P435. HalpinD , StåhlE , LundbackB , AndersonF , PetersonS . Treatment costs and number needed to treat (NNT) with budesonide/formoterol to avoid one exacerbation of COPD [Abstract]. American Thoracic Society 100th International Conference; May 21‐26, 2004; Orlando, Florida. D22 [Poster 525]. HalpinDMG , LarssonT , CalverleyPMA . How many patients with COPD must be treated with budesonide/formoterol compared with formoterol alone to avoid 1 day of oral steroid use? [Abstract]. American Thoracic Society 2005 International Conference; May 20‐25, 2005; San Diego, California. B93 [Poster 314]. JonesPW , StahlE . Budesonide/formoterol in a single inhaler improves health status in patients with COPD [abstract]. American Thoracic Society 99th International Conference; May 16‐21, 2003; Orlando, Florida. B024 [Poster 419]. JonesPW , StåhlE . Budesonide /formoterol sustains clinically relevant improvements in health status in COPD [Abstract]. European Respiratory Journal2005;26 Suppl 49:Abstract 1352. JonesPW , StåhlE . Reducing exacerbations leads to a better health‐related quality of life in patients with COPD. 13th ERS Annual Congress; September 27, 2003; Vienna, Austria. P1586. LofdahlCG . Reducing the impact of COPD exacerbations: Clinical efficacy of budesonide/formoterol. European Respiratory Review2004;13(88):14‐21. LofdahlCG , AndreassonE , SvenssonK , EricssonA . Budesonide/formoterol in a single inhaler improves health status in patients with COPD without increasing healthcare costs [Abstract]. European Respiratory Journal2003;22 Suppl 45:P433. LofdahlCG , EricssonA , SvenssonK , AndreassonE . Cost effectiveness of budesonide/formoterol in a single inhaler for COPD compared with each monocomponent used alone. Pharmacoeconomics2005;23(4):365‐75. ">Calverley 2003</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mild exacerbations</b> = number of days with intake of 4 or more puffs of rescue medication </p> <p><b>Severe exacerbation</b> = intake of a course of oral steroids and/or antibiotics and/or hospitalisation due to respiratory symptoms </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006826-bbs2-0003" title="DohertyDE , KerwinE , TashkinDP , Matiz‐BuenoCE , ShekarT , BanerjeeS , et al. Combined mometasone furoate and formoterol in patients with moderate to very severe chronic obstructive pulmonary disease (COPD): phase 3 efficacy and safety study [Abstract]. Journal of Allergy and Clinical Immunology2012; Vol. 129, issue 2 Suppl:AB75 [283]. DohertyDE , TashkinDP , KerwinE , KnorrBA , ShekarT , BanerjeeS , et al. Effects of mometasone furoate/formoterol fumarate fixed‐dose combination formulation on chronic obstructive pulmonary disease (COPD): results from a 52‐week Phase III trial in subjects with moderate‐to‐very severe COPD. International Journal of Chronic Obstructive Pulmonary Disease2012; Vol. 7, issue 1178‐2005 (Electronic). 1176‐9106 (Linking):57‐71. NCT00383721 . A Randomized, 26‐Week, Placebo‐Controlled Efficacy and Safety Study With a 26‐Week Long‐Term Safety Extension, of High‐ and Medium‐Dose Inhaled Mometasone Furoate/Formoterol Fixed‐Dose Combination Formulation Compared With Formoterol and High‐Dose Inhaled Mometasone Furoate Monotherapy in Subjects With Moderate to Severe COPD, 2006. http://clinicaltrials.gov/show/NCT00383721. [] ">Doherty 2012</a><b>/</b> </p> <p><a href="./references#CD006826-bbs2-0012" title="KerwinE , TashkinDP , Matiz‐BuenoCE , DohertyDE , ShekarT , BanerjeeS , et al. Clinical efficacy and safety of combined mometasone furoate and formoterol in patients with moderate to very severe chronic obstructive pulmonary disease (COPD) [Abstract]. Journal of Allergy and Clinical Immunology2012; Vol. 129, issue 2 Suppl:AB201 [759]. NCT00383435 . A Randomized, 26‐Week, Placebo‐Controlled Efficacy and Safety Study With a 26‐Week Long‐Term Safety Extension, of High‐ and Medium‐Dose Inhaled Mometasone Furoate/Formoterol Fixed‐Dose Combination Formulation Compared With Formoterol and High‐Dose Inhaled Mometasone Furoate Monotherapy in Subjects With Moderate to Severe COPD, 2006. http://clinicaltrials.gov/show/NCT00383435. [] TashkinDP , DohertyDE , KerwinE , Matiz‐BuenoCE , KnorrB , ShekarT , et al. Efficacy and safety of a fixed‐dose combination of mometasone furoate and formoterol fumarate in subjects with moderate to very severe COPD: results from a 52‐week Phase III trial. International Journal of Chronic Obstructive Pulmonary Disease2012; Vol. 7, issue 1178‐2005 (Electronic). 1176‐9106 (Linking):43‐55. ">Tashkin 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mild exacerbation</b> = clinically judged deterioration of COPD symptoms (managed with increased short‐acting bronchodilator use: ≥ 12 inhalations/d of SABA/short‐acting anticholinergic, or ≥ 2 nebulised treatments/d of 2.5 mg SABA/short‐acting anticholinergic) on any two consecutive days </p> <p><b>Moderate exacerbation</b> = clinically judged deterioration of COPD with an acute change in symptoms that required antibiotic and/or oral steroid treatment for lower airway disease </p> <p><b>Severe exacerbation</b> = deterioration of COPD that resulted in emergency treatment or hospitalisation due to COPD </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006826-bbs2-0005" title="LapperreTS , Snoeck‐StrobandJB , GosmanMM , JansenDF , vanSchadewijkA , ThiadensHA , et al. Effect of fluticasone with and without salmeterol on pulmonary outcomes in chronic obstructive pulmonary disease: a randomized trial. Annals of Internal Medicine2009; Vol. 151, issue 8:517‐27. ">Lapperre 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Exacerbations not reported</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006826-bbs2-0007" title="NCT00358358 . Trial SCO104925. See detailed description, 2006. http://clinicaltrials.gov/show/NCT00358358. [] ">NCT00358358</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Exacerbations not reported</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006826-bbs2-0008" title="SFCT01 . A Multicentre, Randomised, Double‐Blind, Parallel Group, Placebo‐Controlled Study to Compare the Efficacy and Safety of Inhaled Salmeterol/Fluticasone Propionate Combination Product 25/250 µg Two Puffs Bd and Fluticasone Propionate 250µg Two Puffs Bd Alone, All Administered Via Metered Dose Inhalers (MDI), in the Treatment of Subjects with Chronic Obstructive Pulmonary Disease (COPD) for 52 Weeks. GlaxoSmithKline Clinical Trials Register (http:ctr.gsk.co.uk)2005. ">SFCT01</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No definition found</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006826-bbs2-0009" title="NCT00120978 . Advair－CRP Study. http://clinicaltrials.gov/show/NCT001209782004. [] SinDD , ManSF , MarciniukDD , FordG , FitzGeraldM , WongE , et al. Can inhaled fluticasone alone or in combination with salmeterol reduce systemic inflammation in chronic obstructive pulmonary disease? Study protocol for a randomized controlled trial [NCT00120978]. BMC Pulmonary Medicine2006;6(6):3. SinDD , ManSF , MarciniukDD , FordG , FitzGeraldM , WongE , et al. The effects of fluticasone with or without salmeterol on systemic biomarkers of inflammation in chronic obstructive pulmonary disease. American Journal of Respiratory and Critical Care Medicine2008; Vol. 177, issue 11:1207‐14. ">Sin 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>“Exacerbations were defined as worsening of COPD symptoms leading to hospitalisation, a visit to the emergency room, or use of an antimicrobial agent and/or systemic corticosteroids as an outpatient” </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006826-bbs2-0010" title="AndersonP . Budesonide/formoterol in a single inhaler (Symbicort) provides early and sustained improvement in lung function in moderate to severe COPD [Abstract]. Thorax2002;57(Suppl III):iii43. AstraZenecaSD . A placebo‐controlled 12 month efficacy study of the fixed combination budesonide/formoterol compared with budesonide and formoterol as monotherapies in patients with chronic obstructive pulmonary disease (COPD). AstraZeneca Clinical Trials2001. BorgstromL , AskingL , OlssonH , PetersonS . Lack of interaction between disease severity and therapeutic response with budesonide/formoterol in a single inhaler [Abstract]. American Thoracic Society 100th International Conference; May 21‐26, 2004; Orlando, Florida. C22 [Poster 505]. CalverleyP , PauwelsR , LofdahlCG , SvenssonK , HigenbottamT , et al. Relationship between respiratory symptoms and medical treatment in exacerbations of COPD. European Respiratory Journal2005;26(3):406‐13. CalverleyPMA . Effect of budesonide/formoterol on severe exacerbations and lung function in moderate to severe COPD. Thorax. BTS Winter Meeting 2002:S145. CalverleyPMA , SzafranskiW , AnderssonA . Budesonide/formoterol is a well‐tolerated long term maintenance therapy for COPD. European Respiratory Journal2005;26 Suppl 49:Poster 1917. CalverleyPMA , ThompsonNC , OlssonH . Budesonide/formoterol in a single inhaler sustains lung function improvements in COPD [Abstract]. European Respiratory Journal2003;22 Suppl 45:P435. CampbellLM , SzafranskiW . Budesonide/formoterol in a single inhaler (Symbicort) provides sustained relief from symptoms in moderate to severe COPD. Thorax. BTS Winter Meeting 2002:S143. CampellLW , SzafranskiW . Budesonide/Formoterol in a single inhaler (Symbicort) reduces severe exacerbations in patients with moderate‐severe COPD. Thorax. BTS Winter Meeting 2002:S141. DahlR , CukierA , OlssonH . Budesonide/formoterol in a single inhaler reduces severe and mild exacerbations in patients with moderate to severe COPD. European Respiratory Journal2002;20 Suppl 38:242 [P1575]. EgedeF , MengaG . Budesonide/formoterol in a single inhaler provides sustained relief from symptoms and night‐time awakenings in moderate‐severe COPD: results from symptoms and night‐time awakenings in moderate to severe COPD: results from a 1‐year study. European Respiratory Journal2002;20 Suppl 38:242 [P1574]. HalpinD , StahlE , LundbackB , AndersonF , PetersonS . Treatment costs and number needed to treat (NNT) with budesonide/formoterol to avoid one exacerbation of COPD [Abstract]. American Thoracic Society 100th International Conference; May 21‐26, 2004; Orlando, Florida. D22 [Poster 525]. JonesPW , StahlE , SvenssonK . Improvement in health status in patients with moderate to severe COPD after treatment with budesonide/formoterol in a single inhaler. European Respiratory Journal2002;20 Suppl 38:250 [P1613]. KorsgaardJ , SansoresR . Budesonide/formoterol (single inhaler) provides sustained relief from shortness of breath and chest tightness in a 1‐year study of patients with moderate to severe COPD. European Respiratory Journal2002;20 Suppl 38:242 [P1577]. LangeP , SaenzC . Budesonide/formoterol in a single inhaler is well tolerated in patients with moderate to severe COPD: results of a 1 year study. European Respiratory Journal2002;20 Suppl 38:242 [P1573]. LofdahlCG . Reducing the impact of COPD exacerbations: clinical efficacy of budesonide/formoterol. European Respiratory Review2004;13(88):14‐21. MilanowskiJ , NahabedianS . Budesonide/formoterol in a single inhaler acts rapidly to improve lung function and relieve symptoms in patients with moderate to severe COPD. European Respiratory Journal2002;20 Suppl 38:242 [P1576]. SzafranskiW , CukierA , RamirezA , MengaG , SansoresR , NahabedianS , et al. Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease. European Respiratory Journal2003;21(1):74‐81. ">Szafranski 2003</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mild exacerbations</b> = a day with ≥ 4 inhalations of reliever medication above the mean run‐in use </p> <p><b>Severe exacerbation</b> = use of oral steroids and/or antibiotics and/or hospitalisation due to respiratory symptoms </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006826-bbs2-0011" title="Astrazeneca(D5899C00002) . A 6‐month double‐blind, double‐dummy, randomized, parallel group, multicenter efficacy &amp; safety study of Symbicort® pMDI 2 × 160/4.5mg &amp; 80/4.5mg bid compared to Formoterol TBH, Budesonide pMDI (&amp; the combination) &amp; placebo in COPD patients. www.astrazenecaclinicaltrials.com (accessed 8 April 2008). BleeckerER , MeyersDA , BaileyWC , SimsA‐M , BujacSR , GoldmanM , et al. ADRB2 polymorphisms and budesonide/formoterol responses in COPDADRB2 polymorphisms and treatment response in COPD. Chest2012;142(2):320‐8. TashkinDP , RennardSI , MartinP , GoldmanM , SilkoffPE . Efficacy of budesonide/formoterol administered via one pressurized metered‐dose inhaler over 6 months in patients with chronic obstructive pulmonary disease [Abstract]. Chest2008; Vol. 134, issue 4:105001s. TashkinDP , RennardSI , MartinP , RamachandranS , MartinUJ , SilkoffPE , et al. Efficacy and safety of budesonide and formoterol in one pressurized metered‐dose inhaler in patients with moderate to very severe chronic obstructive pulmonary disease : results of a 6‐month randomized clinical trial. Drugs2008; Vol. 68, issue 0012‐6667 (Print):1975‐2000. ">Tashkin 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>“Worsening of COPD symptoms that required treatment with</p> <p>oral corticosteroids and/or hospitalisation”</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006826-bbs2-0013" title="BriggsAH , GlickHA , Lozano‐OrtegaG , SpencerM , CalverleyPM , JonesPW , et al. Is treatment with ICS and LABA cost‐effective for COPD? Multinational economic analysis of the TORCH study. European Respiratory Journal2010; Vol. 35, issue 3:532‐9. CalverleyPM , AndersonJA , CelliB , FergusonGT , JenkinsC , JonesPW , et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease.[see comment]. New England Journal of Medicine2007; Vol. 356, issue 8:775‐89. CalverleyPMA , AndersonJA , CelliB , FergusonGT , JenkinsC , JonesPW , et al. Cardiovascular events in patients with chronic obstructive pulmonary disease: TORCH study results. Thorax2010;65:719‐25. CalverleyPMA , AndersonJA , CelliB , FergusonGT , JenkinsC , JonesPW , et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. New England Journal of Medicine2007;356(8):775‐89. CalverleyPMA , CelliB , FergusonG , JenkinsC , JonesPW , PrideNB , et al. Baseline characteristics of the first 5,000 COPD patients enrolled in the TORCH survival study. European Respiratory Journal2003;22 Suppl 45:578s. CelliB , CalverleyPMA , AndersonJA , FergusonGT , JenkinsC , JonesPW , et al. The TORCH (TOwards a Revolution in COPD Health) study: salmeterol/fluticasone propionate (SFC) improves health status, reduces exacerbations and improves lung function over three years. European Respiratory Journal2006;28 Suppl 50:34s. CelliB , VestboJ , JenkinsCR , JonesPW , FergusonGT , CalverleyPM , et al. Sex differences in mortality and clinical expressions of patients with chronic obstructive pulmonary disease: the TORCH experience. American Journal of Respiratory and Critical Care Medicine2011;183(3):317‐22. CelliBR , ThomasNE , AndersonJA , FergusonGT , JenkinsCR , JonesPW , et al. Effect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease: results from the TORCH study. American Journal of Respiratory and Critical Care Medicine2008;174(4):332‐8. CrimC , CalverleyPM , AndersonJA , CelliB , FergusonGT , JenkinsC , et al. Pneumonia risk in COPD patients receiving inhaled corticosteroids alone or in combination: TORCH study results. European Respiratory Journal2009;34(3):641‐7. FergusonGT , CalverleyPM , AndersonJA , JenkinsCR , JonesPW , WillitsLR , et al. Prevalence and progression of osteoporosis in patients with COPD: results from the TOwards a Revolution in COPD Health study. Chest2009; Vol. 136, issue 0012‐3692:1456‐65. FergusonGT , CalverleyPMA , AndersonJA , et al. The TORCH (TOwards a Revolution in COPD Health) study: salmeterol/fluticasone propionate (SFC) improves survival in COPD over three years. European Respiratory Journal2006;28 Suppl 50:34s. GlaxoSmithKlineSCO30003 . A multicentre, randomised, double‐blind, parallel group, placebo‐controlled study to investigate the long‐term effects of salmeterol/fluticasone propionate (SERETIDE/VIANI/ADVAIR) 50/500mcg bd, salmeterol 50mcg bd and fluticasone propionate 500mcg bd, all delivered via the DISKUS/ACCUHALER inhaler, on the survival of subjects with chronic obstructive pulmonary disease (COPD) over 3 years of treatment. GlaxoSmithKline Clinical Trial Register2006. HoughtonCM , LawsonN , BorrillZL , WixonCL , YoxallS , LangleySJ , et al. Comparison of the effects of salmeterol/fluticasone propionate with fluticasone propionate on airway physiology in adults with mild persistent asthma. Respiratory Research2007;8:52. JenkinsCR , CalverleyPMA , CelliB , FergusonG , JonesPW , PrideN , et al. Seasonal patterns of exacerbation rates in the TORCH survival study, 2007. http://www.abstracts2view.comA839. JenkinsCR , CelliB , AndersonJA , FergusonGT , JonesPW , VestboJ , et al. Seasonality and determinants of moderate and severe COPD exacerbations in the TORCH study. European Respiratory Journal2012;39(1):38‐45. JenkinsCR , JonesPW , CalverleyPM , CelliB , AndersonJA , FergusonGT , et al. Efficacy of salmeterol/fluticasone propionate by GOLD stage of chronic obstructive pulmonary disease: analysis from the randomised, placebo‐controlled TORCH study. Respiratory Research2009;10:59. JohnsonM , AgustiAG , BarnesNC . Reflections on TORCH: potential mechanisms for the survival benefit of salmeterol/fluticasone propionate in COPD patients. COPD2008;5(6):369‐75. JonesPW , AndersonJA , CalverleyPM , CelliBR , FergusonGT , JenkinsC , et al. TORCH Investigators. Health status in the TORCH study of COPD: treatment efficacy and other determinants of change. Respiratory Research2011;12:71. JonesPW , CalverleyP , CelliB , FergusonG , JenkinsC , PrideN . Trans‐regional validity of the SGRQ in the TORCH survival study, 2007. http://www.abstracts2view.comA122. McGarveyLP , JohnM , AndersonJA , ZvarichMT , WiseRA . Ascertainment of cause‐specific mortality in COPD: operations of the TORCH Clinical Endpoint Committee. Thorax2007;62:411‐5. NCT00268216 . See detailed description, 2000. http://clinicaltrials.gov/show/NCT00268216. [] SCO30003 . A multicentre, randomised, double‐blind, parallel group, placebo‐controlled study to investigate the long‐term effects of salmeterol/fluticasone propionate (SERETIDE®/VIANI®/ADVAIR®) 50/500mcg bd, salmeterol 50mcg bd and fluticasone propionate 500mcg bd, all delivered via the DISKUS®/ACCUHALER® inhaler, on the survival of subjects with chronic obstructive pulmonary disease (COPD) over 3 years of treatment, 2006. www.ctr.gsk.co.uk. VestboJ , AndersonJA , CalverleyPM , CelliB , FergusonGT , JenkinsC , et al. Adherence to inhaled therapy, mortality and hospital admission in COPD. Thorax2009;64(11):939‐43. VestboJ , CalverleyP , CelliB , FergusonG , JenkinsC , JonesP , et al. The TORCH (TOwards a Revolution in COPD Health) survival study protocol. European Respiratory Journal2004;24(2):206‐10. WiseRA , McGarveyLP , JohnM , AndersonJA , ZvarichMT . Reliability of cause‐specific mortality adjudication in a COPD clinical trial, 2007. http://www.abstracts2view.comA120. ">TORCH</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>“A symptomatic deterioration requiring treatment with antibiotic agents,</p> <p>systemic corticosteroids, hospitalisation, or a combination of these”</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006826-bbs2-0014" title="CalverleyP , PauwelsR , VestboJ , JonesP , PrideN , GulsvikA , et al. Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial. Lancet2003;361(9356):449‐56. CalverleyPMA , PauwelsRA , VestboJ , JonesPW , PrideNB , GulsvikA , et al. Clinical improvements with salmeterol / fluticasone propionate combination in differing severities of COPD, 2003. http://www.abstracts2view.comA035 [Poster D50]. CalverleyPMA , PauwelsRA , VestboJ , JonesPW , PrideNB , GulsvikA , et al. Salmeterol/Fluticasone propionate combination for one year provides greater clinical benefit than its individual components. Proceedings of the 98th International American Thoracic Society Conference http://www.abstracts‐on‐line.com/abstracts/ATS; May 17‐22, 2002; Atlanta, Georgia. A98 [Poster 306]. CalverlyPMA , PauwelsR , VestboJ , JonesP , PrideN , GulsvikA , et al. Safety of salmeterol/fluticasone propionate combination in the treatment of chronic obstructive pulmonary disease. European Respiratory Journal2002;20 Suppl 38:242 [P1572]. HunjanMK , ChandlerF . Numbers needed to treat (NNT) to avoid an exacerbation in patients with chronic obstructive pulmonary disease (COPD) using salmeterol/fluticasone propionate combination (SFC) and associated costs [Abstract]. American Thoracic Society 100th International Conference; May 21‐26, 2004; Orlando, Florida. D22 [Poster 503]. HunjanMK , WilliamsDT . Costs of avoiding exacerbations in patients with chronic obstructive pulmonary disease (COPD) treated with salmeterol/ fluticasone propionate combination (seretide) and salmeterol. European Respiratory Journal2004;24 Suppl 48:291s. HunjanMK , WilliamsDT . Salmeterol/ fluticasone propionate combination is clinically effective in avoiding exacerbations in patients with moderate/severe COPD. European Respiratory Journal2004;24 Suppl 48:513s. JonesPW , EdinHM , AndersonJ . Salmeterol/fluticasone propionate combination improves health status in COPD patients. Proceedings of the 98th International American Thoracic Society Conference http://www.abstracts‐on‐line.com/abstracts/ATS; May 17‐22, 2002; Atlanta, Georgia. A39 [Poster K39]. JonesPW , StåhlE . Budesonide /formoterol sustains clinically relevant improvements in health status in COPD [Abstract]. European Respiratory Journal2005;26 Suppl 49:Abstract 1352. JonesPW , VestboJ , PauwelsRA , CalverleyPMA , AndersonJA , SpencerMD . Informative drop out in COPD studies: investigation of health status of withdrawals in the TRISTAN study. Proceedings of the 13th ERS Annual Congress; September 27, 2003; Vienna, Austria. P1593. NitschmannS . Inhalational combination therapy in chronic obstructive lung disease. Tristan study. German Internist2004;45(6):727‐8. PauwelsR , VestboJ , CalverleyPMA , JonesPW , PrideNB , GulsvikA . Characterization of exacerbations in the TRISTAN study of salmeterol / fluticasone propionate (SFC) combination in moderate to severe COPD, 2006. http://www.abstracts2view.com. PauwelsRA , CalverlyPMA , VestboJ , JonesPW , PrideN , GulsvikA , et al. Reduction of exacerbations with salmeterol/fluticasone combination 50/500 mcg bd in the treatment of chronic obstructive pulmonary disease. European Respiratory Journal2002;20 Suppl 38:240 [P1569]. SFCB3024 . A multicentre, randomised, double‐blind, parallel group, placebo‐controlled study to compare the efficacy and safety of the salmeterol/FP combination product at a strength of 50/500mcg bd with salmeterol 50mcg bd alone and FP 500mcg bd alone, delivered via the DISKUS™/ACCUHALER™, in the treatment of subjects with chronic obstructive pulmonary disease (COPD) for 12 months. GlaxoSmithKline Clinical Trials Register (http:ctr.gsk.co.uk)2005. SpencerM , BriggsAH , GrossmanRF , RanceL . Development of an economic model to assess the cost effectiveness of treatment interventions for chronic obstructive pulmonary disease. Pharmacoeconomics2005;23(6):619‐37. SpencerMD , KariaN , AndersonJ . The clinical significance of treatment benefits with the salmeterol/fluticasone propionate 50/500mcg combination in COPD. European Respiratory Journal2004;24 Suppl 48:290s. VestboJ , CalverleyPMA , PauwelsR , JonesP , PrideN , GulsvikA , et al. Absence of gender susceptibility to the combination of salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease. European Respiratory Journal2002;20 Suppl 38:240 [P1570]. VestboJ , PauwelsR , AndersonJA , JonesP , CalverleyP . Early onset of effect of salmeterol and fluticasone propionate in chronic obstructive pulmonary disease. Thorax2005;60(4):301‐4. VestboJ , PauwelsRS , CalverleyPMA , JonesPW , PrideNB , GulsvikA . Salmeterol / fluticasone propionate combination produces improvement in lung function detectable within 24 hours in moderate to severe COPD, 2003. http://www.abstracts2view.com. VestboJ , SorianoJB , AndersonJA , CalverleyP , PauwelsR , JonesP . Gender does not influence the response to the combination of salmeterol and fluticasone propionate in COPD. Respiratory Medicine2004;98(11):1045‐50. ">TRISTAN</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>“Exacerbations were defined a priori as a worsening of COPD symptoms that required treatment with antibiotics, oral corticosteroids, or both. Episodes that </p> <p>required corticosteroid treatment or hospital admission were noted separately”</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006826-bbs2-0015" title="ZhongN , ZhengJ , WenF , YangL , ChenP , XiuQ , et al. Efficacy and safety of budesonide/formoterol via a dry powder inhaler in Chinese patients with chronic obstructive pulmonary disease. Current Medical Research and Opinion2012; Vol. 28, issue 2:257‐65. ZhongN , ZhengJ , WenF , YangL , ChenP , XiuQ , et al. Efficacy and safety of inhalation of budesonide/formoterol via turbuhaler in Chinese patients with chronic obstructive pulmonary disease [Abstract]. Chest2011; Vol. 140, issue 4:5225A. ">Zhong 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>“An exacerbation was defined as use of oral/IV corticosteroids and/or antibiotics and/or emergency room treatment/hospitalisation due to respiratory symptoms” </p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Exacerbations</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD006826.pub2/full#CD006826-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD006826-tbl-0004"> <div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Rates of NNT and mortality</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b> Study ID</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b> Study duration</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b> ICS rate (%)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b> NNT *</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD006826-bbs2-0002" title="AstraZenecaSD . A placebo‐controlled 12‐month efficacy study of the fixed combination budesonide/formoterol compared to budesonide and formoterol as monotherapies in patients with chronic obstructive pulmonary disease (COPD). AstraZeneca Clinical Trials2002. BorgstromL , AskingL , OlssonH , PetersonS . Lack of interaction between disease severity and therapeutic response with budesonide/formoterol in a single inhaler [Abstract]. American Thoracic Society 100th International Conference; May 21‐26; 2004, Orlando, Florida. C22 [Poster 505]. CalverleyPM , BonsawatW , CsekeZ , ZhongN , PetersonS , OlssonH . Maintenance therapy with budesonide and formoterol in chronic obstructive pulmonary disease. European Respiratory Journal2003;22(6):912‐9. CalverleyPMA , CsekeZ , PetersonS . Budesonide/formoterol reduces the use of oral corticosteroids in the treatment of COPD [Abstract]. European Respiratory Journal2003;22 Suppl 45:P436. CalverleyPMA , KunaP , OlssonH . COPD exacerbations are reduced by budesonide/formoterol in a single inhaler [Abstract]. European Respiratory Journal2003;22 Suppl 45:P1587. CalverleyPMA , OlssonH , Symbicort International COPD Study Group. Budesonide/formoterol ina single inhaler sustains improvements in lung function over 12 months compared with monocomponents and placebo in patients with COPD [abstract]. American Thoracic Society 99th International Conference; May 16‐21, 2003; Seattle, Washington. B024 [Poster 418]. CalverleyPMA , PetersonS . Combining budesonide/formoterol in a single inhale reduces exacerbation frequency in COPD [abstract]. American Thoracic Society 99th International Conference; May 16‐21, 2003; Seattle, Washington. D092 [Poster 211]. CalverleyPMA , StåhlE , JonesPW . Budesonide/formoterol improves the general health status of patients with COPD [Abstract]. American Thoracic Society 2005 International Conference; May 20‐25, 2005; San Diego, California. B93 [Poster 303]. CalverleyPMA , SzafranskiW , AnderssonA . Budesonide/formoterol is a well‐tolerated long term maintenance therapy for COPD. European Respiratory Journal2005;26 Suppl 49:Poster 1917. CalverleyPMA , ThompsonNC , OlssonH . Budesonide/formoterol in a single inhaler sustains lung function improvements in COPD [Abstract]. European Respiratory Journal2003;22 Suppl 45:P435. HalpinD , StåhlE , LundbackB , AndersonF , PetersonS . Treatment costs and number needed to treat (NNT) with budesonide/formoterol to avoid one exacerbation of COPD [Abstract]. American Thoracic Society 100th International Conference; May 21‐26, 2004; Orlando, Florida. D22 [Poster 525]. HalpinDMG , LarssonT , CalverleyPMA . How many patients with COPD must be treated with budesonide/formoterol compared with formoterol alone to avoid 1 day of oral steroid use? [Abstract]. American Thoracic Society 2005 International Conference; May 20‐25, 2005; San Diego, California. B93 [Poster 314]. JonesPW , StahlE . Budesonide/formoterol in a single inhaler improves health status in patients with COPD [abstract]. American Thoracic Society 99th International Conference; May 16‐21, 2003; Orlando, Florida. B024 [Poster 419]. JonesPW , StåhlE . Budesonide /formoterol sustains clinically relevant improvements in health status in COPD [Abstract]. European Respiratory Journal2005;26 Suppl 49:Abstract 1352. JonesPW , StåhlE . Reducing exacerbations leads to a better health‐related quality of life in patients with COPD. 13th ERS Annual Congress; September 27, 2003; Vienna, Austria. P1586. LofdahlCG . Reducing the impact of COPD exacerbations: Clinical efficacy of budesonide/formoterol. European Respiratory Review2004;13(88):14‐21. LofdahlCG , AndreassonE , SvenssonK , EricssonA . Budesonide/formoterol in a single inhaler improves health status in patients with COPD without increasing healthcare costs [Abstract]. European Respiratory Journal2003;22 Suppl 45:P433. LofdahlCG , EricssonA , SvenssonK , AndreassonE . Cost effectiveness of budesonide/formoterol in a single inhaler for COPD compared with each monocomponent used alone. Pharmacoeconomics2005;23(4):365‐75. ">Calverley 2003</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>52 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>202 (123 to 741)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD006826-bbs2-0008" title="SFCT01 . A Multicentre, Randomised, Double‐Blind, Parallel Group, Placebo‐Controlled Study to Compare the Efficacy and Safety of Inhaled Salmeterol/Fluticasone Propionate Combination Product 25/250 µg Two Puffs Bd and Fluticasone Propionate 250µg Two Puffs Bd Alone, All Administered Via Metered Dose Inhalers (MDI), in the Treatment of Subjects with Chronic Obstructive Pulmonary Disease (COPD) for 52 Weeks. GlaxoSmithKline Clinical Trials Register (http:ctr.gsk.co.uk)2005. ">SFCT01</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>52 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD006826-bbs2-0007" title="NCT00358358 . Trial SCO104925. See detailed description, 2006. http://clinicaltrials.gov/show/NCT00358358. [] ">NCT00358358</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.38</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>195 (119 to 717)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD006826-bbs2-0004" title="HananiaNA , DarkenP , HorstmanD , ReisnerC , LeeB , DavisS , et al. The efficacy and safety of fluticasone propionate (250 micro g)/salmeterol (50 micro g) combined in the diskus inhaler for the treatment of COPD. Chest2003;124(3):834‐43. HananiaNA , RamsdellJ , PayneK , DavisS , HorstmanD , LeeB , et al. Improvements in airflow and dyspnea in COPD patients following 24 weeks treatment with salmeterol 50mcg and fluticasone propionate 250mcg alone or in combination via the diskus. American Journal of Respiratory &amp; Critical Care Medicine2001;163(5 Suppl):A279. HorstmanD , DarkenP , DavisS , LeeB . Improvements in FEV1 and symptoms in poorly reversible COPD patients following treatment with salmeterol 50mcg/fluticasone propionate 250mcg combination [Abstract]. European Respiratory Journal2003;22 Suppl 45:P434. MahlerDA , DarkenP , BrownCP , KnobilK . Predicting lung function responses to combination therapy in chronic obstructive pulmonary disease (COPD) [Abstract]. National COPD Conference; November 14‐15, 2003; Arlington, Virginia. Abstract 1081. MahlerDA , DarkenP , BrownCP , KnobilK . Predicting lung function responses to salmeterol/fluticasone propionate combination therapy in COPD [Abstract]. European Respiratory Journal2003;22 Suppl 45:P429. SFCA3007 . A randomized, double‐blind, placebo‐controlled, parallel‐group trial evaluating the safety and efficacy of the DISKUS formulations of salmeterol (SAL) 50mcg BID and fluticasone propionate (FP) 250mcg BID individually and in combination as salmeterol 50mcg/fluticasone propionate 250mcg BID (SFC 50/250) compared to placebo in COPD subjects. GlaxoSmithKline Clinical Trials Register (http:ctr.gsk.co.uk)2005. SpencerM , WireP , LeeB , ChangCN , DarkenP , HorstmanD . Patients with COPD using salmeterol/fluticasone propionate combination therapy experience improved quality of life. European Respiratory Journal2003;22 Suppl 45:51s. SpencerMD , KariaN , AndersonJ . The clinical significance of treatment benefits with the salmeterol/fluticasone propionate 50/500mcg combination in COPD. European Respiratory Journal2004;24 Suppl 48:290s. ">Hanania 2003</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD006826-bbs2-0006" title="MahlerDA , DarkenP , BrownCP , KnobilK . Predicting lung function responses to combination therapy in chronic obstructive pulmonary disease (COPD), 2003. http://www.abstracts2view.com. MahlerDA , WireP , HorstmanD , ChangCN , YatesJ , FischerT , et al. Effectiveness of fluticasone propionate and salmeterol combination delivered via the diskus device in the treatment of chronic obstructive pulmonary disease. American Journal of Respiratory Critical Care Medicine2002;166(8):1084‐91. SFCA3006 . A randomized, double‐blind, placebo‐controlled, parallel‐group trial evaluating the safety and efficacy of the DISKUS formulations of salmeterol (SAL) 50mcg BID and fluticasone propionate (FP) 500mcg BID individually and in combination as salmeterol 50mcg/fluticasone propionate 500mcg BID (SFC 50/500) compared to placebo in COPD subjects. GlaxoSmithKline Clinical Trials Register (http:ctr.gsk.co.uk)2005. SpencerM , WireP , LeeB , ChangCN , DarkenP , HorstmanD . Patients with COPD using salmeterol/fluticasone propionate combination therapy experience improved quality of life. European Respiratory Journal2003;22 Suppl 45:51s. SpencerMD , AndersonJA . Salmeterol/fluticasone combination produces clinically important benefits in dyspnea and fatigue [Abstract]. American Thoracic Society 2005 International Conference; May 20‐25, 2005; San Diego, California. B93 [Poster 308]. SpencerMD , KariaN , AndersonJ . The clinical significance of treatment benefits with the salmeterol/fluticasone propionate 50/500mcg combination in COPD. European Respiratory Journal2004;24 Suppl 48:290s. ">Mahler 2002</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD006826-bbs2-0015" title="ZhongN , ZhengJ , WenF , YangL , ChenP , XiuQ , et al. Efficacy and safety of budesonide/formoterol via a dry powder inhaler in Chinese patients with chronic obstructive pulmonary disease. Current Medical Research and Opinion2012; Vol. 28, issue 2:257‐65. ZhongN , ZhengJ , WenF , YangL , ChenP , XiuQ , et al. Efficacy and safety of inhalation of budesonide/formoterol via turbuhaler in Chinese patients with chronic obstructive pulmonary disease [Abstract]. Chest2011; Vol. 140, issue 4:5225A. ">Zhong 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD006826-bbs2-0010" title="AndersonP . Budesonide/formoterol in a single inhaler (Symbicort) provides early and sustained improvement in lung function in moderate to severe COPD [Abstract]. Thorax2002;57(Suppl III):iii43. AstraZenecaSD . A placebo‐controlled 12 month efficacy study of the fixed combination budesonide/formoterol compared with budesonide and formoterol as monotherapies in patients with chronic obstructive pulmonary disease (COPD). AstraZeneca Clinical Trials2001. BorgstromL , AskingL , OlssonH , PetersonS . Lack of interaction between disease severity and therapeutic response with budesonide/formoterol in a single inhaler [Abstract]. American Thoracic Society 100th International Conference; May 21‐26, 2004; Orlando, Florida. C22 [Poster 505]. CalverleyP , PauwelsR , LofdahlCG , SvenssonK , HigenbottamT , et al. Relationship between respiratory symptoms and medical treatment in exacerbations of COPD. European Respiratory Journal2005;26(3):406‐13. CalverleyPMA . Effect of budesonide/formoterol on severe exacerbations and lung function in moderate to severe COPD. Thorax. BTS Winter Meeting 2002:S145. CalverleyPMA , SzafranskiW , AnderssonA . Budesonide/formoterol is a well‐tolerated long term maintenance therapy for COPD. European Respiratory Journal2005;26 Suppl 49:Poster 1917. CalverleyPMA , ThompsonNC , OlssonH . Budesonide/formoterol in a single inhaler sustains lung function improvements in COPD [Abstract]. European Respiratory Journal2003;22 Suppl 45:P435. CampbellLM , SzafranskiW . Budesonide/formoterol in a single inhaler (Symbicort) provides sustained relief from symptoms in moderate to severe COPD. Thorax. BTS Winter Meeting 2002:S143. CampellLW , SzafranskiW . Budesonide/Formoterol in a single inhaler (Symbicort) reduces severe exacerbations in patients with moderate‐severe COPD. Thorax. BTS Winter Meeting 2002:S141. DahlR , CukierA , OlssonH . Budesonide/formoterol in a single inhaler reduces severe and mild exacerbations in patients with moderate to severe COPD. European Respiratory Journal2002;20 Suppl 38:242 [P1575]. EgedeF , MengaG . Budesonide/formoterol in a single inhaler provides sustained relief from symptoms and night‐time awakenings in moderate‐severe COPD: results from symptoms and night‐time awakenings in moderate to severe COPD: results from a 1‐year study. European Respiratory Journal2002;20 Suppl 38:242 [P1574]. HalpinD , StahlE , LundbackB , AndersonF , PetersonS . Treatment costs and number needed to treat (NNT) with budesonide/formoterol to avoid one exacerbation of COPD [Abstract]. American Thoracic Society 100th International Conference; May 21‐26, 2004; Orlando, Florida. D22 [Poster 525]. JonesPW , StahlE , SvenssonK . Improvement in health status in patients with moderate to severe COPD after treatment with budesonide/formoterol in a single inhaler. European Respiratory Journal2002;20 Suppl 38:250 [P1613]. KorsgaardJ , SansoresR . Budesonide/formoterol (single inhaler) provides sustained relief from shortness of breath and chest tightness in a 1‐year study of patients with moderate to severe COPD. European Respiratory Journal2002;20 Suppl 38:242 [P1577]. LangeP , SaenzC . Budesonide/formoterol in a single inhaler is well tolerated in patients with moderate to severe COPD: results of a 1 year study. European Respiratory Journal2002;20 Suppl 38:242 [P1573]. LofdahlCG . Reducing the impact of COPD exacerbations: clinical efficacy of budesonide/formoterol. European Respiratory Review2004;13(88):14‐21. MilanowskiJ , NahabedianS . Budesonide/formoterol in a single inhaler acts rapidly to improve lung function and relieve symptoms in patients with moderate to severe COPD. European Respiratory Journal2002;20 Suppl 38:242 [P1576]. SzafranskiW , CukierA , RamirezA , MengaG , SansoresR , NahabedianS , et al. Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease. European Respiratory Journal2003;21(1):74‐81. ">Szafranski 2003</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>52 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>186 (113 to 683)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD006826-bbs2-0013" title="BriggsAH , GlickHA , Lozano‐OrtegaG , SpencerM , CalverleyPM , JonesPW , et al. Is treatment with ICS and LABA cost‐effective for COPD? Multinational economic analysis of the TORCH study. European Respiratory Journal2010; Vol. 35, issue 3:532‐9. CalverleyPM , AndersonJA , CelliB , FergusonGT , JenkinsC , JonesPW , et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease.[see comment]. New England Journal of Medicine2007; Vol. 356, issue 8:775‐89. CalverleyPMA , AndersonJA , CelliB , FergusonGT , JenkinsC , JonesPW , et al. Cardiovascular events in patients with chronic obstructive pulmonary disease: TORCH study results. Thorax2010;65:719‐25. CalverleyPMA , AndersonJA , CelliB , FergusonGT , JenkinsC , JonesPW , et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. New England Journal of Medicine2007;356(8):775‐89. CalverleyPMA , CelliB , FergusonG , JenkinsC , JonesPW , PrideNB , et al. Baseline characteristics of the first 5,000 COPD patients enrolled in the TORCH survival study. European Respiratory Journal2003;22 Suppl 45:578s. CelliB , CalverleyPMA , AndersonJA , FergusonGT , JenkinsC , JonesPW , et al. The TORCH (TOwards a Revolution in COPD Health) study: salmeterol/fluticasone propionate (SFC) improves health status, reduces exacerbations and improves lung function over three years. European Respiratory Journal2006;28 Suppl 50:34s. CelliB , VestboJ , JenkinsCR , JonesPW , FergusonGT , CalverleyPM , et al. Sex differences in mortality and clinical expressions of patients with chronic obstructive pulmonary disease: the TORCH experience. American Journal of Respiratory and Critical Care Medicine2011;183(3):317‐22. CelliBR , ThomasNE , AndersonJA , FergusonGT , JenkinsCR , JonesPW , et al. Effect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease: results from the TORCH study. American Journal of Respiratory and Critical Care Medicine2008;174(4):332‐8. CrimC , CalverleyPM , AndersonJA , CelliB , FergusonGT , JenkinsC , et al. Pneumonia risk in COPD patients receiving inhaled corticosteroids alone or in combination: TORCH study results. European Respiratory Journal2009;34(3):641‐7. FergusonGT , CalverleyPM , AndersonJA , JenkinsCR , JonesPW , WillitsLR , et al. Prevalence and progression of osteoporosis in patients with COPD: results from the TOwards a Revolution in COPD Health study. Chest2009; Vol. 136, issue 0012‐3692:1456‐65. FergusonGT , CalverleyPMA , AndersonJA , et al. The TORCH (TOwards a Revolution in COPD Health) study: salmeterol/fluticasone propionate (SFC) improves survival in COPD over three years. European Respiratory Journal2006;28 Suppl 50:34s. GlaxoSmithKlineSCO30003 . A multicentre, randomised, double‐blind, parallel group, placebo‐controlled study to investigate the long‐term effects of salmeterol/fluticasone propionate (SERETIDE/VIANI/ADVAIR) 50/500mcg bd, salmeterol 50mcg bd and fluticasone propionate 500mcg bd, all delivered via the DISKUS/ACCUHALER inhaler, on the survival of subjects with chronic obstructive pulmonary disease (COPD) over 3 years of treatment. GlaxoSmithKline Clinical Trial Register2006. HoughtonCM , LawsonN , BorrillZL , WixonCL , YoxallS , LangleySJ , et al. Comparison of the effects of salmeterol/fluticasone propionate with fluticasone propionate on airway physiology in adults with mild persistent asthma. Respiratory Research2007;8:52. JenkinsCR , CalverleyPMA , CelliB , FergusonG , JonesPW , PrideN , et al. Seasonal patterns of exacerbation rates in the TORCH survival study, 2007. http://www.abstracts2view.comA839. JenkinsCR , CelliB , AndersonJA , FergusonGT , JonesPW , VestboJ , et al. Seasonality and determinants of moderate and severe COPD exacerbations in the TORCH study. European Respiratory Journal2012;39(1):38‐45. JenkinsCR , JonesPW , CalverleyPM , CelliB , AndersonJA , FergusonGT , et al. Efficacy of salmeterol/fluticasone propionate by GOLD stage of chronic obstructive pulmonary disease: analysis from the randomised, placebo‐controlled TORCH study. Respiratory Research2009;10:59. JohnsonM , AgustiAG , BarnesNC . Reflections on TORCH: potential mechanisms for the survival benefit of salmeterol/fluticasone propionate in COPD patients. COPD2008;5(6):369‐75. JonesPW , AndersonJA , CalverleyPM , CelliBR , FergusonGT , JenkinsC , et al. TORCH Investigators. Health status in the TORCH study of COPD: treatment efficacy and other determinants of change. Respiratory Research2011;12:71. JonesPW , CalverleyP , CelliB , FergusonG , JenkinsC , PrideN . Trans‐regional validity of the SGRQ in the TORCH survival study, 2007. http://www.abstracts2view.comA122. McGarveyLP , JohnM , AndersonJA , ZvarichMT , WiseRA . Ascertainment of cause‐specific mortality in COPD: operations of the TORCH Clinical Endpoint Committee. Thorax2007;62:411‐5. NCT00268216 . See detailed description, 2000. http://clinicaltrials.gov/show/NCT00268216. [] SCO30003 . A multicentre, randomised, double‐blind, parallel group, placebo‐controlled study to investigate the long‐term effects of salmeterol/fluticasone propionate (SERETIDE®/VIANI®/ADVAIR®) 50/500mcg bd, salmeterol 50mcg bd and fluticasone propionate 500mcg bd, all delivered via the DISKUS®/ACCUHALER® inhaler, on the survival of subjects with chronic obstructive pulmonary disease (COPD) over 3 years of treatment, 2006. www.ctr.gsk.co.uk. VestboJ , AndersonJA , CalverleyPM , CelliB , FergusonGT , JenkinsC , et al. Adherence to inhaled therapy, mortality and hospital admission in COPD. Thorax2009;64(11):939‐43. VestboJ , CalverleyP , CelliB , FergusonG , JenkinsC , JonesP , et al. The TORCH (TOwards a Revolution in COPD Health) survival study protocol. European Respiratory Journal2004;24(2):206‐10. WiseRA , McGarveyLP , JohnM , AndersonJA , ZvarichMT . Reliability of cause‐specific mortality adjudication in a COPD clinical trial, 2007. http://www.abstracts2view.comA120. ">TORCH</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>156 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>33 (20 to 123)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD006826-bbs2-0003" title="DohertyDE , KerwinE , TashkinDP , Matiz‐BuenoCE , ShekarT , BanerjeeS , et al. Combined mometasone furoate and formoterol in patients with moderate to very severe chronic obstructive pulmonary disease (COPD): phase 3 efficacy and safety study [Abstract]. Journal of Allergy and Clinical Immunology2012; Vol. 129, issue 2 Suppl:AB75 [283]. DohertyDE , TashkinDP , KerwinE , KnorrBA , ShekarT , BanerjeeS , et al. Effects of mometasone furoate/formoterol fumarate fixed‐dose combination formulation on chronic obstructive pulmonary disease (COPD): results from a 52‐week Phase III trial in subjects with moderate‐to‐very severe COPD. International Journal of Chronic Obstructive Pulmonary Disease2012; Vol. 7, issue 1178‐2005 (Electronic). 1176‐9106 (Linking):57‐71. NCT00383721 . A Randomized, 26‐Week, Placebo‐Controlled Efficacy and Safety Study With a 26‐Week Long‐Term Safety Extension, of High‐ and Medium‐Dose Inhaled Mometasone Furoate/Formoterol Fixed‐Dose Combination Formulation Compared With Formoterol and High‐Dose Inhaled Mometasone Furoate Monotherapy in Subjects With Moderate to Severe COPD, 2006. http://clinicaltrials.gov/show/NCT00383721. [] ">Doherty 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>52 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>386 (236 to 1417)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD006826-bbs2-0014" title="CalverleyP , PauwelsR , VestboJ , JonesP , PrideN , GulsvikA , et al. Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial. Lancet2003;361(9356):449‐56. CalverleyPMA , PauwelsRA , VestboJ , JonesPW , PrideNB , GulsvikA , et al. Clinical improvements with salmeterol / fluticasone propionate combination in differing severities of COPD, 2003. http://www.abstracts2view.comA035 [Poster D50]. CalverleyPMA , PauwelsRA , VestboJ , JonesPW , PrideNB , GulsvikA , et al. Salmeterol/Fluticasone propionate combination for one year provides greater clinical benefit than its individual components. Proceedings of the 98th International American Thoracic Society Conference http://www.abstracts‐on‐line.com/abstracts/ATS; May 17‐22, 2002; Atlanta, Georgia. A98 [Poster 306]. CalverlyPMA , PauwelsR , VestboJ , JonesP , PrideN , GulsvikA , et al. Safety of salmeterol/fluticasone propionate combination in the treatment of chronic obstructive pulmonary disease. European Respiratory Journal2002;20 Suppl 38:242 [P1572]. HunjanMK , ChandlerF . Numbers needed to treat (NNT) to avoid an exacerbation in patients with chronic obstructive pulmonary disease (COPD) using salmeterol/fluticasone propionate combination (SFC) and associated costs [Abstract]. American Thoracic Society 100th International Conference; May 21‐26, 2004; Orlando, Florida. D22 [Poster 503]. HunjanMK , WilliamsDT . Costs of avoiding exacerbations in patients with chronic obstructive pulmonary disease (COPD) treated with salmeterol/ fluticasone propionate combination (seretide) and salmeterol. European Respiratory Journal2004;24 Suppl 48:291s. HunjanMK , WilliamsDT . Salmeterol/ fluticasone propionate combination is clinically effective in avoiding exacerbations in patients with moderate/severe COPD. European Respiratory Journal2004;24 Suppl 48:513s. JonesPW , EdinHM , AndersonJ . Salmeterol/fluticasone propionate combination improves health status in COPD patients. Proceedings of the 98th International American Thoracic Society Conference http://www.abstracts‐on‐line.com/abstracts/ATS; May 17‐22, 2002; Atlanta, Georgia. A39 [Poster K39]. JonesPW , StåhlE . Budesonide /formoterol sustains clinically relevant improvements in health status in COPD [Abstract]. European Respiratory Journal2005;26 Suppl 49:Abstract 1352. JonesPW , VestboJ , PauwelsRA , CalverleyPMA , AndersonJA , SpencerMD . Informative drop out in COPD studies: investigation of health status of withdrawals in the TRISTAN study. Proceedings of the 13th ERS Annual Congress; September 27, 2003; Vienna, Austria. P1593. NitschmannS . Inhalational combination therapy in chronic obstructive lung disease. Tristan study. German Internist2004;45(6):727‐8. PauwelsR , VestboJ , CalverleyPMA , JonesPW , PrideNB , GulsvikA . Characterization of exacerbations in the TRISTAN study of salmeterol / fluticasone propionate (SFC) combination in moderate to severe COPD, 2006. http://www.abstracts2view.com. PauwelsRA , CalverlyPMA , VestboJ , JonesPW , PrideN , GulsvikA , et al. Reduction of exacerbations with salmeterol/fluticasone combination 50/500 mcg bd in the treatment of chronic obstructive pulmonary disease. European Respiratory Journal2002;20 Suppl 38:240 [P1569]. SFCB3024 . A multicentre, randomised, double‐blind, parallel group, placebo‐controlled study to compare the efficacy and safety of the salmeterol/FP combination product at a strength of 50/500mcg bd with salmeterol 50mcg bd alone and FP 500mcg bd alone, delivered via the DISKUS™/ACCUHALER™, in the treatment of subjects with chronic obstructive pulmonary disease (COPD) for 12 months. GlaxoSmithKline Clinical Trials Register (http:ctr.gsk.co.uk)2005. SpencerM , BriggsAH , GrossmanRF , RanceL . Development of an economic model to assess the cost effectiveness of treatment interventions for chronic obstructive pulmonary disease. Pharmacoeconomics2005;23(6):619‐37. SpencerMD , KariaN , AndersonJ . The clinical significance of treatment benefits with the salmeterol/fluticasone propionate 50/500mcg combination in COPD. European Respiratory Journal2004;24 Suppl 48:290s. VestboJ , CalverleyPMA , PauwelsR , JonesP , PrideN , GulsvikA , et al. Absence of gender susceptibility to the combination of salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease. European Respiratory Journal2002;20 Suppl 38:240 [P1570]. VestboJ , PauwelsR , AndersonJA , JonesP , CalverleyP . Early onset of effect of salmeterol and fluticasone propionate in chronic obstructive pulmonary disease. Thorax2005;60(4):301‐4. VestboJ , PauwelsRS , CalverleyPMA , JonesPW , PrideNB , GulsvikA . Salmeterol / fluticasone propionate combination produces improvement in lung function detectable within 24 hours in moderate to severe COPD, 2003. http://www.abstracts2view.com. VestboJ , SorianoJB , AndersonJA , CalverleyP , PauwelsR , JonesP . Gender does not influence the response to the combination of salmeterol and fluticasone propionate in COPD. Respiratory Medicine2004;98(11):1045‐50. ">TRISTAN</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>52 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>572 (350 to 2100)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD006826-bbs2-0011" title="Astrazeneca(D5899C00002) . A 6‐month double‐blind, double‐dummy, randomized, parallel group, multicenter efficacy &amp; safety study of Symbicort® pMDI 2 × 160/4.5mg &amp; 80/4.5mg bid compared to Formoterol TBH, Budesonide pMDI (&amp; the combination) &amp; placebo in COPD patients. www.astrazenecaclinicaltrials.com (accessed 8 April 2008). BleeckerER , MeyersDA , BaileyWC , SimsA‐M , BujacSR , GoldmanM , et al. ADRB2 polymorphisms and budesonide/formoterol responses in COPDADRB2 polymorphisms and treatment response in COPD. Chest2012;142(2):320‐8. TashkinDP , RennardSI , MartinP , GoldmanM , SilkoffPE . Efficacy of budesonide/formoterol administered via one pressurized metered‐dose inhaler over 6 months in patients with chronic obstructive pulmonary disease [Abstract]. Chest2008; Vol. 134, issue 4:105001s. TashkinDP , RennardSI , MartinP , RamachandranS , MartinUJ , SilkoffPE , et al. Efficacy and safety of budesonide and formoterol in one pressurized metered‐dose inhaler in patients with moderate to very severe chronic obstructive pulmonary disease : results of a 6‐month randomized clinical trial. Drugs2008; Vol. 68, issue 0012‐6667 (Print):1975‐2000. ">Tashkin 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.73</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>627 (383 to 2299)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD006826-bbs2-0012" title="KerwinE , TashkinDP , Matiz‐BuenoCE , DohertyDE , ShekarT , BanerjeeS , et al. Clinical efficacy and safety of combined mometasone furoate and formoterol in patients with moderate to very severe chronic obstructive pulmonary disease (COPD) [Abstract]. Journal of Allergy and Clinical Immunology2012; Vol. 129, issue 2 Suppl:AB201 [759]. NCT00383435 . A Randomized, 26‐Week, Placebo‐Controlled Efficacy and Safety Study With a 26‐Week Long‐Term Safety Extension, of High‐ and Medium‐Dose Inhaled Mometasone Furoate/Formoterol Fixed‐Dose Combination Formulation Compared With Formoterol and High‐Dose Inhaled Mometasone Furoate Monotherapy in Subjects With Moderate to Severe COPD, 2006. http://clinicaltrials.gov/show/NCT00383435. [] TashkinDP , DohertyDE , KerwinE , Matiz‐BuenoCE , KnorrB , ShekarT , et al. Efficacy and safety of a fixed‐dose combination of mometasone furoate and formoterol fumarate in subjects with moderate to very severe COPD: results from a 52‐week Phase III trial. International Journal of Chronic Obstructive Pulmonary Disease2012; Vol. 7, issue 1178‐2005 (Electronic). 1176‐9106 (Linking):43‐55. ">Tashkin 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.43</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>322 (197 to 1182)</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="4"> <div class="table-footnote"> <p>*Number needed to treat to prevent one death.</p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Rates of NNT and mortality</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD006826.pub2/full#CD006826-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD006826-tbl-0005"> <div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">Included studies</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Study ID</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No. of participants randomised</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Study duration (weeks)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Control</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bourbeau 2007</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>39</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>FPS (50/500 mcg bid)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>FP (500 mg bid)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Calverley 2003</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>511</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>52</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>BDF (320/9 mcg bid)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>BUD (400 mcg bid)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Doherty 2012</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>478</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MF/F (200/5 mcg bid)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MF (200 mcg bid)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Hanania 2003</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>366</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>FPS (50/250 mcg bid)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>FP (250 mcg bid)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Lapperre 2009</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>54</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>130</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>FPS (50/500 mcg bid)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>FP (500 mcg bid)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mahler 2002</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>333</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>FPS (50/500 mcg bid)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>FP (500 mcg bid)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NCT00358358</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>81</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>FPS (50/500 mcg bid)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>FP (500 mcg bid)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>SFCT01</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>256</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>52</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>FPS (50/500 mcg bid)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>FP (500 mcg bid)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sin 2008</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>179</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>FPS (50/500 mcg bid)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>FP (500 mcg bid)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Szafranski 2003</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>406</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>52</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>BDF (320/9 mcg bid)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>BUD (400 mcg bid)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tashkin 2008</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>552</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>BDF (160/4.5 mcg) 2 inhalations bid</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>BUD (160 mcg) 2 inhalations bid</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tashkin 2012</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>427</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MF/F (400/10 mcg bid)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MF (400 mcg bid)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>TORCH</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3091</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>156</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>FPS (50/500 mcg bid)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>FP (500 mcg bid)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>TRISTAN</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>733</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>52</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>FPS (50/500 mcg bid)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>FP (500 mcg bid)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Zhong 2012</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>308</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>BDF (160/4.5 mcg) 2 inhalations bid</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>BUD (200 mcg) 2 inhalations bid</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="5"> <div class="table-footnote"> <p>FPS = fluticasone/salmeterol;</p> <p>FP = fluticasone;</p> <p>BDF = budesonide/formoterol;</p> <p>BUD = budesonide;</p> <p>MF/F = mometasone/formoterol;</p> <p>MF =  mometasone.</p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">Included studies</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD006826.pub2/full#CD006826-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD006826-tbl-0006"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">All Combined Inhalers ‐ Primary Outcomes</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Exacerbation rates (exacerbations requiring oral corticosteroids) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Rate ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.87 [0.80, 0.94]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Fluticasone/salmeterol</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Rate ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.88 [0.80, 0.98]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Budesonide/formoterol</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Rate ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.84 [0.73, 0.97]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3 Mometasone/formoterol</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Rate ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Number of participants with one or more exacerbation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2781</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.87 [0.70, 1.09]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Fluticasone/salmeterol</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1876</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.76, 1.31]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 Budesonide/formoterol</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3 Mometasone/formoterol</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>905</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.67 [0.45, 0.98]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Hospitalisations due to COPD exacerbations <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>7060</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.93 [0.80, 1.07]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 Fluticasone/salmeterol</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4784</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.93 [0.79, 1.10]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 Budesonide/formoterol</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1371</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.85 [0.60, 1.20]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.3 Mometasone/formoterol</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>905</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.46 [0.66, 3.21]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Mortality <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>7518</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.78 [0.64, 0.94]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 Fluticasone/salmeterol</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4836</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.76 [0.62, 0.92]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2 Budesonide/formoterol</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1777</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.13 [0.54, 2.37]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.3 Mometasone/formoterol</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>905</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.89 [0.27, 2.91]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Pneumonia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>7320</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.08 [0.91, 1.28]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 Fluticasone/salmeterol</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5044</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.06 [0.89, 1.27]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2 Budesonide/formoterol</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1371</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.11 [0.47, 2.63]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.3 Mometasone/formoterol</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>905</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.92 [0.66, 5.57]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">All Combined Inhalers ‐ Primary Outcomes</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD006826.pub2/references#CD006826-tbl-0006">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD006826-tbl-0007"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Fluticasone/salmeterol (FPS) versus fluticasone (FP)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Exacerbation rates <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Rate ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.88 [0.80, 0.98]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Poorly reversible population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Rate ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.88 [0.80, 0.98]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Number of participants with one or more exacerbation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1876</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.76, 1.31]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Partially reversible population (mixed population)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>703</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.85 [0.59, 1.22]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 Poorly reversible population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>994</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.22 [0.80, 1.88]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3 Unclear reversibility</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>179</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.19 [0.31, 4.59]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 End of treatment mean number of exacerbations per participant <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 Poorly reversible population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Number of participants with one or more exacerbations by type <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>262</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.15 [0.69, 1.92]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 Requirement for oral steroids</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>262</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.15 [0.69, 1.92]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2 Requirement for antibiotic treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.3 Requirement for oral steroid or antibiotic treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.4 Hospitalisation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Exacerbations by type <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Rate ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 Hospitalisation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Rate ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.95 [0.82, 1.11]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2 Requirement for antibiotic treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Rate ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.3 Requirement for oral steroid or antibiotic treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Rate ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.4 Requirement for oral steroids</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Rate ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.89 [0.81, 0.98]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Mortality <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4836</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.76 [0.62, 0.92]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1 Mortality: three‐year data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3067</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.75 [0.62, 0.92]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.2 Mortality: one‐year data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>994</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.03 [0.23, 4.57]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.3 Mortality: six‐month data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>694</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.4 Mortality: three‐month data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>81</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.35 [0.01, 8.85]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Mortality－cause specific <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.1 COPD‐related death</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.2 Cancer</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.3 Cardiovascular</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Change from baseline in St George's Respiratory Questionnaire (total score) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>SGRQ units (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.30 [‐2.04, ‐0.57]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.1 Poorly reversible population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>SGRQ units (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.30 [‐2.04, ‐0.57]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 Change from baseline in Transitional Dyspnoea Index (TDI) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>690</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.31 [‐0.45, 1.08]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.1 Partially reversible population (mixed population)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>690</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.31 [‐0.45, 1.08]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10 Change from baseline in Chronic Respiratory Disease Questionnaire scores <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>696</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.34 [‐3.15, 7.82]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.1 Partially reversible population (mixed population)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>696</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.34 [‐3.15, 7.82]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11 Change from baseline in predose FEV<sub>1</sub> <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.05 [0.02, 0.09]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.1 Reversible population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.07 [0.01, 0.12]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.2 Poorly reversible population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.04 [‐0.01, 0.09]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">12 Change from baseline in post‐dose FEV<sub>1</sub> <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.05 [0.04, 0.06]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.1 Reversible population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.15 [0.09, 0.21]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.2 Poorly reversible population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.05 [0.03, 0.06]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">13 End of treatment am PEF (L/min) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.1 Poorly reversible population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">14 Absolute shuttle walk test <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Metres (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.1 Poorly reversible population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Metres (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">15 Change from baseline in rescue medication usage (puffs/d) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>686</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.80 [‐1.31, ‐0.29]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.1 Partially reversible population (mixed population)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>686</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.80 [‐1.31, ‐0.29]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">16 Withdrawals <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5106</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.86 [0.76, 0.97]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.1 Partially reversible population (mixed population)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>694</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.87 [0.63, 1.20]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.2 Poorly reversible population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4062</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.86 [0.76, 0.98]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.3 Unclear reversibility</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>350</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.76 [0.35, 1.66]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">17 Withdrawal due to lack of efficacy/exacerbation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4574</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.77 [0.53, 1.13]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>17.1 Partially reversible population (mixed population)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>333</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.02 [0.20, 5.12]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>17.2 Poorly reversible population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4062</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.72 [0.48, 1.08]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>17.3 Unclear reversibility</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>179</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.93 [0.34, 10.82]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">18 Withdrawals due to adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4723</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.75 [0.64, 0.87]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>18.1 Partially reversible population (mixed population)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>342</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.48 [0.22, 1.02]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>18.2 Poorly reversible population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4082</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.77 [0.65, 0.90]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>18.3 Unclear reversibility</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>299</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.71 [0.22, 2.28]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">19 Adverse events－any event <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5094</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.93 [0.80, 1.09]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>19.1 Partially reversible population (mixed population)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>703</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.92 [0.66, 1.30]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>19.2 Poorly reversible population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4092</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.94 [0.78, 1.13]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>19.3 Unclear reversibility</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>299</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.87 [0.49, 1.54]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">20 Adverse events－serious <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5055</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.05 [0.82, 1.34]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>20.1 Partially reversible population (mixed population)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>703</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.77 [0.39, 1.50]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>20.2 Poorly reversible population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4092</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.10 [0.84, 1.45]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>20.3 Unclear reversibility</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>260</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.09 [0.41, 2.85]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">21 Adverse events (specific adverse events) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>21.1 Pneumonia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5044</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.06 [0.89, 1.27]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>21.2 Candidiasis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1817</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.02 [0.70, 1.48]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>21.3 Hoarseness</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>262</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.20 [0.01, 4.14]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>21.4 Palpitations</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>262</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>21.5 Upper respiratory tract infection</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4717</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.14 [0.96, 1.36]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>21.6 Bronchitis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3441</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.23 [0.94, 1.61]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>21.7 Nasopharyngitis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3179</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.05 [0.86, 1.29]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>21.8 Cough</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>342</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.02 [0.32, 3.24]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>21.9 Dyspnoea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>262</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.0 [0.06, 16.16]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>21.10 Headache</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4881</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.95 [0.77, 1.17]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>21.11 Urinary tract infection</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>343</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.11 [0.01, 2.02]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Fluticasone/salmeterol (FPS) versus fluticasone (FP)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD006826.pub2/references#CD006826-tbl-0007">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD006826-tbl-0008"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Budesonide/formoterol (BDF) versus budesonide (BD)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Exacerbations <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Rate Ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.84 [0.73, 0.97]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Partially reversible</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Rate Ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.76, 1.31]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Poorly reversible</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Rate Ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.79 [0.67, 0.93]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Mean exacerbation rates per participant per year <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Rate Ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.84 [0.72, 0.99]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Poorly reversible population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Rate Ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.84 [0.72, 0.99]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Mortality <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1777</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.13 [0.54, 2.37]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 Mortality as primary outcome</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 Mortality data collected as secondary/unpublished outcome</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1777</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.13 [0.54, 2.37]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Quality of life－SGRQ total (change scores) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.80 [‐3.99, ‐1.61]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 Partially reversible population (mixed population)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.57 [‐4.68, ‐0.46]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2 Poorly reversible population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.91 [‐4.35, ‐1.47]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Symptoms (change scores) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.45 [‐0.67, ‐0.22]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 Poorly reversible</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.45 [‐0.67, ‐0.22]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Breathlessness, cough and sputum score (BCSS) change from baseline－average over treatment period <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.11 [‐0.38, 0.16]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1 Partially reversible (mixed population)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.11 [‐0.38, 0.16]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Awakening‐free nights, percentage change from baseline <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.05 [‐0.16, 0.06]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.1 Partially reversible (mixed population)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.98 [‐3.17, 7.13]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.2 Poorly reversible population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.05 [‐0.16, 0.06]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Mean FEV<sub>1</sub> (% increase from baseline) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>% increase (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>10.17 [7.71, 12.62]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.1 Poorly reversible</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>% increase (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>10.17 [7.71, 12.62]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 Pre‐dose FEV<sub>1</sub> [L] change from baseline to the average over the randomised treatment period <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.08 [0.05, 0.11]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.1 Partially reversible population (mixed population)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.08 [0.05, 0.11]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10 1‐Hour post‐dose FEV<sub>1</sub> [L] change from baseline to the average over the randomised treatment period <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.17 [0.14, 0.20]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.1 Partially reversible population (mixed population)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.17 [0.14, 0.20]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11 Morning PEFR change from baseline, average over treatment period (L/min) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>14.08 [8.64, 19.52]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.1 Poorly reversible population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>14.08 [8.64, 19.52]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">12 Evening PEFR mean change from baseline, average over treatment period (L/min) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>12.59 [7.21, 17.97]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.1 Partially reversible population (mixed population)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>12.59 [7.21, 17.97]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">13 Rescue medication use <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.72 [‐0.92, ‐0.52]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.1 Partially reversible population (mixed population)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.65 [‐1.09, ‐0.21]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.2 Poorly reversible</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.73 [‐0.96, ‐0.51]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">14 Sleep score (0 to 4)－change from baseline <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.04 [‐0.14, 0.06]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.1 Partially reversible population (mixed population)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.04 [‐0.14, 0.06]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">15 Dyspnoea score (0 to 4)－change from baseline <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.12 [‐0.20, ‐0.04]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.1 Partially reversible population (mixed population)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.12 [‐0.22, ‐0.02]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.2 Poorly reversible population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.12 [‐0.23, ‐0.01]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">16 Cough score (0 to 4)－change from baseline <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.01 [‐0.08, 0.06]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.1 Partially reversible population (mixed population)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [‐0.11, 0.11]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.2 Poorly reversible population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.02 [‐0.12, 0.08]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">17 Sputum score (0 to 4)－change from baseline <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.02 [‐0.09, 0.13]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>17.1 Partially reversible population (mixed population)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.02 [‐0.09, 0.13]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">18 Withdrawals due to worsening COPD symptoms <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1225</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.68 [0.46, 0.99]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>18.1 Poorly reversible population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1225</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.68 [0.46, 0.99]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">19 Withdrawals due to adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1777</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.95 [0.66, 1.37]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>19.1 Partially reversible population (mixed population)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>552</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.79 [0.43, 1.43]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>19.2 Poorly reversible population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1225</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.07 [0.68, 1.69]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">20 Adverse event－any (one or more) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>860</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.90 [0.68, 1.19]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>20.1 Partially reversible population (mixed population)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>552</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.71, 1.40]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>20.2 Poorly reversible population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>308</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.72 [0.44, 1.19]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">21 Adverse events－serious events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1469</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.93 [0.72, 1.21]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>21.1 Partially reversible population (mixed population)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>552</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.19 [0.70, 2.03]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>21.2 Poorly reversible population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>917</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.86 [0.64, 1.16]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">22 Adverse events (specific adverse events) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>22.1 Pneumonia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1371</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.11 [0.47, 2.63]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>22.2 Candidiasis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1063</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.87 [0.42, 1.80]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>22.3 Dysphonia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1063</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.30 [0.48, 3.51]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>22.4 Palpitations</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>552</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.99 [0.06, 15.95]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>22.5 Laryngeal pharyngitis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>819</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.05 [0.98, 4.29]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>22.6 Bronchitis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>552</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.25 [0.49, 3.22]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>22.7 Sinusitis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>552</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.01 [0.60, 6.77]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>22.8 Diarrhoea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>552</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.99 [0.20, 4.96]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>22.9 Upper airway infection</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>308</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.34 [0.10, 1.08]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>22.10 Nasopharyngitis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>552</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.42 [1.09, 5.39]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>22.11 Hypertension</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>511</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.67 [0.23, 1.90]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>22.12 Back pain</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>511</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.06 [0.61, 6.92]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>22.13 Chest pain</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>511</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.06 [0.61, 6.92]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>22.14 Headache</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>552</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.99 [0.06, 15.95]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>22.15 Dyspnoea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1063</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.01 [0.32, 3.16]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>22.16 Cough</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>552</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Budesonide/formoterol (BDF) versus budesonide (BD)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD006826.pub2/references#CD006826-tbl-0008">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD006826-tbl-0009"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Mometasone/formoterol (MF/F) versus Mometasone (MF)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Patients with one or more exacerbation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>905</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.67 [0.45, 0.98]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Poorly reversible population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>478</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.87 [0.53, 1.42]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Unclear reversibility</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>427</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.43 [0.22, 0.82]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Mortality <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>905</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.89 [0.27, 2.91]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Poorly reversible population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>478</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.51 [0.33, 6.81]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 Unclear reversibility</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>427</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.32 [0.03, 3.10]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Change from baseline in SGRQ (total score) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.29 [‐2.16, 1.57]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 Poorly reversible population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.17 [‐2.68, 2.34]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 Unclear reversibility</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.44 [‐3.23, 2.35]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Change from baseline in FEV<sub>1</sub> AUC<sub>0‐12 h</sub> (mL) week 26 <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>109.34 [57.87, 160.81]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 Poorly reversible population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>119.0 [48.96, 189.04]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2 Unclear reversibility</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>98.0 [22.11, 173.89]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Change from baseline in FEV<sub>1</sub> AUC<sub>0‐12 h</sub> (mL) week 13 <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>116.59 [68.59, 164.59]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 Poorly reversible population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>126.0 [54.16, 197.84]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2 Unclear reversibility</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>109.0 [44.49, 173.51]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Mean change from baseline AM pre‐dose FEV<sub>1</sub> at 13 weeks (mL) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.08 [0.04, 0.11]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1 Poorly reversible population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.07 [0.02, 0.12]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.2 Unclear reversibility</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.08 [0.03, 0.14]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Withdrawals－total <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>905</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.78 [0.56, 1.09]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.1 Poorly reversible population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>478</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.73 [0.45, 1.17]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.2 Unclear reversibility</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>427</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.83 [0.52, 1.33]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Withdrawals due to adverse event <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>905</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.38 [0.71, 2.68]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.1 Poorly reversible population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>478</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.81 [0.69, 4.74]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.2 Unclear reversibility</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>427</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.08 [0.43, 2.71]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 Withdrawal due to treatment failure <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>905</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.68 [0.19, 2.44]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.1 Poorly reversible population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>478</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.37 [0.04, 3.60]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.2 Unclear reversibility</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>427</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.97 [0.19, 4.85]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10 Adverse event－any <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>905</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.11 [0.84, 1.46]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.1 Poorly reversible population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>478</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.35 [0.94, 1.95]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.2 Unclear reversibility</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>427</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.85 [0.56, 1.30]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11 Adverse event－serious <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>905</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.03 [0.63, 1.67]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.1 Poorly reversible population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>478</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.02 [0.53, 1.95]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.2 Unclear reversibility</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>427</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.03 [0.50, 2.15]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">12 Adverse events (specific adverse events) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>12823</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.97 [0.75, 1.25]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.1 Cataract</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>905</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.34 [0.05, 2.20]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.2 COPD requiring hospitalisation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>905</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.46 [0.66, 3.21]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.3 Pneumonia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>905</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.92 [0.66, 5.57]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.4 Candidiasis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>905</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.47 [0.16, 1.36]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.5 Lenticular opacities</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>478</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.56 [0.05, 6.22]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.6 Upper respiratory tract infection</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>905</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.72 [0.77, 3.84]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.7 Headache</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>905</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.82 [0.39, 1.70]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.8 Cough</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>905</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.51 [0.15, 1.73]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.9 Hypertension</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>905</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.94 [0.34, 2.63]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.10 Chest pain</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>427</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.32 [0.01, 7.93]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.11 Influenza</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>905</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.47 [0.14, 1.55]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.12 Nasopharyngitis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>905</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.99 [0.49, 1.99]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.13 Bronchitis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>478</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>5.73 [0.66, 49.40]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.14 Pyrexia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>478</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.13 [0.32, 3.95]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.15 Back pain</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>956</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.75 [0.21, 2.67]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.16 Peripheral oedema</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>478</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.26 [0.20, 25.09]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.17 Dysphonia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>478</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.44 [0.09, 2.32]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Mometasone/formoterol (MF/F) versus Mometasone (MF)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD006826.pub2/references#CD006826-tbl-0009">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD006826.pub2&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD006826-note-0002">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD006826-note-0007">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD006826-note-0001">Français</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734064000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734064000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772746000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD006826\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD006826\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD006826\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD006826\x2epub2"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD006826\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD006826\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD006826\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD006826\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD006826\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD006826\x2epub2"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD006826\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD006826\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD006826\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD006826\x2epub2"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD006826\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD006826\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD006826\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD006826\x2epub2"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=Xx9QLps0&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD006826.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD006826.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD006826.pub2/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD006826.pub2/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD006826.pub2%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740715540910"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD006826.pub2/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740715540914"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD006826.pub2/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918d89996bc79374',t:'MTc0MDcxNTU0MS4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 